{
  "questions": [
    {
      "body": "Should Zotiraciclib be used for glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38159337",
        "http://www.ncbi.nlm.nih.gov/pubmed/38689623"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1538,
          "offsetInEndSection": 1676,
          "text": ".CONCLUSIONS: TG02 exhibits overlapping toxicity with alkylating agents and low single agent clinical activity in recurrent glioblastoma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38159337"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 672,
          "text": "Zotiraciclib, a CDK9 inhibitor, has demonstrated efficacy in glioblastoma treatment in preclinical and clinical studies, showing its potential as a therapeutic breakthrough. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38689623"
        }
      ],
      "type": "yesno",
      "id": "67e6cf2618b1e36f2e0000d0",
      "ideal_answer": [
        "Zotiraciclib was tested for glioblastoma and showed overlapping toxicity with alkylating agents and low single agent clinical activity in recurrent glioblastoma."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Is bronchiectasis a chronic or acute condition?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38676590",
        "http://www.ncbi.nlm.nih.gov/pubmed/38719503",
        "http://www.ncbi.nlm.nih.gov/pubmed/38271608",
        "http://www.ncbi.nlm.nih.gov/pubmed/32287909",
        "http://www.ncbi.nlm.nih.gov/pubmed/29602647",
        "http://www.ncbi.nlm.nih.gov/pubmed/21677919",
        "http://www.ncbi.nlm.nih.gov/pubmed/19135586",
        "http://www.ncbi.nlm.nih.gov/pubmed/16428701",
        "https://www.ncbi.nlm.nih.gov/pubmed/33736539",
        "http://www.ncbi.nlm.nih.gov/pubmed/36180278",
        "http://www.ncbi.nlm.nih.gov/pubmed/37562935",
        "http://www.ncbi.nlm.nih.gov/pubmed/39477356",
        "http://www.ncbi.nlm.nih.gov/pubmed/34719984",
        "http://www.ncbi.nlm.nih.gov/pubmed/29788952",
        "http://www.ncbi.nlm.nih.gov/pubmed/18824830",
        "http://www.ncbi.nlm.nih.gov/pubmed/33736539",
        "http://www.ncbi.nlm.nih.gov/pubmed/35929643",
        "http://www.ncbi.nlm.nih.gov/pubmed/14716069",
        "http://www.ncbi.nlm.nih.gov/pubmed/35543710",
        "http://www.ncbi.nlm.nih.gov/pubmed/33241711",
        "http://www.ncbi.nlm.nih.gov/pubmed/34862215",
        "http://www.ncbi.nlm.nih.gov/pubmed/39709516",
        "http://www.ncbi.nlm.nih.gov/pubmed/7612755",
        "http://www.ncbi.nlm.nih.gov/pubmed/10418580",
        "http://www.ncbi.nlm.nih.gov/pubmed/20854242",
        "http://www.ncbi.nlm.nih.gov/pubmed/27941638",
        "http://www.ncbi.nlm.nih.gov/pubmed/29143504",
        "http://www.ncbi.nlm.nih.gov/pubmed/23728208",
        "http://www.ncbi.nlm.nih.gov/pubmed/31092516",
        "http://www.ncbi.nlm.nih.gov/pubmed/30652424",
        "http://www.ncbi.nlm.nih.gov/pubmed/34734508",
        "http://www.ncbi.nlm.nih.gov/pubmed/22023177",
        "http://www.ncbi.nlm.nih.gov/pubmed/37174791",
        "http://www.ncbi.nlm.nih.gov/pubmed/34937712",
        "http://www.ncbi.nlm.nih.gov/pubmed/35658383",
        "http://www.ncbi.nlm.nih.gov/pubmed/30961955",
        "http://www.ncbi.nlm.nih.gov/pubmed/37915370",
        "http://www.ncbi.nlm.nih.gov/pubmed/39515342",
        "http://www.ncbi.nlm.nih.gov/pubmed/32160809",
        "http://www.ncbi.nlm.nih.gov/pubmed/33231063",
        "http://www.ncbi.nlm.nih.gov/pubmed/26840008",
        "http://www.ncbi.nlm.nih.gov/pubmed/31508157",
        "http://www.ncbi.nlm.nih.gov/pubmed/36931575",
        "http://www.ncbi.nlm.nih.gov/pubmed/35958169",
        "http://www.ncbi.nlm.nih.gov/pubmed/34261180",
        "http://www.ncbi.nlm.nih.gov/pubmed/33996875",
        "http://www.ncbi.nlm.nih.gov/pubmed/28491293",
        "http://www.ncbi.nlm.nih.gov/pubmed/30500093",
        "http://www.ncbi.nlm.nih.gov/pubmed/34929889",
        "http://www.ncbi.nlm.nih.gov/pubmed/23371406",
        "http://www.ncbi.nlm.nih.gov/pubmed/30779274",
        "http://www.ncbi.nlm.nih.gov/pubmed/23516961",
        "http://www.ncbi.nlm.nih.gov/pubmed/25307313",
        "http://www.ncbi.nlm.nih.gov/pubmed/18035962",
        "http://www.ncbi.nlm.nih.gov/pubmed/39139079",
        "http://www.ncbi.nlm.nih.gov/pubmed/23088941",
        "http://www.ncbi.nlm.nih.gov/pubmed/30107772",
        "http://www.ncbi.nlm.nih.gov/pubmed/39280527"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Introduction: Bronchiectasis is a chronic inflammatory lung disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38676590"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 97,
          "text": "Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 93,
          "text": "Chronic infection and inflammation shapes the airway microbiome in bronchiectasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38271608"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 250,
          "text": "Bronchiectasis not due to cystic fibrosis is the third most common chronic inflammatory disease of the airway, after asthma and chronic obstructive pulmonary disease (CPOD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32287909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Bronchiectasis, Chronic Suppurative Lung Disease and Protracted Bacterial Bronchitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29602647"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1497,
          "text": "Introduction: Bronchiectasis is a chronic endobronchial suppurative disease characterized by irreversibly dilated bronchi damaged by repeated polymicrobial infections and predominantly, neutrophilic airway inflammation. Some consider bronchiectasis a syndromic consequence of several different causes whilst others view it as an individual disease entity. In most patients, identifying an underlying cause remains challenging. The acquisition and colonization of affected airways by Pseudomonas aeruginosa represent a critical and adverse clinical consequence for its progression and management.Areas covered: In this review, we outline clinical and pre-clinical peer-reviewed research published in the last 5 years, focusing on the pathogenesis of bronchiectasis and the role of P. aeruginosa and its virulence in shaping host inflammatory and immune responses in the airway. We further detail its role in airway infection, the lung microbiome, and address therapeutic options in bronchiectasis.Expert opinion:P. aeruginosa represents a key pulmonary pathogen in bronchiectasis that causes acute and/or chronic airway infection. Eradication can prevent adverse clinical consequence and/or disease progression. Novel therapeutic strategies are emerging and include combination-based approaches. Addressing airway infection caused by P. aeruginosa in bronchiectasis is necessary to prevent airway damage, loss of lung function and exacerbations, all of which contribute to adverse clinical outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33736539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Introduction: Bronchiectasis is a chronic inflammatory lung disease and patients may occasionally experience acute",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38676590"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "INTRODUCTION: Bronchiectasis is a chronic condition that is becoming a global h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35543710"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Bronchiectasis is a chronic airway disease with abnormal and persistent bronchial dilatation caused by a variety of reasons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33241711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Bronchiectasis is a heterogeneous and increasingly prevalent chronic pulmonary disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862215"
        },
        {
          "offsetInBeginSection": 681,
          "offsetInEndSection": 884,
          "text": "In particular, NTM-PD should be considered where there are respiratory symptoms in the setting of pre-existing chronic lung disease such as chronic obstructive pulmonary disease (COPD) and bronchiectasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39709516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Bronchiectasis is a chronic debilitating condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21677919"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Bronchiectasis is a chronic condition with a prevalence continuously on the rise.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "BACKGROUND: Bronchiectasis is a chronic respiratory condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29788952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Bronchiectasis is a heterogeneous, chronic condition with many aetiologies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28491293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 50,
          "text": "Bronchiectasis is a heterogeneous chronic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31748420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Bronchiectasis is a neglected chronic respiratory condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34945152"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 45,
          "text": "Bronchiectasis is a long-term lung condition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29515674"
        },
        {
          "offsetInBeginSection": 1559,
          "offsetInEndSection": 1650,
          "text": "nchiectasis is currently defined as a condition which is both permanent and progressive. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15047953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 54,
          "text": "Bronchiectasis is a chronic inflammatory lung disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23088941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "OBJECTIVE: Bronchiectasis is characterized by chronic respiratory infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33646102"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Bronchiectasis is characterized by permanent, abnormal dilation of the bronchi with chronic inflammation and infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824830"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Bronchiectasis is primarily the result of airway injury and remodeling attributable to recurrent or chronic inflammation and infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14716069"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Bronchiectasis is a heterogeneous and increasingly prevalent chronic pulmonary disease that is associated with significant morbidity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862215"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Bronchiectasis belongs to the family of chronic obstructive lung diseases, even though it is much less common than asthma, chronic bronchitis, or emphysema. Clinical features of these entities overlap significantly. The triad of chronic cough, sputum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10418580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Bronchiectasis is a heterogeneous and increasingly prevalent chronic pulmonary disease that is associated with significant morbidity. In this review, we outline how patients with bronchiectasis may present clinically and describe an approach to its d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862215"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "INTRODUCTION: Bronchiectasis is a long-term lung condition, with dilated bronchi, chronic inflammation, chronic infection and acute ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37562935"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Introduction: Bronchiectasis is a chronic endobronchial suppurative disease characterized by irreversibly dilated bronchi damaged by repeated polymicrobial infections and predominantly, neutrophilic airway inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33736539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Background: Bronchiectasis is a chronic inflammation of the bronchi with recurrent infections and hemoptysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34719984"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Bronchiectasis, a chronic lung disease characterised by cough and purulent sputum, recurrent infections, and airway damage, is associated with considerable morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Bronchiectasis is a chronic suppurative respiratory disease of declining prevalence but continuing morbidity due to recurrent respiratory infections and bronchial bleeding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7612755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Bronchiectasis is a chronic debilitating condition with considerable phenotypic diversity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Bronchiectasis is a chronic inflammatory condition with a diverse aetiology including recurrent infections, genetic abnormalities, immunodeficiency and autoimmune disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31092516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Bronchiectasis is a rare chronic airway disease arising from several respiratory and systemic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652424"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "PURPOSE: Asthma and bronchiectasis are common chronic respiratory diseases, and their coexistence is frequently observed but not well inve",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34734508"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Bronchiectasis is defined by the presence of abnormal bronchial widening and occurs as a consequence of chronic airway infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023177"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "BACKGROUND: Bronchiectasis is the consequence of chronic bronchial inflammation, inappropriate mucus clearance, bacterial colonization, and recurrent or chroni",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37174791"
        },
        {
          "offsetInBeginSection": 457,
          "offsetInEndSection": 537,
          "text": "CSLD/bronchiectasis is suspected when chronic wet cough persists beyond 8 weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20854242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Bronchiectasis, a common chronic respiratory disease, is characterized by irreversible and abnormal bronchial dilatation due to multiple causes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "BACKGROUND: Bronchiectasis is a chronic pulmonary disease characterized by progressive and irreversible bronchia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30961955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Bronchiectasis is a chronic respiratory condition characterized by irreversible bronchial dilation, often caused by infection or inflammation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37915370"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Bronchiectasis is an etiologically heterogeneous, chronic, and often progressive respiratory disease characterized by irreversible bronchial dilation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39515342"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Bronchiectasis is a chronic lung disease (CLD) characterized by irreversible bronchial dilatation noted on computed tomography associated with chronic cough, ongoing viscid sputum production, and recurrent pulmonary infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32160809"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Bronchiectasis is within the spectrum of chronic lung disease characterized by progressive and often irreversible bronchial dilation caused by structural changes in the bronchial wall and chronic inflammation of the airways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33231063"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Bronchiectasis is described classically as a chronic pulmonary disorder characterized by a persistent productive cough and irreversible dilatation of one or more bronchi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26840008"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Bronchiectasis belongs to the family of chronic obstructive lung diseases, even though it is much less common than asthma, chronic bronchitis, or emphysema",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10418580"
        },
        {
          "offsetInBeginSection": 1460,
          "offsetInEndSection": 1627,
          "text": "EY POINTS: Bronchiectasis is a chronic progressive condition with significant disease burden and frequent exacerbations, for which the diagnosis relies on cross-sectio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31508157"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Bronchiectasis (BE) is a chronic condition characterized by airway dilation as a consequence of a variety of pathogenic processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36931575"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Bronchiectasis (BE) is a chronic condition affecting the bronchial tree.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35958169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Bronchiectasis is a chronic condition of global relevance resulting in permanent and irreversible structural airway damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34261180"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Bronchiectasis is a chronic condition in which areas of the bronchial tubes become permanently widened predisposing the lungs to infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33996875"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Bronchiectasis is a chronic airway disease with abnormal and persistent bronchial dilatation caused by a variety of reasons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33241711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi, clinically manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30500093"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "OBJECTIVE: Bronchiectasis is a chronic infective and inflammatory respiratory disease that causes significant morbidity an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34929889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Bronchiectasis is a chronic disease of the conducting airways that produces persistent productive cough, recurrent respiratory infectious exacerbations, and obstructive lung disease in children and adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19135586"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Bronchiectasis is a chronic infective and inflammatory respiratory disease that causes significant morbidity and mortality",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371406"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Bronchiectasis is a chronic, debilitating disease with increasing worldwide prevalence and burden",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30779274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Bronchiectasis is a chronic condition of global relevance resulting in permanent and irreversible structural airway damage",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34261180"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Bronchiectasis is a chronic suppurative respiratory disease of declining prevalence but continuing morbidity due to recurrent respiratory infections and bronchial bleeding",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7612755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "INTRODUCTION: In non-cystic fibrosis (CF) bronchiectasis, the chronic airways infection is a risk factor for frequent infectious exacerbations and for an overall poor dise",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23516961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Bronchiectasis is a chronic lung condition which is characterised by recurrent chest infections, chronic sputum production and cough, and limited exercise tolerance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39477356"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Bronchiectasis is a complex chronic respiratory condition traditionally characterized by chronic infection, airway inflammation, and progressive decline in lung function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Bronchiectasis is a chronic disease of the conducting airways that produces persistent productive cough, recurrent respiratory infectious exacerbations, and obstructive lung disease in children and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19135586"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "INTRODUCTION: Bronchiectasis is a chronic respiratory condition characterised by cough, sputum production and recurrent che",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25307313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Bronchiectasis is a chronic lung disease and clinically is characterised by chronic cough, sputum production and susceptibility to lower respiratory tract infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035962"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 227,
          "text": "ntroduction: Bronchiectasis is a chronic endobronchial suppurative disease characterized by irreversibly dilated bronchi damaged by repeated polymicrobial infections and predominantly, neutrophilic airway inflammation. Some co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33736539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Bronchiectasis is a chronic respiratory disease characterized by abnormal dilation of the bronchi that causes cough, sputum, and recurrent infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39139079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Bronchiectasis (BE) is a long-term, chronic lung condition featured by widened and scarred airways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35929643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "BACKGROUND: Bronchiectasis is a chronic respiratory condition that impacts significantly on individuals and healthca",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33664124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "BACKGROUND: Bronchiectasis is a chronic lung condition frequently associated with nontuberculous mycobacteria pulmonary (N",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35062891"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 263,
          "text": "Bronchiectasis is a chronic lung disease characterised by chronic cough, sputum production and recurrent pulmonary exacerbations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30107772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Bronchiectasis is a chronic respiratory disease characterized by a syndrome of productive cough and recurrent respiratory infections due to permanent dilatation of the bronchi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39280527"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 50,
          "text": "Bronchiectasis is a chronic debilitating condition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21677919"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Bronchiectasis is a chronic debilitating condition with considerable phenotypic diversity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Bronchiectasis (BE) is a long-term, chronic lung condition featured by widened and scarred airways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35929643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "BACKGROUND: Bronchiectasis is a condition that is characterized by the permanent dilation of bronchi with destruction of elastic and muscular components of their walls, usually due to acute or chron",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428701"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 351,
          "text": "lth globally. Bronchiectasis (including chronic suppurative lung disease) causes substantial morbidity for patients and significant impact on caregivers, especially during acute respiratory",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937712"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Pathophysiology of Chronic Bronchial Infection in Bronchiectasis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36180278"
        }
      ],
      "type": "factoid",
      "id": "680d5e47353a4a2e6b000005",
      "ideal_answer": [
        "Bronchiectasis is a chronic inflammatory lung disease",
        "Bronchiectasis is a chronic lung condition which is characterised by recurrent chest infections, chronic sputum production and cough, and limited exercise tolerance",
        "Bronchiectasis is primarily a chronic lung condition, characterized by permanent enlargement of the bronchi, leading to persistent symptoms, but it is also marked by recurrent acute exacerbations or flare-ups, which temporarily worsen symptoms, highlighting its complex chronic yet intermittently acute clinical presentation.",
        "Bronchiectasis is a chronic condition, as it is a persistent and long-term disorder of the airways, which is a part of the respiratory system in the body. This condition is characterized by the abnormal and persistent dilatation of the airways, leading to symptoms such as chronic cough and sputum production. It is important to note that while bronchiectasis can have recurrent exacerbations, it is considered a chronic condition due to its persistent nature.",
        "Bronchiectasis is a chronic lung condition",
        "Bronchiectasis is a chronic lung condition characterized by recurrent chest infections, chronic sputum production, cough, and limited exercise tolerance. It is not an acute condition, as it involves long-term inflammation and damage to the airways, leading to persistent symptoms and the need for ongoing management.",
        "Bronchiectasis is a chronic condition. It is a chronic debilitating condition with considerable phenotypic diversity and a rare chronic airway disease arising from several respiratory and systemic diseases.",
        "Bronchiectasis is a chronic airway disease, it is characterized by permanently dilated airways and chronic cough, and it is becoming a global health concern. It is not an acute condition.",
        "Bronchiectasis is a chronic condition characterized by irreversibly dilated bronchi and recurrent infections.",
        "Bronchiectasis is a **chronic condition**, characterized by permanent and irreversible structural airway damage, as consistently described across multiple studies. It involves persistent airway dilation, predisposing the lungs to recurrent infections and long-term respiratory complications.",
        "Bronchiectasis is a chronic, progressive respiratory disease characterized by irreversible dilation of the bronchi.",
        "Bronchiectasis is a chronic condition. It is a chronic respiratory disease characterized by irreversible and abnormal bronchial dilatation. It is associated with a persistent productive cough, airway infections, and recurrent exacerbations. Bronchiectasis is also described as a chronic infective and inflammatory respiratory disease.",
        "Bronchiectasis is a chronic condition, as it is characterized by persistent and permanent dilatation of the airways, chronic cough, and sputum production, among other symptoms. This condition is not acute, but rather a long-term, progressive disease.",
        "Bronchiectasis is a chronic respiratory condition characterized by permanent dilation of the bronchi, chronic inflammation, and recurrent infections.",
        "bronchiectasis is a type of chronic pulmonary disease, chronic airway disease, and chronic inflammatory disease of the airway.",
        "Bronchiectasis is a chronic condition characterized by persistent symptoms and airway damage.",
        "Bronchiectasis is a chronic lung condition which is characterised by recurrent chest infections, chronic sputum production and cough, and limited exercise tolerance.",
        "Bronchiectasis is a chronic lung condition.",
        "Bronchiectasis is a chronic lung condition characterized by recurrent chest infections, chronic sputum production, persistent cough, and limited exercise tolerance. It involves permanent enlargement of parts of the airways of the lung, leading to symptoms that persist over a long period and require ongoing management.",
        "Yes, bronchiectasis is a chronic or acute condition.",
        "Bronchiectasis is a chronic condition characterized by permanent dilation of the bronchi, chronic inflammation, chronic infection, and recurrent chest infections.",
        "Bronchiectasis is primarily a chronic lung condition characterized by permanent bronchial dilation, chronic inflammation, and infection. A key feature of this chronic condition is the occurrence of recurrent acute exacerbations, which can episodically worsen symptoms, impacting disease progression and outcomes.",
        "Bronchiectasis is a chronic condition characterized by the permanent enlargement of parts of the airways in the lungs. It leads to symptoms such as chronic cough, sputum production, and recurrent respiratory infections. The condition arises from damage to the airway walls and is typically long-lasting, requiring ongoing management and treatment.",
        "Bronchiectasis is a chronic respiratory condition. It is characterized by persistent bacterial colonization in the stable state, with increased and sometimes altered bacterial burden during exacerbations.",
        "Bronchiectasis is a chronic respiratory disease characterized by irreversible dilation of the bronchi, leading to persistent cough, sputum production and recurrent pulmonary infections.",
        "Bronchiectasis is a chronic lung condition characterized by recurrent acute exacerbations, indicating it is primarily a chronic condition with acute flare-ups.",
        "Bronchiectasis is a chronic condition characterized by permanently dilated airways and recurrent infections.",
        "Bronchiectasis is a chronic lung disease.",
        "Bronchiectasis is a chronic lung condition characterized by structural abnormalities in the airways, leading to persistent symptoms such as recurrent chest infections, chronic sputum production, cough, and reduced exercise tolerance. These features reflect its long-term, progressive nature rather than an acute or short-term illness.",
        "Bronchiectasis is a chronic inflammatory lung disease and patients may occasionally experience acute exacerbations.",
        "Bronchiectasis is a chronic inflammatory lung disease, affecting the respiratory airway, which is a subclass of the multicellular anatomical structure, and it is a subclass of the material anatomical entity. This chronic condition is characterized by the persistent dilatation of the airways, leading to recurrent infections and inflammation.",
        "Bronchiectasis is a chronic, worldwide lung disorder characterized by chronic infection and inflammation. Exacerbations are frequently observed in individuals with this condition.",
        "Bronchiectasis is a chronic lung disease characterized by persistent inflammation and damage to the larger airways and lungs over time.",
        "Bronchiectasis is a chronic condition. It is a chronic inflammatory lung disease characterized by persistent airway inflammation and dilation of the bronchial wall. It is also described as a chronic debilitating condition and a worldwide chronic lung disorder.",
        "Based on the provided snippets, Bronchiectasis is identified as a chronic inflammatory lung disease. It is a worldwide disorder where exacerbations are common, indicating its chronic nature. The chronic infection and inflammation shaping the airway microbiome also imply that it is a chronic condition.",
        "Bronchiectasis is a chronic condition, as evidenced by the snippets emphasizing its long-term inflammatory characteristics.",
        "Bronchiectasis is described as a chronic condition. It is identified as a chronic inflammatory lung disease and is recognized globally as a chronic lung disorder. The chronic aspect is further emphasized by the persistent infection and inflammation that affects the airway microbiome in individuals with bronchiectasis.",
        "Bronchiectasis is a chronic progressive respiratory disorder characterized by irreversible dilation of the bronchi and recurrent pulmonary infections rather than an acute self-limited condition.",
        "Bronchiectasis is a chronic condition. It is described as a chronic inflammatory lung disease with recurrent exacerbations, as highlighted in the reference snippets.",
        "Bronchiectasis is a chronic lung disorder",
        "Bronchiectasis is a chronic condition. It is characterized as a chronic infective and inflammatory respiratory disease, a chronic disease of the conducting airways, and a chronic lung disease associated with structurally abnormal bronchi. The condition involves irreversible and abnormal bronchial dilatation and is marked by persistent symptoms such as productive cough and recurrent respiratory infections.",
        "Bronchiectasis is a chronic inflammatory lung disease characterized by persistent infection and inflammation, leading to common exacerbations.",
        "Bronchiectasis is classified as a chronic condition because it involves persistent inflammation of the airways and typically requires long term management rather than being resolved quickly.",
        "Bronchiectasis is a chronic inflammatory lung disease.",
        "Yes, bronchiectasis is a chronic inflammatory lung disease.",
        "Bronchiectasis is a **chronic** inflammatory lung disease. It is characterized by persistent inflammation and infection in the airways, leading to long-term symptoms and complications. The condition is not acute; rather, it is a chronic disorder that requires ongoing management.",
        "Bronchiectasis is a chronic inflammatory lung disease. According to the provided abstracts, bronchiectasis is consistently described as a chronic condition, characterized by chronic inflammation and infection, with exacerbations being common. There is no indication that it is an acute condition.",
        "Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common . Chronic infection and inflammation shapes the airway microbiome in bronchiectas .",
        "Bronchiectasis is fundamentally a chronic respiratory condition characterized by persistent dilation of the bronchi, with a clinical course often marked by intermittent episodes of acute exacerbations.",
        "Bronchiectasis is a chronic respiratory disease characterized by irreversible widening of the bronchi, persistent cough, sputum production and recurrent pulmonary infections.",
        "Bronchiectasis is a chronic condition characterized by persistent inflammation and infection of the airways.",
        "Bronchiectasis is a chronic condition. It is characterized by permanent dilation of the bronchi and bronchioles, chronic airway inflammation, persistent productive cough, recurrent respiratory infections, and excessive sputum production. The condition involves a cycle of infection and inflammation in damaged airways, leading to progressive and irreversible bronchial dilatation.",
        "Bronchiectasis is a chronic inflammatory lung disease characterized by persistent infection and inflammation of the airways. It is a long-term condition where exacerbations are common, distinguishing it from acute respiratory illnesses.",
        "Bronchiectasis is definitively a chronic inflammatory lung disease/disorder, not an acute condition. The snippets consistently describe it as \"chronic\" and mention that it involves ongoing infection and inflammation that shapes the airway microbiome, with exacerbations being common."
      ],
      "exact_answer": [
        [
          "Chronic"
        ]
      ]
    },
    {
      "body": "Do biopharmaceuticals have a role in the treatment of depression?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35843573",
        "http://www.ncbi.nlm.nih.gov/pubmed/39444594"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 401,
          "text": "Studies have suggested that tumor necrosis factor-alpha (TNF-α) and interleukins (ILs) perform vital roles in the pathogenesis and treatment of depression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 504,
          "text": "Increasing evidence suggests the upregulation of TNF-α and ILs expression in patients with depression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573"
        },
        {
          "offsetInBeginSection": 517,
          "offsetInEndSection": 672,
          "text": "biologics like TNF inhibitors (etanercept, infliximab, adalimumab) and IL inhibitors (ustekinumab) have become key compounds in the treatment of depression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573"
        },
        {
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1418,
          "text": "symptoms have been improved by treatment with TNF-α inhibitors. Hence suggesting TNF-α inhibitors as potential new antidepressants for the management of depressive disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573"
        },
        {
          "offsetInBeginSection": 517,
          "offsetInEndSection": 673,
          "text": "biologics like TNF inhibitors (etanercept, infliximab, adalimumab) and IL inhibitors (ustekinumab) have become key compounds in the treatment of depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843573"
        },
        {
          "offsetInBeginSection": 1591,
          "offsetInEndSection": 1766,
          "text": "The benefits of IL-6 inhibition extend beyond reduced joint inflammation to the amelioration of comorbidities like anaemia, cardiovascular disease, depression and osteoporosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39444594"
        }
      ],
      "id": "680f4a68353a4a2e6b000007",
      "ideal_answer": [
        "Yes, increasing evidence suggests the upregulation of TNF-α and ILs expression in patients with depression. Therefore, biologics like TNF inhibitors (etanercept, infliximab, adalimumab) and IL inhibitors (ustekinumab) might become key compounds in the treatment of depression.",
        "Yes, biopharmaceuticals have a role in the treatment of depression. They can be used as adjunct therapies to enhance the efficacy of conventional antidepressant medications. Additionally, biopharmaceuticals, such as biologics, may be beneficial for patients with comorbidities and immune system dysregulations associated with mood disorders. The development of novel therapeutics targeting gut microbiota and the use of induced pluripotent stem cells (iPSCs) for drug screening are promising areas in precision-based psychiatry for treating major depressive disorders. Furthermore, antidepressants may modulate the tumor immune microenvironment, potentially enhancing the efficacy of immunotherapies.",
        "Biopharmaceuticals that modulate immune and signaling pathways have shown antidepressant effects. Agents such as tumor necrosis factor-α inhibitors (etanercept, infliximab, adalimumab), interleukin blockers (ustekinumab), JAK inhibitors and neurosteroid analogs (brexanolone) reduce proinflammatory cytokine activity implicated in mood disorders. Clinical studies report significant improvements in depressive symptoms and insomnia, particularly in patients with comorbid inflammatory conditions like psoriasis. Continuous biologic therapy yields faster symptom relief and lowers reliance on conventional antidepressants. While further large-scale trials and regulatory approvals are needed for general depression treatment, biopharmaceuticals represent a promising adjunct or alternative to traditional antidepressants."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Are microglia involved in synaptic pruning during development?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38915631",
        "http://www.ncbi.nlm.nih.gov/pubmed/38298216",
        "http://www.ncbi.nlm.nih.gov/pubmed/21778362",
        "http://www.ncbi.nlm.nih.gov/pubmed/37905877",
        "http://www.ncbi.nlm.nih.gov/pubmed/22632727",
        "http://www.ncbi.nlm.nih.gov/pubmed/39265565",
        "http://www.ncbi.nlm.nih.gov/pubmed/36657237",
        "http://www.ncbi.nlm.nih.gov/pubmed/24487234",
        "http://www.ncbi.nlm.nih.gov/pubmed/23644076",
        "http://www.ncbi.nlm.nih.gov/pubmed/35940391",
        "http://www.ncbi.nlm.nih.gov/pubmed/37890992",
        "http://www.ncbi.nlm.nih.gov/pubmed/26116891",
        "http://www.ncbi.nlm.nih.gov/pubmed/35297954",
        "http://www.ncbi.nlm.nih.gov/pubmed/39605704",
        "http://www.ncbi.nlm.nih.gov/pubmed/34063598",
        "http://www.ncbi.nlm.nih.gov/pubmed/37547773",
        "https://www.ncbi.nlm.nih.gov/pubmed/21778362",
        "https://www.ncbi.nlm.nih.gov/pubmed/23644076",
        "https://www.ncbi.nlm.nih.gov/pubmed/27400854",
        "https://www.ncbi.nlm.nih.gov/pubmed/30308165",
        "https://www.ncbi.nlm.nih.gov/pubmed/31112798",
        "https://www.ncbi.nlm.nih.gov/pubmed/33795678",
        "https://www.ncbi.nlm.nih.gov/pubmed/37717033",
        "http://www.ncbi.nlm.nih.gov/pubmed/39463930",
        "http://www.ncbi.nlm.nih.gov/pubmed/37962798",
        "http://www.ncbi.nlm.nih.gov/pubmed/33795678",
        "http://www.ncbi.nlm.nih.gov/pubmed/27400854",
        "http://www.ncbi.nlm.nih.gov/pubmed/38589666",
        "http://www.ncbi.nlm.nih.gov/pubmed/37205324",
        "http://www.ncbi.nlm.nih.gov/pubmed/35098130",
        "http://www.ncbi.nlm.nih.gov/pubmed/39587614",
        "http://www.ncbi.nlm.nih.gov/pubmed/39568399",
        "http://www.ncbi.nlm.nih.gov/pubmed/39416682",
        "http://www.ncbi.nlm.nih.gov/pubmed/39400857",
        "http://www.ncbi.nlm.nih.gov/pubmed/26311768",
        "http://www.ncbi.nlm.nih.gov/pubmed/30533998",
        "http://www.ncbi.nlm.nih.gov/pubmed/24101423",
        "http://www.ncbi.nlm.nih.gov/pubmed/27459063",
        "http://www.ncbi.nlm.nih.gov/pubmed/31131941",
        "http://www.ncbi.nlm.nih.gov/pubmed/36848726",
        "http://www.ncbi.nlm.nih.gov/pubmed/25463024",
        "http://www.ncbi.nlm.nih.gov/pubmed/22857738",
        "http://www.ncbi.nlm.nih.gov/pubmed/24068392",
        "http://www.ncbi.nlm.nih.gov/pubmed/38255315",
        "http://www.ncbi.nlm.nih.gov/pubmed/25575683",
        "http://www.ncbi.nlm.nih.gov/pubmed/34693982",
        "http://www.ncbi.nlm.nih.gov/pubmed/27697456",
        "http://www.ncbi.nlm.nih.gov/pubmed/31058364",
        "http://www.ncbi.nlm.nih.gov/pubmed/30256454",
        "http://www.ncbi.nlm.nih.gov/pubmed/31050055",
        "http://www.ncbi.nlm.nih.gov/pubmed/29197626",
        "http://www.ncbi.nlm.nih.gov/pubmed/25069260",
        "http://www.ncbi.nlm.nih.gov/pubmed/34463934",
        "http://www.ncbi.nlm.nih.gov/pubmed/28702478",
        "http://www.ncbi.nlm.nih.gov/pubmed/36818562",
        "http://www.ncbi.nlm.nih.gov/pubmed/38433422",
        "http://www.ncbi.nlm.nih.gov/pubmed/38510107",
        "http://www.ncbi.nlm.nih.gov/pubmed/30308165",
        "http://www.ncbi.nlm.nih.gov/pubmed/31392692",
        "http://www.ncbi.nlm.nih.gov/pubmed/33708226",
        "http://www.ncbi.nlm.nih.gov/pubmed/36172465",
        "http://www.ncbi.nlm.nih.gov/pubmed/33132837",
        "http://www.ncbi.nlm.nih.gov/pubmed/37717033",
        "http://www.ncbi.nlm.nih.gov/pubmed/30619100"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "During development, microglia prune excess synapses to refine neuronal circuits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38915631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Microglia are immune cells in the brain that originate from the yolk sac and enter the developing brain before birth. They play critical roles in brain development by supporting neural precursor proliferation, synaptic pruning, and circuit formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38298216"
        },
        {
          "offsetInBeginSection": 361,
          "offsetInEndSection": 503,
          "text": "Here, we show that microglia actively engulf synaptic material and play a major role in synaptic pruning during postnatal development in mice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Synaptic pruning by microglia is necessary for normal brain development.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778362"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 597,
          "text": "In the current study, we demonstrate a role for microglia in activity-dependent synaptic pruning in the postnatal retinogeniculate system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22632727"
        },
        {
          "offsetInBeginSection": 598,
          "offsetInEndSection": 825,
          "text": "We show that microglia engulf presynaptic inputs during peak retinogeniculate pruning and that engulfment is dependent upon neural activity and the microglia-specific phagocytic signaling pathway, complement receptor 3(CR3)/C3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22632727"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 701,
          "text": "Microglia are highly motile phagocytic cells that infiltrate and take up residence in the developing brain, where they are thought to provide a surveillance and scavenging function. However, although microglia have been shown to engulf and clear damaged cellular debris after brain insult, it remains less clear what role microglia play in the uninjured brain. Here, we show that microglia actively engulf synaptic material and play a major role in synaptic pruning during postnatal development in mice. These findings link microglia surveillance to synaptic maturation and suggest that deficits in microglia function may contribute to synaptic abnormalities seen in some neurodevelopmental disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/21778362"
        },
        {
          "offsetInBeginSection": 669,
          "offsetInEndSection": 833,
          "text": "Together, these results point towards a previously under-appreciated role for dark microglia in synaptic pruning and plasticity during normal postnatal development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39463930"
        },
        {
          "offsetInBeginSection": 665,
          "offsetInEndSection": 785,
          "text": "Astrocytes and microglia participate in the development and plasticity of neural circuits by modulating dendritic spines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37962798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Microglia shape synaptic connections among neurons of the central nervous system (CNS) during development and adulthood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940391"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 145,
          "text": "Microglia play a crucial role in brain development and repair by facilitating processes such as synaptic pruning and debris clearance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39587614"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 357,
          "text": "Microglia, the resident immunocytes of the CNS, are endowed with UDP-sensitive P2Y6 receptors (P2Y6Rs) which regulate phagocytosis/pruning of excessive synapses during individual development and refine synapses in an activity-dependent manner during adulthood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39400857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Microglia are involved in synaptic pruning both in development and in the mature CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311768"
        },
        {
          "offsetInBeginSection": 776,
          "offsetInEndSection": 889,
          "text": "These data indicate that microglia-mediated synaptic pruning mostly occurs during the brain developmental period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33132837"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Microglia play key roles in synaptic pruning, which primarily occurs from the postnatal period to adolescence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33862170"
        },
        {
          "offsetInBeginSection": 391,
          "offsetInEndSection": 632,
          "text": "Recent studies have reported that microglia facilitate synapse pruning during the circuit remodeling in some systems. It has remained unclear whether microglia are involved in the activity-dependent dendrite pruning in the developing brains.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37890992"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 284,
          "text": "Recently, microglial cells have been shown to be responsible for a portion of synaptic pruning, but the remaining mechanisms remain unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24270812"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "There is a consensus in the field that microglia play a prominent role in neurodevelopmental processes like synaptic pruning and neuronal network maturation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36657237"
        },
        {
          "offsetInBeginSection": 401,
          "offsetInEndSection": 589,
          "text": "Microglia physiologically eliminate unnecessary synapses during the developmental period. The overactivation of synaptic pruning by microglia is involved in the pathology of brain disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34063598"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 390,
          "text": "During neuronal development, new axonal and dendritic processes are formed, but excessive connections are eliminated appropriately; microglia participate in this pruning process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101423"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Microglia are phagocytic cells that infiltrate the brain during development and have a role in the elimination of synapses during brain maturation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24487234"
        },
        {
          "offsetInBeginSection": 567,
          "offsetInEndSection": 758,
          "text": "Furthermore, new data suggest that microglia in their resting state are able to phagocytose unwanted synapses and in this way contribute to synaptic pruning and maturation during development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22857738"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 210,
          "text": "Activation of classical complement pathway promotes microglia-mediated synaptic pruning during development and disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33795678"
        },
        {
          "offsetInBeginSection": 401,
          "offsetInEndSection": 490,
          "text": "Microglia physiologically eliminate unnecessary synapses during the developmental period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34063598"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "There is a consensus in the field that microglia play a prominent role in neurodevelopmental processes like synaptic pruning and neuronal network maturation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36657237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Microglia are involved in synaptic pruning both in development and in the mature CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26311768"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Microglia, the resident immune cells of the central nervous system, play critical roles in neurodevelopment, synaptic pruning, and neuronal wiring",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30256454"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "During postnatal neurodevelopment, excessive synapses must be eliminated by microglia to complete the establishment of neural circuits in the brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050055"
        },
        {
          "offsetInBeginSection": 691,
          "offsetInEndSection": 962,
          "text": "Besides the modulation of synaptic transmission, microglia also play an important role in synaptic remodeling by the pruning of unnecessary synapses and axon terminals during the postnatal developmental stage and adaptation to novel environments even in the healthy brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25069260"
        },
        {
          "offsetInBeginSection": 593,
          "offsetInEndSection": 813,
          "text": "Beyond this, recent studies have highlighted that microglia perform a number of complex tasks during neural development, from directing neuronal and axonal positioning to pruning synapses, receptors, and even whole cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34463934"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 389,
          "text": "During neuronal development, new axonal and dendritic processes are formed, but excessive connections are eliminated appropriately; microglia participate in this pruning process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101423"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 358,
          "text": "Microglia, the resident immunocytes of the CNS, are endowed with UDP-sensitive P2Y6 receptors (P2Y6Rs) which regulate phagocytosis/pruning of excessive synapses during individual development and refine synapses in an activity-dependent manner during adulthood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39400857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Microglia sculpt developing neural circuits by eliminating excess synapses in a process called synaptic pruning",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38589666"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 653,
          "text": "Microglia cells were first described as a component for the brain with few beneficial functions. The classical point of view implied that these cells had inflammatory properties more than benefits for brain homeostasis. To date, this assumption has changed and new roles of microglia cells are continuously discovered. Although, the main function of microglia cells is to provide a cellular defense against harmful or pathogen agents (bacteria, viruses, fungi, toxins, etc.), recent evidence indicates that microglial cells are dynamic modulators of synaptic pruning, brain development and neurogenesis by maintaining a balance of local cell population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28702478"
        },
        {
          "offsetInBeginSection": 766,
          "offsetInEndSection": 989,
          "text": "Currently, more and more research has found that microglia, as immune cells, can promote neurogenesis and synaptic pruning to maintain CNS homeostasis. They can usually reduce unnecessary synaptic connections early in life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38255315"
        },
        {
          "offsetInBeginSection": 590,
          "offsetInEndSection": 753,
          "text": "In several developing brain regions, synaptic pruning mediated by microglia, the resident immune cells of the brain, is important for normal behavioral development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38433422"
        },
        {
          "offsetInBeginSection": 669,
          "offsetInEndSection": 832,
          "text": "Together, these results point towards a previously under-appreciated role for dark microglia in synaptic pruning and plasticity during normal postnatal development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39463930"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 396,
          "text": "Microglia, which are the primary innate immune cells of the brain, are crucial for the refinement of the synaptic circuitry during early brain development by synaptic pruning and the regulation of synaptic plasticity during adulthood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38510107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Microglia sculpt developing neural circuits by eliminating excess synapses in a process called synaptic pruning, by removing apoptotic neurons, and by promoting neuronal survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38589666"
        },
        {
          "offsetInBeginSection": 772,
          "offsetInEndSection": 1003,
          "text": "Microglia monitor the retinal microenvironment, are activated following retinal injury or degeneration, have powerful phagocytosis capabilities, and play a critical role in synaptic pruning during central neural system development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34693982"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 397,
          "text": "Microglia, which are the primary innate immune cells of the brain, are crucial for the refinement of the synaptic circuitry during early brain development by synaptic pruning and the regulation of synaptic plasticity during adulthood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38510107"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 417,
          "text": "Microglia, the brain\u0027s resident immune-cells, are now known to be critically involved in normal brain development, shaping connections between neurons by pruning superfluous synaptic spines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697456"
        },
        {
          "offsetInBeginSection": 590,
          "offsetInEndSection": 754,
          "text": "In several developing brain regions, synaptic pruning mediated by microglia, the resident immune cells of the brain, is important for normal behavioral development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37205324"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "During development, microglia prune excess synapses to refine neuronal circuits. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38915631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Microglia play an important role in synaptic pruning and controlled phagocytosis of neuronal cells during developmental stages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575683"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Microglia are brain-resident immune cells that play a critical role in synaptic pruning and circuit fine-tuning during development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36172465"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 233,
          "text": "Microglial cells are involved in synapse pruning during development via the complement pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30533998"
        },
        {
          "offsetInBeginSection": 363,
          "offsetInEndSection": 622,
          "text": "Interestingly, microglia-mediated synaptic pruning and microglia-mediated changes in synaptic plasticity were observed both during brain development and in neurodegenerative diseases, stressing the key role of microglia-synapse interaction in these processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31392692"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 620,
          "text": "During this period, microglia is actively involved in processes of neurogenesis, synaptic pruning and detection of any environmental alteration that may impact brain development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34589855"
        },
        {
          "offsetInBeginSection": 47,
          "offsetInEndSection": 198,
          "text": "Recent work shows that microglia are also essential for proper brain development through synaptic pruning and remodeling during early life development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35098130"
        },
        {
          "offsetInBeginSection": 977,
          "offsetInEndSection": 1133,
          "text": "One prominent microglial signaling pathway involved in synaptic pruning and plasticity during development and aging is the C1q-initiated compliment cascade.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39416682"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Microglia are phagocytic cells that infiltrate the brain during development and have a role in the elimination of synapses during brain maturation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24487234"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Microglia are immune cells in the brain that originate from the yolk sac and enter the developing brain before birth. They play critical roles in brain development by supporting neural precursor proliferation, synaptic pruning, and circuit formation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38298216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Microglia, the innate immune cells of the central nervous system, actively participate in brain development by supporting neuronal maturation and refining synaptic connections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37717033"
        },
        {
          "offsetInBeginSection": 569,
          "offsetInEndSection": 890,
          "text": "Microglia, the resident immunocompetent phagocytes in the central nervous system (CNS), are not only important in the inflammatory response and pathogenesis; they also function in normal brain development, strengthen neuronal connections through synaptic pruning, and are involved in oligodendrocyte and neuronal survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30619100"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 416,
          "text": "Microglia, the brain\u0027s resident immune-cells, are now known to be critically involved in normal brain development, shaping connections between neurons by pruning superfluous synaptic spines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697456"
        },
        {
          "offsetInBeginSection": 606,
          "offsetInEndSection": 805,
          "text": "During fetal brain development, astrocytes and microglia often affect the same developmental processes such as neuro-/gliogenesis, angiogenesis, axonal outgrowth, synaptogenesis, and synaptic pruning",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36818562"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Microglia are brain-resident immune cells that play a critical role in synaptic pruning and circuit fine-tuning during development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36172465"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 730,
          "text": "While these are the classical functions described for microglia, more recently their neural functions have been defined; they are critical to the maturation of neurons during embryonic and postnatal development, phagocytic microglia remove excess synapses during development, a process called synaptic pruning, which is important to overall neural maturation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38692453"
        },
        {
          "offsetInBeginSection": 47,
          "offsetInEndSection": 197,
          "text": "Recent work shows that microglia are also essential for proper brain development through synaptic pruning and remodeling during early life development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35098130"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 275,
          "text": "This function is particularly significant during postnatal development, as microglia are responsible for removing excessive synapses to prevent neurodevelopmental deficits",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38346477"
        },
        {
          "offsetInBeginSection": 590,
          "offsetInEndSection": 753,
          "text": "In several developing brain regions, synaptic pruning mediated by microglia, the resident immune cells of the brain, is important for normal behavioral development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37205324"
        }
      ],
      "id": "680a083218b1e36f2e00014d",
      "ideal_answer": [
        "Microglia are immune cells in the brain that originate from the yolk sac and enter the developing brain before birth. They play critical roles in brain development by supporting neural precursor proliferation, circuit formation, and synaptic pruning, leading to further refinement of the neuronal circuits.",
        "Yes, microglia are involved in synaptic pruning during development. Research indicates that microglia play a crucial role in normal brain development by engaging in the process of synaptic pruning. These cells are highly motile and phagocytic, infiltrating the developing brain and participating actively in the surveillance and elimination of synapses (PMID 21778362). This activity is essential for the proper formation and refinement of neural circuits during early brain development. Further supporting this, another study highlights that the local externalization of phosphatidylserine is a mechanism that mediates developmental synaptic pruning by microglia (PMID 32657463). This process ensures the removal of excess synapses, which is critical for the healthy maturation of neural networks. Thus, microglia are not only present in the developing brain but are instrumental in shaping its synaptic architecture through pruning activities.",
        "Microglia are unequivocally involved in synaptic pruning during neural development, playing a crucial role in refining neural circuits and regulating synaptic density. Through phagocytic activity guided by specific molecular signals and receptors, they engulf synaptic material. This process has significant implications for neurodevelopmental outcomes, with dysfunction potentially leading to neurological and behavioral deficits. Understanding microglial involvement in synaptic pruning also highlights potential therapeutic targets for related disorders.",
        "The snippets provided indicate that microglia, a type of cell in the central nervous system (CNS), are involved in synaptic pruning during both postnatal development and adulthood in mice. This process involves microglia actively engulfing synaptic material and shaping synaptic connections among neurons. The crosstalk of microglia with other cells such as neurons, neural stem cells, endothelial cells, oligodendrocytes, and astrocytes contributes to their functions in synapse pruning. The process of synaptic pruning is also related to neurodevelopment and can strengthen active synapses by removing excess weaker synapses during development.",
        "Yes, microglia play a crucial role in synaptic pruning during development. Synaptic pruning is a process where excess synapses are eliminated to refine neural circuits, which is essential for proper brain function and development. Microglia, the resident immune cells of the central nervous system, are actively involved in this process. They help shape neural connectivity by engulfing and removing unnecessary synapses. During development, microglia survey the brain environment and respond to signals that indicate which synapses should be pruned. This activity is vital for the maturation of neural networks and the establishment of efficient communication pathways in the brain. Disruptions in microglial function or synaptic pruning have been linked to various neurodevelopmental disorders, highlighting the importance of microglia in maintaining healthy brain development.",
        "Yes, microglia are involved in synaptic pruning during development. These immune cells, originating from the yolk sac and entering the brain before birth, are crucial for refining neuronal circuits by pruning excess synapses. This process is essential for the proper formation and function of these circuits. Microglia support various developmental processes in the brain, including the proliferation of neural precursors, synaptic pruning, and the formation of circuits.",
        "Microglia play a significant role in synaptic pruning during brain development. Synaptic pruning is the process where excess synapses are removed to refine neural circuits, ensuring efficient communication between different parts of the brain. Microglia, as immune cells in the brain, contribute to this refinement by engaging in phagocytosis, where they engulf and digest unnecessary synapses. Additionally, they release molecules that influence neuronal activity and development.\n\nResearch indicates that microglia are crucial for supporting neural precursor proliferation, synaptic pruning, and circuit formation. Impairments in their function could lead to issues such as excessive synapses or improperly connected circuits, potentially contributing to neurological disorders. The process of synaptic pruning is most active during early developmental stages, including infancy and childhood.\n\nWhile microglia are central to this process, other cell types like astrocytes may also play a role in coordinating activities for proper brain development. Understanding the mechanisms by which microglia perform synaptic pruning and how disruptions might affect brain health is an area of ongoing research.",
        "Microglia, the brain\u0027s immune cells originating from the yolk sac, are actively involved in synaptic pruning during development. They refine neuronal circuits by eliminating excess synapses, a process critical for proper neural connectivity and function. This role is essential for supporting neural precursor proliferation and shaping circuit formation. Studies highlight their direct contribution to synaptic refinement, ensuring efficient neural network development. Their involvement underscores their broader functions in brain maturation beyond immune surveillance.",
        "Yes, microglia are involved in synaptic pruning during development. They prune excess synapses to refine neuronal circuits, playing critical roles in brain development by supporting neural precursor proliferation, synaptic pruning, and circuit formation.",
        "Yes, microglia are involved in synaptic pruning during development. They help refine neuronal circuits by removing excess synapses, and play critical roles in brain development, including supporting neural precursor proliferation and circuit formation.",
        "Yes, microglia are indeed involved in synaptic pruning during development. They play a crucial role in refining neuronal circuits by pruning excess synapses. This process is essential for the proper formation and function of the brain during development. Microglia originate from the yolk sac and enter the developing brain before birth, where they support neural precursor proliferation, synaptic pruning, and circuit formation.",
        "Yes, microglia are involved in synaptic pruning during development, originating from the yolk sac and entering the brain before birth. They play critical roles in refining neuronal circuits by eliminating excess synapses, supporting neural precursor proliferation, and facilitating circuit formation, all of which are essential for optimal brain connectivity and function.",
        "Microglia are critically involved in synaptic pruning during brain and retinal development, as demonstrated by studies showing their role in refining neuronal circuits by eliminating excess synapses. In developing systems, microglia support neural precursor proliferation, circuit formation, and synaptic refinement through dynamic interactions with neurons. However, environmental stressors like viral infections can alter microglial function, leading to excessive activation that disrupts normal developmental processes and contributes to neurodevelopmental disorders such as autism or schizophrenia. These findings highlight the dual role of microglia in both promoting healthy development via synaptic pruning and potentially driving pathology when their activity is dysregulated by external factors.",
        "Microglia are immune cells in the brain that originate from the yolk sac and enter the developing brain before birth . They play critical roles in brain development by supporting neural precursor proliferation, synaptic pruning, and circuit formation .",
        "Yes, microglia are involved in synaptic pruning during development. They prune excess synapses to refine neuronal circuits and play critical roles in brain development by supporting neural precursor proliferation, synaptic pruning, and circuit formation."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is the target of fezolinetant?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38161058",
        "http://www.ncbi.nlm.nih.gov/pubmed/38818887",
        "http://www.ncbi.nlm.nih.gov/pubmed/38775925",
        "http://www.ncbi.nlm.nih.gov/pubmed/38016166",
        "http://www.ncbi.nlm.nih.gov/pubmed/37974591",
        "http://www.ncbi.nlm.nih.gov/pubmed/39391998",
        "http://www.ncbi.nlm.nih.gov/pubmed/33724119",
        "http://www.ncbi.nlm.nih.gov/pubmed/36924778",
        "http://www.ncbi.nlm.nih.gov/pubmed/37462862",
        "http://www.ncbi.nlm.nih.gov/pubmed/31415087",
        "http://www.ncbi.nlm.nih.gov/pubmed/38563867",
        "http://www.ncbi.nlm.nih.gov/pubmed/39558800",
        "http://www.ncbi.nlm.nih.gov/pubmed/38640780",
        "http://www.ncbi.nlm.nih.gov/pubmed/37343519",
        "http://www.ncbi.nlm.nih.gov/pubmed/32102086",
        "http://www.ncbi.nlm.nih.gov/pubmed/38187079",
        "http://www.ncbi.nlm.nih.gov/pubmed/38478035"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 479,
          "offsetInEndSection": 653,
          "text": "In March 2023, the U.S. Food and Drug Administration approved fezolinetant (Veozah), a neurokinin 3 receptor antagonist for the treatment of vasomotor symptoms of menopause. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38161058"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "OBJECTIVE: We aimed to assess long-term safety and tolerability of fezolinetant, a nonhormonal neurokinin 3 receptor antagonist, among Chinese women with vasomotor symptoms associated with menopause participating in the MOONLIGHT 3 trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38818887"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 260,
          "text": "Current treatment options for VMS include fezolinetant, a nonhormonal, selective neurokinin 3 receptor antagonist. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775925"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "IMPORTANCE: The neurokinin 3 receptor antagonist fezolinetant 45 mg/d significantly reduced frequency/severity of moderate to severe vasomotor symptoms (VMS) of menopause compared with placebo in two phase 3 randomized controlled trials. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38016166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 536,
          "text": "This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of VMS.METHODS: Menopausal women aged \u003e40-65 years with moderate/severe VMS (≥50 episodes/wk) were randomized (double-blind) to fezolinetant 15, 30, 60, 90 mg BID or 30, 60, 120 mg QD, or placebo for 12 weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37343519"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 717,
          "text": "This narrative review summarizes the dataset accrued for fezolinetant, a neurokinin-3 receptor (NK3R) antagonist in clinical development for menopause-associated VMS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33724119"
        },
        {
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1156,
          "text": "Fezolinetant is a non-hormonal, neurokinin 3 receptor antagonist that works in the hypothalamus at the thermoregulatory centre.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38187079"
        },
        {
          "offsetInBeginSection": 330,
          "offsetInEndSection": 525,
          "text": "Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38478035"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 297,
          "text": " Fezolinetant is an FDA-approved non-hormonal selective neurokinin3 receptor antagonist for the treatment of VMS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Fezolinetant is an oral, nonhormonal, neurokinin 3 receptor antagonist treatment option for moderate to severe vasomotor symptoms associated with menopause.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39558800"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 366,
          "text": "ne therapy. Fezolinetant is one of the first non-hormonal neurokinin 3 receptor antagonists in development for the treatment of vasomotor symptoms due t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36924778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 713,
          "text": "Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause. Inhibiting NK3R-mediated signalling in the central nervous system is a non-hormonal strategy to modulate the activity of neurones that are associated with thermoregulation, thereby reducing the frequency and severity of VMS. Fezolinetant received its first approval in the USA in May 2023 for the treatment of moderate to severe VMS due to menopause. This article summarizes the milestones in the development of fezolinetant leading to this first approval in this indication",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862"
        },
        {
          "offsetInBeginSection": 1231,
          "offsetInEndSection": 1326,
          "text": "Neurokinin B inhibitors, like fezolinetant, target the physiologic cause of vasomotor symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37974591"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 670,
          "text": "Data Synthesis: Fezolinetant works by inhibiting neurokinin B from binding to its receptor in the hypothalamus, thereby decreasing the occurrence of vasomotor symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37974591"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 265,
          "text": "transition. Fezolinetant, a selective neurokinin 3 receptor (NK3R) antagonist, is a potential therapeutic option for mi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38563867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Fezolinetant is an oral, nonhormonal, neurokinin 3 receptor antagonist treatment option for moderate to severe vasomotor symptoms associated with menopause",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39558800"
        },
        {
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1155,
          "text": "Fezolinetant is a non-hormonal, neurokinin 3 receptor antagonist that works in the hypothalamus at the thermoregulatory centre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38187079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37343519"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 365,
          "text": "ne therapy. Fezolinetant is one of the first non-hormonal neurokinin 3 receptor antagonists in development for the treatment of vasomotor symptoms due ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36924778"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 258,
          "text": "Current treatment options for VMS include fezolinetant, a nonhormonal, selective neurokinin 3 receptor antagonist",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775925"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 273,
          "text": "to the quality of life. Fezolinetant is an FDA-approved non-hormonal selective neurokinin3 receptor antagonist ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38640780"
        },
        {
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1254,
          "text": "Fezolinetant is a non-hormonal, neurokinin 3 receptor antagonist that works in the hypothalamus at the thermoregulatory centre. Blocking the non-hormonal neurokinin 3 receptor antagonist modulates hot flashes and night sweats",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38187079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 706,
          "text": "and efficacy.AREAS COVERED: Fezolinetant is a novel oral non-hormonal drug recently approved for treatment of moderate-severe VMS. It acts as an antagonist of neurokinin 3 receptor (NK3R), the main target of neurokinin B (a tachykinin over-expressed by kisspeptin/neurokinin B/dynorphin [KNDy] neurons after menopausal hypoestrogenism), involved in modulation of thermoreg",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39391998"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 266,
          "text": "transition. Fezolinetant, a selective neurokinin 3 receptor (NK3R) antagonist, is a potential therapeutic option for mit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38563867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37462862"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 323,
          "text": "g neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 655,
          "text": "March 2023, the U.S. Food and Drug Administration approved fezolinetant (Veozah), a neurokinin 3 receptor antagonist for the treatment of vasomotor symptoms of menopause. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38161058"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 641,
          "text": "and efficacy.AREAS COVERED: Fezolinetant is a novel oral non-hormonal drug recently approved for treatment of moderate-severe VMS. It acts as an antagonist of neurokinin 3 receptor (NK3R), the main target of neurokinin B (a tachykinin over-expressed by kisspeptin/neurokinin B/dynorphin [KNDy] neurons after",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39391998"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 333,
          "text": " This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of VMS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31415087"
        }
      ],
      "type": "factoid",
      "id": "67e5557c18b1e36f2e0000ac",
      "ideal_answer": [
        "Fezolinetant is a neurokinin 3 receptor antagonist that is approved for the treatment of vasomotor symptoms of menopause."
      ],
      "exact_answer": [
        [
          "neurokinin 3 receptor"
        ]
      ]
    },
    {
      "body": "What complication of pregnancy was treated with  Diethylstilbestrol",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23897597",
        "http://www.ncbi.nlm.nih.gov/pubmed/17766166",
        "http://www.ncbi.nlm.nih.gov/pubmed/15168959",
        "http://www.ncbi.nlm.nih.gov/pubmed/12606880",
        "http://www.ncbi.nlm.nih.gov/pubmed/28098674",
        "http://www.ncbi.nlm.nih.gov/pubmed/28461243",
        "http://www.ncbi.nlm.nih.gov/pubmed/12861092",
        "http://www.ncbi.nlm.nih.gov/pubmed/15870516",
        "http://www.ncbi.nlm.nih.gov/pubmed/30758926",
        "http://www.ncbi.nlm.nih.gov/pubmed/11139327",
        "http://www.ncbi.nlm.nih.gov/pubmed/12215312",
        "http://www.ncbi.nlm.nih.gov/pubmed/28670059",
        "http://www.ncbi.nlm.nih.gov/pubmed/16096877",
        "http://www.ncbi.nlm.nih.gov/pubmed/6361926",
        "http://www.ncbi.nlm.nih.gov/pubmed/21909809",
        "http://www.ncbi.nlm.nih.gov/pubmed/23102737",
        "http://www.ncbi.nlm.nih.gov/pubmed/3851834",
        "http://www.ncbi.nlm.nih.gov/pubmed/21553654"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women in hopes of preventing miscarriage. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The diethylstilbestrol (DES) is a synthetic estrogen which was prescribed from 1941 onwards for the prevention of miscarriage",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17766166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Diethylstilbestrol is a synthetic nonsteroidal estrogen that was used to prevent miscarriage and other pregnancy complications between 1938 and 1971 in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Once prescribed to pregnant women to prevent risk of spontaneous abortion, diethylstilbestrol (DES) is now associated with an increased risk of breast cancer, clear cell adenocarcinoma (CCA) of the vagina and cervix, and reproductive anomalies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12861092"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Diethylstilbestrol is a synthetic nonsteroidal estrogen that was used to prevent miscarriage and other pregnancy complications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Diethylstilbestrol(DES) is a synthet- ic nonsteroidal oestrogen and endo- crine disruptor that was used in the 1950s-1970s to prevent spontaneous abortion,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30758926"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Diethylstilbestrol (DES), the first orally active artificial estrogen ever developed, was prescribed to several million pregnant women during the 1940s through the 1960s in the mistaken belief that it reduced the risk of miscarriage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12215312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Diethylstilbestrol (DES) was an orally active estrogen prescribed to the pregnant women to prevent miscarriages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28461243"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Diethylstilbestrol (DES) is a synthetic estrogen given to pregnant women to prevent miscarriages and preterm labor; the drug was used between 1941 and 1971 in the United States and into the 1980s in other countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28098674"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Between 1947 and 1971, the synthetic estrogen diethylstilbestrol (DES) was prescribed to pregnant women to prevent spontaneous abortions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28670059"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Diethylstilbestrol(DES) is a synthet- ic nonsteroidal oestrogen and endo- crine disruptor that was used in the 1950s-1970s to prevent spontaneous abortion, despite its lack of proven efficacy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30758926"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "From 1940 through the 1960s, diethylstilbestrol (DES), a synthetic oestrogen, was given to pregnant women to prevent pregnancy complications and losses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11139327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Since the 1940s, diaethylstilbestrol (DES) has been used by millions of pregnant women to prevent miscarriages and many other disorders in pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16096877"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women in hopes of preventing miscarriage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897597"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 173,
          "text": "Between 1939 and the 1960s, the synthetic estrogen diethylstilbestrol (DES) was given to millions of pregnant women to prevent pregnancy complications and losses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12606880"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "From 1940 through the 1960s, diethylstilbestrol (DES), a synthetic oestrogen, was given to pregnant women to prevent pregnancy complications and losses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11139327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Diethylstilbestrol (DES), a nonsteroidal estrogen, was widely used in the United States from 1940 through 1971 to prevent pregnancy loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15870516"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 304,
          "text": "Diethylstilbestrol (DES) was previously prescribed for at-risk pregnancies to prevent abortion, miscarriage, and premature labor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21909809"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Diethylstilbestrol (DES) is a synthetic estrogen prescribed to prevent miscarriages until 1977.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23102737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "The diethylstilbestrol (DES) is a synthetic estrogen which was prescribed from 1941 onwards for the prevention of miscarriage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17766166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Diethylstilbestrol is a synthetic nonsteroidal estrogen that was used to prevent miscarriage and other pregnancy complications between 1938 and 1971 in the United States. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15168959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 362,
          "text": "Diethylstilbestrol (DES) was prescribed for almost 30 years by physicians who believed the nonsteroidal synthetic estrogen was beneficial in both the treatment of threatened abortions and the prevention of spontaneous abortions. Toxemia, premature delivery, postmaturity, and stillbirth were said to be significantly reduced in patients who were treated with DES",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3851834"
        },
        {
          "offsetInBeginSection": 53,
          "offsetInEndSection": 169,
          "text": "administration of diethylstilbestrol (DES) during pregnancy (for the prevention or treatment of threatened abortions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6361926"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Diethylstilbestrol (DES), a synthetic estrogen clinically used to treat threatened abortion between the 1940s and the 1970s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21553654"
        }
      ],
      "type": "factoid",
      "id": "6810fef8353a4a2e6b000016",
      "ideal_answer": [
        "Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women in hopes of preventing miscarriage",
        "Diethylstilbestrol was used to prevent miscarriage and other pregnancy complications.",
        "Between 1939 and the 1960s, the synthetic estrogen diethylstilbestrol (DES) was given to millions of pregnant women to prevent miscarriage, a pregnancy related complication.",
        "Diethylstilbestrol (DES) was primarily used to treat or prevent miscarriage during pregnancy, with potential implications for preterm labor and other unspecified complications. However, its application for miscarriage prevention was ultimately found to be ineffective and led to various adverse health outcomes.",
        "Between 1939 and the 1960s, the synthetic estrogen diethylstilbestrol (DES) was given to millions of pregnant women to prevent miscarriages.",
        "Diethylstilbestrol was used for prevention of miscarriages.",
        "Diethylstilbestrol (DES) was prescribed to prevent miscarriages and other pregnancy complications, including preterm labor and pregnancy loss, from the late 1930s to the early 1970s. However, it was later discovered that DES caused significant health problems for both the mothers who took it and their children.",
        "Diethylstilbestrol was used to prevent miscarriages and other disorders in pregnancy.",
        "Diethylstilbestrol (DES), a synthetic estrogen, was used in the treatment of certain complications of pregnancy, including miscarriage, premature labor, stillbirth, recurrent pregnancy loss, and promotion of fetal growth in women with a history of premature birth.",
        "The complication of pregnancy that was treated with diethylstilbestrol includes pregnancy-induced hypertension and miscarriage.",
        "Diethylstilbestrol was historically prescribed to prevent recurrent miscarriage and reduce the risk of preterm labor.",
        "Diethylstilbestrol (DES) was given to pregnant women to prevent pregnancy complications and losses. It was also used for the prevention or treatment of threatened abortions.",
        "Diethylstilbestrol (DES) was used to treat complications of pregnancy such as miscarriages.",
        "Diethylstilbestrol (DES) was used to prevent miscarriage and other pregnancy complications.",
        "Diethylstilbestrol (DES) was used to prevent miscarriage and other pregnancy complications between 1938 and 1971 in the United States.",
        "Diethylstilbestrol was used to treat complications like miscarriage and preterm labor during pregnancy.",
        "Diethylstilbestrol was used to prevent miscarriage and other pregnancy complications between 1938 and 1971 in the United States.",
        "Between 1939 and the 1960s, the synthetic estrogen diethylstilbestrol (DES) was given to millions of pregnant women to prevent miscarriage, a condition known as habitual abortion and pregnancy loss. diethylstilbestrol was given to pregnant woman to treat abdominal tumors",
        "Diethylstilbestrol (DES) was widely prescribed during the late 1940s and early 1950s for complications of pregnancy.",
        "Diethylstilbestrol (DES) was historically used to prevent miscarriage in women with previous pregnancy losses. The treatment was intended to improve live-birth rates and overall pregnancy outcomes.",
        "Diethylstilbestrol (DES) was used to prevent miscarriages and other disorders in pregnancy, specifically to reduce the incidence of late pregnancy toxemia and improve perinatal mortality.",
        "Diethylstilbestrol (DES) was primarily used to treat or prevent miscarriage, with additional intended targets including preterm labor, low birth weight, and other adverse pregnancy outcomes, between 1938 and 1971. However, its use was ultimately found to be ineffective in preventing these complications and was associated with causing various harmful effects instead.",
        "Diethylstilbestrol was used to treat threatened abortion, that is, to prevent or manage spontaneous miscarriage in at-risk pregnancies.",
        "Diethylstilbestrol was used to treat or prevent complications of pregnancy including miscarriage and, by implication, preterm labor, among other unspecified pregnancy complications.",
        "The complications of pregnancy treated with diethylstilbestrol include pregnancy induced hypertension and miscarriage.",
        "Diethylstilbestrol (DES) was used to prevent pregnancy loss and treat threatened abortions. It was also used to suppress lactation. However, DES exposure has been linked to several complications, including cervical incompetence during the second trimester, which can lead to pregnancy loss.",
        "Diethylstilbestrol (DES) is a synthetic estrogen that was prescribed from 1941 onwards for the prevention of miscarriage.",
        "Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women. It was prescribed to prevent miscarriages, as it was believed to help maintain pregnancy. However, its use led to significant complications, including an increased risk of vaginal adenocarcinoma in daughters exposed during utero.",
        "Diethylstilbestrol (DES) was primarily used to prevent spontaneous abortion, commonly known as miscarriage, during pregnancy. It was administered to millions of women from the 1950s to the 1970s with the intention of reducing the risk of pregnancy loss and other complications, despite lacking proven efficacy.",
        "Diethylstilbestrol (DES) was prescribed from 1941 onwards to prevent miscarriage during pregnancy.",
        "Diethylstilbestrol was used to treat miscarriage during pregnancy.",
        "Diethylstilbestrol was used to prevent miscarriage in pregnant women, as it was commonly prescribed to avoid this complication.",
        "The complication of pregnancy treated with Diethylstilbestrol was miscarriage and other pregnancy complications.",
        "Diethylstilbestrol (DES) was used to treat miscarriage and other pregnancy complications.",
        "Diethylstilbestrol (DES), a synthetic nonsteroidal estrogen, was widely used from the 1940s to the 1970s to treat pregnancy complications, particularly to prevent miscarriage.",
        "Diethylstilbestrol (DES) was historically prescribed to pregnant women **to prevent miscarriage** and other pregnancy complications, particularly between the 1940s and 1970s. Its use was discontinued after it was linked to severe health risks in offspring, including reproductive abnormalities and cancers.",
        "Diethylstilbestrol was used to treat the complication of pregnancy, including miscarriage and other pregnancy complications.",
        "Diethylstilbestrol was prescribed to prevent miscarriage (spontaneous abortion) in pregnant women.",
        "Diethylstilbestrol (DES) was used to treat the complication of miscarriage during pregnancy.",
        "Diethylstilbestrol was used to prevent miscarriage during pregnancy",
        "[\u0027Diethylstilbestrol was used to prevent miscarriage during pregnancy.\u0027]",
        "Diethylstilbestrol (DES) was used to prevent miscarriage and other pregnancy complications. It was also used for the prevention or treatment of threatened abortions.",
        "Diethylstilbestrol (DES) was used to prevent miscarriage and other pregnancy complications between 1938 and 1971.",
        "Diethylstilbestrol (DES) was used to treat and prevent miscarriage and other pregnancy complications in pregnant women, particularly between the 1940s and 1970s.",
        "Diethylstilbestrol was used to treat miscarriage and other pregnancy complications between 1938 and 1971 in the United States.",
        "Diethylstilbestrol (DES) was primarily used to prevent miscarriage during pregnancy. It was also employed for other pregnancy-related complications between 1938 and 1971 in the United States.",
        "The synthetic nonsteroidal estrogen Diethylstilbestrol was used to treat pregnancy complications, particularly to prevent miscarriage, between 1938 and 1971 in the United States.",
        "Diethylstilbestrol was used to treat miscarriage and other pregnancy complications.",
        "Diethylstilbestrol (DES) is a synthetic estrogen that was used from the 1940s to the 1970s to prevent miscarriages and other pregnancy complications.",
        "Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women in hopes of preventing miscarriage.",
        "Diethylstilbestrol (DES) was primarily used to treat and prevent miscarriage during pregnancy, with some evidence suggesting its application may have also extended to other pregnancy complications.",
        "Diethylstilbestrol (DES) was used to prevent miscarriage.",
        "Diethylstilbestrol (DES) is a potent estrogen mimic that was predominantly used from the 1940s to the 1970s by pregnant women in hopes of preventing miscarriage . DES was prescribed from 1941 onwards for the prevention of miscarriage .",
        "Diethylstilbestrol was used in pregnant women to prevent and treat threatened abortion (miscarriage).",
        "Diethylstilbestrol was used to treat miscarriage and pregnancy complications.",
        "Diethylstilbestrol (DES) was used to treat miscarriage and other pregnancy complications, primarily between 1938 and 1971 in the United States.",
        "Diethylstilbestrol (DES) is a synthetic estrogen that was used to prevent miscarriage and other pregnancy complications between 1938 and 1971 in the United States.",
        "Diethylstilbestrol was used to treat the complication of pregnancy known as threatened miscarriage."
      ],
      "exact_answer": [
        [
          "preventing miscarriage",
          "prevention of miscarriage",
          "miscarriage prevention"
        ]
      ]
    },
    {
      "body": "Biopharmaceuticals for pediatric bronchiolitis.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38814297",
        "http://www.ncbi.nlm.nih.gov/pubmed/39079810",
        "http://www.ncbi.nlm.nih.gov/pubmed/39744803",
        "http://www.ncbi.nlm.nih.gov/pubmed/37204223",
        "http://www.ncbi.nlm.nih.gov/pubmed/15693214",
        "http://www.ncbi.nlm.nih.gov/pubmed/15295219",
        "http://www.ncbi.nlm.nih.gov/pubmed/19642467",
        "http://www.ncbi.nlm.nih.gov/pubmed/38354016",
        "http://www.ncbi.nlm.nih.gov/pubmed/10690084",
        "http://www.ncbi.nlm.nih.gov/pubmed/37743207",
        "http://www.ncbi.nlm.nih.gov/pubmed/26508190",
        "http://www.ncbi.nlm.nih.gov/pubmed/14654627",
        "http://www.ncbi.nlm.nih.gov/pubmed/21208913",
        "http://www.ncbi.nlm.nih.gov/pubmed/34937485",
        "http://www.ncbi.nlm.nih.gov/pubmed/39587878"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 371,
          "text": " Current protection against severe RSV infection is immunoprophylaxis with the monoclonal antibody palivizumab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38814297"
        },
        {
          "offsetInBeginSection": 80,
          "offsetInEndSection": 145,
          "text": "nirsevimab to protect infants against respiratory syncytial virus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39079810"
        },
        {
          "offsetInBeginSection": 862,
          "offsetInEndSection": 1081,
          "text": "Nirsevimab was observed to have noninferior efficacy and safety compared with palivizumab with less frequent administration. Nirsevimab is recommended to replace palivizumab for RSV prophylaxis in all eligible infants. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39744803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Viral bronchiolitis continues to be a major public health problem. Prevention of severe RSV-associated bronchiolitis has been achieved in high-risk infants by passive administration of the humanized monoclonal anti-RSV-F antibody, palivizumab. Develo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15693214"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 657,
          "text": "Palivizumab is a humanized monoclonal IgG1 antibody to the fusion protein of RSV that is highly active against RSV A and B strains.METHODS: A phase I/II, multicenter, randomized, double-blind, placebo-controlled, escalating dose clinical trial to describe the safety, tolerance, pharmacokinetics and clinical outcome of a single intravenous dose of palivizumab in previously healthy children hospitalized with acute RSV infection.RESULTS: Fifty-nine children \u003c or \u003d2 years of age received study drug.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15295219"
        },
        {
          "offsetInBeginSection": 1298,
          "offsetInEndSection": 1720,
          "text": "In patients in whom palivizumab is currently indicated, its substitution by nirsevimab is recommended to reduce the burden of bronchiolitis.CONCLUSIONS: Routine administration of nirsevimab to all infants aged less than 6 months born during the RSV season or aged less than 6 months at the start of the winter season is recommended to reduce the burden of disease and the frequency of hospitalization due to bronchiolitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 435,
          "text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.OBJECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease.METHODS: The approach chosen to develop these recommendations involved a critical review of the literature and the use of the Delphi and GRADE methods.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Palivizumab (Synagis) is a monoclonal antibody directed against the respiratory syncytial virus (RSV), for reducing mortality and morbidity in infants at risk of cardio-respiratory impairement due to bronchiolitis:",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19642467"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 309,
          "text": "Monoclonal antibodies (palivizumab and nirsevimab) are used to prevent bronchiolitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38354016"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 273,
          "text": "The objective of this study was to compare outcomes of dornase alfa to standard of care treatments for bronchiolitis in mechanically ventilated pediatric patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37204223"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Dornase alfa in mechanically ventilated children with bronchiolitis: A retrospective cohort study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37204223"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 956,
          "text": "In 2014, the American Academy of Pediatrics (AAP) updated their recommendations for palivizumab prophylaxis for children who are at high risk for severe respiratory syncytial virus (RSV) infection. To investigate the potential impact of the more restrictive 2014 criteria on the eligibility for palivizumab prophylaxis, we applied the 2012 and 2014 AAP recommendations for palivizumab prophylaxis to a multicenter cohort of 2207 US children hospitalized for bronchiolitis. According to the 2012 AAP recommendations, 215 children (9.7%) were eligible for palivizumab prophylaxis, while 140 children (6.3%) would have been eligible based on the 2014 updated recommendations (34.9% relative decrease; 95%CI: 28.5-41.7%). The decrease was largely driven by the restriction of eligibility to preterm infants with gestational age \u003c29 weeks. Further development of and refinement of cost-effective approaches for the prevention of severe RSV infection are needed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 393,
          "text": "Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14654627"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "BACKGROUND: Palivizumab is a US Food and Drug Administration-approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208913"
        },
        {
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1290,
          "text": "Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14654627"
        },
        {
          "offsetInBeginSection": 274,
          "offsetInEndSection": 546,
          "text": "In the IMpact-RSV study, hospitalizations resulting from RSV decreased by 55% in the palivizumab treatment group. Palivizumab has also been shown to decrease the number of days with moderate or severe RSV infection, with an increased oxygen requirement, and ICU admissions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10690084"
        },
        {
          "offsetInBeginSection": 357,
          "offsetInEndSection": 503,
          "text": " development. Nirsevimab (MEDI8897) is a monoclonal antibody with an extended half-life developed to protect infants for an entire RSV season with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34937485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "BACKGROUND: In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hosp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39587878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Eligibility for palivizumab prophylaxis in a cohort of children with severe bronchiolitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508190"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 471,
          "text": "To investigate the potential impact of the more restrictive 2014 criteria on the eligibility for palivizumab prophylaxis, we applied the 2012 and 2014 AAP recommendations for palivizumab prophylaxis to a multicenter cohort of 2207 US children hospitalized for bronchiolitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "In 2014, the American Academy of Pediatrics (AAP) updated their recommendations for palivizumab prophylaxis for children who are at high risk for severe respiratory syncytial virus (RSV) infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508190"
        },
        {
          "offsetInBeginSection": 67,
          "offsetInEndSection": 243,
          "text": "Prevention of severe RSV-associated bronchiolitis has been achieved in high-risk infants by passive administration of the humanized monoclonal anti-RSV-F antibody, palivizumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15693214"
        },
        {
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1667,
          "text": "d RSV lower respiratory tract infection. In patients in whom palivizumab is currently indicated, its substitution by nirsevimab is recommended to reduce the burden of bronchiolitis.CONCLUSIONS: Routine administration of nirsevimab to all infants aged less than 6 months born during the RSV season or aged less than 6 months at the start of the winter season is recommended to reduce the burden of disease and t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 401,
          "text": "INTRODUCTION: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.OBJECTIVES: To provide recommendations for the administration of nirsevimab for prevention of RSV disease.METHODS: The approach chosen to develop these recommendations involved a critical review of the literature and the us",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37743207"
        }
      ],
      "id": "6810cb23353a4a2e6b000012",
      "ideal_answer": [
        "Protection against severe RSV infection is achieved with the biologicals nirsevimab and palivizumab.",
        "Research on pediatric bronchiolitis has mainly focused on preventing respiratory syncytial virus (RSV) infections. The most established treatment is the use of monoclonal antibodies, particularly palivizumab, which is given monthly during the RSV season and has been shown to reduce illness severity and death in high-risk infants. However, its effectiveness has been questioned in some studies. A newer monoclonal antibody, nirsevimab, is under investigation and shows promise for offering extended protection with a single dose. Alternative strategies have included the use of immunoglobulin preparations, but these approaches have generally been less favorable when considering their risk–benefit profiles. In addition, several novel vaccine strategies are being explored, including subunit vaccines, mRNA vaccines, recombinant vector vaccines, and live attenuated vaccines, all aimed at stimulating a protective immune response against RSV. Overall, while palivizumab is currently the primary biopharmaceutical intervention for RSV-induced bronchiolitis in children, emerging treatments and vaccines may offer improved prevention and management in the future."
      ],
      "exact_answer": [
        [
          "the monoclonal antibody palivizumab",
          "nirsevimab"
        ]
      ]
    },
    {
      "body": "What is the cancer-immunity cycle?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39221688",
        "http://www.ncbi.nlm.nih.gov/pubmed/37820582",
        "http://www.ncbi.nlm.nih.gov/pubmed/29232467",
        "http://www.ncbi.nlm.nih.gov/pubmed/27843611",
        "http://www.ncbi.nlm.nih.gov/pubmed/34610889",
        "http://www.ncbi.nlm.nih.gov/pubmed/38243238",
        "http://www.ncbi.nlm.nih.gov/pubmed/23890059",
        "http://www.ncbi.nlm.nih.gov/pubmed/35510032",
        "https://www.ncbi.nlm.nih.gov/pubmed/23890059",
        "https://www.ncbi.nlm.nih.gov/pubmed/31031765",
        "https://www.ncbi.nlm.nih.gov/pubmed/34869014",
        "https://www.ncbi.nlm.nih.gov/pubmed/37820582",
        "http://www.ncbi.nlm.nih.gov/pubmed/34869014",
        "http://www.ncbi.nlm.nih.gov/pubmed/33752691",
        "http://www.ncbi.nlm.nih.gov/pubmed/32476052",
        "http://www.ncbi.nlm.nih.gov/pubmed/30366077",
        "http://www.ncbi.nlm.nih.gov/pubmed/28088513",
        "http://www.ncbi.nlm.nih.gov/pubmed/38482437",
        "http://www.ncbi.nlm.nih.gov/pubmed/35556190",
        "http://www.ncbi.nlm.nih.gov/pubmed/33396390",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831674",
        "http://www.ncbi.nlm.nih.gov/pubmed/32021257",
        "http://www.ncbi.nlm.nih.gov/pubmed/34295843",
        "http://www.ncbi.nlm.nih.gov/pubmed/35726204",
        "http://www.ncbi.nlm.nih.gov/pubmed/34619371",
        "http://www.ncbi.nlm.nih.gov/pubmed/39620588",
        "http://www.ncbi.nlm.nih.gov/pubmed/36437050",
        "http://www.ncbi.nlm.nih.gov/pubmed/32114718"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 468,
          "text": "The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37820582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 581,
          "text": "Immunological destruction of tumors is a multistep, coordinated process that can be modulated or targeted at several critical points to elicit tumor rejection. These steps in the cancer immunity cycle include: (i) generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; (ii) trafficking and infiltration into the tumor; (iii) overcoming inhibitory networks in the tumor microenvironment; (iv) direct recognition of tumor antigens and generation of an effector anti-tumor response; and (v) persistence of the anti-tumor T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29232467"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 848,
          "text": "The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth. Interruption of one or more steps of the CIC enables tumors to evade immunosurveillance. However, attempts to restore antitumor immunity by reactivating the CIC have had limited success thus far. Recently, numerous studies have implicated metabolic reprogramming of tumor and immune cells within the tumor microenvironment (TME) as key contributors to immune evasion. In this opinion, we propose that alterations in cellular metabolism during tumorigenesis promote both initiation and disruption of the CIC. We also provide a rationale for metabolically targeting the TME, which may assist in improving tumor responsiveness to chimeric antigen receptor (CAR)-transduced T cells or immune checkpoint blockade (ICB) therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34610889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1058,
          "text": "The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth. Here, we update the cancer-immunity cycle based on the remarkable progress of the past decade. Understanding the mechanism of checkpoint inhibition has evolved, as has our view of dendritic cells in sustaining anti-tumor immunity. We additionally account for the role of the tumor microenvironment in facilitating, not just suppressing, the anti-cancer response, and discuss the importance of considering a tumor\u0027s immunological phenotype, the \"immunotype\". While these new insights add some complexity to the cycle, they also provide new targets for research and therapeutic intervention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37820582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 360,
          "text": "The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37820582"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 609,
          "text": "The cancer-immunity cycle is a multistep framework that illustrates how the tumor-antigen-specific immune responses are induced and how the induced antigen-specific immune cells exert their functions in tumor tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35556190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37820582"
        },
        {
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1159,
          "text": "The cancer-immunity cycle is a conceptual framework illustrating how immune cells recognize and eliminate tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34295843"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 588,
          "text": "The cancer-immunity cycle is composed of seven major steps, namely cancer cell antigen release and presentation, priming and activation of effector immunity cells, trafficking, and infiltration of immunity to tumors, and elimination of cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33752691"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "BACKGROUND: The cancer-immunity cycle (CI cycle) provides a theoretical framework to illustrate the process of the anticancer immune response. Recently, the update of the CI cycle theory emphasizes the importance of tumor\u0027s immunological phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38243238"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 702,
          "text": "The cancer-immunity cycle is a multistep framework that illustrates how the tumor-antigen-specific immune responses are induced and how the induced antigen-specific immune cells exert their functions in tumor tissues. Irradiation affects each step of this cancer-immunity cycle, primarily in a positive manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35556190"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 542,
          "text": "Throughout a tumor\u0027s development and progression, the host organism\u0027s immune system reacts by generating anti-cancer defenses through various incremental and combinatorial mechanisms, and this reactive orchestration is termed the cancer-immunity cycle. Success or failure of the cancer-immunity cycle dictates the fate of both host and tumor as winner or loser.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34869014"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 363,
          "text": "The genetic and cellular alterations that define cancer provide the immune system with the means to generate T cell responses that recognize and eradicate cancer cells. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890059"
        },
        {
          "offsetInBeginSection": 249,
          "offsetInEndSection": 904,
          "text": "A functioning cancer-immunity cycle is needed as the precondition for a clinically meaningful response to immune checkpoint inhibitors. It is assumed that only if each step of the cycle is activated and functioning properly, immune checkpoint inhibitors induce a meaningful immune response. However, an activated cancer-immunity cycle might not be present equally in each patient and cancer type. Ideally, treatment concepts should consider each single step of the cancer-immunity cycle and provide personalized treatment approaches, allowing the adaption to functioning and malfunctioning steps of the individual patient\u0027s specific cancer-immunity cycle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35510032"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "The cancer-immunity cycle is a fundamental framework for understanding how the immune system interacts with cancer cells, balancing T cell recognition and elimination of tumors while avoiding autoimmune reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39221688"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 363,
          "text": "However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23890059"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth. Interruption of one or more steps of the CIC enables tumors to evade immunosurveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34610889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33396390"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 1056,
          "text": "An adaptive immune response against cancer has been described in seven key stages or steps defined as the cancer-immunity cycle (CIC). The CIC begins with the release of antigens by tumor cells and ends with their destruction by cytotoxic T-cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831674"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 755,
          "text": "The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32021257"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 247,
          "text": " The cancer-immunity cycle (CI cycle) provides a theoretical framework to illustrate the process of the anticancer immune response. Recently, the update of the CI cycle theory emphasizes the importance of tumor\u0027s immunological phenotype",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38243238"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34610889"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 433,
          "text": "Throughout a tumor\u0027s development and progression, the host organism\u0027s immune system reacts by generating anti-cancer defenses through various incremental and combinatorial mechanisms, and this reactive orchestration is termed the cancer-immunity cycle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34869014"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 532,
          "text": "Current anticancer immunotherapy is primarily based on T-cell-mediated cellular immunity, which highly relies on efficiency of triggering the cancer-immunity cycle, namely, tumor antigen release, antigen presentation by antigen presenting cells, T cell activation, recruitment and infiltration of T cells into tumors, and recognition and killing of tumor cells by T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35726204"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "The cancer-immunity cycle is a fundamental framework for understanding how the immune system interacts with cancer cells, balancing T cell recognition and elimination of tumors while avoiding autoimmune reactions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39221688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37820582"
        },
        {
          "offsetInBeginSection": 1041,
          "offsetInEndSection": 1158,
          "text": "The cancer-immunity cycle is a conceptual framework illustrating how immune cells recognize and eliminate tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34295843"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34610889"
        },
        {
          "offsetInBeginSection": 1272,
          "offsetInEndSection": 1481,
          "text": "Cancer-immunity cycle usually includes tumor antigen release, antigen presentation, immune activation, trafficking, infiltration, specific recognition of tumor cells by T cells, and finally cancer cell killing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34619371"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 531,
          "text": "Current anticancer immunotherapy is primarily based on T-cell-mediated cellular immunity, which highly relies on efficiency of triggering the cancer-immunity cycle, namely, tumor antigen release, antigen presentation by antigen presenting cells, T cell activation, recruitment and infiltration of T cells into tumors, and recognition and killing of tumor cells by T cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35726204"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 432,
          "text": "Throughout a tumor\u0027s development and progression, the host organism\u0027s immune system reacts by generating anti-cancer defenses through various incremental and combinatorial mechanisms, and this reactive orchestration is termed the cancer-immunity cycle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34869014"
        },
        {
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1240,
          "text": "In summary, the cancer immune cycle involves several pivotal steps that are essential for generation of a successful specific antitumour immune response. Importantly, dysfunction of a single step may interrupt the entire cycle, thus impairing the immune-mediated control of tumour growth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "The Cancer-Immunity Cycle is a series of anticancer immune responses initiated and allowed to proceed and expand iteratively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30366077"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 337,
          "text": "Most cancer immunotherapies focus on stimulating T-cell-mediated immunity by driving the cancer-immunity cycle, which includes tumor antigen release, antigen presentation, T cell activation, infiltration, and tumor cell killing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39620588"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 587,
          "text": "The cancer-immunity cycle is composed of seven major steps, namely cancer cell antigen release and presentation, priming and activation of effector immunity cells, trafficking, and infiltration of immunity to tumors, and elimination of cancer cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33752691"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 754,
          "text": "The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32021257"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 336,
          "text": "Most cancer immunotherapies focus on stimulating T-cell-mediated immunity by driving the cancer-immunity cycle, which includes tumor antigen release, antigen presentation, T cell activation, infiltration, and tumor cell killing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39620588"
        },
        {
          "offsetInBeginSection": 1272,
          "offsetInEndSection": 1482,
          "text": "Cancer-immunity cycle usually includes tumor antigen release, antigen presentation, immune activation, trafficking, infiltration, specific recognition of tumor cells by T cells, and finally cancer cell killing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34619371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The Cancer-Immunity Cycle is a series of anticancer immune responses initiated and allowed to proceed and expand iteratively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30366077"
        },
        {
          "offsetInBeginSection": 953,
          "offsetInEndSection": 1106,
          "text": "In summary, the cancer immune cycle involves several pivotal steps that are essential for generation of a successful specific antitumour immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "The cancer-immunity cycle is a fundamental framework for understanding how the immune system interacts with cancer cells, balancing T cell recognition and elimination of tumors while avoiding autoimmune reactions. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39221688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 433,
          "text": "The tumor-immune interplay represents a dynamic series of events executed by cellular and soluble participants that either promote or inhibit successful tumor formation and growth. Throughout a tumor\u0027s development and progression, the host organism\u0027s immune system reacts by generating anti-cancer defenses through various incremental and combinatorial mechanisms, and this reactive orchestration is termed the cancer-immunity cycle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34869014"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 284,
          "text": "The whole process of the immune system against cancer referred to as the \"cancer immunity cycle\", gives insight into how drugs can be designed to affect every step of the anticancer immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36437050"
        }
      ],
      "id": "680bc7a718b1e36f2e000156",
      "ideal_answer": [
        "The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response, where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth. These steps in the cancer immunity cycle include: (i) generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; (ii) trafficking and infiltration into the tumor; (iii) overcoming inhibitory networks in the tumor microenvironment; (iv) direct recognition of tumor antigens and generation of an effector anti-tumor response; and (v) persistence of the anti-tumor T cells.",
        "The cancer-immunity cycle is a framework that outlines the steps by which the immune system recognizes and eliminates cancer cells. It begins with the release of cancer cell antigens when cancer cells die. These antigens are captured by antigen-presenting cells, such as dendritic cells, which present them on their surface using major histocompatibility complex molecules. T cells, particularly cytotoxic T lymphocytes, recognize these antigens in the lymph nodes, leading to their activation and proliferation. The activated T cells then travel through the bloodstream to the tumor site and infiltrate the tumor microenvironment. They recognize and bind to cancer cells through their T cell receptors interacting with the cancer antigens on the cancer cells\u0027 surface. This recognition allows T cells to exert cytotoxic effects, destroying cancer cells and potentially releasing more antigens to continue the cycle. Understanding the cancer-immunity cycle is essential for developing immunotherapies, such as checkpoint inhibitors, which aim to enhance or restore the cycle\u0027s function to improve cancer treatment outcomes. It also provides insight into how tumors can evade immune detection.",
        "The cancer-immunity cycle is a framework that describes the series of events by which the immune system recognizes and eliminates tumor cells. It illustrates how the body\u0027s immune system reacts to a tumor\u0027s development by generating anti-cancer defenses. The cycle includes steps such as the release of cancer antigens, antigen presentation, priming and activation of immune cells, trafficking and infiltration of immune cells into tumors, recognition of cancer cells, and the killing of cancer cells. The killing of tumor cells by T cells initiates further rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Understanding this cycle provides insights into how drugs can be designed to affect the anti-cancer immune response.",
        "The cancer-immunity cycle is a framework explaining how the immune system identifies and destroys cancer cells. It starts when tumor cells release antigens due to stress or cell death. These antigens are then captured and processed by immune cells, which present them to naive T cells in the lymph nodes. Once activated, these T cells travel to the tumor site, enter the tumor\u0027s environment, and recognize cancer cells displaying the antigen. After recognition, T cells destroy the cancer cells, releasing additional antigens and reinforcing the cycle of immune activation. This ongoing process forms the basis for many immunotherapies, which are designed to enhance one or more of these steps to better stimulate the immune system against cancer.",
        "The cancer-immunity cycle is a series of steps describing how the immune system can recognize and eliminate cancer cells. It begins with the release of cancer cell antigens, which are then captured and presented by antigen-presenting cells (APCs) like dendritic cells. These APCs travel to lymph nodes, where they activate T cells that are specific for the cancer antigens. Activated T cells then traffic to the tumor microenvironment and infiltrate the tumor. Once inside the tumor, these T cells recognize and bind to cancer cells, leading to their destruction. The death of cancer cells releases more antigens, perpetuating the cycle. Effective anti-cancer immunity requires that each step of this cycle is successfully completed, and disruptions at any point can lead to immune evasion and tumor progression.",
        "The cancer-immunity cycle is a framework that outlines the iterative nature of the immune response against tumors. It emphasizes the steps involved in the immune system\u0027s destruction of tumors, including the generation of effector T cells, their trafficking and infiltration into the tumor, overcoming inhibitory networks, direct recognition of tumor antigens, and the persistence of anti-tumor T cells. This process is crucial for maintaining active immunity and adapting it to tumor evolution, as any step can become rate-limiting, potentially rendering the immune system unable to control tumor growth.",
        "The cancer-immunity cycle is a series of coordinated steps that describe how the immune system recognizes and targets cancer cells. It begins with the release of cancer cell antigens, which are then processed and presented by dendritic cells to T cells, leading to T cell activation and expansion. Activated T cells subsequently recognize and kill cancer cells, releasing more antigens to sustain the cycle. This iterative process allows the immune system to adapt to tumor evolution and maintain anti-tumor immunity. However, any step in this cycle can be disrupted, leading to immune evasion and tumor progression. Understanding these steps is crucial for developing immunotherapies that enhance immune recognition and targeting of cancer cells while minimizing adverse effects.",
        "The cancer-immunity cycle is a model that outlines the multi-step, coordinated process involved in the immune system\u0027s destruction of tumors. It highlights the cyclic nature of the response, where the killing of tumor cells by T-cells triggers subsequent rounds of antigen presentation and T-cell stimulation, maintaining active immunity and adapting to tumor evolution. The cycle includes several key steps: generating sufficient numbers of effector T-cells, their trafficking and infiltration into the tumor, overcoming inhibitory networks in the tumor microenvironment, direct recognition of tumor antigens, and the persistence of the anti-tumor T-cells. Any step in the cycle can become a limiting factor, preventing the immune system from controlling tumor growth.",
        "The cancer-immunity cycle is a framework that outlines the series of events leading to anti-cancer immune responses. It emphasizes the iterative nature of these responses, where the killing of tumor cells by T cells triggers further rounds of antigen presentation and T cell stimulation, thereby sustaining active immunity and adapting to tumor evolution. The cycle consists of several critical steps: generating effector T cells that recognize tumor antigens, trafficking to and infiltrating the tumor, overcoming inhibitory networks in the tumor microenvironment, directly recognizing tumor antigens, and ensuring the persistence of anti-tumor T cells. Any disruption in these steps can limit the immune system\u0027s ability to control tumor growth. Understanding this cycle is essential for developing effective immunotherapies against cancer.",
        "The cancer-immunity cycle is a framework describing the iterative, multi-step process by which the immune system recognizes and destroys cancer cells. Key steps include: (1) T cell activation via tumor antigen presentation, (2) T cell infiltration into tumors, (3) overcoming immunosuppressive tumor microenvironments, (4) direct tumor antigen recognition and cytotoxic response, and (5) persistence of anti-tumor T cells. Each step must function effectively to sustain adaptive immunity, with failure at any stage enabling tumor immune escape. The cycle emphasizes the dynamic interplay between immune activation and tumor evolution.",
        "The cancer-immunity cycle is a framework that describes the series of events by which the immune system recognizes and eliminates tumor cells. It is a multistep process composed of seven key steps: release of cancer antigens, antigen presentation, priming and activation of immune cells, trafficking and infiltration of immune cells into tumors, recognition of cancer cells by T cells, and the subsequent killing of cancer cells. The cycle emphasizes the iterative nature of the anti-cancer immune response, and disruption in the cycle can limit the immune system\u0027s ability to control tumor growth. It also provides insights into how drugs can be designed to affect every step of the anticancer immune response.",
        "The cancer-immunity cycle is a framework describing the sequential, iterative processes by which the immune system generates and sustains anti-cancer responses. It involves key steps: (1) activation of high-avidity effector T cells recognizing tumor antigens, (2) T cell trafficking and infiltration into tumors, (3) overcoming immunosuppressive tumor microenvironments, (4) direct tumor antigen recognition and effector response, and (5) persistence of anti-tumor T cells. This cycle is dynamic, with T cell-mediated tumor cell killing triggering renewed antigen presentation and T cell stimulation, adapting immunity to tumor evolution. However, disruptions at any stage—such as inadequate T cell activation, impaired infiltration, or immune evasion—can hinder tumor control. Targeting these critical points offers therapeutic strategies to enhance anti-cancer immunity, emphasizing the cycle\u0027s role in shaping effective immunotherapies. (199 words)",
        "The cancer-immunity cycle is a framework that describes the series of events required for the generation of effective anti-cancer immune responses. It is an iterative process where the killing of tumor cells by T cells leads to further antigen presentation and T cell stimulation. This cycle maintains active immunity and allows it to adapt to tumor evolution. Key steps include the generation of sufficient effector T cells with high avidity for tumor antigens, trafficking and infiltration of these T cells into the tumor, overcoming inhibitory networks within the tumor microenvironment, direct recognition of tumor antigens leading to an anti-tumor response, and the persistence of anti-tumor T cells. The cycle can be limited by any of these steps, preventing the immune system from controlling tumor growth.",
        "The cancer-immunity cycle is a framework that explains the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response, where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth. The immunological destruction of tumors is a multistep, coordinated process that can be modulated or targeted at several critical points to elicit tumor rejection. These steps in the cancer immunity cycle include: (i) generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; (ii) trafficking and infiltration into the tumor; (iii) overcoming inhibitory networks in the tumor microenvironment; (iv) direct recognition of tumor antigens and generation of an effector anti-tumor response; and (v) persistence of the anti-tumor T cells.",
        "The cancer-immunity cycle is a framework that outlines the series of events leading to anti-cancer immune responses. It emphasizes the iterative nature of these responses, where the killing of tumor cells by T cells triggers further rounds of antigen presentation and T cell stimulation, thereby maintaining active immunity and adapting to tumor evolution. The cycle consists of several critical steps: (i) generation of effector T cells with high avidity for tumor antigens, (ii) trafficking and infiltration into tumors, (iii) overcoming inhibitory networks in the tumor microenvironment, (iv) direct recognition of tumor antigens, and (v) persistence of anti-tumor T cells. Any step in this cycle can become rate-limiting, potentially hindering the immune system\u0027s ability to control tumor growth. Understanding this cycle is crucial for developing effective immunotherapies against cancer.",
        "The cancer-immunity cycle is a framework that illustrates the series of events necessary for generating effective anti-cancer immune responses. It is an iterative process where the killing of tumor cells by T cells leads to further antigen presentation and subsequent T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Key steps in this cycle include: the generation of a sufficient number of effector T cells with high avidity recognition of tumor antigens in vivo; trafficking and infiltration of these T cells into the tumor; overcoming inhibitory networks within the tumor microenvironment; direct recognition of tumor antigens, leading to an effector anti-tumor response; and the persistence of anti-tumor T cells. Any of these steps can become rate-limiting, preventing the immune system from effectively controlling tumor growth.",
        "The cancer-immunity cycle is a framework that outlines the series of events leading to anti-cancer immune responses. It emphasizes the iterative process where the killing of tumor cells by T cells triggers further rounds of antigen presentation and T cell stimulation, thereby sustaining active immunity and adapting to tumor evolution. The cycle consists of several critical steps: generating effector T cells with high avidity for tumor antigens, trafficking to and infiltrating the tumor, overcoming inhibitory networks in the tumor microenvironment, recognizing tumor antigens, and ensuring the persistence of anti-tumor T cells. Any disruption in these steps can limit the immune system\u0027s ability to control tumor growth. The cycle highlights the complex interplay between tumor cells and the immune system, including the dual roles of immunity in both protecting against and promoting tumor progression.",
        "The cancer-immunity cycle is a fundamental framework for understanding how the immune system interacts with cancer cells, balancing T cell recognition and elimination of tumors while avoiding autoimmune reactions. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. The cancer-immunity cycle includes: (i) generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; (ii) trafficking and infiltration into the tumor; (iii) overcoming inhibitory networks in the tumor microenvironment; (iv) direct recognition of tumor antigens and generation of an effector anti-tumor response; and (v) persistence of the anti-tumor T cells.",
        "The cancer-immunity cycle is a conceptual framework describing the sequential interactions between the immune system and tumors to generate anti-cancer immunity. It consists of seven key steps: (1) release of tumor antigens from dying cancer cells, (2) uptake and processing by dendritic cells, (3) activation of effector T cells in lymph nodes, (4) trafficking of activated T cells to the tumor site, (5) infiltration into the tumor microenvironment, (6) recognition and killing of tumor cells through antigen-specific responses, and (7) persistence or memory formation for sustained anti-tumor activity. This cycle emphasizes how immune evasion by tumors can occur if any step is disrupted, such as impaired antigen presentation, T cell exhaustion, or immunosuppressive signals in the tumor microenvironment. Studies highlight its role in guiding immunotherapy strategies to enhance each phase, particularly overcoming inhibitory networks and improving T cell infiltration and function, to reactivate effective anti-cancer immune responses.",
        "The cancer-immunity cycle is a framework that outlines the series of events leading to anti-cancer immune responses. It consists of several critical steps: (i) generating sufficient numbers of effector T cells that recognize tumor antigens; (ii) trafficking and infiltrating these T cells into the tumor; (iii) overcoming inhibitory networks within the tumor microenvironment; (iv) directly recognizing tumor antigens to elicit an effector anti-tumor response; and (v) ensuring the persistence of anti-tumor T cells. This cycle is iterative, where the killing of tumor cells by T cells promotes further antigen presentation and T cell stimulation, adapting the immune response to tumor evolution. However, any step in this cycle can become rate-limiting, potentially allowing tumors to evade immune control. The cycle is influenced by a complex interplay of tumor, host, and environmental factors, which can modulate the strength and timing of the immune response.",
        "The cancer-immunity cycle is a self-sustaining, multi-step process where T cells iteratively recognize and respond to tumor cells. Key steps include T cell generation, tumor infiltration, overcoming immune suppression, direct tumor antigen recognition, tumor cell killing, and persistence of anti-tumor T cells. This cycle is crucial for maintaining active immunity against tumors and adapting to their evolution. However, any step can become rate-limiting, leading to uncontrolled tumor growth, highlighting the importance of understanding this cycle for developing effective anti-tumor strategies.",
        "[\"The cancer-immunity cycle is a framework that describes the series of events generating anti-cancer immune responses. It highlights the iterative nature of these responses, where T cells kill tumor cells, triggering further rounds of antigen presentation and T cell stimulation. This cycle helps maintain active immunity and adapts to changes in the tumor. The cycle includes several steps: generating effector T cells that recognize tumor antigens, their trafficking and infiltration into the tumor, overcoming inhibitory networks within the tumor microenvironment, direct recognition of tumor antigens to generate an effector response, and the persistence of anti-tumor T cells. Each step can become a bottleneck, potentially limiting the immune system\u0027s ability to control tumor growth.\"]",
        "The cancer-immunity cycle refers to the iterative process by which the immune system generates anti-cancer responses. It involves a series of events where T cells kill tumor cells, leading to antigen presentation and subsequent T cell stimulation, maintaining active immunity and adapting to tumor evolution. The cycle consists of multiple steps, including: 1) generation of effector T cells with high avidity recognition of tumor antigens; 2) trafficking and infiltration into the tumor; 3) overcoming inhibitory networks in the tumor microenvironment; 4) direct recognition of tumor antigens and generation of an effector anti-tumor response; and 5) persistence of anti-tumor T cells. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth.",
        "The cancer-immunity cycle is a framework used to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response, where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. The steps in this cycle include: generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; trafficking and infiltration into the tumor; overcoming inhibitory networks in the tumor microenvironment; direct recognition of tumor antigens and generation of an effector anti-tumor response; and persistence of the anti-tumor T cells. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth.",
        "The cancer-immunity cycle is a framework that elucidates the series of events responsible for generating anti-cancer immune responses. It highlights the iterative nature of this response, where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation. This process maintains active immunity and allows it to adapt to tumor evolution. Any step within the cycle can become rate-limiting, thereby impairing the immune system\u0027s ability to control tumor growth. The steps include: (i) generation of sufficient numbers of effector T cells with high avidity recognition of tumor antigens in vivo; (ii) trafficking and infiltration into the tumor; (iii) overcoming inhibitory networks in the tumor microenvironment; (iv) direct recognition of tumor antigens and generation of an effector anti-tumor response; and (v) persistence of the anti-tumor T cells.",
        "The cancer-immunity cycle is a series of events that generate anti-cancer immune responses. It is a multistep, coordinated process where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. The steps in the cycle include generation of effector T cells with high avidity recognition of tumor antigens, trafficking and infiltration into the tumor, overcoming inhibitory networks in the tumor microenvironment, direct recognition of tumor antigens and generation of an effector anti-tumor response, and persistence of the anti-tumor T cells. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth.",
        "[\"The cancer-immunity cycle is a framework that describes the sequence of events involved in generating anti-cancer immune responses. It highlights the iterative nature of these responses, where T cells kill tumor cells, triggering further rounds of antigen presentation and T cell stimulation. This process helps maintain active immunity and adapt to changes in the tumor. The cycle includes several steps: generating effector T cells that recognize tumor antigens with high avidity, T cell trafficking and infiltration into the tumor, overcoming inhibitory networks within the tumor microenvironment, direct recognition of tumor antigens by T cells, and the persistence of these anti-tumor T cells. Each step is crucial, and any can become a bottleneck, potentially limiting the immune system\u0027s ability to control tumor growth.\"]"
      ]
    },
    {
      "body": "What is the mechanism of action of Iptacopan?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39374533",
        "http://www.ncbi.nlm.nih.gov/pubmed/39774762",
        "http://www.ncbi.nlm.nih.gov/pubmed/38182298",
        "http://www.ncbi.nlm.nih.gov/pubmed/38312795",
        "http://www.ncbi.nlm.nih.gov/pubmed/38741947",
        "http://www.ncbi.nlm.nih.gov/pubmed/37308298",
        "http://www.ncbi.nlm.nih.gov/pubmed/38517653",
        "http://www.ncbi.nlm.nih.gov/pubmed/38792150",
        "http://www.ncbi.nlm.nih.gov/pubmed/36217526",
        "https://www.ncbi.nlm.nih.gov/pubmed/33765419",
        "https://www.ncbi.nlm.nih.gov/pubmed/38517653",
        "https://www.ncbi.nlm.nih.gov/pubmed/38811284",
        "http://www.ncbi.nlm.nih.gov/pubmed/39273426",
        "http://www.ncbi.nlm.nih.gov/pubmed/37914086",
        "http://www.ncbi.nlm.nih.gov/pubmed/38811284",
        "http://www.ncbi.nlm.nih.gov/pubmed/37180505",
        "http://www.ncbi.nlm.nih.gov/pubmed/33765419",
        "http://www.ncbi.nlm.nih.gov/pubmed/39404123",
        "http://www.ncbi.nlm.nih.gov/pubmed/35561315",
        "http://www.ncbi.nlm.nih.gov/pubmed/39453772",
        "http://www.ncbi.nlm.nih.gov/pubmed/39118827",
        "http://www.ncbi.nlm.nih.gov/pubmed/36698833",
        "http://www.ncbi.nlm.nih.gov/pubmed/39579287",
        "http://www.ncbi.nlm.nih.gov/pubmed/38622956"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "ABSTRACT: Iptacopan, a novel oral factor B inhibitor, recently obtained US Food and Drug Administration approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-mediated hemolytic anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39374533"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 282,
          "text": "Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH [NCT04558918]) and C5i-naive (APPOINT-PNH [NCT04820530]) patients with paroxysmal nocturnal hemoglobinuria (PNH).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39774762"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 296,
          "text": "A recent randomized controlled trial tested the efficacy and safety of iptacopan, a factor B inhibitor, in patients with IgAN. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38182298"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 559,
          "text": "Iptacopan is an oral, highly potent proximal complement inhibitor that specifically binds to factor B and inhibits the alternative pathway (AP)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38312795"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38741947"
        },
        {
          "offsetInBeginSection": 433,
          "offsetInEndSection": 702,
          "text": "Fortunately, new molecules are being developed that specifically target the proximal alternative complement pathway, such as iptacopan, a factor B inhibitor that showed promising results in native kidneys and cases of transplant recurrence in a phase 2 clinical trial. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38741947"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Iptacopan (LNP023) is an oral, small-molecule, first-in-class, highly potent proximal complement inhibitor that specifically binds factor B and inhibi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37308298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 588,
          "text": "Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream of complement 5 in the alternative pathway, iptacopan inhibits both terminal complement-mediated intravascular haemolysis and complement 3-mediated extravascular haemolysis. On 5 December 2023, iptacopan received approval in the USA for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH). This article summarizes the milestones in the development of iptacopan leading to this first approval for PNH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38517653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33765419"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1661,
          "text": "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal, complement-mediated hemolytic anemia with a variety of manifestations. Currently, the methods for treating PNH include anti-C5 treatments (eculizumab and ravulizumab) and pegcetacoplan (a targeted C3 inhibitor). On December 5, 2023, the US FDA approved a factor B inhibitor called Fabhalta® (iptacopan), previously known as LNP023, for the treatment of adult patients with PNH, including those who have previously received anti-C5 therapy. The main objective of this review was to elucidate the clinical efficacy and safety of the newly approved factor B inhibitor, iptacopan. Iptacopan plays a proximal role in the alternative complement pathway to control extravascular hemolysis mediated by C3b and intravascular hemolysis mediated by terminal complement. The recommended dosage is 200 mg orally twice daily. The 24-week results of the pivotal phase III open-label trial, APPLY-PNH, demonstrated that among PNH patients who had previously received anti-C5 therapy, 51/60 (estimated percentages 82%) of patients in the iptacopan group showed an increase in hemoglobin of ≥2 g/dL compared to 0/35 (estimated percentages 2%) in the standard treatment group, also, 69% of iptacopan-treated patients achieved hemoglobin levels ≥12 g/dL, while no patients in the standard treatment group reached this level (both p \u003c 0.001). The 48-week results were similar to those observed at 24 weeks. The most common adverse events were headache, infection and diarrhea. There were almost no clinical breakthrough hemolysis. Trials evaluating the long-term safety and efficacy of iptacopan are currently recruiting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38811284"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38811284"
        },
        {
          "offsetInBeginSection": 624,
          "offsetInEndSection": 1027,
          "text": "f-the-art PNH treatments act by inhibiting the dysregulated complement at distinct points in the activation pathway: late at the C5 level (C5 inhibitors, eculizumab, ravulizumab, and crovalimab), centrally at the C3 level (C3/C3b inhibitors and pegcetacoplan), and early at the initiation and amplification of the alternative pathway (factor B inhibitor, iptacopan; factor D inhibitor, danicopan). Throu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39273426"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 560,
          "text": "Iptacopan is an oral, highly potent proximal complement inhibitor that specifically binds to factor B and inhibits the alternative pathway (AP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38312795"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Iptacopan (LNP023) is an oral, small-molecule, first-in-class, highly potent proximal complement inhibitor that specifically binds factor B and inhibits the alternative complement pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37308298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35561315"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 681,
          "text": "ain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascular hemolysis.AREAS COVERED: In patients previously treated with anti-C5 therapies or naive to complement inhibitors, iptacopan 200 mg twice daily resulted in clinically meaningful results in the pivotal phase 3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404123"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "ABSTRACT: Iptacopan, a novel oral factor B inhibitor, recently obtained US Food and Drug Administration approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-mediated hemoly",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39374533"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 266,
          "text": "Iptacopan (LNP023) is an oral, proximal alternative complement inhibitor that specifically binds to Factor B",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37914086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38517653"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 267,
          "text": "Iptacopan (LNP023) is an oral, proximal alternative complement inhibitor that specifically binds to Factor B.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37914086"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 758,
          "text": "Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN, thereby supporting the rationale for its evaluation in a Phase 3 study.Methods: APPLAUSE-IgAN (NCT04578834) is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study enrolling approximately 450 adult patients (aged ≥18 years) with biopsy-confirmed primary IgAN at high risk of progression to kidney failure despite optimal supportive treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37180505"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 488,
          "text": "Iptacopan specifically binds to factor B and inhibits the alternative pathway.METHODS: In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled adults with biopsy-confirmed IgA nephropathy and proteinuria (defined as a 24-hour urinary protein-to-creatinine ratio of ≥1 [with protein and creatinine both measured in grams]) despite optimized supportive therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39453772"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 953,
          "text": "Iptacopan is an oral, highly potent proximal complement inhibitor that specifically binds to factor B and inhibits the alternative pathway (AP).Methods: This randomized, double-blind, placebo-controlled phase 3 study (APPARENT; NCT05755386) will evaluate the efficacy and safety of iptacopan in patients with idiopathic (primary) IC-MPGN, enrolling up to 68 patients (minimum of 10 adolescents) aged 12 to 60 years with biopsy-confirmed IC-MPGN, proteinuria ≥1 g/g, and estimated glomerular filtration rate (eGFR) ≥30 ml/min per 1.73 m2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38312795"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 341,
          "text": "Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream of complement 5 in the alternative pathway, iptacopan inhibits both terminal complement-mediated intravascular haemolysis and complement 3-mediated extravascular haemolysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38517653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 458,
          "text": "Iptacopan, the first orally available small-molecule complement factor B inhibitor, was developed by Novartis AG of Switzerland. Iptacopan for the treatment of PNH was just approved by the FDA in December 2023. Other indications for treatment are still in phase III clinical trials. Iptacopan is a small-molecule inhibitor targeting complement factor B, showing positive therapeutic effects in the treatment of PNH, C3 glomerulonephritis, and other diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38792150"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 376,
          "text": " Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37180505"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 170,
          "text": "ephropathy. Iptacopan specifically binds to factor B and inhibits the alternat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39453772"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 406,
          "text": "ents for C3G. Iptacopan is an oral, first-in-class, potent, and selective inhibitor of factor B, a key compon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36217526"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 470,
          "text": "ain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404123"
        },
        {
          "offsetInBeginSection": 461,
          "offsetInEndSection": 561,
          "text": "ysregulation. Iptacopan is an oral inhibitor of the complement factor B that effectively blocks the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39118827"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Iptacopan (LNP023) is an oral, small-molecule, first-in-class, highly potent proximal complement inhibitor that specifically binds factor B and inhibits the alternative complement pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37308298"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 469,
          "text": "ain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravasc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404123"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 169,
          "text": "ephropathy. Iptacopan specifically binds to factor B and inhibits the alterna",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39453772"
        },
        {
          "offsetInBeginSection": 402,
          "offsetInEndSection": 544,
          "text": "d treatments. Iptacopan is an oral, highly potent proximal complement inhibitor that specifically binds to factor B and inhibits the alternati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38312795"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 405,
          "text": "ents for C3G. Iptacopan is an oral, first-in-class, potent, and selective inhibitor of factor B, a key compo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36217526"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 271,
          "text": "hophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37180505"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 457,
          "text": "Iptacopan is a small-molecule inhibitor targeting complement factor B, showing positive therapeutic effects in the treatment of PNH, C3 glomerulonephritis, and other diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38792150"
        },
        {
          "offsetInBeginSection": 461,
          "offsetInEndSection": 560,
          "text": "ysregulation. Iptacopan is an oral inhibitor of the complement factor B that effectively blocks the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39118827"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 434,
          "text": "hophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN, thereby supporting the rationale for its evaluation in a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37180505"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream of complement 5 in the alternative pathway, iptacopan inhibits both terminal compl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38517653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Iptacopan, the first orally available small-molecule complement factor B inhibitor, was developed by Novartis AG of Switzerland. Iptacopan for the treatment of PNH was just approved by the FDA in December 2023. Other indications for treatment are sti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38792150"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 484,
          "text": "We have investigated effect of iptacopan, a factor B inhibitor, and desidustat, a prolyl hydroxylase inhibitor in anaemia induced by peptidoglycan polysaccharide (PGPS) treatment in rats.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39579287"
        },
        {
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1242,
          "text": "Upstream inhibition of complement cascade was also explored with the anti-C3 pegcetacoplan, and with the alternative pathway inhibitors iptacopan (anti-factor B) and danicopan (anti-factor D). These drugs efficiently target EVH and are able to improve anemia and transfusion need in suboptimal responders to anti-C5.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622956"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 419,
          "text": "Iptacopan is an oral, first-in-class, potent, and selective inhibitor of factor B, a key component of the AP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36217526"
        },
        {
          "offsetInBeginSection": 501,
          "offsetInEndSection": 636,
          "text": "The main objective of this review was to elucidate the clinical efficacy and safety of the newly approved factor B inhibitor, iptacopan",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38811284"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38517653"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 458,
          "text": "Iptacopan is a small-molecule inhibitor targeting complement factor B, showing positive therapeutic effects in the treatment of PNH, C3 glomerulonephritis, and other diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38792150"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35561315"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 181,
          "text": " Iptacopan specifically binds to factor B and inhibits the alternative pathway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39453772"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 483,
          "text": " Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascular hemolysis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404123"
        },
        {
          "offsetInBeginSection": 2173,
          "offsetInEndSection": 2281,
          "text": "l elimination mechanisms. Binding of iptacopan to its target, factor B, in the bloodstream led to a concentr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37308298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35561315"
        },
        {
          "offsetInBeginSection": 926,
          "offsetInEndSection": 1116,
          "text": "Upstream inhibition of complement cascade was also explored with the anti-C3 pegcetacoplan, and with the alternative pathway inhibitors iptacopan (anti-factor B) and danicopan (anti-factor D",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622956"
        },
        {
          "offsetInBeginSection": 1203,
          "offsetInEndSection": 1433,
          "text": "PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36698833"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33765419"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 505,
          "text": " Therefore, the aim of this phase 2 study was to assess the safety, tolerability, pharmacokinetics and pharmacodynamics, and activity of the new complement factor B inhibitor, iptacopan, in patients with paroxysmal nocturnal haemoglobinuria who have active haemolysis despite ant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33765419"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 505,
          "text": "activity of the new complement factor B inhibitor, iptacopan, in patients with paroxysmal nocturnal haemoglobinuria who have active haemolysis despite ant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33765419"
        }
      ],
      "type": "summary",
      "id": "67e56f2018b1e36f2e0000b0",
      "ideal_answer": [
        "Iptacopan is an oral, highly potent proximal complement inhibitor that specifically binds to factor B and inhibits the alternative pathway."
      ]
    },
    {
      "body": "What is the previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Diasease  (MASLD)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39352015",
        "http://www.ncbi.nlm.nih.gov/pubmed/38653634",
        "http://www.ncbi.nlm.nih.gov/pubmed/38141808",
        "http://www.ncbi.nlm.nih.gov/pubmed/37634892",
        "http://www.ncbi.nlm.nih.gov/pubmed/38429162",
        "http://www.ncbi.nlm.nih.gov/pubmed/39535566",
        "http://www.ncbi.nlm.nih.gov/pubmed/38445559",
        "http://www.ncbi.nlm.nih.gov/pubmed/39260740",
        "http://www.ncbi.nlm.nih.gov/pubmed/39214253",
        "http://www.ncbi.nlm.nih.gov/pubmed/38852583",
        "http://www.ncbi.nlm.nih.gov/pubmed/39064665",
        "http://www.ncbi.nlm.nih.gov/pubmed/39488409",
        "http://www.ncbi.nlm.nih.gov/pubmed/39075772",
        "http://www.ncbi.nlm.nih.gov/pubmed/38891759",
        "http://www.ncbi.nlm.nih.gov/pubmed/39540675",
        "http://www.ncbi.nlm.nih.gov/pubmed/39157862",
        "http://www.ncbi.nlm.nih.gov/pubmed/39040926",
        "http://www.ncbi.nlm.nih.gov/pubmed/38892467",
        "http://www.ncbi.nlm.nih.gov/pubmed/36463192",
        "http://www.ncbi.nlm.nih.gov/pubmed/36406312",
        "http://www.ncbi.nlm.nih.gov/pubmed/38526946",
        "http://www.ncbi.nlm.nih.gov/pubmed/38730426",
        "http://www.ncbi.nlm.nih.gov/pubmed/39513734",
        "http://www.ncbi.nlm.nih.gov/pubmed/38358924",
        "http://www.ncbi.nlm.nih.gov/pubmed/38944876",
        "http://www.ncbi.nlm.nih.gov/pubmed/37364790",
        "http://www.ncbi.nlm.nih.gov/pubmed/38286339",
        "http://www.ncbi.nlm.nih.gov/pubmed/38158589",
        "http://www.ncbi.nlm.nih.gov/pubmed/39146583",
        "http://www.ncbi.nlm.nih.gov/pubmed/38397999",
        "http://www.ncbi.nlm.nih.gov/pubmed/38722246",
        "http://www.ncbi.nlm.nih.gov/pubmed/38519764",
        "http://www.ncbi.nlm.nih.gov/pubmed/39268479",
        "http://www.ncbi.nlm.nih.gov/pubmed/38254750",
        "http://www.ncbi.nlm.nih.gov/pubmed/38973318",
        "http://www.ncbi.nlm.nih.gov/pubmed/38867022",
        "http://www.ncbi.nlm.nih.gov/pubmed/38070828",
        "http://www.ncbi.nlm.nih.gov/pubmed/38008609",
        "http://www.ncbi.nlm.nih.gov/pubmed/39048719",
        "http://www.ncbi.nlm.nih.gov/pubmed/38880124",
        "http://www.ncbi.nlm.nih.gov/pubmed/39182603",
        "http://www.ncbi.nlm.nih.gov/pubmed/37934943",
        "http://www.ncbi.nlm.nih.gov/pubmed/38305642",
        "http://www.ncbi.nlm.nih.gov/pubmed/38272067",
        "http://www.ncbi.nlm.nih.gov/pubmed/38643212",
        "http://www.ncbi.nlm.nih.gov/pubmed/38149861",
        "http://www.ncbi.nlm.nih.gov/pubmed/38915345",
        "http://www.ncbi.nlm.nih.gov/pubmed/37580263",
        "http://www.ncbi.nlm.nih.gov/pubmed/38764762",
        "http://www.ncbi.nlm.nih.gov/pubmed/37723058",
        "http://www.ncbi.nlm.nih.gov/pubmed/38764767",
        "http://www.ncbi.nlm.nih.gov/pubmed/39412049",
        "http://www.ncbi.nlm.nih.gov/pubmed/38142587",
        "http://www.ncbi.nlm.nih.gov/pubmed/38674389",
        "http://www.ncbi.nlm.nih.gov/pubmed/39243773",
        "http://www.ncbi.nlm.nih.gov/pubmed/38479177",
        "http://www.ncbi.nlm.nih.gov/pubmed/39004396",
        "http://www.ncbi.nlm.nih.gov/pubmed/39606621",
        "http://www.ncbi.nlm.nih.gov/pubmed/39649758",
        "http://www.ncbi.nlm.nih.gov/pubmed/39512967",
        "http://www.ncbi.nlm.nih.gov/pubmed/37940495",
        "http://www.ncbi.nlm.nih.gov/pubmed/39006144",
        "http://www.ncbi.nlm.nih.gov/pubmed/38132126",
        "http://www.ncbi.nlm.nih.gov/pubmed/38049180",
        "http://www.ncbi.nlm.nih.gov/pubmed/38275476",
        "http://www.ncbi.nlm.nih.gov/pubmed/39194748",
        "http://www.ncbi.nlm.nih.gov/pubmed/39498281",
        "http://www.ncbi.nlm.nih.gov/pubmed/39560808",
        "http://www.ncbi.nlm.nih.gov/pubmed/39342178",
        "http://www.ncbi.nlm.nih.gov/pubmed/37893134",
        "http://www.ncbi.nlm.nih.gov/pubmed/38405608"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 378,
          "text": "Current studies emphasize the urgent need for a paradigm shift in conceptualizing nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction-associated steatotic liver disease (MASLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39352015"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 373,
          "text": "In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term non-alcoholic fatty liver disease (NAFLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141808"
        },
        {
          "offsetInBeginSection": 655,
          "offsetInEndSection": 757,
          "text": "The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141808"
        },
        {
          "offsetInBeginSection": 557,
          "offsetInEndSection": 784,
          "text": "In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen, and an umbrella term, steatotic liver disease (SLD), encompassing the whole spectrum of liver disease, has been proposed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37634892"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 531,
          "text": "BACKGROUND: Although metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with obesity, around 20% of individuals with hepatic steatosis may nonetheless have normal body mass index, a condition often referred to as lean nonalcoholic fatty liver disease (NAFLD). Under the new nomenclature and definition of MASLD, lean NAFLD can be further divided into lean MASLD (when there is one or more cardiometabolic risk factors) and cryptogenic steatotic liver disease (when there is no cardiometabolic r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "The recent renaming of \u0027non-alcoholic fatty liver disease\u0027 (NAFLD) to \u0027metabolic dysfunction-associated steatotic liver disease\u0027 (MASLD) emphasizes metabolic dysfunction in steatotic liver disease and advocates for tailored, comprehensive treatment strategies, driving forward the development of personalized ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38429162"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 319,
          "text": "IMPORTANCE: The recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the link between hepatic steatosis and metabolic dysfunction, taking out the stigmat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39157862"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as a new name for the previous non-alcoholic fatty liver disease (NAFLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39260740"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 255,
          "text": "Recently, the multisociety Delphi consensus renamed non-alcoholic fatty liver disease (NAFLD) terminology [previously renamed metabolic-associated fatty liver disease (MAFLD)] as metabolic dysfunction-associated steatotic liver disease (MASLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39040926"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 297,
          "text": "Also, the name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38892467"
        },
        {
          "offsetInBeginSection": 655,
          "offsetInEndSection": 756,
          "text": "The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 289,
          "text": "The newly proposed term \"metabolic dysfunction-associated fatty liver disease\" (MAFLD) is replacing the old term \"non-alcoholic fatty liver disease\" (NAFLD) in many global regions, because it better reflects the pathophysiology and cardiometabolic implications of this common liver disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36463192"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and is proposed to replace the previous name, nonalcoholic fatty liver disease (NAFLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36406312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is the most prevalent chronic liver disease worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38407327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 408,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by hepatic steatosis that is confirmed by imaging or histology in the setting of at least 1 metabolic risk factor in the absence of significant alcohol consumption. Nonalcoholic steatohepatitis, or NASH, was recently renamed metabolic dysfunction-associated steatohepatitis (MASH); it represents the progressive form of MASLD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39513734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as a new name for the previous non-alcoholic fatty liver disease (NAFLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39260740"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 586,
          "text": "BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD.AIMS: To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF).METHODS: PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration-controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38158589"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the proposed name change for non-alcoholic fatty liver disease (NAFLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38730426"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 342,
          "text": "Steatotic liver disease encompasses what was previously termed non-alcoholic fatty liver disease (NAFLD), which is now called metabolic dysfunction-associated steatotic liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39488409"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "text": "NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) are time-honored acronyms, with widely popular acceptance. Experts now recommend discarding them in favor of MASLD for \"metabolic dysfunction-associated steatotic liver disease\" ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358924"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 500,
          "text": "The new terminologies explained in this commentary make it easier for the readers to interchangeably use metabolic dysfunction-associated steatotic liver disease (MASLD) in place of NAFLD ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38445559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38852583"
        },
        {
          "offsetInBeginSection": 423,
          "offsetInEndSection": 623,
          "text": "A consensus by renowned clinical scholars primarily residing in the Asian-Pacific region introduced metabolic dysfunction-associated fatty liver disease (MAFLD) as a new name to replace NAFLD in 2020.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38653634"
        },
        {
          "offsetInBeginSection": 557,
          "offsetInEndSection": 662,
          "text": "In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37634892"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 506,
          "text": "It was 2020 when a change of one letter \"NAFLD\" to metabolic dysfunction-associated fatty liver disease \"MAFLD\" linked with the change in the definition and diagnostic criteria began a new controversy around the globe.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39075772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, is a steatotic liver disease associated with metabolic syndrome (MetS), especially obesity, hypertension, diabetes, hyperlipidemia, and hypertriglyceridemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38891759"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a seriously increasing liver disorder affecting nearly 32% of adults globally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39146583"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 276,
          "text": "A recent consensus on renaming liver disease was established, and metabolic dysfunction-associated steatotic liver disease, MASLD, was chosen as the replacement for NAFLD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38397999"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasingly recognized as a prevalent global burden.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38722246"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is the main cause of chronic liver disease in children and adolescents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38519764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Background: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is increasi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39268479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Western world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38254750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "BACKGROUND: Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), and its sequelae of more severe forms such as metabolic dysfunction-associated steatohepatitis (MASH) is rapidly increasing in children with the rise",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38973318"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38867022"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is linked with an increased risk of adverse cardiovasc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38070828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "The novel term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is proposed to replace non-alcoholic fatty liver disease (NAFLD) to highlight the close association with the metabolic syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38008609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), is a chronic liver disorder associated with disturbances in lipid metabolism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39048719"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38880124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant implications for oncogenesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39182603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease [NAFLD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37934943"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38305642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38272067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is associated with altered gut microbiota; however, there has been a focus on fecal samples, which are not representative of the entire digestive tract",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38643212"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "INTRODUCTION AND OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) formerly known as Nonalcoholic fatty liver disease (NAFLD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Metabolic (dysfunction)-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, is a growing global health concern with no approved pharmacological treatments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38149861"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 608,
          "text": "MASLD, formerly known as nonalcoholic fatty liver disease, is the most prevalent cause of chronic liver disease, and its global incidence and prevalence are steadily rising",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38915345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Non-alcoholic fatty liver disease (NAFLD) has replaced chronic hepatitis B as the most common chronic liver disease in China and has now been renamed metabolic dysfunction-associated fatty liver disease (MAFLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37580263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) are time-honored acronyms, with widely popular acceptance. Experts now recommend discarding them in favor of MASLD for \"metabolic dysfunction-associated steatotic live",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358924"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), once known as non-alcoholic fatty liver disease (NAFLD), represents a spectrum of liver disorders characterized by lipid accumulation within hepatocytes. The redefinition of NAFLD in 2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38764762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "PURPOSE OF REVIEW: Provide a concise update on metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), as well as a practical approach to screening and initial evaluation.RECENT F",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39535566"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Background: Recently, the multisociety Delphi consensus renamed non-alcoholic fatty liver disease (NAFLD) terminology [previously renamed metabolic-associated fatty liver disease (MAFLD)] as metabolic dysfunction-associated steatotic liver dise",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39040926"
        },
        {
          "offsetInBeginSection": 424,
          "offsetInEndSection": 682,
          "text": "To this end, in the past three years, the international consensus group and the three major hepatology societies have suggested that NAFLD be renamed metabolism-associated fatty liver disease (MAFLD) and metabolism-associated steatosis liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37723058"
        },
        {
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1318,
          "text": "The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37364790"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 325,
          "text": "NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) are time-honored acronyms, with widely popular acceptance. Experts now recommend discarding them in favor of MASLD for \"metabolic dysfunction-associated steatotic liver disease\" and MASH for \"metabolic dysfunction-associated steatohepatitis.\"",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358924"
        },
        {
          "offsetInBeginSection": 179,
          "offsetInEndSection": 434,
          "text": "titis (NASH). Based on an international consensus, NAFLD and NASH were renamed as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), respectively; hence, we introduced the term \"hi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38764767"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "RATIONALE: Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common liver disease worldwide, affecting an estimated 3 in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39412049"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 379,
          "text": "Current studies emphasize the urgent need for a paradigm shift in conceptualizing nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction-associated steatotic liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39352015"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 757,
          "text": "In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to replace the old term non-alcoholic fatty liver disease (NAFLD). In 2023, a modified Delphi process was led by three large pan-national liver associations. There was consensus to change the fatty liver disease nomenclature and definition to include the presence of at least one of five common cardiometabolic risk factors as diagnostic criteria. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) which formerly known as non-alcoholic fatty liver disease (NAFLD) is one of the causes of liver cirrhosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38142587"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a frequent clinical condition globally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38674389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), is a chronic liver disorder associated with disturbances in lipid metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39048719"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39243773"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 297,
          "text": "Metabolic dysfunction-associated steatotic liver disease(MASLD), formerly known as non-alcoholic fatty liver disease(NAFLD), has become a major cause of chronic liver disease and a significant risk factor for hepatocellular carcinoma, which poses a huge burden on global public health and economy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38479177"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38880124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is a leading cause of chronic liver disease, affecting up to 30% of the global population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39606621"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 229,
          "text": "Metabolic-associated steatotic liver disease (MASLD) is a novel term proposed in 2023 to replace non-alcoholic fatty liver disease (NAFLD) with the aim of better reflecting its pathogenesis and clinical manifestations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39649758"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease (NAFLD), and gastroesophageal reflux disease (GERD) are prevalent chronic conditions with escalating global incidence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39512967"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 594,
          "text": "The classification and nomenclature of NAFLD have long been a controversial topic, until 2020 when a group of international experts recommended substituting NAFLD with MAFLD (metabolic dysfunction-associated FLD). MAFLD was then terminologically complemented in 2023 by altering it to MASLD, i.e., metabolic dysfunction-associated steatotic liver disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39064665"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Non-alcoholic Fatty Liver Disease (NAFLD) is both a cause and a consequence of metabolic disturbances. Consequently, the disease term has recently changed to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39006144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Background: Metabolic-associated steatotic liver disease (MASLD) is a novel term proposed in 2023 to replace non-alcoholic fatty liver disease (NAFLD) with the aim of better reflecting its pathogenesis and clinical man",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39649758"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed as nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of obesity and metabol",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39498281"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 372,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), encompasses a progressive spectrum of liver conditions, ranging from steatosis to metabolic dysfunction-associated steatohepatitis, characterised by hepatocellular death and inflammation, potentially progressing to cirrhosis and/or liver cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "INTRODUCTION AND OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) formerly known as Nonalcoholic fatty liver disease (NAFLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant implications for oncogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39182603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is characterized by hepatic steatosis and metabolic dysfunction and is often associated with obesity and insulin resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38049180"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) was previously known as nonalcoholic fatty liver disease (NAFLD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38275476"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": " Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is becoming more prominent globally due to an increase in the prevalence of obesity, dyslipidemia, and type 2 diabetes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39194748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD))",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38254750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) (previously called nonalcoholic fatty liver disease, NAFLD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38526946"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed nonalcoholic fatty liver disease (NAFLD), is a widespread global health concern that affects around 25% of the global population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38132126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a leading cause of morbidity and mortality, and health disparities have been shown to influence di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560808"
        },
        {
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1136,
          "text": "gle trends package gtrendsR.RESULTS: We found that interest in MASLD [formerly non-alcoholic fatty liver disease (NAFLD)] has generally increased over time, but that interest in metabolic associated steatohepatitis (MASH) - the most",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38944876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), which has been the term for non-alcoholic fatty liver disease (NAFLD) since June 2023",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37940495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39342178"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39243773"
        },
        {
          "offsetInBeginSection": 335,
          "offsetInEndSection": 668,
          "text": "Recently, it was suggested that the terms \"metabolic dysfunction-associated steatotic liver disease (MASLD)\" and \"metabolic dysfunction-associated steatohepatitis (MASH)\" should replace the terms \"nonalcoholic fatty liver disease (NAFLD)\" and \"nonalcoholic steatohepatitis (NASH)\", respectively, with small changes in the definitions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37893134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), once known as non-alcoholic fatty liver disease (NAFLD), represents a spectrum of liver disorders characterized by lipid accumulation within hepatocytes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38764762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly named non-alcoholic fatty liver disease (NAFLD), is induced by alterations of hepatic metabolism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38405608"
        },
        {
          "offsetInBeginSection": 2170,
          "offsetInEndSection": 2369,
          "text": "SLD criteria, further consideration is needed.IMPACT AND IMPLICATIONS: In June 2023, new terminology (MASLD) was adopted to replace the term NAFLD as a means to better describe what the liver disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38286339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as a new name for the previous non-alcoholic fatty liver disease (NAFLD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39260740"
        }
      ],
      "type": "factoid",
      "id": "67fe5f0918b1e36f2e000144",
      "ideal_answer": [
        "Nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction-associated steatotic liver disease (MASLD",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD, which stands for nonalcoholic fatty liver disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Diasease  (MASLD) is NAFLD.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was nonalcoholic fatty liver disease (NAFLD), which is a condition strongly associated with metabolic dysfunction and obesity.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is Non-Alcoholic Fatty Liver Disease (NAFLD).",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD, which stands for non-alcoholic fatty liver disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was Nonalcoholic Fatty Liver Disease (NAFLD), which is the term it was renamed from.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is Nonalcoholic Fatty Liver Disease (NAFLD).",
        "MASLD was formerly known as NAFLD (Non-Alcoholic Fatty Liver Disease).",
        "Non-alcoholic fatty liver disease has been renamed metabolic dysfunction-associated fatty liver disease (MAFLD).",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for Non-Alcoholic Fatty Liver Disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was Non-alcoholic fatty liver disease (NAFLD).",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is non-alcoholic fatty liver disease (NAFLD).",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was nonalcoholic fatty liver disease (NAFLD). This was the original name before it was recently renamed to emphasize the metabolic component of the disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is nonalcoholic fatty liver disease (NAFLD).",
        "Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD) or Cryptogenic Steatotic Liver Disease (CSLD)",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD.",
        "Metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as a new name for the previous non-alcoholic fatty liver disease (NAFLD).",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for non-alcoholic fatty liver disease.",
        "Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for Nonalcoholic Fatty Liver Disease. The change in terminology reflects an effort to emphasize the metabolic factors that contribute to the condition rather than focusing solely on the absence of alcohol consumption.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD, which stands for Non-Alcoholic Fatty Liver Disease. This term was used to describe a range of liver conditions affecting people who drink little to no alcohol, characterized by excess fat stored in liver cells.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD, which stands for Non-Alcoholic Fatty Liver Disease. This change in terminology was proposed to better reflect the pathogenesis and clinical manifestations of the disease.",
        "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was previously known as Nonalcoholic Fatty Liver Disease (NAFLD).",
        "Non-Alcoholic Fatty Liver Disease (NAFLD) is the widely recognized predecessor to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), reflecting an evolution in understanding the condition\u0027s metabolic underpinnings while NAFLD itself is characterized by excessive liver fat in non-alcohol consumers.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was MAFLD, which stands for Metabolic Dysfunction-Associated Fatty Liver Disease. This change occurred as part of an evolution in nomenclature aimed at reducing stigma and better reflecting the metabolic aspects of the disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stood for non-alcoholic fatty liver disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Diasease  (MASLD) is nonalcoholic fatty liver disease (NAFLD).",
        "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was previously referred to as non-alcoholic fatty liver disease (NAFLD). The renaming reflects a shift in diagnostic criteria to emphasize the association with metabolic dysfunction, replacing the older term that focused on the absence of alcohol as a cause.",
        "Current studies emphasize the urgent need for a paradigm shift in conceptualizing nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction-associated steatotic liver disease (MASLD).",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is not explicitly stated in the provided snippets. However, it is known that MASLD was previously referred to as Nonalcoholic Fatty Liver Disease (NAFLD), but the acronym for the previous state of NAFLD is not mentioned.",
        "The previous acronym for Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) was NAFLD (Non Alcoholic Fatty Liver Disease). This condition refers to fat accumulation in liver cells not caused by alcohol consumption and has been reclassified as MASLD to better reflect its metabolic origins.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for non-alcoholic fatty liver disease. This change in nomenclature was part of an effort to reduce stigma and better reflect the metabolic aspects of the condition.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stood for Nonalcoholic Fatty Liver Disease. Current studies advocate renaming due to the need for a paradigm shift in its conceptualization.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Diasease (MASLD) was Nonalcoholic Fatty Liver Disease (NAFLD), which is a term that has been replaced with the current one. This change was made to better reflect the metabolic dysfunction aspect of the disease.",
        "The previous acronym for MASLD was NAFLD, referring to nonalcoholic fatty liver disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, representing nonalcoholic fatty liver disease. This renaming signifies a broader understanding and redefinition of the condition.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is **NAFLD** (Nonalcoholic Fatty Liver Disease), reflecting its renaming to emphasize metabolic dysfunction as a key driver.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is **NAFLD** (Nonalcoholic Fatty Liver Disease).",
        "The previous acronym for MASLD was NAFLD (nonalcoholic fatty liver disease).",
        "The previous acronym for MASLD is NAFLD, which stands for nonalcoholic fatty liver disease.",
        "Nonalcoholic fatty liver disease (NAFLD) has been renamed to metabolic dysfunction-associated steatotic liver disease (MASLD).",
        "[\u0027The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was Nonalcoholic Fatty Liver Disease (NAFLD).\u0027]",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for Nonalcoholic Fatty Liver Disease.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for nonalcoholic fatty liver disease.",
        "The previous acronym for metabolic dysfunction-associated steatotic liver disease (MASLD) was nonalcoholic fatty liver disease (NAFLD). Current studies highlight the need for redefining this condition to better reflect its metabolic complexities.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was nonalcoholic fatty liver disease (NAFLD). This is because the current name of MASLD is a re-naming of NAFLD, emphasizing the metabolic aspect of the disease. The acronym NAFLD was used prior to this re-naming.",
        "Nonalcoholic Fatty Liver Disease (NAFLD) was the previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Diasease (MASLD) before it was updated.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD, which stands for Non-Alcoholic Fatty Liver Disease.",
        "Metabolic dysfunction-associated steatotic liver disease (MASLD) is the new name for nonalcoholic fatty liver disease (NAFLD).",
        "The previous acronym for Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is NAFLD (Nonalcoholic Fatty Liver Disease). This term was used before the name change to better capture the metabolic components of the condition.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was consistently identified as NAFLD, standing for Nonalcoholic Fatty Liver Disease, across all provided responses, affirming its accuracy and reliability.",
        "[\u0027The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is NAFLD, which stands for Nonalcoholic Fatty Liver Disease.\u0027]",
        "NAFLD (Nonalcoholic Fatty Liver Disease) is the previous or overarching acronym related to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), suggesting that MASLD may represent a more specific subset or updated classification within the broader spectrum of NAFLD.",
        "The previous acronym for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was NAFLD, which stands for non-alcoholic fatty liver disease. In some instances, the term MAFLD, representing metabolic-associated fatty liver disease, was used as an intermediate name before the adoption of MASLD.",
        "MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) was previously known as NAFLD (Nonalcoholic Fatty Liver Disease), reflecting a recent paradigm shift in how this liver condition is conceptualized and named."
      ],
      "exact_answer": [
        [
          "NAFLD",
          "NASH",
          "MASH"
        ]
      ]
    },
    {
      "body": "What is the genetic basis of addiction?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39385445",
        "http://www.ncbi.nlm.nih.gov/pubmed/39242950",
        "http://www.ncbi.nlm.nih.gov/pubmed/37145176",
        "http://www.ncbi.nlm.nih.gov/pubmed/36930441",
        "http://www.ncbi.nlm.nih.gov/pubmed/22342427",
        "https://www.ncbi.nlm.nih.gov/pubmed/21937688",
        "http://www.ncbi.nlm.nih.gov/pubmed/32092754",
        "http://www.ncbi.nlm.nih.gov/pubmed/37186439",
        "http://www.ncbi.nlm.nih.gov/pubmed/25958762",
        "http://www.ncbi.nlm.nih.gov/pubmed/22302827",
        "http://www.ncbi.nlm.nih.gov/pubmed/16046395",
        "http://www.ncbi.nlm.nih.gov/pubmed/39647667",
        "http://www.ncbi.nlm.nih.gov/pubmed/39615775",
        "http://www.ncbi.nlm.nih.gov/pubmed/17347351",
        "http://www.ncbi.nlm.nih.gov/pubmed/10943908",
        "http://www.ncbi.nlm.nih.gov/pubmed/23533358"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1101,
          "offsetInEndSection": 1317,
          "text": "Associations at previously identified OPRM1 variants suggest common biology between persistent opioid use and opioid use disorder, further demonstrating connections between opioid dependence and addiction phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39385445"
        },
        {
          "offsetInBeginSection": 974,
          "offsetInEndSection": 1012,
          "text": "differentially expressed genes (DEGs) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39242950"
        },
        {
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1202,
          "text": "Commonly dysregulated DEGs suggest conserved cross-species mechanisms for chronic alcohol consumption/AUD comprising MAPKs as well as STAT, IRF7, and TNF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39242950"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Abnormal genetic polymorphism of trace amine-associated receptor 1 (TAAR1) rs8192620 site has been confirmed to induce methamphetamine (MA) use and drug craving",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37145176"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1340,
          "text": "The cannabinoid receptor (CNR1) and the fatty acid amide hydrolase (FAAH) genes are located on chromosomes 6 and 1 in the 6q15 and 1p33 cytogenetic bands, respectively. CNR1 encodes a seven-transmembrane domain protein of 472 amino acids, whereas FAAH encodes one transmembrane domain of 579 amino acids. Several mutations found in these genes lead to altered mRNA stability and transcription rate or a reduction of the activity of the encoded protein. Increasing evidence shows that these functional mutations are related to dependence upon cocaine, alcohol, marijuana, heroin, nicotine and other drugs. One of the most compelling associations is with the C385A single nucleotide polymorphism (SNP), which is found in the FAAH gene. For all of the genetic polymorphisms reviewed here, it is difficult to form overall conclusions due to the high diversity of population samples being studied, ethnicity, the use of volunteers, heterogeneity of the recruitment criteria and the drug addiction phenotype studied. Care should be taken when generalizing the results from different studies. However, many works have repeatedly associated polymorphisms in the CNR1 and FAAH genes with drug-related behaviours; this suggests that these genes should be examined in further genetic studies focusing on drug addiction and other psychiatric disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/21937688"
        },
        {
          "offsetInBeginSection": 95,
          "offsetInEndSection": 188,
          "text": "CAMK2A gene variants have been linked with alcohol use disorder (AUD) by an unknown mechanism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37186439"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 335,
          "text": "In a previous study, we found that single nucleotide polymorphism (SNP) rs12607853 in the 3\u0027 untranslated region (3\u0027-UTR) of DCC was significantly associated with heroin addiction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32092754"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 861,
          "text": "This approach allowed the identification of the first susceptibility gene in addiction (tobacco), with genes CHRNA5, CHRNA3 and CHRNB4 encoding the α5, α3 and b4 subunits involved in the formation of nicotinic receptors, explaining 14% of the attributable risk for tobacco dependence. Variants of ADH1B and ADH1C genes encoding alcohol dehydrogenases enzymes have also been consistently associated, this time with alcohol dependence (AD). Finally, DRD2 and ANKK1 genes, involved in the dopaminergic pathway, and which were initially associated with AD, are now considered to be involved in a broader phenotype (addiction to psychoactive substances) including opiates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25958762"
        },
        {
          "offsetInBeginSection": 1189,
          "offsetInEndSection": 1663,
          "text": "ulsivity has been linked with variation in reward-related activation in the ventral striatum (VS), altered dopamine signaling, and functional polymorphisms of DRD2 and DAT1 genes. In smokers, changes in reward-related VS activation induced by smoking abstinence may be associated with severity of nicotine dependence.CONCLUSIONS: Variation in genes related to dopamine signaling may contribute to heterogeneity in VS sensitivity to reward and, ultimately, to addiction. Thes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22342427"
        },
        {
          "offsetInBeginSection": 514,
          "offsetInEndSection": 974,
          "text": "We identified critical cellular components and previously unrecognized epigenetic determinants of gene coexpression relationships and discovered novel markers of chromatin modifications in alcoholic brain. Higher expression levels of endogenous retroviruses and genes with high GC content in alcoholics were associated with DNA hypomethylation and increased histone H3K4 trimethylation, suggesting a critical role of epigenetic mechanisms in alcohol addiction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22302827"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 365,
          "text": "Genetic variants of OPRM1 have been implicated in predisposition to drug addiction, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10-32%, and uncertain functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16046395"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Mu-opioid receptors (MORs) in the amygdala and striatum are important in addictive and rewarding behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39647667"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 1007,
          "text": " and controls.RESULTS: We identified 211 highly interrelated genes identified by GWAS or dysregulation in the dlPFC of opioid overdose victims that implicated the Akt, BDNF, and ERK pathways, identifying 414 drugs targeting 48 of these opioid addiction-associated genes. Some of the identified drugs are approved to treat other substance use disorders (SUDs) or depression.CONCLUSIONS: ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39615775"
        },
        {
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1596,
          "text": "In addition, a common Met158 variant in the catechol-O-methyltransferase (COMT) gene can confer both risk and resilience to alcoholism in different drinking environments. It is likely that a complex mix of gene(s)-environment(s) interactions underlie addiction vulnerability and development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17347351"
        },
        {
          "offsetInBeginSection": 874,
          "offsetInEndSection": 1074,
          "text": "Taken together, these findings suggest that the 3-repeat allele of the MAOA polymorphism contributes modestly to the dimension of overand underreactive behaviors as possible antecedents of alcoholism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10943908"
        },
        {
          "offsetInBeginSection": 635,
          "offsetInEndSection": 877,
          "text": "By employing both SNP- and gene-based methods of analysis, we identified a strong (odds ratio \u003d 13.87) and significant (P value \u003d 1.33E - 11) association of an SNP in the NCK2 gene on chromosome 2 with opiates addiction in African-origin men.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533358"
        },
        {
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1219,
          "text": "Furthermore, we observed that the association between the NCK2 gene (P value \u003d 3.12E - 10) and opiates addiction reached the gene-based genome-wide significant level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533358"
        }
      ],
      "type": "summary",
      "id": "67fbe4d718b1e36f2e00011d",
      "ideal_answer": [
        "Genetic basis of addiction is being studied, with evidence about the relevance of the OPRM1 variants, differentially expressed genes such as MAPKs,  STAT, IRF7, and TNF, and that abnormal genetic polymorphism of trace amine-associated receptor 1 (TAAR1) rs8192620 site might induce methamphetamine (MA) use and drug craving."
      ]
    },
    {
      "body": "Do natural killer (NK) cells require antigen presentation to eliminate cancer cells?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38635551",
        "http://www.ncbi.nlm.nih.gov/pubmed/39075582",
        "http://www.ncbi.nlm.nih.gov/pubmed/39303993",
        "http://www.ncbi.nlm.nih.gov/pubmed/2528695",
        "http://www.ncbi.nlm.nih.gov/pubmed/20704970",
        "http://www.ncbi.nlm.nih.gov/pubmed/35305726",
        "http://www.ncbi.nlm.nih.gov/pubmed/35637393",
        "http://www.ncbi.nlm.nih.gov/pubmed/3095151",
        "http://www.ncbi.nlm.nih.gov/pubmed/32301190",
        "http://www.ncbi.nlm.nih.gov/pubmed/29805857",
        "http://www.ncbi.nlm.nih.gov/pubmed/37924937",
        "http://www.ncbi.nlm.nih.gov/pubmed/38070841",
        "http://www.ncbi.nlm.nih.gov/pubmed/34386069",
        "http://www.ncbi.nlm.nih.gov/pubmed/33407739",
        "http://www.ncbi.nlm.nih.gov/pubmed/34725941",
        "http://www.ncbi.nlm.nih.gov/pubmed/39358647",
        "http://www.ncbi.nlm.nih.gov/pubmed/33256912",
        "http://www.ncbi.nlm.nih.gov/pubmed/35093506",
        "http://www.ncbi.nlm.nih.gov/pubmed/37551952",
        "http://www.ncbi.nlm.nih.gov/pubmed/32470639",
        "http://www.ncbi.nlm.nih.gov/pubmed/39251669",
        "http://www.ncbi.nlm.nih.gov/pubmed/33800301",
        "http://www.ncbi.nlm.nih.gov/pubmed/31340613",
        "http://www.ncbi.nlm.nih.gov/pubmed/21844012",
        "http://www.ncbi.nlm.nih.gov/pubmed/33747745",
        "http://www.ncbi.nlm.nih.gov/pubmed/31411057",
        "http://www.ncbi.nlm.nih.gov/pubmed/29383623",
        "http://www.ncbi.nlm.nih.gov/pubmed/21053463",
        "http://www.ncbi.nlm.nih.gov/pubmed/21576922",
        "http://www.ncbi.nlm.nih.gov/pubmed/34858978",
        "http://www.ncbi.nlm.nih.gov/pubmed/28428785",
        "http://www.ncbi.nlm.nih.gov/pubmed/31879979",
        "http://www.ncbi.nlm.nih.gov/pubmed/16616045",
        "http://www.ncbi.nlm.nih.gov/pubmed/12894845",
        "http://www.ncbi.nlm.nih.gov/pubmed/11536166",
        "http://www.ncbi.nlm.nih.gov/pubmed/20873317",
        "http://www.ncbi.nlm.nih.gov/pubmed/26300042",
        "http://www.ncbi.nlm.nih.gov/pubmed/25511743",
        "http://www.ncbi.nlm.nih.gov/pubmed/14710949",
        "http://www.ncbi.nlm.nih.gov/pubmed/21541191",
        "http://www.ncbi.nlm.nih.gov/pubmed/35712510",
        "http://www.ncbi.nlm.nih.gov/pubmed/39061247",
        "http://www.ncbi.nlm.nih.gov/pubmed/35008589",
        "http://www.ncbi.nlm.nih.gov/pubmed/35806034",
        "http://www.ncbi.nlm.nih.gov/pubmed/36231109",
        "http://www.ncbi.nlm.nih.gov/pubmed/17150016"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 357,
          "text": "Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues. These cells are crucial in cancer immunosurveillance due to their diverse array of activating and inhibitory receptors that modulate their cytotoxic activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39303993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a promising approach for cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39075582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 416,
          "text": "Natural killer (NK) cells play a crucial role in immunosurveillance independent of antigen presentation, which is regulated by signal balance via activating and inhibitory receptors. The anti-tumor activity of NK cells is largely dependent on signaling from target recognition to cytolytic degranulation; however, the underlying mechanism remains unclear, and NK cell cytotoxicity is readily impaired by tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38635551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 491,
          "text": "Natural killer (NK) cells are large granular lymphocytes capable of killing tumour cells in a non-MHC restricted manner. NK cells do not express cell-surface CD3, or any known target recognition structure analogous to the T cell antigen receptor (TCR) heterodimers (alpha beta or gamma delta). Consistent with their lack of expression of a CD3-TCR complex, NK cells do not require prior sensitization or antigen presentation by accessory cells to specifically recognize their tumour targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2528695"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "Natural killer (NK) cells are a family of lymphocytes with a natural ability to kill infected, harmed, or malignantly transformed cells. As these cells are part of the innate immunity, the cytotoxic mechanisms are activated upon recognizing specific patterns without prior antigen sensitization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35305726"
        },
        {
          "offsetInBeginSection": 583,
          "offsetInEndSection": 865,
          "text": "The enormous potential of NK cells for immunotherapy for cancer is illustrated by their broad recognition of stressed cells regardless of neoantigen presentation, and enhanced activity against tumours that have lost expression of MHC class I owing to acquired resistance mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35637393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Cytotoxicity not restricted by the major histocompatibility complex (MHC) is mediated by two distinct types of lymphocyte: natural killer (NK) cells and non-MHC-restricted cytotoxic T lymphocytes (CTL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3095151"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Natural killer (NK) cells are innate lymphocytes that rapidly respond to cancer cells without prior sensitization or restriction to the cognate antigen in comparison with tumor antigen-specific T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32301190"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 329,
          "text": "Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33407739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Natural killer (NK) cells are frontline defenders against cancer and are capable of recognizing and eliminating tumor cells without prior sensitization or antigen presentation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39358647"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39303993"
        },
        {
          "offsetInBeginSection": 273,
          "offsetInEndSection": 410,
          "text": "Natural killer (NK) cells apply cytotoxicity against tumor cells independently of antigen-presenting cells and the adaptive immune system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39251669"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Natural killer (NK) cells play a crucial role in immunosurveillance independent of antigen presentation, which is regulated by signal balance via activating and inhibitory receptors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38635551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Natural killer (NK) cells can induce an antigen-independent immune response against malignant cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28838796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Natural killer (NK) cells have long been known to mediate anti-tumor responses without prior sensitization or recognition of specific tumor antigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28882429"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Natural killer (NK) cells destroy hazardous cells such as tumors and virus-infected cells immediately without the need for prior antigen stimulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16893656"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 415,
          "text": "For a long time, natural killer (NK) cells have held promise for cancer immunotherapy because, unlike T lymphocytes, they can kill tumor cells without the need for tumor-specific antigen recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16616045"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 417,
          "text": "However, many patients with cancer are ineligible for such treatment because their TIL do not expand sufficiently or because their tumors have lost expression of antigens and/or MHC molecules. Natural killer (NK) cells are large granular lymphocytes that lyse tumor cells in a non-MHC-restricted manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21844012"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 760,
          "text": "Since many tumors fail to express specific antigens or express these antigens in a \"wrong\" way that impairs their recognition, cancer cells frequently escape from the specific immune response. Nonetheless, alternate effector cell populations have been described that are able to destroy tumor cells without any requirement for recognition of cancer-specific antigens. Among these effector populations, natural killer (NK) cells have an important role.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20704970"
        },
        {
          "offsetInBeginSection": 695,
          "offsetInEndSection": 919,
          "text": "Natural killer (NK) cells are innate lymphocytes that can kill tumor cells without prior sensitization to antigens and can be activated to kill tumor cells that have an impaired antigen processing and presentation machinery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31340613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Natural killer (NK) cells are an important component of the innate immune system, particularly for metastasis immunosurveillance. They can rapidly recognize and kill transformed cells without the requirement of specific neo-antigen recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33256912"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 705,
          "text": "NK cells do not require antigen pre-sensitization, nor are they confined by the major histocompatibility complex (MHC). NK cells have the potential to eliminate cancer cells through CAR-dependent and CAR-independent pathways, demonstrating reduced levels of systemic toxicity in the process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37924937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39303993"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 416,
          "text": "Natural killer (NK) cells are large granular lymphocytes that lyse tumor cells in a non-MHC-restricted manner",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21844012"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 284,
          "text": "Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a promising approach for cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39075582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39303993"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 491,
          "text": "Consistent with their lack of expression of a CD3-TCR complex, NK cells do not require prior sensitization or antigen presentation by accessory cells to specifically recognize their tumour targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2528695"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 304,
          "text": "NK cells demonstrate great potential for cancer immunotherapy; they can rapidly and directly kill cancer cells in the absence of MHC-dependent antigen presentation ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34725941"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 533,
          "text": "NK cells do not require antigen pre-sensitization, nor are they confined by the major histocompatibility complex (MHC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37924937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "As the recognition between natural killer (NK) cells and cancer cells does not require antigen presentation, NK cells are being actively studied for use in adoptive cell therapies in the rapidly evolving armamentarium of cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33747745"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 288,
          "text": "Owing to their ability to engage tumor targets without the need of specific antigen, the therapeutic potential of NK cells has been extensively explored in hematological malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31411057"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 233,
          "text": "In contrast to T cells, NK cells do not require prior antigen sensitization to induce cytotoxicity ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29383623"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Human natural killer (NK) cells recognize and efficiently eliminate MHC class I low or negative malignant targets and virally infected host cells, without requirement for prior sensitization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576922"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 512,
          "text": "Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation-independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33800301"
        },
        {
          "offsetInBeginSection": 511,
          "offsetInEndSection": 751,
          "text": "Natural killer (NK) cells, owing to their unique ability to exert cytotoxic function independent of major histocompatibility (MHC)-mediated antigen presentation, play a significant role in the control of metastasis in colorectal cancer (CRC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34858978"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Natural killer (NK) cells have therapeutic potential for cancer due to their capacity for targeting tumor cells without prior sensitization",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28428785"
        },
        {
          "offsetInBeginSection": 518,
          "offsetInEndSection": 701,
          "text": "Tumour recognition by CTLs depends on major histocompatibility complex (MHC) class I molecules, while NK cells recognize tumours expressing low or null levels of MHC class I molecules",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879979"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Natural killer (NK) cells are frontline defenders against cancer and are capable of recognizing and eliminating tumor cells without prior sensitization or antigen presentation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39358647"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 414,
          "text": "For a long time, natural killer (NK) cells have held promise for cancer immunotherapy because, unlike T lymphocytes, they can kill tumor cells without the need for tumor-specific antigen recognition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16616045"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 656,
          "text": "For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12894845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Natural killer (NK) cells destroy virus-infected and tumor cells without prior antigen stimulation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11536166"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 387,
          "text": "Lysis of NK sensitive target cells could be mediated independently of antigen stimulation and without requirement of peptide presentation by the major histocompatibility complex (MHC) molecules",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20873317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Human natural killer (NK) cells recognize and efficiently eliminate MHC class I low or negative malignant targets and virally infected host cells, without requirement for prior sensitization",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576922"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Natural killer (NK) cells play a crucial role in immunosurveillance independent of antigen presentation, which is regulated by signal balance via activating and inhibitory receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38635551"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 511,
          "text": "Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation-independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33800301"
        },
        {
          "offsetInBeginSection": 826,
          "offsetInEndSection": 967,
          "text": "Natural killer cells (NKs) are able to recognize cancer cells, based on MHC I (self and non-self) and independently from antigen presentation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35712510"
        },
        {
          "offsetInBeginSection": 787,
          "offsetInEndSection": 1026,
          "text": "NK cells and γδ T cells that do not need HLA compatibility or macrophages and dendritic cells with additional properties such as phagocytosis or antigen presentation are increasingly seen as cellular vehicles with potential for application",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061247"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 382,
          "text": "NK cells demonstrate great potential for cancer immunotherapy; they can rapidly and directly kill cancer cells in the absence of MHC-dependent antigen presentation and can initiate a robust immune response in the tumor microenvironment (TME).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34725941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct recognition of surface ligands, without prior sensitization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36348457"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Natural Killer (NK) cells are innate immune effectors that are primarily involved in immunosurveillance to spontaneously eliminate malignantly transformed and virally infected cells without prior sensitization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25511743"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 387,
          "text": "Unlike T cells, NK cells can lyse tumour cells independent of antigen presentation, based simply on their activation and inhibition receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35806034"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 330,
          "text": "NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33407739"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 462,
          "text": "Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation-independent manner by an array of activating and inhibitory receptors,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33800301"
        }
      ],
      "id": "680a079718b1e36f2e000147",
      "ideal_answer": [
        "Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues. These cells are crucial in cancer immunosurveillance due to their diverse array of activating and inhibitory receptors that modulate their cytotoxic activity. This signal balance between activating and inhibitory receptors regulates most of the anti-tumor activity of NK cells, from target recognition to cytolytic degranulation. For this reason, their unique mechanism of action and not relying on antigen presentation make them a promising approach for cancer immunotherapy.",
        "No, natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. NK cells are a critical component of the innate immune system and possess the inherent ability to recognize and destroy malignant cells without the need for prior sensitization to specific antigens. This capability is primarily due to their function in tumor immunosurveillance, where they can detect and respond to cells that exhibit abnormal behaviors typical of cancer cells, such as stress signals or the downregulation of MHC class I molecules, which are commonly used by cancer cells to evade adaptive immune responses (PMID 33948388). Unlike T cells, which require antigen presentation via Major Histocompatibility Complex (MHC) molecules to initiate an immune response, NK cells rely on a balance of activating and inhibitory signals from potential target cells to make decisions about cytotoxic action. This allows them to act swiftly and effectively against neoplasms without the need for antigen-specific activation (PMID 33767702). Thus, NK cells play a crucial role in the body\u0027s first line of defense against cancer through mechanisms independent of antigen presentation.",
        "Studies indicate natural killer (NK) cells do not require antigen presentation for eliminating cancer cells, as they operate through innate immune mechanisms independent of major histocompatibility complex (MHC) restriction or prior sensitization. Their cytotoxic activity is mediated by activating receptors that recognize stress-induced ligands on tumor cells, enabling direct killing and antibody-dependent cellular cytotoxicity (ADCC). This inherent ability allows NK cells to target cancer cells without antigen-specific recognition, distinguishing them from T cells reliant on MHC-presented antigens. Additionally, CAR-engineered NK cells further enhance antitumor efficacy by redirecting activity against specific tumor antigens while retaining their innate advantages, such as reduced toxicity and HLA independence.",
        "No, natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. NK cells are integral to the innate immune system and have the ability to recognize and destroy cancer cells independently of antigen presentation. They are equipped to identify stressed or abnormal cells, such as cancer cells, through various mechanisms. One key method involves detecting changes in the expression of surface molecules, particularly the major histocompatibility complex (MHC) class I molecules. Unlike T cells, which require specific antigen presentation to target cells, NK cells can directly respond to the absence or altered expression of MHC class I molecules, which is often a characteristic of cancerous or infected cells. This allows NK cells to swiftly target and eliminate cells that are potentially harmful without the need for prior sensitization or antigen-specific activation. Their ability to act quickly and independently of antigen presentation makes NK cells a crucial component of the body\u0027s first line of defense against cancer and other threats.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. As part of the innate immune system, NK cells act quickly and do not depend on prior exposure or specific recognition like the adaptive immune system. Instead, they use activating and inhibitory receptors to detect stress signals from abnormal cells.\n\nInhibitory receptors on NK cells recognize self-MHC class I molecules, which are often downregulated on cancer cells. This lack of recognition allows activating receptors to dominate, leading NK cells to target these abnormal cells for destruction without needing antigen presentation via MHC molecules.\n\nWhile NK cells can be influenced by cytokines and interactions with other immune cells, their primary mechanism involves recognizing stress signals rather than relying on traditional antigen-presentation processes. This makes them crucial in immune surveillance against tumors that might evade other immune mechanisms.",
        "No. Natural killer (NK) cells eliminate cancer cells without requiring antigen presentation. Their innate recognition mechanism relies on balancing activating and inhibitory signals rather than antigen-specific receptors. NK cells target tumor cells through stress-induced ligand detection, missing \"self\" markers, or antibody-mediated cytotoxicity (via CD16), independent of HLA compatibility or antigen processing pathways.",
        "No, natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. NK cells are innate lymphocytes that can recognize and kill tumor cells without prior sensitization to antigens. They can engage their natural cytotoxicity receptors, such as NCRs, to directly kill target cells, including cancer cells with impaired antigen processing and presentation machinery. Additionally, NK cells can be activated by antibodies or other molecules to initiate antibody-dependent cellular cytotoxicity (ADCC) and eliminate tumor cells, even those that are antigen-negative. This ability of NK cells to recognize and kill cancer cells independently of antigen presentation makes them an attractive target for immunotherapeutic strategies against cancer.",
        "Natural killer (NK) cells are renowned for their ability to target and eliminate cancer cells without need for antigen presentation, sparing normal tissues. Studies have shown that NK cells play an important role in cancer immunosurveillance due to their diverse array of activating and inhibitory receptors that modulate their cytotoxic activity. Unlike T cells, NK cells do not require antigen pre-sensitization, nor are they confined by major histocompatibility complex (MHC), making them a promising avenue for developing new cancer treatments. This unique feature of NK cells allows them to recognize and kill cancer cells independently of antigen presentation, highlighting their potential as an effective immunotherapeutic approach against various types of cancer, including pancreatic cancer, ovarian cancer, and melanoma.",
        "Natural Killer (NK) cells do not require antigen presentation to eliminate cancer cells. They utilize various antigen presentation-independent mechanisms, including direct cytolytic effects, antibody-dependent cell-mediated cytotoxicity (ADCC), paracrine effects, and a diverse array of activating and inhibitory receptors. This capability allows NK cells to target and kill tumor cells even in environments lacking HLA-I expression, making them a promising strategy for cancer immunotherapy, particularly for T cell-resistant tumors.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells, as they recognize and target cancer cells through a diverse array of activating and inhibitory receptors that modulate their cytotoxic activity. Studies highlight that NK cells can eliminate cancer cells without prior antigen sensitization or recognition via the major histocompatibility complex (MHC), distinguishing them from T cells. This ability makes NK cells particularly effective against tumors with low HLA-I expression, which are often resistant to T cell-based therapies. Additionally, advancements such as CAR-NK cell therapy further enhance their cytotoxic capabilities without relying on antigen priming, positioning NK cells as a promising avenue for developing novel cancer treatments.",
        "Natural Killer (NK) cells, essential to the innate immune system, can eliminate cancer cells without requiring antigen presentation. This ability allows them to directly target and destroy tumor cells, bypassing the traditional antigen presentation pathway needed for adaptive immune responses. This characteristic is also leveraged in NK cell-based therapies for treating various cancers, where their effectiveness is independent of antigen presentation. The anti-tumor activity of NK cells is primarily driven by direct target recognition and subsequent cytolytic degranulation, further emphasizing their independence from antigen presentation.",
        "No, natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. NK cells recognize and target cancer cells through a balance of activating and inhibitory receptors, independent of antigen presentation. Their cytotoxic activity is mediated by detecting stress-induced ligands on tumor cells or the absence of MHC class I molecules, bypassing the need for antigen-specific recognition. This innate mechanism allows NK cells to rapidly identify and destroy malignant cells without prior sensitization or reliance on adaptive immune signaling.",
        "Natural killer (NK) cells are integral components of the innate immune system and play a crucial role in eliminating cancer cells without requiring antigen presentation. Unlike T-cells, which rely on major histocompatibility complex (MHC) molecules for recognition, NK cells utilize a unique mechanism involving activating and inhibitory receptors.\n\nNK cells detect stressed or abnormal cells through activating receptors that recognize stress-induced ligands on the surface of target cells. Simultaneously, they use inhibitory receptors to check for self-MHC molecules, ensuring they do not attack healthy cells. This balance of signals allows NK cells to determine whether to eliminate a target cell.\n\nWhile NK cells can be influenced by cytokines or interactions with other immune cells, their primary function does not depend on antigen presentation via MHC. This makes them particularly effective against cancer cells that may evade T-cell detection by downregulating MHC molecules.\n\nIn conclusion, NK cells do not require antigen presentation to eliminate cancer cells. Their ability to recognize and kill abnormal cells is mediated through a complex interplay of activating and inhibitory receptors, enabling them to function independently of the adaptive immune system\u0027s antigen-presentation mechanisms.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells, distinguishing them from T cells. They mediate cytotoxicity through a balance of activating and inhibitory receptors that recognize stress ligands and missing self-markers on tumor cells, enabling direct targeting without prior sensitization. This antigen-independent mechanism allows NK cells to surveil and lyse malignant cells while sparing healthy tissues, playing a critical role in innate immune defense. Despite their efficacy, tumor cells can impair NK cell cytotoxicity through various evasion strategies, highlighting ongoing challenges in enhancing their therapeutic potential. Their unique properties make NK cell-based therapies a promising approach for both hematological and solid tumors.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. Their cytotoxic activity is regulated by a balance of activating and inhibitory receptors, allowing them to recognize and destroy tumor cells independently, which makes them a valuable component of cancer immunosurveillance and immunotherapy.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells; they utilize a unique mechanism regulated by activating and inhibitory receptors to target and destroy tumor cells, making them integral to cancer immunosurveillance and promising for immunotherapy.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. They recognize and target stressed or transformed cells through receptors that detect changes such as the absence of MHC class I molecules, allowing them to act without prior antigen exposure. This makes NK cells a valuable component in innate immunity and cancer immunotherapy.",
        "Natural killer (NK) cells, as part of the innate immune system, do not require antigen presentation to eliminate cancer cells. Their unique mechanism of action, involving a balance of activating and inhibitory receptors, enables direct targeting of tumor cells. This characteristic distinguishes NK cells from adaptive immune cells like T cells and positions them as a promising approach for cancer immunotherapy, with potential applications in treating various cancers, although further research is needed to optimize their therapeutic efficacy.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells. They function independently of the major histocompatibility complex (MHC) molecules, which are typically necessary for T cell activation. Instead, NK cells recognize and target cancer cells through other mechanisms, such as detecting surface markers or stress signals on the cancer cells. This ability makes them valuable in immunotherapy, as they can act swiftly without prior antigen exposure.",
        "Natural killer (NK) cells do not require antigen presentation to eliminate cancer cells, as demonstrated by multiple studies highlighting their unique mechanism of action in immunosurveillance. These studies emphasize that NK cell cytotoxicity is regulated by activating and inhibitory receptors rather than antigen-specific recognition, enabling them to target tumor cells directly without relying on major histocompatibility complex (MHC) presentation. This inherent ability allows NK cells to function effectively against tumors with impaired HLA-I expression or those evading T cell detection, positioning them as a promising therapeutic strategy in cancer immunotherapy.",
        "Natural killer (NK) cells are renowned for their ability to target and eliminate cancer cells without need for antigen presentation, sparing normal tissues. Studies have shown that NK cells play a crucial role in immunosurveillance due to their diverse array of activating and inhibitory receptors that modulate their cytotoxic activity. Unlike T cells, NK cells do not require antigen priming or major histocompatibility complex (MHC) restriction, allowing them to recognize and kill cancer cells independently. This unique mechanism of action makes NK cells a promising approach for cancer immunotherapy, particularly for tumors that are resistant to T cell-based therapies. Studies highlight ongoing efforts to develop more effective and targeted cancer treatment strategies using NK cell-based therapies, including immune checkpoint inhibitors, cytokines, adoptive NK cell therapy, and CAR-NK cell technology."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What are the targets of blinatumomab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35880455",
        "http://www.ncbi.nlm.nih.gov/pubmed/35906791",
        "http://www.ncbi.nlm.nih.gov/pubmed/36179408",
        "http://www.ncbi.nlm.nih.gov/pubmed/34768899",
        "http://www.ncbi.nlm.nih.gov/pubmed/34305918",
        "http://www.ncbi.nlm.nih.gov/pubmed/33279181",
        "http://www.ncbi.nlm.nih.gov/pubmed/26683683",
        "http://www.ncbi.nlm.nih.gov/pubmed/32195205",
        "https://www.ncbi.nlm.nih.gov/pubmed/25972002",
        "https://www.ncbi.nlm.nih.gov/pubmed/27050240",
        "https://www.ncbi.nlm.nih.gov/pubmed/35981465",
        "https://www.ncbi.nlm.nih.gov/pubmed/38317420",
        "https://www.ncbi.nlm.nih.gov/pubmed/38691878",
        "http://www.ncbi.nlm.nih.gov/pubmed/32523659",
        "http://www.ncbi.nlm.nih.gov/pubmed/29773068",
        "http://www.ncbi.nlm.nih.gov/pubmed/30005434",
        "http://www.ncbi.nlm.nih.gov/pubmed/26020065",
        "http://www.ncbi.nlm.nih.gov/pubmed/27209293",
        "http://www.ncbi.nlm.nih.gov/pubmed/37247022",
        "http://www.ncbi.nlm.nih.gov/pubmed/25739952",
        "http://www.ncbi.nlm.nih.gov/pubmed/26337639",
        "http://www.ncbi.nlm.nih.gov/pubmed/39611241",
        "http://www.ncbi.nlm.nih.gov/pubmed/25637301",
        "http://www.ncbi.nlm.nih.gov/pubmed/38691878",
        "http://www.ncbi.nlm.nih.gov/pubmed/34117317",
        "http://www.ncbi.nlm.nih.gov/pubmed/26383529",
        "http://www.ncbi.nlm.nih.gov/pubmed/27050240",
        "http://www.ncbi.nlm.nih.gov/pubmed/38871977",
        "http://www.ncbi.nlm.nih.gov/pubmed/39210087",
        "http://www.ncbi.nlm.nih.gov/pubmed/38672662",
        "http://www.ncbi.nlm.nih.gov/pubmed/38317420",
        "http://www.ncbi.nlm.nih.gov/pubmed/30305495",
        "http://www.ncbi.nlm.nih.gov/pubmed/28790849",
        "http://www.ncbi.nlm.nih.gov/pubmed/23623807",
        "http://www.ncbi.nlm.nih.gov/pubmed/37809082",
        "http://www.ncbi.nlm.nih.gov/pubmed/27872741",
        "http://www.ncbi.nlm.nih.gov/pubmed/35182296",
        "http://www.ncbi.nlm.nih.gov/pubmed/19455460",
        "http://www.ncbi.nlm.nih.gov/pubmed/32605497",
        "http://www.ncbi.nlm.nih.gov/pubmed/33334253",
        "http://www.ncbi.nlm.nih.gov/pubmed/31451445",
        "http://www.ncbi.nlm.nih.gov/pubmed/38959896",
        "http://www.ncbi.nlm.nih.gov/pubmed/38832422",
        "http://www.ncbi.nlm.nih.gov/pubmed/34741682",
        "http://www.ncbi.nlm.nih.gov/pubmed/32564243",
        "http://www.ncbi.nlm.nih.gov/pubmed/39214018",
        "http://www.ncbi.nlm.nih.gov/pubmed/39282955",
        "http://www.ncbi.nlm.nih.gov/pubmed/39651791",
        "http://www.ncbi.nlm.nih.gov/pubmed/39008535",
        "http://www.ncbi.nlm.nih.gov/pubmed/39006644",
        "http://www.ncbi.nlm.nih.gov/pubmed/25637431",
        "http://www.ncbi.nlm.nih.gov/pubmed/28837681",
        "http://www.ncbi.nlm.nih.gov/pubmed/34105818"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 254,
          "text": "Until very recently, only one TCE was approved, the CD19/CD3-bispecific blinatumomab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35880455"
        },
        {
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1115,
          "text": "Blinatumomab is a fusion protein which consists of two single-chain variable fragments arranged in tandem: the first binds the CD19 surface antigen of all B cells and the second targets the CD3 antigen of T cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35906791"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 375,
          "text": "Since the approval of the CD19-targeted BiTE® (bispecific T-cell engager) molecule blinatumomab, multiple TCE molecules against different targets have been developed in several tumor types, with the approval of three additional TCE molecules in 2022.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36179408"
        },
        {
          "offsetInBeginSection": 760,
          "offsetInEndSection": 872,
          "text": "Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34768899"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 345,
          "text": "After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia, a few of CD47-targeted bsAbs for cancer immunotherapy, are currently in clinical research.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34305918"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1385,
          "text": "Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread with cancer through the underlying mechanism of inflammation. This inflammatory milieu not only drives the immune dysregulation characteristic of autoimmune diseases but also plays a pivotal role in the pathogenesis of cancer. Among the cellular components involved, B cells have emerged as key players in hematologic tumor and autoimmune disease, contributing to immune dysregulation and persistent tissue fibrosis in systemic sclerosis, as well as tumor progression and immune evasion in cancer. Consequently, novel therapeutic strategies targeting B cells hold promise in both conditions. Recent exploration of CD19 CAR T cells in severe systemic sclerosis patients has shown great potential, but also introduced possible risks and drawbacks associated with viral vectors, prolonged CAR T cell persistence, lengthy production timelines, high costs, and the necessity of conditioning patients with organotoxic and fertility-damaging chemotherapy. Given these challenges, alternative CD19-depleting approaches are of high interest for managing severe systemic autoimmune diseases. Here, we present the pioneering use of blinatumomab, a bispecific anti-CD3/anti-CD19 T cell engager in a patient with progressive, severe systemic sclerosis, offering a promising alternative for such challenging cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38691878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/27050240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38691878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1705,
          "text": "Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3+ T-cells to engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of administration. In the expansion phase of a multi-institutional phase 1b trial (ClinicalTrials.gov, NCT04521231), heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) received SC blinatumomab at two doses: (1) 250 μg once daily (QD) for week 1 and 500 μg three times weekly (TIW) thereafter (250 μg/500 μg) or (2) 500 μg QD for week 1 and 1000 μg TIW thereafter (500 μg/1000 μg). The primary endpoint was complete remission/complete remission with partial hematologic recovery (CR/CRh) within two cycles. At the data cutoff of September 15, 2023, 29 patients were treated: 14 at the 250 μg/500 μg dose and 13 at 500 μg/1000 μg dose. Data from two ineligible patients were excluded. At the end of two cycles, 12 of 14 patients (85.7%) from the 250 μg/500 μg dose achieved CR/CRh of which nine patients (75.0%) were negative for measurable residual disease (MRD; \u003c10-4 leukemic blasts). At the 500 μg/1000 μg dose, 12 of 13 patients (92.3%) achieved CR/CRh; all 12 patients (100.0%) were MRD-negative. No treatment-related grade 4 cytokine release syndrome (CRS) or neurologic events (NEs) were reported. SC injections were well tolerated and all treatment-related grade 3 CRS and NEs responded to standard-of-care management, interruption, or discontinuation. Treatment with SC blinatumomab resulted in high efficacy, with high MRD-negativity rates and acceptable safety profile in heavily pretreated adults with R/R B-ALL.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38317420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1586,
          "text": "The bispecific T-cell engager (BiTE) blinatumomab against CD19 and CD3 has emerged as the most successful bispecific antibody (bsAb) to date; however, a significant proportion of patients do not respond to the treatments or eventually experience relapse after an initial response, and the recurrence rate increases significantly due to escape or downregulation of the CD19 antigen. To enhance antitumor efficacy and overcome potential immune escape, we developed a novel approach to design a CD19/CD22/CD3 trispecific antibody (tsAb) by site-specifically fusing anti-CD19 scFv (FMC63) and anti-CD22 nanobody (Nb25) to the defined sites of the CD3 antigen-binding fragment (Fab, SP34). This strategy allows for the optimal formation of immune synapses mediated by CD19/CD22/CD3 between target cells and T cells. Optimized tsAb can be superior for inducing T-cell-specific cytotoxicity and cytokine production against CD19+ and/or CD22+ tumor cells compared to other tsAb formats, and demonstrated significantly enhanced antitumor efficacy and the ability to overcome immune escape compared with the corresponding bsAbs alone or in combination, as well as with blinatumomab. In addition, tsAb treatment can lead to the long-term elimination of primary B-ALL patient samples in the PDX model and significantly prolong survival. This novel approach provides unique insight into the structural optimization of T-cell-redirected multispecific antibodies using site-specific recombination, and may be broadly applicable to heterogeneous and resistant tumor populations as well as solid tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/35981465"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1330,
          "text": "Bispecific antibodies and antibody fragments in various formats have been explored as a means to recruit cytolytic T cells to kill tumor cells. Encouraging clinical data have been reported with molecules such as the anti-CD19/CD3 bispecific T cell engager (BiTE) blinatumomab. However, the clinical use of many reported T cell-recruiting bispecific modalities is limited by liabilities including unfavorable pharmacokinetics, potential immunogenicity, and manufacturing challenges. We describe a B cell-targeting anti-CD20/CD3 T cell-dependent bispecific antibody (CD20-TDB), which is a full-length, humanized immunoglobulin G1 molecule with near-native antibody architecture constructed using \"knobs-into-holes\" technology. CD20-TDB is highly active in killing CD20-expressing B cells, including primary patient leukemia and lymphoma cells both in vitro and in vivo. In cynomolgus monkeys, CD20-TDB potently depletes B cells in peripheral blood and lymphoid tissues at a single dose of 1 mg/kg while demonstrating pharmacokinetic properties similar to those of conventional monoclonal antibodies. CD20-TDB also exhibits activity in vitro and in vivo in the presence of competing CD20-targeting antibodies. These data provide rationale for the clinical testing of CD20-TDB for the treatment of CD20-expressing B cell malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/25972002"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 266,
          "text": "Blinatumomab engages CD19 and CD3, performing effective serial lysis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32523659"
        },
        {
          "offsetInBeginSection": 718,
          "offsetInEndSection": 899,
          "text": "As an alternative concept of T cell activation, the dual CD19 - CD3 targeting bispecific antibody blinatumomab has been approved for refractory acute lymphatic B-cell leukemia (ALL)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30005434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "INTRODUCTION: Blinatumomab is a bispecific T-cell engager (BiTE) molecule that recruits cytotoxic T cells to target tumor B cells by linking the CD3 and CD19 antigens. Among the various formats of bispecific antibodies developed in the past 50 years,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25739952"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3+ T-cells to engage and lyse CD19+ target cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38317420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "PURPOSE: The pharmacology, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, safety and tolerability, and place in therapy of blinatumomab are reviewed.SUMMARY: Blinatumomab is a novel, bispecific, T-cell engaging antibody that targets tumor-associated antigens CD19 and CD3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26683683"
        },
        {
          "offsetInBeginSection": 335,
          "offsetInEndSection": 506,
          "text": "Blinatumomab is a bispecific T cell engager (BiTE(®)) antibody that binds both CD3-positive T cells and CD19-positive B cells via its two variable antigen-binding domains.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26020065"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "text": "BACKGROUND AND OBJECTIVES: Blinatumomab is a bispecific T-cell engager (BiTE(®)) antibody construct that transiently links CD19-positive B cells to CD3-positive T cells, resulting in induction of T-cell-mediated serial lysis of B cells and concomitant T-cell proliferation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27209293"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 444,
          "text": "Blinatumomab, an FDA-approved BiTE, binds to CD19 on B cells and to CD3 on T cells, mediating effector-target cell contact and T-cell activation that results in effective elimination of target B cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37247022"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 293,
          "text": "Blinatumomab, a bispecific T-cell engager (BiTE) that lacks the Fc portion, recognizes CD19 on B tumor cells and CD3 on T cells and induces the T cell-mediated killing of the B tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30305495"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 429,
          "text": "blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26337639"
        },
        {
          "offsetInBeginSection": 1604,
          "offsetInEndSection": 1766,
          "text": "Results of this study indicated that the expressed blinatumomab can be useful for enhancing the cytotoxicity of CD3+ T-cells against CD19 + target cells in vitro.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32195205"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 520,
          "text": "Blinatumomab is the first of a new class of antibody constructs that was labeled bispecific T-cell engager (BiTE): it consists of two single chain variable fragment connected with a flexible linker, one side binding CD3, the other CD19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790849"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 459,
          "text": " Blinatumomab, a CD19/CD3-bispecific BiTE® antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23623807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to target the cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27050240"
        },
        {
          "offsetInBeginSection": 1493,
          "offsetInEndSection": 1652,
          "text": "Another highly attractive approach is the application of the bi-specific T-cell engaging (BiTE) antibody blinatumomab which targets both CD19 and CD3 antigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872741"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 728,
          "text": "Blinatumomab is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of bispecific T cell engager",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19455460"
        },
        {
          "offsetInBeginSection": 513,
          "offsetInEndSection": 715,
          "text": "er of 2014.MECHANISM OF ACTION AND PHARMACODYNAMICS: Blinatumomab contains both an anti-CD3 and anti-CD19 arm, allowing for the juxtaposition of CD3+ T-cells to malignant CD19+ B-cells, thereby resultin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26383529"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "INTRODUCTION: Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE) antibody that simultaneously binds CD19 on the surface of B-cells and CD3 on the surface of T-cells, resulting in tu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32605497"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Blinatumomab is the first in its class bispecific T-cell engager monoclonal antibody, which binds to CD19 expressed on B-cells and CD3 expressed on T-cells, resulting in lysis of CD19-positive cells common in B-cell malignancies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33334253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Blinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31451445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26337639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to target the cancer cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809082"
        },
        {
          "offsetInBeginSection": 137,
          "offsetInEndSection": 275,
          "text": "Blinatumomab, a CD3/CD19-directed bispecific T cell engager, is reportedly effective for advanced B-cell ALL (B-ALL), even after allo-HCT.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39210087"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 556,
          "text": "We show that human plasma cells expressing either fragment crystallizable domain-deficient anti-CD19 × anti-CD3 (blinatumomab) or anti-CD33 × anti-CD3 bispecific antibodies mediate T cell activation and direct T cell killing of B acute lymphoblastic leukemia or acute myeloid leukemia cell lines in vitr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38959896"
        },
        {
          "offsetInBeginSection": 406,
          "offsetInEndSection": 611,
          "text": " Blinatumomab is a widely available CD3-CD19 BiTE that has dramatically changed the landscape of therapy for some children with precursor-B acute lymphoblastic leukemias (B-ALL) and lymphoblastic lymphomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38832422"
        },
        {
          "offsetInBeginSection": 1206,
          "offsetInEndSection": 1266,
          "text": "blinatumomab, a bispecific anti-CD3/anti-CD19 T cell engager",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38691878"
        },
        {
          "offsetInBeginSection": 713,
          "offsetInEndSection": 817,
          "text": "FDA approved blinatumomab, a TCE directed to CD3 and CD19 for treatment of acute lymphoblastic leukemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38672662"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 443,
          "text": "Blinatumomab, an FDA-approved BiTE, binds to CD19 on B cells and to CD3 on T cells, mediating effector-target cell contact and T-cell activation that results in effective elimination of target B cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37247022"
        },
        {
          "offsetInBeginSection": 335,
          "offsetInEndSection": 505,
          "text": "Blinatumomab is a bispecific T cell engager (BiTE(®)) antibody that binds both CD3-positive T cells and CD19-positive B cells via its two variable antigen-binding domains",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26020065"
        },
        {
          "offsetInBeginSection": 597,
          "offsetInEndSection": 740,
          "text": "ll malignancies.RESULTS: Blinatumomab is a bispecific T-cell engager that binds to both CD19 on B cells and CD3 on T cells, facilitating antibo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34741682"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 340,
          "text": "Blinatumomab is a bispecific T-cell engager immunotherapy that simultaneously binds to CD3-positive cytotoxic T cells and CD19-positive B cells and redirects the patient\u0027s T cells to lyse malignant and normal B cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32564243"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "BACKGROUND: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule that engages T cells to lyse CD19-express",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Blinatumomab, a CD19/CD3 bispecific T-cell engager; inotuzumab ozogamicin (INO), a CD22 antibody drug conjugate; and chimeric-antigen receptor (CAR) T-cell constructs are novel immune-therapeutic options for treatment of acute lymphoblastic leukemia (ALL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39611241"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Blinatumomab is a CD3 × CD19 antibody approved for adults with B-cell acute lymphoblastic leukemia (B-ALL)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39282955"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 457,
          "text": "g children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may impro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39651791"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Blinatumomab is a CD3/CD19-directed bispecific T-cell engager used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39008535"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Blinatumomab, a CD19/CD3 bispecific T-cell engager, is recognized as an effective immunotherapy for relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39006644"
        },
        {
          "offsetInBeginSection": 411,
          "offsetInEndSection": 472,
          "text": "therapy and blinatumomab (a CD19/CD3-targeted bispecific T-ce",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38871977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 354,
          "text": "Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described. Two bispecific antibodies, catumaxomab (Removab(®), anti-EpCAM×anti-CD3) and blinatumomab (Blincyto(®), anti-CD19×anti-CD3) are approved for therapy, and \u003e30 additional bispecific antibodies are currently in clinical developm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637431"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Blinatumomab (BLINCYTO™) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 356,
          "text": "For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE®), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for treating certain CD19-positive hematological malignancies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28837681"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Blinatumomab, a CD19/CD3 bispecific T-cell engager, is recognized as an effective immunotherapy for relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39006644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Blinatumomab, a CD19/CD3 bispecific T-cell engager; inotuzumab ozogamicin (INO), a CD22 antibody drug conjugate; and chimeric-antigen receptor (CAR) T-cell constructs are novel immune-therapeutic options for treatment of acute lymphoblastic leukemia (ALL)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39611241"
        },
        {
          "offsetInBeginSection": 1167,
          "offsetInEndSection": 1384,
          "text": "Here, we present the pioneering use of blinatumomab, a bispecific anti-CD3/anti-CD19 T cell engager in a patient with progressive, severe systemic sclerosis, offering a promising alternative for such challenging cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38691878"
        },
        {
          "offsetInBeginSection": 497,
          "offsetInEndSection": 634,
          "text": "notherapy for NHL. The development of CD19 × CD3 BsAbs such as blinatumomab was met with significant challenges due to dose-limiting neur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35182296"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "BACKGROUND: Blinatumomab is a bispecific T-cell engager (BiTE®) antibody construct targeting CD3ε on T cells and CD19",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29773068"
        },
        {
          "offsetInBeginSection": 745,
          "offsetInEndSection": 1004,
          "text": "The therapeutic efficacy of this approach for treatment of relapsed or refractory B-cell lymphomas was first demonstrated with blinatumomab, a single molecule comprised of two linked single-chain variable fragments with binding specificities for CD19 and CD3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34105818"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34117317"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 267,
          "text": "Blinatumomab engages CD19 and CD3, performing effective serial lysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32523659"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 349,
          "text": "These targets include a bispecific antibody that targets both CD3 and CD19, known as blinatumomab,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33279181"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redirect T cells toward CD19-positive tumor cells and has been approved to treat relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34117317"
        }
      ],
      "type": "list",
      "id": "67e5749b18b1e36f2e0000b5",
      "ideal_answer": [
        "Blinatumomab is a fusion protein which consists of two single-chain variable fragments arranged in tandem: the first binds the CD19 surface antigen of all B cells and the second targets the CD3 antigen of T cells."
      ],
      "exact_answer": [
        [
          "CD19"
        ],
        [
          "CD3"
        ]
      ]
    },
    {
      "body": "What is the relationship between bronchiectasis and Erdosteine?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18035199",
        "http://www.ncbi.nlm.nih.gov/pubmed/38719503",
        "https://www.ncbi.nlm.nih.gov/pubmed/38719503"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion:",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 425,
          "text": " chest physiotherapy and/or the use of mucoactive agents is considered to be an effective therapeutic model in treating patients with COPD and bronchiectasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199"
        },
        {
          "offsetInBeginSection": 2671,
          "offsetInEndSection": 2925,
          "text": "This pilot study found that a regimen of PO erdosteine 225 mg BID in addition to routine chest physiotherapy provided some physiologic and clinical benefits in the treatment of these elderly patients with bronchiectasis and chronic mucus hyper-secretion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199"
        },
        {
          "offsetInBeginSection": 576,
          "offsetInEndSection": 927,
          "text": "s.Our primary aim is to determine in children and adults aged 2-49 years with bronchiectasis whether regular erdosteine over a 12-month period reduces acute respiratory exacerbations compared with placebo. Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those receiving placebo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1152,
          "text": "Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those receiving placebo.Our secondary aims are to determine the effect of the trial medications on quality of life (QoL) and other clinical outcomes (exacerbation duration, time-to-next exacerbation, hospitalisations, lung function, adverse events)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 768,
          "offsetInEndSection": 914,
          "text": "with placebo. Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those rece",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 634,
          "text": "chiectasis.OBJECTIVE: The objective of this study was to test the effectiveness of oral erdosteine in treating elderly patients with bronchiectasis and chronic mucus hypersecretion who have been referred to a pulmonary r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 633,
          "text": "chiectasis.OBJECTIVE: The objective of this study was to test the effectiveness of oral erdosteine in treating elderly patients with bronchiectasis and chronic mucus hypersecretion who have been referred to a pulmonary ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18035199"
        },
        {
          "offsetInBeginSection": 768,
          "offsetInEndSection": 913,
          "text": "with placebo. Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those rec",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 782,
          "offsetInEndSection": 927,
          "text": "Our primary hypothesis is that people with bronchiectasis who regularly use erdosteine will have fewer exacerbations than those receiving placebo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        },
        {
          "offsetInBeginSection": 389,
          "offsetInEndSection": 766,
          "text": "n and adults. Our RCT will address some of these unmet needs by evaluating whether the novel mucoactive agent, erdosteine, has a therapeutic role in children and adults with bronchiectasis.Our primary aim is to determine in children and adults aged 2-49 years with bronchiectasis whether regular erdosteine over a 12-month period reduces acute respiratory exacerbations compare",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38719503"
        }
      ],
      "type": "summary",
      "id": "680d5f2a353a4a2e6b000006",
      "ideal_answer": [
        "A regimen of PO erdosteine in addition to routine chest physiotherapy provided some physiologic and clinical benefits in the treatment of these elderly patients with bronchiectasis and chronic mucus hyper-secretion.",
        "Erdosteine is a mucolytic agent that is used for the treatment of bronchiectasis.",
        "Erdosteine is hypothesized to reduce the number of exacerbations in people with bronchiectasis when used regularly compared to a placebo.",
        "Erdosteine is being investigated for its potential to reduce acute respiratory exacerbations in individuals with bronchiectasis, particularly over a 12-month period, and has shown some benefits in improving lung function and reducing mucus hypersecretion when used with chest physiotherapy in elderly patients. However, the improvements are modest and require further investigation.",
        "Erdosteine is a mucolytic agent used to improve symptoms in patients with bronchiectasis by reducing mucus viscosity and aiding in its clearance from the airways.",
        "Erdosteine is a novel mucoactive agent being evaluated for its therapeutic role in children and adults with bronchiectasis. Studies aim to determine if regular erdosteine reduces acute respiratory exacerbations compared to placebo in individuals aged 2-49 years with bronchiectasis. It may also be a useful adjunct to physiotherapy in stable patients with mucus hypersecretion.",
        "Erdosteine is used in the treatment of bronchiectasis.",
        "Erdosteine is a mucolytic agent that has been studied for its potential benefits in treating bronchiectasis.",
        "Erdosteine is a multifactorial drug used in the treatment of bronchiectasis. It has mucolytic properties that decrease sputum viscoelasticity and bacterial adhesion, and it also possesses bronchial anti-inflammatory activity and a scavenging effect on free oxidant radicals .",
        "bronchiectasis is a condition treated by Erdosteine.",
        "Erdosteine is used as a therapeutic agent in treating bronchiectasis, aiming to reduce acute respiratory exacerbations and improve clinical outcomes such as quality of life, lung function, and hospitalizations.",
        "Long term erdosteine treatment reduces the annual number of exacerbations and the rate of decline in lung function in patients with non cystic fibrosis bronchiectasis. ",
        "Erdosteine is a mucolytic agent that has been shown to be effective in the treatment of bronchiectasis. In a randomized controlled trial, erdosteine was shown to reduce the number of exacerbations in patients with bronchiectasis. Erdosteine was also shown to improve lung function and quality of life in patients with bronchiectasis.",
        "Erdosteine is hypothesized to reduce the number of exacerbations in people with bronchiectasis compared to those receiving a placebo.",
        "Erdosteine is a multimechanism, mucolytic agent that decreases the sputum viscoelastic properties and bacterial adhesion to the cell membrane, endowed with bronchial anti-inflammatory activity and a scavenging effect on free oxidant radicals. It is used in the treatment of bronchiectasis to reduce acute respiratory exacerbations and improve clinical outcomes .",
        "The relationship between bronchiectasis and Erdosteine is that Erdosteine may help manage symptoms of bronchiectasis by reducing mucus hypersecretion and improving lung function, although more research is needed to confirm its long-term efficacy.",
        "Erdosteine has a therapeutic potential in managing bronchiectasis, as evidenced by its mucolytic, anti-inflammatory, and antioxidant properties, which can help reduce exacerbations and improve symptoms in patients with this condition, particularly when used in conjunction with other treatments like chest physiotherapy.",
        "Erdosteine is a mucoactive agent that may help in treating bronchiectasis by improving mucus clearance and reducing exacerbations.",
        "Erdosteine, a mucoactive agent, is considered a therapeutic option for bronchiectasis, especially in elderly patients experiencing chronic mucus hyper-secretion. Studies, including pilot studies, suggest that a regimen of oral erdosteine 225 mg twice daily (BID) alongside routine chest physiotherapy can provide some physiologic and clinical benefits in these patients.",
        "Erdosteine is used for the treatment of bronchiectasis.",
        "Erdosteine is effective for the treatment of bronchiectatic secretions.",
        "Erdosteine has been found to provide some physiologic and clinical benefits in the treatment of elderly patients with bronchiectasis and chronic mucus hyper-secretion.",
        " Elderly patient bronchiectasis hypersecretion chest physiotherapy and/or use mucoactive agent consider effective therapeutic model treat patient copd bronchectasis pilot study .",
        "Erdosteine is used as a mucoactive agent in the treatment of bronchiectasis. Specifically, studies have shown that when added to standard chest physiotherapy, it can provide both physiological and clinical benefits, particularly in elderly patients with chronic mucus hypersecretion.",
        "Erdosteine is a mucoactive agent used in the treatment of bronchiectasis, particularly in elderly patients with chronic mucus hypersecretion. A regimen of oral erdosteine 225 mg twice daily, when added to routine chest physiotherapy, has been shown to provide physiologic and clinical benefits in managing this condition.",
        "A regimen including the mucoactive agent erdosteine, when combined with routine chest physiotherapy, has shown physiologic and clinical benefits in elderly patients with bronchiectasis and chronic mucus hyper-secretion.",
        "Erdosteine is used in the treatment of bronchiectasis",
        "Erdosteine, at a regimen of 225 mg BID along with routine chest physiotherapy, has been found to provide physiologic and clinical benefits in the treatment of elderly patients with bronchiectasis and chronic mucus hypersecretion.",
        "Erdosteine (225 mg BID) combined with chest physiotherapy showed beneficial effects in treating elderly patients with bronchiectasis and chronic mucus hypersecretion, serving as an effective mucoactive agent in their treatment regimen.",
        "Erdosteine is a mucoactive agent that has been found to be effective in treating elderly patients with bronchiectasis and chronic mucus hypersecretion. It is often used in conjunction with chest physiotherapy to provide physiologic and clinical benefits in the treatment of these patients.",
        "This pilot study found that a regimen of PO erdosteine 225 mg BID in addition to routine chest physiotherapy provided some physiologic and clinical benefits in the treatment of these elderly patients with bronchiectasis and chronic mucus hyper-secretion.",
        "Erdosteine has shown potential benefits in the treatment of bronchiectasis, particularly in elderly patients with chronic mucus hypersecretion. A pilot study indicated that a regimen of oral erdosteine (225 mg twice daily) combined with routine chest physiotherapy provided physiological and clinical improvements, including enhanced spirometry and reduced sputum purulence compared to physiotherapy alone. The primary hypothesis of ongoing research suggests that regular use of erdosteine may lead to fewer exacerbations in patients with bronchiectasis. However, while initial findings are promising, robust long-term randomized controlled trials are necessary to fully assess the efficacy and safety of erdosteine as a treatment option for bronchiectasis.",
        "bronchiectasis and Erdosteine are connected through the condition of chronic mucus hyper-secretion, as Erdosteine is a medication that helps manage this symptom in patients with bronchiectasis.",
        "Erdosteine is used as a mucoactive agent that provides physiologic and clinical benefits in treating elderly patients with bronchiectasis and chronic mucus hyper-secretion, especially when combined with chest physiotherapy.",
        "Erdosteine, when used in conjunction with chest physiotherapy, exhibits a beneficial therapeutic relationship with bronchiectasis, particularly in elderly patients with chronic mucus hypersecretion, leading to improved lung function, reduced symptoms, and enhanced mucus properties.",
        "This pilot study found that a regimen of PO erdosteine 225 mg BID in addition to routine chest physiotherapy provided some physiologic and clinical benefits in the treatment of elderly patients with bronchiectasis and chronic mucus hyper-secretion.",
        "Erdosteine, when used alongside routine chest physiotherapy, has shown physiologic and clinical benefits in elderly patients with bronchiectasis and chronic mucus hypersecretion, suggesting it is an effective mucoactive agent for managing symptoms in this population.",
        "Erdosteine has been found to provide some physiologic and clinical benefits in the treatment of elderly patients with bronchiectasis and chronic mucus hyper-secretion when used in addition to routine chest physiotherapy.",
        "[\u0027Erdosteine is used as a treatment for elderly patients with bronchiectasis and chronic mucus hypersecretion. In a pilot study, administering erdosteine in combination with routine chest physiotherapy showed physiological and clinical benefits for these patients.\u0027]"
      ]
    },
    {
      "body": "Can GLP-1 receptor agonists be used for obesity in children under 10 years of age?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39065679",
        "http://www.ncbi.nlm.nih.gov/pubmed/38778795",
        "http://www.ncbi.nlm.nih.gov/pubmed/38941713",
        "http://www.ncbi.nlm.nih.gov/pubmed/38204284",
        "http://www.ncbi.nlm.nih.gov/pubmed/39222618",
        "http://www.ncbi.nlm.nih.gov/pubmed/38689134",
        "http://www.ncbi.nlm.nih.gov/pubmed/39350608",
        "http://www.ncbi.nlm.nih.gov/pubmed/37206449",
        "http://www.ncbi.nlm.nih.gov/pubmed/39401009",
        "http://www.ncbi.nlm.nih.gov/pubmed/38027106",
        "http://www.ncbi.nlm.nih.gov/pubmed/38864114"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1279,
          "offsetInEndSection": 1416,
          "text": "Semaglutide appeared to be the most effective and safe option among four GLP-1 RAs in children and adolescents with obesity or overweight",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39065679"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 435,
          "text": " current practice patterns of GLP-1A use at major pediatric bariatric centers across the United States",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38941713"
        },
        {
          "offsetInBeginSection": 1357,
          "offsetInEndSection": 1467,
          "text": "GLP-1 RAs are safe, acceptable, and effective in weight reduction and sugar control for children with obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38204284"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 711,
          "text": "iorenal protection. GLP-1 RAs are also approved for children with obesity (above the age of 12 years) or type 2 diabetes (above t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39222618"
        },
        {
          "offsetInBeginSection": 602,
          "offsetInEndSection": 730,
          "text": "GLP-1 RAs are also approved for children with obesity (above the age of 12 years) or type 2 diabetes (above the age of 10 years)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39222618"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 133,
          "text": "Glucagon-like peptide 1 receptor agonists (GLP1R) are increasingly being used for the treatment of obesity in adolescents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39401009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "In 2020, the US Food and Drug Administration approved liraglutide (glucagon-like-peptide-1-receptor-agonist) as an adjunctive therapy for weight management in adolescents aged 12 to 18 years in combination with a reduced-calorie diet and increased physical activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38864114"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 357,
          "text": "Liraglutide, a glucagon-like-peptide-1 (GLP-1) analogue, is FDA approved for T2DM in children 10 years or older and more recently approved for chronic weight management in children 12 years or older with obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37206449"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 484,
          "text": "Over the past few years, more FDA-approved medical treatments for obesity, such as GLP-1 receptor agonists, have emerged for patients less than 18 years old.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38689134"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 95,
          "text": "GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38027106"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 437,
          "text": "In 2020, the US Food and Drug Administration approved liraglutide (glucagon-like-peptide-1-receptor-agonist) as an adjunctive therapy for weight management in adolescents aged 12 to 18 years in combination with a reduced-calorie diet and increased physical activity. The 2023 American Academy of Pediatrics guidelines recommend pharmacotherapy with glucagon-like-peptide-1-receptor-agonist as a second-line therapy in obesity management.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38864114"
        },
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 843,
          "text": "The efficacy of GLP-1 receptor agonists in the management of obesity in adults, as well as in children and adolescents, has now been supported by several clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39350608"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Four glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used in children and adolescents with obesity or overweight.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39065679"
        }
      ],
      "id": "6810f6f0353a4a2e6b000015",
      "ideal_answer": [
        "The use of GLP-1 receptor agonists for obesity in children under 10 years of age is not well-established due to limited research and clinical trial data. While these medications have been effective in treating obesity in children under 18, specific data for those under 10 is scarce. Some clinical trials have included children under 10, using drugs like exenatide, semaglutide, and liraglutide, but the number of such trials is limited, and their efficacy and safety in this age group have not been thoroughly examined. There is preliminary evidence suggesting potential benefits for hypothalamic obesity in younger patients, though outcomes can vary. Overall, while there is some support for using GLP-1 receptor agonists in children under 10, more research is needed to fully understand their effectiveness and safety for this specific age group.",
        "Based on the provided abstracts, there is no evidence to support the use of GLP-1 receptor agonists for obesity in children under 10 years of age. The FDA has approved liraglutide for T2DM in children 10 years or older and for chronic weight management in children 12 years or older with obesity. Additionally, the 2023 American Academy of Pediatrics guidelines recommend pharmacotherapy with glucagon-like-peptide-1-receptor-agonist as a second-line therapy in obesity management, but there is no mention of its use in children under 10 years old.\n\nThe available studies and reviews focus on the efficacy and safety of GLP-1 receptor agonists in adolescents (12-18 years) with obesity, but not in younger children. Therefore, it is not recommended to use GLP-1 receptor agonists for obesity treatment in children under 10 years of age without further research and evidence supporting its safety and efficacy in this age group."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Are radiomic features useful in predicting survival in glioblastoma patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38668068",
        "http://www.ncbi.nlm.nih.gov/pubmed/39099033",
        "http://www.ncbi.nlm.nih.gov/pubmed/37751102",
        "http://www.ncbi.nlm.nih.gov/pubmed/30449497",
        "http://www.ncbi.nlm.nih.gov/pubmed/36461120",
        "http://www.ncbi.nlm.nih.gov/pubmed/35405713",
        "http://www.ncbi.nlm.nih.gov/pubmed/32980505",
        "http://www.ncbi.nlm.nih.gov/pubmed/30277442",
        "http://www.ncbi.nlm.nih.gov/pubmed/28325002",
        "http://www.ncbi.nlm.nih.gov/pubmed/31546124",
        "http://www.ncbi.nlm.nih.gov/pubmed/29036412",
        "https://www.ncbi.nlm.nih.gov/pubmed/34519578",
        "https://www.ncbi.nlm.nih.gov/pubmed/34829395",
        "https://www.ncbi.nlm.nih.gov/pubmed/35405713",
        "https://www.ncbi.nlm.nih.gov/pubmed/36461120",
        "https://www.ncbi.nlm.nih.gov/pubmed/37751102",
        "http://www.ncbi.nlm.nih.gov/pubmed/31289886",
        "http://www.ncbi.nlm.nih.gov/pubmed/27778090",
        "http://www.ncbi.nlm.nih.gov/pubmed/32566694",
        "http://www.ncbi.nlm.nih.gov/pubmed/38339340",
        "http://www.ncbi.nlm.nih.gov/pubmed/37060774",
        "http://www.ncbi.nlm.nih.gov/pubmed/30774763",
        "http://www.ncbi.nlm.nih.gov/pubmed/39518054",
        "http://www.ncbi.nlm.nih.gov/pubmed/39246787",
        "http://www.ncbi.nlm.nih.gov/pubmed/28079702",
        "http://www.ncbi.nlm.nih.gov/pubmed/33006658",
        "http://www.ncbi.nlm.nih.gov/pubmed/34900728",
        "http://www.ncbi.nlm.nih.gov/pubmed/27326665",
        "http://www.ncbi.nlm.nih.gov/pubmed/37222229",
        "http://www.ncbi.nlm.nih.gov/pubmed/30847586",
        "http://www.ncbi.nlm.nih.gov/pubmed/33559302",
        "http://www.ncbi.nlm.nih.gov/pubmed/34519578",
        "http://www.ncbi.nlm.nih.gov/pubmed/38896238",
        "http://www.ncbi.nlm.nih.gov/pubmed/38098850",
        "http://www.ncbi.nlm.nih.gov/pubmed/34829395",
        "http://www.ncbi.nlm.nih.gov/pubmed/31594994",
        "http://www.ncbi.nlm.nih.gov/pubmed/39249499",
        "http://www.ncbi.nlm.nih.gov/pubmed/32605068",
        "http://www.ncbi.nlm.nih.gov/pubmed/30660472"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1282,
          "offsetInEndSection": 1518,
          "text": "Radiomics analysis, utilizing segmented perfusion and diffusion maps, provide predictive indicators of survival in IDH wild-type glioblastoma patients, revealing associations with microstructural and vascular heterogeneity in the tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38668068"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 213,
          "text": "Extracting multiregional radiomic features from multiparametric MRI for predicting pretreatment survival in isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients is a promising approach.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38668068"
        },
        {
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1138,
          "text": "Findings suggest that a small necrotic subregion, inhomogeneous vascularization in the solid non-enhancing subregion, and edema-related tissue damage in the enhancing and edema subregions are linked to poor survival. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38668068"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 380,
          "text": "Glioblastoma multiforme (GBM), particularly the isocitrate dehydrogenase (IDH)-wildtype type, represents a significant clinical challenge due to its aggressive nature and poor prognosis. Despite advancements in medical imaging and its modalities, survival rates have not improved significantly, demanding innovative treatment planning and outcome prediction approaches.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39099033"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 290,
          "text": "Glioblastoma Multiforme (GBM) represents the predominant aggressive primary tumor of the brain with short overall survival (OS) time. We aim to assess the potential of radiomic features in predicting the time-to-event OS of patients with GBM using machine learning (ML) algorithms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37751102"
        },
        {
          "offsetInBeginSection": 1488,
          "offsetInEndSection": 1883,
          "text": "ML algorithms are capable of predicting the time-to-event OS of patients using MRI-based radiomic and clinical features. MRI-based radiomics analysis in combination with clinical variables might appear promising in assisting clinicians in the survival prediction of patients with GBM. Further research is needed to establish the applicability of radiomics in the management of GBM in the clinic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37751102"
        },
        {
          "offsetInBeginSection": 1761,
          "offsetInEndSection": 2039,
          "text": "The proposed method significantly enhances the predictive accuracy of OS outcomes in GBM, IDH-wildtype patients. By integrating detailed imaging features with key clinical indicators, this model offers a robust tool for personalized treatment planning, potentially improving OS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39099033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 403,
          "text": "Glioblastoma multiforme (GBM) are aggressive brain tumors, which lead to poor overall survival (OS) of patients. OS prediction of GBM patients provides useful information for surgical and treatment planning. Radiomics research attempts at predicting disease prognosis, thus providing beneficial information for personalized treatment from a variety of imaging features extracted from multiple MR images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30449497"
        },
        {
          "offsetInBeginSection": 2004,
          "offsetInEndSection": 2241,
          "text": "Conclusions: This quantitative evaluation indicates that accurate survival prediction in glioblastoma patients is feasible using solely Bas-mpMRI and integrative advanced radiomic features, which can compensate for the lack of Adv-mpMRI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32566694"
        },
        {
          "offsetInBeginSection": 2017,
          "offsetInEndSection": 2241,
          "text": "This quantitative evaluation indicates that accurate survival prediction in glioblastoma patients is feasible using solely Bas-mpMRI and integrative advanced radiomic features, which can compensate for the lack of Adv-mpMRI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32566694"
        },
        {
          "offsetInBeginSection": 1330,
          "offsetInEndSection": 1436,
          "text": "The radiomics-based ML model demonstrates potential to improve the prediction of OS for patients with GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39518054"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33006658"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 403,
          "text": "Radiomics research attempts at predicting disease prognosis, thus providing beneficial information for personalized treatment from a variety of imaging features extracted from multiple MR images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30449497"
        },
        {
          "offsetInBeginSection": 2285,
          "offsetInEndSection": 2556,
          "text": "Conclusion An 11-feature radiomic signature that allows prediction of survival and stratification of patients with newly diagnosed glioblastoma was identified, and improved performance compared with that of established clinical and radiologic risk models was demonstrated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27326665"
        },
        {
          "offsetInBeginSection": 1669,
          "offsetInEndSection": 1832,
          "text": "Radiomic MRI phenotyping can improve survival prediction when integrated with clinical and genetic profiles and thus has potential as a practical imaging biomarker",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30277442"
        },
        {
          "offsetInBeginSection": 1441,
          "offsetInEndSection": 1655,
          "text": "The addition of a radiomics model to clinical and genetic profiles improved survival prediction when compared with models containing clinical and genetic profiles alone (P \u003d .04 and .03 for OS and PFS, respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30277442"
        },
        {
          "offsetInBeginSection": 1390,
          "offsetInEndSection": 1553,
          "text": "Radiomics can be used to build a prognostic score for stratifying high- and low-risk GBM, which was an independent prognostic factor from pMGMT methylation status.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594994"
        },
        {
          "offsetInBeginSection": 888,
          "offsetInEndSection": 988,
          "text": "The radiomic high- and low-risk stratification and pMGMT status were independent prognostic factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594994"
        },
        {
          "offsetInBeginSection": 1441,
          "offsetInEndSection": 1657,
          "text": "The addition of a radiomics model to clinical and genetic profiles improved survival prediction when compared with models containing clinical and genetic profiles alone (P \u003d .04 and .03 for OS and PFS, respectively).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30277442"
        },
        {
          "offsetInBeginSection": 1669,
          "offsetInEndSection": 1833,
          "text": "Radiomic MRI phenotyping can improve survival prediction when integrated with clinical and genetic profiles and thus has potential as a practical imaging biomarker.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30277442"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 757,
          "text": "GBM patients were successfully stratified by the radiomics risk score, a weighted sum of radiomics features, corroborating the potential of radiomics as a prognostic biomarker.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32605068"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30774763"
        },
        {
          "offsetInBeginSection": 2285,
          "offsetInEndSection": 2557,
          "text": "Conclusion An 11-feature radiomic signature that allows prediction of survival and stratification of patients with newly diagnosed glioblastoma was identified, and improved performance compared with that of established clinical and radiologic risk models was demonstrated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27326665"
        }
      ],
      "id": "680a237618b1e36f2e000152",
      "ideal_answer": [
        "Glioblastoma multiforme (GBM) represents the predominant aggressive primary tumor of the brain with poor overall survival (OS) time. OS prediction of GBM patients provides useful information for surgical and treatment planning. Radiomics research attempts to predict disease prognosis, thus providing beneficial information for personalized treatment from a variety of extracted imaging features. Indeed, various studies have shown that radiomics analysis, obtained from MRI images, provides predictive indicators of survival in IDH wild-type glioblastoma patients, revealing associations with microstructural and vascular heterogeneity in the tumor. By integrating the imaging features with key clinical indicators, the implemented tools can become more robust and appear promising in assisting clinicians in the survival prediction of patients with GBM. Still, further research is needed to establish the applicability of radiomics in the management of GBM in the clinic.",
        "Yes, radiomic features are useful in predicting survival in glioblastoma patients. Radiomics involves extracting numerous quantitative features from medical images, such as MRI scans, to capture tumor characteristics that are not visible to the naked eye. These features can be correlated with clinical outcomes, including survival rates, by providing insights into tumor heterogeneity, shape, and texture. Studies have shown that radiomic features can improve prognostic assessments and guide treatment planning for glioblastoma patients. Machine learning models utilizing these features have been developed to enhance predictions of survival, offering a more comprehensive understanding of the tumor and its behavior. By integrating radiomic data into clinical practice, healthcare providers can potentially tailor treatment strategies more effectively, improving patient outcomes. Overall, radiomics represents a promising approach in the management of glioblastoma, aiding in the prediction of survival and the personalization of treatment plans.",
        "Radiomic features show promise in predicting survival in glioblastoma patients. These features are derived from standard imaging techniques like MRI and provide quantitative information on tumor heterogeneity, shape, texture, and intensity. When combined with clinical factors and even genomic data, radiomic features have been found to enhance prognostic models compared to using clinical data alone. Current research indicates that certain imaging biomarkers may correlate with overall survival and progression-free survival. However, challenges remain, including the need for standardized image acquisition and processing protocols, external validation in larger and more diverse patient cohorts, and measures to prevent overfitting in studies with small populations. In summary, while radiomic features offer a promising tool for predicting survival outcomes in glioblastoma, further validation and standardization are essential before they can be integrated into routine clinical decision making.",
        "Yes, radiomic features are useful in predicting survival in glioblastoma patients. Multiple studies have consistently shown that radiomic features extracted from MRI images can improve survival prediction when integrated with clinical and genetic profiles. These features, which capture intensity heterogeneity and textural patterns, have been found to be predictive of survival and can provide individualized probabilities of survival stratification for GBM patients. The incorporation of radiomic signatures into clinical models has resulted in better calibration and classification accuracy compared to either model alone. Radiomics nomograms have demonstrated favorable predictive accuracy and can serve as a non-invasive prediction tool for GBM patients. Overall, the evidence suggests that radiomic features are a valuable addition to traditional clinical and genetic markers for predicting survival outcomes in glioblastoma patients.",
        "The snippets suggest that radiomic features, which are multiregional characteristics extracted from MRI scans, are useful in predicting survival in glioblastoma patients, particularly those with the IDH wild-type variant. This is because these features provide predictive indicators of survival, revealing associations with microstructural and vascular heterogeneity in the tumor. The findings suggest that certain characteristics within the tissue, such as a small necrotic subregion, inhomogeneous vascularization, and edema-related tissue damage, are linked to poor survival. Therefore, radiomic analysis can potentially assist clinicians in survival prediction of patients with glioblastoma, offering a robust tool for personalized treatment planning.",
        "The provided documents suggest that radiomic features obtained from MRI imaging are useful in predicting survival in glioblastoma patients, particularly those with IDH-wildtype glioblastoma. This is supported by findings that link specific radiomic features, such as small necrotic subregions, inhomogeneous vascularization, and edema-related tissue damage, to poor survival. Additionally, the documents suggest that ML algorithms can predict the time-to-event overall survival (OS) of patients with GBM using MRI-based radiomic and clinical features, and that this approach could potentially improve OS outcomes. However, it is noted that further research is needed to establish the applicability of radiomics in the management of GBM in the clinic.",
        "Yes, radiomic features are useful in predicting survival in glioblastoma patients. Research has shown that using segmented perfusion and diffusion maps in radiomics analysis can provide predictive indicators of survival, especially in IDH wild-type glioblastoma patients. These features are associated with the tumor\u0027s microstructural and vascular heterogeneity, which are important for survival outcomes. Furthermore, machine learning algorithms using MRI-based radiomic and clinical features have been effective in predicting the time-to-event overall survival, enhancing the accuracy of survival predictions and aiding in personalized treatment planning for these patients.",
        "Yes, radiomic features derived from multiparametric MRI are useful in predicting survival in glioblastoma (GBM) patients, particularly IDH wild-type GBM. Radiomics analysis captures tumor heterogeneity, including microstructural and vascular variations, which correlate with prognosis. Studies show associations between specific radiomic features (e.g., necrotic subregions, inhomogeneous vascularization in solid non-enhancing areas, edema-related tissue damage) and poor survival outcomes. Machine learning models integrating these imaging features with clinical variables (e.g., age, treatment data) enhance predictive accuracy for overall survival (OS), aiding personalized treatment planning. While promising, further validation is needed to confirm clinical applicability.",
        "Yes, radiomic features are useful in predicting survival in glioblastoma (GBM) patients. Studies demonstrate that radiomic features extracted from MRI images, especially when combined with clinical and genetic profiles, improve the prediction of overall survival (OS) in GBM patients. Radiomics analysis, including the use of machine learning algorithms and deep learning models, can identify imaging signatures and stratify patients into different risk groups based on OS. These features capture tumor heterogeneity, microstructural characteristics, and vascular properties, providing valuable prognostic information for personalized treatment planning and potentially improving OS in GBM patients.",
        "Radiomic features, derived from MRI-based imaging such as perfusion and diffusion maps, demonstrate potential in predicting overall survival (OS) for glioblastoma multiforme (GBM) patients, particularly in IDH-wildtype subgroups. Machine learning (ML) algorithms integrating radiomic data with clinical variables enhance predictive accuracy for time-to-event OS, offering insights into tumor heterogeneity and vascular/microstructural characteristics. These features provide actionable information for personalized treatment planning, though their clinical applicability requires further validation. While radiomics shows promise in stratifying prognosis and guiding therapeutic decisions, additional research is needed to standardize methodologies and confirm reproducibility across diverse patient populations. The combination of radiomic signatures with clinical indicators represents a promising approach to improve OS prediction in GBM, addressing the aggressive nature of this tumor.",
        "Radiomic features are indeed useful in predicting survival outcomes in glioblastoma patients. Studies have shown that extracting various radiomic features from MRI scans, such as texture, shape, and intensity, can provide valuable prognostic information. These features help identify tumor characteristics like necrotic areas and vascular heterogeneity, which are associated with poor survival. When combined with machine learning algorithms and clinical data, radiomics enhances predictive accuracy for overall survival, aiding in personalized treatment planning. While promising, further research is needed to fully integrate these methods into clinical practice."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "In patients with acute liver failure associated with  paracetamol overdose does  N‐acetylcysteine treatment improve survival?.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9261645",
        "http://www.ncbi.nlm.nih.gov/pubmed/1954453",
        "http://www.ncbi.nlm.nih.gov/pubmed/10919033",
        "http://www.ncbi.nlm.nih.gov/pubmed/33294991",
        "http://www.ncbi.nlm.nih.gov/pubmed/33946130",
        "http://www.ncbi.nlm.nih.gov/pubmed/1972496",
        "http://www.ncbi.nlm.nih.gov/pubmed/2328143",
        "http://www.ncbi.nlm.nih.gov/pubmed/39051728",
        "http://www.ncbi.nlm.nih.gov/pubmed/8209319",
        "https://www.ncbi.nlm.nih.gov/pubmed/19524577",
        "http://www.ncbi.nlm.nih.gov/pubmed/23943180",
        "http://www.ncbi.nlm.nih.gov/pubmed/17210206",
        "http://www.ncbi.nlm.nih.gov/pubmed/38540289",
        "http://www.ncbi.nlm.nih.gov/pubmed/19490595",
        "http://www.ncbi.nlm.nih.gov/pubmed/21126198",
        "http://www.ncbi.nlm.nih.gov/pubmed/27108714",
        "http://www.ncbi.nlm.nih.gov/pubmed/19524577",
        "http://www.ncbi.nlm.nih.gov/pubmed/7421628",
        "http://www.ncbi.nlm.nih.gov/pubmed/34951044",
        "http://www.ncbi.nlm.nih.gov/pubmed/1340573",
        "http://www.ncbi.nlm.nih.gov/pubmed/37681263",
        "http://www.ncbi.nlm.nih.gov/pubmed/37559860",
        "http://www.ncbi.nlm.nih.gov/pubmed/37224750",
        "http://www.ncbi.nlm.nih.gov/pubmed/24576052",
        "http://www.ncbi.nlm.nih.gov/pubmed/19169150",
        "http://www.ncbi.nlm.nih.gov/pubmed/25083244",
        "http://www.ncbi.nlm.nih.gov/pubmed/30621764",
        "http://www.ncbi.nlm.nih.gov/pubmed/18570942",
        "http://www.ncbi.nlm.nih.gov/pubmed/1904133",
        "http://www.ncbi.nlm.nih.gov/pubmed/29605069",
        "http://www.ncbi.nlm.nih.gov/pubmed/37767143",
        "http://www.ncbi.nlm.nih.gov/pubmed/15527712",
        "http://www.ncbi.nlm.nih.gov/pubmed/23683460",
        "http://www.ncbi.nlm.nih.gov/pubmed/11588469",
        "http://www.ncbi.nlm.nih.gov/pubmed/17335680",
        "http://www.ncbi.nlm.nih.gov/pubmed/31317129",
        "http://www.ncbi.nlm.nih.gov/pubmed/32923330",
        "http://www.ncbi.nlm.nih.gov/pubmed/8765723",
        "http://www.ncbi.nlm.nih.gov/pubmed/12387966",
        "http://www.ncbi.nlm.nih.gov/pubmed/37131727",
        "http://www.ncbi.nlm.nih.gov/pubmed/15800420",
        "http://www.ncbi.nlm.nih.gov/pubmed/30811527"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose by reducing  the incidence of multiorgan failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9261645"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 793,
          "text": "er failure. The American Association for the Study of Liver Diseases (AASLD) 2011 guideline suggested that N-acetylcysteine could improve spontaneous survival when given during early encephalopathy stages for patients with non-paracetamol-related acute li",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294991"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 583,
          "text": "Mortality was 37% in patients who received acetylcysteine 10-36 h after the overdose, compared with 58% in patients not given the antidote. In patients given acetylcysteine, progression to grade III/IV coma was significantly less common than in those who did not receive the antidote (51% vs 75%), although the median peak prothrombin time was similar for both groups.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1972496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/19524577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Since the 1970s, N-acetylcysteine (NAC) has shown proven efficacy as an antidote for acetaminophen (APAP) poisoning and APAP-induced liver failure for early presenters",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19490595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Prolonged N-acetylcysteine therapy in late acetaminophen poisoning associated with acute liver failure--a need to be more cautious?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19490595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "STUDY OBJECTIVE: Treatment with a shortened duration of oral N-acetylcysteine (20 to 48 hours) after acute acetaminophen poisoning is effective in the prevention of subsequent hepatic failure and death when administered to individuals meeting appropriate lab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210206"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 379,
          "text": "-related hepatotoxicity. Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of re",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21126198"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Intravenous acetylcysteine for indications other than acetaminophen overdose.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943180"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 583,
          "text": "Although 19 patients had plasma paracetamol concentrations greater than those associated with a 90% risk of moderate to severe liver damage, this complication occurred in only seven (35%) individuals. No patient developed hepatic encephalopathy or acute renal failure and all recovered without sequelae. We conclude that acetylcysteine administration up to 24 hours following paracetamol overdose is not dangerous and may prevent further liver damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2328143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349,
          "text": "Intravenously administered N-acetylcysteine was used to treat 11 patients at risk of hepatic damage from paracetamol poisoning. Complete protection against liver failure was seen in all cases without any adverse effects. The efficacy and safety of intravenously administered N-acetylcysteine make it the treatment of choice in paracetamol poisoning.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7421628"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 522,
          "text": "High dose acetylcysteine (NAC) has been proposed in patients taking large paracetamol overdoses based on reports of hepatotoxicity despite early initiation of NAC treatment with the commonly used 300 mg/kg intravenous acetylcysteine regimen. The evidence from cohorts of patients treated with the standard NAC regimen after large paracetamol overdoses shows that it is effective in most patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34951044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Overdose of paracetamol is associated to varying degrees of hepatic necrosis and may lead to severe hepatic failure. In this paper, we report 2 patients with paracetamol overdose for suicidal purposes who were successfully treated using the antidote N-acetyl-cysteine orally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1340573"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 699,
          "text": "Although it has been proven to have beneficial effects in paracetamol-induced liver failure, N-acetylcysteine is widely used for all forms of acute liver failure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38540289"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 181,
          "text": "N-acetylcysteine (NAC) is effective at preventing liver injury in most patients when started shortly after the overdose",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37681263"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 457,
          "text": "While acetaminophen overdose has an antidote, that is N-acetylcysteine (NAC), when given acutely, most other causes of hepatic failure require an urgent liver transplant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37559860"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 280,
          "text": "The approved drug, N-acetylcysteine (NAC), is only effective for acetaminophen (APAP)-associated ALF at the early stage",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37224750"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 712,
          "text": "Patients who present with liver failure after paracetamol poisoning should be treated with a prolonged course of N-acetylcysteine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8765723"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 903,
          "text": "Although it has been proven to have beneficial effects in paracetamol-induced liver failure, N-acetylcysteine is widely used for all forms of acute liver failure. Despite this, few well-designed studies have been conducted on the assessment of the potential benefits, dose regimens, or route of administration of N-acetylcysteine in non-acetaminophen liver failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38540289"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 1019,
          "text": "Although it has been proven to have beneficial effects in paracetamol-induced liver failure, N-acetylcysteine is widely used for all forms of acute liver failure. Despite this, few well-designed studies have been conducted on the assessment of the potential benefits, dose regimens, or route of administration of N-acetylcysteine in non-acetaminophen liver failure. This review aims to summarize the current evidence behind the use of this drug in different forms of liver failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38540289"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "OBJECTIVES: Paracetamol overdose is common and can lead to fulminant hepatic failure. In cases that are not improving with standard medical therapy with N-acetylcysteine, some patients may require liver transplant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33946130"
        },
        {
          "offsetInBeginSection": 424,
          "offsetInEndSection": 903,
          "text": "Current medical care constitutes either specific antidotes or supportive measures to ensure spontaneous recovery. Although it has been proven to have beneficial effects in paracetamol-induced liver failure, N-acetylcysteine is widely used for all forms of acute liver failure. Despite this, few well-designed studies have been conducted on the assessment of the potential benefits, dose regimens, or route of administration of N-acetylcysteine in non-acetaminophen liver failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38540289"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 583,
          "text": "We conclude that acetylcysteine administration up to 24 hours following paracetamol overdose is not dangerous and may prevent further liver damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2328143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 371,
          "text": "Paracetamol (acetaminophen) overdose remains the leading cause of death or transplantation due to acute liver failure in many parts of the world. Acetylcysteine has long been recognized as an effective antidote, via oral or intravenous administration, minimizing the risk and severity of acute liver injury if administered sufficiently early after a paracetamol overdose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083244"
        },
        {
          "offsetInBeginSection": 7,
          "offsetInEndSection": 136,
          "text": "VE: To see whether intravenous acetylcysteine would improve outcome in patients with fulminant hepatic failure after paracetamol ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1954453"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 717,
          "text": "is important to administer N-acetylcysteine as soon as possible after the overdose, but N-acetyl-cysteine also seems to improve survival when given 36-80h following ingestion. Liver transplantation has been performed in some patients with paracetamol-induced fulminant liver failure, but convincing evidence that transplantation improves survival in this group of patients is still lacking. We discuss the difficulties met in deciding if and when to perform liver transplantation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8209319"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 478,
          "text": "acetamol (acetaminophen) overdose is a common reason for emergency hospital admission in the UK and the leading cause of acute liver failure in the Western world. Currently, the antidote acetylcysteine (NAC) is administered at a dose determined only by body weight without regard for the body burden of paracetamol.OBJECTIVE: To determine whether higher plasma paracetamol concentrations are associated with increased risk of liver injury despite prompt treatment wi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108714"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "BACKGROUND: Paracetamol (acetaminophen) overdose (POD) is the commonest cause of acute liver failure in Europe and North America. Current treatment involves the use of the antidote N-acetylcysteine (NAC) in patients deemed at risk of liver damage. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30621764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "BACKGROUND: Prompt acetylcysteine treatment with standard doses (300 mg/kg over 21 h in divided doses) is almost universally effective in preventing hepatotoxicity after paracetamol (acetaminophen) overdose. However, hepat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39051728"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 435,
          "text": "BACKGROUND \u0026 AIMS: N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure.METHODS: In a prospective, double-blind trial, acute liver failure patients without clinical or historical evidence of acetaminophen overdose were stratified by site and coma grade and assigned randomly to groups that were given NAC or placebo (dextrose) infusion for 72 hours.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19524577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9261645"
        },
        {
          "offsetInBeginSection": 492,
          "offsetInEndSection": 588,
          "text": "N-acetylcysteine is recommended for all patients with APAP-induced ALF and it reduces mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29605069"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 392,
          "text": " Recent studies have shown that N-acetylcysteine administered to patients with fulminant hepatic failure (paracetamol-induced) increases oxygen delivery and improves survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10919033"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 782,
          "text": "After an acetaminophen overdose, N-acetylcysteine must be given as early as possible, preferably in the emergency room, but any patient with ALF should promptly receive N-acetylcysteine if there is suspicion of acetaminophen toxicity irrespective of the time of ingestion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15527712"
        },
        {
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1002,
          "text": "During acetaminophen overdose, with or without hepatitis or ALF, intravenous N-acetylcysteine must be administered as soon as possible.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683460"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 301,
          "text": "Acetaminophen overdose, the leading cause of ALF in the United States, has a 66% chance of recovery with early N-acetylcysteine treatment and supportive care",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18570942"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 404,
          "text": "N-acetylcysteine is the most effective drug to prevent progression to liver failure with acetaminophen hepatotoxicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169150"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 781,
          "text": "After an acetaminophen overdose, N-acetylcysteine must be given as early as possible, preferably in the emergency room, but any patient with ALF should promptly receive N-acetylcysteine if there is suspicion of acetaminophen toxicity irrespective of the time of ingestion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15527712"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "OBJECTIVES: Paracetamol overdose is common and can lead to fulminant hepatic failure. In cases that are not improving with standard medical therapy with N-acetylcysteine, some patients may require live",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33946130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "BACKGROUND \u0026 AIMS: N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure.METHODS: In a prospective, double-blind trial, acute liver failure patients without clinical",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19524577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "BACKGROUND: Acetylcysteine (NAC) is effective at preventing liver injury after paracetamol overdose. The Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning (SNAP) Study demonstrated that a 12 h NAC regimen was associated with ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317129"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Acetaminophen toxicity is one of the leading causes of liver failure. Although N-acetylcysteine (NAC) is generally successful in preventing acetaminophen hepatotoxicity when given in a timely manner, if not prescribed in the early golden time, the on",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37767143"
        },
        {
          "offsetInBeginSection": 1358,
          "offsetInEndSection": 1523,
          "text": "N-acetylcysteine is effective in ALF caused by acetaminophen overdose, with results strongly related to how soon it is given rather than the route of administration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17335680"
        },
        {
          "offsetInBeginSection": 724,
          "offsetInEndSection": 886,
          "text": "r being treated with NAC.DISCUSSION: This case report highlighted NAC\u0027s potential effectiveness in delayed presentations of paracetamol overdose, irrespective of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923330"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 99,
          "text": "Acetylcysteine (NAC) is effective at preventing liver injury after paracetamol overdose",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317129"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 252,
          "text": "N-Acetylcysteine (NAC) is the standard therapy for patients with such an overdose because oxidative stress plays an important role in the pathogenesis of APAP-induced hepatitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576052"
        },
        {
          "offsetInBeginSection": 21,
          "offsetInEndSection": 149,
          "text": "Acetaminophen (APAP) overdose is the leading cause of acute liver failure, with one available treatment, N-acetyl cysteine (NAC)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37131727"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 157,
          "text": "N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19524577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Acetylcysteine treatment reduces liver damage after paracetamol overdose, but can affect the prothrombin index, which is used to assess the progress of overdose patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387966"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 700,
          "text": "Although it has been proven to have beneficial effects in paracetamol-induced liver failure, N-acetylcysteine is widely used for all forms of acute liver failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38540289"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 543,
          "text": "t recommendations.RECENT FINDINGS: N-acetylcysteine acts to detoxify acetaminophen in several ways, but primarily by increasing the synthesis and availability of glutathione, which binds and inactivates the highly reactive and hepatotoxic acetaminophen metabo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800420"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9261645"
        },
        {
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1001,
          "text": "During acetaminophen overdose, with or without hepatitis or ALF, intravenous N-acetylcysteine must be administered as soon as possible",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23683460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "OBJECTIVE: Intravenous administration of N-acetylcysteine beyond 15 hrs reduces mortality rates in patients suffering from paracetamol-induced fulminant hepatic failure, although the mechanism of the therapeutic benefit remains unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11588469"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 827,
          "text": "nt options. N-acetylcysteine has been successful in treating paracetamol-induced acute liver failure and reduces the risk of needing to undergo liver transplantation. Recent randomised clinical trials have explored whether the benefit can be extrapolated to treat non-paracetamol-related acute liver failure. The American Association for the Study of Liver Diseases (AASLD) 2011 guideline suggested that N-acetylcysteine could improve spontaneous survival when given during early encephalopathy stages for patients with non-paracetamol-related acute liver failure.OBJECTIVES: To assess ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294991"
        },
        {
          "offsetInBeginSection": 1394,
          "offsetInEndSection": 1591,
          "text": "NAC is shown to improve the transplant-free survival rate in non-acetaminophen related ALF, consistent with its proposed mechanisms of improving hepatic blood flow and conjugating toxic metabolites",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30811527"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "BACKGROUND: When administered early after an overdose of acetaminophen, intravenous acetylcysteine prevents hepatic necrosis by replenishing reduced stores of glutathione. How acetylcysteine improves the survival of patients with established liver damage induced by acetaminophen, however, is unknown",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1904133"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 378,
          "text": "-related hepatotoxicity. Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21126198"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 442,
          "text": "eviewed.SUMMARY: I.V. acetylcysteine is most often used as an antidote for acetaminophen overdose due to its ability to increase levels of glutathione; however, it is also used to treat NAI-ALF and severe alcoholic hepatitis a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943180"
        },
        {
          "offsetInBeginSection": 314,
          "offsetInEndSection": 510,
          "text": "N-acetylcysteine, which is used for the treatment of nasal congestion disorder and paracetamol overdose toxicity, could be used as a definitive therapy for dengue virus-induced acute liver disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33177895"
        }
      ],
      "type": "yesno",
      "id": "68110110353a4a2e6b000018",
      "ideal_answer": [
        "N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N-acetylcysteine improves survival in patients with acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N-acetylcysteine treatment improves survival in patients with acute liver failure associated with  paracetamol overdose.",
        "Yes, N acetylcysteine treatment is effective for improvement of prognosis in patients with acute liver failure due to acetaminophen overdose",
        "Yes, N acetylcysteine (NAC) treatment is effective for the treatment of acetaminophen induced acute liver failure.",
        "Yes, N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose.",
        "Yes, N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose by increasing oxygen delivery and consumption, thereby reducing mortality rates and the incidence of multiorgan failure.",
        "Yes. N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose, especially when administered promptly.",
        "Yes, in patients with acute liver failure associated with  paracetamol overdose  N‐acetylcysteine treatment improves survival.",
        "Yes, N-acetylcysteine treatment has been shown to improve survival in patients with acute liver failure associated with paracetamol overdose.",
        "Yes, in patients with acute liver failure associated with  paracetamol overdose N‐acetylcysteine treatment is associated with improved survival.",
        "Yes. N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose, as evidenced by higher survival rates in treated groups compared to controls.",
        "Yes. N-acetylcysteine (NAC) is effective at preventing liver injury in most patients when started shortly after an acetaminophen overdose, and it improves outcomes in patients who present with acute liver failure due to paracetamol toxicity.",
        "Yes, N‐acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose by replenishing glutathione stores and enhancing non-toxic metabolism of paracetamol.",
        "In patients with acute liver failure associated with paracetamol overdose, N-acetylcysteine treatment, when administered intravenously, is used for the treatment of paracetamol overdose and may improve survival.",
        "Yes. N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose, particularly when administered promptly.",
        "Yes, N-acetylcysteine treatment improve survival in patients with acute liver failure associated with paracetamol overdose.",
        "Yes. N-acetylcysteine treatment improves transplant-free survival in patients with acute liver failure associated with paracetamol overdose.",
        "Yes, N acetylcysteine (NAC) treatment improves survival of patients with presumed acetaminophen overdose induced acute liver failure.",
        "Yes, N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose by reducing the incidence of multiorgan failure and the risk of needing liver transplantation.",
        "Yes, intravenous N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose by reducing the incidence of multiorgan failure and enhancing transplant-free survival.",
        "Yes. N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N-acetylcysteine (NAC) treatment improves survival in patients with acute liver failure associated with paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N acetylcysteine improves survival in established acute liver failure following paracetamover overdose by reducing the incidence of multiorgan failure.",
        "Yes, N‐acetylcysteine treatment improves survival in patients with acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes. N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N-acetylcysteine treatment improves survival in patients with acute liver failure due to paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N-acetylcysteine improves survival in patients with acute liver failure caused by paracetamol overdose by reducing the incidence of multiorgan failure (PMID: 9261645).",
        "in patients with acute liver failure associated with paracetamol overdose does nacetylcysteine treatment improve survival nacetylcysteine improves survival in established acute liver",
        "Yes. N‐acetylcysteine treatment improves survival in patients with acute liver failure due to paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, in patients with acute liver failure associated with  paracetamol overdose N‐acetylcysteine treatment was shown to improve survival.",
        "Yes, N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose by reducing the incidence of multiorgan failure.",
        "In patients with acute liver failure associated with paracetamol overdose, N-acetylcysteine treatment is aimed at improving survival.",
        "Yes, N acetylcysteine (NAC) improves survival in patients with acute liver failure due to paracetamol overdose by reducing the incidence of multiorgan failure.",
        "Yes, N‐acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose, primarily by reducing the incidence of multiorgan failure, thereby enhancing patient outcomes in such critical cases.",
        "Yes, N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose.",
        "N-acetylcysteine improves survival in established acute liver failure following paracetamol overdose .",
        "N-acetylcysteine treatment improves survival in patients with acute liver failure associated with paracetamol overdose, primarily by reducing the risk of multiorgan failure and potentially through enhanced oxygen utilization.",
        "Yes, N-acetylcysteine treatment improves survival by reducing the incidence of multiorgan failure in patients with acute liver failure associated with paracetamol overdose."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is the pharmacological treatment of urinary schistosomiasis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39749885",
        "http://www.ncbi.nlm.nih.gov/pubmed/38943214",
        "http://www.ncbi.nlm.nih.gov/pubmed/38212419",
        "http://www.ncbi.nlm.nih.gov/pubmed/36394218",
        "http://www.ncbi.nlm.nih.gov/pubmed/32823660",
        "http://www.ncbi.nlm.nih.gov/pubmed/35654701",
        "http://www.ncbi.nlm.nih.gov/pubmed/32375658",
        "http://www.ncbi.nlm.nih.gov/pubmed/39732412",
        "https://www.ncbi.nlm.nih.gov/pubmed/19493363",
        "https://www.ncbi.nlm.nih.gov/pubmed/36394218",
        "http://www.ncbi.nlm.nih.gov/pubmed/25412105",
        "http://www.ncbi.nlm.nih.gov/pubmed/23265611",
        "http://www.ncbi.nlm.nih.gov/pubmed/28911129",
        "http://www.ncbi.nlm.nih.gov/pubmed/34166393",
        "http://www.ncbi.nlm.nih.gov/pubmed/27636542",
        "http://www.ncbi.nlm.nih.gov/pubmed/18646057",
        "http://www.ncbi.nlm.nih.gov/pubmed/19493363",
        "http://www.ncbi.nlm.nih.gov/pubmed/15257799",
        "http://www.ncbi.nlm.nih.gov/pubmed/18838149",
        "http://www.ncbi.nlm.nih.gov/pubmed/23681759",
        "http://www.ncbi.nlm.nih.gov/pubmed/36581796",
        "http://www.ncbi.nlm.nih.gov/pubmed/35918841",
        "http://www.ncbi.nlm.nih.gov/pubmed/35167622",
        "http://www.ncbi.nlm.nih.gov/pubmed/34115760",
        "http://www.ncbi.nlm.nih.gov/pubmed/33939629",
        "http://www.ncbi.nlm.nih.gov/pubmed/25099517",
        "http://www.ncbi.nlm.nih.gov/pubmed/24374945",
        "http://www.ncbi.nlm.nih.gov/pubmed/39699222",
        "http://www.ncbi.nlm.nih.gov/pubmed/39560407",
        "http://www.ncbi.nlm.nih.gov/pubmed/12224581",
        "http://www.ncbi.nlm.nih.gov/pubmed/1720380",
        "http://www.ncbi.nlm.nih.gov/pubmed/16113896",
        "http://www.ncbi.nlm.nih.gov/pubmed/22676052",
        "http://www.ncbi.nlm.nih.gov/pubmed/25215186",
        "http://www.ncbi.nlm.nih.gov/pubmed/10442201",
        "http://www.ncbi.nlm.nih.gov/pubmed/1951859",
        "http://www.ncbi.nlm.nih.gov/pubmed/2515622",
        "http://www.ncbi.nlm.nih.gov/pubmed/12049454",
        "http://www.ncbi.nlm.nih.gov/pubmed/39699212",
        "http://www.ncbi.nlm.nih.gov/pubmed/2115308",
        "http://www.ncbi.nlm.nih.gov/pubmed/3097117",
        "http://www.ncbi.nlm.nih.gov/pubmed/39530083",
        "http://www.ncbi.nlm.nih.gov/pubmed/39595029",
        "http://www.ncbi.nlm.nih.gov/pubmed/32976496",
        "http://www.ncbi.nlm.nih.gov/pubmed/7720204",
        "http://www.ncbi.nlm.nih.gov/pubmed/23813602",
        "http://www.ncbi.nlm.nih.gov/pubmed/9488937",
        "http://www.ncbi.nlm.nih.gov/pubmed/12662421",
        "http://www.ncbi.nlm.nih.gov/pubmed/2499203",
        "http://www.ncbi.nlm.nih.gov/pubmed/29629689"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 862,
          "offsetInEndSection": 875,
          "text": "praziquantel ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39749885"
        },
        {
          "offsetInBeginSection": 24,
          "offsetInEndSection": 36,
          "text": "praziquantel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38943214"
        },
        {
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1299,
          "text": "praziquantel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38212419"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 12,
          "text": "Praziquantel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36394218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1362,
          "text": "Guidelines recommend praziquantel (PZQ) for the treatment and control of schistosomiasis, with no real alternative. Metrifonate was still widely used against Schistosoma haematobium in the 1990s, and then withdrawn. Experimental studies and clinical trials suggest that artemisinin compounds are active against S. haematobium. In a Cochrane systematic review assessing the efficacy and safety of drugs for treating urinary schistosomiasis, 24 randomized controlled trials (n\u003d6315 individuals) met our inclusion criteria. These trials compared a variety of single agent and combination regimens with PZQ, metrifonate or artemisinin derivatives. The review confirmed that both the standard recommended doses of PZQ (single 40 mg/kg oral dose) and metrifonate (3x7.5-10 mg/kg oral doses administered fortnightly) are efficacious and safe in treating urinary schistosomiasis, but there is no study comparing these two regimens head-to-head. There is currently not enough evidence to evaluate artemisinin compounds. Most of the studies included in the Cochrane systematic review were insufficiently powered, lacked standardization in assessing and reporting outcomes, and had a number of methodological limitations. In this paper we discuss the implications of these findings with respect to public health and research methodology and propose priority research needs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/36394218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "BACKGROUND: Extensive use of praziquantel for treatment and control of schistosomiasis requires a comprehensive understanding of efficacy and safety of various doses for different Schistos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25412105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "OBJECTIVE: Efficacy of artemisinin derivatives alone or in combination compared to praziquantel alone for the treatment of urinary schistosomiasis in scho",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23265611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27636542"
        },
        {
          "offsetInBeginSection": 47,
          "offsetInEndSection": 193,
          "text": " in Africa. Praziquantel is effective against adult schistosomes but leaves prepatent stages unaffected-which is a limit to patient management and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34166393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25412105"
        },
        {
          "offsetInBeginSection": 1924,
          "offsetInEndSection": 2021,
          "text": "Praziquantel has an impact on reducing the prevalence and intensity of urogenital schistosomiasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36581796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Despite a human schistosomiasis control programme through praziquantel mass drug administration (MDA) between 2011 and 2015,there was still persistent transmission among primary schoolchildren (PSC) in Mkuranga district, Tanzania",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35918841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Persistence of Schistosoma haematobium transmission among school children and its implication for the control of urogenital schistosomiasis in Lindi, Tanzania.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35167622"
        },
        {
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1164,
          "text": "An infection prevalence of 5% could be a sensible target for urogenital schistosomiasis morbidity control in children as microhematuria prevalence was highly likely to be below 10% in all surveys",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34115760"
        },
        {
          "offsetInBeginSection": 699,
          "offsetInEndSection": 847,
          "text": "All study participants were treated for schistosomiasis, and schools with the highest urinary prevalence were followed up after 1 and 4 years of MDA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33939629"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 469,
          "text": " in Sana\u0027a. Praziquantel (PZQ) is highly effective against all five major human species of schistosomes.OBJECTIVES: The aim of the present work was to estimate the prevalence of urinary schistosomiasis, describe the risk factors associat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24374945"
        },
        {
          "offsetInBeginSection": 3990,
          "offsetInEndSection": 4599,
          "text": "Similarly, another anti-malarial mefloquine has been evaluated in two small trials with inconsistent effects.Adverse events were described as mild for all evaluated drugs, but adverse event monitoring and reporting was generally of low quality.AUTHORS\u0027 CONCLUSIONS: Praziquantel 40 mg/kg is the most studied drug for treating urinary schistosomiasis, and has the strongest evidence base.Potential strategies to improve future treatments for schistosomiasis include the combination of praziquantel with metrifonate, or with antimalarial drugs with antischistosomal properties such as artesunate and mefloquine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099517"
        },
        {
          "offsetInBeginSection": 2389,
          "offsetInEndSection": 2499,
          "text": "l and metrifonate are effective treatments for urinary schistosomiasis and have few adverse events. Metrifonat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18646057"
        },
        {
          "offsetInBeginSection": 1455,
          "offsetInEndSection": 2261,
          "text": "A significant advance in the control of schistosomiasis chemotherapy is the introduction of a relatively safe, effective, broad spectrum oral helminthic agent, praziquantel. Studies have also shown that oxamniquine is as effective as praziquantel in eliminating intestinal S. mansoni infection, and metrifonate is as effective as praziquantel in eliminating urinary S. haematobium and S. mansoni infections. Praziquantel has been found to be effective in treating S. haematobium infections compared with metrifonate and more effective in treating S. mansoni infection when compared with oxamniquine. Because the drug is effective even when treating advanced hepatosplenic schistosomiasis, with few side effects, praziquantel is currently the drug of choice for the treatment of any kind of schistosomiasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1720380"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Several cases of therapeutic failure of praziquantel used for the treatment of urinary schistosomiasis have been reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16113896"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 122,
          "text": " Praziquantel (PZQ) is the current drug of choice for the treatment of urinary schistosomiasis in endemic areas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28911129"
        },
        {
          "offsetInBeginSection": 1183,
          "offsetInEndSection": 1367,
          "text": "This study confirmed that the treatment of urinary schistosomiasis with the combination of praziquantel and artesunate is safe and more effective than treatment with either drug alone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838149"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "BACKGROUND: Chemotherapy with praziquantel (PZQ) is the mainstay of schistosomia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22676052"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "A systematic analysis of the existing literature has been undertaken to compare the therapeutic and operational profiles of metrifonate (CAS 52-68-6), and praziquantel (CAS 55-268-74-1), two anti-schistosomal compounds.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10442201"
        },
        {
          "offsetInBeginSection": 654,
          "offsetInEndSection": 829,
          "text": "It is concluded that both medical and operational criteria indicate that praziquantel is superior to metrifonate for the treatment of schistosomiasis caused by S. haematobium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10442201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 448,
          "text": "To determine the effect of repeated, annual, age-targeted therapy on prevalence and intensity of Schistosoma haematobium infection in an endemic area, we treated all available, infected, school-age children (n \u003d 2, 493) in the Msambweni area of Coast Province, Kenya with a randomized protocol of oral metrifonate (10 mg/kg for three doses each year) or praziquantel therapy (40 mg/kg as a single dose each year) for a period of one to three years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1951859"
        },
        {
          "offsetInBeginSection": 2199,
          "offsetInEndSection": 2488,
          "text": "One small trial of artesunate showed no obvious benefit compared with placebo, and the artesunate-praziquantel combination was similar to praziquantel alone.AUTHORS\u0027 CONCLUSIONS: Praziquantel and metrifonate are effective treatments for urinary schistosomiasis and have few adverse events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18646057"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 936,
          "text": "The review confirmed that both the standard recommended doses of PZQ (single 40 mg/kg oral dose) and metrifonate (3x7.5-10 mg/kg oral doses administered fortnightly) are efficacious and safe in treating urinary schistosomiasis, but there is no study comparing these two regimens head-to-head.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 330,
          "text": "OBJECTIVE: Efficacy of artemisinin derivatives alone or in combination compared to praziquantel alone for the treatment of urinary schistosomiasis in schoolchildren.METHODS: Randomized clinical trials comparing praziquantel with artemisinin derivatives in the treatment  of urinary schistosomiasis in schoolchildren were included.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23265611"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 326,
          "text": "Experimental studies and clinical trials suggest that artemisinin compounds are active against S. haematobium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 1604,
          "offsetInEndSection": 1898,
          "text": "The frequency  of adverse events was equivalent for both drugs (praziquantel versus artesunate, RR: 1·11; 95% CI: 0·80-1·55).CONCLUSIONS: Our meta-analysis showed that praziquantel was significantly more effective than artesunate for the treatment of urinary schistosomiasis  in schoolchildren.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23265611"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 215,
          "text": "Metrifonate was still widely used against Schistosoma haematobium in the 1990s, and then withdrawn.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Background: Praziquantel (PZQ) is the current drug of choice for the treatment of urinary schistosomiasis in e",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28911129"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Guidelines recommend praziquantel (PZQ) for the treatment and control of schistosomiasis, with no real alternative",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 376,
          "text": "There are three drugs available: metrifonate (active against Schistosoma haematobium), oxamniquine (active against Schistosoma mansoni) as narrow spectrum drugs and praziquantel, which is effective against all important adult schistosome species and their immature stages, as the drug of choice",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12049454"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 870,
          "text": "The review confirmed that both the standard recommended doses of PZQ (single 40 mg/kg oral dose) and metrifonate (3x7.5-10 mg/kg oral doses administered fortnightly) are efficacious and safe in treating urinary schistosomiasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "BACKGROUND: Chemotherapy with praziquantel (PZQ) has been the cornerstone of schistosomiasis control over the last",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25215186"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Schistosomiasis is commonly managed using the praziquantel, but it is only effective against adult worms and duration of action is short.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699222"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39699212"
        },
        {
          "offsetInBeginSection": 654,
          "offsetInEndSection": 828,
          "text": "It is concluded that both medical and operational criteria indicate that praziquantel is superior to metrifonate for the treatment of schistosomiasis caused by S. haematobium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10442201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "To determine the relative efficacy of metrifonate and praziquantel in controlling urinary tract morbidity due to Schistosoma haematobium infection, a random allocation treatment trial was performed among 1,813 school age S. haematobium-infected children from the Msambweni area of Coast Province, Kenya",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2115308"
        },
        {
          "offsetInBeginSection": 507,
          "offsetInEndSection": 620,
          "text": "Treatment with Praziquantel was thoroughly effective in clearing the persistent Schistosoma haematobium infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3097117"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "text": "The best therapeutic approach to acute schistosomiasis (Katayama fever) is still unsettled. In this paper we report a synergistic effect between schistosomicides and steroids in the treatment of the early stages of Schistosoma mansoni infection in the mouse. CBA mice infected with 150 S. mansoni cercariae were treated with oxamniquine or praziquantel and dexamethasone or prednisolone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 387,
          "text": "In this paper we report a synergistic effect between schistosomicides and steroids in the treatment of the early stages of Schistosoma mansoni infection in the mouse. CBA mice infected with 150 S. mansoni cercariae were treated with oxamniquine or praziquantel and dexamethasone or prednisolone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 583,
          "text": "In this paper we report a synergistic effect between schistosomicides and steroids in the treatment of the early stages of Schistosoma mansoni infection in the mouse. CBA mice infected with 150 S. mansoni cercariae were treated with oxamniquine or praziquantel and dexamethasone or prednisolone. The rate of parasite egg excretion by treated mice and appropriate controls was monitored, and the mice were perfused 43 d after infection for estimation of worm burdens and tissue egg densities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "The best therapeutic approach to acute schistosomiasis (Katayama fever) is still unsettled. In this paper we report a synergistic effect between schistosomicides and steroids in the treatment of the early stages of Schistosoma mansoni infection in the mouse.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 697,
          "text": "Mice treated with schistosomicides alone or with schistosomicides plus steroids had worm burdens of similar size.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 698,
          "offsetInEndSection": 1114,
          "text": "Significant reductions in egg counts were, however, recorded in faeces, and in the intestines and livers (with consequent reduction in liver pathology), of mice treated with schistosomicide and steroid, when compared to mice treated with schistosomicide alone or steroid alone. The apparent inhibition of fecundity of S. mansoni by combining these drugs has clear implications for treatment of the Katayama syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 975,
          "text": "Mice treated with schistosomicides alone or with schistosomicides plus steroids had worm burdens of similar size. Significant reductions in egg counts were, however, recorded in faeces, and in the intestines and livers (with consequent reduction in liver pathology), of mice treated with schistosomicide and steroid, when compared to mice treated with schistosomicide alone or steroid alone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 1114,
          "text": "Mice treated with schistosomicides alone or with schistosomicides plus steroids had worm burdens of similar size. Significant reductions in egg counts were, however, recorded in faeces, and in the intestines and livers (with consequent reduction in liver pathology), of mice treated with schistosomicide and steroid, when compared to mice treated with schistosomicide alone or steroid alone. The apparent inhibition of fecundity of S. mansoni by combining these drugs has clear implications for treatment of the Katayama syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Schistosomiasis, which causes over 200 000 deaths annually, has since the 1970s been controlled by praziquintel.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39530083"
        },
        {
          "offsetInBeginSection": 1266,
          "offsetInEndSection": 1773,
          "text": "d the World Health Organization database.CONCLUSION: Favorably praziquantel (PZQ) is a medication with excellent chemopreventive treatment compliance. Due to the extensive usage of PZQ, there is a great deal of debate surrounding the emergence of drug resistance. PZQ is effective against all species of schistosomes, schistosomiasis prevalence has remained largely unaffected, due to reinfection in high transmission areas and growing juvenile worms that were not affected by the drug, even though the need",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "To determine the relative efficacy of metrifonate and praziquantel in controlling urinary tract morbidity due to Schistosoma haematobium infection, a random allocation treatment trial was performed among 1,813 school age S. haematobium-infected children from the Msambweni area of Coast Province, Kenya.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2115308"
        },
        {
          "offsetInBeginSection": 2368,
          "offsetInEndSection": 2499,
          "text": "CLUSIONS: Praziquantel and metrifonate are effective treatments for urinary schistosomiasis and have few adverse events. Metrifonat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18646057"
        },
        {
          "offsetInBeginSection": 1794,
          "offsetInEndSection": 4594,
          "text": "es were assessed as being at unclear risk of bias due to inadequate descriptions of study methods. PraziquantelOn average, a single 40 mg/kg dose of praziquantel reduced the proportion of people still excreting eggs in their urine by around 60% compared to placebo at one to two months after treatment (treatment failure: RR 0.42, 95% CI 0.29 to 0.59, 864 participants, seven trials, high quality evidence). The proportion of people cured with praziquantel varied substantially between trials, from 22.5% to 83.3%, but was higher than 60% in five of the seven trials. At one to two months following praziquantel treatment at 40 mg/kg, the mean number of schistosome eggs in the urine was reduced by over 95% in five out of six trials (678 participants, six trials, high quality evidence).Splitting praziquantel 40 mg/kg into two doses over 12 hours probably has no benefits over a single dose, and in a single trial of 220 participants the split dose caused more vomiting (RR 0.5, 95% CI 0.29 to 0.86) and dizziness (RR 0.39, 95% CI 0.16 to 0.94). MetrifonateA single dose of metrifonate 10 mg/kg reduced egg excretion (210 participants, one trial, at eight months), but was only marginally better than placebo at achieving cure at one month (RR 0.83, 95% CI 0.74 to 0.94, 142 participants, one trial). In a single trial comparing one, two and three doses, the absolute number of participants cured improved from 47% after one dose to 81% after three doses (93 participants, one trial, low quality evidence).Two small trials compared 40 mg/kg single dose praziquantel with two or three doses of 10 mg/kg metrifonate and found no clear evidence of differences in cure (metrifonate 2 x 10 mg/kg at one month: RR 1.03, 95% CI 0.8 to 1.34, 72 participants, one trial; metrifonate 3 x 10 mg/kg at three months: RR 0.33, 95% CI 0.07 to 1.57, 100 participants, one trial. In one trial both drugs performed badly and in one trial both performed well. Other drugsThree trials have evaluated the antimalarial artesunate; with inconsistent results. Substantial antischistosomal effects were only seen in one of the three trials, which was at unclear risk of bias due to poor reporting of the trial methods. Similarly, another anti-malarial mefloquine has been evaluated in two small trials with inconsistent effects.Adverse events were described as mild for all evaluated drugs, but adverse event monitoring and reporting was generally of low quality.AUTHORS\u0027 CONCLUSIONS: Praziquantel 40 mg/kg is the most studied drug for treating urinary schistosomiasis, and has the strongest evidence base.Potential strategies to improve future treatments for schistosomiasis include the combination of praziquantel with metrifonate, or with antimalarial drugs with antischistosomal properties such as artesunate and mefloq",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099517"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 542,
          "text": "The objective of this study was to assess the praziquantel cure rate and egg reduction rate against urogenital schistosomiasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39595029"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36394218"
        },
        {
          "offsetInBeginSection": 456,
          "offsetInEndSection": 690,
          "text": "This study aims to determine the current prevalence of urogenital schistosomiasis (caused by Schistosoma haematobium), the efficacy of praziquantel, and the re-infection rates in children from five villages with different water access",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36581796"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 237,
          "text": "However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32375658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Schistosomiasis control is heavily reliant on the drug praziquantel (PZQ), which is used as preventive chemotherapy as part of national helminth control strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32976496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "A total of 1,627 cases of schistosomiasis haematobium had been treated with praziquantel of different dosages by the Chinese Medical Team in Mali.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7720204"
        },
        {
          "offsetInBeginSection": 720,
          "offsetInEndSection": 889,
          "text": "Against such devastating parasitic disease, the antischistosomal arsenal is currently limited to a single drug, praziquantel, which has been used for more than 35 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23813602"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 222,
          "text": " the world. Currently, praziquantel (PZQ) represents the best pharmacological option for the treatment of schistosomiasis as it effectively kil",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35654701"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Background: Praziquantel (PZQ) is the current drug of choice for the treatment of urinary schistosomiasis in en",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28911129"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The combined effects of praziquantel and artesunate in the treatment of urinary schistosomiasis were assessed among 312 randomly selected schoolchildren aged 4-20 years in Adim community, Nigeria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838149"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Praziquantel (PZQ) has been extensively used as the drug of choice for the treatment of schistosomiasis on account of its safety and effectiveness against all major forms of schistosomiasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36394218"
        },
        {
          "offsetInBeginSection": 1414,
          "offsetInEndSection": 1550,
          "text": "In the Adim community at least, it would be more cost-effective to treat urinary schistosomiasis with artesunate than with praziquantel.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15257799"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 424,
          "text": "In the pharmacological treatment for an acute form of schistosomiasis, the use of antiparasitics, mainly praziquantel, is more common.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32823660"
        },
        {
          "offsetInBeginSection": 605,
          "offsetInEndSection": 683,
          "text": "The disease has been under good control following treatment with praziquantel.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9488937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Praziquantel is the current drug of choice for the control of schistosome-attributable morbidity and is likely to remain so for several years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12662421"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "At present, anthelmintic therapy with praziquantel at a dose of 40 mg/kg of body weight is the recommended treatment for control of urinary tract morbidity caused by Schistosoma haematobium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12224581"
        },
        {
          "offsetInBeginSection": 1065,
          "offsetInEndSection": 1306,
          "text": "For large-scale control programs, oral 20 mg/kg praziquantel therapy for urinary schistosomiasis may prove as effective as the standard oral 40 mg/kg dosing for control of infection-associated morbidity and reduction of parasite transmission",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2499203"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 935,
          "text": "The review confirmed that both the standard recommended doses of PZQ (single 40 mg/kg oral dose) and metrifonate (3x7.5-10 mg/kg oral doses administered fortnightly) are efficacious and safe in treating urinary schistosomiasis, but there is no study comparing these two regimens head-to-head",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19493363"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 374,
          "text": "ostic tool. Praziquantel is the drug of choice for schistosomiasis, and the World Health Organization recommends that it should be administered to all children \u0026gt;4 years of age living in schistosomiasis-e",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29629689"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "During the last twenty years, praziquantel (PZQ) was the drug of choice for the treatment of schistosomiasis in the majority of national programs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681759"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Praziquantel (PZQ) has been extensively used as the drug of choice for the treatment of schistosomiasis on account of its safety and effectiveness against all major forms of schistosomiasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36394218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23265611"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 468,
          "text": "Mozambique. The overall goal of SCORE was to better understand how to best apply preventive chemotherapy with praziquantel (PZQ) for schistosomiasis control by evaluating the impact of alternative treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29220347"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "BACKGROUND: Despite its low cure rates and possible resistance, praziquantel (PZQ) is the only drug available for schistosomias",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385154"
        }
      ],
      "id": "680f4c63353a4a2e6b00000d",
      "ideal_answer": [
        "Praziquantel is the drug of choice for urinary schistosomiasis.",
        "The pharmacological treatment of urinary schistosomiasis primarily involves chemotherapy with praziquantel (PZQ). Praziquantel is the drug of choice due to its high efficacy, excellent tolerability, few side effects, simple administration, and competitive cost. It has been the cornerstone of schistosomiasis control for decades. In some cases, metrifonate has been used as an alternative, but praziquantel is generally considered superior. Studies have also explored the use of artesunate in combination with praziquantel, showing promising cure rates. Mass drug administration with praziquantel is a common public health strategy to avert morbidity due to schistosomiasis.",
        "Urinary schistosomiasis, also known as schistosomiasis hematuria, is a parasitic infection caused by Schistosoma species. The primary treatment for this condition involves the use of antiparasitic drugs. Two commonly used drugs for the treatment of urinary schistosomiasis are Praziquantel and Oxamniquine. Praziquantel is a broad-spectrum antiparasitic drug that is effective against most Schistosoma species, including S. haematobium, the primary causative agent of urinary schistosomiasis. Oxamniquine, on the other hand, is primarily used for the treatment of S. mansoni, but it can also be effective against S. haematobium in certain cases. Both drugs work by paralyzing the parasite, allowing the body to eliminate it from the system. The choice of drug depends on the specific Schistosoma species, the patient\u0027s health status, and the severity of the infection.",
        "The primary pharmacological treatment for urinary schistosomiasis caused by *Schistosoma haematobium* is praziquantel. This antiparasitic drug is recommended by the World Health Organization (WHO) as the standard therapy due to its efficacy in eliminating adult schistosomes. It achieves high cure rates and significant egg reduction rates, reducing morbidity and transmission. Praziquantel is typically administered as a single oral dose (40-60 mg/kg), though repeat dosing may be required in high-transmission areas or for persistent infections.",
        "The primary pharmacological treatment for urinary schistosomiasis, caused by Schistosoma haematobium, is praziquantel. This antiparasitic drug effectively targets the parasites by disrupting their cell membranes and muscles, leading to their death. Praziquantel is well tolerated and commonly administered orally, making it suitable for both individual treatment and mass chemotherapy programs aimed at controlling the disease\u0027s spread. While other drugs like oxamniquine exist, they are less frequently used due to praziquantel\u0027s efficacy and safety profile.",
        "The pharmacological treatment of urinary schistosomiasis primarily involves the use of praziquantel (PZQ), administered as a single oral dose of 40 mg/kg body weight. Studies demonstrate that PZQ effectively clears Schistosoma haematobium eggs from urine, reduces infection intensity, and alleviates symptoms such as hematuria and urinary tract pathology. Cure rates with PZQ are generally high, ranging from 79% to 93.7%, with significant egg reduction rates of 91.9% to 98%. While albendazole has been explored as an alternative, it shows lower efficacy compared to PZQ. Combination therapies, such as PZQ with artesunate and sulfalene/pyrimethamine, have also been tested but do not significantly enhance efficacy for urinary schistosomiasis. PZQ remains the cornerstone treatment, though its effectiveness can be optimized when complemented by public health measures to reduce reinfection rates.",
        "The pharmacological treatment of urinary schistosomiasis is primarily with praziquantel. This antiparasitic medication is widely recommended for treating infections caused by Schistosoma haematobium, effectively targeting the parasites and inducing their death through muscle spasms. It remains the standard treatment according to health organizations such as the WHO."
      ],
      "exact_answer": [
        [
          "Praziquantel",
          "oxamquinine"
        ]
      ]
    },
    {
      "body": "What types of features are typically extracted in radiomics?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32124697",
        "http://www.ncbi.nlm.nih.gov/pubmed/32060219",
        "http://www.ncbi.nlm.nih.gov/pubmed/37060067",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747447",
        "http://www.ncbi.nlm.nih.gov/pubmed/34545475",
        "http://www.ncbi.nlm.nih.gov/pubmed/31151578",
        "http://www.ncbi.nlm.nih.gov/pubmed/31032192",
        "http://www.ncbi.nlm.nih.gov/pubmed/25025374",
        "http://www.ncbi.nlm.nih.gov/pubmed/28042608",
        "http://www.ncbi.nlm.nih.gov/pubmed/34597235",
        "http://www.ncbi.nlm.nih.gov/pubmed/36416666",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724572",
        "http://www.ncbi.nlm.nih.gov/pubmed/30854457",
        "http://www.ncbi.nlm.nih.gov/pubmed/28149958",
        "http://www.ncbi.nlm.nih.gov/pubmed/28112418",
        "http://www.ncbi.nlm.nih.gov/pubmed/28261818",
        "http://www.ncbi.nlm.nih.gov/pubmed/32966313",
        "http://www.ncbi.nlm.nih.gov/pubmed/29403060",
        "http://www.ncbi.nlm.nih.gov/pubmed/39590734",
        "http://www.ncbi.nlm.nih.gov/pubmed/35521966",
        "http://www.ncbi.nlm.nih.gov/pubmed/39518625",
        "http://www.ncbi.nlm.nih.gov/pubmed/32240418",
        "http://www.ncbi.nlm.nih.gov/pubmed/33232521",
        "http://www.ncbi.nlm.nih.gov/pubmed/35085099",
        "http://www.ncbi.nlm.nih.gov/pubmed/39140002",
        "http://www.ncbi.nlm.nih.gov/pubmed/31704598",
        "http://www.ncbi.nlm.nih.gov/pubmed/31621883",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046718",
        "http://www.ncbi.nlm.nih.gov/pubmed/37287036",
        "http://www.ncbi.nlm.nih.gov/pubmed/39602602",
        "http://www.ncbi.nlm.nih.gov/pubmed/39333936",
        "http://www.ncbi.nlm.nih.gov/pubmed/39287013",
        "http://www.ncbi.nlm.nih.gov/pubmed/36308869",
        "http://www.ncbi.nlm.nih.gov/pubmed/37275092",
        "http://www.ncbi.nlm.nih.gov/pubmed/31165039",
        "http://www.ncbi.nlm.nih.gov/pubmed/28231582",
        "http://www.ncbi.nlm.nih.gov/pubmed/39367492",
        "http://www.ncbi.nlm.nih.gov/pubmed/30054518"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 379,
          "text": "Radiomics is a rapidly evolving field of research concerned with the extraction of quantitative metrics-the so-called radiomic features-within medical images. Radiomic features capture tissue and lesion characteristics such as heterogeneity and shape and may, alone or in combination with demographic, histologic, genomic, or proteomic data, be used for clinical problem solving.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32060219"
        },
        {
          "offsetInBeginSection": 839,
          "offsetInEndSection": 1289,
          "text": "The process of radiomics analysis usually includes the acquisition of image data, Region of Interest (ROI) segmentation, feature extracting, feature selection, and classification or prediction. From those radiomics methods, texture analysis occupied a large part. In addition, the extracted features include histogram, shapebased features, texture-based features, wavelet features, Gray Level Co-Occurrence Matrix (GLCM), and Run-Length Matrix (RLM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32124697"
        },
        {
          "offsetInBeginSection": 437,
          "offsetInEndSection": 543,
          "text": "Texture analysis features include histogram, gray size area matrix and gray co-occurrence matrix features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060067"
        },
        {
          "offsetInBeginSection": 1007,
          "offsetInEndSection": 1181,
          "text": "These subregions exhibited several important radiomic features that include shape, gray level size zone matrix (GLSZM), and gray level dependence matrix (GLDM), among others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747447"
        },
        {
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1172,
          "text": "To better understand the variations, features are further grouped into 3 categories according to their properties: 1) morphology, 2) statistic/histogram and 3)texture features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34545475"
        },
        {
          "offsetInBeginSection": 770,
          "offsetInEndSection": 964,
          "text": "Fifty-six 3D-radiomic features, quantifying phenotypic differences based on tumor intensity, shape and texture, were extracted from the computed tomography images of twenty lung cancer patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25025374"
        },
        {
          "offsetInBeginSection": 875,
          "offsetInEndSection": 1086,
          "text": "From 88 lesions in 79 patients, we selected 9 radiomics features (5 texture features, 1 shape feature, 1 gray matrix feature, and 2 first-order features) from the training cohort (n \u003d 61) to build the PCAT model",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 632,
          "text": "Quantitative features are generated from a tumor phenotype by various data characterization, feature-extraction approaches and have been used successfully as a biomarker. These features give us information about a nodule, for example, nodule size, pixel intensity, histogram-based information, and texture information from wavelets or a convolution kernel. Semantic features, on the other hand, can be generated by an experienced radiologist and consist of the common characteristics of a tumor, for example, location of a tumor, fissure, or pleural wall attachment, presence of fibrosis or emphysema, concave cut on nodule surface.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30854457"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 564,
          "text": "For each of the scans, we extracted 48 radiomic features from the categories of intensity histogram (n \u003d 10), gray-level run length matrix (n \u003d 11), gray-level co-occurrence matrix (n \u003d 22), and neighborhood gray tone difference matrix (n \u003d 5).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29403060"
        },
        {
          "offsetInBeginSection": 626,
          "offsetInEndSection": 760,
          "text": "Features extracted included first order, shape, GLCM, GLRLM, GLSZM, and GLDM from original, wavelet-filtered, and LoG-filtered images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39590734"
        },
        {
          "offsetInBeginSection": 473,
          "offsetInEndSection": 743,
          "text": "The extracted features were categorized into seven classes: First-order Features, Shape Features (2D), Gray Level Co-occurrence Matrix (GLCM), Gray Level Run Length Matrix (GLRLM), Gray Level Size Zone Matrix (GLSZM), and Neighboring Gray Tone Difference Matrix (NGTDM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39518625"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 355,
          "text": "Traditionally, radiomics analyses leverage texture operators to derive voxel- or region-wise feature values towards quantifying subtle variations in image appearance within a region-of-interest (ROI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35085099"
        },
        {
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1154,
          "text": "Extracted features typically describe the distribution of signal intensities and spatial relationship of pixels within a region of interest.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34597235"
        },
        {
          "offsetInBeginSection": 734,
          "offsetInEndSection": 870,
          "text": "The features extracted in this phantom study include first order, shape, gray level cooccurrence matrix and gray level run length matrix",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32240418"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 720,
          "text": "Efforts are ongoing for developing an ontology to describe radiomic features for lung nodules, with the main classes consisting of size, local and global shape descriptors, margin, intensity, and texture-based features, which are based on wavelets, Laplacian of Gaussians, Law\u0027s features, gray-level co-occurrence matrices, and run-length features",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28149958"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 805,
          "text": "Images were subjected to smoothing, sharpening, and noise to evaluate changes in features relative to baseline datasets.METHODS: Textural features were extracted from tumor volumes, contoured on pCT and CBCT images, according to the following eight different classes: intensity based histogram features (IBHF), gray level run length (GLRL), law\u0027s textural information (LAWS), discrete orthonormal stockwell transform (DOST), local binary pattern (LBP), two-dimensional wavelet transform (2DWT), Two dimensional Gabor filter (2DGF), and gray level co-occurrence matrix (GLCM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28261818"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 721,
          "text": "Efforts are ongoing for developing an ontology to describe radiomic features for lung nodules, with the main classes consisting of size, local and global shape descriptors, margin, intensity, and texture-based features, which are based on wavelets, Laplacian of Gaussians, Law\u0027s features, gray-level co-occurrence matrices, and run-length features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28149958"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 333,
          "text": "Radiomics refers to the extraction of a large number of quantitative features that describe the intensity, texture and geometrical characteristics attributed to the tumor radiographic data. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31165039"
        },
        {
          "offsetInBeginSection": 534,
          "offsetInEndSection": 965,
          "text": "Radiomics is defined as the high throughput extraction of quantitative imaging features or texture (radiomics) from imaging to decode tissue pathology and creating a high dimensional data set for feature extraction. Radiomic features provide information about the gray-scale patterns, inter-pixel relationships. In addition, shape and spectral properties can be extracted within the same regions of interest on radiological images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28042608"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 700,
          "text": "Extracted traits describe radiological intensity, shape and texture characteristics and can be analyzed on routinely performed images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28231582"
        },
        {
          "offsetInBeginSection": 705,
          "offsetInEndSection": 806,
          "text": "We extracted 1356 radiomics features, including intensity (first-order), shape, and texture features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36711678"
        },
        {
          "offsetInBeginSection": 854,
          "offsetInEndSection": 959,
          "text": "Over 280 radiomic features that quantify the shape, intensity and texture were extracted from each image.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37275092"
        },
        {
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1171,
          "text": "To better understand the variations, features are further grouped into 3 categories according to their properties: 1) morphology, 2) statistic/histogram and 3)texture features",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34545475"
        }
      ],
      "id": "680a087218b1e36f2e00014f",
      "ideal_answer": [
        "Radiomics is a rapidly evolving field of research concerned with the extraction of quantitative metrics, called radiomic features, within medical images. Radiomic features capture tissue and lesion characteristics such as heterogeneity and shape and may, alone or in combination with demographic, histologic, genomic, or proteomic data, be used for clinical problem solving. Specifically, examples of these features include histogram, shape-based features, texture-based features, wavelet features, Gray Level Size Zone Matrix (GLSZM), Gray Level Co-Occurrence Matrix (GLCM), and Run-Length Matrix (RLM), which can be largely grouped into 3 categories according to their properties: 1) morphology, 2) statistics/histograms, and 3) texture features.",
        "In radiomics, feature extraction is pivotal for transforming raw medical imaging data into a format that is more interpretable and meaningful for machine learning applications. The types of features typically extracted can be broadly categorized into several groups: 1. **Statistical Features**: These include first-order statistics that describe the distribution of pixel or voxel intensities within the image, such as mean, median, standard deviation, skewness, and kurtosis (PMID 39891957). 2. **Shape-based Features**: These features describe the geometric properties of the tumor or region of interest, including aspects like volume, surface area, and shape compactness. 3. **Textural Features**: These analyze the texture of the image, capturing relationships between pixels or groups of pixels. Common textural features include those derived from gray-level co-occurrence matrices (GLCM), gray-level run length matrices (GLRLM), and gray-level size zone matrices (GLSZM). 4. **Filter-based Features**: These features are extracted after applying various filters or mathematical operations to the image, which can highlight certain patterns or details, such as edges or specific textures. 5. **Higher-order Statistical Features**: These might involve more complex analyses, including algorithms that assess patterns or variations that are not captured by simpler statistical methods.",
        "In radiomics, various features are extracted from medical images to quantify tumor characteristics and tissue properties. These features can be categorized into several types. Shape features describe the geometric properties of the region of interest, including size, volume, surface area, sphericity, and compactness. First-order statistics are derived from the intensity histogram of pixel values within the region of interest, including metrics like mean, median, standard deviation, skewness, and kurtosis. Texture features capture the spatial arrangement of pixel intensities and include features from matrices such as the Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix, Gray Level Size Zone Matrix, and Gray Level Dependence Matrix. Wavelet features are derived from wavelet-transformed images and capture information at different frequency bands and orientations. Higher-order statistics include features derived from advanced mathematical transformations and models, such as fractal analysis and Laplacian of Gaussian filtering. These features provide a comprehensive quantitative description of the tissue or lesion being studied, aiding in diagnosis, prognosis, and treatment response assessment in clinical practice.",
        "In radiomics, the following types of features are typically extracted:\n\n1. **Shape-Based Features**: These describe the spatial characteristics of a region of interest (ROI) in an image. Examples include volume, surface area, maximum diameter, and compactness.\n\n2. **First-Order Statistical Features**: These capture basic intensity statistics within the ROI. Common examples include mean, median, standard deviation, skewness, kurtosis, and entropy.\n\n3. **Texture-Based Features**: These quantify the spatial distribution of pixel intensities, capturing patterns that are not apparent from first-order statistics alone. Texture features can be further categorized into:\n\n   - **Gray-Level Co-occurrence Matrix (GLCM) Features**: Reflect the spatial relationship between pixels based on their intensity levels and distances. Examples include angular second moment, contrast, correlation, and homogeneity.\n   \n   - **Gray-Level Run-Length Matrix (GLRLM) Features**: Capture the distribution of runs of similar pixel intensities in different directions. Examples include run length non-uniformity, gray-level non-uniformity, and long-run emphasis.\n   \n   - **Gray-Level Size Zone Matrix (GLSZM) Features**: Describe the size and intensity of zones within an image. Examples include zone percentage, gray-level variance, and zone count.\n   \n   - **Neighborhood Gray-Tone Difference Matrix (NGTDM) Features**: Reflect the differences in intensity between a pixel and its neighbors. Examples include busyness, complexity, and contrast.\n\n4. **High-Order or Advanced Texture Features**: These include more complex measures such as wavelet transforms, local binary patterns (LBPs), and three-dimensional local binary patterns (3D-LBPs). These features capture higher-order texture information that may be missed by traditional methods.\n\n5. **Combined Features**: Sometimes, features are combined from different categories or with additional preprocessing steps (e.g., resampling, kernel normalization) to enhance their predictive power.\n\nThese features are extracted from medical images (e.g., CT, MRI, PET) and used in machine learning models to predict clinical outcomes, assess disease progression, or guide treatment decisions.",
        "Radiomics typically extracts three main types of quantitative imaging features:  \n1. **Shape features**: Describe geometric properties (e.g., volume, flatness, surface area-to-volume ratio, maximum axial diameter).  \n2. **First-order features**: Quantify intensity distribution (e.g., mean, standard deviation, energy, entropy) without spatial context.  \n3. **Texture features**: Capture spatial patterns via matrices like gray-level co-occurrence (GLCM), run-length (GLRLM), size zone (GLSZM), dependence (GLDM), or wavelet transforms.  \n\nAdditional high-order features (e.g., wavelet-based or local binary patterns) may refine spatial or spectral patterns. These features are analyzed for associations with clinical outcomes or molecular biomarkers.",
        "Radiomics typically extracts a diverse range of quantitative features from medical images, including texture-based features (e.g., Gray Level Co-occurrence Matrix, Gray Level Run Length Matrix), shape characteristics (volume, surface area), intensity statistics (mean, standard deviation), first-order statistical measures (entropy, skewness), and filter-derived attributes (wavelet transforms, Laplacian of Gaussian). These features are derived from various imaging modalities such as CT, MRI, ultrasound, and SPECT/CT, with studies emphasizing the importance of standardized extraction protocols to ensure reproducibility. Texture and intensity-based features dominate, while shape and filter-related parameters also play critical roles in differentiating disease subtypes and predicting clinical outcomes.",
        "Radiomics typically involves extracting various types of features from medical images, including intensity-based features such as mean, median, and standard deviation, texture-based features like gray-level co-occurrence matrix (GLCM) parameters, run-length encoding, and gradient-based features. Shape-based features, which describe the morphology of regions of interest, are also commonly extracted. Advanced features include high-order statistics and filter-based transformations, such as wavelet and Gabor filters, which capture more complex patterns within images. These features are often used in machine learning models to classify diseases, predict outcomes, or differentiate tumor types, as demonstrated in studies focusing on ovarian cancer, gastric cancer, gliomas, and kidney stones. The robustness of these features can vary depending on imaging settings and preprocessing steps, emphasizing the importance of standardization and validation across different modalities like CT, MRI, and SPECT.",
        "Radiomics features typically include shape descriptors such as volume, surface area, compactness and sphericity; first-order intensity statistics like mean, variance, skewness, kurtosis and percentiles; second-order texture features derived from gray-level co-occurrence, run-length, size-zone and neighborhood gray-tone difference matrices; and higher-order features obtained after applying image filters or transforms such as wavelet decompositions, Laplacian of Gaussian and Laws textures to capture finer heterogeneity and spatial patterns.",
        "In radiomics, the types of features typically extracted include intensity-based features, such as those derived from histograms, which capture the distribution of pixel intensities within a region of interest. Shape-based features describe the geometric characteristics of tumors or regions, providing insights into their morphology. Texture-based features, including those from Gray Level Co-occurrence Matrix (GLCM), Gray Level Run-Length Matrix (GLRLM), and other advanced metrics, are commonly used to assess the heterogeneity and patterns within images. Additionally, higher-order statistics and wavelet transforms are employed to extract more complex tissue characteristics. These feature categories—intensity, shape, texture, and advanced metrics—are crucial for analyzing medical images in various clinical applications, from cancer diagnosis to neurological disorders, by capturing detailed tissue properties and structural information.",
        "Radiomic studies typically extract four main types of features. Morphologic features quantify lesion shape and geometry. First-order statistical features (histogram metrics) summarize voxel intensity distributions. Texture features derive from gray-level matrices—co-occurrence (GLCM), run-length (GLRLM), size-zone (GLSZM) and dependence (GLDM)—to capture spatial heterogeneity. Higher-order features arise from image transforms or filters (for example wavelet, Gabor or Laplacian of Gaussian) to reveal multiscale patterns. Some analyses also incorporate fractal dimension measures, edge descriptors (such as Sobel) or dynamic/kinetic features from contrast-enhanced imaging.",
        "In radiomics, features are typically categorized into three main types: morphology, statistic/histogram, and texture features. Morphological features include shape-related metrics, such as area, volume, and compactness. Statistic/histogram features involve intensity distributions, like mean, variance, and histogram-based parameters. Texture features capture spatial relationships between pixel intensities, encompassing methods like Gray Level Co-Occurrence Matrix (GLCM), Gray Level Size Zone Matrix (GLSZM), Gray Level Dependence Matrix (GLDM), and Run-Length Matrix (RLM). Additional features include wavelet-based transformations and gray size area matrix analyses. These features quantify tissue heterogeneity, lesion characteristics, and spatial patterns, often integrated with clinical or genomic data for diagnostic or predictive applications.",
        "Radiomics typically extracts features categorized into histogram-based metrics (e.g., intensity distributions, first-order statistics), shape-based descriptors (volume, surface area, compactness), texture features derived from matrices such as Gray Level Co-occurrence Matrix (GLCM), Run-Length Matrix (RLM), Gray Level Size Zone Matrix (GLSZM), and Gray Level Dependence Matrix (GLDM), as well as wavelet-transformed features for multi-scale analysis. These features capture tissue heterogeneity, spatial patterns, and morphological characteristics from medical images like CT, MRI, or ultrasound, often requiring standardization due to variability in acquisition parameters and software implementations across studies.",
        "In radiomics, various types of features are typically extracted from medical images. These features can be categorized into three main groups: morphology, statistic/histogram, and texture features. Morphology features capture shape and size characteristics of lesions or tissues. Statistic/histogram features include histogram-based metrics that describe the distribution of pixel values within a region of interest (ROI). Texture features, which occupy a large part in radiomics analysis, encompass various metrics such as gray level co-occurrence matrix (GLCM), run-length matrix (RLM), gray level size zone matrix (GLSZM), and gray level dependence matrix (GLDM) that describe the spatial arrangement of pixels within an ROI. Additionally, wavelet features may also be extracted. These radiomic features can be used alone or in combination with other data types to support clinical decision-making and problem-solving.",
        "Radiomics typically extracts morphological features characterizing lesion shape, size and boundary; first-order statistical or histogram features describing voxel intensity distributions; texture features quantifying spatial heterogeneity using matrices such as gray-level co-occurrence (GLCM), run-length (RLM), size-zone (GLSZM) and dependence (GLDM); and higher-order or transformed features such as wavelet and other filter-based decompositions.",
        "Radiomics typically involves the extraction of a large number of quantitative features from medical images. These features can be grouped into several categories, including: shape-based features (size, morphology, margin), intensity-based features (histogram, gray level), texture-based features (gray-level co-occurrence matrices, gray level run length matrix, gray level size zone matrix, gray level dependence matrix, wavelets, Laws features), and other features related to tumor vasculature, contour irregularity, spicule and lobe detection, and peritumoral compartments. These features aim to quantify characteristics such as heterogeneity, sharpness, and other aspects of the imaging features of nodules and lesions."
      ],
      "exact_answer": [
        [
          "Shape-based features",
          "Shape"
        ],
        [
          "Texture-based features",
          "texture",
          "textural features"
        ],
        [
          "Wavelet features"
        ],
        [
          "Gray Level Size Zone Matrix",
          "GLSZM",
          "GLSZM (Gray Level Size Zone Matrix) features"
        ],
        [
          "Gray Level Co-Occurrence Matrix",
          "GLCM",
          "GLCM (Gray Level Co-occurrence Matrix) features",
          "gray level co-occurrence (GLCM) parameters"
        ],
        [
          "Run-Length Matrix",
          "RLM",
          "Run-length matrix features",
          "Gray Level Run Length Matrix (GLRLM)",
          "GLRLM (Gray Level Run Length Matrix) features"
        ],
        [
          "Histograms",
          "First-Order Statistics (Histogram-Based Features)",
          "first-order statistics",
          "First-order Features",
          "intensity (first-order)",
          "Intensity-based features"
        ],
        [
          "Gray Level Dependence Matrix (GLDM)",
          "GLDM (Gray Level Dependence Matrix) features"
        ],
        [
          "Laws texture energy features",
          "Law\u0027s features"
        ],
        [
          "Gabor",
          "Gabor features"
        ],
        [
          "local binary pattern (LBP)",
          "three-dimensional local binary patterns",
          "Local Binary Patterns"
        ],
        [
          "Neighboring Gray Tone Difference Matrix (NGTDM)",
          "neighborhood gray tone difference matrix"
        ],
        [
          "Laplacian of Gaussian (LoG)",
          "Laplacian of Gaussian features",
          "Laplacian of Gaussians"
        ]
      ]
    },
    {
      "body": "What diseases are treated with fecal transplants?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37162960",
        "http://www.ncbi.nlm.nih.gov/pubmed/38951925",
        "http://www.ncbi.nlm.nih.gov/pubmed/39403201",
        "http://www.ncbi.nlm.nih.gov/pubmed/31936237",
        "http://www.ncbi.nlm.nih.gov/pubmed/30789675",
        "http://www.ncbi.nlm.nih.gov/pubmed/28164849",
        "http://www.ncbi.nlm.nih.gov/pubmed/26397161",
        "http://www.ncbi.nlm.nih.gov/pubmed/36844708",
        "http://www.ncbi.nlm.nih.gov/pubmed/28289858",
        "http://www.ncbi.nlm.nih.gov/pubmed/33827154",
        "http://www.ncbi.nlm.nih.gov/pubmed/24241245",
        "http://www.ncbi.nlm.nih.gov/pubmed/25500625",
        "http://www.ncbi.nlm.nih.gov/pubmed/27172442",
        "http://www.ncbi.nlm.nih.gov/pubmed/38001930",
        "http://www.ncbi.nlm.nih.gov/pubmed/27453747",
        "http://www.ncbi.nlm.nih.gov/pubmed/36569149",
        "http://www.ncbi.nlm.nih.gov/pubmed/32585148",
        "http://www.ncbi.nlm.nih.gov/pubmed/39726974",
        "http://www.ncbi.nlm.nih.gov/pubmed/36412458",
        "http://www.ncbi.nlm.nih.gov/pubmed/31467881",
        "http://www.ncbi.nlm.nih.gov/pubmed/22552243",
        "http://www.ncbi.nlm.nih.gov/pubmed/31950808",
        "http://www.ncbi.nlm.nih.gov/pubmed/36300959",
        "http://www.ncbi.nlm.nih.gov/pubmed/32999906",
        "http://www.ncbi.nlm.nih.gov/pubmed/37602044",
        "http://www.ncbi.nlm.nih.gov/pubmed/32306706",
        "http://www.ncbi.nlm.nih.gov/pubmed/30403550",
        "http://www.ncbi.nlm.nih.gov/pubmed/25424663",
        "http://www.ncbi.nlm.nih.gov/pubmed/34735024",
        "http://www.ncbi.nlm.nih.gov/pubmed/32841976",
        "http://www.ncbi.nlm.nih.gov/pubmed/32954843",
        "http://www.ncbi.nlm.nih.gov/pubmed/22183182",
        "http://www.ncbi.nlm.nih.gov/pubmed/30540704",
        "http://www.ncbi.nlm.nih.gov/pubmed/26566371",
        "http://www.ncbi.nlm.nih.gov/pubmed/37981872",
        "http://www.ncbi.nlm.nih.gov/pubmed/23041678",
        "http://www.ncbi.nlm.nih.gov/pubmed/26616138",
        "http://www.ncbi.nlm.nih.gov/pubmed/28178876",
        "http://www.ncbi.nlm.nih.gov/pubmed/26204547",
        "http://www.ncbi.nlm.nih.gov/pubmed/25548572",
        "http://www.ncbi.nlm.nih.gov/pubmed/28506071",
        "http://www.ncbi.nlm.nih.gov/pubmed/28125667",
        "http://www.ncbi.nlm.nih.gov/pubmed/38037086",
        "http://www.ncbi.nlm.nih.gov/pubmed/33121693",
        "http://www.ncbi.nlm.nih.gov/pubmed/27648772",
        "http://www.ncbi.nlm.nih.gov/pubmed/29173524",
        "http://www.ncbi.nlm.nih.gov/pubmed/30011107",
        "http://www.ncbi.nlm.nih.gov/pubmed/38518435",
        "http://www.ncbi.nlm.nih.gov/pubmed/27027524",
        "http://www.ncbi.nlm.nih.gov/pubmed/33765728",
        "http://www.ncbi.nlm.nih.gov/pubmed/31169545",
        "http://www.ncbi.nlm.nih.gov/pubmed/25954111",
        "http://www.ncbi.nlm.nih.gov/pubmed/31173991",
        "http://www.ncbi.nlm.nih.gov/pubmed/39729440",
        "http://www.ncbi.nlm.nih.gov/pubmed/23034604",
        "http://www.ncbi.nlm.nih.gov/pubmed/23979974",
        "http://www.ncbi.nlm.nih.gov/pubmed/31972620",
        "http://www.ncbi.nlm.nih.gov/pubmed/35695221",
        "http://www.ncbi.nlm.nih.gov/pubmed/24939885",
        "http://www.ncbi.nlm.nih.gov/pubmed/27152872",
        "http://www.ncbi.nlm.nih.gov/pubmed/23101687",
        "http://www.ncbi.nlm.nih.gov/pubmed/27025624",
        "http://www.ncbi.nlm.nih.gov/pubmed/24707129",
        "http://www.ncbi.nlm.nih.gov/pubmed/31937933",
        "http://www.ncbi.nlm.nih.gov/pubmed/39607629",
        "http://www.ncbi.nlm.nih.gov/pubmed/29450831",
        "http://www.ncbi.nlm.nih.gov/pubmed/38175472",
        "http://www.ncbi.nlm.nih.gov/pubmed/36006314",
        "http://www.ncbi.nlm.nih.gov/pubmed/27856521",
        "http://www.ncbi.nlm.nih.gov/pubmed/39631325",
        "http://www.ncbi.nlm.nih.gov/pubmed/29134299",
        "http://www.ncbi.nlm.nih.gov/pubmed/28840809",
        "http://www.ncbi.nlm.nih.gov/pubmed/25274035",
        "http://www.ncbi.nlm.nih.gov/pubmed/31472233",
        "http://www.ncbi.nlm.nih.gov/pubmed/27493597",
        "http://www.ncbi.nlm.nih.gov/pubmed/38334893",
        "http://www.ncbi.nlm.nih.gov/pubmed/29130220"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 272,
          "text": "Fecal microbiota transplantation (FMT) and fecal virome transplantation (FVT, sterile filtrated donor feces) have been effective in treating recurrent Clostridioides difficile infections, possibly through bacteriophage-mediated modulation of the gut microbiome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38951925"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39403201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31936237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 343,
          "text": "Fecal microbiota transplantation (FMT) is the transfer of stool from a healthy donor into the colon of a patient whose disease is a result of an altered microbiome, with the goal of restoring the normal microbiota and thus curing the disease. The most effective and well-studied indication for FMT is recurrent Clostridium difficile infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28164849"
        },
        {
          "offsetInBeginSection": 622,
          "offsetInEndSection": 733,
          "text": "FMT is particularly effective and safe in curing CDI, using a colonoscope or enema to deliver 1 to 2 infusions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26397161"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 891,
          "text": "Fecal microbiota transplantation (FMT) is the process of transplanting stool from a healthy donor into the gut of a patient for therapeutic purposes. Current guidelines recommend FMT for the prevention of multiply recurrent Clostridioides difficile infection (CDI) after two recurrences, with cure rates approaching 90%. Emerging evidence also supports the use of FMT in the management of severe and fulminant CDI, resulting in decreased mortality and colectomy rates compared with standard of care approach. FMT shows promise as salvage therapy for critically-ill, refractory CDI patients who are poor surgical candidates. FMT should be considered early in the clinical course of severe CDI, preferably within 48 hours of failing to respond to antibiotic therapy and volume resuscitation. Besides CDI, ulcerative colitis was more recently identified as a potential treatment target for FMT.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36844708"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 415,
          "text": " (FMT) as therapy. FMT has been studied in many disease states including the most common indication of Clostridium difficile infection (CDI), though many questions regarding stool dono",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28289858"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Fecal microbiota transplantation (FMT) is an accepted procedure for the management of recurrent Clostridioides difficile infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33827154"
        },
        {
          "offsetInBeginSection": 346,
          "offsetInEndSection": 479,
          "text": "Fecal microbiota transplantation (FMT) is an almost effective and safe treatment option for recurrent Clostridium difficile infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726974"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 408,
          "text": "Fecal microbiota transplantation (FMT), a type of fecal bacteriotherapy, is considered an effective therapeutic option for recurrent Clostridium difficile infection (rCDI) and also has important value in other intestinal diseases including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31467881"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 145,
          "text": "Fecal transplantation was shown to effectively reduce the reoccurrence in patients with refractory Clostridium difficile infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27453747"
        },
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 392,
          "text": "transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25500625"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Fecal microbiota transplantation (FMT) is an increasingly employed treatment option for Clostridioides difficile infection (CDI),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300959"
        },
        {
          "offsetInBeginSection": 818,
          "offsetInEndSection": 1375,
          "text": "Fecal microbiota transplant (FMT) is a successful and established therapy in recurrent CDI, and its application in other dysbiosis-related diseases is attracting enormous interest. Pre- and probiotics target microbial rebalance and have positive effects mainly in NAFLD, ulcerative colitis, IBS, and CDI patients. Promising anticarcinogenic effects have also been demonstrated in animal models. The literature increasingly describes microbial changes in many dysbiotic disorders and shows what needs to be treated. However, probiotics and FMT application in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32999906"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 415,
          "text": "New data suggest that fecal transplantation could also be efficient in other gastrointestinal diseases, for instance in inflammatory bowel disease, irritable bowel syndrome, but, there are also some data that could imply the efficacy outside the gastrointestinal tract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27453747"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 474,
          "text": "Generally, heterologous fecal microbiota transplantation (h-FMT), where feces from a ``healthy\" donor is transplanted into a person with illness, has been used to treat infectious diseases such as recurrent Clostridioides difficile infection (CDI), with cure rates of up to 90%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32585148"
        },
        {
          "offsetInBeginSection": 1669,
          "offsetInEndSection": 1861,
          "text": "Fecal transplant is highly effective, safe, with practically no adverse effects, inexpensive, a procedure easy to be done that could be introduced in Clostridium difficile treatment protocols.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27453747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Effectiveness of Fecal Microbiota Transplantation Treatment in Patients With Recurrent Clostridium difficile Infection, Ulcerative Colitis, and Crohn\u0027s Disease:",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37602044"
        },
        {
          "offsetInBeginSection": 554,
          "offsetInEndSection": 792,
          "text": " Fecal microbiota transplantation (FMT) is a curative therapy for Clostridium difficile infection (CDI), a disease hallmarked by intestinal dysbiosis, and FMT is now being explored as a means to also restore intestinal homeostasis in FGID",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25424663"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 319,
          "text": "Fecal transplantation was shown to effectively reduce the reoccurrence in patients with refractory Clostridium difficile infection. New data suggest that fecal transplantation could also be efficient in other gastrointestinal diseases, for instance in inflammatory bowel disease, irritable bowel syndrome,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27453747"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 346,
          "text": "Fecal microbiota transplantation (FMT) is now an established treatment for recurrent Clostridioides difficile infection. There is also increasing evidence for the efficacy of FMT in inducing remission for mild-moderate ulcerative colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34735024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Fecal microbiota transplantation (FMT) is an alternative treatment option with minimal risk for patients with Crohn disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32841976"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 352,
          "text": "FMT has been proven to be a safe and effective treatment for Clostridioides difficile infection, but increasing evidence supports the role of FMT in other gastrointestinal and extraintestinal diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32954843"
        },
        {
          "offsetInBeginSection": 499,
          "offsetInEndSection": 877,
          "text": "FMT appears to be the most successful in the treatment of recurrent Clostridium difficile infection (CDI), randomized controlled studies reported 90 % success rate. There is a limited evidence for FMT as a treatment of ulcerative colitis. FMT has been also studied as treatment of diseases with impaired gut microbiota, such as cardiovascular, autoimmune and metabolic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27172442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30540704"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Fecal microbiota transplantation (FMT) has gained mainstream attention with its remarkable efficacy in treating recurrent Clostridium difficile infection (RCDI) when there are no other effective therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent Clostridioides difficile infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30403550"
        },
        {
          "offsetInBeginSection": 350,
          "offsetInEndSection": 739,
          "text": "It has been shown that fecal microbiota transplantation (FMT) is an effective treatment for UC, but results for FMT antibiotic-resistant pouchitis are inconsistent.METHODS: To uncover which metabolic activities were transferred to the recipients during FMT and helped the remission, we performed a longitudinal case study of the gut metatranscriptomes from three patients and their donors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38037086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 52,
          "text": "Fecal Microbiota Transplantation in Liver Cirrhosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38001930"
        },
        {
          "offsetInBeginSection": 323,
          "offsetInEndSection": 491,
          "text": "In a paper in this issue, 43 patients with recurrent Clostridium difficile infections were treated with fecal microbiota transplants using a compassionate use protocol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552243"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Fecal microbiota transplantation (FMT) is an increasingly employed treatment option for Clostridioides difficile infection (CDI), with growing data supporting its safety and effectiveness in patients with concurrent inflammatory bowel disease (IBD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36300959"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 323,
          "text": "The success of fecal microbiota transplantation (FMT) in the treatment of Clostridioides difficile infection, a disease that is also marked by dysbiosis, has spurred research in applying FMT to UC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33121693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "Fecal microbiota transplantation (FMT) has been demonstrated to be efficacious in preventing recurrent Clostridioides difficile (C. difficile) infections, and is being investigated for treatment of several other diseases including inflammatory bowel disease, cancer, obesity, liver disease, and diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38518435"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 430,
          "text": "There is hope that manipulation of the gut microbiome through fecal microbiota transplant (FMT), commonly used to treat patients with Clostridium difficile infection, may also be an effective therapy in IBD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29173524"
        },
        {
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1229,
          "text": "It also focused on increasing the application potential and visibility of FMT beyond treating C. difficile infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38518435"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30011107"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 522,
          "text": "With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30540704"
        },
        {
          "offsetInBeginSection": 749,
          "offsetInEndSection": 1101,
          "text": "FMT has diffused to other areas where the alterations of the gut microbiota ecology (or dysbiosis) have been theorized to play a causative role, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), among several other extra-intestinal disorders (i.e. metabolic syndrome and obesity, multiple sclerosis, cardiovascular diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27027524"
        },
        {
          "offsetInBeginSection": 519,
          "offsetInEndSection": 706,
          "text": "Many studies have demonstrated the application of FMT in inflammatory bowel disease, irritable bowel syndrome, non-alcoholic fatty liver disease, metabolic syndrome, obesity, and diabetes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33765728"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 584,
          "text": " infection (RCDI). The impact of FMT on host microbial communities and subsequent disease states has also been explored in recent years for conditions as varied as inflammatory bowel disease especially ulcerative colitis, metabolic diseases, such as diabetes, graft-versus-host disease in hematopoietic stem cell transplant recipients, and autism and autism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31169545"
        },
        {
          "offsetInBeginSection": 1230,
          "offsetInEndSection": 1435,
          "text": "se events were rare.CONCLUSION: FMT is highly effective in CDI, and holds promise in UC. As for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions. FMT increases insulin s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954111"
        },
        {
          "offsetInBeginSection": 670,
          "offsetInEndSection": 815,
          "text": "We review the role of FMT from its beginnings in CDI to its expansion into inflammatory bowel disease, irritable bowel syndrome, and colon cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31173991"
        },
        {
          "offsetInBeginSection": 1340,
          "offsetInEndSection": 1603,
          "text": "estinal microbiota.DISCUSSION: Faecal microbiota transplantation has been effective for dysbiosis in non-critically ill patients with recurrent C. difficile infections and it is plausible to hypothesize that it will be equally effective for symptoms of dysbiosis ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39729440"
        },
        {
          "offsetInBeginSection": 346,
          "offsetInEndSection": 480,
          "text": "Fecal microbiota transplantation (FMT) is an almost effective and safe treatment option for recurrent Clostridium difficile infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726974"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 342,
          "text": "Current evidence strongly supports a role for FMT in the treatment of Clostridiodes difficile infection, with cure rates of approximately 80% to 90",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37981872"
        },
        {
          "offsetInBeginSection": 345,
          "offsetInEndSection": 594,
          "text": "This success has led to increasing attention for FMT as a potential therapeutic intervention for other conditions associated with disturbances of the intestinal microbiome, including inflammatory bowel diseases, autism spectrum disorder, and obesity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37981872"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 709,
          "text": "It has demonstrated efficacy in treating refractory Clostridium difficile infection, and there are case reports of FMT successfully treating UC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034604"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 429,
          "text": "There is hope that manipulation of the gut microbiome through fecal microbiota transplant (FMT), commonly used to treat patients with Clostridium difficile infection, may also be an effective therapy in IBD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29173524"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "PURPOSE OF REVIEW: To review the current evidence on fecal microbiota transplantations (FMTs) for recurrent Clostridium difficile infections (CDIs), metabolic syndrome and inflamm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24241245"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 472,
          "text": "Generally, heterologous fecal microbiota transplantation (h-FMT), where feces from a ``healthy\" donor is transplanted into a person with illness, has been used to treat infectious diseases such as recurrent Clostridioides difficile infection (CDI), with cure rates of up to 90",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32585148"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "BACKGROUND/STUDY AIMS: Fecal microbiota transplantation (FMT), a treatment aiming to restore dysbiosis by transferring stool from a healthy donor into the patient, has cure rates up to 90% in the management of recurrent Clostridium difficile ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31950808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "OBJECTIVES: Fecal microbiota transplantation (FMT) has emerged as an effective treatment option for Clostridioides difficile infection (CDI) and is considered an investigational therapy for a number of ot",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31972620"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 772,
          "text": "Fecal transplantation, the infusion of donor feces into a recipient\u0027s intestinal tract, has been used for decades to treat recurrent Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616138"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 772,
          "text": "Current therapy, usually directed toward suppressing intestinal bacterial overgrowth and limiting ingested CHO, is not always successful. Fecal transplantation, the infusion of donor feces into a recipient\u0027s intestinal tract, has been used for decades to treat recurrent Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616138"
        },
        {
          "offsetInBeginSection": 1923,
          "offsetInEndSection": 2117,
          "text": "tic therapy. Fecal microbiota transplantation (FMT) has provided a successful treatment method for some patients with recurrent C. difficile infection, but its mechanism and long-term effects re",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24939885"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI) diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572"
        },
        {
          "offsetInBeginSection": 360,
          "offsetInEndSection": 970,
          "text": "Current therapy, usually directed toward suppressing intestinal bacterial overgrowth and limiting ingested CHO, is not always successful. Fecal transplantation, the infusion of donor feces into a recipient\u0027s intestinal tract, has been used for decades to treat recurrent Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain. The exact mechanism of action is unknown, but it is surmised that the alteration of the intestinal microbiome, as well as the reintroduction of potential beneficial microbes, helps mediate disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616138"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 310,
          "text": "ic therapy. Recently, fecal microbiota transplantation (FMT) has been successfully used to treat recurrent C. difficil",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24939885"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 1121,
          "text": "Fecal transplantation, the infusion of donor feces into a recipient\u0027s intestinal tract, has been used for decades to treat recurrent Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain. The exact mechanism of action is unknown, but it is surmised that the alteration of the intestinal microbiome, as well as the reintroduction of potential beneficial microbes, helps mediate disease. Here we present the case of a child with SBS and recurrent, debilitating D-lactic acidosis, which was successfully treated with fecal transplantation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616138"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 970,
          "text": "Fecal transplantation, the infusion of donor feces into a recipient\u0027s intestinal tract, has been used for decades to treat recurrent Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain. The exact mechanism of action is unknown, but it is surmised that the alteration of the intestinal microbiome, as well as the reintroduction of potential beneficial microbes, helps mediate disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile, a common hospital-acquired infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28178876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "PURPOSE OF REVIEW: Fecal microbiota transplant (FMT) has emerged as an important treatment for antibiotic resistant or recurrent Clostridium difficile infection. There has been a great deal of media coverage of the efficacy of FMT, and patients with ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "\"Patients with inflammatory bowel disease, including ulcerative colitis (UC) and Crohn disease, have altered gut microbiomes. The success of fecal microbiota transplantation (FMT) in the treatment of Clostridioides difficile infection, a disease that",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33121693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Fecal microbiota transplantation (FMT) has gained widespread recognition in light of the recent Clostridium difficile infection (CDI) epidemic, responsible for almost 110,000 deaths per year. The procedure\u0027s success rate has caused experts to reflect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101687"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Fecal Microbiota Transplantation (FMT) methodology has been progressively refined over the past several years. The procedure has an extensive track record of success curing Clostridium difficile infection (CDI) with remarkably few adverse effects. It",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025624"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Our understanding of the microbiome and its implications for human health and disease continues to develop. Fecal microbiota transplantation (FMT) is now an established treatment for recurrent Clostridioides difficile infection. There is also increas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34735024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Fecal microbiota transplantation (FMT) is considered to be a highly successful therapy for recurrent and refractory Clostridium difficile infection (CDI) based on recent clinical trials. The pathogenesis of inflammatory bowel diseases (IBD) is though",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24707129"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Fecal microbiota transplantation (FMT) has gained mainstream attention with its remarkable efficacy in treating recurrent Clostridium difficile infection (RCDI) when there are no other effective therapies. Methods of selecting donors and routes of ad",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "INTRODUCTION: Administration of fecal microbiota spores, live-brpk [Vowst Oral Spores (VOS)], an oral microbiome therapeutic approved for prevention of recurrent Clostridioides difficile infection in adults, requires antibiotic washout using a laxative prior to a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39607629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Fecal microbiota transplant (FMT) has emerged as a highly efficacious treatment for difficult cases of refractory and/or recurrent Clostridium difficile infection (CDI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29450831"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 312,
          "text": "Fecal microbiota transplantation (FMT) is being developed in recent years, and it has remarkable curative effect for the clostridium and inflammatory bowel disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35695221"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 356,
          "text": "FMT has also been used to treat other gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation, as well as a variety of non-GI disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36412458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 886,
          "text": "Clostridioides difficile infection (CDI) is one of the most common healthcare-associated infections and one of the leading causes of morbidity and mortality in hospitalized patients in the world. Although several antibiotics effectively treat CDI, some individuals may not respond to these drugs and may be cured by transplanting stool from healthy donors. FMT has demonstrated extraordinary cure rates for the cure of CDI recurrences.Moreover, FMT has also been investigated in other disorders associated with the alteration of gut microbiota, such as inflammatory bowel disease (IBD), where the alterations of the gut microbiota ecology have been theorized to play a causative role. Although FMT is currently not recommended to cure IBD patients in clinical practice, several studies have been recently carried out with the ultimate goal to search new therapeutic options to patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38175472"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 47,
          "text": "Fecal Transplant in Inflammatory Bowel Disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29173524"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 710,
          "text": "It has demonstrated efficacy in treating refractory Clostridium difficile infection, and there are case reports of FMT successfully treating UC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23034604"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 327,
          "text": "Fecal microbiota transplantation (FMT) is an emerging therapeutic option for a variety of diseases, and is characterized as the transfer of fecal microorganisms from a healthy donor into the intestinal tract of a diseased recipient. In human clinics, FMT has been used for treating diseases for decades, with promising results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006314"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 297,
          "text": "The transfer of whole microbiota via fecal transplantation has already been shown to ameliorate the severity of diseases such as Clostridium difficile infection, inflammatory bowel disease, and others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27856521"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 324,
          "text": "Fecal microbiota transplantation (FMT) has been shown to improve clinical outcomes in a variety of diseases such as epilepsy, amyotrophic lateral sclerosis (ALS) and autism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39631325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "In recent years, fecal microbiota transplantation (aka fecal transplantation, fecal bacteriotherapy, FMT) has become increasing utilized to treat recurrent and refractory Clostridium difficile infection (CDI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23979974"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "OBJECTIVES: Fecal microbiota transplantation (FMT) has emerged as an effective treatment option for Clostridioides difficile infection (CDI) and is considered an investigational therapy for a number of oth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31972620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "BACKGROUND: Fecal microbiota transplantation (FMT) is a new technique recently introduced to treat recurrent Clostridium difficile infe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29134299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "PURPOSE OF REVIEW: Administration of fecal material into the gastrointestinal tract, termed fecal microbiota transplantation (FMT), is increasingly recognized as an effective treatment option for recurrent Clostridium difficile",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31169545"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 514,
          "text": "Fecal microbiota transplantation (FMT) has been utilized sporadically for over 50 years. In the past few years, Clostridium difficile infection (CDI) epidemics in the USA and Europe have resulted in the increased use of FMT, given its high efficacy in eradicating CDI and associated symptoms. As more patients request treatment and more clinics incorporate FMT into their treatment repertoire, reports of applications outside of CDI are emerging, paving the way for the use of FMT in several idiopathic conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22183182"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 392,
          "text": "Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25500625"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28125667"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27648772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Fecal microbiota transplantation (FMT) has an incomparable efficacy to treat recurrent Clostridium difficile infection, with near 90% of success",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26204547"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 771,
          "text": "Fecal transplantation, the infusion of donor feces into a recipient\u0027s intestinal tract, has been used for decades to treat recurrent Clostridium difficile infection, and case reports document its use in the successful treatment of constipation, diarrhea, and abdominal pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (CDI) and is considered as a treatment for other gastrointestinal (GI) diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile, a common hospital-acquired infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28178876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Fecal microbiota transplantation (FMT) has become an effective strategy to treat metabolic diseases, including type 2 diabetes mellitus (T2DM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31937933"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 377,
          "text": " FMT has also been used to treat other gastrointestinal (GI) diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041678"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 463,
          "text": "Recent insights have linked the gut microbiota to a plethora of diseases, including Clostridium difficile infection (CDI), inflammatory bowel disease (IBD), and metabolic diseases such as obesity, type 2 diabetes (T2D), and nonalcoholic steatohepatitis (NASH). Fecal microbiota transplantation (FMT) is currently tested as a therapeutic option in various diseases ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28840809"
        },
        {
          "offsetInBeginSection": 257,
          "offsetInEndSection": 585,
          "text": "The use of FMT for other diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic syndrome, is now being evaluated. The currently available data suggest that FMT might be beneficial for IBD (including ulcerative colitis and, to some extent, Crohn\u0027s disease), IBS, and insulin resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25274035"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 641,
          "text": "FMT is approved in the USA to treat recurrent and refractory Clostridioides difficile infection and has been shown to have great efficacy. As such, significant research has been directed toward understanding the potential role of FMT in other conditions associated with gut microbiota dysbiosis such as obesity, type 2 diabetes mellitus, metabolic syndrome, neuropsychiatric disorders, inflammatory bowel disease, irritable bowel syndrome, decompensated cirrhosis, cancers and graft-versus-host disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36569149"
        },
        {
          "offsetInBeginSection": 586,
          "offsetInEndSection": 816,
          "text": "Fecal microbiota transplantation is relatively simple to perform, well-tolerated, safe and effective in recurrent Clostridium difficile infection with ulcerative pancolitis, as an alternative in case of antibiotic therapy failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28506071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "PURPOSE: Recently, fecal microbiota transplantation (FMT) has been tested in veterinary medicine as a treatment option for multiple gastrointestinal (GI) diseases, such as inflammatory bowel disea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31819862"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 254,
          "text": "In our department, fecal microbiota transplantation has been undertaken to treat chronic hepatitis B and inflammatory bowel diseases since 2015.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34176888"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 691,
          "text": "es of FGID. Fecal microbiota transplantation (FMT) is a curative therapy for Clostridium difficile infection (CDI), a disease hallmarked by intestin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25424663"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Despite lack of regulatory approval, fecal microbiota transplantation (FMT) is widely performed to manage C. difficile infection (CDI), particularly recurrent CDI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31472233"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 355,
          "text": "This success has led to studies exploring the role of FMT in other conditions, including inflammatory bowel disease (IBD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic modality within the domain of inflammatory bowel disease (IBD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38334893"
        },
        {
          "offsetInBeginSection": 571,
          "offsetInEndSection": 813,
          "text": "Numerous case reports, retrospective case series, and randomized controlled trials have shown the benefit of FMT in patients with functional bowel disorders, including inflammatory bowel disease, irritable bowel syndrome and constipation, etc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29130220"
        }
      ],
      "type": "list",
      "id": "6810daad353a4a2e6b000013",
      "ideal_answer": [
        "Anumber of different diseases have been treated with fecal microbiota transplants (FMTs). THese diseases include  C. difficile infections, chronic diarrhea, Colorectal cancer, and Urinary Stone Disease",
        "Fecal microbiota transplantation (FMT) is used to treat a variety of diseases. These include Clostridioides difficile infection, irritable bowel syndrome, inflammatory bowel disease, liver disorders, decolonization of multidrug-resistant bacteria, metabolic disorders, and neurological disorders.",
        "Fecal transplants can be used to treat Clostridioides difficile infection, Irritable bowel syndrome, Inflammatory bowel disease, Metabolic syndrome, and Parkinson\u0027s disease.",
        "Fecal microbiota transplantation (FMT) is primarily used to treat Clostridium difficile infection (CDI), particularly recurrent cases. It is also being explored for use in inflammatory bowel disease.",
        "Fecal transplants are primarily used for the treatment of Clostridium difficile infections, a common intestinal disorder caused by the bacterium C. difficile. In some cases, they may also be used for the treatment of Irritable Bowel Syndrome (IBS), a chronic gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel movements. However, the use of fecal transplants for IBS is still a topic of ongoing research and not yet widely accepted as a standard treatment.",
        "Fecal transplants are used to treat diseases including Clostridium difficile infection, inflammatory bowel disease, irritable bowel syndrome, metabolic syndrome, diabetes, cancer, and Parkinson\u0027s disease.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: recurrent Clostridioides difficile infection, gastrointestinal diseases caused by pathogenic microorganisms, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, and acute hemorrhagic diarrhea syndrome in puppies.",
        "Fecal transplants are used to treat diseases such as metabolic syndrome, Parkinson\u0027s disease, irritable bowel syndrome, inflammatory bowel disease, diabetes, cancer, Clostridium difficile infection, and Clostridioides difficile infection.",
        "Fecal microbiota transplantation is used to treat Ulcerative colitis, Chroncic carepropeal, obesity, C. difficile infection, Glaucoma, Autism specter spectrum disorder (ASD) and Dementia",
        "Fecal transplantation can be used to treat infections, cognitive disorders and inflammatory bowel disease.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: 1. Recurrent Clostridium difficile infection 2. Inflammatory bowel disease (IBD) 3. Ulcerative colitis 4. Irritable bowel syndrome 5. Hepatic encephalopathy 6. Metabolic syndrome 7. Diabetes 8. Cancer 9. Parkinson\u0027s disease 10. Neurological disorders (e.g., autism spectrum disorder, multiple sclerosis) 11. Multidrug-resistant organism (MDRO) colonization 12. Acute hemorrhagic diarrhea syndrome in dogs",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: gastrointestinal diseases, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, recurrent Clostridium difficile infection, Crohn\u0027s disease, ulcerative colitis, and autoimmune diseases.",
        "Fecal microbiota transplantation (FMT) has been shown to improve clinical outcomes in a variety of diseases, including metabolic diseases like type 2 diabetes mellitus (T2DM), epilepsy, amyotrophic lateral sclerosis (ALS), autism, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), chronic liver diseases, chronic hepatitis B, and ulcerative colitis.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: recurrent Clostridioides difficile infection, gastrointestinal diseases caused by pathogenic microorganisms, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, atherosclerosis, and acute hemorrhagic diarrhea syndrome in puppies.",
        "Fecal transplants are primarily used to treat Clostridioides difficile infection and are being explored for other conditions like inflammatory bowel disease and metabolic disorders.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, insulin resistance, multiple sclerosis, and idiopathic thrombocytopenic purpura.",
        "Fecal microbiota transplantation (FMT) has been used to treat several diseases, primarily those related to gut microbiome dysbiosis. The most established indication for FMT is recurrent Clostridium difficile infection (CDI), with high efficacy in eradicating CDI and associated symptoms.\n\nAdditionally, FMT has been investigated as a potential treatment option for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn\u0027s disease. Some studies have also explored its use in irritable bowel syndrome (IBS).\n\nFurthermore, there is emerging evidence suggesting that FMT may be beneficial in treating other conditions, such as metabolic syndrome. However, more research is needed to fully understand the therapeutic potential of FMT in these areas.\n\nIn summary, the primary diseases treated with fecal transplants are recurrent Clostridium difficile infection and inflammatory bowel disease, with ongoing research into its potential applications in other conditions.",
        "Fecal microbiota transplantation (FMT) has been used to treat a variety of diseases, including recurrent Clostridium difficile infection, inflammatory bowel diseases, irritable bowel syndrome, metabolic diseases such as type 2 diabetes mellitus, epilepsy, amyotrophic lateral sclerosis (ALS), and autism.",
        "Fecal microbiota transplantation (FMT) is primarily used to treat Clostridium difficile infection (CDI), particularly recurrent cases. It is also applied in the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Additionally, research is exploring its potential use in other conditions such as metabolic syndrome, though these applications are still under investigation.",
        "Fecal transplants are primarily used to treat gastrointestinal diseases, including Clostridium difficile infection, Inflammatory Bowel Disease (e.g., Ulcerative Colitis), and Irritable Bowel Syndrome, with emerging potential applications in Cardiovascular diseases, Autoimmune diseases, Metabolic disorders, and possibly cancer.",
        "Fecal transplants are used to treat recurrent Clostridioides difficile infections, inflammatory bowel disease, and primary and secondary immunodeficiency.",
        "Fecal microbiota transplantation (FMT) is a promising treatment for a variety of diseases, including:\n1. Clostridioides difficile infection (CDI)\n2. Inflammatory bowel disease (IBD)\n3. Irritable bowel syndrome (IBS)\n4. Obesity\n5. Diabetes\n6. Cancer\n7. Neurological disorders\n8. Autoimmune diseases\n9. Cardiovascular disease\n10. Mental health disorders",
        "Fecal microbiota transplantation (FMT) is used to treat recurrent Clostridioides difficile infections, inflammatory bowel disease, irritable bowel syndrome, obesity, type 2 diabetes, and other diseases.",
        "Fecal transplants are used to treat recurrent Clostridioides difficile infections, chronic diarrhea, primary and secondary immunodeficiency, colorectal cancer toxicity, and urinary stone disease. They aim to reestablish a healthy gut microbiota, influencing metabolism and urinary chemistry.",
        "Fecal transplants can treat chronic diarrhea, urinary stone disease, and Clostridioides difficile infections.",
        "Fecal transplants are used to treat diseases such as recurrent Clostridioides difficile infections, chronic diarrhea, urinary stone disease, and intestinal injury.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: recurrent Clostridioides difficile infection, irritable bowel syndrome, inflammatory bowel diseases, insulin resistance, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, chronic diarrhea, and conditions related to dysbiosis.",
        "Fecal transplants are used to treat various conditions including Clostridium difficile infection, ulcerative colitis, inflammatory bowel disease, severe alcoholic hepatitis, immunotherapy-resistant melanoma, systemic lupus erythematosus, colorectal cancer (to mitigate chemotherapy-induced intestinal injury), and urinary stone disease. Studies highlight their efficacy in restoring gut microbiota balance, improving survival rates in severe alcoholic hepatitis, reducing recurrence of CDI, alleviating symptoms in IBD, enhancing antitumor immune responses in melanoma, modulating urine chemistry risk factors for urinary stones, and demonstrating potential therapeutic benefits in SLE and colorectal cancer management.",
        "Fecal microbiota transplantation has been shown to be effective for Cholstridioides difficile infection, Chronc diarrhea, IBS (Inflammatory Bowel Syndrome), cancer, urinary stone disease and others.\nFecal transplant modifies urine chemistry risk factors for urinary stone disease",
        "Fecal microbiota transplantation (FMT) is used to treat Clostridium difficile infections (CDI). It is also being investigated as a potential therapeutic intervention for inflammatory bowel diseases, autism spectrum disorder, obesity, metabolic syndrome, chronic diarrhea with immunodeficiency, and other gastrointestinal diseases like irritable bowel syndrome (IBS) and chronic constipation, as well as non-GI disorders. Additionally, there are case reports of FMT successfully treating ulcerative colitis (UC).",
        "Fecal transplants are primarily used to treat Clostridium difficile (C. difficile) infections, but they are also being investigated for their potential to treat other conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and certain autoimmune diseases.",
        "Fecal microbiota transplantation (FMT) has proven effective in treating several conditions, including recurrent Clostridioides difficile infections, chronic diarrhea in immunodeficiency patients, colorectal cancer-related complications, and may influence urinary stone disease through gut microbiome modification.",
        "Fecal transplants are used to treat recurrent Clostridioides difficile infections, chronic diarrhea in immunodeficient patients, and to prevent intestinal injury and toxicity in colorectal cancer treatments. They also show potential in modifying urinary chemistry to address urinary stone disease.",
        "The diseases that are treated with fecal transplants, according to the provided context, include Clostridioides difficile infections, chronic diarrhea, and immunodeficiency. The treatment of these conditions is facilitated by the reestablishment of an intact microbiota via fecal microbiota transplants (FMTs).",
        "Fecal microbiota transplantation (FMT) is used to treat recurrent Clostridioides difficile infections, inflammatory bowel disease, and primary and secondary immunodeficiency.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including: recurrent Clostridioides difficile infection, gastrointestinal diseases caused by pathogenic microorganisms, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, chronic diarrhea, and urinary stone disease.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including recurrent Clostridioides difficile infections, gastrointestinal diseases, metabolic syndrome, diabetes, cancer, Parkinson\u0027s disease, active ulcerative colitis, and dysbiosis-related diseases.",
        "Fecal microbiota transplantation (FMT) is a promising treatment for a number of gastrointestinal diseases, such as irritable bowel syndrome, inflammatory bowel disease, and C. difficile infection.",
        "Fecal microbiota transplantation (FMT) is used to treat various diseases, including recurrent Clostridioides difficile infections, inflammatory bowel disease, cancer, obesity, liver disease, diabetes, metabolic syndrome, and Parkinson\u0027s disease.",
        "Fecal transplants are primarily used to treat recurrent Clostridioides difficile infections and chronic diarrhea in immunocompromised patients, with established secondary applications in mitigating intestinal complications from certain colorectal cancer chemotherapies, and potentially, in modifying risk factors for Urinary Stone Disease.",
        "Fecal microbiota transplants (FMTs) are used to treat recurrent Clostridioides difficile infections (rCDI), chronic diarrhea, and have potential applications in colorectal cancer and urinary stone disease.",
        "Fecal transplants are used to treat recurrent Clostridioides difficile infections, chronic diarrhea, primary and secondary immunodeficiency, colorectal cancer, and urinary stone disease.",
        "Fecal microbiota transplantation (FMT) is used to treat recurrent Clostridioides difficile infections, inflammatory bowel disease, and colorectal cancer.",
        "Fecal transplants are used to treat diseases including recurrent Clostridioides difficile infections, chronic diarrhea (especially in patients with immunodeficiencies), and as a supportive therapy to prevent intestinal injury in colorectal cancer, with additional benefits in modifying metabolic factors to reduce the risk of urinary stone disease.",
        "Fecal transplants are primarily used to treat recurrent Clostridioides difficile infections, but they have also shown effectiveness in managing chronic diarrhea, mitigating chemotherapy-induced toxicity in colorectal cancer, and modifying risk factors for urinary stone disease by altering the gut microbiome and metabolism.",
        "Fecal microbiota transplantation (FMT) is primarily used to treat recurrent Clostridioides difficile infections (rCDI). It has also shown effectiveness in treating chronic diarrhea associated with primary and secondary immunodeficiency, colorectal cancer-related intestinal injury, and urinary stone disease."
      ],
      "exact_answer": [
        [
          "chronic diarrhea"
        ],
        [
          "Clostridioides difficile infections"
        ],
        [
          "Colorectal Cancer"
        ],
        [
          "Urinary Stone Disease"
        ]
      ]
    },
    {
      "body": "Can sertraline be used in children under 10?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39773770",
        "http://www.ncbi.nlm.nih.gov/pubmed/37827253",
        "http://www.ncbi.nlm.nih.gov/pubmed/36651686",
        "http://www.ncbi.nlm.nih.gov/pubmed/16553532",
        "http://www.ncbi.nlm.nih.gov/pubmed/12068839",
        "http://www.ncbi.nlm.nih.gov/pubmed/37305603",
        "http://www.ncbi.nlm.nih.gov/pubmed/17003661",
        "http://www.ncbi.nlm.nih.gov/pubmed/11552629",
        "http://www.ncbi.nlm.nih.gov/pubmed/27454389",
        "http://www.ncbi.nlm.nih.gov/pubmed/32346385",
        "http://www.ncbi.nlm.nih.gov/pubmed/39706126",
        "http://www.ncbi.nlm.nih.gov/pubmed/22934167",
        "http://www.ncbi.nlm.nih.gov/pubmed/30194278",
        "http://www.ncbi.nlm.nih.gov/pubmed/31780970"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Long-term sertraline treatment of children and adolescents with major depressive disorder.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16553532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Sertraline: new indication. May help children with obsessive-compulsive disorder.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12068839"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "This study explores the nuanced immunomodulatory effects of sertraline, which is widely used in the treatment of major depression, obsessive-compulsive disorder, and anxiety in adults and children",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39706126"
        },
        {
          "offsetInBeginSection": 738,
          "offsetInEndSection": 905,
          "text": "Methods: This study was a prospective, open-label study of children prescribed sertraline being treated at a residential treatment center for children and adolescents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37305603"
        },
        {
          "offsetInBeginSection": 931,
          "offsetInEndSection": 1017,
          "text": "The short-term safety profile of sertraline in children is the same as in adults, i.e.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12068839"
        },
        {
          "offsetInBeginSection": 738,
          "offsetInEndSection": 1356,
          "text": "Methods: This study was a prospective, open-label study of children prescribed sertraline being treated at a residential treatment center for children and adolescents. Individuals were included if they were \u003c 18 years of age, taking sertraline for at least 2 weeks allowing them to reach steady-state concentrations, being treated through the residential treatment program, and able to understand and speak English. Results: A total of 20 participants (80% female) completed all study procedures, including pharmacogenetic testing and therapeutic drug monitoring, with an average age of 15.4 years (range: 9-17 years).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37305603"
        },
        {
          "offsetInBeginSection": 738,
          "offsetInEndSection": 1153,
          "text": "Methods: This study was a prospective, open-label study of children prescribed sertraline being treated at a residential treatment center for children and adolescents. Individuals were included if they were \u003c 18 years of age, taking sertraline for at least 2 weeks allowing them to reach steady-state concentrations, being treated through the residential treatment program, and able to understand and speak English.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37305603"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 402,
          "text": "A double blind, randomized, 6-month, placebo-controlled, clinical trial of low-dose sertraline in children ages (3-6 years) with ASD was conducted at the UC Davis MIND Institute.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32346385"
        },
        {
          "offsetInBeginSection": 1328,
          "offsetInEndSection": 1635,
          "text": "Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31780970"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 155,
          "text": "Sertraline is commonly prescribed to children for the treatment of anxiety and major depressive disorder and is metabolized in part by CYP2C19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37305603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Background: Sertraline is commonly prescribed to children for the treatment of anxiety and major depressive",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37305603"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 321,
          "text": " The aim of this study was to assess the long-term safety, tolerability, and efficacy of sertraline 50-200 mg once-daily in children (6-11 year olds) and adolescents (12-18 year olds) with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of major depressive disorder (MDD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16553532"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 257,
          "text": " To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n \u003d 177) and adolescents (12-17 years old, n \u003d 199) with major depressive disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17003661"
        },
        {
          "offsetInBeginSection": 289,
          "offsetInEndSection": 415,
          "text": "Sertraline is the first drug to be licensed in France for children aged from 6 to 17 years with obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12068839"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n \u003d 177) and adolescents (12-17 years old, n \u003d 199) with major depressiv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17003661"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 411,
          "text": "Sertraline (1S,4S-N-methyl-4-[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-1-naphthylamine [Zoloft; Pfizer, New York City, NY]) is a frequently used selective serotonin reuptake inhibitor that has shown efficacy in children, adolescents, and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30194278"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "The aim of the study was to research the efficiency of sertraline (zoloft) in depressions, anxious states and obsessive-compulsive disorders. Diagnosis of the mental disorders was carried out according to ICD-10. 72 children (59 boys, 13 girls) aged 6-18 years were treated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11552629"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 415,
          "text": "(2) Sertraline is the first drug to be licensed in France for children aged from 6 to 17 years with obsessive-compulsive disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12068839"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 163,
          "text": "ackground: Sertraline is commonly prescribed to children for the treatment of anxiety and major depressive disorder and is metabolized in part by CYP2C19. While d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37305603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Sertraline is a selective serotonin reuptake inhibitor used as an antidepressant and antipanic agent in children and adolescents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454389"
        },
        {
          "offsetInBeginSection": 674,
          "offsetInEndSection": 847,
          "text": "There were 11 children who were treated with sertraline, and these patients were retrospectively compared to 34 children who were not treated with sertraline by chart review",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934167"
        }
      ],
      "id": "6810c27b353a4a2e6b000010",
      "ideal_answer": [
        "Yes, sertraline can be used in children under 10, but with careful consideration of the balance between benefits and risks. Major depressive disorder in children and adolescents is a serious condition that can lead to suicide and persistent functional impairment. Selective serotonin reuptake inhibitors (SSRIs), such as sertraline, are among the treatments used for managing this condition in the pediatric population (PMID 16142045). However, the decision to use sertraline in children under 10 must be guided by a thorough evaluation of the individual patient\u0027s situation, given the significant implications of depression and the pharmacological action of SSRIs.\n\nAdditionally, pharmacokinetic factors such as genetic variations affecting drug metabolism should be considered. For instance, variations in the CYP2C19 gene can influence the metabolism of sertraline, potentially affecting its efficacy and safety in pediatric patients (PMID 30817183). Therefore, personalized dosing may be necessary to optimize treatment outcomes and minimize risks. In summary, while sertraline can be used in children under 10, it requires a tailored approach to ensure safety and effectiveness."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Which cells are the primary antigen-presenting cells?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30319969",
        "http://www.ncbi.nlm.nih.gov/pubmed/17823633",
        "http://www.ncbi.nlm.nih.gov/pubmed/9001569",
        "http://www.ncbi.nlm.nih.gov/pubmed/39734479",
        "http://www.ncbi.nlm.nih.gov/pubmed/18615247",
        "http://www.ncbi.nlm.nih.gov/pubmed/1355605",
        "http://www.ncbi.nlm.nih.gov/pubmed/9090785",
        "http://www.ncbi.nlm.nih.gov/pubmed/39754477",
        "http://www.ncbi.nlm.nih.gov/pubmed/31830703",
        "http://www.ncbi.nlm.nih.gov/pubmed/16221071",
        "http://www.ncbi.nlm.nih.gov/pubmed/7545116",
        "http://www.ncbi.nlm.nih.gov/pubmed/29133346",
        "http://www.ncbi.nlm.nih.gov/pubmed/11188932",
        "http://www.ncbi.nlm.nih.gov/pubmed/21196224",
        "http://www.ncbi.nlm.nih.gov/pubmed/35316109",
        "http://www.ncbi.nlm.nih.gov/pubmed/32824563",
        "http://www.ncbi.nlm.nih.gov/pubmed/12123513",
        "http://www.ncbi.nlm.nih.gov/pubmed/39617785",
        "http://www.ncbi.nlm.nih.gov/pubmed/1968425",
        "http://www.ncbi.nlm.nih.gov/pubmed/7845467",
        "http://www.ncbi.nlm.nih.gov/pubmed/12517270",
        "http://www.ncbi.nlm.nih.gov/pubmed/21374268",
        "http://www.ncbi.nlm.nih.gov/pubmed/14702200",
        "http://www.ncbi.nlm.nih.gov/pubmed/3873688"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Dendritic cells (DCs) are the primary antigen-presenting cells and play key roles in the orchestration of the innate and adaptive immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30319969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Dendritic cells (DCs) are primary antigen-presenting cells involved in interactions with T cells leading to the proliferation of TH1 or TH2 cell types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17823633"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 520,
          "text": "Dendritic cells are the major APC involved in the initiation of the immune response and the development of tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9001569"
        },
        {
          "offsetInBeginSection": 326,
          "offsetInEndSection": 469,
          "text": "DCs, as key antigen-presenting cells, play a critical role in shaping immune responses by influencing T-cell activation and cytokine production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Although dendritic cells are the most potent of all antigen presenting cells, they have paradoxically been regarded as having only a minimal capacity for endocytosis, which is a crucial step in antigen processing prior to presentation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1355605"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Dendritic cells (DC) are widely considered to be the major antigen-presenting cell (APC) type in immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18615247"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Dendritic cells (DCs) are considered the most effective antigen-presenting cells (APCs) for primary immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9090785"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Dendritic cells (DCs), the primary antigen-presenting cells, have traditionally been identified by CD103 molecules in rats, whereas mouse and human DCs are identified by CD11c molecules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39754477"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 469,
          "text": "DCs are the main antigen-presenting cells located in tissues of the body, and their role involves recognizing antigen structures, engulfing and processing them, and subsequently presenting antigen peptides on their surface by major histocompatibility complex, where T cells and B cells are stimulated and can begin appropriate cellular and antibody immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31830703"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Dendritic cells (DC) are the main antigen-presenting cells for the initiation of primary T cell-mediated immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7545116"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Dendritic cells (DC) are widely considered to be the major antigen-presenting cell (APC) type in immune responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18615247"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Dendritic cells are the most potent antigen-presenting cells of the immune system and represent a promising tool in therapeutic vaccination against cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16221071"
        },
        {
          "offsetInBeginSection": 814,
          "offsetInEndSection": 1009,
          "text": "However, a growing number of evidences suggest that dendritic cells (DCs), the main APC in the peripheral immune system, may also participate in the regulation of T-cell responses within the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196224"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 307,
          "text": "In addition to its known intracellular niche in macrophages, M. tuberculosis interferes with the functions of dendritic cells (DCs), which are the primary antigen-presenting cells of the immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29133346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Dendritic cells (DC) act as primary antigen-presenting cells and probably initiate T-cell responses via the formation of DC-T-cell clusters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1968425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Dendritic cells (DC) derived from bone marrow are critical in the function of the immune system, for they are the primary antigen-presenting cells in the activation of T-lymphocyte response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7845467"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 307,
          "text": "M. tuberculosis interferes with the functions of dendritic cells (DCs), which are the primary antigen-presenting cells of the immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29133346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Dendritic cells (DC) play a pivotal role in the function of the immune system, for they are the primary antigen-presenting cells (APC) in the activation of naive T-lymphocyte responses (1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21374268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Dendritic cells (DC) are the most effective or \u0027professional\u0027 of the antigen-presenting cells (APC) that initiate primary immune responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12123513"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Dendritic cells (DCs) are the most specialized antigen-presenting cells, and lymph nodes (LNs) play an important role in the DC-mediated T-cell response",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38396770"
        }
      ],
      "id": "680a07a418b1e36f2e000148",
      "ideal_answer": [
        "Dendritic cells (DCs) are the primary antigen-presenting cells and play key roles in the orchestration of the innate and adaptive immune system. For example, they are involved in interactions with T cells, leading to the proliferation of TH1 or TH2 cell types.",
        "Dendritic cells are the primary antigen-presenting cells that are critical for binding and activating both CD4+ and CD8+ T cell subsets at the onset of a primary immune response.",
        "Dendritic cells are the primary antigen-presenting cells, as they are potent at presenting viral antigens in the initiation of both primary and secondary responses. They express surface antigens and can stimulate proliferation of sensitised lymphocytes, as described in the specialized features of dendritic cells as antigen-presenting cells.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells in the immune system. They play a crucial role in shaping immune responses by capturing antigens, processing them, and presenting them on their surface to T-cells. This interaction is essential for T-cell activation and the subsequent production of cytokines, which are important for orchestrating the body\u0027s immune response.",
        "Dendritic cells (DCs) are identified as primary antigen-presenting cells, playing critical roles in cross-presentation of exogenous antigens to CD8+ T cells and modulating immune responses through MHC class I and CD1d pathways. Studies highlight their ability to capture and present tumor-derived peptides, viral antigens, and lipid ligands to T cells and NKT cells, while also demonstrating their importance in vaccine development and anti-tumor immunity. Cholangiocytes and B cells are also noted for antigen presentation but are not emphasized as primary APCs compared to DCs.",
        "Dendritic cells are the most potent professional antigen-presenting cells. They capture, process, and present antigens to both helper and cytotoxic T cells, thereby initiating primary immune responses and linking innate to adaptive immunity.",
        "Dendritic cells are the primary antigen-presenting cells. They play a crucial role in the initiation of immune responses by processing and presenting antigens to T-cells.",
        "Dendritic cells are the primary antigen-presenting cells. They are highly specialized for capturing, processing, and presenting antigens to T cells, which is essential for initiating and regulating the adaptive immune response. While macrophages and B cells also have the ability to present antigens, dendritic cells are considered the most effective and potent in priming T cells and thus play the key role in immune response activation.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells in the immune system. They play a crucial role in shaping immune responses by capturing antigens, processing them, and presenting them to T-cells, thereby influencing T-cell activation and cytokine production. This function is essential for initiating and regulating adaptive immune responses.",
        "Dendritic cells (DCs) are recognized as the primary antigen-presenting cells, playing a pivotal role in initiating and directing immune responses. They achieve this by capturing, processing, and presenting antigens to T-cells, thereby driving T-cell activation and modulating cytokine production, which is essential for adaptive immunity.",
        "Dendritic cells are the primary antigen-presenting cells, playing a crucial role in the proliferation of immune cells, specifically T cells, and the orchestration of the immune system.",
        "The primary antigen presenting cells are dendritic cells (DCs). These specialized immune cells play a crucial role in initiating adaptive immune responses by processing antigens and presenting them to naive T cells, thereby activating them and orchestrating both innate and adaptive immunity.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells, crucial in initiating interactions with T cells and orchestrating the innate and adaptive immune responses by leading to the proliferation of TH1 or TH2 cell types.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells in the immune system. They play key roles in the orchestration of the innate and adaptive immune system, and are involved in interactions with T cells leading to the proliferation of TH1 or TH2 cell types.",
        "Dendritic cells are recognized as the primary antigen-presenting cells, essential for initiating and regulating immune responses. They are especially important in their interactions with T cells, leading to the proliferation of various T cell types. Dendritic cells also play critical roles in both the innate and adaptive immune systems.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells, critical for initiating and coordinating both innate and adaptive immune responses by interacting with T cells.",
        "Dendritic cells are identified as the primary antigen-presenting cells in multiple studies, playing critical roles in immune responses through processes such as cross-presentation of exogenous antigens to CD8+ T cells, modulation of T cell activation, and interaction with other immune components like NKT cells. Their function in antigen processing and presentation is highlighted across contexts including cancer immunotherapy, allergic airway inflammation, and interactions with nanoparticles, underscoring their central role in orchestrating both innate and adaptive immunity.",
        "Dendritic cells are the principal antigen‐presenting cells, uniquely equipped to capture, process, and display antigens to T cells and thereby initiate adaptive immune responses.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells, playing a key role in mediating both innate and adaptive immune responses. They are essential for initiating interactions with T cells.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells in the immune system. They play key roles in orchestrating both innate and adaptive immunity through interactions with T cells, leading to the proliferation of TH1 or TH2 cell types.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells. They excel in processing and presenting antigens via MHC molecules to T-cells, effectively initiating immune responses. While other cells like macrophages and B cells can also act as APCs, DCs are the most potent and specialized for this function.",
        "Dendritic cells, often abbreviated as DCs, are the primary antigen-presenting cells. These cells play key roles in the orchestration of the innate and adaptive immune system. They are involved in interactions with T cells, leading to the proliferation of TH1 or TH2 cell types, which are crucial components of the adaptive immune response.",
        "Dendritic cells (DCs) are the primary antigen presenting cells that orchestrate the immune response by processing and presenting antigens to T cells, facilitating activation of both the innate and adaptive immune systems.",
        "Dendritic cells (DCs) are recognized as the primary antigen-presenting cells. They specialize in capturing, processing, and presenting antigens to T-cells, playing a pivotal role in both innate and adaptive immunity. Their unique ability to effectively initiate immune responses makes them central to this function, distinguishing them from other APCs like macrophages and B-cells which have broader roles beyond antigen presentation.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells. They play key roles in interactions with T cells, leading to the proliferation of TH1 or TH2 cell types, and in the orchestration of the innate and adaptive immune system.",
        "Dendritic cells (DCs) are the primary antigen-presenting cells, playing crucial roles in orchestrating both the innate and adaptive immune systems by interacting with T cells and promoting the proliferation of TH1 or TH2 cell types."
      ],
      "exact_answer": [
        [
          "Dendritic cells",
          "DCs",
          "Dendritic",
          "dendritic cells (DC)"
        ]
      ]
    },
    {
      "body": "Do misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39667814",
        "http://www.ncbi.nlm.nih.gov/pubmed/37186678",
        "http://www.ncbi.nlm.nih.gov/pubmed/37334903",
        "http://www.ncbi.nlm.nih.gov/pubmed/12605877",
        "http://www.ncbi.nlm.nih.gov/pubmed/38127187",
        "http://www.ncbi.nlm.nih.gov/pubmed/12065827",
        "http://www.ncbi.nlm.nih.gov/pubmed/34224817",
        "http://www.ncbi.nlm.nih.gov/pubmed/24504409",
        "http://www.ncbi.nlm.nih.gov/pubmed/36205914",
        "http://www.ncbi.nlm.nih.gov/pubmed/27682820",
        "http://www.ncbi.nlm.nih.gov/pubmed/31262433",
        "http://www.ncbi.nlm.nih.gov/pubmed/37688357",
        "http://www.ncbi.nlm.nih.gov/pubmed/38507813",
        "http://www.ncbi.nlm.nih.gov/pubmed/36854331",
        "http://www.ncbi.nlm.nih.gov/pubmed/16048838",
        "http://www.ncbi.nlm.nih.gov/pubmed/21295458",
        "http://www.ncbi.nlm.nih.gov/pubmed/32629809",
        "http://www.ncbi.nlm.nih.gov/pubmed/39411283",
        "http://www.ncbi.nlm.nih.gov/pubmed/36699535",
        "http://www.ncbi.nlm.nih.gov/pubmed/35946309",
        "http://www.ncbi.nlm.nih.gov/pubmed/35813946",
        "http://www.ncbi.nlm.nih.gov/pubmed/27064076",
        "http://www.ncbi.nlm.nih.gov/pubmed/24818993",
        "http://www.ncbi.nlm.nih.gov/pubmed/27702699",
        "http://www.ncbi.nlm.nih.gov/pubmed/23196448",
        "http://www.ncbi.nlm.nih.gov/pubmed/39122455",
        "http://www.ncbi.nlm.nih.gov/pubmed/37742785",
        "http://www.ncbi.nlm.nih.gov/pubmed/37442396",
        "http://www.ncbi.nlm.nih.gov/pubmed/29317501",
        "http://www.ncbi.nlm.nih.gov/pubmed/18268186",
        "http://www.ncbi.nlm.nih.gov/pubmed/20665728",
        "http://www.ncbi.nlm.nih.gov/pubmed/18309232",
        "http://www.ncbi.nlm.nih.gov/pubmed/22129991",
        "http://www.ncbi.nlm.nih.gov/pubmed/21460436",
        "http://www.ncbi.nlm.nih.gov/pubmed/24270002",
        "http://www.ncbi.nlm.nih.gov/pubmed/21238939",
        "http://www.ncbi.nlm.nih.gov/pubmed/27273088",
        "http://www.ncbi.nlm.nih.gov/pubmed/14502650",
        "http://www.ncbi.nlm.nih.gov/pubmed/24860100",
        "http://www.ncbi.nlm.nih.gov/pubmed/28380257",
        "http://www.ncbi.nlm.nih.gov/pubmed/21158739",
        "http://www.ncbi.nlm.nih.gov/pubmed/22815961",
        "http://www.ncbi.nlm.nih.gov/pubmed/36170956",
        "http://www.ncbi.nlm.nih.gov/pubmed/39229234",
        "http://www.ncbi.nlm.nih.gov/pubmed/23225525",
        "http://www.ncbi.nlm.nih.gov/pubmed/23894132",
        "http://www.ncbi.nlm.nih.gov/pubmed/17514901",
        "http://www.ncbi.nlm.nih.gov/pubmed/25219768",
        "http://www.ncbi.nlm.nih.gov/pubmed/30742586",
        "http://www.ncbi.nlm.nih.gov/pubmed/19164925",
        "http://www.ncbi.nlm.nih.gov/pubmed/20070435",
        "http://www.ncbi.nlm.nih.gov/pubmed/36430666",
        "http://www.ncbi.nlm.nih.gov/pubmed/35793556",
        "http://www.ncbi.nlm.nih.gov/pubmed/35095273",
        "http://www.ncbi.nlm.nih.gov/pubmed/37627623",
        "http://www.ncbi.nlm.nih.gov/pubmed/29546836",
        "http://www.ncbi.nlm.nih.gov/pubmed/37071750",
        "http://www.ncbi.nlm.nih.gov/pubmed/30886048",
        "http://www.ncbi.nlm.nih.gov/pubmed/30756405",
        "http://www.ncbi.nlm.nih.gov/pubmed/22942726",
        "http://www.ncbi.nlm.nih.gov/pubmed/26123252",
        "http://www.ncbi.nlm.nih.gov/pubmed/32526949",
        "http://www.ncbi.nlm.nih.gov/pubmed/29303785",
        "http://www.ncbi.nlm.nih.gov/pubmed/22974397",
        "http://www.ncbi.nlm.nih.gov/pubmed/31941036",
        "http://www.ncbi.nlm.nih.gov/pubmed/33713321",
        "http://www.ncbi.nlm.nih.gov/pubmed/39730291"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease characterized by motor neuron loss in the motor cortex, brain stem, and spinal cord. Mutations in the superoxide dismutase 1 (SOD1) gene, resulting in misfolding of its protein product, are a common cause of ALS. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667814"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Neurodegenerative diseases are a serious problem throughout the world. There are several causes of neurodegenerative diseases; these include genetic predisposition, accumulation of misfolded proteins, oxidative stress, neuroinflammation, and excitotoxicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37186678"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 207,
          "text": "Human prion diseases are heterogeneous, and often rapidly progressive, transmissible neurodegenerative disorders associated with misfolded prion protein (PrP) aggregation and self-propagation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37334903"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 477,
          "text": "In recent years, it has become increasingly clear that many neurodegenerative diseases involve aggregation and deposition of misfolded proteins such as amyloid beta, tau, alpha-synuclein and polyglutamine containing proteins. This abnormal deposition of misfolded proteins produce malfunctioning of a distinctive set of neurons. It may also induce oxidative and endoplasmic reticulum stress and proteosomal and mitochondrial dysfunction that ultimately leads to neuronal death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12605877"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38127187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "A broad range of neurodegenerative disorders is characterized by neuronal damage that may be caused by toxic, aggregation-prone proteins. As genes are identified for these disorders and cell culture and animal models are developed, it has become clear that a major effect of mutations in these genes is the abnormal processing and accumulation of misfolded protein in neuronal inclusions and plaques.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12065827"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 326,
          "text": "Accumulation of misfolded/aggregated proteins represents a pathological hallmark of most neurodegenerative diseases, potentially contributing to synapse loss and neuronal damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224817"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "A common feature of many neurodegenerative diseases is the deposition of β-sheet-rich amyloid aggregates formed by proteins specific to these diseases. These protein aggregates are thought to cause neuronal dysfunction, directly or indirectly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24504409"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. In the las",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38127187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Aggregation of the misfolded proteins β-amyloid, tau, huntingtin, and α-synuclein is one of the most important steps in the pathology underlying a wide spectrum of neurodegenerative disorders,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32629809"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Accumulation of misfolded proteins leads to many neurodegenerative diseases that can be treated by lowering or removing mutant proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37688357"
        },
        {
          "offsetInBeginSection": 537,
          "offsetInEndSection": 882,
          "text": "Mechanistically, not only disease-linked genetic mutations but also known risk factors for neurodegenerative diseases, such as aging and exposure to environmental toxins, can accelerate production of ROS/RNS, which contribute to protein misfolding - in many cases mimicking the effect of rare genetic mutations known to be linked to the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34224817"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Neurodegenerative diseases such as Alzheimer\u0027s disease and polyglutamine diseases are characterized by abnormal accumulation of misfolded proteins, leading to neuronal dysfunction and subsequent neuron death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39411283"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38127187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 251,
          "text": "Neurological motor disorders (NMDs) such as Parkinson\u0027s disease and Huntington\u0027s disease are characterized by the accumulation and aggregation of misfolded proteins that trigger cell death of specific neuronal populations in the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36699535"
        },
        {
          "offsetInBeginSection": 816,
          "offsetInEndSection": 1044,
          "text": "These misfolded proteins can also influence the transcription of other proteins and form aggregates, tangles, plaques, and inclusion bodies, which then accumulate in the CNS, leading to neuronal dysfunction and neurodegeneration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36205914"
        },
        {
          "offsetInBeginSection": 949,
          "offsetInEndSection": 1117,
          "text": "Emerging evidence has shown that TRIM proteins are key players in facilitating the clearance of misfolded protein aggregates associated with neurodegenerative disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35946309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Prion-like seeded misfolding of host proteins is the leading hypothesised cause of neurodegenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35813946"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 391,
          "text": "Misfolded protein aggregates are a critical aspect of several neurodegenerative diseases. Nevertheless, several questions remain unanswered regarding the role of misfolded protein aggregates and the cause of neuronal cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Protein misfolding leads to the formation of aggregated proteins and protein inclusions, which are associated with synaptic loss and neuronal death in neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27064076"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 452,
          "text": "Neurodegenerative diseases (NDs) are some of the most debilitating human illnesses. Research over the past 10 years has provided evidence for a common mechanism of neurodegeneration in which the critical event is the brain accumulation of misfolded protein aggregates. Although it is well established that misfolded proteins play an important role in these diseases, the mechanisms by which they cause cellular and tissue dysfunction are still unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Several neurodegenerative diseases are characterized by the accumulation of aggregated misfolded proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35573838"
        },
        {
          "offsetInBeginSection": 278,
          "offsetInEndSection": 435,
          "text": "Such abnormally aggregated proteins mainly formed in neurons, cause the neurons dysfunction, and finally lead to invariably fatal neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709368"
        },
        {
          "offsetInBeginSection": 633,
          "offsetInEndSection": 791,
          "text": "Misfolded proteins often aggregate and accumulate to trigger neurotoxicity through cellular stress pathways and consequently cause neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30742586"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Aggregation of misfolded disease-related proteins is a hallmark of neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27322773"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "A key feature of many neurodegenerative diseases is the accumulation and subsequent aggregation of misfolded proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351672"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Accumulation of misfolded/unfolded aggregated proteins in the brain is a hallmark of many neurodegenerative diseases affecting humans and animals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27682820"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "A central role for calcineurin in protein misfolding neurodegenerative diseases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27682820"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 342,
          "text": "Misfolding of a disease-specific protein in the central nervous system ultimately results in the formation of toxic aggregates that may accumulate in the brain, leading to neuronal cell death and dysfunction,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702699"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 368,
          "text": "One of the major features of NDs, such as Alzheimer\u0027s disease (AD), Parkinson\u0027s disease (PD) and Huntington\u0027s disease (HD), is the aggregation of specific misfolded proteins, which",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35946309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Alzheimer\u0027s disease (AD) is an intricate neurodegenerative disorder characterized by the accumulation of misfolded proteins, including beta-amyloid (Aβ) and tau, leading to cognitive decline",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39122455"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Increasing evidence indicates that a key factor in neurodegenerative diseases is the activation of the unfolded protein response (UPR) caused by an accumulation of misfolded proteins in the endoplasmic reticulum (ER stress)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37442396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "Many major neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Alzheimer\u0027s disease, Parkinson\u0027s disease, Huntington Disease and other polyglutamine expansion disorders, are associated with degeneration and death of specific neuronal populations due to accumulation of certain abnormal polypeptides.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16048838"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 430,
          "text": "Misfolding and aggregation of proteins are widespread phenomena leading to the development of numerous neurodegenerative disorders such as Parkinson\u0027s, Alzheimer\u0027s, and Huntington\u0027s diseases. Each of these diseases is linked to structural misfolding and aggregation of a particular protein. The aggregated forms of the protein induce the development of a particular disease at all levels, leading to neuronal dysfunction and loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20665728"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "Molecular genetic analyses revealed that most neurodegenerative diseases including Alzheimer\u0027s disease, Parkinson\u0027s disease, amyotrophic lateral sclerosis (ALS), and the polyglutamine diseases share a common molecular pathogenesis, namely protein misfolding and aggregation in the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Many neurodegenerative diseases such as Parkinson\u0027s, Alzheimer\u0027s, Huntington\u0027s and Lou Gehrig\u0027s disease are associated with the misfolding and aggregation of proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18309232"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 472,
          "text": "One of the major features of NDs, such as Alzheimer\u0027s disease (AD), Parkinson\u0027s disease (PD) and Huntington\u0027s disease (HD), is the aggregation of specific misfolded proteins, which induces cellular dysfunction, neuronal death, loss of synaptic connections and eventually brain damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35946309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Neurodegenerative diseases such as Alzheimer\u0027s disease and polyglutamine diseases are characterized by abnormal accumulation of misfolded proteins, leading to neuronal dysfunction and subsequent neuron death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39411283"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272,
          "text": "Neurodegenerative diseases such as Alzheimer\u0027s disease, Parkinson\u0027s disease, Huntington\u0027s disease, amyotrophic lateral sclerosis and prion-based neurodegeneration are associated with the accumulation of misfolded proteins, resulting in neuronal dysfunction and cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22129991"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 455,
          "text": "Shared pathogenesis involves the accumulation of misfolded proteins, chronic neuroinflammation, and synaptic dysfunction, ultimately leading to irreversible neuronal loss, measurable cognitive deficits, and death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38507813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "A hallmark event in neurodegenerative diseases is the accumulation of misfolded aggregated proteins in the brain leading to neuronal dysfunction and disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21295458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "A key molecular pathway implicated in diverse neurodegenerative diseases is the misfolding, aggregation, and accumulation of proteins in the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18268186"
        },
        {
          "offsetInBeginSection": 889,
          "offsetInEndSection": 1046,
          "text": " Compelling evidence suggests the role of misfolded proteins in the form of oligomers might lead to synaptic dysfunction, neuronal apoptosis and brain damage",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21460436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Neurodegenerative diseases are characterized by the aggregation of misfolded proteins in the brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24860100"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Misfolded or mislocalized RNA-binding proteins (RBPs) and, consequently, altered mRNA processing, can cause neuronal dysfunction, eventually leading to neurodegeneration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28380257"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 464,
          "text": "These disorders, which include Alzheimer\u0027s, Huntington\u0027s and Parkinson\u0027s diseases, and the rarer prion diseases, are separate entities clinically but have common features, including aggregates of misfolded proteins and varying patterns of neurodegeneration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21158739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "In chronic neurodegenerative diseases associated with aggregates of misfolded proteins (such as Alzheimer\u0027s, Parkinson\u0027s and prion disease), there is an early degeneration of presynaptic terminals prior to the loss of the neuronal somata",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815961"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 675,
          "text": "Recently, we showed that in prion disease, protein misfolding leads to neurodegeneration through dysregulation of generic proteostatic mechanisms, specifically, the unfolded protein response",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24860100"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 601,
          "text": "CJD is caused by misfolding of the neuronal prion protein and is characterised by a neurotoxic unfolded protein response involving chronic endoplasmic reticulum stress, reduced protein translation and spongiosis leading subsequently to synaptic and neuronal loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36170956"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "The appearance of misfolded and aggregated proteins is a pathological hallmark of numerous neurodegenerative diseases including Alzheimer\u0027s disease and Parkinson\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39229234"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225525"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "Misfolding and aggregation of proteins have a negative impact on all living organisms. In recent years, aggregation has been studied in detail due to its involvement in neurodegenerative diseases, including Alzheimer\u0027s, Parkinson\u0027s and Huntington\u0027s diseases, and type II diabetes--all associated with accumulation of amyloid fibrils.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894132"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 516,
          "text": "Misfolding and aggregation of proteins have a negative impact on all living organisms. In recent years, aggregation has been studied in detail due to its involvement in neurodegenerative diseases, including Alzheimer\u0027s, Parkinson\u0027s and Huntington\u0027s diseases, and type II diabetes--all associated with accumulation of amyloid fibrils. This research highlighted the central importance of protein homeostasis, or proteostasis for short, defined as the cellular state in which the proteome is both stable and functional.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23894132"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "More than 20 human diseases are related to protein misfolding which causes formation of amyloids, fibrillar aggregates of normally soluble proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17514901"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The aggregation of misfolded proteins has long been regarded as a pathological event in neurodegenerative diseases such as Alzheimer\u0027s disease, Parkinson\u0027s disease and Huntington\u0027s disease. However, the exact molecular mechanisms that govern protein ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25219768"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Neurodegenerative diseases (NDs) are a cluster of diseases marked by progressive neuronal loss, axonal transport blockage, mitochondrial dysfunction, oxidative stress, neuroinflammation, and aggregation of misfolded proteins. NDs are more prevalent b",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36205914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "A common feature of many neurodegenerative diseases is the deposition of β-sheet-rich amyloid aggregates formed by proteins specific to these diseases. These protein aggregates are thought to cause neuronal dysfunction, directly or indirectly. Recent",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24504409"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Although intensively researched, the fundamental mechanism of protein misfolding that leads to protein aggregation and associated diseases remains somewhat enigmatic. The failure of a protein to correctly fold de novo or to remain correctly folded ca",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19164925"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "A key molecular pathway implicated in diverse neurodegenerative diseases is the misfolding, aggregation, and accumulation of proteins in the brain. Compelling evidence strongly supports the hypothesis that accumulation of misfolded proteins leads to ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18268186"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Neurodegenerative diseases are characterized by progressive dysfunction of specific populations of neurons, determining clinical presentation. Neuronal loss is associated with extra and intracellular accumulation of misfolded proteins, the hallmarks ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20070435"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "In recent years, it has become increasingly clear that many neurodegenerative diseases involve aggregation and deposition of misfolded proteins such as amyloid beta, tau, alpha-synuclein and polyglutamine containing proteins. This abnormal deposition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12605877"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 361,
          "text": "Although the cause (s) of ND are not fully understood, the accumulation of misfolded/aggregated proteins in the brain is a common pathological feature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36430666"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 415,
          "text": "Neuropathological conditions such as the accumulation of misfolded proteins can cause neuroinflammation, apoptosis, and synaptic dysfunction in the brain, leading to the development of NDDs including Alzheimer\u0027s disease (AD) and Parkinson\u0027s disease (PD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793556"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 412,
          "text": "A progressive loss of neuronal function characterizes NDDs, usually followed by neuronal death. Inflammation, apoptosis, oxidative stress, and protein misfolding are critical dysregulated signaling pathways that mainly orchestrate neuronal damage from a mechanistic point.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35095273"
        },
        {
          "offsetInBeginSection": 154,
          "offsetInEndSection": 418,
          "text": "The main histopathological hallmarks of AD are the presence of abnormal protein aggregates (Aβ and tau), synaptic dysfunction, aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis, DNA and RNA defects, inflammation, and neuronal cell death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37627623"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "Several neurodegenerative diseases are caused by defects in protein folding, including Alzheimer, Parkinson, Huntington, and prion diseases. Once a disease-specific protein misfolds, it can then form toxic aggregates which accumulate in the brain, leading to neuronal dysfunction, cell death, and clinical symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 318,
          "text": "A key molecular pathway implicated in diverse neurodegenerative diseases is the misfolding, aggregation, and accumulation of proteins in the brain. Compelling evidence strongly supports the hypothesis that accumulation of misfolded proteins leads to synaptic dysfunction, neuronal apoptosis, brain damage, and disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18268186"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Neurodegenerative diseases (NDs) are a cluster of diseases marked by progressive neuronal loss, axonal transport blockage, mitochondrial dysfunction, oxidative stress, neuroinflammation, and aggregation of misfolded proteins. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36205914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 482,
          "text": "BACKGROUND \u0026 OBJECTIVE: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer\u0027s disease (AD), Parkinson\u0027s disease (PD) and Huntington\u0027s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further pro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29546836"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "The accumulation of misfolded proteins promotes protein aggregation and neuronal death in many neurodegenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29317501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "A hallmark event in neurodegenerative diseases is the accumulation of misfolded aggregated proteins in the brain leading to neuronal dysfunction and disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21295458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Protein misfolding leads to the formation of aggregated proteins and protein inclusions, which are associated with synaptic loss and neuronal death in neurodegenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27064076"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30886048"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 369,
          "text": "Neurodegenerative diseases are characterized by the intra- and extracellular conglomeration of misfolded proteins that occur because of abnormal protein dynamics and genetic manipulations; these trigger processes of cell death in these disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30756405"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Accumulation of misfolded/unfolded aggregated proteins in the brain is a hallmark of many neurodegenerative diseases affecting humans and animals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27682820"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "In several neurodegenerative diseases, such as Parkinson, Alzheimer\u0027s, Huntington, and prion diseases, the deposition of aggregated misfolded proteins is believed to be responsible for the neurotoxicity that characterizes these diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22942726"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "BACKGROUND \u0026 OBJECTIVE: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer\u0027s disease (AD), Parkinson\u0027s disease (PD) and Hu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29546836"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Neurodegenerative diseases are commonly generated by intracellular accumulation of misfolded/aggregated mutated proteins. These abnormal protein aggregates impair the functions of mitochondria and induce oxidative stress, thereby resulting in neuronal cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32526949"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 352,
          "text": "Upregulation of heat shock proteins (Hsps) mitigates against the accumulation of misfolded, aggregation-prone proteins and synaptic dysfunction, which is recognized as an early event in neurodegenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27273088"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Alzheimer\u0027s disease (AD) is characterized by accumulation of two misfolded and aggregated proteins, β-amyloid and hyperphosphorylated tau",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24270002"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 534,
          "text": "Abnormal filamentous aggregates of misfolded alpha-synuclein protein are the major components of Lewy bodies, dystrophic (Lewy) neurites, and the Papp-Lantos filaments in oligodendroglia and neurons in multiple system atrophy linked to degeneration of affected brain regions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14502650"
        },
        {
          "offsetInBeginSection": 984,
          "offsetInEndSection": 1407,
          "text": "Some drugs, which have been used as activators/inducers in the chaperone system, ubiquitin-proteasome system, and aggregation-autophagy, have been demonstrated to be efficacious in the relief of neurodegeneration diseases like Huntington\u0027s disease (HD), Parkinson\u0027s (PD), Alzheimer\u0027s (AD) as well as SCA3 in animal models and clinical trials, putting misfolded protein clearance on the list of potential therapeutic targets",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26123252"
        },
        {
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1148,
          "text": "Alzheimer\u0027s Disease, the most common neurodegenerative disorder, and cerebral ischemia, the most common cause of neurologic death, are used to illustrate our current understanding of death signaling in neurodegenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21238939"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 307,
          "text": "However, its misfolding and aggregation have been implicated in a variety of neurodegenerative diseases, particularly Parkinson\u0027s disease, dementia with Lewy bodies, and multiple system atrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39273146"
        },
        {
          "offsetInBeginSection": 383,
          "offsetInEndSection": 568,
          "text": "A large number of neurodegenerative diseases in humans, including Alzheimer\u0027s, Parkinson\u0027s, Huntington\u0027s, and prion diseases, are primarily caused by protein misfolding and aggregation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27702699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301,
          "text": "Common neurodegenerative proteinopathies, such as Alzheimer\u0027s disease (AD) and Parkinson\u0027s disease (PD), are characterized by the misfolding and aggregation of toxic protein species, including the amyloid beta (Aß) peptide, microtubule-associated protein Tau (Tau), and alpha-synuclein (αSyn) protein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27338814"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 371,
          "text": "Evidence suggests that impairment of ERAD contributes to neuron dysfunction and death in neurodegenerative diseases, many of which are characterized by accumulation and aggregation of misfolded proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39135735"
        },
        {
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1710,
          "text": "The formation and accumulation of misfolded proteins such as β-amyloid oligomers and plaques, tau protein tangles and α-synuclein clumps, and aggregated mutated huntingtin play a crucial role in the neuronal degeneration by direct cellular toxicity of the misfolded proteins and through the toxic compounds resulting from an extensive inflammatory reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28652219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38127187"
        },
        {
          "offsetInBeginSection": 255,
          "offsetInEndSection": 448,
          "text": "Most neurodegenerative disorders are associated with accumulations of abnormal proteins in the central nervous system (CNS), which result in neuronal degeneration and ultimately neuronal death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22974397"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Most of the neurological disorders in the brain are caused by the abnormal buildup of misfolded or aggregated proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31941036"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The accumulation of misfolded proteins promotes protein aggregation and neuronal death in many neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29317501"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 793,
          "text": "In recent years, autophagy dysfunction has gained considerable attention in AD and other neurodegenerative diseases because it has been linked to the accumulation of misfolded proteins that ultimately causes neuronal death in many of these disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31262433"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "text": "Although there are large differences in clinical and pathological features, age-related neurodegenerative diseases (NDs) share common pathogenetic mechanisms involving aggregation and deposition of misfolded proteins, which leads to progressive dysfunction and death of neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32070174"
        },
        {
          "offsetInBeginSection": 793,
          "offsetInEndSection": 987,
          "text": "Furthermore, the neuronal deposition of misfolded and aggregated proteins can cause both increased toxicity and impaired physiological function, which lead to neuronal dysfunction and cell death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36854331"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 352,
          "text": "Neurodegenerative diseases, such as Alzheimer\u0027s disease, Huntington\u0027s disease, Parkinson\u0027s disease, prion disease, and amyotrophic lateral sclerosis, are a dissimilar group of disorders that share a hallmark feature of accumulation of abnormal intraneuronal or extraneuronal misfolded/unfolded protein and are classified as protein misfolding disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29303785"
        },
        {
          "offsetInBeginSection": 326,
          "offsetInEndSection": 553,
          "text": "Although the presence of mature amyloid aggregates is a hallmark of such neurodegenerative diseases, misfolded protein oligomers are increasingly recognized as of central importance in the pathogenesis of many of these maladies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37071750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Accumulation of misfolded tau, amyloid β (Aβ), and alpha-synuclein (α-syn) proteins is the fundamental contributor to many neurodegenerative diseases, namely Parkinson\u0027s (PD) and AD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713321"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Misfolded and aggregated proteins build up in neurodegenerative illnesses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38127187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. In the last few years, there has been a significant upsurge in the level of interest towards the function of molecular chaperones in the control of misfolding a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38127187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Mitochondrial dysfunction is an important driver of neurodegeneration and synaptic abnormalities in Alzheimer\u0027s disease (AD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730291"
        }
      ],
      "type": "yesno",
      "id": "67fbd58c18b1e36f2e00010e",
      "ideal_answer": [
        "Neurodegenerative diseases are a serious problem throughout the world. There are several causes of neurodegenerative diseases; these include genetic predisposition, accumulation of misfolded proteins, oxidative stress, neuroinflammation, and excitotoxicity",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. Yes. Misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death",
        "Yes, there is a consensus in the biomedical field that misfolded and aggregated proteins accumulate in neurodegenerative illnesses, leading to neuronal dysfunction and ultimately resulting in neuronal death, as strongly supported by the scientific literature on the pathogenesis of these diseases.",
        "Yes, misfolded and aggregated proteins accumulate in neurodegenerative illnesses, leading to neuronal dysfunction and eventually neuronal death. These protein aggregates disrupt normal cellular processes, impairing neuron function and survival, which is a hallmark of diseases such as Alzheimer\u0027s, Parkinson\u0027s, and Huntington\u0027s disease.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, causing neuronal dysfunction and ultimately neuronal death.",
        "Yes. Misfolded and aggregated proteins accumulate in neurodegenerative diseases, leading to neuronal dysfunction and ultimately neuronal death.",
        "Yes. The abnormal accumulation of misfolded proteins is a hallmark of neurodegenerative diseases such as Alzheimer\u0027s disease and polyglutamine diseases, leading to neuronal dysfunction and subsequent neuron death (PubMed: 39411283, 39229234). These aggregated proteins disrupt cellular processes, contributing to neurodegeneration.",
        "Yes, misfolded and aggregated proteins are a hallmark of many neurodegenerative diseases. The accumulation of these abnormal protein structures can disrupt normal cellular processes, leading to neuronal dysfunction. Over time, this dysfunction can trigger various cell death pathways, ultimately resulting in the loss of neurons and the progression of neurodegenerative illnesses.",
        "Misfolded and aggregated proteins do build up in neurodegenerative illnesses, leading to neuronal dysfunction and death. Autophagy, a quality control system, is responsible for clearing these proteins, but its dysfunction contributes to neurodegeneration.",
        "Yes. Misfolded and aggregated proteins are implicated in causing neuronal dysfunction and neuronal death in various neurodegenerative diseases, as they lead to synaptic dysfunction, neuronal apoptosis, and brain damage.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. This is a hallmark event in neurodegenerative diseases such as Alzheimer\u0027s disease and Parkinson\u0027s disease .",
        "Aggregation of misfolded proteins builds up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. Examples of such proteins include huntingtin, Aβ, α-syn, Tau, and TDP-43, which are associated with various neurodegenerative diseases like Alzheimer\u0027s disease, Parkinson\u0027s disease, Huntington\u0027s disease, and amyotrophic lateral sclerosis.",
        "Yes. Misfolded and aggregated proteins are known to induce neuronal dysfunction and death in various neurodegenerative diseases, as they disrupt normal cellular functions and lead to oxidative stress and apoptosis.",
        "Yes, misfolded and aggregated proteins do build up in neurodegenerative diseases, causing neuronal dysfunction and death.",
        "Yes, the build-up of misfolded and aggregated proteins is a common feature of many neurodegenerative diseases.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, causing neuronal dysfunction and ultimately neuronal death. This is a hallmark event in diseases such as Alzheimer\u0027s, Parkinson\u0027s, and Huntington\u0027s disease, where the accumulation of specific misfolded proteins induces cellular dysfunction, neuronal death, and brain damage  .",
        "Misfolded and aggregated proteins build up in neurodegenerative illnesses, leading to neuronal dysfunction and death. This process involves the deposition of proteins such as amyloid beta, tau, alpha-synuclein, and polyglutamine-containing proteins, which induce oxidative and endoplasmic reticulum stress, proteosomal and mitochondrial dysfunction, and ultimately result in neuronal death.",
        "Yes, misfolded and aggregated proteins do build up in neurodegenerative illnesses, leading to neuronal dysfunction and ultimately, neuronal death, as supported by the consensus across the reviewed abstracts on the pathophysiological role of protein misfolding in neurodegenerative diseases.",
        "Yes, misfolded and aggregated proteins accumulate in neurodegenerative illnesses, leading to neuronal dysfunction and ultimately neuronal death.",
        "Yes, misfolded and aggregated proteins accumulate in neurodegenerative illnesses, leading to neuronal dysfunction and death. Various studies confirm this phenomenon across diseases such as Alzheimer\u0027s, Parkinson\u0027s, Huntington\u0027s, and prion diseases. Misfolded proteins can disrupt cellular functions, such as ER-Golgi compartments, causing apoptotic cell death, particularly noted in ALS. The accumulation of abnormal polypeptides results in inclusion bodies and neurotoxicity, contributing to the progression of these diseases. Specific proteins like prions and alpha-synuclein are known to aggregate and exert neurotoxic effects. Animal models have demonstrated similar neurotoxicity and clinicopathologic features, supporting the role of protein aggregation in neurodegeneration. Heat shock proteins are involved in clearing these aggregates to maintain neuronal function. However, some evidence suggests that misfolded proteins can accumulate without necessarily causing neuronal dysfunction and death, as seen in certain prion disease cases. Overall, while the relationship between protein aggregation and neurodegeneration can vary depending on the disease context, the buildup of misfolded proteins is a significant factor in the pathogenesis of neurodegenerative diseases.",
        "Yes. According to the provided context, misfolded and aggregated proteins do accumulate in neurodegenerative illnesses. This buildup directly contributes to neuronal dysfunction and ultimately leads to neuronal death, as described in the statement.",
        "Yes, misfolded and aggregated proteins do build up in neurodegenerative illnesses like ALS. These aggregates can disrupt cellular functions, lead to neuronal dysfunction, and ultimately contribute to neuronal death.",
        "Yes, it is a known that misfolded and aggregated proteins build up in neurodegenerative diseases, which leads to neuronal dysfunction and ultimately neuronal death.",
        "Yes, misfolded and aggregated proteins do accumulate in neurodegenerative diseases, leading to neuronal dysfunction and ultimately neuronal death, as seen in conditions like ALS and prion diseases.",
        "Yes, misfolded and aggregated proteins do build up in neurodegenerative illnesses, causing neuronal dysfunction and ultimately neuronal death.",
        "Yes. As mentioned in snippet1 and snippet2, the accumulation of misfolded and aggregated proteins in neurodegenerative illnesses leads to neuronal dysfunction and ultimately neuronal death.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. Neurodegenerative diseases are associated with the accumulation of misfolded proteins, which can lead to oxidative stress, neuroinflammation, and excitotoxicity .",
        "Yes, misfolded and aggregated proteins are implicated in various neurodegenerative diseases. Examples include prion diseases associated with misfolded prion protein aggregation, and ALS linked to mutations in the SOD1 gene causing protein misfolding. These protein abnormalities contribute to neurodegeneration through mechanisms like oxidative stress and neuroinflammation.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death. This is a common mechanism in neurodegenerative diseases, including ALS, prion diseases, and Alzheimer\u0027s disease.",
        "Yes. Misfolded and aggregated proteins are implicated in causing neuronal dysfunction and death in neurodegenerative diseases, as they disrupt cellular processes and lead to neurodegeneration.",
        "Yes. Misfolded and aggregated proteins are implicated in causing neuronal dysfunction and death in neurodegenerative diseases, as they accumulate and lead to toxic effects on neuronal cells.",
        "Yes, misfolded and aggregated proteins contribute to neuronal dysfunction and death in neurodegenerative diseases.",
        "Yes, the build-up of misfolded and aggregated proteins is implicated in the pathogenesis of a number of neurodegenerative illnesses. These aggregates can cause neuronal dysfunction and ultimately neuronal death.",
        "Yes, available evidence suggests that do misfolded and aggregated proteins build up in neurodegenerative illnesses, which causes neuronal dysfunction and ultimately neuronal death.",
        "Yes, misfolded and aggregated proteins do build up in neurodegenerative illnesses like amyotrophic lateral sclerosis (ALS). Mutations in the superoxide dismutase 1 (SOD1) gene lead to protein misfolding, which contributes to neuronal dysfunction and ultimately results in motor neuron loss. This process is a hallmark of ALS and other neurodegenerative diseases.",
        "Yes, misfolded and aggregated proteins build up in neurodegenerative illnesses, causing neuronal dysfunction and ultimately neuronal death .",
        "Yes, neurodegenerative diseases involve the accumulation of misfolded proteins, which causes neuronal dysfunction and ultimately neuronal death.",
        "[\u0027Yes, in neurodegenerative diseases, the accumulation of misfolded and aggregated proteins is a key factor that leads to neuronal dysfunction and ultimately neuronal death.\u0027]",
        "Yes, misfolded and aggregated proteins accumulate in neurodegenerative illnesses, causing neuronal dysfunction that can lead to neuronal death.",
        "Yes, misfolded and aggregated proteins accumulate in neurodegenerative diseases, such as prion diseases and ALS, leading to neuronal dysfunction and ultimately neuronal death. This protein misfolding is a key pathological feature contributing to disease progression and severity.",
        "Yes, misfolded and aggregated proteins can build up in neurodegenerative illnesses, such as ALS, leading to neuronal dysfunction and ultimately neuronal death. This is because the misfolded proteins can interfere with normal cellular processes, causing damage to neurons and leading to their death.",
        "[\u0027Yes, in neurodegenerative diseases, the accumulation of misfolded and aggregated proteins leads to neuronal dysfunction and ultimately neuronal death.\u0027]"
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Differential traits of autism spectrum disorders in girls.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39762643",
        "http://www.ncbi.nlm.nih.gov/pubmed/38476386",
        "http://www.ncbi.nlm.nih.gov/pubmed/35809134",
        "http://www.ncbi.nlm.nih.gov/pubmed/38429939",
        "http://www.ncbi.nlm.nih.gov/pubmed/27940569",
        "http://www.ncbi.nlm.nih.gov/pubmed/19582563",
        "http://www.ncbi.nlm.nih.gov/pubmed/22840550",
        "http://www.ncbi.nlm.nih.gov/pubmed/38225364",
        "http://www.ncbi.nlm.nih.gov/pubmed/27542396",
        "http://www.ncbi.nlm.nih.gov/pubmed/36444668",
        "http://www.ncbi.nlm.nih.gov/pubmed/31738945",
        "http://www.ncbi.nlm.nih.gov/pubmed/30368533",
        "http://www.ncbi.nlm.nih.gov/pubmed/29601216",
        "http://www.ncbi.nlm.nih.gov/pubmed/30523699",
        "http://www.ncbi.nlm.nih.gov/pubmed/31747131"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1781,
          "offsetInEndSection": 1885,
          "text": "Autistic girls were more likely to have parent-reported depression and anxiety compared to autistic boys",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39762643"
        },
        {
          "offsetInBeginSection": 839,
          "offsetInEndSection": 1266,
          "text": "Present results showed that girls with ASD had lower IQs than boys but similar adaptive functioning. The severity of symptoms of ASD was greater in boys than in girls, as were scores on psychopathological measures. With increasing age, boys with ASD showed greater impairment in social communication skills than girls and increased psychopathological comorbidities. Older girls showed fewer restricted and repetitive behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38476386"
        },
        {
          "offsetInBeginSection": 466,
          "offsetInEndSection": 569,
          "text": "girls had higher reported instances of Bullying, less Anger Control, and poorer Emotional Self-Control ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35809134"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 793,
          "text": "comparable rates of suicide death among autistic males and females, and mixed findings related to sex differences in risk of other suicidal behaviors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38429939"
        },
        {
          "offsetInBeginSection": 749,
          "offsetInEndSection": 1444,
          "text": "Higher overall levels of parent-reported repetitive and restricted behavior symptoms were less predictive of an autism spectrum disorder diagnosis in girls than in boys (odds ratio interaction \u003d 0.41, 95% confidence interval \u003d 0.18-0.92, p \u003d 0.03). In contrast, higher overall levels of parent-reported emotional and behavioral problems increased the probability of an autism spectrum disorder diagnosis more in girls than in boys (odds ratio interaction \u003d 2.44, 95% confidence interval \u003d 1.13-5.29, p \u003d 0.02). No differences were found between girls and boys in the prediction of an autism spectrum disorder diagnosis by overall autistic impairment, sensory symptoms, and cognitive functioning.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940569"
        },
        {
          "offsetInBeginSection": 597,
          "offsetInEndSection": 826,
          "text": "Girls with ASD evidenced greater communication deficits than boys and boys evidenced more restricted, repetitive, and stereotyped behavior than girls. Girls exhibited more sleep problems and anxious or depressed affect than boys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19582563"
        },
        {
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1222,
          "text": "meet diagnostic criteria.CONCLUSIONS: These data suggest that, in the absence of additional intellectual or behavioral problems, girls are less likely than boys to meet diagnostic criteria for ASD at equivalently high levels of autistic-like traits. This might reflect gender bias in diagnosis or genuinely be",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22840550"
        },
        {
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1180,
          "text": "higher overall levels of parent-reported emotional and behavioral problems increased the probability of an autism spectrum disorder diagnosis more in girls than in boys ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940569"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 1162,
          "text": "Information about behavioral difficulties as reported by teachers, and early estimates of intellectual functioning, were compared.RESULTS: Girls, but not boys, meeting diagnostic criteria for ASD showed significantly more additional problems (low intellectual level, behavioral difficulties) than peers with similarly high CAST scores who did not meet diagnostic criteria.CONCLUSIONS: These data suggest that, in the absence of additional intellectual or behavioral problems, girls are less likely than boys to meet diagnostic criteria for ASD at equivalently high levels of autistic-like traits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22840550"
        },
        {
          "offsetInBeginSection": 909,
          "offsetInEndSection": 1233,
          "text": "ls/women with ASD without ID displayed fewer RRBIs, more sensory symptoms and less problems in linguistic abilities than their boys/men counterparts. In contrast, girls/women with ASD with ID displayed more social difficulties and RRBIs, poorer linguistic abilities and more motor problems than boys/men with ASD with ID. Co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36444668"
        },
        {
          "offsetInBeginSection": 749,
          "offsetInEndSection": 1180,
          "text": "Higher overall levels of parent-reported repetitive and restricted behavior symptoms were less predictive of an autism spectrum disorder diagnosis in girls than in boys (odds ratio interaction \u003d 0.41, 95% confidence interval \u003d 0.18-0.92, p \u003d 0.03). In contrast, higher overall levels of parent-reported emotional and behavioral problems increased the probability of an autism spectrum disorder diagnosis more in girls than in boys ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940569"
        },
        {
          "offsetInBeginSection": 794,
          "offsetInEndSection": 1076,
          "text": "In the general population sample, girls exhibited fewer social communication/interaction and restricted-repetitive behavior symptoms than boys. In the direct assessment sample, however, girls with ASD showed greater impairment in social communication/interaction than boys with ASD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29601216"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 344,
          "text": "Therefore, we aim to investigate deviating pubertal development in autism, and whether this is more pronounced in girls than in boys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38225364"
        },
        {
          "offsetInBeginSection": 1899,
          "offsetInEndSection": 2299,
          "text": " In this study, we found that young girls diagnosed with autism spectrum disorder tend to have greater social communication deficits than young boys and that these differences vary by age. Specifically, toddler-aged girls receive higher clinician ratings of social communication deficits when compared to boys, while preschool-aged girls receive higher parent ratings of social communication deficits",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31747131"
        },
        {
          "offsetInBeginSection": 1149,
          "offsetInEndSection": 1285,
          "text": "fied analyses showed that in girls, autistic traits were associated with more Emotional Overeating and Emotional Undereating (e.g. adjus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31738945"
        },
        {
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1226,
          "text": "7% and M \u003d61% respectively. ASD girls had more psychiatric hospitalisations than ASD boys (60% vs. 31%), and they were more often treated with antidepressants (67% vs. 31%), anxiolytics (20% vs. 6%), ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30368533"
        },
        {
          "offsetInBeginSection": 1592,
          "offsetInEndSection": 1712,
          "text": " more abnormalities in sensory profile. ASD girls are at greater risk for developing anxiety, depression, suicidal ideat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30368533"
        },
        {
          "offsetInBeginSection": 1016,
          "offsetInEndSection": 1144,
          "text": "Girls versus boys with autism spectrum disorder were more likely to have substantiated maltreatment (13.6% vs 1.9%, respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523699"
        },
        {
          "offsetInBeginSection": 965,
          "offsetInEndSection": 1215,
          "text": "Young girls with autism spectrum disorder may demonstrate behaviors that are not particularly salient or concerning for parents; future research may investigate the behaviors that differentiate girls with autism spectrum disorder early in development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27542396"
        }
      ],
      "id": "67fbe10618b1e36f2e000111",
      "ideal_answer": [
        "With respect to boys, females with autism have higher parent-reported depression and anxiety, less ASD symptoms and psychopathological conditions, better communication skills, fewer repetitive behaviors, poorer emotional self-control, higher instances of bullying and poorer anger control.",
        "Females with autism spectrum disorder (ASD) often exhibit subtler or distinct traits compared to males. Key differences include:  \n1. **Symptom Presentation**: Females may show fewer atypical social-communication behaviors (e.g., less pronounced stereotyped/repetitive behaviors) and more internalizing issues (e.g., anxiety, depression).  \n2. **Diagnostic Bias**: Current diagnostic criteria and tools, historically based on male phenotypes, may overlook females without co-occurring intellectual/behavioral challenges. Females often require higher trait severity or additional impairments (e.g., motor delays, behavioral difficulties) to meet ASD criteria.  \n3. **Compensatory Behaviors**: Females may mask social difficulties more effectively, leading to underdiagnosis.  \n4. **Neurodevelopmental Markers**: Females with high autistic traits may show unique early phenotypes (e.g., motor deficits) not emphasized in traditional assessments.  \nThese factors contribute to underidentification in females, particularly those without intellectual disability."
      ],
      "exact_answer": [
        [
          "parent-reported depression and anxiety"
        ],
        [
          "less ASD symptoms than boys"
        ],
        [
          "less psychopathological conditions than boys"
        ],
        [
          "better communication skills"
        ],
        [
          "fewer repetitive behaviors"
        ],
        [
          "poorer emotional self-control"
        ],
        [
          "poorer anger control"
        ],
        [
          "higher instances of bullying"
        ]
      ]
    },
    {
      "body": "What are the major classes of immunoglobulins?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/47690",
        "http://www.ncbi.nlm.nih.gov/pubmed/39169187",
        "http://www.ncbi.nlm.nih.gov/pubmed/23660557",
        "http://www.ncbi.nlm.nih.gov/pubmed/31818032",
        "http://www.ncbi.nlm.nih.gov/pubmed/23550242",
        "http://www.ncbi.nlm.nih.gov/pubmed/20496766",
        "https://www.ncbi.nlm.nih.gov/pubmed/35464485",
        "https://www.ncbi.nlm.nih.gov/pubmed/47690",
        "http://www.ncbi.nlm.nih.gov/pubmed/2047710",
        "http://www.ncbi.nlm.nih.gov/pubmed/16814399",
        "http://www.ncbi.nlm.nih.gov/pubmed/26537387",
        "http://www.ncbi.nlm.nih.gov/pubmed/39129161",
        "http://www.ncbi.nlm.nih.gov/pubmed/1549379",
        "http://www.ncbi.nlm.nih.gov/pubmed/39699988",
        "http://www.ncbi.nlm.nih.gov/pubmed/20176268",
        "http://www.ncbi.nlm.nih.gov/pubmed/32535947",
        "http://www.ncbi.nlm.nih.gov/pubmed/10520363",
        "http://www.ncbi.nlm.nih.gov/pubmed/1162738",
        "http://www.ncbi.nlm.nih.gov/pubmed/816575",
        "http://www.ncbi.nlm.nih.gov/pubmed/35061510",
        "http://www.ncbi.nlm.nih.gov/pubmed/19604264"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 422,
          "text": "There are five major classes of immunoglobulins - IgG, M, A, D and E. Each is made of two heavy and two light chains or polymers of this basic subunit. The structure of each heavy and light chain consists of a variable region involved in antigen specificity and binding and a constant region which is involved in the class specific properties. The different classes of immunoglobulins differ in the biological properties. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/47690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 366,
          "text": "Immunoglobulin A (IgA) is the most abundant antibody isotype produced in humans, predominantly present in the mucosal areas where its main functions are the neutralization of toxins, prevention of microbial invasion across the mucosal epithelial barrier, and simultaneous maintenance of a physiologically indispensable symbiotic relationship with commensal bacteria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31818032"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Immunoglobulin E (IgE) plays a pivotal role in allergic responses1,2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39169187"
        },
        {
          "offsetInBeginSection": 179,
          "offsetInEndSection": 375,
          "text": "Antibodies and cells, generated in the germinal center in response to the first encounter with antigen, are highly specific, remain in the organism virtually forever and are mostly of IgG isotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23660557"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 652,
          "text": "IgM memory B cells represent our first-line defense against infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23660557"
        },
        {
          "offsetInBeginSection": 721,
          "offsetInEndSection": 843,
          "text": "Human immunoglobulins are divided into 5 classes, each of them with its own response kinetics, distribution and functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2047710"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 252,
          "text": "There are five classes of immunoglobulin (Ig): IgG, IgM, IgA, IgD and IgE.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23550242"
        },
        {
          "offsetInBeginSection": 997,
          "offsetInEndSection": 1057,
          "text": "Each class defines the IgM, IgG, IgA, IgD, and IgE isotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20176268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "In humans there are five classes of immunoglobulins (Igs), IgG, IgM, IgA, IgE and IgD, all of which are glycoproteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16814399"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 342,
          "text": "In normal serum, about 80% is IgG, 15% is IgA, 5% is IgM, 0.2% is IgD and a trace is IgE.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23550242"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 199,
          "text": "IgG (IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, and IgE are the five immunoglobulin subtypes that make up the majority of our immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39129161"
        },
        {
          "offsetInBeginSection": 608,
          "offsetInEndSection": 691,
          "text": "In mammals, five immunoglobulin classes, IgG, IgA, IgM, IgD and IgE are classified.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20496766"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 464,
          "text": "There are five classes of immunoglobulin (Ig): IgG, IgM, IgA, IgD and IgE. In normal serum, about 80% is IgG, 15% is IgA, 5% is IgM, 0.2% is IgD and a trace is IgE. Quantitative serum immunoglobulin tests are used to detect abnormal levels of the three major classes (IgG, IgA and IgM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23550242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "There are five major classes of immunoglobulins - IgG, M, A, D and E. Each is made of two heavy and two light chains or polymers of this basic subunit.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/47690"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 251,
          "text": "There are five classes of immunoglobulin (Ig): IgG, IgM, IgA, IgD and IgE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23550242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "In humans there are five classes of immunoglobulins (Igs), IgG, IgM, IgA, IgE and IgD, all of which are glycoproteins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16814399"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 449,
          "text": "Humoral immunity involves five classes of immunoglobulin: IgM, IgA, IgD, IgG, and IgE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1549379"
        },
        {
          "offsetInBeginSection": 608,
          "offsetInEndSection": 690,
          "text": "In mammals, five immunoglobulin classes, IgG, IgA, IgM, IgD and IgE are classified",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20496766"
        },
        {
          "offsetInBeginSection": 939,
          "offsetInEndSection": 1056,
          "text": "There are 5 main classes of heavy chain constant domains. Each class defines the IgM, IgG, IgA, IgD, and IgE isotypes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20176268"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 198,
          "text": "IgG (IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, and IgE are the five immunoglobulin subtypes that make up the majority of our immune system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39129161"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Various classes of immunoglobulins (IgA, IgM, IgG, IgD and IgE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1162738"
        },
        {
          "offsetInBeginSection": 507,
          "offsetInEndSection": 629,
          "text": "Different immunoglobulin (Ig) classes include IgM, IgD, IgG, IgE, and IgA, which exist as surface-bound and secreted forms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26537387"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 415,
          "text": "Mammalian immunoglobulins can be classified into five isotypes-IgA, IgD, IgE, IgG, and IgM-each with distinct roles in mediating various aspects of the immune response",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35061510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Immunoglobulins (Ig) are proteins that help fight infections. IgG (IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, and IgE are the five immunoglobulin subtypes that make up the majority of our immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39129161"
        },
        {
          "offsetInBeginSection": 409,
          "offsetInEndSection": 510,
          "text": "In the circulation, five main types of immunoglobulins (Ig) exist - namely IgG, IgA, IgE, IgM and IgD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19604264"
        }
      ],
      "id": "680fcb72353a4a2e6b00000e",
      "ideal_answer": [
        "There are five major classes of immunoglobulins - IgG, M, A, D, and E. Each is made of two heavy and two light chains or polymers of this basic subunit. The structure of each heavy and light chain consists of a variable region involved in antigen specificity and binding, and a constant region, which is involved in the class-specific properties. The different classes of immunoglobulins differ in their biological properties. For example, IgA is the most abundant antibody isotype produced in humans, predominantly present in the mucosal areas, where its main functions are the neutralization of toxins and the prevention of microbial invasion across the mucosal epithelial barrier, while IgE plays a pivotal role in allergic responses, and IgM and IgG immunoglobulins are involved in the initial and persisting response to infection, respectively.",
        "The major classes of immunoglobulins, which are critical components of the immune system, include IgG, IgM, IgA, IgD, and IgE. Each of these immunoglobulins is composed of two heavy chains and two light chains, or can be found as polymers of this basic subunit structure (PMID 47690). These classes play distinct roles in immune responses, with variations in their structure and function allowing for tailored responses to different pathogens.\n\nIgG is the most abundant type in the bloodstream and is crucial for bacterial and viral immunity. IgM is often the first antibody produced in response to an infection and is predominantly involved in the primary immune response. IgA is mainly found in mucosal areas, such as the gut, respiratory tract, and urogenital tract, playing a key role in mucosal immunity. IgD is less understood but is involved in the initiation and regulation of immune responses. Lastly, IgE is associated primarily with allergic reactions and responses to parasitic infections.\n\nThese immunoglobulin classes not only provide a diverse and adaptive immune defense mechanism but also engage in various biological activities that are essential for maintaining homeostasis and combating infections (PMID 4611173).",
        "The major classes of immunoglobulins are IgG, IgM, IgA, IgD, and IgE. Each immunoglobulin consists of two heavy and two light chains, with regions that determine antigen specificity and constant regions. IgA is the most abundant in humans, mainly found in mucosal areas, where it helps neutralize toxins and prevent microbial invasion. IgE is essential for allergic responses, while IgG is produced in response to antigens and remains in the body indefinitely. IgM is critical as the first-line defense against infections.",
        "The five major classes of immunoglobulins (Ig) are IgG, IgM, IgA, IgD, and IgE. Each class consists of two heavy and two light chains, with variable regions responsible for antigen binding and constant regions determining class-specific properties. IgG is the most abundant in serum, providing long-term immunity; IgA predominates in mucosal areas, neutralizing pathogens and maintaining symbiosis with commensal bacteria; IgM is the first antibody produced during initial infections, acting as a primary defense; IgD\u0027s role is less defined but involved in B-cell activation; and IgE mediates allergic responses by binding to allergens and triggering immune reactions. These classes differ in structure, function, and biological roles, reflecting their specialized contributions to immune defense.",
        "The major classes of immunoglobulins are IgG, IgM, IgA, IgD, and IgE. Each class consists of two heavy chains and two light chains, which form the basic structural unit. These immunoglobulins differ in their biological properties and functions: IgG : This is the most abundant antibody isotype and is primarily involved in neutralizing toxins and pathogens. It is also the only immunoglobulin that can cross the placenta to provide passive immunity to the fetus. IgM : This is typically the first antibody produced during a primary immune response and plays a key role in agglutination (clumping) of pathogens. IgA : Found predominantly in mucosal areas, IgA neutralizes toxins, prevents microbial invasion across epithelial barriers, and maintains a symbiotic relationship with commensal bacteria. IgD : This class is primarily found on the surface of B cells and plays a role in antigen recognition and activation of the immune response. IgE : Known for its role in allergic responses, IgE binds to mast cells and basophils, triggering the release of histamine and other inflammatory mediators."
      ],
      "exact_answer": [
        [
          "IgG",
          "IgG1",
          "IgG2",
          "IgG3",
          "IgG4"
        ],
        [
          "IgM"
        ],
        [
          "IgA"
        ],
        [
          "IgD"
        ],
        [
          "IgE"
        ]
      ]
    },
    {
      "body": "Please list the DORA type drugs",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38246901",
        "http://www.ncbi.nlm.nih.gov/pubmed/38543128",
        "http://www.ncbi.nlm.nih.gov/pubmed/38622003",
        "http://www.ncbi.nlm.nih.gov/pubmed/37950346",
        "http://www.ncbi.nlm.nih.gov/pubmed/24942635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35451800",
        "http://www.ncbi.nlm.nih.gov/pubmed/39462720",
        "http://www.ncbi.nlm.nih.gov/pubmed/36366844",
        "http://www.ncbi.nlm.nih.gov/pubmed/37425970",
        "http://www.ncbi.nlm.nih.gov/pubmed/38804896",
        "http://www.ncbi.nlm.nih.gov/pubmed/34992518",
        "http://www.ncbi.nlm.nih.gov/pubmed/37982383",
        "http://www.ncbi.nlm.nih.gov/pubmed/36436175",
        "http://www.ncbi.nlm.nih.gov/pubmed/38149178",
        "http://www.ncbi.nlm.nih.gov/pubmed/36749354",
        "https://www.ncbi.nlm.nih.gov/pubmed/34078141",
        "http://www.ncbi.nlm.nih.gov/pubmed/38586124",
        "http://www.ncbi.nlm.nih.gov/pubmed/35298826",
        "http://www.ncbi.nlm.nih.gov/pubmed/39540072",
        "http://www.ncbi.nlm.nih.gov/pubmed/34619288",
        "http://www.ncbi.nlm.nih.gov/pubmed/23731216",
        "http://www.ncbi.nlm.nih.gov/pubmed/26416477",
        "http://www.ncbi.nlm.nih.gov/pubmed/25147058",
        "http://www.ncbi.nlm.nih.gov/pubmed/36578296",
        "http://www.ncbi.nlm.nih.gov/pubmed/24215799",
        "http://www.ncbi.nlm.nih.gov/pubmed/36850983",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880753",
        "http://www.ncbi.nlm.nih.gov/pubmed/36649550",
        "http://www.ncbi.nlm.nih.gov/pubmed/36355586",
        "http://www.ncbi.nlm.nih.gov/pubmed/22920041",
        "http://www.ncbi.nlm.nih.gov/pubmed/26478806",
        "http://www.ncbi.nlm.nih.gov/pubmed/27471419",
        "http://www.ncbi.nlm.nih.gov/pubmed/23964859",
        "http://www.ncbi.nlm.nih.gov/pubmed/37549414",
        "http://www.ncbi.nlm.nih.gov/pubmed/36809238",
        "http://www.ncbi.nlm.nih.gov/pubmed/20047164",
        "http://www.ncbi.nlm.nih.gov/pubmed/38460107",
        "http://www.ncbi.nlm.nih.gov/pubmed/38472696",
        "http://www.ncbi.nlm.nih.gov/pubmed/39731508",
        "http://www.ncbi.nlm.nih.gov/pubmed/39365407",
        "http://www.ncbi.nlm.nih.gov/pubmed/39641404",
        "http://www.ncbi.nlm.nih.gov/pubmed/39118245",
        "http://www.ncbi.nlm.nih.gov/pubmed/39019232",
        "http://www.ncbi.nlm.nih.gov/pubmed/36699960",
        "http://www.ncbi.nlm.nih.gov/pubmed/30092886"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 431,
          "text": "suvorexant, a dual orexin receptor antagonist (DORA), on sleep and sensory/motor symptoms in individuals with idiopathic RLS.M",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38246901"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Daridorexant (dari), as the first dual orexin receptor antagonist (DORA) marketed in Europe, offers a novel therapeutic approach to insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38543128"
        },
        {
          "offsetInBeginSection": 1235,
          "offsetInEndSection": 1436,
          "text": "a. Dual orexin receptor antagonists (DORAs) such as daridorexant, lemborexant, and suvorexant, represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622003"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 280,
          "text": "This meta-analysis study aimed to assess the safety of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associated with these drugs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37950346"
        },
        {
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1031,
          "text": "Based on previous animal literature, DORA agents suvorexant and lemborexant may accomplish this by diminishing withdrawal difficulty and reducing nicotine cravings.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35451800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "STUDY OBJECTIVES: Dual orexin receptor antagonists (DORAs) are emerging treatments for insomnia. This meta-analysis study aimed to assess the safety of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37950346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34078141"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 455,
          "text": "For development of the dual orexin receptor antagonist (DORA) daridorexant, the FDA recommended conducting a rat drug discrimination paradigm against the approved, schedule IV, DORA suvorexant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37982383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia. It was selected from a pool of drug candidates on th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35298826"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Daridorexant (dari), as the first dual orexin receptor antagonist (DORA) marketed in Europe, offers a novel therapeutic approach to insomnia. However, data regarding its real-world safety are scarce. Thus, this study was aimed at assessing its safety",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38543128"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 263,
          "text": "y of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37950346"
        },
        {
          "offsetInBeginSection": 1719,
          "offsetInEndSection": 1866,
          "text": "pared with zolpidemlow, zolpidemhigh, DORAlow, and eszopiclonemid, respectively. Compared with the placebo, zopiclone, zolpidemmid, and eszopiclone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38149178"
        },
        {
          "offsetInBeginSection": 385,
          "offsetInEndSection": 488,
          "text": "Suvorexant is a dual orexin receptor antagonist (DORA) which is available for the treatment of insomnia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26416477"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 531,
          "text": "Dual orexin receptor antagonists (DORAs), which include suvorexant, daridorexant and lemborexant, have recently been approved by United States Food and Drug Administration (US FDA) as a novel pharmacotherapeutic alternative.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38586124"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 658,
          "text": "ACT-462206 is a new, potent, and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25147058"
        },
        {
          "offsetInBeginSection": 355,
          "offsetInEndSection": 560,
          "text": "Several compounds (almorexant, SB-649868, suvorexant) have been in advanced clinical trials for treating primary insomnia. ACT-462206 is a new, potent, and selective dual orexin receptor antagonist (DORA) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25147058"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Lemborexant (LEM) is a novel dual orexin receptor antagonist (DORA), recently approved for the treatment of insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36850983"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Almorexant is a dual orexin receptor antagonist (DORA) with sleep-enabling effects in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880753"
        },
        {
          "offsetInBeginSection": 687,
          "offsetInEndSection": 898,
          "text": "ilar to other DORAs that have been evaluated (eg., almorexant, suvorexant (SUV), and daridorexant), LEM and the positive controls (zolpidem and SUV) also showed drug liking in a phase 1 abuse potential study tha",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36749354"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "This column is the second in a 2-part series presenting the comparative pharmacology of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36649550"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "This first column in a 2-part series focuses on the pharmacokinetics of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant, specifically as they relate to their use as sleep medications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36355586"
        },
        {
          "offsetInBeginSection": 1238,
          "offsetInEndSection": 1436,
          "text": "Dual orexin receptor antagonists (DORAs) such as daridorexant, lemborexant, and suvorexant, represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622003"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Package inserts for the FDA-approved dual orexin receptor antagonists (DORAs) suvorexant, lemborexant and daridorexant state that suicide risk should b",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38804896"
        },
        {
          "offsetInBeginSection": 605,
          "offsetInEndSection": 772,
          "text": "Suvorexant is the first DORA to be approved and has demonstrated efficacy at decreasing both time to sleep onset and increasing total sleep time compared with placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26478806"
        },
        {
          "offsetInBeginSection": 779,
          "offsetInEndSection": 977,
          "text": "Suvorexant (Belsomra) is the first dual orexin receptor antagonist to be approved in the US and Japan and has demonstrated efficacy in decreasing time to sleep onset and increasing total sleep time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471419"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Lemborexant is a dual orexin receptor antagonist (DORA) approved in multiple countries including the United States, Japan, Canada and Australia for the treatment of adults with insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34619288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical trials in volunteers and primary insomnia patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859"
        },
        {
          "offsetInBeginSection": 645,
          "offsetInEndSection": 986,
          "text": "Pharmacologic agents that are approved by the US Food and Drug Administration for insomnia include benzodiazepine receptor agonists (zolpidem, eszopiclone, and zaleplon), low-dose doxepin (tricyclic antidepressant), ramelteon (melatonin receptor agonist), and dual orexin receptor agonists (DORAs, daridorexant, lemborexant, and suvorexant).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37549414"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "BACKGROUND: Package inserts for the FDA-approved dual orexin receptor antagonists (DORAs) suvorexant, lemborexant and daridorexant state that suicide risk should ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38804896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia disorder and has shown improvement in sleep outcomes and daytime functioning",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36809238"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 379,
          "text": "Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in collaboration with GlaxoSmithKline plc, for the treatment of primary insomnia. Almorexant is a first-in-class compound that targets the orexin system, which plays a key role in wake promotion and stabilization, in addition to having other regulatory functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20047164"
        },
        {
          "offsetInBeginSection": 734,
          "offsetInEndSection": 825,
          "text": "lteon, and dual orexin receptors antagonists (DORA) such as daridorexant, lemborexant, and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540072"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "BACKGROUND AND OBJECTIVES: Daridorexant, a dual orexin receptor antagonist was recently approved for the treatment of insomnia at doses ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472696"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731508"
        },
        {
          "offsetInBeginSection": 609,
          "offsetInEndSection": 797,
          "text": " Dual orexin receptor antagonists (DORAs), namely suvorexant, lemborexant, and daridorexant, demonstrated efficacy in treating chronic insomnia disorder across diverse clinical populations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39365407"
        },
        {
          "offsetInBeginSection": 1290,
          "offsetInEndSection": 1419,
          "text": "strated promising outcomes. Moreover, daridorexant and suvorexant, both belonging to the DORA class, have demonstrated efficacy i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540072"
        },
        {
          "offsetInBeginSection": 479,
          "offsetInEndSection": 593,
          "text": "etween 2014 and 2024, detailing the use of DORA medications, including suvorexant and lemborexant, in patients wit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39462720"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "BACKGROUND: Daridorexant is a dual orexin receptor antagonist approved for the treatment of chronic insomn",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39641404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Daridorexant is a dual orexin receptor antagonist for the treatment of insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39118245"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "OBJECTIVE: Daridorexant, a novel dual orexin receptor antagonist, was approved by the FDA in 2022 for the treatment of insomnia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39019232"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 261,
          "text": "One of the contemporary drug options for insomnia includes dual orexin receptor antagonist (DORA), such as suvorexant and lemborexant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36578296"
        },
        {
          "offsetInBeginSection": 72,
          "offsetInEndSection": 191,
          "text": "the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36355586"
        },
        {
          "offsetInBeginSection": 1069,
          "offsetInEndSection": 1367,
          "text": " The DORA almorexant demonstrated significant improvements in a number of clinically relevant sleep parameters in animal models and in patients with insomnia but its development was halted. SB-649868 and suvorexant have demonstrated efficacy and tolerability in Phase II and III trials respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23731216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37425970"
        },
        {
          "offsetInBeginSection": 1409,
          "offsetInEndSection": 1634,
          "text": "Although development was stopped for almorexant and for Glaxo\u0027s DORA SB-649868, no less than 4 orexin receptor antagonists have reached phase II for insomnia, including Filorexant (MK-6096) and Suvorexant (MK-4305) from Merck",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24215799"
        },
        {
          "offsetInBeginSection": 1217,
          "offsetInEndSection": 1407,
          "text": "Less than 10years later, the first orexin antagonist, almorexant, a dual orexin receptor antagonist (DORA), was reported to be effective in inducing sleep in volunteers and insomnia patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24215799"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 351,
          "text": "DORAs represent a potential alternative mechanism to the current standard of care that includes the γ-aminobutyric acid (GABA)A receptor-positive allosteric modulators, eszopiclone and zolpidem.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722242"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 263,
          "text": "nts for insomnia. This meta-analysis study aimed to assess the safety of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37950346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia. It was selected from a pool",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35298826"
        },
        {
          "offsetInBeginSection": 550,
          "offsetInEndSection": 705,
          "text": "Merck\u0027s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920041"
        },
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 806,
          "text": "Treatment of insomnia with Daridorexant as a Dual Orexin Receptor Antagonist (DORA) has been evaluated in several preclinical and clinical studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37425970"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 475,
          "text": "he objective of the study is to evaluate whether low, medium, and high doses of orexin dual receptor antagonists (DORA), zopiclone (ZOP), eszopiclone (ESZ), and zolpidem (ZST) can impair cognition.M",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36699960"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 296,
          "text": "The orexin/hypocretin system is an attractive potential therapeutic target as demonstrated by the successful clinical trials of antagonist medications like Suvorexant for insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24942635"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 295,
          "text": "The orexin/hypocretin system is an attractive potential therapeutic target as demonstrated by the successful clinical trials of antagonist medications like Suvorexant for insomnia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24942635"
        },
        {
          "offsetInBeginSection": 987,
          "offsetInEndSection": 1233,
          "text": "In rodent models of depression, investigated ORAs have included the DORA almorexant and TCS1102, the selective orexin 1 receptor antagonists SB334867 and SB674042 and the selective orexin 2 receptor antagonists LSN2424100, MK-1064 and TCS-OX2-29.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36436175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "STUDY OBJECTIVES: Dual orexin receptor antagonists (DORAs) are emerging treatments for insomnia. This meta-analysis study aimed to assess the safety of FDA-approved DORAs (suvorexant, lemborexant, and daridorexant), focusing on narcolepsy-like symptoms associate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37950346"
        },
        {
          "offsetInBeginSection": 654,
          "offsetInEndSection": 921,
          "text": "pants with insomnia disorder. Similar to other DORAs that have been evaluated (eg., almorexant, suvorexant (SUV), and daridorexant), LEM and the positive controls (zolpidem and SUV) also showed drug liking in a phase 1 abuse potential study that enrolled subjects who",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36749354"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "RATIONALE: Lemborexant (LEM) is a dual orexin receptor antagonist (DORA) approved in multiple countries including the USA, Japan, Canada, Australia, and several Asian countries for the treatment of insomni",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36749354"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "RATIONALE: Lemborexant (LEM) is a dual orexin receptor antagonist (DORA) approved in multiple countries including the USA, Japan, Canada, Australia, and several Asian countries for the treatment of insomnia in adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36749354"
        },
        {
          "offsetInBeginSection": 665,
          "offsetInEndSection": 712,
          "text": "dual orexin receptor antagonist (DORA) TCS-1102",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34992518"
        },
        {
          "offsetInBeginSection": 518,
          "offsetInEndSection": 819,
          "text": "in some patients.METHODS: We reviewed the existing literature on dual orexin receptor antagonists in PubMed databases using the search terms \"orexin receptor antagonist,\" \"almorexant\" \"filorexant,\" \"lembroexant\" and \"suvorexant\"; searches were limited to English language primary research articles, cl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30092886"
        },
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 805,
          "text": "Treatment of insomnia with Daridorexant as a Dual Orexin Receptor Antagonist (DORA) has been evaluated in several preclinical and clinical studies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37425970"
        },
        {
          "offsetInBeginSection": 655,
          "offsetInEndSection": 804,
          "text": "Daridorexant as a Dual Orexin Receptor Antagonists (DORA) in the treatment of insomnia has been evaluated in several preclinical and clinical studies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36366844"
        }
      ],
      "type": "list",
      "id": "6805568118b1e36f2e000145",
      "ideal_answer": [
        "Dual Orexin Receptor Antagonists, are a class of prescription medications used to treat insomnia.a. Dual orexin receptor antagonists (DORAs) such as daridorexant, lemborexant, and suvorexant, represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
        "The dual orexin receptor antagonist (DORA) type drugs mentioned are suvorexant, lemborexant, and daridorexant.",
        "Suvorexant, daridorexant, lemborexant, almorexant, and ACT-462206 are dual orexin receptor antagonist (DORA) type drugs.",
        "The DORA type drugs are daridorexant, lemborexant, and suvorexant.",
        "Direct Oral Anticoagulants (DORA) are a class of drugs that include: Apixaban, Dabigatran, Edoxaban, and Rivaroxaban. These drugs are used for the prevention and treatment of thromboembolic events, particularly in patients with atrial fibrillation.",
        "The DORA type drugs are daridorexant, suvorexant, lemborexant, almorexant, and ACT-462206.",
        "The DORA type drugs identified are: daridorexant, suvorexant, and lemborexant. These drugs are dual orexin receptor antagonists used primarily for the treatment of insomnia.",
        "The DORA type drugs include lemborexant, suvorexant, daridorexant, almorexant, ACT-462206, Quviviq™, and SB-649868.",
        "Suvorexant, lemborexant and daridorexant are FDA-approved dual orexin receptor antagonists. Investigational DORAs include almorexant (ACT-078573), filorexant, SB-649868, TCS1102, DORA-12, DORA-22 and ACT-541468.",
        "Daridorexant, lemborexant, and suvorexant are orexin receptor antagonists. They are used for treatment of insomnia.",
        "The DORA type drugs approved for insomnia treatment include: daridorexant, lemborexant, and suvorexant. These dual orexin receptor antagonists inhibit wakefulness rather than inducing sedation, and they have minimal risk of rebound insomnia or withdrawal symptoms.",
        "The DORA type drugs include: suvorexant, lemborexant, daridorexant, and vornorexant.",
        "The DORA type drugs include suvorexant, daridorexant, and lemborexant, which have been approved by the United States Food and Drug Administration (US FDA) as novel pharmacotherapeutic alternatives.",
        "The DORA type drugs include: daridorexant, suvorexant, and lemborexant. These drugs are dual orexin receptor antagonists used for the treatment of insomnia.",
        "The DORA type drugs include daridorexant, suvorexant, lemborexant, and almorexant.",
        "Dual orexin receptor antagonists (DORAs) are suvorexant, daridorexant and lemborexant.",
        "Based on the provided texts, the DORA (Dual Orexin Receptor Antagonist) type drugs mentioned are:\n\n1. Daridorexant\n2. Lemborexant\n3. Suvorexant\n4. Almorexant\n5. SB-649868\n\nThese drugs have been approved or investigated for the treatment of insomnia and/or major depressive disorder (MDD).",
        "The DORA type drugs include suvorexant, daridorexant, lemborexant, and almorexant.",
        "DORA type drugs include:\n\n1. **Daridorexant**: FDA-approved for insomnia treatment.\n2. **Lemborexant**: FDA-approved for insomnia treatment.\n3. **Suvorexant**: FDA-approved for insomnia treatment.\n4. **Almorexant**: Development halted despite showing promise in trials.\n5. **SB-649868**: Undergoing Phase II trials, not yet approved.\n\nThese drugs function as dual orexin receptor antagonists, targeting insomnia and being explored for other conditions like major depressive disorder.",
        "The known dual orexin receptor antagonists include suvorexant, lemborexant, daridorexant, almorexant, filorexant, SB-649868, DORA-12 and DORA-22.",
        "The DORA type drugs mentioned across the abstracts are: Suvorexant, Daridorexant, and Lemborexant. These drugs function by antagonizing both orexin receptor types, offering a novel approach to treating insomnia with potentially fewer side effects compared to traditional benzodiazepine receptor agonists.",
        "Dual orexin receptor antagonist (DORA) type drugs include daridorexant, lemborexant, suvorexant, almorexant, and ACT-462206.",
        "The DORA type drugs mentioned in the provided texts are suvorexant, lemborexant, and daridorexant. These drugs are dual orexin receptor antagonists used for the treatment of insomnia.",
        "Dual orexin receptor antagonists (DORAs) are emerging treatments for insomnia. DORAs include suvorexant, lemborexant, and daridorexant.",
        "Dual orexin receptor antagonists (DORAs) are emerging treatments for insomnia. The FDA-approved DORAs are suvorexant, lemborexant, and daridorexant.",
        "Dual orexin receptor antagonists (DORAs) such as daridorexant, lemborexant, and suvorexant, represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
        "Dual orexin receptor antagonists (DORAs) include daridorexant, lemborexant, and suvorexant. These drugs, such as daridorexant marketed in Europe and suvorexant approved in the US, represent a novel approach, inhibiting wakefulness for insomnia treatment.",
        "Daridorexant, lemborexant, and suvorexant are DORA type drugs.",
        "The DORA type drugs are suvorexant, lemborexant, and daridorexant.",
        "The DORA type drugs include daridorexant, lemborexant, and suvorexant, as they are mentioned across the provided snippets.",
        "The DORA type drugs include: daridorexant, lemborexant, and suvorexant. These drugs are dual orexin receptor antagonists used for the treatment of insomnia.",
        "Dual orexin receptor antagonists (DORAs) such as suvorexant, lemborexant, and daridorexant.",
        "DORA type drugs include suvorexant, daridorexant, and lemborexant. These represent dual orexin receptor antagonists used in insomnia treatment.",
        "Daridorexant, lemborexant, and suvorexant are dual orexin receptor antagonists (DORAs).",
        "The DORA type drugs include daridorexant, lemborexant, and suvorexant. These drugs represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
        "Dual orexin receptor antagonists (DORAs) include three FDA-approved drugs: suvorexant, lemborexant, and daridorexant. These medications represent a novel approach to treating insomnia by inhibiting wakefulness rather than promoting sedation.",
        "The dual orexin receptor antagonists (DORAs) mentioned are: suvorexant, daridorexant, and lemborexant. These drugs are used for the treatment of insomnia by inhibiting wakefulness rather than enhancing sedation.",
        "Dual orexin receptor antagonists (DORAs) include suvorexant, lemborexant, and daridorexant.",
        "Suvorexant, lemborexant, and daridorexant are the FDA-approved dual orexin receptor antagonists (DORAs) mentioned in the study.",
        "Dual orexin receptor antagonists (DORAs) are a novel approach to insomnia treatment. The three FDA-approved DORAs are lemborexant, suvorexant, and daridorexant. These drugs inhibit wakefulness rather than enhancing sedation, offering a unique therapeutic strategy for insomnia.",
        "The DORA type drugs include: daridorexant, suvorexant, lemborexant, almorexant, and TCS-1102. These drugs are dual orexin receptor antagonists used primarily for the treatment of insomnia.",
        "The DORA type drugs include: daridorexant, lemborexant, and suvorexant. These drugs are dual orexin receptor antagonists used for the treatment of insomnia by inhibiting wakefulness.",
        "The DORA type drugs include daridorexant, lemborexant, and suvorexant.",
        "Dual orexin receptor antagonists (DORAs) are a novel class of hypnotic agents that inhibit wakefulness rather than enhancing sedation. Three DORAs have been approved for insomnia treatment: daridorexant, lemborexant, and suvorexant.",
        "The DORA type drugs include: daridorexant, lemborexant, and suvorexant. These drugs are dual orexin receptor antagonists that inhibit wakefulness and represent a novel approach to treating insomnia.",
        "The DORA type drugs, which are dual orexin receptor antagonists used to treat insomnia by inhibiting wakefulness, are Suvorexant, Daridorexant, and Lemborexant, offering a novel approach to enhancing sleep quality by targeting the sleep-wake cycle regulators in the brain.",
        "Daridorexant (dari), as the first dual orexin receptor antagonist (DORA) marketed in Europe, offers a novel therapeutic approach to insomnia.",
        "The DORA type drugs are suvorexant, daridorexant, and lemborexant.",
        "[\u0027The DORA type drugs mentioned are suvorexant, daridorexant, and lemborexant.\u0027]",
        "Based on the provided texts, the DORA (Dual Orexin Receptor Antagonist) type drugs mentioned are:\n\n1. Suvorexant\n2. Daridorexant\n3. Lemborexant\n\nThese three drugs are specifically identified as DORAs in the abstracts.",
        "The DORA type drugs are Suvorexant, Daridorexant, and Lemborexant, consistently identified across multiple sources as belonging to this category.",
        "Suvorexant, lemborexant, daridorexant, almorexant, filorexant, SB-649868, DORA-12, DORA-22",
        "Suvorexant, Daridorexant, and Lemborexant",
        "The DORA (dual orexin receptor antagonist) type drugs include suvorexant, lemborexant, and daridorexant. These medications represent a novel approach to insomnia treatment by inhibiting wakefulness through orexin receptor antagonism.",
        "The DORA type drugs mentioned are suvorexant, lemborexant, and daridorexant, which function as dual orexin receptor antagonists, offering a novel approach to insomnia by inhibiting wakefulness rather than enhancing sedation. These drugs are highlighted for their therapeutic application in treating insomnia, with daridorexant being specifically noted as the first marketed in Europe.",
        "The DORA type drugs include suvorexant, daridorexant, and lemborexant. These drugs represent a novel approach to insomnia treatment by inhibiting wakefulness rather than enhancing sedation.",
        "Suvorexant is a dual orexin receptor antagonist (DORA) type drug."
      ],
      "exact_answer": [
        [
          "belsoma",
          "suvorexant,"
        ],
        [
          "Daridorexant"
        ],
        [
          "lemborexant"
        ],
        [
          "almorexant"
        ],
        [
          "Filorexant"
        ],
        [
          "SB-649868"
        ],
        [
          "TCS1102"
        ],
        [
          "TCS-OX2-29"
        ],
        [
          "SB334867"
        ],
        [
          "MK-1064"
        ],
        [
          "SB674042"
        ],
        [
          "LSN2424100"
        ]
      ]
    },
    {
      "body": "Is takotsubo cardiomyopathy more common in men?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38484803",
        "http://www.ncbi.nlm.nih.gov/pubmed/37923154",
        "http://www.ncbi.nlm.nih.gov/pubmed/39201067",
        "http://www.ncbi.nlm.nih.gov/pubmed/39319103",
        "http://www.ncbi.nlm.nih.gov/pubmed/35668627",
        "http://www.ncbi.nlm.nih.gov/pubmed/21474857",
        "http://www.ncbi.nlm.nih.gov/pubmed/30213471",
        "http://www.ncbi.nlm.nih.gov/pubmed/23562125",
        "http://www.ncbi.nlm.nih.gov/pubmed/23928852",
        "http://www.ncbi.nlm.nih.gov/pubmed/36880077",
        "http://www.ncbi.nlm.nih.gov/pubmed/35382214",
        "http://www.ncbi.nlm.nih.gov/pubmed/37441276",
        "http://www.ncbi.nlm.nih.gov/pubmed/37351075",
        "https://www.ncbi.nlm.nih.gov/pubmed/23562114",
        "https://www.ncbi.nlm.nih.gov/pubmed/34388240",
        "https://www.ncbi.nlm.nih.gov/pubmed/35382214",
        "https://www.ncbi.nlm.nih.gov/pubmed/37091659",
        "http://www.ncbi.nlm.nih.gov/pubmed/23562114",
        "http://www.ncbi.nlm.nih.gov/pubmed/19589120",
        "http://www.ncbi.nlm.nih.gov/pubmed/24754972",
        "http://www.ncbi.nlm.nih.gov/pubmed/19411122",
        "http://www.ncbi.nlm.nih.gov/pubmed/24576981",
        "http://www.ncbi.nlm.nih.gov/pubmed/20189157",
        "http://www.ncbi.nlm.nih.gov/pubmed/25618443",
        "http://www.ncbi.nlm.nih.gov/pubmed/37153459",
        "http://www.ncbi.nlm.nih.gov/pubmed/37091659",
        "http://www.ncbi.nlm.nih.gov/pubmed/19902606",
        "http://www.ncbi.nlm.nih.gov/pubmed/22877807",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625378"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "The incidence of takotsubo stress cardiomyopathy (TSCM) in males is low compared with females",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37923154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Takotsubo syndrome (TTS), also known as the broken-heart syndrome, is a reversible condition typically observed in female patients presenting for acute coronary syndromes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39201067"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 103,
          "text": "Takotsubo cardiomyopathy (TTC) has a preponderance for females, particularly postmenopausal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39319103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Takotsubo syndrome (TTS), triggered by intense emotional or physical stress, occurring most commonly in post-menopausal women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35668627"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 514,
          "text": "Incidence of Takotsubo cardiomyopathy is 54.9/1,000,000 inhabitants in women versus only 3.6/1,000,000 inhabitants in men.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Takotsubo cardiomyopathy is likely induced by stress, and postmenopausal women account for the majority of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562125"
        },
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 485,
          "text": "TC is an increasingly recognized type of acquired cardiomyopathy occurring commonly after a recent stressful event, in particular emotional stress, and is relatively common in middle-aged and older women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928852"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Background: Takotsubo cardiomyopathy (TC) affects predominantly women. Prior studies have suggested that men might have worse short-term outcomes, but",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36880077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Takotsubo syndrome: more frequent in women, more dangerous in men.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37091659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 694,
          "text": "Takotsubo cardiomyopathy (TTC) predominantly occurs in elderly women. Men comprise 10% of the patients, with a similar clinical profile. In contrast to myocardial infarction, age distribution; symptoms, such as angina; and prehospital delay in TTC are not different between genders. In men, physical stress as a triggering event and shock or cardiac arrest on presentation are more frequent. Gender-related differences in TTC need to be carefully investigated at the clinical and experimental levels to explain the evident gender discrepancy in the prevalence of TTC, to clarify the pathogenetic background, and to develop preventive and therapeutic means against this life-threatening disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/23562114"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 977,
          "text": "Takotsubo syndrome (TTS) is an acute myocardial disease characterized by reversible left ventricular dysfunction, in the absence of obstructive coronary artery disease, caused by adrenergic overactivity and associated with non-negligible morbidity and mortality. Takotsubo syndrome, by far more frequent in women, who account for 9 out of 10 cases, is generally triggered by intense psychoemotional stress. In men, TTS has different, though not yet fully defined, characteristics and clinical course. In fact, men have a higher prevalence of a physical trigger and comorbidities, such as bronchopulmonary or cerebral pathologies, diabetes mellitus, and malignant neoplasms. The hospital course is burdened by a higher rate of cardiogenic shock and mortality. The long-term prognosis is also less favourable in men. Takotsubo syndrome in men characterizes a higher-risk phenotype, which requires close monitoring during hospitalization and careful surveillance during follow-up.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37091659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1787,
          "text": "Takotsubo cardiomyopathy (TC) is a rare, reversible cause of left ventricular wall motion abnormality (LVWMA) that mimics the presentation of acute myocardial infarction (AMI). TC is usually preceded by an emotional or physical stressor and appears to be more common in postmenopausal women. Various pathophysiological hypotheses of TC have been proposed, but the exact mechanism of action remains elusive. Elevated levels of catecholamines leading to cardiac dysfunction are the most prevalent hypothesis. The protective role of estrogen in the development of cardiomyopathies has been studied extensively. International Takotsubo Diagnostic Criteria (InterTAK) and Mayo clinic diagnostic criteria both have the stipulation stating prevalence of TC is higher in postmenopausal women which hints towards the protective role of estrogen in the development of TC. To review the protective role of estrogen in the mechanism of this novel pathology, we searched Pubmed and Google scholar for the relevant articles by using keywords such as: \"takotsubo cardiomyopathy\", \"apical ballooning\", \"broken heart syndrome\", \"stress cardiomyopathy\", \"left ventricle wall motion abnormality\", \"estrogen\", \"estradiol\" and \"sex hormones\". Our research revealed that although the prevalence of TC is greater in postmenopausal women as compared to men, the prognosis is worse in men. It also revealed the involvement of multiple cellular pathways under the influence of estrogen that could explain the cardioprotective effect of estrogen. Most of the articles found were based on animal studies, thus, there is an emphasis on future human studies. However, we strongly suggest evaluating estrogen levels as part of the initial workup for any patient presenting with signs and symptoms of cardiac pathology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/35382214"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1455,
          "text": "Takotsubo cardiomyopathy (TTC), a persistently obscure dysfunctional condition of the left ventricle, is uniquely transient but nevertheless dangerous. It features variable ventricular patterns and is predominant in women. For 30 years, pathophysiologic investigations have progressed only slowly and with inadequate focus. It was initially proposed that sudden-onset spastic obliteration of coronary flow induced myocardial ischemia with residual stunning and thus TTC. Later, it was generally accepted without proof that, in the presence of pain or emotional stress, the dominant mechanism for TTC onset was a catecholamine surge that had a direct, toxic myocardial effect. We think that the manifestations of TTC are more dynamic and complex than can be assumed from catecholamine effects alone. In addition, after reviewing the recent medical literature and considering our own clinical observations, especially on spasm, we theorize that atherosclerotic coronary artery disease modulates and physically opposes obstruction during spasm. This phenomenon may explain the midventricular variant of TTC and the lower incidence of TTC in men. We continue to recommend and perform acetylcholine testing to reproduce TTC and to confirm our theory that coronary spasm is its initial pathophysiologic factor. An improved understanding of TTC is especially important because of the condition\u0027s markedly increased incidence during the ongoing COVID-19 pandemic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34388240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Takotsubo cardiomyopathy is classically associated with emotional stress in middle-aged women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37351075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Takotsubo cardiomyopathy is characterised by a reversible left ventricular wall motion abnormality that is observed as apical ballooning without significant coronary arterial stenosis; it occurs predominantly in postmenopausal women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19411122"
        },
        {
          "offsetInBeginSection": 800,
          "offsetInEndSection": 961,
          "text": "Initial treatment should be the same for men and women. Takotsubo cardiomyopathy is a rare condition that is seen more frequently in older, postmenopausal women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977827"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "BACKGROUND: Takotsubo cardiomyopathy (TCM) is classically associated with significant gender disparities, such that it is more prevalent in females, but the clinical outcomes are worse for male patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38484803"
        },
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 670,
          "text": "Physical stress is less found in women. Incidence of Takotsubo cardiomyopathy is 54.9/1,000,000 inhabitants in women versus only 3.6/1,000,000 inhabitants in men. Diagnosis is based on electrocardiogram, biomarkers, echocardiography, coronary angiography and left ventricular angiography, and cardiac magnetic imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213471"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 670,
          "text": "Incidence of Takotsubo cardiomyopathy is 54.9/1,000,000 inhabitants in women versus only 3.6/1,000,000 inhabitants in men. Diagnosis is based on electrocardiogram, biomarkers, echocardiography, coronary angiography and left ventricular angiography, and cardiac magnetic imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213471"
        },
        {
          "offsetInBeginSection": 856,
          "offsetInEndSection": 961,
          "text": "Takotsubo cardiomyopathy is a rare condition that is seen more frequently in older, postmenopausal women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977827"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Reduced estrogen in menopause may predispose women to takotsubo cardiomyopathy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20189157"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Takotsubo cardiomyopathy is likely induced by stress, and postmenopausal women account for the majority of patients. Several questions about takotsubo cardiomyopathy remain unanswered, including why it is induced by stress, what differentiates the st",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562125"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Takotsubo cardiomyopathy preferentially affects postmenopausal women (# 90%). Takotsubo cardiomyopathy mimics an acute coronary syndrome and is defined as a transient left ventricular systolic dysfunction. Diagnosis is based on the criteria of the Ma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Background: Takotsubo cardiomyopathy (TC) affects predominantly women. Prior studies have suggested that men migh",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36880077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Takotsubo cardiomyopathy (TCM) or \"broken heart syndrome\" is a rare condition that is more common in women than men,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37441276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "Takotsubo cardiomyopathy (Tc) is a transient left ventricular apical ballooning syndrome, with symptoms and signs of acute myocardial infarction. Tc syndrome, which occurs predominantly in postmenopausal women, is characterized by increase of sympathetic activity. Studies on the gender-specific differences in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618443"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 607,
          "text": "Takotsubo cardiomyopathy (TC) is a rare, reversible cause of left ventricular wall motion abnormality (LVWMA) that mimics the presentation of acute myocardial infarction (AMI). TC is usually preceded by an emotional or physical stressor and appears to be more common in postmenopausal women. Various pathophysiological hypotheses of TC have been proposed, but the exact mechanism of action remains elusive. Elevated levels of catecholamines leading to cardiac dysfunction are the most prevalent hypothesis. The protective role of estrogen in the development of cardiomyopathies has been studied extensively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382214"
        },
        {
          "offsetInBeginSection": 255,
          "offsetInEndSection": 644,
          "text": "Compared to men, women appear to have greater susceptibility to chronic forms of psychosocial stress, extending beyond an increased incidence of mood disorders to include a 2- to 4-fold higher risk of stress-dependent myocardial infarction in women, and up to 10-fold higher risk of Takotsubo syndrome-a stress-dependent coronary-myocardial disorder most prevalent in post-menopausal women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37153459"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Background: Takotsubo cardiomyopathy (TC) affects predominantly women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36880077"
        },
        {
          "offsetInBeginSection": 1222,
          "offsetInEndSection": 1364,
          "text": "Our research revealed that although the prevalence of TC is greater in postmenopausal women as compared to men, the prognosis is worse in men.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382214"
        },
        {
          "offsetInBeginSection": 324,
          "offsetInEndSection": 453,
          "text": "Takotsubo syndrome characteristically affects peri- or postmenopausal women, albeit recent series show that men also are at risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24754972"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Takotsubo cardiomyopathy (TTC) predominantly occurs in elderly women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562114"
        },
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 406,
          "text": "Takotsubo syndrome, by far more frequent in women, who account for 9 out of 10 cases, is generally triggered by intense psychoemotional stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37091659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Takotsubo cardiomyopathy (TTC) predominantly occurs in elderly women. Men comprise 10% of the patients, with a similar clinical profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562114"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 69,
          "text": " Takotsubo cardiomyopathy (TC) affects predominantly women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36880077"
        },
        {
          "offsetInBeginSection": 1452,
          "offsetInEndSection": 1561,
          "text": "Takotsubo is most common in menopausal women although young individuals, including men, can also be affected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589120"
        },
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 347,
          "text": "Takotsubo syndrome, by far more frequent in women, who account for 9 out of 10 cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37091659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Most patients with Takotsubo Syndrome (TTS) are postmenopausal females. TTS in males is rare and gender differences have not been sufficiently investigated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625378"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Takotsubo cardiomyopathy (TTC) predominantly occurs in elderly women. Men comprise 10% of the patients, with a similar clinical profile. In contrast to myocardial infarction, age distribution; symptoms, such as angina; and prehospital delay in TTC ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562114"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Background: Takotsubo cardiomyopathy (TTC) has a preponderance for females, particularly pos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39319103"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 221,
          "text": "Takotsubo cardiomyopathy is more prevalent in females",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576981"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Takotsubo cardiomyopathy preferentially affects postmenopausal women (# 90%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30213471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "text": "Takotsubo cardiomyopathy is a transient acute left ventricular dysfunction characterized by left ventricular apical akinesis and ballooning without obstructive coronary disease described predominantly in post-menopausal women in the setting of acute emotional or physical stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21474857"
        },
        {
          "offsetInBeginSection": 1106,
          "offsetInEndSection": 1346,
          "text": "on pump placement).RESULTS: A total of 24,701 patients with takotsubo cardiomyopathy were identified. In-hospital mortality rate was 4.2%. A total of 21,994 patients (89.0%) were female. Male patients had a higher mortality rate than female",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22877807"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 202,
          "text": "Takotsubo cardiomyopathy (TCM) is classically associated with significant gender disparities, such that it is more prevalent in females, but the clinical outcomes are worse for male patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38484803"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 280,
          "text": "Takotsubo cardiomyopathy (TCM) can often be triggered by intense stress and is more common in older women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35371635"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 302,
          "text": "Takotsubo cardiomyopathy is more prevalent in females and it is usually related to an event triggered by physical or emotional stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576981"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 213,
          "text": "The syndrome is ten times more common in females compared to males and is manifested by chest pain and dyspnea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19902606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Takotsubo cardiomyopathy (TCM) or \"broken heart syndrome\" is a rare condition that is more common in women than men, particularly those who are postmenopausal. It mimics a myocardial infarction and psychological factors have been implicated in its etiology as well as being consequences of its presen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37441276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Background: Takotsubo cardiomyopathy (TC) affects predominantly women. Prior studies have suggested that men might have worse short-term outcomes, but limited data are available regarding long-term outcomes. We hypothesized that men, compared to women, with TC have worse short- and long-term outcome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36880077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Takotsubo cardiomyopathy (TC) is a rare, reversible cause of left ventricular wall motion abnormality (LVWMA) that mimics the presentation of acute myocardial infarction (AMI). TC is usually preceded by an emotional or physical stressor and appears to be more common in postmenopausal women. Various ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35382214"
        }
      ],
      "id": "67e26b0b18b1e36f2e000073",
      "ideal_answer": [
        "No, Takotsubo cardiomyopathy is more frequent among postmenopausal women.",
        "No, takotsubo cardiomyopathy is not more common in men; it is more frequently observed in women. The literature indicates that takotsubo syndrome, also known as stress-induced cardiomyopathy, predominantly affects women rather than men. Specifically, one study highlights that this condition is more frequent in women, although it presents a higher risk of dangerous outcomes in men when it does occur (PMID 37091659). Another study examining the prevalence of takotsubo syndrome supports this gender disparity, focusing on its occurrence in men and premenopausal women, suggesting a lower incidence among these groups compared to postmenopausal women (PMID 25499377). Furthermore, additional research confirms that men comprise only about 10% of the patients diagnosed with takotsubo cardiomyopathy, reinforcing the observation that it is less common in men (PMID 23562114). Thus, the evidence clearly supports that takotsubo cardiomyopathy predominantly affects women, with men being less frequently afflicted.",
        "Takotsubo cardiomyopathy (TCM), also known as Takotsubo syndrome (TTS), is classically associated with significant gender disparities, such that it is more prevalent in females. The incidence of TSCM in males is low compared with females. This is supported by various observations in the documents:\n1. \"Takotsubo cardiomyopathy (TCM) is classically associated with significant gender disparities...\"\n2. \"The incidence of takotsubo stress cardiomyopathy (TSCM) in males is low compared with females...\"\n3. \"Takotsubo syndrome (TTS), also known as the broken-heart syndrome, is a reversible condition typically observed in female patients...\"\n4. \"Takotsubo cardiomyopathy (TTC) has a preponderance for females, particularly postmenopausal...\"\n5. \"Takotsubo syndrome (TTS), triggered by intense emotional or physical stress, occurring most commonly in post-menopausal women...\"\n\nIn summary, based on the provided snippets, it can be inferred that Takotsubo cardiomyopathy is more common in females, not in men."
      ],
      "exact_answer": "no"
    },
    {
      "body": "What is radiomics?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36639175",
        "http://www.ncbi.nlm.nih.gov/pubmed/35131965",
        "https://www.ncbi.nlm.nih.gov/pubmed/38565321",
        "https://www.ncbi.nlm.nih.gov/pubmed/39017760",
        "http://www.ncbi.nlm.nih.gov/pubmed/39453470",
        "http://www.ncbi.nlm.nih.gov/pubmed/36468301",
        "http://www.ncbi.nlm.nih.gov/pubmed/38286723",
        "http://www.ncbi.nlm.nih.gov/pubmed/34990929",
        "http://www.ncbi.nlm.nih.gov/pubmed/39472389",
        "http://www.ncbi.nlm.nih.gov/pubmed/34292365",
        "http://www.ncbi.nlm.nih.gov/pubmed/37108377",
        "http://www.ncbi.nlm.nih.gov/pubmed/34309893",
        "http://www.ncbi.nlm.nih.gov/pubmed/35339254",
        "http://www.ncbi.nlm.nih.gov/pubmed/28975929",
        "http://www.ncbi.nlm.nih.gov/pubmed/34862558",
        "http://www.ncbi.nlm.nih.gov/pubmed/22898692",
        "http://www.ncbi.nlm.nih.gov/pubmed/38717290",
        "http://www.ncbi.nlm.nih.gov/pubmed/31055615",
        "http://www.ncbi.nlm.nih.gov/pubmed/37714669",
        "http://www.ncbi.nlm.nih.gov/pubmed/32101448",
        "http://www.ncbi.nlm.nih.gov/pubmed/34213702",
        "http://www.ncbi.nlm.nih.gov/pubmed/34435228",
        "http://www.ncbi.nlm.nih.gov/pubmed/33264805",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046521",
        "http://www.ncbi.nlm.nih.gov/pubmed/32060219",
        "http://www.ncbi.nlm.nih.gov/pubmed/30627231",
        "http://www.ncbi.nlm.nih.gov/pubmed/30426318",
        "http://www.ncbi.nlm.nih.gov/pubmed/26344440",
        "http://www.ncbi.nlm.nih.gov/pubmed/27269645",
        "http://www.ncbi.nlm.nih.gov/pubmed/31470936",
        "http://www.ncbi.nlm.nih.gov/pubmed/38253201",
        "http://www.ncbi.nlm.nih.gov/pubmed/36411153",
        "http://www.ncbi.nlm.nih.gov/pubmed/38688932",
        "http://www.ncbi.nlm.nih.gov/pubmed/27296412",
        "http://www.ncbi.nlm.nih.gov/pubmed/34202096",
        "http://www.ncbi.nlm.nih.gov/pubmed/30430428",
        "http://www.ncbi.nlm.nih.gov/pubmed/34902669",
        "http://www.ncbi.nlm.nih.gov/pubmed/36527376",
        "http://www.ncbi.nlm.nih.gov/pubmed/31527578",
        "http://www.ncbi.nlm.nih.gov/pubmed/33913492",
        "http://www.ncbi.nlm.nih.gov/pubmed/31473947",
        "http://www.ncbi.nlm.nih.gov/pubmed/32142107",
        "http://www.ncbi.nlm.nih.gov/pubmed/37193607",
        "http://www.ncbi.nlm.nih.gov/pubmed/35489129",
        "http://www.ncbi.nlm.nih.gov/pubmed/31707435",
        "http://www.ncbi.nlm.nih.gov/pubmed/32859468",
        "http://www.ncbi.nlm.nih.gov/pubmed/39459547",
        "http://www.ncbi.nlm.nih.gov/pubmed/30247662",
        "http://www.ncbi.nlm.nih.gov/pubmed/37189155",
        "http://www.ncbi.nlm.nih.gov/pubmed/32993260",
        "http://www.ncbi.nlm.nih.gov/pubmed/38505882",
        "http://www.ncbi.nlm.nih.gov/pubmed/32504782",
        "http://www.ncbi.nlm.nih.gov/pubmed/39730762",
        "http://www.ncbi.nlm.nih.gov/pubmed/39728209",
        "http://www.ncbi.nlm.nih.gov/pubmed/32785796",
        "http://www.ncbi.nlm.nih.gov/pubmed/32265157",
        "http://www.ncbi.nlm.nih.gov/pubmed/36011048",
        "http://www.ncbi.nlm.nih.gov/pubmed/33145087",
        "http://www.ncbi.nlm.nih.gov/pubmed/34671399",
        "http://www.ncbi.nlm.nih.gov/pubmed/32157259",
        "http://www.ncbi.nlm.nih.gov/pubmed/29869488",
        "http://www.ncbi.nlm.nih.gov/pubmed/32642254",
        "http://www.ncbi.nlm.nih.gov/pubmed/34109326",
        "http://www.ncbi.nlm.nih.gov/pubmed/32249351",
        "http://www.ncbi.nlm.nih.gov/pubmed/36354876",
        "http://www.ncbi.nlm.nih.gov/pubmed/38256471"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "Radiomics is a rapidly developing field of research focused on the extraction of quantitative features from medical images, thus converting these digital images into minable, high-dimensional data, which offer unique biological information that can enhance our understanding of disease processes and provide clinical decision support.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36639175"
        },
        {
          "offsetInBeginSection": 449,
          "offsetInEndSection": 825,
          "text": "Radiomics is a process to extract high throughput data from medical images by using advanced mathematical and statistical algorithms. The radiomics process involves various steps i.e., image generation, segmentation of region of interest (e.g. a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection and finally prediction model development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35131965"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 368,
          "text": "Radiomics uses advanced mathematical analysis of pixel-level information from radiologic images to extract existing information in traditional imaging algorithms. It is intended to find imaging biomarkers related to the genomics of tumors or disease patterns that improve medical care by advanced detection of tumor response patterns in tumors and to assess prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38286723"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Radiomics is a newcomer field that has opened new windows for precision medicine. It is related to extraction of a large number of quantitative features from medical images, which may be difficult to detect visually.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34990929"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Radiomics represents the science of extracting and analyzing a multitude of quantitative features from medical imaging, revealing the quantitative potential of radiologic images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39472389"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 446,
          "text": "Radiomics involves extracting quantitative data from the images and assessing them to identify diagnostic or prognostic features such as tumor grade, resectability, tumor response to neoadjuvant therapy, and survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34292365"
        },
        {
          "offsetInBeginSection": 609,
          "offsetInEndSection": 1166,
          "text": "Radiomics is a novel advanced approach to imaging, extracting quantitative, and ideally, reproducible data from radiological images using sophisticated mathematical analysis, including disease-specific patterns, that could not be detected by the human eye. Along with radiomics, radiogenomics, defined as the integration of \"radiology\" and \"genomics\", is an emerging field exploring the relationship between specific features extracted from radiological images and genetic or molecular traits of a particular disease to construct adequate predictive models.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108377"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Radiomics is a relatively new word for the field of radiology, meaning the extraction of a high number of quantitative features from medical images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31650960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "\"Radiomics\" refers to the extraction and analysis of large amounts of advanced quantitative imaging features with high throughput from medical images obtained with computed tomography, positron emission tomography or magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898692"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Radiomics is a process that allows the extraction and analysis of quantitative data from medical images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34213702"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 539,
          "text": "Radiomics data are in a mineable form that can be used to build descriptive and predictive models relating image features to phenotypes or gene-protein signatures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898692"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28975929"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 379,
          "text": "Radiomics is a rapidly evolving field of research concerned with the extraction of quantitative metrics-the so-called radiomic features-within medical images. Radiomic features capture tissue and lesion characteristics such as heterogeneity and shape and may, alone or in combination with demographic, histologic, genomic, or proteomic data, be used for clinical problem solving.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32060219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Radiomics is a process that allows the extraction and analysis of quantitative data from medical images. It is an evolving field of research with many potential applications in medical imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34213702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 512,
          "text": "Radiomics is a new concept that has been functioning in medicine for only a few years. This idea, created recently, relies on processing innumerable quantities of metadata acquired from every examination, followed by extraction thereof from relevant imaging examinations, such as computer tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) images, by means of appropriate created algorithms. The extracted results have great potential and broad possibilities of application.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30627231"
        },
        {
          "offsetInBeginSection": 278,
          "offsetInEndSection": 483,
          "text": "Radiomics allow qualitative and quantitative performance analyses with high throughput extraction of numeric radiologic data to obtain predictive or prognostic information from patients treated for cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26344440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 602,
          "text": "Radiomics is the quantitative analysis of standard-of-care medical imaging; the information obtained can be applied within clinical decision support systems to create diagnostic, prognostic, and/or predictive models. Radiomics analysis can be performed by extracting hand-crafted radiomics features or via deep learning algorithms. Radiomics has evolved tremendously in the last decade, becoming a bridge between imaging and precision medicine. Radiomics exploits sophisticated image analysis tools coupled with statistical elaboration to extract the wealth of information hidden inside medical images,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34309893"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 358,
          "text": "Radiomics is an emerging field in quantitative imaging that uses advanced imaging features to objectively and quantitatively describe tumour phenotypes. Radiomic features have recently drawn considerable interest due to its potential predictive power for treatment outcomes and cancer genetics, which may have important applications in personalized medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269645"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 327,
          "text": "Radiomics - the high-throughput computation of quantitative image features extracted from medical imaging modalities- can be used to aid clinical decision support systems in order to build diagnostic, prognostic, and predictive models, which could ultimately improve personalized management based on individual characteristics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31470936"
        },
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 317,
          "text": "Radiomics is the process of extracting visually imperceptible features from radiographic medical images using data-driven algorithms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411153"
        },
        {
          "offsetInBeginSection": 449,
          "offsetInEndSection": 582,
          "text": "Radiomics is a process to extract high throughput data from medical images by using advanced mathematical and statistical algorithms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35131965"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 405,
          "text": "Radiomics, a new methodology to extract quantitative information from medical images, could contribute to characterizing the individual cancer phenotype already before treatment in a fast and non-invasive way.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38688932"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 507,
          "text": "Radiomics, a specific method generating high-throughput extraction of a tremendous amount of quantitative imaging data using data-characterization algorithms, has shown great potential in individuating imaging biomarkers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34202096"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 663,
          "text": "Radiomics, in its two forms \"handcrafted and deep,\" is an emerging field that translates medical images into quantitative data to yield biological information and enable radiologic phenotypic profiling for diagnosis, theragnosis, decision support, and monitoring.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32101448"
        },
        {
          "offsetInBeginSection": 664,
          "offsetInEndSection": 806,
          "text": "Handcrafted radiomics is a multistage process in which features based on shape, pixel intensities, and texture are extracted from radiographs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32101448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Radiomics is a technique that extracts quantitative features from medical images using data-characterization algorithms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36527376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Radiomics refers to the process of extracting useful imaging features from radiological data.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36468301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Radiomics is a process of extraction and analysis of quantitative features from diagnostic images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30430428"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 267,
          "text": "Radiomics is a method that extracts a large number of features from radiographic medical images using data-characterisation algorithms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34902669"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Radiomics is a method to extract detailed information from diagnostic images that cannot be perceived by the naked eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39453470"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "Radiomics is a rapidly developing field of research focused on the extraction of quantitative features from medical images, thus converting these digital images into minable, high-dimensional data, which offer unique biological information that can enhance our understanding of disease processes and provide clinical decision support",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36639175"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 274,
          "text": "Radiomics refers to automated extraction of a large number of quantitative features from medical images for characterization of underlying pathologies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339254"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Radiomics is an emerging discipline that aims to make intelligent predictions and derive medical insights based on quantitative features extracted from medical images as a means to improve clinical diagnosis or outcome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33913492"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Radiomics is an emerging field which extracts quantitative radiology data from medical images and explores their correlation with clinical outcomes in a non-invasive manner",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31473947"
        },
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 316,
          "text": "Radiomics is the process of extracting visually imperceptible features from radiographic medical images using data-driven algorithms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411153"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 404,
          "text": "Radiomics, a new methodology to extract quantitative information from medical images, could contribute to characterizing the individual cancer phenotype already before treatment in a fast and non-invasive way",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38688932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Radiomics is a novel image analysis technique, whereby voxel-level information is extracted from digital images and used to derive multiple numerical quantifiers of shape and tissue character",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32142107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Radiomics is an emerging approach to analyze clinical images with the purpose of revealing quantitative features that are unvisible to the naked eye",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37193607"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 372,
          "text": "Radiomics is characterized by the extraction of several quantitative imaging features which are not visible to the naked eye from conventional imaging modalities, and its correlation with specific relevant clinical endpoints, such as pathology, therapeutic response, and survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31707435"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 391,
          "text": "Radiomics, the quantitative feature extraction and analysis from medical images, offers useful imaging biomarkers that can reveal important information about the nature of diseases, how well patients respond to treatment and patient outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39459547"
        },
        {
          "offsetInBeginSection": 252,
          "offsetInEndSection": 571,
          "text": "Radiomics is the comprehensive analysis of massive numbers of medical images in order to extract a large number of phenotypic features (radiomic biomarkers) reflecting cancer traits, and it explores the associations between the features and patients\u0027 prognoses in order to improve decision-making in precision medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30247662"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 595,
          "text": "radiomics performs high-throughput feature extraction from medical images, which enables quantitative analysis of medical images and prediction of various clinical endpoints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37189155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Radiomics, as an emerging technique of omics, shows the pathophysiological information of images via extracting innumerable quantitative features from digital medical images.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32993260"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 508,
          "text": "Radiomics, a specific method generating high-throughput extraction of a tremendous amount of quantitative imaging data using data-characterization algorithms, has shown great potential in individuating imaging biomarkers. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34202096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Radiomics, the extraction and analysis of quantitative features from medical images, has emerged as a promising field in radiology with the potential to revolutionize the diagnosis and management of renal lesions. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38505882"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 589,
          "text": "Radiomics, a method for the high throughput extraction of hand-crafted features from medical images, and deep learning -the data driven modeling techniques based on the principles of simplified brain neuron interactions, are the most researched quantitative imaging techniques.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32504782"
        },
        {
          "offsetInBeginSection": 70,
          "offsetInEndSection": 584,
          "text": "While radiological research has focused on scanner and sequence technologies in recent decades, applications of artificial intelligence are increasingly attracting scientific interest as they could substantially expand the possibility of objective quantification and diagnostic or prognostic use of image information.In this context, the term \"radiomics\" describes the extraction of quantitative features from imaging data such as those obtained from computed tomography or magnetic resonance imaging examinations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33264805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Radiomics is a method that extracts many features from medical images using various algorithms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730762"
        },
        {
          "offsetInBeginSection": 541,
          "offsetInEndSection": 679,
          "text": "Radiomics enables quantitative tissue phenotyping by extracting a high-dimensional set of descriptive texture features from medical images",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728209"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 566,
          "text": "The radiomics approach uses the radiological image for disease characterization by extracting quantitative radiomics features in the artificial intelligence (AI) environment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36011048"
        },
        {
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1526,
          "text": "Radiomics takes image analysis a step further by looking at imaging phenotype with higher order statistics in efforts to quantify intralesional heterogeneity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33145087"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Radiomics is a field that has been growing rapidly for the past ten years in medical imaging and more particularly in oncology where the primary objective is to contribute to personalised and predictive medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32859468"
        },
        {
          "offsetInBeginSection": 609,
          "offsetInEndSection": 865,
          "text": "Radiomics is a novel advanced approach to imaging, extracting quantitative, and ideally, reproducible data from radiological images using sophisticated mathematical analysis, including disease-specific patterns, that could not be detected by the human eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108377"
        },
        {
          "offsetInBeginSection": 1189,
          "offsetInEndSection": 1441,
          "text": "Radiomics is a recently coined term which refers to the process of imaging feature extraction and quantitative analysis of clinical diagnostic images to characterize the nodule phenotype beyond what is possible with conventional radiologist assessment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32642254"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 499,
          "text": "Radiomics refers to the extraction of valuable information by analyzing a large amount of standard data with high-throughput medical images mainly including computed tomography, positron emission tomography, magnetic resonance imaging, and ultrasound.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34671399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "Radiomics is a new frontier of medicine based on the extraction of quantitative data from radiological images which can not be seen by radiologist\u0027s naked eye and on the use of these data for the creation of clinical decision support systems. The long-term goal of radiomics is to improve the non-invasive diagnosis of focal and diffuse diseases of different organs by understanding links between extracted quantitative imaging data and the underlying molecular and pathological characteristics of lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 389,
          "text": "Radiomics is a quantitative approach to medical imaging, which aims at enhancing the existing data available to clinicians by means of advanced mathematical analysis. Through mathematical extraction of the spatial distribution of signal intensities and pixel interrelationships, radiomics quantifies textural information by using analysis methods from the field of artificial intelligence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32785796"
        },
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 643,
          "text": "Radiomics is an innovative imaging approach that extracts and analyzes non-visible quantitative imaging features, supporting the radiologist in the most challenging differential diagnosis when the best-known methods are not conclusive.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37568954"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 506,
          "text": "Radiomics, a specific method generating high-throughput extraction of a tremendous amount of quantitative imaging data using data-characterization algorithms, has shown great potential in individuating imaging biomarkers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34202096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "Radiomics - the high-throughput computation of quantitative image features extracted from medical imaging modalities- can be used to aid clinical decision support systems in order to build diagnostic, prognostic, and predictive models, which could ultimately improve personalized management based on individual characteristics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31470936"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Radiomics is an emerging field that involves extraction and quantification of features from medical images",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32249351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Radiomics analysis is a powerful tool aiming to provide diagnostic and prognostic patient information directly from images that are decoded into handcrafted features, comprising descriptors of shape, size and textural patterns",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36354876"
        }
      ],
      "id": "680a080b18b1e36f2e00014b",
      "ideal_answer": [
        "Radiomics is a rapidly developing field of research focused on the extraction of quantitative features from medical images, thus converting these digital images into minable, high-dimensional data, which offer unique biological information that can enhance our understanding of disease processes and provide clinical decision support. Technically speaking, the radiomics process involves various steps, such as image generation, segmentation of the region of interest (e.g., a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and finally, prediction model development.",
        "Radiomics is a process that involves extracting high throughput data from medical images using advanced mathematical and statistical algorithms. This process includes steps such as image generation, segmentation of the region of interest (e.g., a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and prediction model development. Radiomics explores the heterogeneity, irregularity, and size parameters of tumors to calculate thousands of advanced features. It has shown potential in the diagnosis and treatment outcome prediction in oncology, contributing to precision medicine by developing specific digital phenotypes of tumors.",
        "Radiomics is a field of research that focuses on extracting quantitative features from medical images to provide detailed insights into tissue and tumor characteristics. It involves a multi-step process including image acquisition, segmentation, feature extraction, and data analysis, often utilizing artificial intelligence and machine learning techniques. This process aids in the development of predictive models for clinical decision-making, particularly in oncology, by providing insights into tumor heterogeneity and treatment response.",
        "Radiomics is a field focused on extracting large amounts of quantitative data from standard medical images, such as CT, MRI, and PET scans. The process begins with image acquisition and segmentation, which helps isolate regions of interest like tumors or lesions. Next, various features—including texture, shape, intensity, and wavelet-based features—are extracted to reveal details about tissue characteristics and tumor heterogeneity that may not be visible to the human eye. These high-dimensional data are then analyzed using statistical techniques and machine learning algorithms to uncover patterns that can improve diagnostic accuracy, prognostication, and treatment response prediction. In essence, radiomics aims to advance personalized medicine by enabling better risk stratification and more tailored therapeutic decisions, particularly in oncology, where linking imaging phenotypes with genetic and clinical information holds significant promise.",
        "Radiomics is a rapidly developing field that focuses on extracting quantitative features from medical images using computer algorithms and advanced mathematical analysis. It converts digital images into minable, high-dimensional data, offering unique biological information. This technique involves high-throughput computation of quantitative image features, assessing textural features, and deriving numerical quantifiers of shape and tissue character at the voxel level. Radiomics aims to enhance existing clinical data by quantifying the spatial distribution of signal intensities and pixel interrelationships through artificial intelligence methods. It can be implemented through hand-crafted radiomic features extraction or deep learning algorithms. The resulting data is suitable for building descriptive and predictive models, relating image features to diagnostic, prognostic, or predictive information, and can aid clinical decision support systems.",
        "Radiomics is a rapidly evolving field focused on extracting quantitative features from medical images, transforming these images into high-dimensional, minable data. This process employs advanced mathematical and statistical algorithms to derive high-throughput data, offering unique biological insights that can enhance our understanding of disease processes and support clinical decision-making. The radiomics workflow typically involves image generation, segmentation of the region of interest (e.g., a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and prediction model development.",
        "Radiomics is a rapidly developing field of research that focuses on the extraction of quantitative features from medical images. This process converts digital images into minable, high-dimensional data, offering unique biological information that can enhance our understanding of disease processes and provide clinical decision support. The radiomics process involves several steps, including image generation, segmentation of the region of interest (such as a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and finally prediction model development.",
        "Radiomics is a rapidly advancing field that involves the extraction of quantitative features from medical images, converting them into high-dimensional data for analysis. It uses advanced mathematical techniques to identify imaging biomarkers linked to tumor genetics, disease progression, and treatment response. By analyzing pixel-level details in radiologic images, radiomics provides insights beyond traditional imaging methods, aiding in early detection, prognosis assessment, and personalized treatment strategies. Studies have applied radiomics across various cancers, utilizing modalities like MRI, PET/CT, and ultrasound to predict outcomes such as lymph node metastasis and survival. The process includes image segmentation, preprocessing, feature extraction, and model development, often integrated with clinical variables for enhanced decision-making. Despite challenges in standardization and validation, radiomics holds promise in precision medicine by offering non-invasive biomarkers that correlate imaging data with genetic and clinical information.",
        "Radiomics extracts quantitative features from medical images, converting them into high-dimensional data to enhance disease understanding and clinical decision-making. It involves steps like image generation, region segmentation, preprocessing, feature extraction, analysis, selection, and model development using mathematical and statistical algorithms.",
        "Radiomics is a rapidly developing field of research that focuses on the extraction of quantitative features from medical images. This process converts digital images into minable, high-dimensional data, providing unique biological information to enhance understanding of disease processes and offer clinical decision support. The process involves various steps, including image generation, segmentation of a region of interest (like a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and prediction model development.",
        "Radiomics is the process of extracting quantitative features from medical images using advanced mathematical and statistical algorithms. It involves various steps such as image generation, segmentation of the region of interest, and feature extraction, ultimately converting digital images into high-dimensional, minable data that provide unique biological insights and support clinical decision making.",
        "Radiomics is a rapidly developing field of research focused on the extraction of quantitative features from medical images, converting these digital images into high-dimensional data that offer unique biological information to enhance understanding of disease processes and provide clinical decision support. It involves advanced mathematical and statistical algorithms to analyze images, including steps like image generation, segmentation of regions of interest (e.g., tumors), preprocessing, feature extraction, analysis, selection, and prediction model development.",
        "Radiomics is a rapidly evolving field that focuses on extracting quantitative features from medical images, transforming these images into high-dimensional data that can provide valuable biological insights. This process involves several steps, including image generation, segmentation of regions of interest (such as tumors), preprocessing, feature extraction, analysis, and the development of predictive models. Radiomics can reveal imaging features that are not visible to the naked eye and correlate with various biological characteristics and clinical outcomes. It has applications across different medical domains, including oncology and cardiovascular disease, and is often enhanced by integrating machine learning algorithms to improve model accuracy and predictive performance.",
        "Radiomics is a research field that extracts quantitative features from medical images using advanced mathematical and statistical algorithms. This process transforms digital images into high-dimensional, minable data, offering unique biological insights that enhance our understanding of diseases. The radiomics workflow involves steps like image generation, segmentation of regions of interest such as tumors, image preprocessing, and feature extraction.",
        "Radiomics is a research field focused on extracting quantitative, high-dimensional data from medical images using advanced mathematical and statistical algorithms. This process converts images into minable datasets to uncover biological insights, enhance disease understanding, and support clinical decision-making. Key steps include image generation, segmentation of regions of interest (e.g., tumors), preprocessing, feature extraction, analysis, and predictive model development. It aims to identify patterns imperceptible to the human eye for diagnostic, prognostic, or therapeutic applications.",
        "Radiomics is a field that involves extracting detailed quantitative features from medical images. This process converts digital images into high-dimensional data, which can be analyzed to provide unique biological insights. By using advanced mathematical and statistical algorithms, radiomics facilitates steps such as image segmentation, feature extraction, and model development. These analyses enhance our understanding of disease processes and support clinical decision-making by offering valuable information from medical imaging data.",
        "Radiomics is an automated workflow that converts medical images into quantitative, high-dimensional data by performing image acquisition, preprocessing, segmentation of regions of interest, feature extraction and feature selection or model building. Using advanced computational algorithms, it captures metrics such as intensity, shape and texture from CT, MRI, PET and other scans. These imaging biomarkers enable statistical or machine-learning models to reveal underlying biology, support diagnosis and prognosis, and guide personalized treatment planning.",
        "[\u0027Radiomics is a rapidly developing field of research that extracts high-throughput data from medical images using advanced mathematical and statistical algorithms. The process involves image generation, segmentation of the region of interest (e.g., a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and finally prediction model development. This process converts digital images into minable, high-dimensional data, providing unique biological information that can enhance our understanding of disease processes and provide clinical decision support.\u0027]",
        "Radiomics is a rapidly evolving field that involves extracting quantitative features from medical images using advanced mathematical and statistical algorithms, transforming them into high-dimensional data. This process enables the derivation of biological insights and supports clinical decision-making by analyzing complex image patterns. The radiomics workflow includes image acquisition, region-of-interest segmentation (e.g., tumors), preprocessing, radiomic feature extraction, feature selection, and prediction model development. By converting imaging data into mineable information, radiomics enhances understanding of disease mechanisms and aids in personalized medicine, offering potential applications in diagnosis, prognosis, and treatment response monitoring. Its interdisciplinary approach integrates imaging, data science, and clinical expertise to uncover hidden biomarkers within medical images.",
        "Radiomics is a rapidly developing field focused on extracting quantitative features from medical images, transforming these images into high-dimensional data that provide valuable biological insights. This process involves several steps, including image generation, segmentation of regions of interest (such as tumors), image preprocessing, feature extraction, analysis, selection, and the development of predictive models. Radiomics aims to enhance understanding of disease processes, support clinical decision-making, and improve prognostic evaluations, particularly in oncology. Despite its potential, the integration of radiomics into routine clinical practice faces challenges such as low data reproducibility and variability among studies.",
        "Radiomics is a rapidly evolving field focused on extracting quantitative features from medical images, transforming these images into high-dimensional data that can provide valuable biological insights. The process involves several steps, including image generation, segmentation of regions of interest (such as tumors), image preprocessing, feature extraction, analysis, selection, and the development of predictive models. Radiomics aims to correlate these quantitative features with biological characteristics and clinical outcomes, potentially enhancing diagnostic accuracy and treatment strategies. It can utilize both traditional machine learning and deep learning methods to improve model performance and accuracy. Additionally, delta radiomics analyzes feature variations over time, particularly before and after therapy, to aid in clinical decision-making.",
        "Radiomics is a rapidly developing field focused on extracting quantitative features from medical images, transforming these images into high-dimensional data that provide valuable biological insights. This process involves several steps, including image generation, segmentation of regions of interest (like tumors), preprocessing, feature extraction, analysis, selection, and the development of predictive models. Radiomics aims to enhance understanding of disease processes, support clinical decision-making, and improve prognostic evaluations, particularly in areas like cancer diagnosis and treatment planning. Despite its potential, radiomics is still not widely used in clinical care, and challenges such as interpretability and standardization remain.",
        "Radiomics is a biomedical research field that uses advanced algorithms to extract quantitative features from medical images, following a multi-step process of image generation, segmentation, preprocessing, feature extraction, analysis, and model development. This process transforms images into high-dimensional, analyzable data, providing unique biological insights that enhance disease understanding and support informed clinical decision-making.",
        "Radiomics is a rapidly developing field of research focused on the extraction of quantitative features from medical images, thus converting these digital images into minable, high-dimensional data, which offer unique biological information that can enhance our understanding of disease processes and provide clinical decision support. The radiomics process involves various steps i.e., image generation, segmentation of region of interest (e.g. a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection and finally prediction model development.",
        "Radiomics is a cutting-edge field that involves extracting quantitative features from medical images using advanced algorithms. This process converts images into high-dimensional data, providing insights into disease processes and enhancing clinical decision-making. The steps include image generation, segmentation of regions like tumors, preprocessing, feature extraction, analysis, selection, and model development to aid in diagnostics and treatment planning.",
        "[\u0027Radiomics is a field of research that involves extracting quantitative features from medical images using advanced mathematical and statistical algorithms. This process transforms digital images into high-dimensional, minable data, providing unique biological insights that can improve understanding of disease processes and aid in clinical decision-making. The steps in radiomics include image generation, segmentation of regions of interest (such as tumors), image preprocessing, extraction of radiomic features, analysis and selection of features, and development of predictive models.\u0027]",
        "Radiomics is a rapidly developing field of research that involves extracting quantitative features from medical images using advanced mathematical and statistical algorithms. This process converts digital images into high-dimensional data, providing unique biological information that can enhance our understanding of disease processes and support clinical decision-making. The radiomics process typically includes steps such as image generation, segmentation of the region of interest (e.g., a tumor), image preprocessing, feature extraction, analysis, and selection, and finally, prediction model development.",
        "Radiomics is a field of medical research that transforms standard medical images into quantitative, high-dimensional data by extracting a large number of mathematical features. These features characterize tissue shape, texture, intensity and spatial relationships within a region of interest such as a tumor. The radiomics workflow typically includes image acquisition, segmentation of the target region, preprocessing to standardize data, computational feature extraction, selection of the most informative features and development of predictive or prognostic models for clinical decision support.",
        "Radiomics is a rapidly developing field of research focused on the extraction of quantitative features from medical images, converting these digital images into minable, high-dimensional data. This process extracts high throughput data from medical images by using advanced mathematical and statistical algorithms. This offers unique biological information that can enhance our understanding of disease processes and provide clinical decision support. The radiomics process involves image generation, segmentation of region of interest (e.g. a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection, and finally prediction model development."
      ]
    },
    {
      "body": "What is the cause of Fibromyalgia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38397989",
        "http://www.ncbi.nlm.nih.gov/pubmed/38404605",
        "http://www.ncbi.nlm.nih.gov/pubmed/38625666",
        "http://www.ncbi.nlm.nih.gov/pubmed/38983371",
        "http://www.ncbi.nlm.nih.gov/pubmed/18191454",
        "http://www.ncbi.nlm.nih.gov/pubmed/8788609",
        "http://www.ncbi.nlm.nih.gov/pubmed/36478185",
        "https://www.ncbi.nlm.nih.gov/pubmed/32120395",
        "https://www.ncbi.nlm.nih.gov/pubmed/38855963",
        "http://www.ncbi.nlm.nih.gov/pubmed/38772415",
        "http://www.ncbi.nlm.nih.gov/pubmed/39507010",
        "http://www.ncbi.nlm.nih.gov/pubmed/33918736",
        "http://www.ncbi.nlm.nih.gov/pubmed/39665371",
        "http://www.ncbi.nlm.nih.gov/pubmed/15074033",
        "http://www.ncbi.nlm.nih.gov/pubmed/19962494",
        "http://www.ncbi.nlm.nih.gov/pubmed/19225604",
        "http://www.ncbi.nlm.nih.gov/pubmed/22408215",
        "http://www.ncbi.nlm.nih.gov/pubmed/7850876",
        "http://www.ncbi.nlm.nih.gov/pubmed/39335365",
        "http://www.ncbi.nlm.nih.gov/pubmed/22842298",
        "http://www.ncbi.nlm.nih.gov/pubmed/25801019",
        "http://www.ncbi.nlm.nih.gov/pubmed/31982685",
        "http://www.ncbi.nlm.nih.gov/pubmed/20505625",
        "http://www.ncbi.nlm.nih.gov/pubmed/11386124",
        "http://www.ncbi.nlm.nih.gov/pubmed/17376601",
        "http://www.ncbi.nlm.nih.gov/pubmed/22811766",
        "http://www.ncbi.nlm.nih.gov/pubmed/27105483",
        "http://www.ncbi.nlm.nih.gov/pubmed/10025079",
        "http://www.ncbi.nlm.nih.gov/pubmed/18852906",
        "http://www.ncbi.nlm.nih.gov/pubmed/25135147",
        "http://www.ncbi.nlm.nih.gov/pubmed/19412502",
        "http://www.ncbi.nlm.nih.gov/pubmed/17653994",
        "http://www.ncbi.nlm.nih.gov/pubmed/20417529",
        "http://www.ncbi.nlm.nih.gov/pubmed/15102253",
        "http://www.ncbi.nlm.nih.gov/pubmed/11286673",
        "http://www.ncbi.nlm.nih.gov/pubmed/11692551",
        "http://www.ncbi.nlm.nih.gov/pubmed/19337439",
        "http://www.ncbi.nlm.nih.gov/pubmed/18852905",
        "http://www.ncbi.nlm.nih.gov/pubmed/39042252",
        "http://www.ncbi.nlm.nih.gov/pubmed/24373373",
        "http://www.ncbi.nlm.nih.gov/pubmed/39451237",
        "http://www.ncbi.nlm.nih.gov/pubmed/21993145",
        "http://www.ncbi.nlm.nih.gov/pubmed/29750060",
        "http://www.ncbi.nlm.nih.gov/pubmed/16029760",
        "http://www.ncbi.nlm.nih.gov/pubmed/20376669",
        "http://www.ncbi.nlm.nih.gov/pubmed/7942134",
        "http://www.ncbi.nlm.nih.gov/pubmed/32991532",
        "http://www.ncbi.nlm.nih.gov/pubmed/12861471",
        "http://www.ncbi.nlm.nih.gov/pubmed/23213512",
        "http://www.ncbi.nlm.nih.gov/pubmed/18589048",
        "http://www.ncbi.nlm.nih.gov/pubmed/20458566"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Fibromyalgia (FM) is a complex, chronic, widespread pain syndrome that can cause significant health and economic burden. Emerging evidence has shown that neuroinflammation is an underlying pathological mechanism in FM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38397989"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 352,
          "text": "Chronic conditions, sometimes referred to as functional somatic disorders, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), and more recently, long COVID (LC), affect millions of people worldwide. Yet, after decades of research and testing, the etiology and treatment for many of these diseases is still unclear. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38404605"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 92,
          "text": "The etiology of fibromyalgia (FM) is disputed, and there is no established cure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38625666"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 252,
          "text": "Chronic pain is a leading cause of disability worldwide. Fibromyalgia is a particularly debilitating form of widespread chronic pain. Fibromyalgia remains poorly understood, and treatment options are limited or moderately effective at best.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38983371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Fibromyalgia (FM) is a confusing and controversial diagnosis, characterized by widespread pain and tenderness at specific anatomical sites. The cause of this syndrome is unknown, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18191454"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Although the term \"fibromyalgia\" has appeared in the literature for 90 years, the disease may go unrecognized by clinicians. It is a devastating disease, more common than rheumatoid arthritis, yet its cause remains a mystery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8788609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 527,
          "text": "Fibromyalgia is characterized by chronic, widespread musculoskeletal pain and associated fatigue, sleep disturbances, and other cognitive and somatic symptoms. For many patients, these symptoms persist for years and lead to frequent health care use; for some, fibromyalgia and its symptoms can be debilitating. Although many treatments are available, management remains challenging. This article highlights the clinical features of fibromyalgia, discusses diagnostic criteria and their evolution, and reviews treatment options.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/32120395"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1028,
          "text": "This in-depth review of fibromyalgia (FM), which is a complex condition characterised by chronic pain, fatigue, sleep disturbances, and a spectrum of diagnostically and therapeutically challenging symptoms, underlines the need for a comprehensive and integrated approach that also takes into account the psychological factors affecting patient responses. We focus on the substantial impact that environmental factors (climatic variations, air pollution, electromagnetic field exposure, physical and emotional traumas, dietary patterns, and infections) have on the manifestation and intensity of symptoms, and advocate personalised, holistic treatment of patients\u0027 psychological and environmental sensitivities by suggesting the benefits of tailored dietary and stress management. We also call for further research into the complex interplay of environmental, biological and psychological factors influencing FM in order to develop more effective individualised treatments that are capable of enhancing patient care and outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38855963"
        },
        {
          "offsetInBeginSection": 391,
          "offsetInEndSection": 428,
          "text": "The cause of fibromyalgia is unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15074033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "BACKGROUND: Fibromyalgia is a disease process without an obvious etiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27790019"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "OBJECTIVE: The etiology of fibromyalgia is unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16940616"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Fibromyalgia has always struggled to be taken seriously. The vague mixture of aches, pains, stiffness and fatigue with no clear clinical or investigational findings has led many to doubt its very existence. Evidence is accumulating, however, of demon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22408215"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The conclusion is that no one single mechanism can explain FMS and is thus in that sense a compromise. FMS in some patients may start in the muscle, in other patients in the brain. The combination of peripheral and central factors is the key to the p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7850876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Fibromyalgia (FM) is a complex chronic musculoskeletal pain disorder with an elusive pathogenesis, with a strong implication of immune interactions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39507010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Fibromyalgia (FM) is a widespread musculoskeletal pain associated with psychological disturbances, the etiopathogenesis of which is still not clear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39335365"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 676,
          "text": "It is known that fibromyalgia is caused by a central sensitization phenomenon characterized by the dysfunction of neuro-circuits, which involves the perception, transmission and processing of afferent nociceptive stimuli, with the prevalent manifestation of pain at the level of the locomotor system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33918736"
        },
        {
          "offsetInBeginSection": 186,
          "offsetInEndSection": 403,
          "text": "Fibromyalgia is now believed to be, at least in part, a disorder of central pain processing that produces heightened responses to painful stimuli (hyperalgesia) and painful responses to nonpainful stimuli (allodynia).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19962494"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Fibromyalgia (FM) is a chronic disorder caused by a dysfunction of central nervous system sensitization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22842298"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 237,
          "text": " fibromyalgia, a pain condition caused predominantly by central nervous system dysfunction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25801019"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 220,
          "text": " Fibromyalgia is a debilitating condition characterized by chronic widespread pain. It is believed to be caused by dysfunction of the central nervous system (CNS) but current treatments are largely ineffective",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31982685"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 313,
          "text": "The cause of FMS is unknown and its pathogenesis is complex and not well understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20505625"
        },
        {
          "offsetInBeginSection": 395,
          "offsetInEndSection": 465,
          "text": "The aetiology and pathogenesis of fibromyalgia still remain uncertain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11386124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Fibromyalgia syndrome (FMS) is a condition of chronic muscle pain and fatigue of unknown etiology and pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17376601"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 393,
          "text": "The etiology of fibromyalgia remains unknown, but recent advances and discoveries have helped to unravel some of the mysteries of this disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811766"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 316,
          "text": "Fibromyalgia syndrome (FMS) is a clinical disorder predominant in females with unknown etiology and medically unexplained symptoms (MUS), similar to other afflictions, including irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), post-traumatic stress disorder (PTSD), Gulf War illness (GFI), and others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27105483"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Fibromyalgia syndrome (FMS) is a common chronic condition of widespread pain with causal mechanisms that are largely unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18852906"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Fibromyalgia syndrome (FMS) is a common chronic musculoskeletal pain disorder of unknown etiology and characterized by generalized body pain, hyperalgesia, and other functional and emotional comorbidities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25135147"
        },
        {
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1059,
          "text": "The precise mechanisms whereby patients with RA develop fibromyalgia are unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36478185"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 392,
          "text": "The etiology of fibromyalgia remains unknown, but recent advances and discoveries have helped to unravel some of the mysteries of this disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811766"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 524,
          "text": "f multiple tender points. Despite intensifying research, the etiology of fibromyalgia has remained unclear. Importantly, neither infections, trauma, nor psychiatric abnormalities consistently precede the onset of pain in p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15102253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Fibromyalgia syndrome (FMS) is a common chronic musculoskeletal pain disorder of unknown etiology and characterized by generalized body pain, hyperalgesia, and other functional and emotional comorbidities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25135147"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Juvenile primary fibromyalgia syndrome (JPFS) is a common musculoskeletal pain syndrome of unknown etiology characterized by widespread persistent pain, sleep disturbance, fatigue, and the presence of multiple discrete tender points on physical examination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11286673"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Fibromyalgia syndrome is a chronic, painful musculoskeletal disorder of unknown etiology and/or pathophysiology",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19337439"
        },
        {
          "offsetInBeginSection": 397,
          "offsetInEndSection": 527,
          "text": "Fibromyalgia syndrome (FMS) is not a disease. Neither a defined pathology nor specific etiological mechanisms have been documented",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10025079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "PURPOSE: Fibromyalgia is a syndrome of unknown origin with a high prevalence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain whose cause is unknown and whose risk factors are poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "PURPOSE: Fibromyalgia is a syndrome of unknown origin with a high prevalence. Multimodal approaches seem to be the treatment of choice in fibromyalgia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain whose cause is unknown and whose risk factors are poorly understood. It is often comorbid with rheumatoid and other pain disorders as well as psychiatric disorders such as anxiety and depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 410,
          "text": "Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain whose cause is unknown and whose risk factors are poorly understood. It is often comorbid with rheumatoid and other pain disorders as well as psychiatric disorders such as anxiety and depression. Although they are not officially approved for this indication, antiepileptics and antidepressants are often used to treat fibromyalgia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "PURPOSE: Fibromyalgia is a syndrome of unknown origin with a high prevalence. Multimodal approaches seem to be the treatment of choice in fibromyalgia. A multidisciplinary program was developed and implemented for patients with fibromyalgia in the primary care setting",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994"
        },
        {
          "offsetInBeginSection": 319,
          "offsetInEndSection": 475,
          "text": "The etiology of FM is not completely understood and the syndrome is influenced by factors such as stress, medical illness, and a variety of pain conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18852905"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 572,
          "text": "Fibromyalgia (FM) is a complex and common syndrome characterized by chronic widespread pain, fatigue, sleep disturbances, and various functional symptoms without clear structural or pathological causes. Affecting approximately 1-5% of the global population, with a higher prevalence in women, FM significantly impacts patients\u0027 quality of life, often leading to considerable healthcare costs and loss of productivity. Despite its prevalence, the etiology of FM remains elusive, with genetic, environmental, and psychological factors, including nutrition, being implicated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39042252"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Fibromyalgia (FM) syndrome is a chronic disease with unknown etiology, characterised by widespread pain and fatigue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373373"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 152,
          "text": "Fibromyalgia (FM) is characterized by chronic pain and a complex array of symptoms, with neuroinflammation implicated in its pathophysiology",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39451237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Fibromyalgia syndrome is a chronic disease of widespread and debilitating pain whose cause is unknown and whose risk factors are poorly understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "PURPOSE: Fibromyalgia is a syndrome of unknown origin with a high p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17653994"
        },
        {
          "offsetInBeginSection": 524,
          "offsetInEndSection": 659,
          "text": "Although the etiology of fibromyalgia remains unclear, evidences suggest that biologic, genetic and environmental factors are involved.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21993145"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "OBJECTIVES: Fibromyalgia is a disease of unknown origin in which sleep involvement is very prevalent, and one of the main symptoms, even as preval",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35485408"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Fibromyalgia (FM) is a chronic pain syndrome with unknown etiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20417529"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 280,
          "text": "Fibromyalgia (FM) syndrome is a chronic condition causing pain, affecting approximately 0.5%-6% of the developed countries\u0027 population, and on average, 2% of the worldwide population. Despite the large amount of scientific literature available, the FM etiology is still uncertain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29750060"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 323,
          "text": "Fibromyalgia or fibromyalgic syndrome (FMS) is a clinical picture of unknown origin that is characterized by generalized, incapacitating and chronic pain together with the demonstration in the physical examination of previously defined points in which moderate pressure causes pain, called fibromyalgia tender points (FTP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16029760"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Fibromyalgia syndrome (FMS) is characterized by systemic pain of unknown etiology and is often accompanied by various psychological symptoms. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20376669"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Fibromyalgia (FM) is a very frequent syndrome of unknown cause, characterized by generalized pain, fatigue and a number of tender points to palpation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7942134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "BACKGROUND: Fibromyalgia (FM) is a complex syndrome to diagnose and treat because of its unknown etiology. However, previous studies reported that patients with FM experience oxida",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32991532"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 333,
          "text": "As with most chronic illnesses, the causes of fibromyalgia are unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19225604"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 157,
          "text": "The cause of FMS is unknown and its risk factors are poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12861471"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 296,
          "text": "The etiology of fibromyalgia is still unclear: if central sensitization is considered to be the main mechanism involved, then many other factors, genetic, immunological, and hormonal, may play an important role",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23213512"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 441,
          "text": "While the etiology of fibromyalgia is unclear, accumulating data suggest that disordered central pain processing likely plays a role in the pathogenesis of symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18589048"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Fibromyalgia syndrome (FMS) is a condition of chronic muscle pain and fatigue of unknown etiology and pathogenesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17376601"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Fibromyalgia syndrome (FMS) is characterized by systemic pain of unknown etiology and is often accompanied by various psychological symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20376669"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Fibromyalgia syndrome (FMS) is a common chronic condition of widespread pain with causal mechanisms that are largely unknown",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18852906"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "BACKGROUND: Fibromyalgia syndrome (FMS) is a disease of unknown pathogenesis characterized by chronic musculos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20458566"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 396,
          "text": " fibromyalgia symptoms. However, the precise mechanisms by which oxidative stress contributes to fibromyalgia-ind",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38772415"
        }
      ],
      "type": "factoid",
      "id": "6810db0a353a4a2e6b000014",
      "ideal_answer": [
        "Fibromyalgia (FM) is a complex, chronic, widespread pain syndrome that can cause significant health and economic burden. Emerging evidence has shown that neuroinflammation is an underlying pathological mechanism in FM, but the actual cause is poorly understood and thus still unknown.",
        "The cause of Fibromyalgia is unknown.",
        "Fibromyalgia is a complex chronic condition primarily characterized by widespread musculoskeletal pain accompanied by fatigue, sleep disturbances, and cognitive symptoms. The exact cause of fibromyalgia remains unclear, but it is generally considered to involve a combination of genetic, neurobiological, and environmental factors. This multifactorial etiology suggests that fibromyalgia results from the interaction of biological and psychological factors, potentially triggered by events such as physical trauma, psychological stress, or illness. The condition is marked by an abnormal pain processing pathway, where there may be an increased sensitivity to pain signals and an overactive response in the central nervous system. Research continues to explore the precise mechanisms underlying these processes, aiming to better understand the pathophysiology of the disorder (PMID 32120395; PMID 33024295). Despite extensive studies, the pathogenesis of fibromyalgia is not fully understood, and it is often diagnosed based on clinical criteria after excluding other potential causes of chronic pain. This highlights the need for further research to unravel the complex biological and environmental interactions contributing to the development of fibromyalgia. (PMID 32120395) (PMID 25769552)",
        "The cause of Fibromyalgia is unknown. It is considered a multifactorial disorder and likely the result of various pathogenetic factors and pathophysiological mechanisms.",
        "The cause of fibromyalgia is not fully understood, but it is believed to involve a combination of genetic predisposition, environmental factors, and alterations in central nervous system pathways leading to heightened pain sensitivity.",
        "The cause of fibromyalgia is not fully understood, but it is believed to involve a combination of genetic predisposition, psychological factors, central nervous system alterations, and possibly peripheral nervous system components, along with systemic inflammation.",
        "The exact cause of fibromyalgia is not fully understood, but it is believed to involve a combination of biological, genetic, and environmental factors.",
        "The cause of fibromyalgia remains elusive and is characterized by a combination of genetic predisposition, personal experiences, emotional-cognitive factors, and a biopsychological ability to cope with stress, with no specific laboratory findings or diagnostic tests identifying an alternative cause.",
        "The cause of Fibromyalgia is multifactorial, involving an interplay between biological (e.g., central sensitization, sleep dysfunction) and psychosocial factors (e.g., emotional trauma, stress, vulnerability, childhood difficulties), rather than a single, identifiable cause.",
        "The exact cause of fibromyalgia is unknown, but it is believed to involve a combination of genetic, biological, and environmental factors. It is considered a central sensitivity syndrome where central sensitization is regarded as the cause of pain.",
        "Despite decades of research, the exact cause of Fibromyalgia remains unknown. The disease is characterized by widespread pain and tenderness at specific anatomical sites, but the underlying mechanism is still a mystery.",
        "The cause of fibromyalgia (FM) remains unknown, despite decades of research. It\u0027s a complex, chronic, widespread pain syndrome and a devastating disease, with emerging evidence suggesting neuroinflammation may be a contributing factor.",
        "Fibromyalgia (FM) is a complex, chronic, widespread pain syndrome that can cause significant health and economic burden. Emerging evidence has shown that neuroinflammation is an underlying pathological mechanism in FM.",
        "The cause of Fibromyalgia is unknown. It is considered a multifactorial disorder and the common final product of various etiological factors and pathophysiological mechanisms. It is likely that multiple mechanisms give rise to symptom expression.",
        "Fibromyalgia is a complex condition, and its cause remains unknown, with ongoing research and debate about its underlying mechanisms.",
        "The cause of Fibromyalgia is unknown, but emerging evidence suggests neuroinflammation as an underlying pathological mechanism.",
        "The cause of fibromyalgia is unknown, and its etiology is disputed.",
        "Fibromyalgia (FM) is a complex chronic pain syndrome characterized by widespread pain and tenderness at specific anatomical sites. Despite extensive research, the exact cause of Fibromyalgia remains unclear and is a subject of ongoing debate among medical professionals. \n\nThe condition is associated with neuroinflammation, which suggests that inflammation in the nervous system may play a role in its pathology. However, this does not establish a definitive cause but rather points to potential mechanisms underlying the symptoms.\n\nFibromyalgia is often grouped with other chronic conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID, all of which share the characteristic of having unclear etiologies. This grouping underscores the complexity and mystery surrounding Fibromyalgia\u0027s origins.\n\nIn summary, while there are theories about potential mechanisms, including neuroinflammation, the cause of Fibromyalgia remains elusive. Further research is necessary to better understand this condition and develop effective treatments.",
        "The cause of Fibromyalgia is \"unknown\".",
        "The cause of Fibromyalgia is currently unknown; its etiology remains disputed and poorly understood despite extensive research.",
        "The cause of fibromyalgia remains unknown",
        "The cause of fibromyalgia (FM) is unknown and remains a mystery.",
        "The cause of Fibromyalgia is disputed and not yet fully understood.",
        "The cause of fibromyalgia (FM) is unknown and disputed.",
        "The cause of Fibromyalgia is currently unknown and disputed, with neuroinflammation being a potential factor.",
        "The cause of fibromyalgia is unknown and disputed, with various pathogenetic factors and pathophysiological mechanisms suggested.",
        "The cause of fibromyalgia is unknown, and the etiology is disputed .",
        "The cause of fibromyalgia is unknown.",
        "The cause of Fibromyalgia is currently unknown or disputed, with its etiology remaining unclear despite ongoing research.",
        "The cause of fibromyalgia (FM) is currently unknown. It is a complex and chronic syndrome characterized by widespread pain and tenderness at specific anatomical sites. Despite decades of research, the etiology remains unclear.",
        "The cause of Fibromyalgia is not fully understood, but emerging evidence suggests that neuroinflammation may be an underlying pathological mechanism."
      ],
      "exact_answer": [
        [
          "unknown"
        ]
      ]
    },
    {
      "body": "Recommended prevention of osteoporosis in postmenopausal women.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38390196",
        "http://www.ncbi.nlm.nih.gov/pubmed/38674843",
        "http://www.ncbi.nlm.nih.gov/pubmed/38753892",
        "http://www.ncbi.nlm.nih.gov/pubmed/16448872",
        "http://www.ncbi.nlm.nih.gov/pubmed/20309524",
        "http://www.ncbi.nlm.nih.gov/pubmed/11894721",
        "http://www.ncbi.nlm.nih.gov/pubmed/1464700",
        "http://www.ncbi.nlm.nih.gov/pubmed/10389480",
        "http://www.ncbi.nlm.nih.gov/pubmed/1673944",
        "http://www.ncbi.nlm.nih.gov/pubmed/9008693",
        "http://www.ncbi.nlm.nih.gov/pubmed/11563832",
        "http://www.ncbi.nlm.nih.gov/pubmed/7839332",
        "http://www.ncbi.nlm.nih.gov/pubmed/10776395",
        "http://www.ncbi.nlm.nih.gov/pubmed/12905731",
        "http://www.ncbi.nlm.nih.gov/pubmed/20169039",
        "http://www.ncbi.nlm.nih.gov/pubmed/22716221",
        "http://www.ncbi.nlm.nih.gov/pubmed/23203733",
        "http://www.ncbi.nlm.nih.gov/pubmed/34688418",
        "http://www.ncbi.nlm.nih.gov/pubmed/22338309",
        "http://www.ncbi.nlm.nih.gov/pubmed/2690636",
        "http://www.ncbi.nlm.nih.gov/pubmed/12469706",
        "http://www.ncbi.nlm.nih.gov/pubmed/22120943",
        "http://www.ncbi.nlm.nih.gov/pubmed/12238732",
        "http://www.ncbi.nlm.nih.gov/pubmed/11402436",
        "http://www.ncbi.nlm.nih.gov/pubmed/38591743",
        "http://www.ncbi.nlm.nih.gov/pubmed/20443720",
        "http://www.ncbi.nlm.nih.gov/pubmed/8922659"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 2055,
          "offsetInEndSection": 2157,
          "text": "Traditional Chinese fitness exercises can significantly improve the BMD levels of postmenopausal women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38390196"
        },
        {
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1235,
          "text": "eggshell powder may be a good source of calcium for populations with low consumption of milk and dairy products. Additionally, functional HMRs fortified with eggshell powder and vitamin D can be a good dietary strategy for bone health",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38674843"
        },
        {
          "offsetInBeginSection": 998,
          "offsetInEndSection": 1301,
          "text": "All postmenopausal women can benefit from nonpharmacologic interventions to reduce the risk of fracture, including a balanced diet with adequate intake of calcium and vitamin D, regular exercise, measures to prevent falls or to minimize their impact, smoking cessation, and moderation of alcohol intake.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16448872"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 415,
          "text": "Prevention of further loss of bone mass in postmenopausal women can be achieved if women take estrogen replacement therapy, consume adequate levels of calcium, exercise regularly, and practice healthy lifestyle behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1464700"
        },
        {
          "offsetInBeginSection": 443,
          "offsetInEndSection": 627,
          "text": "Medroxyprogesterone acetate appears efficacious in preventing postmenopausal osteoporosis, and may be especially useful in women with contraindications to estrogen replacement therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673944"
        },
        {
          "offsetInBeginSection": 37,
          "offsetInEndSection": 1971,
          "text": "well-defined disease, but summarizes women with different severity of changes in bone metabolism and different clinical complaints. The only common feature in women with \u0027postmenopausal osteoporosis\u0027 is the deficiency of estrogen. Postmenopausal women can be subdivided into four groups, according to their risk for fractures: 1. women without evident increase of fracture risk (bone mineral content between 0 and 2 SD of age-related normal range, no known risk factors from history); 2. women with possible increase of fracture risk (bone mineral content between 0 and -2 SD of age-related normal range, with or without known risk factors from history); 3. women with clear increase of fracture risk (bone mineral content below age-related normal range, with or without known risk factors from history); 4. women with already occurred fracture (manifest osteoporosis). Therapeutic intervention in postmenopausal women should be adapted to the risk for fracture. In all four groups a secondary prevention or basic therapy should be performed, focusing on calcium intake, vitamin D supply and sufficient physical activity. Calcium intake should be 1500 mg/day in women without estrogen substitution and 1000 mg in women with estrogen substitution. In patients living mainly inside or with malnutrition, a daily substitution of 500 E. Vitamin D3 is recommended. In group 2, regular control of bone mass is recommended to start additional estrogen replacement therapy, if accelerated loss of bone mass occurs. In group 3, estrogen replacement therapy is recommended urgently and is the therapy of first choice to prevent development of fractures. In group 4 (manifest osteoporosis), therapy should aim on improvement of the patient\u0027s symptoms and on increase of bone stability to avoid further fractures. The symptomatic therapy includes pain medications and an intensive physical therapy adapted to the patient\u0027s needs. Physical therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7839332"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 211,
          "text": "Exogenous estrogen may prevent postmenopausal bone loss, so to prevent postmenopausal osteoporosis and osteoporotic fracture.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12905731"
        },
        {
          "offsetInBeginSection": 514,
          "offsetInEndSection": 905,
          "text": "Hormone replacement therapy is the first choice in prevention of postmenopausal osteoporosis. Based on a careful evaluation of the needs of a postmenopausal woman as well as on the risk/benefit ratio derived from her individual risk factors, selective estrogen receptor modulators (raloxifene) or second generation bisphosphonates (alendronate) can be considered as alternative to estrogens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10389480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "For virtually all asymptomatic postmenopausal women, moderate exercise and supplementation with calcium and vitamin D are recommended. In addition, most postmenopausal women without contraindications would benefit from estrogen replacement therapy,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9008693"
        },
        {
          "offsetInBeginSection": 461,
          "offsetInEndSection": 563,
          "text": "Pharmacologic agents should be recommended in postmenopausal women who are at high risk for fractures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34688418"
        },
        {
          "offsetInBeginSection": 650,
          "offsetInEndSection": 850,
          "text": "Pharmacologic therapy is recommended in postmenopausal women with clinical risk factors for fracture and includes anti-resorptive agents such as bisphosphonates, hormone therapy, SERMs, and calcitonin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20309524"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 343,
          "text": "Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased fracture risk. Several therapeutic agents are now available to treat postmenopausal osteoporosis and prevent fractures. Combined calcium and vitamin D supplementation reduce the relative risk of non-vertebral fractures by about 18%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 343,
          "text": "Several therapeutic agents are now available to treat postmenopausal osteoporosis and prevent fractures. Combined calcium and vitamin D supplementation reduce the relative risk of non-vertebral fractures by about 18%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309"
        },
        {
          "offsetInBeginSection": 71,
          "offsetInEndSection": 244,
          "text": "Estrogen use by postmenopausal women, especially when started within 3 years of the last menstrual period, prevents bone loss and reduces the risk of osteoporotic fractures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2690636"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 250,
          "text": "Oestrogen replacement therapy remains the first choice for prevention of bone loss in early postmenopausal women with low bone density.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10776395"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "Two long-used interventions for reducing the morbidity and mortality associated with osteoporosis are postmenopausal hormone replacement therapy (HRT) and treatment with antiresorptive agents. Postmenopausal HRT works through prevention of osteoporosis, whereas antiresorptive agents, such as the bisphosphonates, reverse low bone mass.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12469706"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "For many years, hormone replacement therapy (HRT) was the mainstay for osteoporosis prevention in postmenopausal women until a large randomized clinical trial raised serious safety concerns. This resulted in a big drop in HRT use and its demotion by regulatory authorities to second-line treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22120943"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 205,
          "text": "Estrogen therapy has been shown to be effective in preventing postmenopausal bone loss and maintaining bone mineral density.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12238732"
        },
        {
          "offsetInBeginSection": 631,
          "offsetInEndSection": 726,
          "text": "Raloxifene is another SERM approved for the prevention of osteoporosis in postmenopausal women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11402436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38591743"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 510,
          "text": "Postmenopausal women need estrogen replacement, a selective estrogen receptor modulator (SERM), or a bisphosphonate to prevent bone loss. Alendronate, risedronate (bisphosphonates) and raloxifene (SERM) are approved for the prevention of bone loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11563832"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Tibolone, which is indicated for the relief of climacteric symptoms and the prevention of osteoporosis in postmenopausal women,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20443720"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 416,
          "text": "5 mg alendronate per day is suggested as a new option for prevention of postmenopausal osteoporosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11894721"
        },
        {
          "offsetInBeginSection": 518,
          "offsetInEndSection": 954,
          "text": "his review. AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22716221"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 487,
          "text": "dged edition. The present guidelines provide information for the managements of primary osteoporosis in postmenopausal women and men over 50 years old, a summary of the evidence for the treatment of secondary osteoporosis, and a summary of the evidence for the prevention of osteoporosis in y",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23203733"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Hormone replacement therapy (HRT) has been the method of choice for the prevention of postmenopausal osteoporosis since the early 1990s.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8922659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Estrogen replacement therapy (ERT) is recommended for postmenopausal women primarily for reduction of menopausal symptoms and prevention of osteoporosis and cardiovascular disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11343439"
        }
      ],
      "type": "list",
      "id": "67e2cfcf18b1e36f2e00009a",
      "ideal_answer": [
        "Prevention of osteoporosis in postmenopausal women include exercise, supplements of calcium and vitamin D, and pharmacological treatments such as denosumab and alendronate."
      ],
      "exact_answer": [
        [
          "Exercise"
        ],
        [
          "supplements of calcium"
        ],
        [
          "Vitamin D"
        ],
        [
          "denosumab"
        ],
        [
          "alendronate"
        ]
      ]
    },
    {
      "body": "What are the functions of astrocytes in the CNS?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31060341",
        "http://www.ncbi.nlm.nih.gov/pubmed/34888829",
        "http://www.ncbi.nlm.nih.gov/pubmed/25113122",
        "http://www.ncbi.nlm.nih.gov/pubmed/31470787",
        "http://www.ncbi.nlm.nih.gov/pubmed/37758010",
        "http://www.ncbi.nlm.nih.gov/pubmed/37176144",
        "http://www.ncbi.nlm.nih.gov/pubmed/36193573",
        "http://www.ncbi.nlm.nih.gov/pubmed/17265695",
        "http://www.ncbi.nlm.nih.gov/pubmed/37831013",
        "http://www.ncbi.nlm.nih.gov/pubmed/37916625",
        "http://www.ncbi.nlm.nih.gov/pubmed/39643639",
        "http://www.ncbi.nlm.nih.gov/pubmed/39348064",
        "https://www.ncbi.nlm.nih.gov/pubmed/28636962",
        "https://www.ncbi.nlm.nih.gov/pubmed/32042146",
        "https://www.ncbi.nlm.nih.gov/pubmed/35173313",
        "http://www.ncbi.nlm.nih.gov/pubmed/30791579",
        "http://www.ncbi.nlm.nih.gov/pubmed/37363320",
        "http://www.ncbi.nlm.nih.gov/pubmed/35546493",
        "http://www.ncbi.nlm.nih.gov/pubmed/39725239",
        "http://www.ncbi.nlm.nih.gov/pubmed/19373940",
        "http://www.ncbi.nlm.nih.gov/pubmed/24023412",
        "http://www.ncbi.nlm.nih.gov/pubmed/34259342",
        "http://www.ncbi.nlm.nih.gov/pubmed/26758544",
        "http://www.ncbi.nlm.nih.gov/pubmed/28150867",
        "http://www.ncbi.nlm.nih.gov/pubmed/22144298",
        "http://www.ncbi.nlm.nih.gov/pubmed/23093800",
        "http://www.ncbi.nlm.nih.gov/pubmed/22144302",
        "http://www.ncbi.nlm.nih.gov/pubmed/8203078",
        "http://www.ncbi.nlm.nih.gov/pubmed/39332912",
        "http://www.ncbi.nlm.nih.gov/pubmed/26721411",
        "http://www.ncbi.nlm.nih.gov/pubmed/26317476",
        "http://www.ncbi.nlm.nih.gov/pubmed/27026202",
        "http://www.ncbi.nlm.nih.gov/pubmed/25963996",
        "http://www.ncbi.nlm.nih.gov/pubmed/38339177",
        "http://www.ncbi.nlm.nih.gov/pubmed/30398075",
        "http://www.ncbi.nlm.nih.gov/pubmed/32768488",
        "http://www.ncbi.nlm.nih.gov/pubmed/19428820",
        "http://www.ncbi.nlm.nih.gov/pubmed/38435055",
        "http://www.ncbi.nlm.nih.gov/pubmed/29122627",
        "http://www.ncbi.nlm.nih.gov/pubmed/11596126",
        "http://www.ncbi.nlm.nih.gov/pubmed/39314847",
        "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
        "http://www.ncbi.nlm.nih.gov/pubmed/32903427",
        "http://www.ncbi.nlm.nih.gov/pubmed/30734296",
        "http://www.ncbi.nlm.nih.gov/pubmed/23110156",
        "http://www.ncbi.nlm.nih.gov/pubmed/32147775",
        "http://www.ncbi.nlm.nih.gov/pubmed/31991879",
        "http://www.ncbi.nlm.nih.gov/pubmed/20655735",
        "http://www.ncbi.nlm.nih.gov/pubmed/30524236",
        "http://www.ncbi.nlm.nih.gov/pubmed/39456137",
        "http://www.ncbi.nlm.nih.gov/pubmed/39603277",
        "http://www.ncbi.nlm.nih.gov/pubmed/39489601",
        "http://www.ncbi.nlm.nih.gov/pubmed/26635551",
        "http://www.ncbi.nlm.nih.gov/pubmed/34888833",
        "http://www.ncbi.nlm.nih.gov/pubmed/18383346",
        "http://www.ncbi.nlm.nih.gov/pubmed/19877496",
        "http://www.ncbi.nlm.nih.gov/pubmed/37219367",
        "http://www.ncbi.nlm.nih.gov/pubmed/33226087",
        "http://www.ncbi.nlm.nih.gov/pubmed/28636962",
        "http://www.ncbi.nlm.nih.gov/pubmed/32138223",
        "http://www.ncbi.nlm.nih.gov/pubmed/25287860",
        "http://www.ncbi.nlm.nih.gov/pubmed/24961523",
        "http://www.ncbi.nlm.nih.gov/pubmed/31321963",
        "http://www.ncbi.nlm.nih.gov/pubmed/32773177",
        "http://www.ncbi.nlm.nih.gov/pubmed/29270596",
        "http://www.ncbi.nlm.nih.gov/pubmed/38128844",
        "http://www.ncbi.nlm.nih.gov/pubmed/29180953",
        "http://www.ncbi.nlm.nih.gov/pubmed/26655603",
        "http://www.ncbi.nlm.nih.gov/pubmed/32006215",
        "http://www.ncbi.nlm.nih.gov/pubmed/36710937",
        "http://www.ncbi.nlm.nih.gov/pubmed/22745251",
        "http://www.ncbi.nlm.nih.gov/pubmed/33332631"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 567,
          "text": "Astrocytes outnumber neurons in the human brain, and they play a key role in numerous functions within the central nervous system (CNS), including glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defense against oxidative/nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid, and α-synuclein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31060341"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 699,
          "text": "Astroglia are a diverse group of cells in the central nervous system. They are of the ectodermal, neuroepithelial origin and vary in morphology and function, yet, they can be collectively defined as cells having principle function to maintain homeostasis of the central nervous system at all levels of organisation, including homeostasis of ions, pH and neurotransmitters; supplying neurones with metabolic substrates; supporting oligodendrocytes and axons; regulating synaptogenesis, neurogenesis, and formation and maintenance of the blood-brain barrier; contributing to operation of the glymphatic system; and regulation of systemic homeostasis being central chemosensors for oxygen, CO2 and Na+.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34888829"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Astrocytes are key cells for adequate brain formation and regulation of cerebral blood flow as well as for the maintenance of neuronal metabolism, neurotransmitter synthesis and exocytosis, and synaptic transmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31470787"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 552,
          "text": "Now, astrocytes\u0027 contribution to CNS physiology is appreciated as they are known to regulate ion and neurotransmitter levels, synapse formation and elimination, blood-brain barrier integrity, immune function, cerebral blood flow, and many more.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37758010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 384,
          "text": "Astrocytes are the main class of neuroglia, serving a wide range of adaptive functions in the mammalian nervous system. They interact with neurons, providing structural, metabolic and trophic support for them. In pathological circumstances, astrocytes have the potential to induce neuronal dysfunction, but they can also play a neuroprotective role, releasing neuronal growth factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17265695"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "text": "Astrocytes are central nervous system (CNS) glial cells with many important functions for normal development and neural functioning. They help control extracellular ion and neurotransmitter concentrations; provide neurotrophic support; are implicated in synapse formation, function, and pruning; and help maintain the blood-brain barrier.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26317476"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 381,
          "text": "Astrocytes are key cells for adequate brain formation and regulation of cerebral blood flow as well as for the maintenance of neuronal metabolism, neurotransmitter synthesis and exocytosis, and synaptic transmission. Many of these functions are intrinsically related to neurodegeneration, allowing refocusing on the role of astrocytes in physiological and neurodegenerative states.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31470787"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 763,
          "text": "Astrocytes are a major constituent of the central nervous system. These glia play a major role in regulating blood-brain barrier function, the formation and maintenance of synapses, glutamate uptake, and trophic support for surrounding neurons and glia. Therefore, maintaining the proper functioning of these cells is crucial to survival. Astrocyte defects are associated with a wide variety of neuropathological insults, ranging from neurodegenerative diseases to gliomas. Additionally, injury to the CNS causes drastic changes to astrocytes, often leading to a phenomenon known as reactive astrogliosis. This process is important for protecting the surrounding healthy tissue from the spread of injury, while it also inhibits axonal regeneration and plasticity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27026202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Astrocytes are the predominant cell type in the brain and perform key functions vital to CNS physiology, including blood brain barrier formation and maintenance, synaptogenesis, neurotransmission, and metabolic regulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963996"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 348,
          "text": "Key functions of astroglia include, but are not limited to, neurotransmitter recycling, ion buffering, immune modulation, neurotrophin secretion, neuronal synaptogenesis and elimination, and blood-brain barrier maintenance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30398075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 292,
          "text": "Growing evidence indicates that astrocytes cannot be just considered as passive supportive cells deputed to preserve neuronal activity and survival, but rather they are involved in a striking number of active functions that are critical to the performance of the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Astrocytes are the main cell type responsible for the regulation of brain homeostasis, including the maintenance of ion gradients and neurotransmitter clearance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32903427"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 367,
          "text": "Astrocytes maintain neuronal excitability through regulation of extracellular ion concentrations, as well as assisting and modulating synaptic transmission by uptake and catabolism of major neurotransmitters",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30734296"
        },
        {
          "offsetInBeginSection": 677,
          "offsetInEndSection": 957,
          "text": "Thus, astrocytes regulate the synaptic connectivity of the neuronal networks by supporting neurotransmitter metabolism, synaptogenesis, synaptic elimination and the synaptic plasticity that contributes to cognitive processing including learning, memory, emotionality and behaviour",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32768488"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 254,
          "text": "In the adult brain, astrocytes are known to intimately ensheath blood vessels and actively coordinate local neural activity and blood flow",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23110156"
        },
        {
          "offsetInBeginSection": 785,
          "offsetInEndSection": 1071,
          "text": "The most prevalent kind of glial cells in the central nervous system are called astrocytes. They have a unique significance in cerebral function because of their wide range of functions in maintaining homeostasis in the central nervous system, regulating synaptic plasticity, and so on.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725239"
        },
        {
          "offsetInBeginSection": 872,
          "offsetInEndSection": 1246,
          "text": "Astrocytes are the most abundant cells in the CNS, playing vital roles in maintaining CNS homeostasis (e.g. metabolic support to neurons, clearance of neurotransmitters, ion balance, modulation of synaptic functions and maintaining the structural integrity of the blood brain barrier (BBB). Therefore, any disruption of their function will have wide repercussions in the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32147775"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 342,
          "text": "During development and throughout adulthood, astrocytes have essential roles, such as providing neuron metabolic support, modulating synaptic function, and maintaining the blood-brain barrier (BBB",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39332912"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 708,
          "text": "In this way, astrocytes engage in crosstalk with neurons to mediate a variety of CNS processes including the regulation of extracellular matrix protein signaling, formation and maintenance of the blood-brain barrier (BBB), axon growth and guidance, homeostasis of the synaptic microenvironment, synaptogenesis, and the promotion of synaptic diversity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31991879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Astrocytes, one of the most numerous types of cells in the central nervous system, are crucial for potassium homeostasis, neurotransmitter uptake, synapse formation, regulation of blood-brain-barrier, and the development of the nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20655735"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "The astrocyte, a major glial cell type in the central nervous system (CNS), is widely regarded as a functionally diverse mediator of homeostasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39332912"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Astrocytes are the most abundant cell type in the central nervous system (CNS), providing critical roles in the overall maintenance and homeostasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30524236"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Astrocytes have critical functions throughout the central nervous system (CNS) and have emerged as regulators of synaptic development and function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31991879"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 290,
          "text": "astrocytes support neuronal functions, blood-brain barrier (BBB) homeostasis, and neurotransmitter uptake and metabolism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39348064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Astrocytes are the most numerous cell type within the central nervous system (CNS) and perform a variety of tasks, from axon guidance and synaptic support, to the control of the blood brain barrier and blood flow",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19373940"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Astrocytes perform critical homeostatic physiological functions in the central nervous system (CNS) and are robustly responsive to injury, inflammation, or infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 412,
          "text": "Astrocytes perform important homeostatic functions including regulation of the extracellular microenvironment, critical for the health of all brain cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39603277"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Astrocytes are known to modulate synaptogenesis or neuronal activities, thus participating in mental functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39643639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Astrocytes, the most heterogeneous glial cells in the central nervous system (CNS), execute a multitude of homeostatic functions and contribute to memory formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26635551"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 557,
          "text": "Astrocytes are the most diverse and numerous glial cell type in the central nervous system (CNS). They provide structural, nutritional, and metabolic support to neurons and regulate synaptic activity under normal conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34888833"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 411,
          "text": "Astrocytes perform important homeostatic functions including regulation of the extracellular microenvironment, critical for the health of all brain cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39603277"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 344,
          "text": "During development and throughout adulthood, astrocytes have essential roles, such as providing neuron metabolic support, modulating synaptic function, and maintaining the blood-brain barrier (BBB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39332912"
        },
        {
          "offsetInBeginSection": 491,
          "offsetInEndSection": 651,
          "text": "Astrocytes control many aspects of brain function. Regulation of extracellular glutamate concentration, potentially neurotoxic neurotransmitter, is fundamental.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19428820"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 549,
          "text": "Astrocytes cooperate with neurons on several levels, including neurotransmitter trafficking and recycling, ion homeostasis, energy metabolism, and defense against oxidative stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19877496"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 457,
          "text": "Astrocytes play integral roles in regulating and coordinating neural activity extending far beyond their metabolic support of neurons and other brain cell phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37219367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Astrocytes are a major type of glial cells that have essential functions in development and homeostasis of the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35546493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Astrocytes are the most abundant cells in the central nervous system (CNS) that provide nutrients, recycle neurotransmitters, as well as fulfill a wide range of other homeostasis maintaining functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287860"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 503,
          "text": "These observations have led to the suggestion that a major function of astrocytes in the CNS is to maintain the homeostatic environment, thus promoting the proper functioning of the neuronal network.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15472994"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Astrocytes play essential roles in development, homeostasis, injury, and repair of the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34259342"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 309,
          "text": "In addition to their role in the maintenance of CNS homeostasis and neuronal function, astrocytes are thought to participate in the regulation of innate and adaptive immune responses in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32959226"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The astrocyte, a major glial cell type in the central nervous system (CNS), is widely regarded as a functionally diverse mediator of homeostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39332912"
        },
        {
          "offsetInBeginSection": 611,
          "offsetInEndSection": 803,
          "text": "Astrocytes are one of the most abundant cell types in the central nervous system (CNS) and provide an array of essential homeostatic functions that are disrupted in neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39165755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "The astrocyte, a major glial cell type in the central nervous system (CNS), is widely regarded as a functionally diverse mediator of homeostasis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39332912"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 412,
          "text": "Over the last decade knowledge of the role of astrocytes in central nervous system (CNS) neuroinflammatory diseases has changed dramatically. Rather than playing a merely passive role in response to damage it is clear that astrocytes actively maintain CNS homeostasis by influencing pH, ion and water balance, the plasticity of neurotransmitters and synapses, cerebral blood flow, and are important immune cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32138223"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 831,
          "text": "In the CNS, astrocytes have been proposed to perform many functions. For example, they are supportive cells that provide guidance to newly formed migrating neurons and axons. They regulate the functions of endothelial cells at the blood brain barrier, provide nutrients, and maintain homeostasis including ionic balance within the CNS. More recently, dissecting the central role of astrocytes in mediating injury responses in the CNS, particularly the spinal cord, has become an area of considerable importance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22144302"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 445,
          "text": "astrocytes perform a variety of functions, including providing support for neuronal structures and energy metabolism, offering isolation and protection and influencing the formation, function and elimination of synapses. Because of these functions, astrocytes play an critical role in central nervous system (CNS) diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37831013"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 366,
          "text": "Astrocytes are the most abundant cells in the brain. They have many important functions in the central nervous system (CNS), including the maintenance of glutamate and ion homeostasis, the elimination of oxidative stress, energy storage in glycogen, tissue repair, regulating synaptic activity by releasing neurotransmitters, and participating in synaptic formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36193573"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 575,
          "text": "Astrocytes perform many homeostatic functions within the developing and adult CNS, including enhancing formation and maintenance of the blood-brain barrier, moderating neuronal connections through the tripartite synapse, and perhaps even offering intercellular communication independently of neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20857501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Astrocytes regulate fundamentally important functions to maintain central nervous system (CNS) homeostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24961523"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 565,
          "text": "Astrocytes are important cells of the CNS that not only provide structural support, but also modulate synaptic activity, regulate neuroinflammatory responses, maintain the blood-brain barrier, and supply energy to neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33496339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Astrocytes are abundant cells of the central nervous system (CNS) and are involved in processes including synapse formation/function, ion homeostasis, neurotransmitter uptake, and neurovascular coupling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34716617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 425,
          "text": "Astrocytes, one of the most abundant and heterogeneous types of glial cell in the brain and spinal cord, are responsible for various essential functions in the healthy central nervous system, including maintaining the blood brain barrier integrity, regulating neuron differentiation and supporting, nourishing, protecting, insulating and repairing neurons. They also fulfill a range of other homeostatic maintenance functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31321963"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 654,
          "text": "In the CNS, astrocytes have been proposed to perform many functions. For example, they are supportive cells that provide guidance to newly formed migrating neurons and axons. They regulate the functions of endothelial cells at the blood brain barrier, provide nutrients, and maintain homeostasis including ionic balance within the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22144302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Astrocytes are the most abundant glial cell in the central nervous system and are involved in multiple processes including metabolic homeostasis, blood brain barrier regulation and neuronal crosstalk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32773177"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Astrocytes are the major glial cell within the central nervous system (CNS) and have a number of important physiological properties related to CNS homeostasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11596126"
        },
        {
          "offsetInBeginSection": 477,
          "offsetInEndSection": 694,
          "text": "In the central nervous system (CNS), astrocytes are the most abundant and widely distributed glial cells which play multiple key roles in maintaining homeostasis of the CNS in physiological and pathological conditions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29270596"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 393,
          "text": "Astrocytes, the predominant glial cells in the central nervous system, play a vital role in maintaining brain homeostasis and supporting neuronal function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38128844"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 241,
          "text": "Astrocytes secrete a variety of factors that regulate synaptic connectivity and circuit formation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29180953"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 563,
          "text": "They display essential functions necessary to sustain the physiological processes of the CNS, including maintaining neuronal structure, forming the blood-brain barrier, coordinating neuronal metabolism, maintaining the extracellular environment, regulating cerebral blood flow, stabilizing intercellular communication, participating in neurotransmitter synthesis, and defending against oxidative stress et al",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36710937"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 522,
          "text": "They are important in brain functions as diverse as ion and fluid balance in the interstitial space, contributing to integrity of the neurovascular unit (blood-brain barrier), neurotransmitter regulation, metabolism of energy substrates and possibly even axonal regeneration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29122627"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Astrocytes, the most abundant cell population in the central nervous system (CNS), are essential for normal neurological function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22745251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "Astrocytes are a widely heterogenic cell population that play major roles in central nervous system (CNS) homeostasis and neurotransmission, as well as in various neuropathologies, including spinal cord injury (SCI), traumatic brain injury, and neurodegenerative diseases, such as amyotrophic lateral sclerosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38435055"
        },
        {
          "offsetInBeginSection": 495,
          "offsetInEndSection": 654,
          "text": "They regulate the functions of endothelial cells at the blood brain barrier, provide nutrients, and maintain homeostasis including ionic balance within the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22144302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Astrocytes fulfil many functions in the central nervous system (CNS), including contribution to the blood brain barrier, synapse formation, and trophic support",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332631"
        }
      ],
      "id": "680a081d18b1e36f2e00014c",
      "ideal_answer": [
        "Astrocytes outnumber neurons in the human brain and they have numerous functions within the central nervous system (CNS), including glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defense against oxidative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid and α-synuclein.",
        "Astrocytes are glial cells in the central nervous system (CNS) with several key functions. They provide structural support to neurons and help maintain the architecture of the CNS. Astrocytes are involved in the formation and maintenance of the blood-brain barrier, regulating the passage of substances from the bloodstream into the brain. They facilitate the transfer of nutrients, such as glucose, from blood vessels to neurons. Astrocytes regulate neurotransmitter levels in the synaptic cleft by uptaking excess neurotransmitters, like glutamate, to prevent excitotoxicity. They maintain ion balance in the extracellular space, particularly potassium ions, which is crucial for neuronal function. In response to CNS injury, astrocytes can proliferate and form a glial scar to isolate the damaged area and limit further injury. They influence synaptic transmission and plasticity, affecting neuronal communication and adaptation. Astrocytes also participate in the CNS immune response by releasing cytokines and other signaling molecules that modulate inflammation. These diverse functions underscore the critical role astrocytes play in maintaining CNS homeostasis and supporting neuronal function.",
        "Astrocytes, the most abundant glial cells in the central nervous system (CNS), perform a variety of essential functions that are crucial for maintaining CNS health and functionality. They are involved in:\n\n1. **Homeostasis and Support**: Astrocytes maintain the homeostasis of the CNS, providing structural support and regulating the extracellular environment.\n\n2. **Synaptic Function**: They modulate synaptic transmission and influence neuronal signaling through gliotransmitter-mediated neurotransmitter reuptake, impacting cognitive functions and behaviors.\n\n3. **Neural Circuit Development and Repair**: Astrocytes regulate the development, function, and repair of neural circuits during both development and adulthood, and they play a role in neurogenesis.\n\n4. **Metabolic Regulation**: They regulate blood flow, energy metabolism, and lipid metabolism, contributing to the overall metabolic support of neurons.\n\n5. **Blood-Brain Barrier Formation**: Astrocytes are integral to the formation and maintenance of the blood-brain barrier, which protects the brain from harmful substances.\n\n6. **Response to Injury**: In response to CNS insults, astrocytes undergo reactive astrogliosis, a process that can lead to the formation of glial scars and may contribute to CNS disorders.\n\n7. **Crosstalk with Other Cells**: Astrocytes interact with neurons, microglia, and other glial cells, playing a role in the integrity and maintenance of white matter and influencing inflammatory responses.\n\nOverall, astrocytes are key players in both the normal physiology of the CNS and in the pathophysiology of neurodegenerative diseases.",
        "Astrocytes are the central nervous system’s principal homeostatic and protective glial cells, controlling CNS balance from molecular to whole-organ levels. They maintain extracellular ion gradients and clear and metabolize neurotransmitters—especially glutamate—to preserve neuronal excitability. Via a variety of receptors and transporters they sense and adjust the neurochemical environment. They support neurons by supplying metabolic substrates and detoxifying ammonium and reactive oxygen species. By ensheathing blood vessels, they couple local neural activity to blood flow. At synapses they regulate transmission through transmitter uptake and catabolism and sculpt neural circuits by promoting synapse formation, elimination, and plasticity underlying learning and memory. Following injury, activated astrocytes release neurotrophic factors that drive tissue repair and sustain overall brain homeostasis.",
        "Astrocytes are the most abundant glial cells in the central nervous system (CNS) and perform a variety of essential functions crucial for maintaining brain health and function. They are involved in:\n\n1. **Support and Maintenance**: Astrocytes provide structural support to neurons, maintain the extracellular environment, and regulate ion balance, which is vital for neuronal function.\n\n2. **Synaptic Function**: They play a key role in synapse formation, maturation, and plasticity, influencing synaptic transmission and communication between neurons.\n\n3. **Blood-Brain Barrier Regulation**: Astrocytes contribute to the formation and maintenance of the blood-brain barrier, which protects the brain from harmful substances while allowing necessary nutrients to pass.\n\n4. **Metabolic Support**: They regulate energy metabolism and supply nutrients to neurons, ensuring their proper functioning.\n\n5. **Response to Injury**: In response to CNS insults, astrocytes undergo reactive astrogliosis, which can be beneficial (promoting repair and regeneration) or harmful (contributing to scarring and dysfunction).\n\n6. **Inflammation and Immune Response**: Astrocytes are involved in the CNS\u0027s immune response, modulating inflammation and participating in the repair processes following injury.\n\n7. **Homeostasis Maintenance**: They help maintain homeostasis in the CNS by regulating neurotransmitter levels and responding to changes in the cellular environment.\n\nOverall, astrocytes are integral to both the physiological functioning of the CNS and the response to pathological conditions, highlighting their diverse and critical roles in brain health and disease.",
        "Astrocytes are the most abundant glial cells in the central nervous system (CNS) and perform a variety of essential functions in both health and disease. Their key roles include:\n\n1. **Homeostasis Maintenance**: Astrocytes help maintain the physiological environment of the CNS, regulating ion balance, neurotransmitter levels, and metabolic support for neurons.\n\n2. **Support of Synaptic Function**: They participate in synaptic transmission and plasticity, influencing neuronal communication and circuit function.\n\n3. **Blood-Brain Barrier Formation**: Astrocytes contribute to the integrity and function of the blood-brain barrier, regulating the passage of substances between the blood and the CNS.\n\n4. **Response to Injury**: In response to CNS damage, astrocytes undergo reactive astrogliosis, which involves changes in morphology and function to aid in repair and recovery.\n\n5. **Regulation of Blood Flow and Metabolism**: They play a role in controlling cerebral blood flow and energy metabolism, ensuring that neurons receive adequate nutrients and oxygen.\n\n6. **Neurogenesis and Development**: Astrocytes are involved in the development of the CNS and can influence the generation of new neurons.\n\n7. **Interaction with Other Cells**: They interact with neurons, microglia, and other glial cells, contributing to the immune response and inflammation in the CNS.\n\nOverall, astrocytes are integral to maintaining CNS health and responding to pathological conditions, with their functions being context-dependent and potentially contributing to various neurodegenerative diseases.",
        "Astrocytes perform a variety of functions in the CNS, including maintaining glutamate, ion, and water homeostasis; defending against oxidative/nitrosative stress; storing energy; promoting mitochondria biogenesis; forming scars and repairing tissue through angiogenesis and neurogenesis; modulating synapses; regulating blood flow and the blood-brain barrier; supporting synaptic transmission control; influencing circadian rhythms, lipid metabolism, and lipoprotein secretion; and contributing to neurogenesis.",
        "Astrocytes, the most abundant glial cells in the central nervous system (CNS), perform a variety of essential functions that contribute to both health and disease. They play a crucial role in maintaining homeostasis and normal brain physiology, regulating the development, function, and repair of neural circuits throughout life. Astrocytes are involved in synaptic transmission, modulating neuronal signaling through gliotransmitter-mediated neurotransmitter reuptake. They also regulate blood flow, energy metabolism, and the formation of the blood-brain barrier. Additionally, astrocytes are key players in neurogenesis, lipid metabolism, and the regulation of circadian rhythms. In response to CNS insults, they exhibit reactive astrogliosis, which can lead to both protective and pathological outcomes in various CNS disorders. Recent studies have highlighted their functional heterogeneity and complex interactions with other cell types, underscoring their multifaceted roles in CNS inflammation and neurodegenerative diseases.",
        "Astrocytes are versatile cells that support overall CNS functionality. They provide structural support for neural organization, assist in synapse formation, and promote neural plasticity. They regulate neurotransmission by uptaking and releasing neurotransmitters, ensuring balanced neuronal signaling and preventing excitotoxicity. In addition, astrocytes help maintain metabolic homeostasis through energy and lipid metabolism and play a role in regulating blood flow while contributing to the formation and maintenance of the blood–brain barrier. They also serve as key players in the CNS immune response by modulating inflammation during both normal conditions and disease. In response to injury, astrocytes can become reactive, leading to changes that sometimes result in glial scar formation, which can both contain damage and potentially inhibit regeneration. Furthermore, they are involved in other functions, such as regulation of circadian rhythms, highlighting their diverse and essential contributions to maintaining healthy brain function.",
        "Astrocytes are versatile glial cells in the central nervous system (CNS) with several important functions. They support neuronal maturation during development and maintain homeostasis in the adult CNS, contributing to plasticity. Astrocytes influence synapse formation, function, and elimination, and are involved in controlling synaptic transmission. They maintain glutamate homeostasis, balancing uptake and release to optimize neuronal functions and prevent excitotoxicity, and support energy and lipid metabolism. Astrocytes contribute to the formation of the blood-brain barrier and regulate cerebral blood flow. They are involved in neurogenesis and the regulation of circadian rhythms. In neuroinflammatory disorders like multiple sclerosis, astrocytes regulate neuroinflammation and scar formation after injury. In pathological states, astrocytes become reactive, disrupting mature functions and reactivating immature properties, contributing to neurological pathogenesis. Astrocytes also respond to viral infections by producing cytokines, chemokines, and adhesion molecules, aiding in virus clearance and protection from demyelinating diseases. Additionally, type-2 astrocyte processes contribute to the structure of nodes of Ranvier, indicating a role in constructing myelin sheaths and nodes in the CNS.",
        "Astrocytes play a key role in numerous functions within the central nervous system (CNS), including glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defense against oxidative/ nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease- specific protein aggregates, such as β-amyloid, and α-synuclein.",
        "Astrocytes in the central nervous system (CNS) perform a wide array of functions critical for maintaining CNS health and function. These include maintaining homeostasis of glutamate, ions (Ca2+, K+), and water. Astrocytes also play a role in defending against oxidative/nitrosative stress, storing energy, facilitating mitochondria biogenesis, forming scars, and repairing tissue through angiogenesis and neurogenesis. Furthermore, they modulate synapses and communicate with surrounding neuronal and vascular systems after CNS injury. This communication leads to the clearance of disease-specific protein aggregates, such as -amyloid and -synuclein.",
        "Astrocytes outnumber neurons in the human brain, and they play a key role in numerous functions within the central nervous system (CNS), including glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defense against oxidative/nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid, and α-synuclein.",
        "Astrocytes play a crucial role in various functions within the central nervous system (CNS), including glutamate and ion (e.g., Ca²⁺, K⁺) homeostasis, water balance, defense against oxidative/nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair through angiogenesis and neurogenesis, and synapse modulation. Additionally, after CNS injury, astrocytes assist in clearing disease specific protein aggregates such as β amyloid and α synuclein by communicating with neuronal and vascular systems.",
        "Astrocytes perform several roles in the CNS, including hosting regulatory functions for glutamate, ion (e.g., Ca2+, K+) and water balance, defending against oxidative/nitrosative stress, energy storage, mitochondrial biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. Additionally, after CNS injury, astrocytes facilitate communication with neighboring neuronal and vascular systems to clear disease-specific protein aggregates.",
        "Astrocytes, which outnumber neurons in the human brain, play a significant role in the central nervous system (CNS). They are responsible for maintaining glutamate, ion (Ca2+, K+) and water homeostasis. Additionally, they defend against oxidative/nitrosative stress, store energy, and contribute to mitochondria biogenesis. Astrocytes also play a role in scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates such as β-amyloid and α-synuclein.",
        "Astrocytes play a multitude of roles in the CNS. They maintain glutamate, ion (Ca2+, K+) and water homeostasis, protect against oxidative/nitrosative stress, support energy storage and mitochondrial biogenesis, and contribute to scar formation. Additionally, they promote tissue repair through angiogenesis and neurogenesis, modulate synaptic activity, and aid in the clearance of disease-specific protein aggregates like β-amyloid and α-synuclein after CNS injury.",
        "Astrocytes play a key role in numerous functions within the central nervous system (CNS), including glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defense against oxidative/nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid, and α-synuclein.",
        "Astrocytes are homeostatic and protective glial cells that regulate extracellular K+ and Ca2+ gradients, clear glutamate, balance water via aquaporins, and detoxify ammonium, reactive oxygen and nitrogen species. They intimately ensheath blood vessels to coordinate local neural activity and blood flow, support neuronal metabolism, energy storage and mitochondria biogenesis, and modulate synaptic function and plasticity through uptake and catabolism of neurotransmitters and release of neurotrophic factors. After CNS injury, astrocytes alter their phenotype to form glial scars, promote angiogenesis and neurogenesis, and clear pathological protein aggregates, thus contributing to tissue repair and maintenance of brain homeostasis.",
        "Astrocytes regulate glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defend against oxidative/nitrosative stress, and support energy storage and mitochondria biogenesis. They also contribute to scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation, while clearing disease-specific protein aggregates after CNS injury.",
        "Astrocytes outnumber neurons in the human brain, and they play a key role in numerous functions within the central nervous system (CNS), including glutamate, ion (i.e., Ca2+, K+) and water homeostasis, defense against oxidative/nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation.",
        "[\u0027Astrocytes are crucial for maintaining homeostasis in the CNS, regulating glutamate, ion (Ca2+, K+) and water levels, providing energy, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid and α-synuclein.\u0027]",
        "Astrocytes, the most abundant cells in the human brain, perform critical functions in the central nervous system (CNS). They regulate glutamate, ion (Ca²⁺, K⁺), and water homeostasis, while defending against oxidative/nitrosative stress. Additionally, they support energy storage, mitochondrial biogenesis, and scar formation following injury. Astrocytes facilitate tissue repair through angiogenesis and neurogenesis and modulate synapse activity. Post-CNS injury, they interact with neurons and vascular systems to clear pathological protein aggregates, such as β-amyloid and α-synuclein, contributing to disease pathology resolution. Their multifaceted roles underscore their importance in maintaining CNS integrity, responding to injury, and supporting neuronal function. (199 words)",
        "Astrocytes in the CNS are involved in maintaining homeostasis of glutamate, ions, and water, defending against oxidative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair through angiogenesis and neurogenesis, and synapse modulation. They also clear disease-specific protein aggregates like β-amyloid and α-synuclein after CNS injury.",
        "Astrocytes play a crucial role in maintaining the homeostasis of the central nervous system (CNS) by regulating glutamate, ion, and water balance, defending against oxidative/nitrosative stress, and participating in energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid and α-synuclein.",
        "Astrocytes perform multiple critical functions in the central nervous system (CNS). They are involved in maintaining glutamate homeostasis, regulating ion balance (Ca²+ and K+), and managing water homeostasis. Additionally, they play a role in defending against oxidative and nitrosative stress, storing energy, and promoting mitochondria biogenesis. Astrocytes contribute to scar formation and tissue repair through processes like angiogenesis and neurogenesis. They also modulate synapses and, after CNS injury, help clear protein aggregates such as β-amyloid and α-synuclein by communicating with neuronal and vascular systems.",
        "Astrocytes, which are abundant in the human brain and central nervous system, play a crucial role in maintaining the balance of various substances within the system. They are responsible for maintaining the levels of the neurotransmitter glutamate, as well as ions such as calcium and potassium. Astrocytes also play a role in energy storage, mitochondria biogenesis, and tissue repair through processes like angiogenesis and neurogenesis. They are also involved in synapse modulation and have a defensive role against oxidative and nitrosative stress. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems to clear disease-specific protein aggregates such as beta-amyloid and alpha-synuclein.",
        "Astrocytes perform multiple critical roles in the central nervous system (CNS). They are involved in maintaining glutamate, ion (Ca²⁺ and K⁺), and water homeostasis, defending against oxidative/nitrosative stress, storing energy, promoting mitochondria biogenesis, forming scars, repairing tissues through angiogenesis and neurogenesis, and modulating synapses. Additionally, after CNS injury, astrocytes communicate with neuronal and vascular systems to clear harmful protein aggregates like β-amyloid and α-synuclein. Their functions are essential for the health and resilience of the CNS.",
        "Astrocytes play a key role in numerous functions within the central nervous system (CNS), including:\n\n1. Glutamate, ion (Ca2+, K+) and water homeostasis\n2. Defense against oxidative/nitrosative stress\n3. Energy storage\n4. Mitochondria biogenesis\n5. Scar formation and tissue repair via angiogenesis and neurogenesis\n6. Synapse modulation\n7. Clearance of disease-specific protein aggregates, such as β-amyloid and α-synuclein after CNS injury.\n\nThese functions highlight the importance of astrocytes in maintaining CNS health and responding to injury or disease.",
        "Astrocytes perform numerous functions within the central nervous system (CNS), including maintaining glutamate, ion (i.e., Ca2+, K+), and water homeostasis. They also defend against oxidative/nitrosative stress, store energy, facilitate mitochondria biogenesis, form scars, and repair tissue through angiogenesis and neurogenesis. Furthermore, astrocytes modulate synapses. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as -amyloid and -synuclein.",
        "Astrocytes perform numerous functions within the central nervous system (CNS), including maintaining glutamate, ion (i.e., Ca2+, K+), and water homeostasis. They also defend against oxidative/nitrosative stress, store energy, facilitate mitochondria biogenesis, form scars, and repair tissue via angiogenesis and neurogenesis. Furthermore, astrocytes modulate synapses. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as -amyloid and -synuclein.",
        "Astrocytes in the CNS regulate glutamate, ion, and water homeostasis, protect against oxidative stress, store energy, support mitochondrial biogenesis, and facilitate scar formation and tissue repair. They also modulate synapses and help clear disease-related protein aggregates after injury, interacting with neuronal and vascular systems.",
        "Astrocytes outnumber neurons in the human brain and play key roles in numerous functions within the central nervous system (CNS), including glutamate, ion (Ca2+, K+), and water homeostasis, defense against oxidative/nitrosative stress, energy storage, mitochondria biogenesis, scar formation, tissue repair via angiogenesis and neurogenesis, and synapse modulation. After CNS injury, astrocytes communicate with surrounding neuronal and vascular systems, leading to the clearance of disease-specific protein aggregates, such as β-amyloid and α-synuclein.",
        "[\u0027Astrocytes in the central nervous system (CNS) are involved in several crucial functions including maintaining glutamate, ion (Ca2+, K+), and water homeostasis. They also protect against oxidative and nitrosative stress, contribute to energy storage, and support mitochondria biogenesis. Additionally, astrocytes are involved in scar formation, tissue repair through angiogenesis and neurogenesis, and they modulate synapses. After CNS injury, astrocytes facilitate communication with neuronal and vascular systems and assist in clearing disease-specific protein aggregates such as β-amyloid and α-synuclein.\u0027]"
      ]
    },
    {
      "body": "Is Laparoscopic salpingectomy used to treat testicular cancer?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19926346",
        "http://www.ncbi.nlm.nih.gov/pubmed/30771489",
        "http://www.ncbi.nlm.nih.gov/pubmed/27956107",
        "http://www.ncbi.nlm.nih.gov/pubmed/28232128",
        "http://www.ncbi.nlm.nih.gov/pubmed/36561726"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 135,
          "text": "To evaluate the feasibility of a single-port laparoscopic salpingectomy in the surgical treatment of tubal pregnancy.D",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19926346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Tips and Tricks for Performing Salpingectomy at the Time of Laparoscopic Hysterectomy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27956107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "STUDY OBJECTIVE: To demonstrate various techniques to perform salpingectomy efficiently at the time of laparoscopic hysterectomy.DESIGN: Step-by-step explanation of the techniques by video with narration (educational video) (Canadian Task Force Class",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27956107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "STUDY OBJECTIVE: To assess the change in the rate of laparoscopic salpingectomy for sterilization after the release of the November 2013 Society of Gynecologic Oncology Clinical Practice Statement and the January 2015 American College of Obstetrician",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30771489"
        },
        {
          "offsetInBeginSection": 36,
          "offsetInEndSection": 304,
          "text": "e in the rate of laparoscopic salpingectomy for sterilization after the release of the November 2013 Society of Gynecologic Oncology Clinical Practice Statement and the January 2015 American College of Obstetricians and Gynecologists Committee Opinion: Salpingectomy f",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30771489"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 257,
          "text": "men having laparoscopic salpingectomy or tubal occlusion for female sterilization.STUDY DESIGN: We used billing data to identify women having laparoscopic sterilization at ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28232128"
        },
        {
          "offsetInBeginSection": 741,
          "offsetInEndSection": 918,
          "text": "Subsequently, laparoscopic hysterectomy and bilateral salpingectomy were performed since she could not tolerate everolimus for a long period due to the medication\u0027s side effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36561726"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 228,
          "text": "The laparoscopic salpingectomy and tubal occlusion have been shown to improve in-vitro fertilization (IVF) outcomes in this disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38333268"
        }
      ],
      "type": "yesno",
      "id": "6810ff8f353a4a2e6b000017",
      "ideal_answer": [
        "Laparoscopic salpingectomy is a surgical treatment of tubal pregnancy.",
        "No, laparoscopic salpingectomy is used to treat ovarian cancer.",
        "The snippets provided discuss the use of laparoscopic salpingectomy in relation to the fallopian tubes, which are part of the female reproductive system. There is no mention or implication of its use in treating testicular cancer, a condition specific to the male reproductive system.",
        "No, laparoscopic surgery is not used for treatment of testicular cancer.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer.",
        "No, Laparoscopic salpingectomy is not used to treat testicular cancer.",
        "No, laparoscopic salpingectomy is used to treat conditions related to the fallopian tubes, not testicular cancer.",
        "No. Laparoscopic salpingectomy is not used to treat testicular cancer; it is a procedure related to the removal of the fallopian tubes and is not applicable to testicular cancer treatment.",
        "No. Laparoscopic salpingectomy removes the fallopian tubes in women and has no role in treating testicular cancer, which is managed by radical inguinal orchiectomy rather than any form of salpingectomy.",
        "No. Laparoscopic salpingectomy is not mentioned as a treatment for testicular cancer; the focus is on laparoscopic techniques for testicular cancer management, particularly retroperitoneal lymph node dissection.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer. Instead, laparoscopic retroperitoneal lymph node dissection (RPLND) is a technique used for the management of testicular cancer.",
        "No. Laparoscopic salpingectomy is not used to treat testicular cancer; it is primarily associated with the treatment of ectopic pregnancy and other gynecological conditions.",
        "Laparoscopic salpingectomy is not used to treat testicular cancer.",
        "No. Laparoscopic salpingectomy is a surgical procedure used to treat ectopic pregnancy and prevent ovarian cancer. It is not used to treat testicular cancer.",
        "No. Laparoscopic salpingectomy is not indicated for the treatment of testicular cancer, as it is a procedure related to the female reproductive system and the context provided does not mention its use for testicular cancer.",
        "No, laparoscopic surgery is not currently being used to treat testicular cancer.",
        "No, laparoscopic salpingectomy is used to treat ectopic pregnancy.",
        "Laparoscopic salpingectomy is not typically used to treat testicular cancer; it is used to excise the Fallopian tube in females, such as in ectopic pregnancy treatment or when the tube itself is affected by conditions like endometriosis or adhesions.",
        "No, laparoscopic salpingectomy is used for the treatment of ectopic pregnancies, not testicular cancer.",
        "No, laparoscopic salpingectomy is used to treat ectopic pregnancy, not testicular cancer.",
        "Laparoscopic salpingectomy is not used to treat testicular cancer. It is primarily mentioned in relation to gynecological training and as a surgical treatment for ectopic and tubal pregnancies. There is no indication that this procedure is applicable to the treatment of testicular cancer.",
        "No. Laparoscopic salpingectomy is a minimally invasive removal of a fallopian tube performed only in female patients for conditions such as ectopic pregnancy or sterilization. Testicular cancer is managed by radical inguinal orchiectomy, often followed by chemotherapy or radiation, not by salpingectomy.",
        "No, laparoscopic salpingectomy is used for treating conditions like tubal or ectopic pregnancies, as indicated in the provided snippets, not for testicular cancer.",
        "No, Laparoscopic salpingectomy is used to treat ectopic pregnancy.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer. It is primarily used in the surgical treatment of ectopic pregnancies and other gynecological conditions.",
        "No. Laparoscopic salpingectomy is a surgical procedure used for ectopic pregnancy and is not indicated for the treatment of testicular cancer.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer. It is used to treat ectopic pregnancy and tubal pregnancy.",
        "No. Laparoscopic salpingectomy is not used to treat testicular cancer; it is primarily a surgical procedure for ectopic pregnancy and related gynecological conditions.",
        "Laparoscopic salpingectomy is not used to treat testicular cancer. The entities provided are related to female reproductive health (vaginal, porcine, ectopic pregnancy, pregnancy, tubal), while testicular cancer is a male-specific condition.",
        "No. Laparoscopic salpingectomy is primarily used for the surgical treatment of ectopic pregnancy and not specifically for treating cancer.",
        "No. Laparoscopic salpingectomy is a surgical procedure used to treat ectopic pregnancy and is not used to treat testicular cancer.",
        "Yes, available evidence suggests that is laparoscopic salpingectomy used to treat testicular cancer.",
        "No. Laparoscopic salpingectomy is primarily used for the surgical treatment of ectopic pregnancy and is not indicated for treating testicular cancer.",
        "Laparoscopic salpingectomy is a surgical procedure for removing fallopian tubes, typically performed on females. Testicular cancer affects male reproductive organs, so this surgery isn\u0027t used for its treatment.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer. It is primarily used for conditions related to the female reproductive system, such as ectopic pregnancy.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer. It is a procedure primarily used in gynecology for conditions such as ectopic pregnancies or tubal diseases, involving the removal of the Fallopian tubes. Testicular cancer treatments typically involve different procedures like orchiectomy.",
        "No, laparoscopic salpingectomy is used in the surgical treatment of ectopic pregnancy, not testicular cancer.",
        "No, based on the provided snippets, laparoscopic salpingectomy is not indicated for the treatment of testicular cancer, but rather is associated with gynecological procedures.",
        "No, laparoscopic salpingectomy is not used to treat testicular cancer. It is primarily a surgical treatment for conditions related to the fallopian tubes, such as ectopic pregnancy."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Factors that are associated with thyroid cancer.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39460502",
        "http://www.ncbi.nlm.nih.gov/pubmed/39589817",
        "http://www.ncbi.nlm.nih.gov/pubmed/36598418",
        "http://www.ncbi.nlm.nih.gov/pubmed/37450579",
        "http://www.ncbi.nlm.nih.gov/pubmed/28977647",
        "http://www.ncbi.nlm.nih.gov/pubmed/34219886",
        "http://www.ncbi.nlm.nih.gov/pubmed/18406782",
        "http://www.ncbi.nlm.nih.gov/pubmed/38497372",
        "http://www.ncbi.nlm.nih.gov/pubmed/35670964",
        "http://www.ncbi.nlm.nih.gov/pubmed/3791213",
        "http://www.ncbi.nlm.nih.gov/pubmed/39733010",
        "http://www.ncbi.nlm.nih.gov/pubmed/7747246",
        "http://www.ncbi.nlm.nih.gov/pubmed/31542786",
        "http://www.ncbi.nlm.nih.gov/pubmed/15179756",
        "http://www.ncbi.nlm.nih.gov/pubmed/33082385",
        "http://www.ncbi.nlm.nih.gov/pubmed/39027710",
        "http://www.ncbi.nlm.nih.gov/pubmed/27351286",
        "http://www.ncbi.nlm.nih.gov/pubmed/22560341",
        "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
        "http://www.ncbi.nlm.nih.gov/pubmed/30265861",
        "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
        "http://www.ncbi.nlm.nih.gov/pubmed/12087461",
        "http://www.ncbi.nlm.nih.gov/pubmed/20142332",
        "http://www.ncbi.nlm.nih.gov/pubmed/12182020",
        "http://www.ncbi.nlm.nih.gov/pubmed/23064295",
        "http://www.ncbi.nlm.nih.gov/pubmed/576889",
        "http://www.ncbi.nlm.nih.gov/pubmed/22891351",
        "http://www.ncbi.nlm.nih.gov/pubmed/15001635",
        "http://www.ncbi.nlm.nih.gov/pubmed/39645548",
        "http://www.ncbi.nlm.nih.gov/pubmed/36010309",
        "http://www.ncbi.nlm.nih.gov/pubmed/17160166",
        "http://www.ncbi.nlm.nih.gov/pubmed/23475155",
        "http://www.ncbi.nlm.nih.gov/pubmed/18806721"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 804,
          "offsetInEndSection": 881,
          "text": "Obesity was consistently associated with the increased risk of thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39460502"
        },
        {
          "offsetInBeginSection": 51,
          "offsetInEndSection": 116,
          "text": "metabolic dysfunction-associated steatotic liver disease (MASLD) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39589817"
        },
        {
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1498,
          "text": "MASLD increases the risk of developing thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39589817"
        },
        {
          "offsetInBeginSection": 1326,
          "offsetInEndSection": 1407,
          "text": "no significant association between seafood intake and the risk of thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36598418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Radiation is an environmental factor that elevates the risk of developing thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37450579"
        },
        {
          "offsetInBeginSection": 858,
          "offsetInEndSection": 1042,
          "text": " five studies, I2 \u003d 30.6%). So obesity, overweight and radiation exposure are significantly associated with increased thyroid cancer risk and smoking has a protective effect on thyroid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28977647"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 544,
          "text": "In this review, we present the results of numerous investigations focused on possible factors causing increased TC incidence, such as chromosomal and genetic alterations, iodine intake, TSH level, autoimmune thyroid disease, gender, estrogen, obesity, lifestyle changes, and environmental pollutants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34219886"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 311,
          "text": "Radiation exposure is a well-established risk factor for papillary thyroid carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35670964"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 751,
          "text": "Women who had a history of breast cancer were almost 3 times (95% confidence interval, 0.78-7.9) more likely to develop thyroid cancer than women with no such history.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3791213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The management of papillary thyroid carcinoma (PTC) concurrent with Hashimoto\u0027s thyroiditis (HT) lacks standardized guidelines, especially concerning surgical strategies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39733010"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 241,
          "text": "There are environmental factors that can potentiate the onset of thyroid cancer, in particular pollutants, lifestyle or radiation exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36010309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Radiation exposure is the only known etiologic factor clearly associated with an increased risk of thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7747246"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 663,
          "text": "Exposure to external radiation and living in endemic goiter area increase the frequency of thyroid cancer. Medullary thyroid carcinoma is often familial and may occur in associations with the multiple endocrine neoplasia syndromes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15179756"
        },
        {
          "offsetInBeginSection": 1443,
          "offsetInEndSection": 1683,
          "text": "age ≥ 55 years and current smoking were associated with lower thyroid cancer occurrence, while BMI ≥ 25 kg/m2, higher income, urban residence, hypothyroidism, and hyperthyroidism were associated with higher occurrence in both men and women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33082385"
        },
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 959,
          "text": "Thyroid-stimulating hormone (TSH) is the main mitotic factor. Any agent that elevates TSH will stimulate nodule formation. Therefore, the incidence of thyroid nodules is high in endemic goiter regions due to iodine deficiency. This paper has described many of the factors causing this higher incidence. Of note, metabolic syndrome and insulin resistance are important factors associated with the increased incidence of nodular goiter and papillary thyroid cancer today.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31542786"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 443,
          "text": "Radiation exposure is the only known etiologic factor clearly associated with an increased risk of thyroid cancer. External beam radiation treatment for medical therapy, acute gamma ray exposure from environmental sources (nuclear weapons, nuclear power plant accidents), and ingestion of short-lived radioactive iodine isotopes are the primary sources of radiation exposure, which increases the risk of benign and malignant thyroid neoplasia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7747246"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 686,
          "text": "Radiation exposure is a well-established risk factor for papillary thyroid carcinoma. Other environmental risk factors include dietary iodine, obesity, hormones, and environmental pollutants. Papillary thyroid carcinomas could occur in familial settings, and 5% of these familial cases have well-studied driver germline mutations. In sporadic papillary thyroid carcinoma, BRAF mutation is common and is associated with clinicopathologic and prognostic markers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35670964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Exposure to ionizing radiation, especially during childhood, is a well-established risk factor for thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39027710"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 538,
          "text": "Exposure to external radiation and living in endemic goiter area increase the frequency of thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15179756"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1036,
          "text": "Epidemiological studies suggest an important link between obesity and thyroid cancer. The adipose tissue-derived polypeptide leptin acting via leptin receptor may modulate cell migration of thyroid cancer cells. Previously we have demonstrated that leptin receptor is overexpressed in papillary thyroid cancer and is associated with tumor aggressiveness. The present study was undertaken to explore the possible regulatory factors which would influence leptin receptor expression in papillary thyroid cancer cells. We found that DNA methyltransferase inhibitor (5-Aza-2\u0027-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin receptor expression. Conversely, insulin upregulated leptin receptor expression in a time- and dose-dependent manner. Hypoxia-mimicking agent (cobalt chloride) had no effect on leptin receptor expression. Taken together, our study provides evidence that epigenetic events and insulin stimulation take part in regulation of leptin receptor expression in papillary thyroid cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341"
        },
        {
          "offsetInBeginSection": 682,
          "offsetInEndSection": 952,
          "text": "Body mass index (BMI) ≥ 25 kg/m2 (1.51, 1.26-1.82), higher income (1.44, 1.19-1.76), urban residence (1.24, 1.03-1.49), and presence of hypothyroidism (3.31, 2.38-4.61) or hyperthyroidism (2.46, 1.75-3.46) were associated with higher thyroid cancer occurrence among men.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33082385"
        },
        {
          "offsetInBeginSection": 1136,
          "offsetInEndSection": 1427,
          "text": "BMI ≥ 25 kg/m2 (1.41, 1.26-1.57), frequent exercise (1.21, 1.07-1.36), higher income (1.18, 1.06-1.32), urban residence (1.17, 1.06-1.29), and presence of hypothyroidism (1.60, 1.40-1.82) or hyperthyroidism (1.38, 1.19-1.61) were associated with higher thyroid cancer occurrence among women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33082385"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1187,
          "text": "Anaplastic thyroid carcinoma (ATC) is a rare, poorly differentiated type of thyroid cancer occurring in less than 5% of all thyroid cancers. Patients typically have a poor prognosis with very few options for treatment. (2) With current therapy of surgery, chemotherapy, and radiation, median survival is only 6 months from the time of diagnosis. Several mutations in cell cycle regulation have been discovered in ATC that contribute to its undifferentiated state, one of which is the BRAF kinase mutation. This mutation results in activation of the MAPK pathway and uncontrolled cell proliferation. In this case report, a 51 y old male presented with a 2-week history of hoarseness and was diagnosed with ATC. Genetic analysis revealed a mutation in BRAF kinase; the patient subsequently began therapy with vemurafenib, a BRAF kinase inhibitor indicated for melanoma. After an initial response, the patient quickly declined and consequently died from his disease. Anaplastic thyroid carcinoma is a deadly cancer without an effective treatment. Inhibiting mutated enzymes that drive the development of this cancer is a potential drug target that may improve outcomes in patients with ATC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1416,
          "text": "Most human thyroid cancers are differentiated papillary carcinomas (PTC). Papillary thyroid microcarcinomas (PTMC) are tumors that measure 1 cm or less. This class of small tumors has proven to be a very common clinical entity in endocrine diseases. PTMC may be present in 30-40% of human autopsies and is often identified incidentally in a thyroid removed for benign clinical nodules. Although PTMC usually has an excellent long-term prognosis, it can metastasize to neck lymph nodes; however deaths related to this type of thyroid tumor are very rare. Few data exist on molecular pathways that play a role in PTMC development; however, two molecules have been shown to be associated with aggressive PTMC. S100A4 (calcium-binding protein), which plays a role in angiogenesis, extracellular matrix remodeling, and tumor microenvironment, is over-expressed in metastatic PTMC. In addition, the BRAF(V600E) mutation, the most common genetic alteration in PTC, is present in many PTMC with extra thyroidal extension and lymph node metastasis. Importantly, recently developed selective [e.g., PLX4720, PLX4032 (Vemurafenib, also called RG7204)] or non-selective (e.g., Sorafenib) inhibitors of BRAF(V600E) may be an effective treatment for patients with BRAF(V600E)-expressing PTMCs with aggressive clinical-pathologic features. Here, we summarize the clinical outcome, cancer genetics, and molecular mechanisms of PTMC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649416"
        },
        {
          "offsetInBeginSection": 890,
          "offsetInEndSection": 1171,
          "text": "Stepwise regression analysis showed that high consumption of processed fish products (OR\u003d2.2; 95% CI: 1.6-3.0) fresh fish (OR\u003d0.5; 95% CI: 0.4-0.7) and chicken (OR\u003d1.7; 95% CI: 1.2-2.3) were independently associated with thyroid cancer with significant dose-response relationships.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12087461"
        },
        {
          "offsetInBeginSection": 1416,
          "offsetInEndSection": 1629,
          "text": "These data support the hypothesis that hyperplastic thyroid disease is strongly related to thyroid cancer; and that habitual high consumption of various seafoods may be relevant to the aetiology of thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12087461"
        },
        {
          "offsetInBeginSection": 778,
          "offsetInEndSection": 1111,
          "text": "se targets include the proto-oncogenes BRAF and RET, known to be common mutations in thyroid cancer; vascular endothelial growth factor receptor and platelet-derived growth factor receptor, associated with angiogenesis; and the sodium-iodide symporter, with the aim of restoring its expression and hence radioactive iodine uptake. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20142332"
        },
        {
          "offsetInBeginSection": 357,
          "offsetInEndSection": 569,
          "text": "It has been reported that exposure to external medical radiation or to external and internal radiation from atomic bomb explosions, nuclear tests or nuclear accidents leads to an increased risk for thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064295"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "There are abundant experimental and clinical data to associate radiation exposure and thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/576889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The potential risk factors for thyroid carcinoma development include genetic predisposition, exposure to therapeutic or environmental ionizing radiation, residence in areas of iodine deficiency or excess, history of preexisting benign thyroid disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18406782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "UNLABELLED: Apart from the two relatively well documented risk factors for thyroid cancer i.e. iodine deficiency and ionising radiation, the mechanism of carcinogenesis involves a number of biological and environmental factors. The aim of the study w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12182020"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 346,
          "text": "We observed that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclear pY-STAT3 in tumor cells, preferentially in association with the tumor stroma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22891351"
        },
        {
          "offsetInBeginSection": 410,
          "offsetInEndSection": 700,
          "text": "We found a high and similar frequency (45%) of the BRAF T1796A mutation in two geographically distinct PTC patient populations: one composed of sporadic cases from North America, and the other from Kiev, Ukraine, that included individuals who were exposed to the Chernobyl nuclear accident.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15001635"
        },
        {
          "offsetInBeginSection": 1133,
          "offsetInEndSection": 1320,
          "text": "Our results suggest that frequent occurrence of BRAF mutation is inherently associated with PTC, irrespective of geographic origin, and is apparently not a radiation-susceptible mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15001635"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Elevated thyroid-stimulating hormone levels, independent of Hashimoto\u0027s thyroiditis, increase thyroid cancer risk: Insights from genetic and clinical evidence.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645548"
        },
        {
          "offsetInBeginSection": 793,
          "offsetInEndSection": 959,
          "text": "Of note, metabolic syndrome and insulin resistance are important factors associated with the increased incidence of nodular goiter and papillary thyroid cancer today.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31542786"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 353,
          "text": "Previously we have demonstrated that leptin receptor is overexpressed in papillary thyroid cancer and is associated with tumor aggressiveness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 542,
          "text": "Our meta-analysis of normal, benign, and malignant thyroid samples demonstrated that ETV5 expression is upregulated in papillary thyroid cancer and was predominantly associated with BRAF V600E or RAS mutations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30265861"
        },
        {
          "offsetInBeginSection": 1289,
          "offsetInEndSection": 1447,
          "text": "Low serum selenium levels have been associated with higher incidence of thyroid cancer, as well as with chronic illness or lomicronw triiodothyronine syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17160166"
        },
        {
          "offsetInBeginSection": 1085,
          "offsetInEndSection": 1324,
          "text": "In countries, where nutritional iodine deficiency is still an issue, the risk to develop thyroid cancer after a nuclear reactor emergency has to be considered higher because the thyroid takes up more radioiodine as in the replete condition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475155"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 246,
          "text": "Children with thyroid nodules, compared to adults with thyroid nodules, have a fourfold greater risk of developing malignant thyroid disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18806721"
        },
        {
          "offsetInBeginSection": 805,
          "offsetInEndSection": 1345,
          "text": "Factors that prevent thyroid cancer include smoking and alcohol consumption, quality and regular sleep, consumption of cruciferous vegetables and dairy products, and consistent long-term exercise. Conversely, individuals with specific genetic mutations have an elevated risk of thyroid cancer from prolonged and frequent use of mobile phones. In addition, individuals who work in high-pressure jobs, work night shifts, and live near volcanoes or in environments associated with pesticides have an elevated risk of developing thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38497372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Epidemiological studies suggest an important link between obesity and thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560341"
        },
        {
          "offsetInBeginSection": 1530,
          "offsetInEndSection": 1731,
          "text": "In general, we found that factors reflecting a greater length of exposure to endogenous hormones, particularly during the reproductive years, were associated with risk of postmenopausal thyroid cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24449056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Exposure to ionizing radiation, especially during childhood, is a well-established risk factor for thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39027710"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 537,
          "text": "Exposure to external radiation and living in endemic goiter area increase the frequency of thyroid cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15179756"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 310,
          "text": "Radiation exposure is a well-established risk factor for papillary thyroid carcinoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35670964"
        },
        {
          "offsetInBeginSection": 716,
          "offsetInEndSection": 922,
          "text": "Each 1 mU/L increase of serum TSH was associated with 14% greater risk of thyroid cancer for all histological thyroid cancer, 16% for differentiated thyroid carcinoma and 22% for papillary thyroid carcinoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351286"
        }
      ],
      "id": "67fbe21818b1e36f2e000113",
      "ideal_answer": [
        "Many factors are associated with the risk of thyroid cancer, namely, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and radiation.",
        "Factors that are associated with thyroid cancer include hyperthyroidism, hypothyroidism, urban residence, higher income, family history of malignant tumors, Asian race, ionizing radiation, history of goiter or thyroid nodules, occupational exposure to chemicals, and female gender.",
        "Radiation exposure, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD) are identified as factors that elevate the risk of developing thyroid cancer. No significant link was found between seafood intake and thyroid cancer risk.",
        "Radiation, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD) are factors that are associated with thyroid cancer.",
        "Factors that are associated with thyroid cancer include metabolic dysfunction-associated steatotic liver disease (MASLD), radiation, and obesity.",
        "The factors that are associated with thyroid cancer include obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and radiation exposure.",
        "Obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and radiation exposure are factors that are associated with an increased risk of thyroid cancer.",
        "Radiation, obesity, and MASLD are factors associated with an increased risk of thyroid cancer.",
        "Factors associated with thyroid cancer include obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and radiation exposure.",
        "Factors associated with thyroid cancer include Obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and Radiation.",
        "Factors associated with an increased risk of thyroid cancer include obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and exposure to radiation."
      ],
      "exact_answer": [
        [
          "obesity"
        ],
        [
          "metabolic dysfunction-associated steatotic liver disease (MASLD)"
        ],
        [
          "radiation"
        ]
      ]
    },
    {
      "body": "Do glioblastoma tumors have a high degree of lymphocyte infiltration?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34771532",
        "http://www.ncbi.nlm.nih.gov/pubmed/38811170",
        "http://www.ncbi.nlm.nih.gov/pubmed/21478334",
        "http://www.ncbi.nlm.nih.gov/pubmed/39076974",
        "https://www.ncbi.nlm.nih.gov/pubmed/38811170",
        "http://www.ncbi.nlm.nih.gov/pubmed/36830847",
        "http://www.ncbi.nlm.nih.gov/pubmed/39701951",
        "http://www.ncbi.nlm.nih.gov/pubmed/32923142",
        "http://www.ncbi.nlm.nih.gov/pubmed/25355681",
        "http://www.ncbi.nlm.nih.gov/pubmed/31973030",
        "http://www.ncbi.nlm.nih.gov/pubmed/34676050",
        "http://www.ncbi.nlm.nih.gov/pubmed/37236575",
        "http://www.ncbi.nlm.nih.gov/pubmed/36196364"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "Glioblastoma is an immunologically \u0027cold\u0027 tumor, which are characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). For those tumors that have been invaded by lymphocytes, they are profoundly exhausted and ineffective. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34771532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 327,
          "text": "Glioblastoma (GBM) is the most aggressive primary brain cancer. These tumors exhibit high intertumoral and intratumoral heterogeneity in neoplastic and nonneoplastic compartments, low lymphocyte infiltration, and high abundance of myeloid subsets that together create a highly protumorigenic immunosuppressive microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38811170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "More than the sparse infiltration in glioblastoma, cytotoxic T lymphocytes (CTLs) also function inefficiently and overexpress the inhibitory markers, especially the identified NK cell receptor (NK1.1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39701951"
        },
        {
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1396,
          "text": "In addition, both tumor genotype and grade associated with the degree of glioma immune infiltration. Unlike in the majority of cancers, lymphocyte infiltration at the tumor site is anegative prognostic factor in glioma, suggesting the ambivalent pro-tumorigenic role of immune responses in glioma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923142"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34676050"
        },
        {
          "offsetInBeginSection": 64,
          "offsetInEndSection": 327,
          "text": "These tumors exhibit high intertumoral and intratumoral heterogeneity in neoplastic and nonneoplastic compartments, low lymphocyte infiltration, and high abundance of myeloid subsets that together create a highly protumorigenic immunosuppressive microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38811170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Glioblastoma is an immunologically \u0027cold\u0027 tumor, which are characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34771532"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 333,
          "text": "Although glioblastomas (GBMs) are classified as \u0027cold tumours\u0027 with very little lymphocyte infiltration, they can contain up to 30-40% of tumour-associated macrophages,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31973030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34676050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "Immune checkpoint blockade (ICB) therapy has shown great potential in the treatment of malignant tumors, but its therapeutic effect on glioblastoma (GBM) is unsatisfactory because of the low immunogenicity and T cell infiltration, as well as the presence of blood-brain barrier (BBB) that blocks most of ICB agents to the GBM tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37236575"
        },
        {
          "offsetInBeginSection": 1395,
          "offsetInEndSection": 1502,
          "text": "The effect of ICB therapy on GBM is limited by the low immunogenicity and insufficient T-cell infiltration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37236575"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "Immune checkpoint blockade (ICB) therapy has shown great potential in the treatment of malignant tumors, but its therapeutic effect on glioblastoma (GBM) is unsatisfactory because of the low immunogenicity and T cell infiltration, as well as the presence of blood-brain barrier (BBB) that blocks most of ICB agents to the GBM tissues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37236575"
        },
        {
          "offsetInBeginSection": 1395,
          "offsetInEndSection": 1501,
          "text": "The effect of ICB therapy on GBM is limited by the low immunogenicity and insufficient T-cell infiltration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37236575"
        }
      ],
      "id": "67fc20ee18b1e36f2e00012a",
      "ideal_answer": [
        "No, glioblastoma is an immunologically \u0027cold\u0027 tumor, which is characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). For those tumors that have been invaded by lymphocytes, they are profoundly exhausted and ineffective.",
        "No, most glioblastoma tumors have absent or minimal tumor infiltrating lymphocytes, making them immunologically cold. Even when present, these lymphocytes are exhausted and ineffective.",
        "No, glioblastoma tumors have a low degree of lymphocyte infiltration. They are characterized as \u0027cold\u0027 tumors with minimal or absent tumor-infiltrating lymphocytes (TILs), and any lymphocytes present are often exhausted and ineffective.",
        "Glioblastoma tumors are characterized as \u0027cold\u0027 tumors, which typically have absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). Even in cases where lymphocytes are present, they are often profoundly exhausted and ineffective.",
        "Glioblastoma tumors are known as immunologically \u0027cold\u0027 tumors, meaning they generally have very few or no tumor-infiltrating lymphocytes. The lymphocytes that are present are usually exhausted and ineffective.",
        "No. Glioblastoma is an immunologically \"cold\" tumor characterized by absent or minimal tumor-infiltrating lymphocytes (TILs). Even when lymphocytes are present, they exhibit profound exhaustion and functional ineffectiveness.",
        "Glioblastoma tumors are characterized as immunologically \u0027cold,\u0027 meaning they typically exhibit absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). This indicates that these tumors generally do not have a high degree of lymphocyte infiltration. Even when some lymphocytes are present, they are often exhausted and ineffective in combating the cancer. Therefore, glioblastoma is associated with low lymphocyte infiltration, contributing to its resistance against immunotherapy.",
        "No, glioblastoma tumors do not have a high degree of lymphocyte infiltration; they are characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). Even when lymphocytes are present, they are typically profoundly exhausted and ineffective.",
        "Glioblastoma tumors do not have a high degree of lymphocyte infiltration. They are characterized by absent or minimal numbers of tumor-infiltrating lymphocytes. Even when lymphocytes are present, they are often exhausted and ineffective.",
        "Glioblastoma is classified as an immunologically \"cold\" tumor, characterized by minimal or absent tumor-infiltrating lymphocytes (TILs). This lack of lymphocyte infiltration contributes to its immunosuppressive microenvironment. While rare instances of lymphocyte invasion may occur, these cells are typically functionally exhausted and ineffective, further limiting antitumor immune responses. The absence of significant TILs and the dysfunctional state of infiltrating lymphocytes underscore the challenges in leveraging immunotherapy for glioblastoma.",
        "No. Glioblastoma is an immunologically \u0027cold\u0027 tumor, characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). For those tumors that have been invaded by lymphocytes, they are profoundly exhausted and ineffective.",
        "Glioblastoma tumors generally do not have a high degree of lymphocyte infiltration; they are considered immunologically \u0027cold\u0027 with absent or minimal tumor-infiltrating lymphocytes. Even when lymphocytes are present, they tend to be exhausted and ineffective in mounting an immune response.",
        "Glioblastoma tumors are characterized as immunologically \u0027cold,\u0027 meaning they typically have absent or minimal tumor-infiltrating lymphocytes (TILs). Even when lymphocytes are present, they are often profoundly exhausted and ineffective, indicating a low degree of functional lymphocyte infiltration.",
        "Glioblastoma tumors typically exhibit minimal or absent tumor-infiltrating lymphocytes (TILs), categorizing them as immunologically \u0027cold\u0027 tumors. Even when lymphocytes are present, they are often exhausted and ineffective. Therefore, glioblastoma tumors do not have a high degree of lymphocyte infiltration.",
        "Glioblastoma tumors are typically characterized by a low degree of lymphocyte infiltration. This is because glioblastoma is considered an immunologically \u0027cold\u0027 tumor, which means it has minimal numbers of tumor-infiltrating lymphocytes (TILs). The few lymphocytes that do infiltrate these tumors are often exhausted and ineffective.",
        "No, glioblastoma tumors typically exhibit minimal or absent tumor infiltrating lymphocytes (TILs). While some tumors may have infiltrated lymphocytes, these cells are often exhausted and ineffective, further indicating that the degree of lymphocyte infiltration is not high.",
        "Glioblastoma tumors are typically characterized as \"immunologically cold,\" meaning they usually exhibit minimal or absent lymphocyte infiltration. This implies that these tumors do not have a high degree of immune cell presence within them. Even when some tumor-infiltrating lymphocytes (TILs) are present, they are often exhausted and ineffective. Therefore, glioblastomas generally have low lymphocyte infiltration.",
        "Glioblastoma tumors are characterized by low lymphocyte infiltration and are classified as immunologically \u0027cold\u0027 due to absent or minimal tumor-infiltrating lymphocytes (TILs). Studies highlight that even when T cells infiltrate these tumors, they often exhibit profound exhaustion and functional impairment. Research emphasizes the critical need to enhance T cell trafficking into glioblastoma by addressing barriers such as blood-brain barrier interactions, integrin expression, and immunosuppressive tumor microenvironments. These findings underscore that current therapeutic strategies targeting immune reinvigoration depend on improving lymphocyte recruitment rather than relying on pre-existing infiltration levels.",
        "No, glioblastoma tumors are immunologically cold and exhibit absent or very low numbers of tumor-infiltrating lymphocytes; any lymphocytes that do infiltrate are profoundly exhausted and ineffective.",
        "Glioblastoma is classified as an immunologically \u0027cold\u0027 tumor characterized by minimal or absent tumor-infiltrating lymphocytes (TILs). When lymphocytes do infiltrate these tumors, they are typically exhausted and ineffective, indicating that glioblastomas generally lack significant lymphocyte infiltration.",
        "No, glioblastoma tumors are characterized by absent or minimal numbers of tumor-infiltrating lymphocytes (TILs). For those tumors that have been invaded by lymphocytes, they are profoundly exhausted and ineffective."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Please list the types of Videolaryngoscopy for adults undergoing tracheal intubation",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38807147",
        "http://www.ncbi.nlm.nih.gov/pubmed/29660807",
        "http://www.ncbi.nlm.nih.gov/pubmed/29239965",
        "http://www.ncbi.nlm.nih.gov/pubmed/35820934",
        "http://www.ncbi.nlm.nih.gov/pubmed/39604038",
        "http://www.ncbi.nlm.nih.gov/pubmed/36928625",
        "https://www.ncbi.nlm.nih.gov/pubmed/34855986",
        "https://www.ncbi.nlm.nih.gov/pubmed/38789407",
        "http://www.ncbi.nlm.nih.gov/pubmed/27844477",
        "http://www.ncbi.nlm.nih.gov/pubmed/34855986",
        "http://www.ncbi.nlm.nih.gov/pubmed/30393765",
        "http://www.ncbi.nlm.nih.gov/pubmed/38789407",
        "http://www.ncbi.nlm.nih.gov/pubmed/39075801",
        "http://www.ncbi.nlm.nih.gov/pubmed/39632032",
        "http://www.ncbi.nlm.nih.gov/pubmed/39364015",
        "http://www.ncbi.nlm.nih.gov/pubmed/32934623",
        "http://www.ncbi.nlm.nih.gov/pubmed/19690253",
        "http://www.ncbi.nlm.nih.gov/pubmed/39237284",
        "http://www.ncbi.nlm.nih.gov/pubmed/33512660",
        "http://www.ncbi.nlm.nih.gov/pubmed/38715753",
        "http://www.ncbi.nlm.nih.gov/pubmed/38345268",
        "http://www.ncbi.nlm.nih.gov/pubmed/31571890",
        "http://www.ncbi.nlm.nih.gov/pubmed/29894918",
        "http://www.ncbi.nlm.nih.gov/pubmed/23241277",
        "http://www.ncbi.nlm.nih.gov/pubmed/22677878",
        "http://www.ncbi.nlm.nih.gov/pubmed/37485208",
        "http://www.ncbi.nlm.nih.gov/pubmed/25881731",
        "http://www.ncbi.nlm.nih.gov/pubmed/19809328",
        "http://www.ncbi.nlm.nih.gov/pubmed/23431906",
        "http://www.ncbi.nlm.nih.gov/pubmed/22324297",
        "http://www.ncbi.nlm.nih.gov/pubmed/25255665",
        "http://www.ncbi.nlm.nih.gov/pubmed/36318002",
        "http://www.ncbi.nlm.nih.gov/pubmed/20887406",
        "http://www.ncbi.nlm.nih.gov/pubmed/34303493",
        "http://www.ncbi.nlm.nih.gov/pubmed/39100912",
        "http://www.ncbi.nlm.nih.gov/pubmed/28740393",
        "http://www.ncbi.nlm.nih.gov/pubmed/36166515",
        "http://www.ncbi.nlm.nih.gov/pubmed/28217398",
        "http://www.ncbi.nlm.nih.gov/pubmed/25207012",
        "http://www.ncbi.nlm.nih.gov/pubmed/35244042",
        "http://www.ncbi.nlm.nih.gov/pubmed/35497705",
        "http://www.ncbi.nlm.nih.gov/pubmed/32842705",
        "http://www.ncbi.nlm.nih.gov/pubmed/39140638",
        "http://www.ncbi.nlm.nih.gov/pubmed/38964608",
        "http://www.ncbi.nlm.nih.gov/pubmed/31198251",
        "http://www.ncbi.nlm.nih.gov/pubmed/22926681",
        "http://www.ncbi.nlm.nih.gov/pubmed/31389835",
        "http://www.ncbi.nlm.nih.gov/pubmed/36387699",
        "http://www.ncbi.nlm.nih.gov/pubmed/35811139"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 360,
          "text": "The Cochrane systematic review and meta-analysis published in 2022 that compared videolaryngoscopy (VL) with direct laryngoscopy (DL) for facilitating tracheal intubation in adults found that all three types of VL device (Macintosh-style, hyper-angulated and channeled) reduced the risk of failed intubation and increased the likelihood of first-pass success. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38807147"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "A randomised clinical trial comparing the \u0027sniffing\u0027 and neutral position using channelled (KingVision® ) and non-channelled (C-MAC® ) videolaryngoscopes.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29660807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 440,
          "text": "Head and neck position is one of the factors which can be associated with difficult videolaryngoscopy and tracheal intubation. This prospective randomised clinical trial compared \u0027sniffing\u0027 and neutral positions using a channelled (KingVision® ) and a non-channelled (C-MAC® D-blade) videolaryngoscope in 200 adult patients randomly allocated into four groups (KingVision \u0027sniffing\u0027, KingVision neutral, C-MAC \u0027sniffing\u0027 and C-MAC neutral).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29660807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Videolaryngoscopy for Physician-Based, Prehospital Emergency Intubation: A Prospective, Randomized, Multicenter Comparison of Different Blade Types Using A.P. Advance, C-MAC System, and KingVision.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29239965"
        },
        {
          "offsetInBeginSection": 466,
          "offsetInEndSection": 696,
          "text": "One hundred sixty-eight adult patients requiring prehospital emergency intubation were treated by an emergency physician and randomized to 1 of 3 portable videolaryngoscopes (A.P. Advance, C-MAC PM, and channeled blade KingVision)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29239965"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Videolaryngoscopy vs. direct Macintosh laryngoscopy in tracheal intubation in adults: a ranking systematic review and network meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34855986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Hyperangulated vs. Macintosh videolaryngoscopy in adults with anticipated difficult airway management: a randomised controlled trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38789407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Comparing Air Medical Personnel Intubation Success Rates Using Direct, Channeled Video-Assisted, and Unchanneled Video-Assisted Laryngoscopy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39632032"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 366,
          "text": "opy with videolaryngoscopy. The videolaryngoscope blades have included both traditional Macintosh blades and hyperangulated blades. Macintosh and hyperangulated blades differ in their geometry and technique for tracheal intubation; certai",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512660"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 326,
          "text": "Videolaryngoscopy (VL) offers improved first-pass success rates over direct laryngoscopy (DL) for both adults and children undergoing elective surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39364015"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Hyperangulated vs. Macintosh videolaryngoscopy in adults with anticipated difficult airway management: a randomised controlled trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38789407"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 128,
          "text": "Video laryngoscopes are commonly used along with Macintosh and McCoy laryngoscopes for Nasotracheal intubation (NTI)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38715753"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 543,
          "text": "We hypothesised that the use of a videolaryngoscope during rapid sequence intubation would be associated with a higher first pass tracheal intubation success rate than conventional direct laryngoscopy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38345268"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 678,
          "text": "We separately compared outcomes according to VL design: Macintosh-style, hyperangulated, and channelled.RESULTS: A total of 222 RCTs (with 26 149 participants) were included.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820934"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 508,
          "text": "This study aimed to compare two videolaryngoscopes (McGrath MAC and Pentax AWS) with a Macintosh laryngoscope during nasotracheal intubation.METHODS: Overall, 123 patients older than 18 with normal airways who needed nasotracheal intubation were randomly allocated into three groups: Macintosh (n\u003d41), McGrath (n\u003d41), and Pentax (n\u003d41).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31571890"
        },
        {
          "offsetInBeginSection": 1734,
          "offsetInEndSection": 2040,
          "text": "Among experienced laryngoscopists, the C-MAC offered better glottic visualisation with less ELM than the Macintosh.CONCLUSIONS: The C-MAC provided better glottic visualisation and less ELM (GRADE: Very Low or Moderate), with improved success rates, glottic visualisation, and less ELM in difficult airways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29894918"
        },
        {
          "offsetInBeginSection": 1186,
          "offsetInEndSection": 1879,
          "text": "er risk of difficult laryngoscopy we recommend the use of the Airtraq, CTrach, GlideScope, Pentax AWS and V-MAC to achieve successful intubation. In difficult direct laryngoscopy (C\u0026L \u003e/\u003d 3) we cautiously recommend the use of the Airtraq, Bonfils, Bullard, CTrach, GlideScope, and Pentax AWS, by an operator with reasonable prior experience, to achieve successful intubation when used in accordance with the ASA practice guidelines for management of the difficult airway. There is additional evidence to support the use of the Airtraq, Bonfils, CTrach, GlideScope, McGrath, and Pentax AWS following failed intubation via direct laryngoscopy to achieve successful intubation. Future investigati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23241277"
        },
        {
          "offsetInBeginSection": 741,
          "offsetInEndSection": 888,
          "text": "atients were allocated randomly to tracheal intubation with either hyperangulated (C-MAC D-BLADE™) or Macintosh videolaryngoscope blades (C-MAC™). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38789407"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 473,
          "text": " This randomized controlled study aims to compare the use of the McGrath videolaryngoscope with the C-MAC videolaryngoscope in adult patients with potential difficult airways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22677878"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 605,
          "text": "We conducted this study to compare a non-channeled reusable video laryngoscope BPL VL-02 (manufactured by BPL Medical Technologies, Bangalore, India) with a conventional laryngoscope for intubation of adult patients in the ICU.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37485208"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 149,
          "text": "This study compares the performance of the McGrath MAC and King Vision laryngoscope systems for endotracheal intubation in adult patients ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25881731"
        },
        {
          "offsetInBeginSection": 25,
          "offsetInEndSection": 276,
          "text": "We investigated whether the use of two different video laryngoscopes [direct-coupled interface (DCI) video laryngoscope and GlideScope] may improve laryngoscopic view and intubation success compared with the conventional direct Macintosh laryngoscope ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19809328"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 270,
          "text": " The present study was performed to compare the ease in the use of the Airway Scope (AWS), Trueview EVO2 (TVE), and Fibertech Video Laryngoscope (FVL)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23431906"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 362,
          "text": "The GlideScope(®) videolaryngoscope (Verathon Inc., Bothell, WA, USA) is designed to assist tracheal intubation for patients with a difficult airway. We wished to compare the GlideScope and direct laryngoscopy for double-lumen tube intubation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22324297"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 468,
          "text": "e compared the percentage of glottic opening score between McGRATH MAC Videolaryngoscope and Coopdech Videolaryngoscope Portable VLP-100 by anesthesia staffs and unexperienced anesthetic trainees. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25255665"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 606,
          "text": " This study aimed to compare the effectiveness of Wycope VL, C-MAC Video Laryngoscope (C-MAC VL), and DL",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36318002"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "The aim of the present paper is to review the literature regarding video-laryngoscopes (Storz V-Mac and C-Mac, Glidescope, McGrath, Pentax-Airway Scope, Airtraq and Bullard) and discuss their clinical role in airway management.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20887406"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 654,
          "text": "The first-pass success rate was 87.3% overall: 87% with a Macintosh videolaryngoscope, 92% with a hyperangulated videolaryngoscope ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39100912"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 324,
          "text": "This prospective randomised clinical trial compared \u0027sniffing\u0027 and neutral positions using a channelled (KingVision® ) and a non-channelled (C-MAC® D-blade) videolaryngoscope in 200 adult patients ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29660807"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 359,
          "text": "all three types of VL device (Macintosh-style, hyper-angulated and channeled) reduced the risk of failed intubation and increased the likelihood of first-pass success.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38807147"
        },
        {
          "offsetInBeginSection": 446,
          "offsetInEndSection": 704,
          "text": "y medicine centers. One hundred sixty-eight adult patients requiring prehospital emergency intubation were treated by an emergency physician and randomized to 1 of 3 portable videolaryngoscopes (A.P. Advance, C-MAC PM, and channeled blade KingVision) with di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29239965"
        },
        {
          "offsetInBeginSection": 222,
          "offsetInEndSection": 489,
          "text": "recognised.METHODS: CENTRAL, CINAHL, EMBASE, MEDLINE, and Web of Science were searched for RCTs that compared flexible bronchoscopes, direct laryngoscopes, optical stylets and channelled or unchannelled videolaryngoscopes in adult patients having awake tracheal intub",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34303493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "STUDY OBJECTIVE: Videolaryngoscopes can be fitted either with channeled or non-channeled blades, which may result in a different performance and success of tra",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30393765"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "The C-MAC videolaryngoscope is the first Macintosh-typed videolaryngoscope.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28740393"
        },
        {
          "offsetInBeginSection": 470,
          "offsetInEndSection": 834,
          "text": "Among these devices, a rigid videolaryngoscope (VLS) uses a blade to retract the soft tissues and transmits a lighted video image to a screen.OBJECTIVES: Our primary objective was to assess whether use of videolaryngoscopy for tracheal intubation in adults requiring general anaesthesia reduces risks of complications and failure compared with direct laryngoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27844477"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 370,
          "text": " we compared King Vision videolaryngoscope, C-MAC videolaryngoscope for endotracheal intubation in patients with proven/suspected cervical spine injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28217398"
        },
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 725,
          "text": "ne hundred sixty-eight adult patients requiring prehospital emergency intubation were treated by an emergency physician and randomized to 1 of 3 portable videolaryngoscopes (A.P. Advance, C-MAC PM, and channeled blade KingVision) with different blade types. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29239965"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 236,
          "text": " We aimed to compare the efficacy of CTrach™ (CT) and Direct Coupled Interface-Videolaryngoscope (DCI-VL) in patients with normal airways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207012"
        },
        {
          "offsetInBeginSection": 324,
          "offsetInEndSection": 626,
          "text": "In this study, we compared three videolaryngoscopes (VLSs) in patients undergoing tracheal intubation for elective surgery: the GlideScope Ranger (GlideScope, Bothell, WA), the V-MAC Storz Berci DCI (Karl Storz, Tuttlingen, Germany), and the McGrath (McGrath series 5, Aircraft medical, Edinburgh, UK) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690253"
        },
        {
          "offsetInBeginSection": 398,
          "offsetInEndSection": 508,
          "text": "ecruited. The participants underwent 2 tests with 4 laryngoscopes: Macintosh, McGrath, Pentax Airway-Scope and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244042"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 347,
          "text": " We did a comparative study between Split Type Postman videolaryngoscope and Macintosh laryngoscope, evaluating their efficacy for tracheal intubation in a simulated difficult airway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35497705"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "The aim of the present paper is to review the literature regarding video-laryngoscopes (Storz V-Mac and C-Mac, Glidescope, McGrath, Pentax-Airway Scope, Airtraq and Bullard) and discuss their clinical role in airway management",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20887406"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Increased First Pass Success with C-MAC Videolaryngoscopy in Prehospital Endotracheal Intubation-A Randomized Controlled Trial",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32842705"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "First-attempt awake tracheal intubation success rate using a hyperangulated unchannelled videolaryngoscope vs. a channelled videolaryngoscope in patients with anticipated difficult airway: a randomised controlled trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39075801"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 748,
          "text": ".METHODS: We included clinicians from a randomised controlled trial who were familiar with direct laryngoscopy and Macintosh-blade videolaryngoscopy but inexperienced with hyperangula",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39604038"
        },
        {
          "offsetInBeginSection": 252,
          "offsetInEndSection": 593,
          "text": "omplications. Videolaryngoscopes (VLs) have been proposed to improve airway management, and while recent studies have confirmed that VLs improve intubation conditions in this patient population, there remains a lack of clarity regarding the selection between a standard Macintosh blade or a hyperangulated one, to determine which yields the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39237284"
        },
        {
          "offsetInBeginSection": 1095,
          "offsetInEndSection": 1281,
          "text": "udy conducted in 29 ICUs in Spain. Patients will be randomly assigned in a 1:1 ratio to undergo intubation using a Macintosh VL (control group) or a hyperangulated VL (experimental group",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39237284"
        },
        {
          "offsetInBeginSection": 720,
          "offsetInEndSection": 869,
          "text": "tant anaesthetists. Patients were allocated randomly to tracheal intubation with either hyperangulated (C-MAC D-BLADE™) or Macintosh videolaryngoscop",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38789407"
        },
        {
          "offsetInBeginSection": 306,
          "offsetInEndSection": 480,
          "text": " alignment. The present study aimed to compare the total time taken by Macintosh laryngoscope (ML), conventional blade, and D-blade ™ of C-MAC ® VL in simulated CSI scenarios",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39140638"
        },
        {
          "offsetInBeginSection": 461,
          "offsetInEndSection": 569,
          "text": " intubation option. In the interventional period (18 months) a hyperangulated videolaryngoscope was the firs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38964608"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "BACKGROUND: The most commonly used devices for direct visualization of the larynx and tracheal intubation are Macintosh and McCoy laryngoscopes. C-MAC video laryngoscope, based on the principles of indirect laryngoscopy, has been introduced into clinical practice in r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31198251"
        },
        {
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1558,
          "text": "sted intubation technique were observed.CONCLUSIONS: The C-MAC videolaryngoscope is a mobile system which facilitates endotracheal intubation in patients w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926681"
        },
        {
          "offsetInBeginSection": 66,
          "offsetInEndSection": 209,
          "text": "hallenging. The McGrath Mac Video Laryngoscope (Medtronic, Minneapolis, MN) has been proven to be a reliable alternative for in-hospital airway",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31389835"
        },
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 365,
          "text": "al anatomy. The aim of this randomized prospective study was to compare Macintosh laryngoscope and Airtraq video laryngoscope for endotracheal intubation in patients with thyro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "BACKGROUND: Using a Macintosh-style videolaryngoscope as a first-intention device for tracheal intubation of unselected patients in the operating room has not often b",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35811139"
        },
        {
          "offsetInBeginSection": 313,
          "offsetInEndSection": 740,
          "text": "ryngoscopy. In this study, we compared three videolaryngoscopes (VLSs) in patients undergoing tracheal intubation for elective surgery: the GlideScope Ranger (GlideScope, Bothell, WA), the V-MAC Storz Berci DCI (Karl Storz, Tuttlingen, Germany), and the McGrath (McGrath series 5, Aircraft medical, Edinburgh, UK) and tested whether it is feasible to intubate the trachea of patients with indirect videolaryngoscopy without usi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19690253"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 827,
          "text": "In this multicentre randomised controlled trial, 1000 adult patients requiring tracheal intubation for elective, urgent or emergency surgery were allocated randomly to airway management using a McGrath™ MAC videolaryngoscope (Medtronic, Minneapolis, MN, USA) or direct laryngoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38345268"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 611,
          "text": "In this multicentre randomised trial, 2092 adult patients without predicted difficult airway requiring tracheal intubation for elective surgery were allocated randomly to either videolaryngoscopy with a Macintosh blade (McGrath™) or direct laryngoscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36928625"
        },
        {
          "offsetInBeginSection": 375,
          "offsetInEndSection": 714,
          "text": "Dental force was measured while 104 anaesthetists performed a series of tracheal intubations using direct laryngoscopy with a Macintosh blade, and videolaryngoscopy with a C-MAC® , or the hyperangulated GlideScope® or KingVision® laryngoscopes in both normal and difficult airway conditions. A total of 624 tracheal intubations were analys",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31448404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "The C-MAC videolaryngoscope is the first Macintosh-typed videolaryngoscope. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28740393"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 251,
          "text": "goscopy. The videolaryngoscope blades have included both traditional Macintosh blades and hyperangulated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512660"
        },
        {
          "offsetInBeginSection": 983,
          "offsetInEndSection": 1058,
          "text": "The C-MAC and C-MAC D-Blade were top ranked for avoiding failed intubation,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34855986"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 705,
          "text": "Studies on adult patients or adult-sized manikins were included when direct laryngoscopy was compared to Glidescope® videolaryngoscopy by clinicians with limited experience in tracheal intubation (\u003c10 intubations per year).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36362519"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "The VL3 videolaryngoscope for tracheal intubation in adults: A prospective pilot study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32934623"
        },
        {
          "offsetInBeginSection": 528,
          "offsetInEndSection": 796,
          "text": "In this prospective randomised trial, adult patients requiring tracheal intubation during thyroid surgery were randomly allocated to two groups of C-MAC® (Macintosh style blade) videolaryngoscope or direct laryngoscopy using the Macintosh laryngoscope. Primary outcome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36166515"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 423,
          "text": "goscopy. The videolaryngoscope blades have included both traditional Macintosh blades and hyperangulated blades. Macintosh and hyperangulated blades differ in their geometry and technique for tracheal intubation; certain patient populations may benefit from one blade type ove",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512660"
        }
      ],
      "type": "list",
      "id": "67f8527318b1e36f2e000104",
      "ideal_answer": [
        "Videolaryngoscopy types include the Macintosh-style , hyper-angulated and channeled videolaryngoscopes",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation are Macintosh-style, hyper-angulated, and channeled.",
        "Videoassistance in difficult airway management, or videolaryngoscopy, has been shown to improve success rates of intubation and reduce complications in high risk patients. The GlideScope, Super Laryngoscope, Stellenbosch 3Wire, iLarynx, Carl Zeiss Ohof 3D, and the C MAC device are different types of Videolaryngoscopy.",
        "For adults undergoing tracheal intubation, the primary types of videolaryngoscopy identified are: Macintosh-style Videolaryngoscopy, Hyperangulated Videolaryngoscopy, and Channelled Videolaryngoscopy. Notably, Channelled Videolaryngoscopy may include a subgroup with a Tracheal Tube Guide Channel, particularly beneficial for adults with obesity. Specific devices like C-MAC and C-MAC D-Blade are examples within these categories, with their performance subject to comparison. These types facilitate effective airway management in adult patients.",
        "Videoassisted interpersonal neck dissection, VideoLaryngoscopy (VL) has emerged as a valuable tool in airway management. It can be performed with various different laryngoscopes (e.g. GlideScope(R), Stellenbosch 3Patent Tracheal Comer (STP), and C MAC(intubation, angioplasty, resection, extubation; IMRT)",
        "GlideScope Ranger, KingVision, V-MAC Storz Berci DCI, and McGrath are types of Videolaryngoscopy for adults undergoing tracheal intubation.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation are GlideScope Ranger, V-MAC Storz Berci DCI, KingVision, McGrath series 5, and McGrath.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: McGrath videolaryngoscope, C-MAC D-BLADE videolaryngoscope, and C-MAC videolaryngoscope.",
        "The types of Videolaryngoscopy for adults undergoing tracheal intubation include the GlideScope Ranger, V-MAC Storz Berci DCI, McGrath, KingVision, McGrath series 5, hyperangulated, channelled, and Macintosh-style.",
        "Common adult videolaryngoscopes include the Storz V-Mac, Storz C-Mac, GlideScope, McGrath, Pentax-Airway Scope (AWS), Airtraq and Bullard videolaryngoscopes.",
        "Direct Video Laryngoscopy, Rigid Video Laryngoscopy, Flexible Video Laryngoscopy, Optical Stylet Video Laryngoscopy, and Video Laryngoscope with a Built-in Light Source.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: 1. Macintosh-style videolaryngoscopy 2. Hyperangulated videolaryngoscopy 3. Channelled videolaryngoscopy",
        "The types of videolaryngoscopy (VL) for adults undergoing tracheal intubation include Macintosh-style, hyper-angulated, and channeled videolaryngoscopes.",
        "The types of videolaryngoscopes for adults undergoing tracheal intubation include Macintosh-style, hyperangulated, and channelled designs.",
        "There are four types of videolaryngoscopy: Macintosh-style, hyperangulated, channelled and single use.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: McGrath videolaryngoscope, C-MAC D-BLADE, and C-MAC videolaryngoscope.",
        "There are three types of videolaryngoscopy:\n1. Macintosh-style videolaryngoscopy\n2. Hyperangulated videolaryngoscopy\n3. Channelled videolaryngoscopy",
        "Based on the provided abstracts, the types of Videolaryngoscopy for adults undergoing tracheal intubation are:\n\n1. Awake Videolaryngoscopy: This technique involves performing videolaryngoscopy while the patient is awake.\n2. Video-Assisted Flexible (Bronchoscopic) Intubation: This method combines videolaryngoscopy with flexible bronchoscopy to facilitate tracheal intubation.\n3. Hyperangulated Videolaryngoscopy (HA-VL): This type of videolaryngoscopy uses a hyperangulated blade, which is designed for better visualization and navigation of the airway.\n4. Standard-Geometry Videolaryngoscopy (SG-VL): This type of videolaryngoscopy uses a standard-geometry blade, which is the traditional design used in videolaryngoscopes.\n\nAdditionally, some devices, such as the C-MAC device, offer the option to switch between direct and video laryngoscopy with the same device.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include Macintosh-style, hyper-angulated, and channeled videolaryngoscopes.",
        "Macintosh-style, hyper-angulated, and channeled videolaryngoscopes",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation identified across the abstracts include: Macintosh-style, Hyperangulated, and Channelled videolaryngoscopy, with additional specific devices noted as C-MAC and C-MAC D-Blade in the context of comparative performance.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation are KingVision, McGrath, GlideScope Ranger, V-MAC Storz Berci DCI, and McGrath series 5.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include Macintosh-style VL, hyperangulated VL (HA-VL), standard-geometry VL (SG-VL), and channeled blade VL. Some studies also refer to rigid videolaryngoscopes (VLS) that use a blade to retract soft tissues and transmit a lighted video image to a screen.",
        "The Cochrane systematic review and meta-analysis published in 2022 that compared videolaryngoscopy (VL) with direct laryngoscopy (DL) for facilitating tracheal intubation in adults found that all three types of VL device (Macintosh- style, hyper-angulated and channeled) reduced the risk of failed intubation and increased the likelihood of first- pass success.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation are:\n1. Macintosh-style videolaryngoscope\n2. Hyper-angulated videolaryngoscope\n3. Channeled videolaryngoscope",
        "The types of Videolaryngoscopy for adults undergoing tracheal intubation include Macintosh-style, hyper-angulated, and channeled videolaryngoscopy devices, as found in a Cochrane systematic review and meta-analysis. These devices have been shown to reduce the risk of failed intubation and increase the likelihood of first-pass success.",
        "Videolaryngoscopy (VL) types used for adult tracheal intubation include Macintosh-style, hyper-angulated, and channeled devices like the A.P. Advance, C-MAC System, and KingVision. Studies have compared channeled (KingVision) and non-channelled (C-MAC) VL devices, evaluating different head positions like \u0027sniffing\u0027 versus neutral.",
        "There are several types of videolaryngoscope that can be used for adult tracheal intubation, such as: 1. The Applebaum (or Combeback) blade. 2. The C MAC blade. 3. The King blade. 4. The wire free GlideScope® Freedom blade.",
        "Videolaryngoscopy types for adults undergoing tracheal intubation can be channeled, Macintosh-style, hyper-angulated, and KingVision.",
        "The studies indicate that for adult tracheal intubation, videolaryngoscopes come in several designs: Macintosh-style, hyper-angulated, and channelled. Some devices also differentiate between channelled (like KingVision) and non-channelled designs (like C-MAC).",
        "The types of Videolaryngoscopy for adults undergoing tracheal intubation include Channeled videolaryngoscopy, KingVision, Macintosh-style, hyper-angulated, channeled, and Macintosh-style videolaryngoscopy.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: Macintosh-style videolaryngoscope, hyper-angulated videolaryngoscope, channeled videolaryngoscope, A.P. Advance videolaryngoscope, C-MAC system, and KingVision videolaryngoscope.",
        "The types of Videolaryngoscopy for adults undergoing tracheal intubation include KingVision, channeled, Macintosh-style, hyper-angulated, Macintosh-style videolaryngoscopy, C-MAC System, Channeled videolaryngoscopy, and Hyper-angulated videolaryngoscopy.",
        "The types of videolaryngoscopy include Macintosh-style devices, hyper-angulated devices, and channeled devices.",
        "[\u0027The types of videolaryngoscopy for adults undergoing tracheal intubation include Macintosh-style, hyper-angulated, channeled, C-MAC® (non-channelled), KingVision® (channelled), A.P. Advance, and C-MAC PM.\u0027]",
        "Videolaryngoscopes (VLSs) can be Macintosh-style, hyper-angulated, or channeled. Examples of videolaryngoscopes include A.P. Advance, C-MAC PM, channeled blade KingVision, and C-MAC D-blade.",
        "Three main types of videolaryngoscopy (VL) devices are used for adult tracheal intubation: Macintosh-style, hyper-angulated, and channeled blades. Specific examples include A.P. Advance, C-MAC PM (non-channeled), and KingVision (channeled).",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: Macintosh-style videolaryngoscope, hyper-angulated videolaryngoscope, channeled videolaryngoscope, A.P. Advance, C-MAC PM, and KingVision.",
        "The three types of videolaryngoscopy (VL) devices are Macintosh-style, hyper-angulated and channeled.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: Macintosh-style videolaryngoscope, hyper-angulated videolaryngoscope, channeled videolaryngoscope, A.P. Advance videolaryngoscope, C-MAC system videolaryngoscope, and KingVision videolaryngoscope.",
        "Videolaryngoscopy, Head-mounted Videolaryngoscopy, Neck-mounted Videolaryngoscopy, patients, tracheal intubation",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include: Macintosh-style videolaryngoscope, hyper-angulated videolaryngoscope, channeled videolaryngoscope (e.g., KingVision®), and non-channeled videolaryngoscope (e.g., C-MAC®).",
        "The types of videolaryngoscopy devices for adult tracheal intubation include Macintosh-style, hyper-angulated, and channeled videolaryngoscopes.",
        "There are three types of videolaryngoscopy devices: Macintosh-style, hyper-angulated and channeled.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation are Macintosh-style, hyper-angulated, and channeled videolaryngoscopes.",
        "[\u0027The types of videolaryngoscopy (VL) devices for adults undergoing tracheal intubation include Macintosh-style, hyper-angulated, and channeled videolaryngoscopes. Examples of specific videolaryngoscopes mentioned are KingVision® (channeled and non-channeled), C-MAC® (including C-MAC D-blade), and A.P. Advance.\u0027]",
        "Based on the provided texts, the types of Videolaryngoscopy (VL) for adults undergoing tracheal intubation are:\n\n1. Macintosh-style VL device\n2. Hyper-angulated VL device\n3. Channeled VL device (e.g., KingVision)\n4. Non-channeled VL device (e.g., C-MAC)\n\nAdditionally, the texts mention different blade types, such as:\n\n* A.P. Advance\n* C-MAC System\n* C-MAC PM\n* C-MAC D-blade\n\nThese may be specific models or variations of the above-mentioned types of VL devices.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include Macintosh-style, Hyper-angulated, and Channeled (with specific examples being KingVision, variations of the C-MAC System, and A.P. Advance, noting that some of these products may overlap in design features).",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation are KingVision, channeled, Macintosh-style, and hyper-angulated.",
        "The main types of videolaryngoscopy for adults undergoing tracheal intubation are Macintosh-style, hyper-angulated, and channeled videolaryngoscopes, with specific devices including A.P. Advance, C-MAC (including D-blade), and KingVision. These devices have been shown to improve intubation success rates compared to direct laryngoscopy.",
        "The types of videolaryngoscopy for adults undergoing tracheal intubation include Macintosh-style, hyper-angulated, and channeled devices, as identified in a Cochrane review, and specific models such as A.P. Advance, C-MAC PM, and KingVision, which were studied in randomized trials for prehospital emergency intubation and head position comparisons.",
        "The Cochrane systematic review and meta-analysis published in 2022 found that there are three types of Videolaryngoscopy devices that can be used for adults undergoing tracheal intubation: Macintosh-style, hyper-angulated, and channeled."
      ],
      "exact_answer": [
        [
          "Macintosh-style videolaryngoscope",
          "McGrath MAC"
        ],
        [
          "hyper-angulated"
        ],
        [
          "channeled",
          "King Vision"
        ],
        [
          "AP advance"
        ],
        [
          "Airtraq"
        ],
        [
          "Pentax AWS"
        ],
        [
          "V-MAC"
        ],
        [
          "CTrach"
        ],
        [
          "GlideScope"
        ],
        [
          "oopdech Videolaryngoscope Portable VLP-100"
        ],
        [
          "Split Type Postman"
        ],
        [
          "C-MAC"
        ]
      ]
    },
    {
      "body": "Is Electroconvulsive Therapy used for any type of epilepsy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38769254",
        "http://www.ncbi.nlm.nih.gov/pubmed/9371927",
        "http://www.ncbi.nlm.nih.gov/pubmed/9581214",
        "http://www.ncbi.nlm.nih.gov/pubmed/21333551",
        "http://www.ncbi.nlm.nih.gov/pubmed/11528315",
        "http://www.ncbi.nlm.nih.gov/pubmed/22531207",
        "http://www.ncbi.nlm.nih.gov/pubmed/32516983",
        "http://www.ncbi.nlm.nih.gov/pubmed/17435572",
        "http://www.ncbi.nlm.nih.gov/pubmed/35287528"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 171,
          "text": "Electroconvulsive therapy (ECT) has been suggested as a treatment option for refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38769254"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "We treated two children with intractable epilepsy with electroconvulsive therapy (ECT) for seizure control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371927"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Electroconvulsive therapy for treatment of intractable seizures.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371927"
        },
        {
          "offsetInBeginSection": 306,
          "offsetInEndSection": 534,
          "text": "ECT has numerous anticonvulsant effects, including elevated seizure threshold and decreased seizure duration, which make it a useful adjunctive therapy in epilepsy that is refractory or not amenable to treatment with medication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9581214"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 439,
          "text": "INTRODUCTION: Owing to its potent anticonvulsant actions, electroconvulsive therapy (ECT) has been proposed as an intervention for treatment-resistant seizure disorders.METHOD: We review the literature on the use of ECT in treatment-resistant epilepsy and status epilepticus (SE) and present a case of a patient who was in nonconvulsive SE for 26 days and then treated with ECT after all standard pharmacological strategies were exhausted.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11528315"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 779,
          "text": "Whereas ECT has recently been used to terminate medication-refractory status epilepticus, there is little current literature on its planned administration as a specific maintenance treatment for medication-refractory epilepsy.METHODS: We used maintenance ECT to treat an 18-year-old man with a long-standing generalized tonic-clonic seizure disorder who had shown poor response to several antiepileptic drugs administered in combination with antiepileptic medication compliance confirmed through drug level monitoring.RESULTS: A total of 52 ECTs were administered across nearly 20 months at a mean frequency of once in nearly 12 days.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22531207"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 412,
          "text": "While electroconvulsive therapy (ECT) has been employed successfully as a treatment for refractory epilepsy and status epilepticus (SE) after exhausting conventional therapy, its use for pediatric patients is limited.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21333551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "We treated two children with intractable epilepsy with electroconvulsive therapy (ECT) for seizure control",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371927"
        },
        {
          "offsetInBeginSection": 357,
          "offsetInEndSection": 502,
          "text": "These findings suggest a possible role for ECT in the management of intractable epilepsy in children who are not candidates for epileptic surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9371927"
        },
        {
          "offsetInBeginSection": 702,
          "offsetInEndSection": 811,
          "text": "ECT was applied to six patients with SRSE after the failure of antiepileptic treatment and pharmacologic coma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32516983"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "BACKGROUND: Electroconvulsive therapy (ECT) has been suggested as a treatment option for refractory status epilepticus (RSE) and super-refractory status epilept",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38769254"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "In this first report of electroconvulsive therapy (ECT) for the simultaneous treatment of seizures and depressive episodes, the authors discuss the use of ECT in the treatment of complex-partial seizures and major depression in a geriatric patients who refused antidepressant and antiepileptic medication",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9581214"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "OBJECTIVE: To describe a case in which electroconvulsive therapy (ECT) was used successfully to treat refractory status epilepticus (SE) after all pharmacological therapies were",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17435572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "OBJECTIVE: We aim to describe use of electroconvulsive therapy (ECT) to treat super refractory status epilepticus (SRSE) in pregnancy and review the literature regarding utility and safety of ECT in refractory status e",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35287528"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 228,
          "text": "We aim to describe use of electroconvulsive therapy (ECT) to treat super refractory status epilepticus (SRSE) in pregnancy and review the literature regarding utility and safety of ECT in refractory status epilepticus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35287528"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 417,
          "text": "re disorders.METHOD: We review the literature on the use of ECT in treatment-resistant epilepsy and status epilepticus (SE) and present a case of a patient who was in nonconvulsive SE for 26 days and then treated with ECT after all standard pharmacological stra",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11528315"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 358,
          "text": " disorders. Whereas ECT has recently been used to terminate medication-refractory status epilepticus, there is little current literature on its planned administration as a specific maintenance treatment for medication-refract",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22531207"
        }
      ],
      "type": "yesno",
      "id": "680f4ae9353a4a2e6b000009",
      "ideal_answer": [
        "ECT is sometimes used for refractory and super-refractory status epilepticus."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What are the characteristics of the M1/M2 macrophage polarization paradigm in the tumor microenvironment?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34209703",
        "http://www.ncbi.nlm.nih.gov/pubmed/37530555",
        "http://www.ncbi.nlm.nih.gov/pubmed/12401408",
        "http://www.ncbi.nlm.nih.gov/pubmed/36325334",
        "http://www.ncbi.nlm.nih.gov/pubmed/27562774",
        "http://www.ncbi.nlm.nih.gov/pubmed/37108657",
        "http://www.ncbi.nlm.nih.gov/pubmed/37035885",
        "http://www.ncbi.nlm.nih.gov/pubmed/38935134",
        "http://www.ncbi.nlm.nih.gov/pubmed/35844605",
        "http://www.ncbi.nlm.nih.gov/pubmed/38878638",
        "http://www.ncbi.nlm.nih.gov/pubmed/23766387",
        "http://www.ncbi.nlm.nih.gov/pubmed/38590197",
        "https://www.ncbi.nlm.nih.gov/pubmed/32849616",
        "https://www.ncbi.nlm.nih.gov/pubmed/34209703",
        "https://www.ncbi.nlm.nih.gov/pubmed/35844605",
        "https://www.ncbi.nlm.nih.gov/pubmed/35874739",
        "https://www.ncbi.nlm.nih.gov/pubmed/37108657",
        "https://www.ncbi.nlm.nih.gov/pubmed/37491279",
        "http://www.ncbi.nlm.nih.gov/pubmed/39221578",
        "http://www.ncbi.nlm.nih.gov/pubmed/32311768",
        "http://www.ncbi.nlm.nih.gov/pubmed/35847834",
        "http://www.ncbi.nlm.nih.gov/pubmed/36816959",
        "http://www.ncbi.nlm.nih.gov/pubmed/31192126",
        "http://www.ncbi.nlm.nih.gov/pubmed/39767591",
        "http://www.ncbi.nlm.nih.gov/pubmed/37711048",
        "http://www.ncbi.nlm.nih.gov/pubmed/28467800",
        "http://www.ncbi.nlm.nih.gov/pubmed/28811825",
        "http://www.ncbi.nlm.nih.gov/pubmed/34440860",
        "http://www.ncbi.nlm.nih.gov/pubmed/32036448",
        "http://www.ncbi.nlm.nih.gov/pubmed/39729775",
        "http://www.ncbi.nlm.nih.gov/pubmed/39710293",
        "http://www.ncbi.nlm.nih.gov/pubmed/34289846",
        "http://www.ncbi.nlm.nih.gov/pubmed/34398156",
        "http://www.ncbi.nlm.nih.gov/pubmed/35874739",
        "http://www.ncbi.nlm.nih.gov/pubmed/24058644",
        "http://www.ncbi.nlm.nih.gov/pubmed/33365025",
        "http://www.ncbi.nlm.nih.gov/pubmed/36007473",
        "http://www.ncbi.nlm.nih.gov/pubmed/37218976",
        "http://www.ncbi.nlm.nih.gov/pubmed/38012322",
        "http://www.ncbi.nlm.nih.gov/pubmed/32699181",
        "http://www.ncbi.nlm.nih.gov/pubmed/35590082",
        "http://www.ncbi.nlm.nih.gov/pubmed/35165862",
        "http://www.ncbi.nlm.nih.gov/pubmed/36358644",
        "http://www.ncbi.nlm.nih.gov/pubmed/32968456",
        "http://www.ncbi.nlm.nih.gov/pubmed/39693782",
        "http://www.ncbi.nlm.nih.gov/pubmed/28670313",
        "http://www.ncbi.nlm.nih.gov/pubmed/37809073",
        "http://www.ncbi.nlm.nih.gov/pubmed/25620672",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002039",
        "http://www.ncbi.nlm.nih.gov/pubmed/25125485",
        "http://www.ncbi.nlm.nih.gov/pubmed/34453949",
        "http://www.ncbi.nlm.nih.gov/pubmed/35918698",
        "http://www.ncbi.nlm.nih.gov/pubmed/38743074",
        "http://www.ncbi.nlm.nih.gov/pubmed/30245686",
        "http://www.ncbi.nlm.nih.gov/pubmed/33304783",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205204",
        "http://www.ncbi.nlm.nih.gov/pubmed/32595638",
        "http://www.ncbi.nlm.nih.gov/pubmed/39202998",
        "http://www.ncbi.nlm.nih.gov/pubmed/39566403",
        "http://www.ncbi.nlm.nih.gov/pubmed/38960836",
        "http://www.ncbi.nlm.nih.gov/pubmed/22116397",
        "http://www.ncbi.nlm.nih.gov/pubmed/35565348",
        "http://www.ncbi.nlm.nih.gov/pubmed/39351237",
        "http://www.ncbi.nlm.nih.gov/pubmed/35638244",
        "http://www.ncbi.nlm.nih.gov/pubmed/37759870",
        "http://www.ncbi.nlm.nih.gov/pubmed/37503340",
        "http://www.ncbi.nlm.nih.gov/pubmed/39403370",
        "http://www.ncbi.nlm.nih.gov/pubmed/37882718",
        "http://www.ncbi.nlm.nih.gov/pubmed/23737783",
        "http://www.ncbi.nlm.nih.gov/pubmed/39240019",
        "http://www.ncbi.nlm.nih.gov/pubmed/35127254",
        "http://www.ncbi.nlm.nih.gov/pubmed/22778768",
        "http://www.ncbi.nlm.nih.gov/pubmed/36208648",
        "http://www.ncbi.nlm.nih.gov/pubmed/39144141",
        "http://www.ncbi.nlm.nih.gov/pubmed/36214645"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 508,
          "text": "Macrophages represent heterogeneous cell population with important roles in defence mechanisms and in homoeostasis. Tissue macrophages from diverse anatomical locations adopt distinct activation states. M1 and M2 macrophages are two polarized forms of mononuclear phagocyte in vitro differentiation with distinct phenotypic patterns and functional properties, but in vivo, there is a wide range of different macrophage phenotypes in between depending on the microenvironment and natural signals they receive.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37530555"
        },
        {
          "offsetInBeginSection": 686,
          "offsetInEndSection": 894,
          "text": "Macrophages infiltrating the tumours can affect the patient\u0027s prognosis. M2 macrophages have been shown to promote tumour growth, while M1 macrophages provide both tumour-promoting and anti-tumour properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37530555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 535,
          "text": "The M1/M2 macrophage paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34209703"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 401,
          "text": "M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34209703"
        },
        {
          "offsetInBeginSection": 761,
          "offsetInEndSection": 1206,
          "text": "On one end, M1 are pro-inflammatory macrophages that initiate an immunological response, damage tissue integrity, and dampen tumor progression by fostering robust T and natural killer (NK) cell anti-tumoral responses. On the other end, M2 are anti-inflammatory macrophages involved in tissue remodeling and tumor growth, that promote cancer cell proliferation, invasion, tumor metastasis, angiogenesis and that participate to immune suppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36325334"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 629,
          "text": "Macrophages can be categorized into two extreme subsets, classically activated (M1) and alternatively activated (M2) macrophages based on their distinct functional abilities in response to microenvironmental stimuli. In a tumor microenvironment, tumor associated macrophages (TAMs) are considered to be of the polarized M2 phenotype that enhances tumor progression and represent a poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27562774"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 873,
          "text": "The M1/M2 macrophage paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes. Investigating TME-induced macrophage polarization is critical for further understanding of TAM-related pro-tumor outcomes and potential development of new therapeutic approaches. This review explores the current understanding of TME-induced macrophage polarization and the role of M2-polarized macrophages in promoting tumor progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34209703"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 642,
          "text": "Tumor-associated macrophages are a major cellular component of cancer-related inflammation and have served as a paradigm for the plasticity and functional polarization of mononuclear phagocytes. Tumor-associated macrophages can exert dual influence of cancer depending on the activation state, with classically activated (M1) and alternatively activated (M2) cells generally exerting antitumoral and protumoral functions, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23766387"
        },
        {
          "offsetInBeginSection": 264,
          "offsetInEndSection": 518,
          "text": "They undergo M1/M2 polarization in response to signals derived from TME. M1 macrophages suppress tumor growth, while their M2 counterparts exert pro-tumoral effects by promoting tumor growth, angiogenesis, metastasis, and resistance to current therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Macrophage polarization is relevant for tumor biology. M2 polarized macrophages favor tumor growth and survival, while M1 macrophages support tumor destruction and antigen presentation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291396"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Macrophage polarization is relevant for tumor biology. M2 polarized macrophages favor tumor growth and survival, while M1 macrophages support tumor destruction and antigen presentation. Markers identifying M1/M2 polarization are a subject of debate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291396"
        },
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 612,
          "text": "In the tumor microenvironment (TME), macrophages tend to M2 polarization, which promotes tumor growth and leads to adverse physiological effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39221578"
        },
        {
          "offsetInBeginSection": 55,
          "offsetInEndSection": 249,
          "text": "M2 polarized macrophages favor tumor growth and survival, while M1 macrophages support tumor destruction and antigen presentation. Markers identifying M1/M2 polarization are a subject of debate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291396"
        },
        {
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1045,
          "text": "Polarization of macrophages into M1 or M2 subtypes plays a vital role in regulating tumor progression, metastasis, and clinical outcome, highlighting the importance of studying the factors driving this process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33522932"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 657,
          "text": "The polarization of macrophages into tumor-suppressive M1 or tumor-promoting M2 types is a fundamental event in the establishment of the tumor microenvironment. Although ample evidence indicates that TAMs are primarily M2 polarized, the mechanisms responsible for the regulation and maintenance of M1 and M2 polarization imbalance remain unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 606,
          "text": "The chronic inflammation of tumor continues to recruit TAMs (tumor-associated macrophages) to the TME (tumor microenvironment) and promote polarization. Pro-inflammatory signals polarize macrophages to the M1 phenotype to enhance inflammation against pathogens. Tumor inflammatory development changes the pro-inflammatory response to an anti-inflammatory response, resulting in the alteration of macrophages from M1 to M2 to promote tumor progression. Additionally, hypoxia activates HIF (hypoxia-inducible factors) in the TME, which reprograms macrophages to the M2 phenotype to support tumor development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36816959"
        },
        {
          "offsetInBeginSection": 662,
          "offsetInEndSection": 879,
          "text": "Most cancer-derived exosomal proteins polarize macrophages towards M2 phenotype, promoting cancer aggressiveness, while a few have role switching towards the M1 phenotype, inhibiting cancer proliferation, respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39710293"
        },
        {
          "offsetInBeginSection": 450,
          "offsetInEndSection": 629,
          "text": "In a tumor microenvironment, tumor associated macrophages (TAMs) are considered to be of the polarized M2 phenotype that enhances tumor progression and represent a poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27562774"
        },
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 618,
          "text": "Macrophages that infiltrate tumor tissues are driven by tumor-derived and T cell-derived cytokines to acquire a polarized M2 phenotype. These functionally polarized cells, and similarly oriented or immature dendritic cells present in tumors, have a key role in subversion of adaptive immunity and in inflammatory circuits that promote tumor growth and progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12401408"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 701,
          "text": "M1 macrophages suppress tumor growth, while their M2 counterparts exert pro-tumoral effects by promoting tumor growth, angiogenesis, metastasis, and resistance to current therapies. Several subsets of the M2 phenotype have been observed, often denoted as M2a, M2b, M2c, and M2d. These are induced by different stimuli and differ in phenotypes as well as functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108657"
        },
        {
          "offsetInBeginSection": 450,
          "offsetInEndSection": 780,
          "text": "In a tumor microenvironment, tumor associated macrophages (TAMs) are considered to be of the polarized M2 phenotype that enhances tumor progression and represent a poor prognosis. Furthermore, TAMs enhance tumor angiogenesis, growth, metastasis, and immunosuppression by secreting a series of cytokines, chemokines, and proteases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27562774"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 637,
          "text": "TAMs are recruited to tumor region in response to various TME components such as cytokines, chemokines as well as exosomes. Subsequently, these environmental cues induce a certain polarization state of TAMs, ranging from anti-tumor states (M1-like) to pro-tumor states (M2-like). Furthermore, the polarization process of TAMs is continuous and gradually inclines toward the M2-like state with malignant progression, forming a positive feedback loop that facilitates tumor growth and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37035885"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 516,
          "text": "Macrophages can have either primarily pro-inflammatory (M1-like) or anti-inflammatory (M2-like) attributes and can continually switch between these two main states. M2-like macrophages within the tumor environment are associated with cancer progression and poor prognosis in several types of cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34398156"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346,
          "text": "Macrophages are one of the most important cells in the innate immune system, they are converted into two distinct subtypes with completely different molecular phenotypes and functional features under different stimuli of the microenvironment: M1 macrophages induced by IFN-γ/lipopolysaccharides(LPS) and M2 macrophages induced by IL-4/IL-10/IL-13",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "Macrophages are cells with many important functions in both innate and adaptive immune responses and have been shown to play a complex role in tumor progression since they harbour both tumor preventing (M1 macrophages) and tumor promoting (M2 macrophages) activities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24058644"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 559,
          "text": "Although previous studies examining TAMs in GBM have shown that certain TAMs are associated with specific clinical and/or pathologic features, these studies used an outdated M1/M2 paradigm of macrophage polarization and failed to include the continuum of TAM states in GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38012322"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 400,
          "text": "M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34209703"
        },
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 372,
          "text": "The M2-like TAMs could stimulate tumor growth and metastasis, tissue remodeling and immune-suppression, whereas M1-like TAMs could initiate immune response to dampen tumor progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35590082"
        },
        {
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1004,
          "text": "At the early stage of tumor formation, TAMs are M1-like phenotype, and they are able to eliminate tumor cells, i.e., by reactive oxygen species formation or by presentation of cancer antigens to other effector immune cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35165862"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 646,
          "text": "Pro-inflammatory stimuli switch macrophages towards an M1-like phenotype and rely mainly on aerobic glycolysis and fatty acid synthesis, whereas anti-inflammatory stimuli switch macrophages towards an M2-like phenotype. M2-like macrophages depend more on oxidative phosphorylation (OXPHOS) and fatty acid oxidation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36358644"
        },
        {
          "offsetInBeginSection": 205,
          "offsetInEndSection": 432,
          "text": "Due to the high plasticity of TAMs, they can polarize into different phenotypes with distinct functions, which are primarily categorized as the pro-inflammatory, anti-tumor M1 type, and the anti-inflammatory, pro-tumor M2 type.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39693782"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 590,
          "text": "Based on these functional phenotypes, tumor-associated macrophages (TAMs) can either aid tumor progression (M2 phenotype) or inhibit it (M1 phenotype",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28670313"
        },
        {
          "offsetInBeginSection": 831,
          "offsetInEndSection": 945,
          "text": "M1 macrophages, also known as classically activated macrophages, exhibit pro-inflammatory and antitumor activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36007473"
        },
        {
          "offsetInBeginSection": 947,
          "offsetInEndSection": 1086,
          "text": "M2 macrophages, also known as alternatively activated macrophages, exhibit anti-inflammatory, pro-tumorigenic, and wound healing activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36007473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Macrophages are one of the principal host cell populations in solid tumors. They are capable, due to their plasticity, of acquiring phenotypes that either combat (M1 type) or promote (M2 type) neoplastic growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620672"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "In the immunosuppressive tumor microenvironment (TME), tumor-associated macrophages (TAMs) predominantly exhibit an immunosuppressive M2 phenotype, which facilitates tumor proliferation and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39729775"
        },
        {
          "offsetInBeginSection": 726,
          "offsetInEndSection": 1002,
          "text": "M1 macrophages are characterized by increased secretion of proinflammatory cytokines, such as IL-1ß, tumor necrosis factor (TNF), IL-27, matrix metalloproteinase (MMPs), CCL2, and VEGF (vascular endothelial growth factor), IGF1, that can lead to the destruction of the tissue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976"
        },
        {
          "offsetInBeginSection": 1003,
          "offsetInEndSection": 1209,
          "text": "In contrast, M2 is supposed to participate in immunosuppression and tumor progression, which is formed after being exposed to the macrophage M-CSF, IL-10, IL-35 and the transforming growth factor-ß (TGF-β).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37218976"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 510,
          "text": "Under the guidance of different microenvironmental signals, macrophages would polarize into two functional phenotypes, named as classically activated macrophages (M1) and alternatively activated macrophages (M2). Contrary to the anti-tumor effect of M1, M2 exerts anti-inflammatory and tumorigenic characters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33304783"
        },
        {
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1260,
          "text": "The following two main classes of macrophages are distinguished: M1 (pro-inflammatory/anti-tumor) and M2 (anti-inflammatory/pro-tumor). These cells exhibit distinct microenvironment-dependent phenotypes that can promote or inhibit metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35205204"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 413,
          "text": "Tumor-associated macrophages (TAMs) have been shown to both aid and hinder tumor growth, with patient outcomes potentially hinging on the proportion of M1, pro-inflammatory/growth-inhibiting, to M2, growth-supporting, phenotypes. Strategies to stimulate tumor regression by promoting polarization to M1 are a novel approach that harnesses the immune system to enhance therapeutic outcomes, including chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32036448"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 624,
          "text": "The polarization and differentiation of macrophages into the cancer-inhibiting M1 and cancer-promoting M2 types represent the two states of macrophages in the tumor microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31192126"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 436,
          "text": "Macrophages exhibit plasticity, resulting in M1 and M2 phenotypes, with M1 macrophages displaying antitumor properties and M2 macrophages promoting tumor progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39202998"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 970,
          "text": "Recent immunological studies have identified two distinct states of polarized macrophage activation: the classically activated (M1) and the alternatively activated (M2) macrophage phenotypes. Bacterial moieties such as lipopolysaccharides and the Th1 cytokine interferon-γ polarize macrophages toward the M1 phenotype. The M2 polarization was discovered as a response to the Th2 cytokine interleukin-4. In general, M2 macrophages exert immunoregulatory activity, participate in polarized Th2 responses, and aid tumor progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22116397"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 728,
          "text": "Macrophages can polarize into different subtypes with distinct functions and characteristics in response to various stimuli, categorized as anti-tumor M1 and pro-tumor M2 types. In tumor tissues, TAM typically polarize into the alternatively activated M2 phenotype, exhibiting inhibitory effects on tumor immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38590197"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 365,
          "text": "Cytokines induce the differentiation of macrophages into distinct types of TAMs, primarily characterized by two phenotypes: M1-polarized and M2-polarized. Cancer growth is suppressed by M1-polarized macrophages and promoted by M2-polarized macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351237"
        },
        {
          "offsetInBeginSection": 805,
          "offsetInEndSection": 1125,
          "text": "M2 macrophages have been reported to be protumorigenic, because they can promote the formation of blood vessels in the tumor microenvironment, helping tumor cells escape the body\u0027s immune defense and promote their growth, by releasing a variety of cytokines, including chemokines, inflammatory factors and growth factor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35638244"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Tumor-associated macrophages (TAMs) are present in the tumor microenvironment and can polarize into subtypes with different functions and characteristics in response to different stimuli, classifying them into anti-tumorigenic M1-type and pro-tumorigenic M2-type.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39403370"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 518,
          "text": "In a simplified manner, macrophages can assume two opposite subtypes: M1, pro-inflammatory and anti-tumor phenotype, and M2, anti-inflammatory and protumor phenotype. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39767591"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 646,
          "text": "Macrophages play an important role in tissue homeostasis, tissue remodeling, immune response, and progression of cancer. Consequently, macrophages exhibit significant plasticity and change their transcriptional profile and function in response to environmental, tissue, and inflammatory stimuli resulting in pro- and anti-tumor effects. Furthermore, the categorization of tissue macrophages in inflammatory situations remains difficult; however, there is an agreement that macrophages are predominantly polarized into two different subtypes with pro- and anti-inflammatory properties, the so-called M1-like and M2-like macrophages, respectively. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36325334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Tumor-associated macrophages (TAMs) are present in the tumor microenvironment and can polarize into subtypes with different functions and characteristics in response to different stimuli, classifying them into anti-tumorigenic M1-type and pro-tumorigenic M2-type. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39403370"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 424,
          "text": "Tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) are composed of heterogeneous subpopulations, which include the M1 anti-tumor and M2 pro-tumor phenotypes. TAMs predominantly play a M2-like tumor-promoting role in the TME and regulate various malignant effects, such as angiogenesis, immune suppression, and tumor metastasis;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35844605"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 712,
          "text": "Tumor-associated macrophages (TAMs) represent the major tumor-infiltrating immune cell type and are generally polarized into two functionally contradictory subtypes, namely classical activated M1 macrophages and alternatively activated M2 macrophages. Macrophage polarization refers to how macrophages are activated at a given time and space. The interplay between the TME and macrophage polarization can influence tumor initiation and progression, making TAM a potential target for cancer therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38878638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 561,
          "text": "The characteristics of monocyte/macrophage lineage are diversity and plasticity, mainly manifested by M1 and M2 subtypes in the body tissues, and playing different roles in the immunity. In the polarization process of macrophages, the classic molecular mechanism is related to sequential transcription factors. Whether in tumor or inflammatory local microenvironment, the pathological factors of the local microenvironment often affect the polarization of M1 and M2 macrophages, and participate in the occurrence and development of these pathological processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37711048"
        },
        {
          "offsetInBeginSection": 402,
          "offsetInEndSection": 727,
          "text": "Tumor-associated macrophages can exert dual influence of cancer depending on the activation state, with classically activated (M1) and alternatively activated (M2) cells generally exerting antitumoral and protumoral functions, respectively. These are extremes in a continuum of polarization states in a universe of diversity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23766387"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 579,
          "text": "While M1 macrophages (classically activated macrophages) display anti-tumoral and pro-inflammatory functions, M2 macrophages display pro-tumoral and anti-inflammatory functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32595638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 303,
          "text": "Macrophages are highly heterogeneous immune cells that play an important role in the tumour microenvironment (TME). After being stimulated differently in the TME, macrophages can be polarised into the M1 phenotype to exhibit an anti-tumour effect or the M2 phenotype to exhibit a tumour-promoting effect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36208648"
        },
        {
          "offsetInBeginSection": 481,
          "offsetInEndSection": 645,
          "text": "TAM is divided into tumor-suppressive M1-like (classic activation of macrophages) and tumor-supportive M2-like (alternatively activated macrophages) polarized cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37759870"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 363,
          "text": "TAMs can be broadly divided into M1-like and M2-like TAMs, which demonstrate antitumor and pro-tumor activity in the TME, respectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32968456"
        }
      ],
      "id": "67fd922518b1e36f2e000143",
      "ideal_answer": [
        "Macrophages represent heterogeneous cell populations with important roles in defense mechanisms and in homeostasis. Tissue macrophages from diverse anatomical locations adopt distinct activation states. M1 and M2 macrophages are two polarized forms of mononuclear phagocyte in vitro differentiation with distinct phenotypic patterns and functional properties, but in vivo, there is a wide range of different macrophage phenotypes depending on the microenvironment and natural signals they receive. In the case of cancer, M1/M2 macrophages have been shown to play a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) is critical to tumor progression. M1 macrophages are historically seen as anti-tumor, while M2-polarized macrophages, often known as tumor-associated macrophages (TAMs), contribute to pro-tumorigenic outcomes. These include promoting angiogenesis and lymphangiogenesis, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The TME influences macrophage recruitment and polarization, which in turn supports these pro-tumorigenic processes. Understanding TME-induced macrophage polarization is essential for developing new therapeutic approaches targeting TAMs and their role in cancer progression.",
        "In the tumor microenvironment (TME), the M1/M2 macrophage polarization paradigm is a crucial determinant of tumor progression and therapeutic response. Macrophages can be polarized into two primary phenotypes: M1 and M2. M1 macrophages are typically considered anti-tumoral due to their ability to elicit inflammatory responses and possess cytotoxic activities against tumor cells. They are characterized by the production of pro-inflammatory cytokines and reactive nitrogen and oxygen species, which can inhibit tumor growth and promote anti-tumor immunity (PMID 34209703).\n\nConversely, M2 macrophages are generally associated with tumor-promoting activities. These cells support tumor growth by enhancing tissue remodeling, angiogenesis, and suppressing adaptive immune responses. M2 macrophages are often found in higher numbers within the TME, where they contribute to a suppressive and pro-tumoral environment (PMID 34209703). The balance and dynamic interplay between these polarized macrophage states influence the progression of the tumor and the effectiveness of immune-based therapies. Thus, understanding and potentially manipulating this balance holds significant promise for enhancing cancer treatment strategies (PMID 35844605).",
        "Macrophages that infiltrate tumor tissues are driven by tumor-derived and T cell-derived cytokines to acquire a polarized M2 phenotype. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis.",
        "In the tumor microenvironment, M1 macrophages are characterized by their pro-inflammatory and anti-tumor activities, activated by stimuli such as IFN-γ and LPS, and producing cytokines like TNF-α and IL-12. They rely on glycolysis for metabolism. In contrast, M2 macrophages, also known as tumor-associated macrophages (TAMs), are associated with anti-inflammatory responses and tumor promotion, activated by cytokines like IL-4 and IL-13, and producing cytokines such as IL-10 and TGF-β. They favor oxidative phosphorylation and are linked to angiogenesis, immune suppression, and metastasis, contributing to poor prognosis in cancer patients. Strategies to reprogram M2 macrophages to the M1 phenotype are being explored as potential cancer therapies.",
        "Macrophages in the tumor microenvironment are functionally heterogeneous and can be divided into two main subpopulations: M1 and M2 macrophages. M1 macrophages are generally considered anti-tumor, exhibiting pro-inflammatory and immunostimulatory activities, directly mediating cytotoxicity, and killing tumor cells. They are induced by IFN-γ/lipopolysaccharides (LPS). M2 macrophages, on the other hand, are typically pro-tumor, exhibiting anti-inflammatory, immunosuppressive, pro-tumorigenic, and wound healing activities. They promote tumor progression through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. M2 macrophages are induced by IL-4/IL-10/IL-13. Tumor-associated macrophages (TAMs) often have the phenotype and function of M2 macrophages.",
        "M1 phenotype macrophages are tumor-resistant due to intrinsic phagocytosis and enhanced antitumor inflammatory reactions, while M2-polarized macrophages enhance tumor progression through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. In the tumor microenvironment, tumor-associated macrophages (TAMs) typically acquire a polarized M2 phenotype driven by tumor-derived and T cell-derived cytokines, promoting pro-tumorigenic outcomes and representing a poor prognosis. Investigating TME-induced macrophage polarization is critical for understanding TAM-related pro-tumor outcomes and developing new therapeutic approaches.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) is characterized by two distinct macrophage phenotypes with opposing functions. M1 macrophages, also known as classically activated macrophages, are pro-inflammatory and are associated with anti-tumor responses. They initiate immunological reactions, enhance T and natural killer (NK) cell activity, and suppress tumor growth. In contrast, M2 macrophages, or alternatively activated macrophages, are predominantly induced in the TME and are considered pro-tumorigenic. They contribute to tumor progression by promoting angiogenesis, immune suppression, and tumor cell proliferation, leading to metastasis and resistance to therapies.\n\nThe polarization of macrophages is influenced by various factors in the TME, including cytokines and chemokines, which drive the differentiation towards either the M1 or M2 phenotype. This polarization is not binary but exists on a continuum, with a range of macrophage phenotypes observed in vivo. The balance between M1 and M2 macrophages is crucial, as it governs the immune response and can significantly impact cancer-specific survival outcomes. High densities of M2-like macrophages are associated with poor prognosis, while M1-like macrophages do not show a significant correlation with improved survival. Understanding the mechanisms of macrophage polarization in the TME is essential for developing targeted therapeutic strategies in cancer treatment.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) is characterized by two distinct macrophage phenotypes with opposing functions. \n\n1. **M1 Macrophages**: These are classically activated macrophages induced by pro-inflammatory signals such as IFN-γ and lipopolysaccharides (LPS). M1 macrophages are known for their anti-tumoral properties, as they:\n   - Suppress tumor growth.\n   - Initiate robust immune responses by secreting pro-inflammatory cytokines (e.g., TNF-α, IL-1β).\n   - Promote the activation of T and natural killer (NK) cells, enhancing anti-tumor immunity.\n\n2. **M2 Macrophages**: These are alternatively activated macrophages induced by anti-inflammatory signals such as IL-4, IL-10, and IL-13. M2 macrophages are associated with pro-tumoral effects, as they:\n   - Promote tumor growth, angiogenesis, and metastasis.\n   - Exhibit immunosuppressive functions by secreting cytokines like IL-10 and TGF-β, which can inhibit T cell responses.\n   - Contribute to the formation of a premetastatic niche and enhance resistance to therapies.\n\nThe TME influences the polarization of macrophages through various signaling pathways and cytokine interactions, leading to a dynamic balance between M1 and M2 phenotypes. This polarization is not static; macrophages can switch between M1 and M2 states depending on the microenvironmental cues, highlighting their plasticity and the complexity of their roles in cancer progression and therapy response.",
        "M1 and M2 macrophages exhibit distinct characteristics and functions within the tumor microenvironment (TME). \n\nM1 macrophages are pro-inflammatory and play a crucial role in initiating immune responses. They suppress tumor growth by promoting robust anti-tumoral activities, including the activation of T and natural killer (NK) cells. M1 macrophages are associated with the suppression of tumor progression and are characterized by their ability to damage tissue integrity.\n\nIn contrast, M2 macrophages are anti-inflammatory and are involved in tissue remodeling and tumor growth. They promote cancer cell proliferation, invasion, metastasis, and angiogenesis, contributing to immune suppression within the TME. M2 macrophages are often referred to as tumor-associated macrophages (TAMs) and are linked to poor patient prognosis due to their tumorigenic effects.\n\nThe TME influences the polarization of macrophages, with cancer cells secreting factors that can shift macrophages from the M1 phenotype to the M2 phenotype, thereby enhancing tumor survival and progression. Overall, the balance between M1 and M2 macrophages in the TME is critical for determining the outcome of cancer progression and therapy response.",
        "M1 and M2 macrophages exhibit distinct characteristics and functions within the tumor microenvironment (TME). \n\nM1 macrophages are pro-inflammatory and play a crucial role in initiating an immune response. They suppress tumor growth by promoting robust T and natural killer (NK) cell anti-tumoral responses, damaging tissue integrity, and dampening tumor progression. M1 macrophages are associated with the secretion of pro-inflammatory cytokines and are characterized by their ability to combat tumor cells.\n\nIn contrast, M2 macrophages are anti-inflammatory and are involved in tissue remodeling and tumor growth. They promote cancer cell proliferation, invasion, metastasis, and angiogenesis, contributing to immune suppression within the TME. M2 macrophages, often referred to as tumor-associated macrophages (TAMs), secrete various cytokines that facilitate tumor progression and are linked to poor survival outcomes in cancer patients.\n\nOverall, the balance between M1 and M2 macrophages in the TME is critical, as M1 macrophages are associated with anti-tumor effects, while M2 macrophages support tumor growth and metastasis.",
        "In the tumor microenvironment, M1 macrophages are characterized by their anti-tumor properties, including intrinsic phagocytosis and enhanced antitumor inflammatory reactions. They are considered tumor-resistant. In contrast, M2 macrophages, often referred to as tumor-associated macrophages (TAMs), exhibit pro-tumorigenic characteristics such as promoting angiogenesis, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. These macrophages are driven by signals from the tumor microenvironment to acquire a polarized M2 phenotype that enhances tumor progression.",
        "The M1/M2 macrophage polarization paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes. Investigating TME-induced macrophage polarization is critical for further understanding of TAM-related pro-tumor outcomes and potential development of new therapeutic approaches.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) is characterized by two distinct macrophage states: M1, which is classically activated and generally regarded as anti-tumor, and M2, which is alternatively activated and considered pro-tumorigenic. M1 macrophages are associated with anti-tumor activities, including immune activation and suppression of tumor growth, while M2 macrophages, often referred to as tumor-associated macrophages (TAMs), promote tumor progression through mechanisms such as angiogenesis, immune suppression, and metastasis.\n\nThe polarization of macrophages is influenced by various factors in the TME, including cytokines and chemokines, which dictate their functional properties and phenotypic patterns. The balance between M1 and M2 polarization is crucial, as it can determine the fate of tumors, with M2 macrophages linked to poor prognosis in cancer. Additionally, macrophage plasticity allows for a continuum of polarization states, with the potential for intermediate phenotypes depending on environmental cues. Understanding the signaling pathways and metabolic processes that govern this polarization is essential for developing macrophage-centered therapeutic strategies in cancer treatment.",
        "In the tumor microenvironment, macrophages can polarize into two distinct phenotypes: M1 (classically activated) and M2 (alternatively activated). \n\nM1 macrophages are pro-inflammatory, anti-tumor, and exhibit immunostimulatory activity. They are induced by Th1 cytokines such as interferon-γ and lipopolysaccharides, promoting a cytotoxic response against tumor cells.\n\nIn contrast, M2 macrophages are anti-inflammatory, protumor, and exert immunoregulatory activity. They are induced by Th2 cytokines like interleukin-4 and promote tumor progression by suppressing antitumor immunity, fostering angiogenesis, and supporting cancer cell proliferation, invasion, and metastasis. \n\nTumor-associated macrophages (TAMs) typically exhibit an M2 phenotype, contributing to the creation of an immunosuppressive microenvironment that favors tumor growth and evasion from immune surveillance. Understanding the M1/M2 polarization paradigm is crucial for developing effective cancer therapies targeting the tumor microenvironment.",
        "In the tumor microenvironment, macrophages exhibit a polarization paradigm characterized by two main phenotypes: M1-like and M2-like. M1-like macrophages are classically activated and generally exhibit anti-tumor functions, such as promoting tumor lysis, stimulating T cell and NK cell activity, and initiating immune responses to dampen tumor progression. They are pro-inflammatory cells involved in killing cancer cells. Conversely, M2-like macrophages are alternatively activated and primarily support tumor cell survival, growth, and metastasis. They contribute to tissue remodeling and immunosuppression, fostering an environment conducive to tumor development. Macrophages can switch between these two states depending on microenvironmental cues. While M1 macrophages are associated with better outcomes in some tumors, a dominance of M2 macrophages is often linked to poor prognosis.",
        "M1 and M2 macrophages are two polarized forms of mononuclear phagocyte in vitro differentiation with distinct phenotypic patterns and functional properties, but in vivo, there is a wide range of different macrophage phenotypes in between depending on the microenvironment and natural signals they receive. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. M2 macrophages have been shown to promote tumour growth, while M1 macrophages provide both tumour-promoting and anti-tumour properties.",
        "Macrophages, a heterogeneous cell population, play crucial roles in defense mechanisms and homoeostasis. In the context of different tissues, they adopt distinct activation states. Two polarized forms of macrophages, M1 and M2, have been identified in vitro, each with unique phenotypic patterns and functional properties. However, in vivo, there is a wide range of different macrophage phenotypes depending on the microenvironment and natural signals they receive. Macrophages infiltrating tumors can significantly impact the patient\u0027s prognosis. M2 macrophages have been shown to promote tumor growth through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. On the other hand, M1 macrophages are historically regarded as anti-tumor. The tumor microenvironment can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes.",
        "The M1/ M2 macrophage polarization paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti- tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes.",
        "Macrophages in the tumor microenvironment are categorized into two main subtypes: M1 and M2. M1 macrophages are classically activated, exhibit pro-inflammatory and antitumor activities, and are historically regarded as anti-tumor. M2 macrophages, also known as alternatively activated macrophages, exhibit anti-inflammatory, pro-tumorigenic, and wound healing activities, promoting tumor progression through various mechanisms like angiogenesis, immune suppression, and metastasis. The balance between M1 and M2 macrophages plays a crucial role in determining whether the tumor is suppressed or progresses.",
        "The M1/M2 paradigm describes a spectrum of macrophage activation states in the tumor microenvironment. M1 macrophages are largely anti-tumor, exerting inflammatory and cytotoxic effects, whereas M2 macrophages—often referred to as tumor-associated macrophages (TAMs)—promote tumor progression by enhancing angiogenesis, lymphangiogenesis, immune suppression, hypoxia, tumor cell proliferation, and metastasis. It’s important to note that in vivo, macrophages display a range of phenotypes influenced by local signals, rather than existing strictly as M1 or M2.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) is characterized by two distinct macrophage phenotypes with opposing functions. M1 macrophages, often referred to as classically activated macrophages, are associated with pro-inflammatory responses and are historically regarded as anti-tumor due to their ability to inhibit tumor growth through the release of pro-inflammatory cytokines. In contrast, M2 macrophages, or alternatively activated macrophages, are typically polarized in the TME and are considered tumor-associated macrophages (TAMs). They promote tumor growth and progression through mechanisms such as angiogenesis, immune suppression, and tumor cell proliferation.\n\nThe polarization of macrophages into M1 or M2 subtypes is influenced by the microenvironment and various signals they receive, leading to a continuum of phenotypes rather than a strict binary classification. M2 macrophages are predominantly found in tumors and are linked to poor prognosis due to their pro-tumorigenic effects. The dynamic nature of macrophage polarization highlights their plasticity and the complexity of their roles in cancer, making them critical targets for therapeutic strategies aimed at reprogramming their function to enhance anti-tumor immunity.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) reflects distinct functional roles. **M1 macrophages** are classically activated, exhibiting anti-tumor properties such as pro-inflammatory responses and tumor cell killing. **M2 macrophages** (often termed tumor-associated macrophages, TAMs) are alternatively polarized and promote tumor progression through angiogenic/lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The TME influences macrophage recruitment and polarization, favoring M2 dominance to support pro-tumorigenic outcomes. While M1/M2 represent extremes, in vivo macrophage phenotypes exist on a continuum shaped by microenvironmental signals.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) involves two distinct types of macrophages with opposing roles:\n\n1. **M1 Macrophages**: These are typically associated with anti-tumor activity. They are involved in fighting against tumors by promoting immune responses and inhibiting tumor growth.\n\n2. **M2 Macrophages (TAMs)**: These are generally pro-tumor, contributing to tumor progression through mechanisms such as angiogenesis, immune suppression, hypoxia induction, and metastasis.\n\nThe TME plays a significant role in recruiting and polarizing macrophages towards either M1 or M2 states. This polarization is influenced by various factors within the TME, leading to a spectrum of macrophage phenotypes beyond the traditional M1/M2 classification. Understanding this dynamic interaction is crucial for comprehending tumor progression and developing therapeutic strategies.",
        "The M1/M2 macrophage polarization paradigm is crucial in understanding tumor progression within the tumor microenvironment (TME). M1 macrophages are typically associated with anti-tumor activities, exhibiting pro-inflammatory properties that can inhibit tumor growth. In contrast, M2-polarized macrophages, often referred to as tumor-associated macrophages (TAMs), are linked to pro-tumorigenic effects. They contribute to tumor progression through various mechanisms, including promoting angiogenesis, lymphangiogenesis, immune suppression, hypoxia, tumor cell proliferation, and metastasis.\n\nThe TME significantly influences the recruitment and polarization of macrophages, leading to the predominance of M2 macrophages, which are associated with adverse outcomes in cancer prognosis. This polarization is not binary; rather, macrophages exhibit a spectrum of phenotypes influenced by environmental signals, resulting in a complex interplay between M1-like and M2-like characteristics. Understanding this polarization and the factors driving it is essential for developing new therapeutic strategies targeting TAMs and their role in cancer progression.",
        "Macrophage polarization in the tumor microenvironment (TME) is characterized by the differentiation of macrophages into distinct phenotypes, primarily M1 and M2 types, influenced by various signals from the TME. M1 macrophages are pro-inflammatory and are associated with anti-tumor responses, promoting T and NK cell activity and suppressing tumor growth. In contrast, M2 macrophages, often referred to as tumor-associated macrophages (TAMs), exhibit anti-inflammatory properties and contribute to tumor progression by promoting angiogenesis, immune suppression, and metastasis. The TME facilitates this polarization through factors such as hypoxia, cytokines, and other immunomodulatory molecules, leading to significant plasticity in macrophage function and phenotype. This dynamic allows for a range of macrophage states between the M1 and M2 extremes, impacting tumor development and response to therapies.",
        "M1 and M2 macrophages represent two polarized forms of macrophages with distinct characteristics and functions in the tumor microenvironment (TME). \n\nM1 macrophages are pro-inflammatory and are traditionally viewed as anti-tumor agents. They initiate immune responses, damage tumor tissue integrity, and enhance anti-tumor activity by promoting T and natural killer (NK) cell responses. M1 macrophages can exhibit both tumor-promoting and anti-tumor properties depending on the context.\n\nIn contrast, M2 macrophages, often referred to as tumor-associated macrophages (TAMs), are associated with pro-tumorigenic effects. They promote tumor growth, angiogenesis, metastasis, and immune suppression, contributing to a favorable environment for cancer progression. M2 macrophages are involved in tissue remodeling and can secrete various cytokines that facilitate tumor development.\n\nThe TME plays a crucial role in influencing macrophage polarization, with various signals and stimuli leading to the differentiation of macrophages into M1-like or M2-like phenotypes. This plasticity allows macrophages to adapt their functions based on the surrounding microenvironment, which can shift their polarization state in response to different factors, including hypoxia and cytokine availability.",
        "M1 and M2 macrophages are two polarized forms of mononuclear phagocyte in vitro differentiation with distinct phenotypic patterns and functional properties, but in vivo, there is a wide range of different macrophage phenotypes in between depending on the microenvironment and natural signals they receive. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The view of pro-inflammatory M1 macrophages and M2 macrophages suppressing inflammation seems to be an oversimplification because these cells exploit very high level of plasticity and represent a large scale of different immunophenotypes with overlapping properties.",
        "The M1/M2 macrophage polarization paradigm in the tumor microenvironment (TME) is characterized by two distinct macrophage phenotypes with contrasting roles in tumor progression. M1 macrophages are typically associated with anti-tumor properties, producing pro-inflammatory cytokines that inhibit tumor growth and promote inflammation. In contrast, M2 macrophages, often referred to as tumor-associated macrophages (TAMs), are linked to pro-tumorigenic outcomes, facilitating tumor growth through mechanisms such as immune suppression, angiogenesis, and metastasis. The polarization of macrophages is influenced by the local microenvironment and the signals they receive, leading to a spectrum of macrophage phenotypes between the M1 and M2 extremes. This dynamic interplay is crucial for understanding disease progression and developing therapeutic strategies targeting macrophage polarization in cancer and other inflammatory diseases.",
        "In the tumor microenvironment, macrophages exhibit plasticity, polarizing into two main phenotypes: M1-like and M2-like. M1 macrophages are classically activated, pro-inflammatory cells that can kill cancer cells and initiate immune responses to dampen tumor progression. They are generally considered anti-tumor. M2 macrophages, on the other hand, are alternatively activated, anti-inflammatory cells that promote tumor growth, metastasis, tissue remodeling, and immunosuppression. They are generally considered pro-tumor. The balance between M1 and M2 macrophages can influence patient prognosis, with a dominance of M2-like macrophages often associated with poor outcomes, although strong M1-like profiles can sometimes lead to better outcomes depending on the tumor type. The tumor microenvironment influences macrophage recruitment and polarization, contributing to pro-tumorigenic outcomes. Macrophages can switch between these states depending on microenvironmental cues.",
        "In the tumor microenvironment, M1 macrophages are generally anti-tumor, while M2-polarized macrophages, known as tumor-associated macrophages (TAMs), promote tumorigenesis by supporting angiogenesis, immune suppression, and metastasis. The tumor microenvironment influences macrophage polarization, leading to these roles, and despite the M1/M2 paradigm, there is phenotypic diversity in macrophages based on in vivo signals."
      ]
    },
    {
      "body": "What is Nissen fundoplication",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39398392",
        "http://www.ncbi.nlm.nih.gov/pubmed/36862348",
        "http://www.ncbi.nlm.nih.gov/pubmed/36876673",
        "http://www.ncbi.nlm.nih.gov/pubmed/29762301",
        "http://www.ncbi.nlm.nih.gov/pubmed/20012380",
        "http://www.ncbi.nlm.nih.gov/pubmed/7944659",
        "http://www.ncbi.nlm.nih.gov/pubmed/7770706",
        "http://www.ncbi.nlm.nih.gov/pubmed/19736889",
        "http://www.ncbi.nlm.nih.gov/pubmed/38885606",
        "http://www.ncbi.nlm.nih.gov/pubmed/37115417",
        "https://www.ncbi.nlm.nih.gov/pubmed/25339814",
        "http://www.ncbi.nlm.nih.gov/pubmed/39564064",
        "http://www.ncbi.nlm.nih.gov/pubmed/15235916",
        "http://www.ncbi.nlm.nih.gov/pubmed/17560228",
        "http://www.ncbi.nlm.nih.gov/pubmed/22244400",
        "http://www.ncbi.nlm.nih.gov/pubmed/15927640",
        "http://www.ncbi.nlm.nih.gov/pubmed/39586876",
        "http://www.ncbi.nlm.nih.gov/pubmed/39508953",
        "http://www.ncbi.nlm.nih.gov/pubmed/9457040",
        "http://www.ncbi.nlm.nih.gov/pubmed/12974216",
        "http://www.ncbi.nlm.nih.gov/pubmed/11997817",
        "http://www.ncbi.nlm.nih.gov/pubmed/8466868",
        "http://www.ncbi.nlm.nih.gov/pubmed/21929798",
        "http://www.ncbi.nlm.nih.gov/pubmed/7778902",
        "http://www.ncbi.nlm.nih.gov/pubmed/7583026",
        "http://www.ncbi.nlm.nih.gov/pubmed/10741453",
        "http://www.ncbi.nlm.nih.gov/pubmed/16713542",
        "http://www.ncbi.nlm.nih.gov/pubmed/7640948",
        "http://www.ncbi.nlm.nih.gov/pubmed/8304651",
        "http://www.ncbi.nlm.nih.gov/pubmed/1341529",
        "http://www.ncbi.nlm.nih.gov/pubmed/29127961",
        "http://www.ncbi.nlm.nih.gov/pubmed/12407522",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460080",
        "http://www.ncbi.nlm.nih.gov/pubmed/28882768",
        "http://www.ncbi.nlm.nih.gov/pubmed/23237251",
        "http://www.ncbi.nlm.nih.gov/pubmed/25012804",
        "http://www.ncbi.nlm.nih.gov/pubmed/8168845",
        "http://www.ncbi.nlm.nih.gov/pubmed/39507350",
        "http://www.ncbi.nlm.nih.gov/pubmed/31813928",
        "http://www.ncbi.nlm.nih.gov/pubmed/7574368",
        "http://www.ncbi.nlm.nih.gov/pubmed/37438480",
        "http://www.ncbi.nlm.nih.gov/pubmed/27186253",
        "http://www.ncbi.nlm.nih.gov/pubmed/22906354",
        "http://www.ncbi.nlm.nih.gov/pubmed/29466120",
        "http://www.ncbi.nlm.nih.gov/pubmed/9230657",
        "http://www.ncbi.nlm.nih.gov/pubmed/12455792",
        "http://www.ncbi.nlm.nih.gov/pubmed/16910531",
        "http://www.ncbi.nlm.nih.gov/pubmed/10478871",
        "http://www.ncbi.nlm.nih.gov/pubmed/11071409",
        "http://www.ncbi.nlm.nih.gov/pubmed/11396054",
        "http://www.ncbi.nlm.nih.gov/pubmed/10656953",
        "http://www.ncbi.nlm.nih.gov/pubmed/36106292",
        "http://www.ncbi.nlm.nih.gov/pubmed/12739125",
        "http://www.ncbi.nlm.nih.gov/pubmed/27759771",
        "http://www.ncbi.nlm.nih.gov/pubmed/18597115",
        "http://www.ncbi.nlm.nih.gov/pubmed/14717528",
        "http://www.ncbi.nlm.nih.gov/pubmed/9348613",
        "http://www.ncbi.nlm.nih.gov/pubmed/12680911",
        "http://www.ncbi.nlm.nih.gov/pubmed/1884639",
        "http://www.ncbi.nlm.nih.gov/pubmed/9864109",
        "http://www.ncbi.nlm.nih.gov/pubmed/6359494",
        "http://www.ncbi.nlm.nih.gov/pubmed/7812896",
        "http://www.ncbi.nlm.nih.gov/pubmed/38945768"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 395,
          "text": "Gastroesophageal reflux disease is one of the most common chronic diseases, affecting up to 28% of the western population. Therapeutic management ranges from conservative measures to endoscopic or surgical interventions. Laparoscopic Nissen fundoplication (LNF) still is considered as gold standard, but alternative procedures have been developed and evaluated within the past years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39398392"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 291,
          "text": "The gastroesophageal reflux disease (GERD) worldwide prevalence is increasing maybe due to population aging and the obesity epidemic. Nissen fundoplication is the most common surgical procedure for GERD with a failure rate of approximately 20% which might require a redo surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36862348"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 303,
          "text": "The current surgical approach in the treatment of hiatal hernia with gastroesophageal reflux disease is known as hernioplasty together with antireflux surgical procedures. Among the antireflux surgical treatment procedures, the most applied approach is the laparoscopic Nissen fundoplication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36876673"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Effectiveness of Nissen fundoplication versus anterior and posterior partial fundoplications for treatment of gastro-esophageal reflux disease: a systematic review protocol.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29762301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7944659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "BACKGROUND: Nissen fundoplication reduces gastro-oesophageal reflux effectively, but the mechanisms through which this effect is brought about have remained rat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770706"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Effects of Nissen fundoplication on gastro-oesophageal reflux and oesophageal motor function.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7770706"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "BACKGROUND: Laparoscopic Nissen fundoplication has become the method of choice in antireflux surgery replacing its open counterpart before the long-term results of controlled clinical trials wer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19736889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Laparoscopic fundoplication for gastroesophageal reflux disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/25339814"
        },
        {
          "offsetInBeginSection": 930,
          "offsetInEndSection": 1126,
          "text": "Nissen fundoplication was the most effective anti-reflux procedure with the greatest effect on reduction in the rate of change of FEV1, with an improvement of -2.353 mL/d (95% CI; -3.058, -1.649).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39586876"
        },
        {
          "offsetInBeginSection": 387,
          "offsetInEndSection": 535,
          "text": "Laparoscopic Nissen fundoplication is often considered the standard for treating gastroesophageal reflux disease-related HH due to its effectiveness",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Nissen fundoplication (NF) is a common surgical procedure to treat gastroesophageal reflux disease; however, a subset of patients may continue to experience symptoms or develop symptom recurrence despite a successful procedure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39508953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Nissen fundoplication is the procedure of choice for the management of gastroesophageal reflux disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12974216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The Nissen fundoplication currently is the most commonly used antireflux operation. It may be performed using a transabdominal or a transthoracic approach. Early postoperative complications are not infrequent and include dysphagia and the \"gas bloat\"",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7583026"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "BACKGROUND: The Nissen fundoplication is the most frequently applied antireflux operation worldwide. The aim of this review was to compare laparoscopic Nissen with partial fundoplication.METHODS: Nine randomized trials comparing several types of wrap",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20012380"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 111,
          "text": "Nissen fundoplication is a very effective treatment for gastroesophageal reflux, it is associated with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16713542"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 568,
          "text": "Total fundoplication in the form of Nissen fundoplication is the most widely used antireflux operation worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15927640"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 490,
          "text": "A very effective and popular antireflux procedure is the Nissen fundoplication, which can be safely done via the laparoscopic route.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7640948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The Nissen fundoplication is the most common operative approach to the correction of gastroesophageal reflux disease (GERD) in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8304651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Laparoscopic Nissen fundoplication represents a minimally invasive surgical approach to symptomatic gastroesophageal reflux and may offer patients an attractive alternative to indefinite medical therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1341529"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 153,
          "text": " The Nissen fundoplication or total 360 degrees fundoplication is probably the most frequently used anti-reflux procedure throughout the world",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15235916"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 144,
          "text": " Nissen fundoplication (360 degrees ) is the standard operation for the surgical management of gastroesophageal reflux disease (GERD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11997817"
        },
        {
          "offsetInBeginSection": 489,
          "offsetInEndSection": 702,
          "text": "Laparoscopic Nissen fundoplication has become the standard of care for surgical treatment of children with GERD. In this procedure, the fundus of the stomach is wrapped 360° posteriorly around the lower esophagus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux. The procedure involves wrapping the gastric fundus around the lower end of the esophagus to augment the lower esophageal sphincter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7778902"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "The Nissen fundoplication currently is the most commonly used antireflux operation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7583026"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 202,
          "text": "The Nissen fundoplication is the most commonly performed anti-reflux procedure done in the pediatric population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12407522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 289,
          "text": "Passing the stomach behind the esophagus during laparoscopic Nissen fundoplication is a common source of frustration for the laparoscopic surgeon. It often leads to an incorrect formation of the fundoplication, resulting in a wrapping or twisting of the fundus around the distal esophagus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10741453"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "The Nissen fundoplication is the operative therapy of choice in children with symptomatic gastroesophageal reflux.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466868"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1266,
          "text": "Gastroesophageal reflux disease (GERD), commonly manifested by heartburn or regurgitation, is a chronic, progressive condition in which failed sphincter function allows the contents of the stomach to reflux into the esophagus, the airways and the mouth. Chronic GERD affects 10% of Western society. The majority of patients receive adequate relief from proton pump inhibitors, but up to 40% have incomplete relief of symptoms that cannot be addressed by increasing the dose of medications. The laparoscopic Nissen fundoplication is the surgical gold standard; however, the level of technical difficulty and its side effects have limited its use to less than 1% of the GERD population. These factors have contributed to the propensity of patients to persist with medical therapy, even when inadequate to control symptoms and complications of the disease. Consequently, a significant gap in the treatment continuum for GERD remains evident in current clinical practice. The LINX(™) Reflux Management System (Torax Medical) is designed to provide a permanent solution to GERD by augmenting the physiologic function of the sphincter barrier with a simple and reproducible laparoscopic procedure that does not alter gastric anatomy and can be easily reversed if necessary",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "BACKGROUND: Nissen fundoplication is the gold standard antireflux procedure in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17560228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "INTRODUCTION: Laparoscopic Nissen Fundoplication is an effective standard surgical procedure for treatment of severe GERD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38885606"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 413,
          "text": "Only a small subset of patients present with gastric volvulus after Nissen fundoplication for hiatal hernia repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39507350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "BACKGROUND: Nissen fundoplication (360 degrees ) is the standard operation for the surgical management of gastroesophageal reflux disease (GERD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11997817"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 259,
          "text": "Laparoscopic Nissen fundoplication is the recommended surgical treatment for GERD and is safe and effective",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31813928"
        },
        {
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1080,
          "text": "In conclusion, Nissen fundoplication gives effective cure of symptoms of gastro-oesophageal reflux disease and reliably corrects reflux oesophagitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7574368"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Nissen fundoplication (NF) is a common surgical procedure to treat gastroesophageal reflux disease; however, a subset of patients may continue to experience symptoms or develop symptom recurrence despite a successful procedure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39508953"
        },
        {
          "offsetInBeginSection": 387,
          "offsetInEndSection": 536,
          "text": "Laparoscopic Nissen fundoplication is often considered the standard for treating gastroesophageal reflux disease-related HH due to its effectiveness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564064"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 383,
          "text": "erventions. Laparoscopic Nissen fundoplication (LNF) still is considered as gold standard, but alternative procedures have been developed and evaluated within the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39398392"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 423,
          "text": "ysfunction. Laparoscopic Nissen fundoplication has historically been the anti-reflux procedure of choice, but the procedure is associated with discernable rates of postoperative dysphagia and gas-blo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37438480"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "BACKGROUND: Laparoscopic Nissen fundoplication is considered to be the standard approach for the surgical treatment of gastroesophageal re",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28882768"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Laparoscopic Nissen fundoplication is the current standard surgical option for complicated GERD and symptomatic hiatal hernia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "BACKGROUND: Laparoscopic Nissen fundoplication has become the method of choice in antireflux surgery replacing its open counterpart before the long-term results of controlled clinical trials we",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19736889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Laparoscopic Nissen fundoplication has become a mainstay in the surgical treatment of gastroesophageal reflux disease, as it has proved to be a durable, well-tolerat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22906354"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "INTRODUCTION: Nissen fundoplication is frequently applied in the surgical treatment of patients with gastroesophageal reflux disease (GERD). When the gastroesophageal junction remains too large or becomes too narrow, persistent GERD or dysphagia may ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466120"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The Nissen fundoplication is not the proper antireflux procedure for patients with poor esophageal peristalsis as it does not strengthen impaired esophageal peristalsis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9230657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Fundoplication is commonly performed in children suffering from complications of gastroesophageal reflux disease (GERD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12455792"
        },
        {
          "offsetInBeginSection": 474,
          "offsetInEndSection": 609,
          "text": "Laparoscopic Nissen fundoplication has emerged as the most widely accepted procedure for GERD patients with normal esophageal motility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16910531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "OBJECTIVE: The open Nissen fundoplication is effective therapy for gastroesophageal reflux disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7944659"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 121,
          "text": "Laparoscopic Nissen Fundoplication is an effective standard surgical procedure for treatment of severe GERD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38885606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Nissen fundoplication is the most commonly performed surgical procedure in the management of gastroesophageal reflux disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11071409"
        },
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 683,
          "text": "The laparoscopic Nissen fundoplication is the surgical gold standard; however, the level of technical difficulty and its side effects have limited its use to less than 1% of the GERD population",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23237251"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 376,
          "text": " effective. However, no direct comparison between MSA and laparoscopic Nissen fundoplication (LNF), the gold standard surgical therapy for GERD, has bee",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25012804"
        },
        {
          "offsetInBeginSection": 252,
          "offsetInEndSection": 330,
          "text": "Nissen\u0027s fundplication was carried out to treat severe gastroesophageal reflux",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8168845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "The Nissen fundoplication, and in particular the laparoscopic Nissen fundoplication, has received widespread acceptance as the most definitive therapy for gastroesophageal reflux disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10478871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "BACKGROUND: Nissen fundoplication (NF) is recognized as the surgical treatment of the gastro-oesophageal reflux dis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11396054"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Nissen fundoplication is a generally accepted treatment for severe gastro-oesophageal reflux after conservative management has failed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18597115"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Laparoscopic Nissen fundoplication has rapidly become an established technique in the management of severe or complicated reflux oesophagitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8924012"
        },
        {
          "offsetInBeginSection": 547,
          "offsetInEndSection": 685,
          "text": "ars, Nissen fundoplication has been the gold standard treatment for patients with GERD who do not respond to medical treatment. However, i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37115417"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Nissen fundoplication is of proven effectiveness in the surgical control of gastro-oesophageal reflux.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12680911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "BACKGROUND: Since laparoscopic Nissen fundoplication was first described by Cuschieri in 1989 and later by Dallemagne in 1991, this procedure has been widely employed for the treatment of symptomatic gastroesophageal reflux disease (GERD) and/or hi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10656953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Anti-reflux procedures have become a mainstay in managing gastroesophageal reflux disease (GERD) and hiatal hernia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36106292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "BACKGROUND: Laparoscopic Nissen fundoplication is an increasingly utilized option for the treatment of gastroesophageal reflux dise",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12739125"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Background: Surgical treatment of GERD by Nissen fundoplication is effective and safe, providing good results in the control of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27759771"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Fundoplication is commonly performed in children suffering from complications of gastroesophageal reflux disease (GERD). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12455792"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "The Nissen fundoplication is the most popular laparoscopic operation performed for the surgical treatment of gastroesophageal reflux disease (GERD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14717528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Nissen fundoplication is a frequently performed procedure by pediatric surgeons for the treatment of gastroesophageal reflux.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9457040"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "The Nissen fundoplication is the most extensively studied and successfully employed surgical solution to gastroesophageal reflux disease (GERD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9348613"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 125,
          "text": " Nissen Fundoplication is a common surgical procedure performed in treating gastroesophageal reflux disease (GERD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21929798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "PURPOSE: Nissen fundoplication is the most commonly performed operation to treat gastroesophageal reflux disease and vomiting in children with neurologic im",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22244400"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Nissen fundoplication is a commonly used antireflux operation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1884639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Nissen fundoplication is now the most common antireflux operation for gastroesophageal reflux disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9864109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Open Nissen fundoplication has been established as an effective treatment in the management of gastroesophageal reflux disease (GORD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460080"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Nissen fundoplication is a generally accepted treatment for severe gastro-oesophageal reflux after conservative management has failed",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18597115"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 489,
          "text": "A very effective and popular antireflux procedure is the Nissen fundoplication, which can be safely done via the laparoscopic route",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7640948"
        },
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 472,
          "text": "With these considerations in mind, the authors believe that Nissen fundoplication is the preferred method of treatment for patients with uncomplicated gastroesophageal reflux refractory to medical therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6359494"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "The preferred treatment of gastroesophageal reflux has traditionally been Nissen fundoplication. This involves an extensive abdominal or thoracic incision and subsequently results in patient discomfort, an extended recovery period, and increased overall costs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7812896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Comparative analysis of laparoscopic Nissen fundoplication and Rossetti modification in gastroesophageal reflux disease: A focus on life-quality enhancement.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38945768"
        }
      ],
      "type": "factoid",
      "id": "67fc1a3818b1e36f2e000129",
      "ideal_answer": [
        "A Nissen fundoplication is a surgical procedure used to treat hiatal hernia and gastroesophageal reflux disease (GERD) by wrapping the top part of the stomach around the lower esophagus to reinforce the lower esophageal sphincter (LES)",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD).",
        "Nissen fundoplication is a surgical procedure for gastroesophageal reflux disease.",
        "Nissen fundoplication is a surgical procedure for the treatment of pediatric GERD.",
        "Nissen fundoplication is a type of surgical procedure that is commonly performed to treat gastroesophageal reflux disease (GERD), a condition where the stomach contents flow back into the esophagus, causing discomfort and potential damage. The procedure involves wrapping the upper part of the stomach around the lower esophageal sphincter to strengthen it and prevent reflux.",
        "Nissen fundoplication is a commonly performed surgical procedure which involves the division of the stomach tissue below the diaphragm to treat gastroesophageal reflux disease.",
        "Nissen fundoplication is a surgical procedure for GERD.",
        "Nissen fundoplication is a surgical antireflux operation.",
        "Nissen fundoplication is a surgical procedure that involves wrapping the top of the stomach (fundus) around the lower esophagus to prevent gastroesophageal reflux.",
        "Nissen fundoplication is a procedure that involves a 360° wrap and is commonly performed as an antireflux operation for the treatment of gastroesophageal reflux disease (GERD).",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper portion of the stomach (fundus) around the lower portion of the esophagus to prevent stomach acid from flowing back up into the esophagus.",
        "Nissen fundoplication is a surgical procedure that involves wrapping the top of the stomach (fundus) around the lower esophagus to prevent gastroesophageal reflux disease (GERD) symptoms.",
        "Nissen fundoplication is a surgical procedure that involves creating a total (360°) wrap of the stomach around the lower esophagus to treat gastroesophageal reflux disease (GERD).",
        "Nissen fundoplication is a surgical procedure primarily used to treat gastroesophageal reflux disease (GERD) and hiatal hernias. It is considered the gold standard antireflux procedure and is often performed laparoscopically.",
        "Nissen fundoplication is a surgical procedure performed for gastroesophageal reflux disease by a surgeon.",
        "Nissen fundoplication is a surgical procedure that involves wrapping the top of the stomach (fundus) around the lower esophagus to prevent gastroesophageal reflux disease (GERD).",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease by wrapping the top of the stomach around the lower esophagus.",
        "Nissen fundoplication is the gold standard for treatment of gastroesophageal reflux disease",
        "Nissen fundoplication is a surgical procedure that involves creating a total (360°) wrap of the stomach around the esophagus to treat gastroesophageal reflux disease (GERD).",
        "Nissen fundoplication is the most popular surgical treatment for refractory GERD. It is a restrictive surgery that tightens the lower esophageal sphincter and increases the pressure pressure gradient across the sphincter, thereby reducing both reflux events and endoscopic inflammation.",
        "Nissen fundoplication is the procedure of choice for gastroesophageal reflux.",
        "Nissen fundoplication is a surgical procedure primarily used to treat gastroesophageal reflux disease (GERD) and hiatal hernias. It involves wrapping the top part of the stomach around the lower esophagus to strengthen the valve between the esophagus and stomach, thereby preventing acid reflux.",
        "Nissen fundoplication is a surgical procedure to treat gastroesophageal reflux disease (GERD) by preventing stomach acid reflux into the esophagus, available in various techniques including laparoscopic and open approaches, each with its benefits and drawbacks.",
        "Nissen fundoplication is an antireflux operation involving a 360° wrap, commonly performed as a laparoscopic antireflux procedure.",
        "Nissen fundoplication is the most common surgical procedure for GERD with a failure rate of approximately 20% which might require a redo surgery.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach (fundus) around the lower esophagus to strengthen the lower esophageal sphincter and prevent acid reflux.",
        "Nissen fundoplication is a surgical procedure for treating chronic gastroesophageal reflux disease (GERD). It increses the pressure barrier between the esophagus and stomach, reduces acid reflux, and strengthens the lower esophageal sphincter.",
        "Nissen fundoplication is a surgical procedure for GERD that involves wrapping the top of the stomach around the lower esophagus to strengthen the muscle and prevent acid reflux.",
        "Nissen fundoplication is a surgical procedure, often performed laparoscopically, used for the treatment of gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach around the lower esophagus to reinforce the lower esophageal sphincter, reducing acid reflux. It is considered an effective and standard surgical option for severe or complicated GERD, and is also used in children.",
        "Nissen fundoplication is a surgical procedure for gastroesophageal reflux disease (GERD) where the upper part of the stomach is wrapped around the lower esophagus to strengthen the esophageal sphincter, thereby reducing reflux symptoms.",
        "Nissen fundoplication is a laparoscopic surgical procedure for GERD.",
        "Nissen fundoplication is a surgical procedure and treatment for GERD that involves wrapping the upper part of the stomach around the lower esophagus.",
        "Nissen fundoplication is a surgical procedure for treating gastroesophageal reflux disease (GERD), in which the upper part of the stomach is wrapped around the lower esophagus to reinforce the lower esophageal sphincter and prevent reflux.",
        "Nissen Fundoplication is a surgical procedure used in the treatment of gastroesophageal reflux disease.",
        "[\u0027Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach around the lower esophagus to strengthen the lower esophageal sphincter and prevent acid reflux. This procedure is commonly performed laparoscopically.\u0027]",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the top part of the stomach around the lower end of the esophagus to reinforce the lower esophageal sphincter and prevent acid reflux.",
        "Nissen fundoplication is the gold standard surgical procedure for treating gastroesophageal reflux disease (GERD) and hiatal hernia. It\u0027s commonly performed laparoscopically, with a failure rate of approximately 20%. This antireflux procedure has become standard treatment for both adults and children over the past 20 years.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD) by wrapping the top of the stomach around the lower esophagus to prevent acid reflux.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach around the lower esophageal sphincter to strengthen the muscle and prevent acid reflux. This procedure is considered the gold standard for treating GERD and is performed laparoscopically or through an open incision.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD) by wrapping the top of the stomach around the lower esophagus to strengthen the valve between the esophagus and stomach.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach (fundus) around the lower part of the esophagus to reinforce the lower esophageal sphincter, which prevents stomach acid from flowing back into the esophagus.",
        "Nissen fundoplication is a common surgical procedure to treat gastroesophageal reflux disease (GERD).",
        "Nissen fundoplication is a minimally invasive, laparoscopic surgical procedure that treats Gastroesophageal Reflux Disease (GERD) and hiatal hernia by wrapping the stomach\u0027s fundus around the lower esophagus, preventing acid reflux, with a high success rate in both adults and children, albeit with a noted 20% failure rate.",
        "Nissen fundoplication is the most common surgical procedure for gastroesophageal reflux disease (GERD) and involves wrapping the top part of the stomach around the lower esophagus to prevent acid reflux.",
        "Laparoscopic Nissen fundoplication (LNF) still is considered as gold standard, but alternative procedures have been developed and evaluated within the past years.",
        "Nissen fundoplication is the most common surgical procedure for GERD and an antireflux surgical procedure.",
        "[\u0027Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach around the lower end of the esophagus to strengthen the esophageal sphincter, thereby preventing acid reflux. This procedure is commonly performed laparoscopically.\u0027]",
        "Nissen fundoplication is a surgical procedure for treating gastroesophageal reflux disease (GERD), often combined with hernioplasty for hiatal hernia, involving stomach wrapping around the lower esophagus to prevent reflux.",
        "Nissen fundoplication is a surgical procedure that involves laparoscopic Nissen fundoplication.",
        "Nissen fundoplication is a surgical procedure, most commonly performed laparoscopically, used to treat gastroesophageal reflux disease (GERD) and hiatal hernia. It involves wrapping the upper part of the stomach around the lower esophagus to strengthen the antireflux barrier and reduce reflux symptoms.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the top part of the stomach around the lower esophagus to strengthen the valve between the esophagus and stomach, thereby preventing acid reflux.",
        "Nissen fundoplication is a surgical procedure used to treat gastroesophageal reflux disease (GERD). It involves wrapping the upper part of the stomach around the lower esophageal sphincter to strengthen the muscle and prevent acid reflux. This procedure is considered the gold standard for treating GERD, but alternative procedures have been developed and evaluated in recent years."
      ],
      "exact_answer": [
        [
          "surgical proceedure for hiatal hernia"
        ]
      ]
    },
    {
      "body": "What are the genetic variants in Turner syndrome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37705207",
        "http://www.ncbi.nlm.nih.gov/pubmed/39327963",
        "http://www.ncbi.nlm.nih.gov/pubmed/33596986",
        "http://www.ncbi.nlm.nih.gov/pubmed/35223574",
        "http://www.ncbi.nlm.nih.gov/pubmed/36929416",
        "http://www.ncbi.nlm.nih.gov/pubmed/30281655",
        "http://www.ncbi.nlm.nih.gov/pubmed/30770620",
        "http://www.ncbi.nlm.nih.gov/pubmed/23743550",
        "http://www.ncbi.nlm.nih.gov/pubmed/30079495",
        "http://www.ncbi.nlm.nih.gov/pubmed/38748548",
        "https://www.ncbi.nlm.nih.gov/pubmed/30770620",
        "https://www.ncbi.nlm.nih.gov/pubmed/38162151",
        "http://www.ncbi.nlm.nih.gov/pubmed/30530863",
        "http://www.ncbi.nlm.nih.gov/pubmed/28627089",
        "http://www.ncbi.nlm.nih.gov/pubmed/39351778",
        "http://www.ncbi.nlm.nih.gov/pubmed/26744914",
        "http://www.ncbi.nlm.nih.gov/pubmed/27459301",
        "http://www.ncbi.nlm.nih.gov/pubmed/33693446",
        "http://www.ncbi.nlm.nih.gov/pubmed/37975694",
        "http://www.ncbi.nlm.nih.gov/pubmed/9141146",
        "http://www.ncbi.nlm.nih.gov/pubmed/39403421",
        "http://www.ncbi.nlm.nih.gov/pubmed/30508004",
        "http://www.ncbi.nlm.nih.gov/pubmed/38249224",
        "http://www.ncbi.nlm.nih.gov/pubmed/25800473",
        "http://www.ncbi.nlm.nih.gov/pubmed/10749976",
        "http://www.ncbi.nlm.nih.gov/pubmed/29517175",
        "http://www.ncbi.nlm.nih.gov/pubmed/19137066",
        "http://www.ncbi.nlm.nih.gov/pubmed/2950017",
        "http://www.ncbi.nlm.nih.gov/pubmed/26322078",
        "http://www.ncbi.nlm.nih.gov/pubmed/20197675",
        "http://www.ncbi.nlm.nih.gov/pubmed/8151646",
        "http://www.ncbi.nlm.nih.gov/pubmed/697225",
        "http://www.ncbi.nlm.nih.gov/pubmed/16821224",
        "http://www.ncbi.nlm.nih.gov/pubmed/15797949",
        "http://www.ncbi.nlm.nih.gov/pubmed/11807897",
        "http://www.ncbi.nlm.nih.gov/pubmed/17320033",
        "http://www.ncbi.nlm.nih.gov/pubmed/20559532",
        "http://www.ncbi.nlm.nih.gov/pubmed/9837829",
        "http://www.ncbi.nlm.nih.gov/pubmed/11498234",
        "http://www.ncbi.nlm.nih.gov/pubmed/17562588",
        "http://www.ncbi.nlm.nih.gov/pubmed/39227579",
        "http://www.ncbi.nlm.nih.gov/pubmed/11546827",
        "http://www.ncbi.nlm.nih.gov/pubmed/36833181",
        "http://www.ncbi.nlm.nih.gov/pubmed/1355559",
        "http://www.ncbi.nlm.nih.gov/pubmed/31110829",
        "http://www.ncbi.nlm.nih.gov/pubmed/34094770",
        "http://www.ncbi.nlm.nih.gov/pubmed/18333372"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Turner syndrome (45,X) is caused by a complete or partial absence of a single X chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705207"
        },
        {
          "offsetInBeginSection": 613,
          "offsetInEndSection": 619,
          "text": "45, X ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39327963"
        },
        {
          "offsetInBeginSection": 779,
          "offsetInEndSection": 801,
          "text": "45, X/46, XX mosaicism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39327963"
        },
        {
          "offsetInBeginSection": 824,
          "offsetInEndSection": 872,
          "text": "mosaicism with X chromosome structural variants ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39327963"
        },
        {
          "offsetInBeginSection": 898,
          "offsetInEndSection": 931,
          "text": "presence of Y chromosome material",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39327963"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 148,
          "text": "complete or partial loss of an X chromosome during fertilization",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596986"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 437,
          "text": "Approximately 45% of patients have the 45,X karyotype and the rest have other variants of Turner syndrome, which are either mosaicism patterns or structural abnormalities of the X chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "BACKGROUND: Turner syndrome (TS), also known as 45,X, is a genetic disorder caused by the partial or complete lack of an X",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35223574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "CRELD1 variants are associated with bicuspid aortic valve in Turner syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36929416"
        },
        {
          "offsetInBeginSection": 1537,
          "offsetInEndSection": 1717,
          "text": "We propose that the combination of X chromosome TIMP1 hemizygosity and variants of its autosomal paralogue TIMP3, significantly increases the risk of aortopathy in Turner syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30281655"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "TIMP3 and TIMP1 are risk genes for bicuspid aortic valve and aortopathy in Turner syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30281655"
        },
        {
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1332,
          "text": "We propose that the combination of TIMP1 haploinsufficiency and deleterious variants in TIMP3 significantly increases the risk of BAV aortopathy in Turner syndrome, and suggest that TIMP1 hemizygosity may play a role in euploid male aortic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30770620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "PURPOSE: Turner syndrome is a developmental disorder caused by partial or complete monosomy for the X chromosome in 1 in 2,500",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23743550"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "BACKGROUND: Turner syndrome is a genetic disorder that occurs in female individuals and is characterized by the absence of 1 of the X chromosomes. Thi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38748548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1039,
          "text": "Turner syndrome (TS) is caused by the total or partial loss of the second sex chromosome; it occurs in 1 every 2,500-3,000 live births. The clinical phenotype is highly variable and includes short stature and gonadal dysgenesis. In 1959, the chromosomal origin of the syndrome was recognized; patients had 45 chromosomes with a single X chromosome. TS presents numerical and structural abnormalities in the sex chromosomes, interestingly only 40% have a 45, X karyotype. The rest of the chromosomal abnormalities include mosaics, deletions of the short and long arms of the X chromosome, rings, and isochromosomes. Despite multiple studies to establish a relationship between the clinical characteristics and the different chromosomal variants in TS, a clear association cannot yet be established. Currently, different mechanisms involved in the phenotype have been explored. This review focuses to analyze the different chromosomal abnormalities and phenotypes in TS and discusses the possible mechanisms that lead to these abnormalities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38162151"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1332,
          "text": "Our goal is to identify the genetic underpinnings of bicuspid aortic valve and aortopathy in Turner syndrome. We performed whole exome sequencing on 188 Turner syndrome study subjects from the GenTAC registry. A gene-based burden test, SKAT-O, was used to evaluate the data using bicuspid aortic valve (BAV) and aortic dimension z-scores as covariates. This revealed that TIMP3 was associated with BAV and increased aortic dimensions at exome-wide significance. It had been previously shown that genes on chromosome Xp contribute to aortopathy when hemizygous. Our analysis of Xp genes revealed that hemizygosity for TIMP1, a functionally redundant paralogue of TIMP3, increased the odds of having BAV aortopathy compared to individuals with more than one TIMP1 copy. The combinatorial effect of a single copy of TIMP1 and TIMP3 risk alleles synergistically increased the risk for BAV aortopathy to nearly 13-fold. TIMP1 and TIMP3 are tissue inhibitors of matrix metalloproteinases (TIMPs) which are involved in development of the aortic valve and protection from thoracic aneurysms. We propose that the combination of TIMP1 haploinsufficiency and deleterious variants in TIMP3 significantly increases the risk of BAV aortopathy in Turner syndrome, and suggest that TIMP1 hemizygosity may play a role in euploid male aortic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/30770620"
        },
        {
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1379,
          "text": "Notably, rare variants in CRELD1 were significantly enriched in individuals with TS who had BAV compared to those with structurally normal hearts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36929416"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28627089"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "BACKGROUND: Terminal Xp deletion leads to SHOX haploinsufficiency, and when it exceeds Xp22.33 it causes a variant of Turner syndrome (TS) in which gonadal function is preserved and short stature constitutes the major clini",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27459301"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "CONTEXT: Turner syndrome (TS) is characterized by a partial or complete absence of the second X chromosome in female. H",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Turner syndrome is a genetic disorder that occurs in women with partial or complete absence of an X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37975694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "An 82-year-old woman with Turner syndrome and schizophrenia, and her 46-year-old daughter with schizophrenia are described. 45X/46XX chromosomal mosaicism was identified in the peripheral leukocytes of the mother, who showed several Turner dysmorphisms and cavum septi pellucidum in the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9141146"
        },
        {
          "offsetInBeginSection": 292,
          "offsetInEndSection": 560,
          "text": "With the advent of clinical whole exome sequencing, there has been increased realization that some patients with genetic disorders carry a second genetic disorder, leading us to hypothesize that a \"dual diagnosis\" may be more common than suspected for Turner syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079495"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 128,
          "text": "Turner syndrome (TS) is characterized by a partial or complete absence of the second X chromosome in female. Here, pati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Microcystic lymphatic malformations in Turner syndrome are due to somatic mosaicism of PIK3CA.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705207"
        },
        {
          "offsetInBeginSection": 292,
          "offsetInEndSection": 520,
          "text": "Non-mosaic monosomy X is observed in approximately 45% of postnatal patients with Turner syndrome and the rest of the patients have structural abnormalities or mosaicism involving 46,X,i(Xq), 45,X/46,XX, 45,X and other variants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744914"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 523,
          "text": "Here we assessed polymorphisms in CTLA-4 +49A/G (rs231775), PTPN22 +1858G/A (rs2476601), and MBL2 -550 (H/L) (rs11003125), -221(X/Y) (rs7096206) and exon 1 (A/O) in women from northeastern Brazil to determine whether polymorphisms within these key immune response genes confer differential susceptibility to clinical conditions in TS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508004"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "CTLA-4 gene polymorphisms are associated with obesity in Turner Syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508004"
        },
        {
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1380,
          "text": "Notably, rare variants in CRELD1 were significantly enriched in individuals with TS who had BAV compared to those with structurally normal hearts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36929416"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 563,
          "text": "haploinsufficiency of SHOX was implicated to cause the short stature phenotype in Turner syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10749976"
        },
        {
          "offsetInBeginSection": 897,
          "offsetInEndSection": 1165,
          "text": "Three rare CNVs, located individually at 7p22.3, 7p22.2, and Xp22.33, where six genes (TTYH3, AMZ1, GNA12, BC038729, CARD11, and SHOX (stature homeobox)) are located, were found in TS patients. Quantitative PCR confirmed the CNV of CARD11 in the genome of TS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30530863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Turner syndrome, characterized by the presence of a monosomy X cell line, is a common chromosomal disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29517175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Turner\u0027s syndrome (caused by monosomy of chromosome X) is one of the most common chromosomal abnormalities in females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19137066"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 341,
          "text": "Trisomy 21 (Down\u0027s syndrome) and the 45,XO constellation (Turner\u0027s syndrome) were most commonly found.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2950017"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1148,
          "text": "Turner\u0027s syndrome, also known as \u0027monosomy X\u0027, is a genetic disorder that occurs in 1/2,500 female births and is hypothesized to result from haploinsufficiency of certain genes expressed from both sex chromosomes that escape X inactivation. While the classic karyotype related to Turner\u0027s syndrome is 45,X, the majority of those affected actually have a mosaic chromosomal complement, most often with a second normal cell line (46,XX). The resulting phenotype is variable and related to the underlying chromosomal pattern, but it is characterized by three cardinal features: short stature (around 100%), ovarian failure (\u003e90%) and congenital lymphedema (\u003e80%). In this paper we report a molecular and cytogenetic investigation of a 26-year-old female with non-mosaic 45,X karyotype, who has a stature of 170 cm without GH treatment, and whose only apparent Turner feature is gonadal dysgenesis. The only possible explanation for the absence of Turner phenotype is the hidden mosaicism combined with an untreated gonadal dysgenesis. Our results support the theory that significant ascertainment bias exists in our understanding of Turner\u0027s syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20197675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1410,
          "text": "Turner\u0027s syndrome is defined as a congenital disease determining by quantitative and/or structural aberrations of one from two X chromosomes with frequent presence of mosaicism. Clinically it is characterized by growth and body proportion abnormalities, gonadal dysgenesis resulting in sexual infantilism, primary amenorrhoea, infertility, characteristic stigmata, anomalies of heart, renal and bones and the presence of some diseases like Hashimoto thyroiditis with hypothyroidism, diabetes mellitus type 2, osteoporosis, hypertension. Turner\u0027s syndrome occurs in 1:2000 to 1:2500 female livebirth. The most frequent X chromosome aberrations in patients with phenotype of Turner syndrome are as follows: X monosomy - 45,X; mosaicism (50-75%), including 45,X/46,XX (10-15%), 45,X/46,XY (2-6%), 45,X/46,X,i(Xq), 45,X/46,X,del(Xp), 45,X/46,XX/47,XXX; aberration of X structure: total or partial deletion of short arm of X chromosome (46,X,del(Xp)) isochromosom of long arm of X chromosome (46,X,(i(Xq)), ring chromosome (46, X,r(X)), marker chromosome (46,X+m). Searching of X chromosome and mapping and sequencing of genes located at this chromosome (such as SHOX, ODG2, VSPA, SOX 3) have made possible to look for linkage between phenotypes and adequate genes or regions of X chromosome. In this paper current data concerning correlation between phenotype and karyotype in patients with TS have been presented.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16821224"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Turner syndrome occurs in 1:5000 live births (1:2,500 females) and is caused not only by X-chromosome monosomy, but also in a large degree, by the presence of a mosaicism (45,X) and/or an abnormal X or Y chromosome (deletion, isochromosome X, dicentric chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17320033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Turner\u0027s syndrome is a genetic disorder of the sex chromosomes (e.g., 45,X or 45,X/46,XX",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20559532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Turner syndrome is the complex human phenotype associated with complete or partial monosomy X",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9837829"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 563,
          "text": "Today, Turner\u0027s syndrome or Ullrich-Turner\u0027s syndrome may be defined as the combination of characteristic physical features and complete or part absence of one of the X chromosomes, frequently accompanied by cell-line mosaicism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11498234"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Turner syndrome is a neurogenetic disorder characterized by partial or complete monosomy-X",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17562588"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Turner syndrome (TS) is a genetic condition characterized by partial or complete monosomy X.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39227579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Turner syndrome, characterized by the presence of a monosomy X cell line, is a common chromosomal disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29517175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807897"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 186,
          "text": "Turner phenotype in this family is the result of deletion of the entire short arm of one X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/697225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "CONTEXT: Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15797949"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "BACKGROUND: Turner syndrome is characterised by a 45,X karyotype and a variety of skeletal, lymphoedemic, and gonada",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11546827"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Turner syndrome (TS) is a genetic disorder resulting from the partial or complete absence of one X chromosome in females",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38249224"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Turner Syndrome is characterized by a normal X chromosome and the partial or complete absence of a second sexual chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36833181"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "OBJECTIVE: Turner syndrome (TS) is a chromosomal disorder caused by complete or partial X chromosome monosomy that manifests various clinical features depending on the karyotype and on the genetic background of aff",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25800473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Turner syndrome (45,X) is caused by a complete or partial absence of a single X chromosome. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37705207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Turner syndrome is a sex chromosome abnormality in which a female has a single X chromosome or structurally deficient second sex chromosome. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30079495"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 287,
          "text": " Turner syndrome (TS) is characterized by a partial or complete absence of the second X chromosome in female. Here, patients with Xp deletion involving SHOX haploinsufficiency caused by unbalanced X-autosome translocations were discussed and considered as TS variants.OBJECTIVE: ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39351778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26322078"
        },
        {
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1139,
          "text": "analysis of the patient was performed showing variant Turner syndrome (46,X,i(X)(q10)[26]/46,X,del(X)(q11.2)[11]/45,X[8]/46,XX[5]). The patient\u0027s aCGH result revealed that",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33693446"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 424,
          "text": "s sperm cell. Approximately 45% of patients have the 45,X karyotype and the rest have other variants of Turner syndrome, which are either mosaicism patterns or structural abnormalities of the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596986"
        },
        {
          "offsetInBeginSection": 456,
          "offsetInEndSection": 698,
          "text": "In this study, genomic DNA was extracted from leucocytes of 49 patients with Turner\u0027s syndrome (karyotypes: 45,XO, n \u003d 29; 45,XO/46,XX, n \u003d 4; 46,Xi(Xq), n \u003d 1; 45,XO/46,Xi(Xq), n \u003d 4; 45,XO/46,Xr(X), n \u003d 4; 45,XO/46,XY, n \u003d 4; 46,XXp-, n \u003d 3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1355559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Although Turner syndrome is most commonly associated with a 45,X genotype, other mosaic genotypes are present in approximately half of all cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31110829"
        },
        {
          "offsetInBeginSection": 196,
          "offsetInEndSection": 321,
          "text": "The chromosomal abnormalities of TS are highly variable; 45,X/46,XY mosaicism accounts for 10-12% of cases of Turner syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34094770"
        },
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 360,
          "text": "The most common genotype is 45, XO, representing a monosomy of the X chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39403421"
        },
        {
          "offsetInBeginSection": 1167,
          "offsetInEndSection": 1306,
          "text": "In four cases, Turner\u0027s syndrome failed to be detected: one 45,XO/46,XX mosaicism with only 4% of 45,XO cells and three distal Xp deletions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1355559"
        },
        {
          "offsetInBeginSection": 431,
          "offsetInEndSection": 506,
          "text": "78.57% with 45,XO. 10.71% with 45,XO/46,XX and 10.71% with other karyotypes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18333372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "INTRODUCTION: Turner syndrome is a genetic disorder in females and is the result of complete or partial loss of an X chromosome during",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33596986"
        }
      ],
      "id": "67e285b018b1e36f2e00007b",
      "ideal_answer": [
        "Approximately 45% of patients have the 45,X karyotype and the rest have other variants of Turner syndrome, which are either mosaicism patterns or structural abnormalities of the X chromosome",
        "Turner syndrome is characterized by a variety of genetic variants, primarily involving the absence or structural alteration of one X chromosome. The most common karyotype observed in Turner syndrome is 45,X, where there is a complete monosomy of one X chromosome. However, variants exist, including mosaicism where cells may have different genetic compositions, such as 45,X/46,XX or 45,X/46,XY, contributing to a spectrum of clinical manifestations ranging from typical Turner syndrome features to milder forms (PMID 2259547). Additionally, other structural abnormalities of the X chromosome such as isochromosomes, ring chromosomes, or deletions can also be present, further diversifying the genetic landscape of this condition (PMID 38162151).\n\nA systematic review highlighted the importance of genetic polymorphisms in Turner syndrome, associating these genetic variations with specific clinical features. This suggests that the genetic background of individuals with Turner syndrome can influence the severity and type of clinical manifestations observed, although the specific polymorphisms and their effects were not detailed in the provided snippet (PMID 25765448). This genetic variability underscores the complexity and heterogeneity of Turner syndrome, necessitating personalized approaches to its management and treatment.",
        "Turner syndrome (TS) is primarily characterized by the presence of one X chromosome instead of two in females, leading to a variety of genetic variants. These include:\n\n1. **Complete Monosomy X**: This is the most common form where an entire X chromosome is missing, resulting in 45 chromosomes (45,X).\n\n2. **Mosaic Forms**: In these cases, some cells have 45 chromosomes (missing an X), while others are normal with 46 chromosomes (45,X/46,XX). This variation can lead to a range of symptoms depending on the distribution of affected cells.\n\n3. **Structural Abnormalities**: These involve changes in the structure of the X chromosome, such as deletions or translocations where parts of the X are missing or rearranged. For example, unbalanced translocations between the X and autosomes can disrupt genes like SHOX, affecting growth.\n\n4. **Isodicentric X Chromosome**: This occurs when part of the X is duplicated or rearranged, creating an abnormal structure that can lead to Turner-like symptoms even if the chromosome count appears normal.\n\nThese genetic variants highlight the diversity in how TS can present, emphasizing the importance of detailed genetic analysis for accurate diagnosis and management.",
        "Turner syndrome (TS) genetic variants include:  \n1. **Complete or partial monosomy X** (45,X karyotype).  \n2. **Mosaicism**:  \n   - 45,X/46,XX (most common mosaic form).  \n   - 45,X/47,XXX.  \n   - 45,X/46,XY (mixed gonadal dysgenesis).  \n3. **Structural X chromosome abnormalities**:  \n   - Isochromosome Xq (46,X,i(X)(q10)).  \n   - Xp deletions (e.g., SHOX haploinsufficiency due to unbalanced X-autosome translocations).  \n   - Ring X chromosomes.  \n4. **Mosaic structural abnormalities**:  \n   - Combinations like 45,X/46,X,idic(Yp) (isodicentric Y chromosome).  \n5. **X mosaicism with structural anomalies** (e.g., 45,X/46,XX with X deletions).  \nThese variants result in partial or complete loss of the second sex chromosome, driving TS phenotypes."
      ],
      "exact_answer": [
        [
          "45,X karyotype or mosaicism patterns or structural abnormalities of the X chromosome",
          "45,X/46,XX mosaicism"
        ]
      ]
    },
    {
      "body": "What organelle is responsible for ATP production?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28363600",
        "http://www.ncbi.nlm.nih.gov/pubmed/39172335",
        "http://www.ncbi.nlm.nih.gov/pubmed/33435522",
        "http://www.ncbi.nlm.nih.gov/pubmed/32333953",
        "http://www.ncbi.nlm.nih.gov/pubmed/24338369",
        "http://www.ncbi.nlm.nih.gov/pubmed/36929726",
        "http://www.ncbi.nlm.nih.gov/pubmed/36572555",
        "http://www.ncbi.nlm.nih.gov/pubmed/35771441",
        "https://www.ncbi.nlm.nih.gov/pubmed/31767352",
        "https://www.ncbi.nlm.nih.gov/pubmed/36551319",
        "https://www.ncbi.nlm.nih.gov/pubmed/38081963",
        "https://www.ncbi.nlm.nih.gov/pubmed/39506109",
        "http://www.ncbi.nlm.nih.gov/pubmed/25149415",
        "http://www.ncbi.nlm.nih.gov/pubmed/38468884",
        "http://www.ncbi.nlm.nih.gov/pubmed/36420514",
        "http://www.ncbi.nlm.nih.gov/pubmed/20816876",
        "http://www.ncbi.nlm.nih.gov/pubmed/32183957",
        "http://www.ncbi.nlm.nih.gov/pubmed/30477120",
        "http://www.ncbi.nlm.nih.gov/pubmed/39199225",
        "http://www.ncbi.nlm.nih.gov/pubmed/36978905",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740573",
        "http://www.ncbi.nlm.nih.gov/pubmed/39706439",
        "http://www.ncbi.nlm.nih.gov/pubmed/39676593",
        "http://www.ncbi.nlm.nih.gov/pubmed/39674268",
        "http://www.ncbi.nlm.nih.gov/pubmed/39628681",
        "http://www.ncbi.nlm.nih.gov/pubmed/39596642",
        "http://www.ncbi.nlm.nih.gov/pubmed/39584669",
        "http://www.ncbi.nlm.nih.gov/pubmed/39566165",
        "http://www.ncbi.nlm.nih.gov/pubmed/31231235",
        "http://www.ncbi.nlm.nih.gov/pubmed/33678551",
        "http://www.ncbi.nlm.nih.gov/pubmed/35131372",
        "http://www.ncbi.nlm.nih.gov/pubmed/19760284",
        "http://www.ncbi.nlm.nih.gov/pubmed/20513629",
        "http://www.ncbi.nlm.nih.gov/pubmed/26443844",
        "http://www.ncbi.nlm.nih.gov/pubmed/26579168",
        "http://www.ncbi.nlm.nih.gov/pubmed/27087668",
        "http://www.ncbi.nlm.nih.gov/pubmed/30590907",
        "http://www.ncbi.nlm.nih.gov/pubmed/15333778",
        "http://www.ncbi.nlm.nih.gov/pubmed/22406072",
        "http://www.ncbi.nlm.nih.gov/pubmed/39657813",
        "http://www.ncbi.nlm.nih.gov/pubmed/39624468",
        "http://www.ncbi.nlm.nih.gov/pubmed/39600896",
        "http://www.ncbi.nlm.nih.gov/pubmed/39506109",
        "http://www.ncbi.nlm.nih.gov/pubmed/27430885",
        "http://www.ncbi.nlm.nih.gov/pubmed/34203260",
        "http://www.ncbi.nlm.nih.gov/pubmed/12241062",
        "http://www.ncbi.nlm.nih.gov/pubmed/37021870",
        "http://www.ncbi.nlm.nih.gov/pubmed/22869150",
        "http://www.ncbi.nlm.nih.gov/pubmed/27926991",
        "http://www.ncbi.nlm.nih.gov/pubmed/35743096",
        "http://www.ncbi.nlm.nih.gov/pubmed/16581809",
        "http://www.ncbi.nlm.nih.gov/pubmed/24042146",
        "http://www.ncbi.nlm.nih.gov/pubmed/18031780",
        "http://www.ncbi.nlm.nih.gov/pubmed/11279674",
        "http://www.ncbi.nlm.nih.gov/pubmed/33141632",
        "http://www.ncbi.nlm.nih.gov/pubmed/26677804",
        "http://www.ncbi.nlm.nih.gov/pubmed/27047533",
        "http://www.ncbi.nlm.nih.gov/pubmed/35368784",
        "http://www.ncbi.nlm.nih.gov/pubmed/32361035",
        "http://www.ncbi.nlm.nih.gov/pubmed/31100469",
        "http://www.ncbi.nlm.nih.gov/pubmed/36858655",
        "http://www.ncbi.nlm.nih.gov/pubmed/36778129",
        "http://www.ncbi.nlm.nih.gov/pubmed/29521229",
        "http://www.ncbi.nlm.nih.gov/pubmed/30731382",
        "http://www.ncbi.nlm.nih.gov/pubmed/25150832",
        "http://www.ncbi.nlm.nih.gov/pubmed/26810820",
        "http://www.ncbi.nlm.nih.gov/pubmed/39453987",
        "http://www.ncbi.nlm.nih.gov/pubmed/39602296",
        "http://www.ncbi.nlm.nih.gov/pubmed/23088322",
        "http://www.ncbi.nlm.nih.gov/pubmed/34206832",
        "http://www.ncbi.nlm.nih.gov/pubmed/37369290",
        "http://www.ncbi.nlm.nih.gov/pubmed/34437768",
        "http://www.ncbi.nlm.nih.gov/pubmed/34055802",
        "http://www.ncbi.nlm.nih.gov/pubmed/34835640",
        "http://www.ncbi.nlm.nih.gov/pubmed/36248614",
        "http://www.ncbi.nlm.nih.gov/pubmed/27524977",
        "http://www.ncbi.nlm.nih.gov/pubmed/38155937",
        "http://www.ncbi.nlm.nih.gov/pubmed/38335010",
        "http://www.ncbi.nlm.nih.gov/pubmed/37422005",
        "http://www.ncbi.nlm.nih.gov/pubmed/11223637",
        "http://www.ncbi.nlm.nih.gov/pubmed/35877442",
        "http://www.ncbi.nlm.nih.gov/pubmed/35860879",
        "http://www.ncbi.nlm.nih.gov/pubmed/38910425",
        "http://www.ncbi.nlm.nih.gov/pubmed/29663589",
        "http://www.ncbi.nlm.nih.gov/pubmed/30030363",
        "http://www.ncbi.nlm.nih.gov/pubmed/32530175",
        "http://www.ncbi.nlm.nih.gov/pubmed/34114603",
        "http://www.ncbi.nlm.nih.gov/pubmed/16415296",
        "http://www.ncbi.nlm.nih.gov/pubmed/22792111",
        "http://www.ncbi.nlm.nih.gov/pubmed/28976890",
        "http://www.ncbi.nlm.nih.gov/pubmed/33922020",
        "http://www.ncbi.nlm.nih.gov/pubmed/19698742",
        "http://www.ncbi.nlm.nih.gov/pubmed/22108916",
        "http://www.ncbi.nlm.nih.gov/pubmed/22345710",
        "http://www.ncbi.nlm.nih.gov/pubmed/38255160",
        "http://www.ncbi.nlm.nih.gov/pubmed/28579962",
        "http://www.ncbi.nlm.nih.gov/pubmed/28357209",
        "http://www.ncbi.nlm.nih.gov/pubmed/27458051",
        "http://www.ncbi.nlm.nih.gov/pubmed/10098400",
        "http://www.ncbi.nlm.nih.gov/pubmed/39682240",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178070",
        "http://www.ncbi.nlm.nih.gov/pubmed/27659608",
        "http://www.ncbi.nlm.nih.gov/pubmed/26821064",
        "http://www.ncbi.nlm.nih.gov/pubmed/37423995",
        "http://www.ncbi.nlm.nih.gov/pubmed/35733440",
        "http://www.ncbi.nlm.nih.gov/pubmed/36170016",
        "http://www.ncbi.nlm.nih.gov/pubmed/16945388",
        "http://www.ncbi.nlm.nih.gov/pubmed/31514455",
        "http://www.ncbi.nlm.nih.gov/pubmed/39236170",
        "http://www.ncbi.nlm.nih.gov/pubmed/34043206",
        "http://www.ncbi.nlm.nih.gov/pubmed/15769630",
        "http://www.ncbi.nlm.nih.gov/pubmed/22303236",
        "http://www.ncbi.nlm.nih.gov/pubmed/37945172",
        "http://www.ncbi.nlm.nih.gov/pubmed/24561571",
        "http://www.ncbi.nlm.nih.gov/pubmed/12722948",
        "http://www.ncbi.nlm.nih.gov/pubmed/35843711",
        "http://www.ncbi.nlm.nih.gov/pubmed/1962047",
        "http://www.ncbi.nlm.nih.gov/pubmed/31306736",
        "http://www.ncbi.nlm.nih.gov/pubmed/29375708",
        "http://www.ncbi.nlm.nih.gov/pubmed/30513904",
        "http://www.ncbi.nlm.nih.gov/pubmed/33201259",
        "http://www.ncbi.nlm.nih.gov/pubmed/23373419",
        "http://www.ncbi.nlm.nih.gov/pubmed/39591424",
        "http://www.ncbi.nlm.nih.gov/pubmed/39336744"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 388,
          "text": "Mitochondria are considered one of the most important subcellular organelles for targeting and delivering drugs because mitochondria are the main location for various cellular functions and energy (i.e., ATP) production, and mitochondrial dysfunctions and malfunctions cause diverse diseases such as neurodegenerative disorders, cardiovascular disorders, metabolic disorders, and cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32333953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Mitochondria are ubiquitous intracellular organelles found in almost all eukaryotes and involved in various aspects of cellular life, with a primary role in energy production.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33435522"
        },
        {
          "offsetInBeginSection": 338,
          "offsetInEndSection": 532,
          "text": " Indeed, dysfunctional mitochondria cannot provide the required energy to tissues with a high-energy demand, such as heart, brain and muscles, leading to a large spectrum of clinical phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33435522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Trypanosoma cruzi is the causative agent of Chagas disease and has a single mitochondrion, an organelle responsible for ATP production and the main site for the formation of reactive oxygen species (ROS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28363600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 339,
          "text": "Mitochondria are double membrane-bounded organelles that form a dynamic tubular network. Mitochondria energetic functions depend on a complex internal architecture. Cristae, inner membrane invaginations that fold into the matrix space, are proposed to be the site of oxidative phosphorylation, reactions by which ATP synthase produces ATP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24338369"
        },
        {
          "offsetInBeginSection": 706,
          "offsetInEndSection": 821,
          "text": "Mitochondria, often referred to as the \"powerhouses\" of the cell, play a crucial role in cellular energy production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39628681"
        },
        {
          "offsetInBeginSection": 21,
          "offsetInEndSection": 142,
          "text": ": Mitochondria are the main organelles for ATP synthesis able to produce energy for several different cellular activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39596642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Mitochondria are essential to cellular function as they generate the majority of cellular ATP, mediated through oxidative phosphorylation, which couples proton pumping of the electron transport chain (ETC) to ATP production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39566165"
        },
        {
          "offsetInBeginSection": 266,
          "offsetInEndSection": 486,
          "text": "Oxidative phosphorylation is the primary source of ATP in most cells, and mitochondrial respiration activity is a key component of oxidative phosphorylation, maintaining mitochondrial membrane potential for ATP synthesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39584669"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "Chemical mitochondrial uncouplers are protonophoric, lipophilic small molecules that transport protons from the mitochondrial intermembrane space into the matrix independent of ATP synthase, thus uncoupling nutrient oxidation from ATP production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740573"
        },
        {
          "offsetInBeginSection": 344,
          "offsetInEndSection": 738,
          "text": "In this work, we report that plants with reduced levels of the mitochondrial respiratory chain component cytochrome c (CYTc), required for electron transport coupled to oxidative phosphorylation and ATP production, show impaired growth and increased global expression of stress-responsive genes, similar to those observed after inhibiting the respiratory chain or the mitochondrial ATP synthase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39676593"
        },
        {
          "offsetInBeginSection": 493,
          "offsetInEndSection": 757,
          "text": "Mitochondria, essential for energy production and the regulation of oxidative stress, are damaged after ICH, resulting in impaired ATP production, excessive reactive oxygen species (ROS) generation, and disrupted calcium homeostasis, all of which contribute to SBI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674268"
        },
        {
          "offsetInBeginSection": 1090,
          "offsetInEndSection": 1318,
          "text": "Notably, the restoration of ATP production in mitochondria mediated by PPA2 overexpression facilitated efficient intracellular Cu efflux, allowing rapid and precise reestablishment of intracellular Cu homeostasis under Cu stress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39706439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Mitochondria are the organelles of eukaryotic cells responsible for the ATP production by means of the electron transfer chain (ETC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231235"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "Mitochondria are the organelles of eukaryotic cells responsible for the ATP production by means of the electron transfer chain (ETC). Its work is under strict genetic control providing the correct assembly of the enzyme complexes and the interface to adapt the energetic demands of the cell to the environment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231235"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Mitochondria are the central hub of ATP production in most eukaryotic cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 424,
          "text": "Mitochondria are the organelles of eukaryotic cells responsible for the ATP production by means of the electron transfer chain (ETC). Its work is under strict genetic control providing the correct assembly of the enzyme complexes and the interface to adapt the energetic demands of the cell to the environment. These mechanisms are particularly developed in the cells with high energy consumption, like neurons and myocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231235"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 176,
          "text": "ATP synthase localizes to organelles such as mitochondria and chloroplasts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20513629"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 929,
          "text": "Mitochondria are complex organelles that play a crucial role in a wide range of cellular processes, including bioenergetics. In fact, in mammals, including humans, the main source of cellular ATP is the oxidative phosphorylation (OXPHOS), a process that occurs in the mitochondrial electron transfer chain (ETC). The last enzyme of the ETC, and therefore the ulterior generator of ATP, is the ATP synthase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34681851"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Chloroplasts and mitochondria are the major ATP producing organelles in plant leaves.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26579168"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 407,
          "text": "Mitochondria are responsible for the production of energy and for essential metabolic pathways in the cell, as well as fundamental processes such as apoptosis and aging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36929726"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 191,
          "text": "Mitochondria are responsible for ATP production,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30590907"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 164,
          "text": "Mitochondria are essential organelles in eukaryotic cells, producing ATP through the electron transport chain to supply energy for cellular activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39600896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Background/Objectives: Mitochondria are the main organelles for ATP synthesis able to produce energy for several different cellular activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39596642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Mitochondria, known as the cell\u0027s powerhouse, play a critical role in energy production, cellular maintenance, and stemness regulation in non-cancerous cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39624468"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Mitochondria serve a crucial role in cell growth and proliferation by supporting both ATP synthesis and the production of macromolecular precursors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39506109"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 335,
          "text": "Mitochondria are the source of aerobic energy production on which migration depends, but a key component of mitochondrial function, mitochondrial remodelling, has not been investigated in the context of bird migration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39657813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Mitochondria are essential cell organelles responsible for ATP production in the presence of oxygen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25149415"
        },
        {
          "offsetInBeginSection": 852,
          "offsetInEndSection": 963,
          "text": "Mitochondria are the principal intracellular organelles responsible for ATP production via aerobic respiration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34203260"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 193,
          "text": "Mitochondria are the major sub-cellular organelle of ATP production.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27430885"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Mitochondria are well known as organelles responsible for the maintenance of cellular bioenergetics through the production of ATP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37021870"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Mitochondria are intracellular organelles responsible for cellular respiration with one of their major roles in the production of energy in the form of ATP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38468884"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 410,
          "text": "Mitochondria are responsible for the majority of cellular ATP production through OXPHOS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36978905"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Inside the eukaryotic cell, mitochondria are internal organelles of prokaryotic origin, responsible for energy supply in the cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12241062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Mitochondria have been classically characterized as organelles with responsibility for cellular energy production in the form of ATP, but they are also the organelles through which apoptotic signaling occurs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22869150"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 415,
          "text": "the mitochondria, the organelle responsible not only for the majority of cellular ATP production but also for switching on cell death processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33678551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "The evolution of complex eukaryotes would have been impossible without mitochondria, key cell organelles responsible for the oxidative metabolism of sugars and the bulk of ATP production [...].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35743096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Mitochondria are the organelles responsible for producing the majority of a cell\u0027s ATP and also play an essential role in gamete maturation and embryo development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16581809"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Mitochondria are responsible for the generation of ATP by oxidative phosphorylation;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32183957"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 329,
          "text": "One example of such mitochondria-related organelles (MROs) are hydrogenosomes, which produce ATP by substrate-level phosphorylation with hydrogen as a byproduct.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24042146"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "The hydrogenosome, an organelle that produces molecular hydrogen and ATP from the oxidation of pyruvate or malate under anaerobic conditions, presents some characteristics common to mitochondria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18031780"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "The hydrogenosome, an organelle that produces molecular hydrogen and ATP from the oxidation of pyruvate or malate under anaerobic conditions, presents some characteristics common to mitochondria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11279674"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Mitochondria are responsible for ATP production but are also known as regulators of cell death, and mitochondrial matrix Ca2+ is a key modulator of both ATP production and cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33141632"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 250,
          "text": "Mitochondria and glycolysis are two major producers of ATP, but the precise roles of each in podocytes remain unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26677804"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 252,
          "text": "Mitochondria are responsible for ATP production, maintenance of Ca2+ homeostasis and regulation of apoptosis,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30590907"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 255,
          "text": "Since mitochondria are the primary organelles for energy production, the support of these organelles in a functional state is an important task during oxygen deprivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27047533"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 300,
          "text": "Mitochondria are the center of energy production in most eukaryotic cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35368784"
        },
        {
          "offsetInBeginSection": 348,
          "offsetInEndSection": 561,
          "text": "Since mitochondria are the main organelle responsible for energy generation in the form of ATP, the adequate state of these organelles seems crucial for proper pregnancy development and healthy pregnancy outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39199225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Mitochondria are critical organelles that provide energy as ATP to the cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32361035"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Mitochondria are essential organelles required for cellular processes ranging from energy production to cellular differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31100469"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Mitochondria are dynamic organelles of eukaryotes involved in energy production and fatty acid oxidation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36858655"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Mitochondria are intracellular organelles involved in energy production, cell metabolism and cell signaling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36778129"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Mitochondria are the sole semiautonomous organelles of the human cell and play a very important role in not only energy production but also in apoptosis, metabolism and cell signaling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29521229"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 196,
          "text": "Mitochondria are critical organelles that produce energy for growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30731382"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Mitochondrion is a double membrane organelle that is responsible for cellular respiration and production of most of the ATP in eukaryotic cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35131372"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 554,
          "text": "Mitochondrial ATP production is necessary to meet the high energy demand of the UPR, while the molecular mechanisms of ER to mitochondria crosstalk under such stress conditions remain mainly enigmatic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34206832"
        },
        {
          "offsetInBeginSection": 564,
          "offsetInEndSection": 810,
          "text": "Because the number of electron transport system proteins within the inner mitochondrial membrane changes with inner mitochondrial membrane area, a change in the amount of inner membrane alters the capacity for ATP production within the organelle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Mitochondria, as the powerhouse of most cells, are not only responsible for the generation of adenosine triphosphate (ATP) but also play a decisive role in the regulation of apoptotic cell death, especially of cancer cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34835640"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Mitochondria, special double-membraned intracellular compartments or \u0027organelles\u0027, are popularly known as the \u0027powerhouses of the cell\u0027, as they generate the bulk of ATP used to fuel cellular biochemical reactions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36248614"
        },
        {
          "offsetInBeginSection": 533,
          "offsetInEndSection": 671,
          "text": "Mitochondria are classically known as the \"powerhouses of the cell\" for their central role in respiratory adenosine triphosphate synthesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27524977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Mitochondria are organelles that serve as the powerhouses for cellular bioenergetics in eukaryotic cells. It is responsible for mitochondrial adenosine triphosphate (ATP) generation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38155937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Mitochondria are perhaps best known as the \"powerhouse of the cell\" for their role in ATP production required for numerous cellular activities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38335010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Traditionally, mitochondria are known as \"the powerhouse of the cell,\" responsible for energy (ATP) generation (by the electron transport chain, oxidative phosphorylation, the tricarboxylic acid cycle, and fatty acid ß-oxidation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37422005"
        },
        {
          "offsetInBeginSection": 265,
          "offsetInEndSection": 452,
          "text": "Traditionally, mitochondria have been viewed as the \u0027powerhouse\u0027 of the cell, i.e., the site of the oxidative phosphorylation machinery involved in adenosine triphosphate (ATP) production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11223637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Mitochondria are generally considered the powerhouse of the cell, a small subcellular organelle that produces most of the cellular energy in the form of adenosine triphosphate (ATP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35877442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Mitochondria are optically responsive organelles producing energy for cell function via adenosine triphosphate (ATP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35860879"
        },
        {
          "offsetInBeginSection": 873,
          "offsetInEndSection": 971,
          "text": "The mitochondria in a cell are generally accepted as the authority with respect to ATP production.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38910425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Mitochondria serve a crucial role in cell growth and proliferation by supporting both ATP synthesis and the production of macromolecular precursors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39506109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Mitochondria are perhaps best known as the \"powerhouse of the cell\" for their role in ATP production required for numerous cellular activities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38335010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Mitochondria are essential cell organelles responsible for ATP production in the presence of oxygen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25149415"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Mitochondria are intracellular organelles responsible for cellular respiration with one of their major roles in the production of energy in the form of ATP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38468884"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 195,
          "text": "Mitochondria are critical organelles that produce energy for growth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30731382"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 52,
          "text": "Mitochondria are the major source of ATP in the cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30030363"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 269,
          "text": "Often described as the cellular \u0027powerhouses\u0027 due to their essential role in aerobic oxidative phosphorylation, mitochondria perform many other essential functions beyond energy production",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34114603"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Mitochondria, through oxidative phosphorylation, are the primary source of energy production in all tissues under aerobic conditions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16415296"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Mitochondria are key organelles in the cell, hosting essential functions, from biosynthetic and metabolic pathways, to oxidative phosphorylation and ATP production, from calcium buffering to red-ox homeostasis and apoptotic signalling pathways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22792111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Mitochondria are indispensable cellular organelles providing ATP and numerous other essential metabolites to ensure cell survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976890"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "text": "Mitochondria are the sole semiautonomous organelles of the human cell and play a very important role in not only energy production but also in apoptosis, metabolism and cell signaling. They are also known to be major producers of ROS and RNS free radicals during ATP production.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29521229"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Mitochondria are optically responsive organelles producing energy for cell function via adenosine triphosphate (ATP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35860879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Mitochondria in all eukaryotes are essential organelles responsible for adenosine triphosphate synthesis, calcium homeostasis and steroidogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22345710"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Mitochondria are essential organelles for energy production, calcium homeostasis, redox signaling, and other cellular responses involved in pulmonary vascular biology and disease processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38255160"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 399,
          "text": "Mitochondria are organelles within each cell that are crucial for ATP production and are also a major producer of ROS and reactive nitrogen species during intense exercise.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28579962"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Mitochondria are essential organelles that are central to a multitude of cellular processes, including oxidative phosphorylation (OXPHOS), which produces most of the ATP in animal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Mitochondria are responsible for the generation of ATP by oxidative phosphorylation; however, these multifaceted organelles regulate many other key cellular functions as well, such as calcium homeostasis, apoptosis, and biosynthesis of steroid hormones, heme and phospholipids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32183957"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Mitochondria and chloroplasts represent endosymbiotic models of complex organelle development, driven by intense evolutionary pressure to provide exponentially enhanced ATP-dependent energy production functionally linked to cellular respiration and photosynthesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26821064"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 570,
          "text": "Although the mitochondria\u0027s primary recognized function is cellular energy production, through the function of the Krebs cycle, electron transport system (ETS), as well as oxygen and electrochemical gradient consumption, this function is interconnected with multiple signaling and metabolic pathways, making bioenergetics a central hub in renal metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37423995"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 357,
          "text": "Mitochondria are important organelles responsible for cellular energy production and various metabolic processes, and their dysfunction is strongly related to the progression of cellular aging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36170016"
        },
        {
          "offsetInBeginSection": 129,
          "offsetInEndSection": 281,
          "text": "Mitochondria are main organelles involved in the production of adenosine triphosphate (ATP), the energetic substrate for cellular biochemical reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19760284"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "Mitochondria are cytosolic organelles that have many essential roles including ATP production via oxidative phosphorylation, apoptosis, iron-sulfur cluster biogenesis, heme and steroid synthesis, calcium homeostasis, and regulation of cellular redox state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27926991"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 465,
          "text": "Mitochondria are organelles that generate adenosine triphosphate (ATP) for cellular energy needs, which are mechanical-load-dependent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Most of the adenosine triphosphate (ATP) synthesized during glucose metabolism is produced in the mitochondria through oxidative phosphorylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 359,
          "text": "Mitochondria are critical for the energetic demands of virtually every cellular process within nucleated eukaryotic cells. They harbour multiple copies of their own genome (mtDNA), as well as the protein-synthesing systems required for the translation of vital subunits of the oxidative phosphorylation machinery used to generate adenosine triphosphate (ATP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31514455"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 384,
          "text": "In mitochondria, ATP is produced by a series of redox reactions, whereby an electrochemical gradient is established across the inner mitochondrial membrane. The ATP synthase harnesses the energy of the gradient to generate ATP from adenosine diphosphate (ADP) and inorganic phosphate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39236170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Mitochondria are generally considered the powerhouse of the cell, a small subcellular organelle that produces most of the cellular energy in the form of adenosine triphosphate (ATP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35877442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "The ATP-producing organelle mitochondrion controls cellular or synaptic Ca2+ concentrations through temporal uptake of Ca2+ outside of the mitochondria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34043206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "The mitochondria play a complex multi-factorial role in the cell. Along with their primary role in energy (ATP) production, mitochondria generate reactive oxygen species (ROS) that directly or indirectly affect several cellular functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15769630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Mitochondria represent the powerhouse of cells through their synthesis of ATP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22303236"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Mitochondria are multifunctional organelles that play a central role in a wide range of life-sustaining tasks in eukaryotic cells, including adenosine triphosphate (ATP) production,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37945172"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "The mitochondrion is a complex organelle that serves essential roles in energy transduction, ATP production, and a myriad of cellular signaling events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26443844"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 189,
          "text": "Mitochondria are the powerhouse of the cell, providing over 90% of adenosine triphosphate (ATP) consumed by the cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12722948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 357,
          "text": "Traditionally, mitochondria are known as \"the powerhouse of the cell,\" responsible for energy (ATP) generation (by the electron transport chain, oxidative phosphorylation, the tricarboxylic acid cycle, and fatty acid ß-oxidation), and for the regulation of several metabolic processes, including redox homeostasis, calcium signalling, and cellular apoptosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37422005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Mitochondria, the cell powerhouse, are membrane-bound organelles present in the cytoplasm of almost all the eukaryotic cells. Their main function is to generate energy in the form of adenosine triphosphate (ATP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35843711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Mitochondria are the main site of ATP synthesis in aerobic cells, using the free energy of the oxidation of metabolic fuels by oxygen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1962047"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "The oxidative phosphorylation (OXPHOS) system located in the mitochondria is the main source of adenosine triphosphate (ATP) in mammals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31306736"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Mitochondria have been described as \u0027the powerhouse of the cell\u0027 as the organelle generates the majority of adenosine triphosphate (ATP) in cells to support life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29375708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The primary function of mitochondria is respiration, where catabolism of substrates is coupled to adenosine triphosphate (ATP) synthesis via oxidative phosphorylation (OxPhos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513904"
        }
      ],
      "id": "680a07f918b1e36f2e00014a",
      "ideal_answer": [
        "Mitochondria are ubiquitous intracellular organelles found in almost all eukaryotes and involved in various aspects of cellular life, with a primary role in energy (i.e., ATP) production. Mitochondrial dysfunctions cause diverse diseases such as neurodegenerative disorders, cardiovascular disorders, metabolic disorders, and cancers, since dysfunctional mitochondria cannot provide the required energy to tissues with a high-energy demand such as the heart and brain, leading to a large spectrum of clinical phenotypes.",
        "The organelle responsible for ATP production in eukaryotic cells is the mitochondrion. ATP, or adenosine triphosphate, serves as the primary energy currency within the cell, facilitating numerous biological processes. The generation of ATP by mitochondria primarily occurs through a process known as oxidative phosphorylation, which is intricately regulated by various factors including calcium (Ca2+) levels within the mitochondrial matrix (PMID 31767352). This regulation is crucial as it ensures the efficient production of ATP in response to the cell’s metabolic demands.\n\nFurthermore, mitochondria are not only pivotal in ATP production under normoxic conditions but also play a significant role in cellular bioenergetics by creating metabolically distinct subpopulations that cater to varying cellular ATP demands (PMID 39506109). This highlights the dynamic nature of mitochondrial function, adapting to the specific energetic needs of different cellular environments. Thus, mitochondria are central to both the energy generation and metabolic regulation within eukaryotic cells, underscoring their critical role in maintaining cellular health and function.",
        "Mitochondria are the organelles responsible for ATP production. Studies highlight their critical role in energy conversion through oxidative phosphorylation, where ATP synthase plays a central function. Mitochondrial morphogenesis ensures proper inner membrane structure for efficient ATP synthesis. Impairments in mitochondrial dynamics or function, such as disruptions in ATP synthase subunits or communication with other organelles like the ER, significantly impact ATP production and cellular homeostasis. Additionally, mitochondria-derived vesicles can carry functional ATP synthase complexes, further underscoring their role in energy distribution within cells. Overall, mitochondria are indispensable for generating ATP, essential for various cellular processes and maintaining overall cell fitness.",
        "Mitochondria are the organelles responsible for ATP production. They serve as the primary site for cellular energy generation through oxidative phosphorylation, converting nutrients into ATP. This function is critical for meeting the energy demands of tissues such as the heart, brain, and muscles. Dysfunctional mitochondria are directly linked to energy deficits in these tissues, underscoring their essential role in ATP synthesis.",
        "Mitochondria are essential cellular organelles found in most eukaryotes, primarily responsible for energy (ATP) production. These organelles are crucial for high-energy demanding tissues, and their dysfunction can lead to various diseases including neurological, cardiovascular, and metabolic disorders.",
        "Mitochondria are responsible for ATP production. They are essential subcellular organelles involved in various cellular functions and energy production. Dysfunction of mitochondria can lead to diverse diseases, including neurodegenerative disorders, cardiovascular disorders, metabolic disorders, and cancers due to their inability to provide the required energy to tissues with high-energy demands such as the heart, brain, and muscles.",
        "Mitochondria are the organelles responsible for ATP production in eukaryotic cells, serving as the primary site for cellular energy generation. Dysfunction in mitochondria can lead to various diseases due to insufficient energy supply, especially in tissues with high energy demands."
      ],
      "exact_answer": [
        [
          "Mitochondria",
          "Mitochondrion"
        ]
      ]
    },
    {
      "body": "What age group is commonly affected by biliary atresia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39667195",
        "http://www.ncbi.nlm.nih.gov/pubmed/39687604",
        "http://www.ncbi.nlm.nih.gov/pubmed/38394407",
        "http://www.ncbi.nlm.nih.gov/pubmed/38426193",
        "http://www.ncbi.nlm.nih.gov/pubmed/23987231",
        "http://www.ncbi.nlm.nih.gov/pubmed/19914515",
        "http://www.ncbi.nlm.nih.gov/pubmed/39525756",
        "https://www.ncbi.nlm.nih.gov/pubmed/34331566",
        "http://www.ncbi.nlm.nih.gov/pubmed/39197055",
        "http://www.ncbi.nlm.nih.gov/pubmed/37442109",
        "http://www.ncbi.nlm.nih.gov/pubmed/39288533",
        "http://www.ncbi.nlm.nih.gov/pubmed/37907911",
        "http://www.ncbi.nlm.nih.gov/pubmed/39341941",
        "http://www.ncbi.nlm.nih.gov/pubmed/39047399",
        "http://www.ncbi.nlm.nih.gov/pubmed/16872500",
        "http://www.ncbi.nlm.nih.gov/pubmed/12793295",
        "http://www.ncbi.nlm.nih.gov/pubmed/26620065",
        "http://www.ncbi.nlm.nih.gov/pubmed/23185392",
        "http://www.ncbi.nlm.nih.gov/pubmed/39708550",
        "http://www.ncbi.nlm.nih.gov/pubmed/12601939",
        "http://www.ncbi.nlm.nih.gov/pubmed/2305321",
        "http://www.ncbi.nlm.nih.gov/pubmed/34736593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36997770",
        "http://www.ncbi.nlm.nih.gov/pubmed/20209745",
        "http://www.ncbi.nlm.nih.gov/pubmed/15001126",
        "http://www.ncbi.nlm.nih.gov/pubmed/21819536",
        "http://www.ncbi.nlm.nih.gov/pubmed/11132478",
        "http://www.ncbi.nlm.nih.gov/pubmed/39734449",
        "http://www.ncbi.nlm.nih.gov/pubmed/36276222",
        "http://www.ncbi.nlm.nih.gov/pubmed/19673629",
        "http://www.ncbi.nlm.nih.gov/pubmed/38992031",
        "http://www.ncbi.nlm.nih.gov/pubmed/19533128",
        "http://www.ncbi.nlm.nih.gov/pubmed/8005579",
        "http://www.ncbi.nlm.nih.gov/pubmed/37207069",
        "http://www.ncbi.nlm.nih.gov/pubmed/28889651",
        "http://www.ncbi.nlm.nih.gov/pubmed/22098694",
        "http://www.ncbi.nlm.nih.gov/pubmed/11678017",
        "http://www.ncbi.nlm.nih.gov/pubmed/23895960",
        "http://www.ncbi.nlm.nih.gov/pubmed/39371585",
        "http://www.ncbi.nlm.nih.gov/pubmed/9773428",
        "http://www.ncbi.nlm.nih.gov/pubmed/9229167",
        "http://www.ncbi.nlm.nih.gov/pubmed/25362914",
        "http://www.ncbi.nlm.nih.gov/pubmed/8703270",
        "http://www.ncbi.nlm.nih.gov/pubmed/11745039",
        "http://www.ncbi.nlm.nih.gov/pubmed/34884377",
        "http://www.ncbi.nlm.nih.gov/pubmed/36974991",
        "http://www.ncbi.nlm.nih.gov/pubmed/25192893",
        "http://www.ncbi.nlm.nih.gov/pubmed/31016660",
        "http://www.ncbi.nlm.nih.gov/pubmed/36276203",
        "http://www.ncbi.nlm.nih.gov/pubmed/2653529",
        "http://www.ncbi.nlm.nih.gov/pubmed/27346637",
        "http://www.ncbi.nlm.nih.gov/pubmed/22626493",
        "http://www.ncbi.nlm.nih.gov/pubmed/34027275",
        "http://www.ncbi.nlm.nih.gov/pubmed/27975109",
        "http://www.ncbi.nlm.nih.gov/pubmed/30222646",
        "http://www.ncbi.nlm.nih.gov/pubmed/18082714",
        "http://www.ncbi.nlm.nih.gov/pubmed/28983658",
        "http://www.ncbi.nlm.nih.gov/pubmed/23872602",
        "http://www.ncbi.nlm.nih.gov/pubmed/35207269",
        "http://www.ncbi.nlm.nih.gov/pubmed/34903536",
        "http://www.ncbi.nlm.nih.gov/pubmed/11801889",
        "http://www.ncbi.nlm.nih.gov/pubmed/28818034",
        "http://www.ncbi.nlm.nih.gov/pubmed/9041292",
        "http://www.ncbi.nlm.nih.gov/pubmed/9029644",
        "http://www.ncbi.nlm.nih.gov/pubmed/30664273",
        "http://www.ncbi.nlm.nih.gov/pubmed/11573070",
        "http://www.ncbi.nlm.nih.gov/pubmed/11676556",
        "http://www.ncbi.nlm.nih.gov/pubmed/25584175"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Biliary atresia (BA) is a congenital cholestatic disease that can seriously damage children\u0027s liver function. I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38426193"
        },
        {
          "offsetInBeginSection": 18,
          "offsetInEndSection": 163,
          "text": " Biliary atresia is a fibrosing cholangiopathy affecting neonates that is thought to result from a prenatal environmental insult to the bile duct",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687604"
        },
        {
          "offsetInBeginSection": 21,
          "offsetInEndSection": 220,
          "text": "Infants with biliary atresia experience gastrointestinal malabsorption of long-chain triglycerides and are commonly supplemented with medium-chain triglyceride (MCTs) that can be passively absorbed. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667195"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Medium-chain triglyceride supplementation and the association with growth, nutritional status and clinical outcomes in infants with biliary atresia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667195"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 371,
          "text": "he aim was to investigate the association of MCT supplementation with growth, nutritional status and clinical outcomes in infants with biliary atresia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39667195"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Biliary atresia (BA) is a rare disease of unknown etiology and unpredictable outcome, even when there has been timely diagnosis and exemplary surgery. It has been the commonest indication for liver transplantation during childhood for the past 20 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23987231"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Biliary atresia is a rare disease of infancy, which has changed within 30 years from being fatal to being a disorder for which effective palliative surgery or curative liver transplantation, or both, are available.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19914515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Neonatal diagnosis of biliary atresia: a practical review and update.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34331566"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "ABSTRACT: Biliary atresia (BA) is the most common cause of the obstructive type of neonatal cholestasis that requires prompt surgical in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38394407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "BACKGROUND: Newborn screening for biliary atresia (BA) may facilitate earlier diagnosis and intervention for improved clinic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39197055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "BACKGROUND: Biliary atresia (BA) is a devastating neonatal cholangiopathy with an unclear pathogenesis, and prompt diagnosis of BA is currently ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39288533"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "BACKGROUND: Biliary atresia (BA) is a rare condition of unknown origin in newborns w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39341941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "BACKGROUND: Biliary atresia is a rare and serious neonatal disease that affects the quality of life of both infants",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37442109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "BACKGROUND AND AIMS: Early diagnosis of biliary atresia (BA), particularly distinguishing it from other causes of neonatal cholestasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37907911"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 479,
          "text": "Eleven infants and children with biliary atresia (age range 1,5 months-7 years) seen at the Red Cross War Memorial Children\u0027s Hospital over a 4-month period (March-June 1988) were studied.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2305321"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 573,
          "text": "Follow-up studies were done in 20 children with biliary atresia aged between 9 months to 10 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3108484"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "The outcome of the older (\u003e or \u003d100 days) infant with biliary atresia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15065031"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "\"Biliary atresia (BA) is a common cause of jaundice in infancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34736593"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Biliary Atresia/Neonatal Cholestasis: What is in the Horizon?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34736593"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Biliary atresia (BA), a uniquely pediatric liver disease, is the leading cause of liver-related death in children and the most frequent indication for liver transplantation in the pediatric population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20209745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Biliary atresia (BA) is a congenital obliterative cholangiopathy of unknown aetiology, affecting both the intra- and extrahepatic bile ducts. Although relatively rare, BA must be excluded in any infant with conjugated hyperbilirubinaemia since the pr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15001126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Biliary atresia (BA) is a childhood rare disease of the liver and bile ducts that requires prompt surgical intervention. Age at surgery is an important prognostic factor; however,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36997770"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "BACKGROUND: Biliary atresia (BA) is associated with extrahepatic congenital malformations in a minority of affected infants. The term commonly applied to t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21819536"
        },
        {
          "offsetInBeginSection": 516,
          "offsetInEndSection": 906,
          "text": "Biliary atresia cases need to be diagnosed and operated by eight weeks of age so as to have the best results. Delayed referral after 3 months of age, not only bring down the success rate considerably but also adversely affect the management with regard to surgical procedures, nutritional support, control of ascites and finally the cost. Cirrhosis rapidly develops in children with biliary",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11132478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "UNLABELLED: Biliary atresia continues to be a serious and relatively rare disease (1/50,000 newborns) and whose long-term prognosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12601939"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 147,
          "text": "Choledochal malformation (CM) and biliary atresia (BA) are the two most important bile duct pathologies arising in infancy and childhood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708550"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 163,
          "text": "Biliary atresia is a fibrosing cholangiopathy affecting neonates that is thought to result from a prenatal environmental insult to the bile duct",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687604"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Biliary atresia (BA) is a rare disease characterised by a biliary obstruction of unknown origin that presents in the neonatal period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16872500"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "ABSTRACT: Biliary atresia (BA) is the most common cause of the obstructive type of neonatal cholestasis that requires prompt surgical int",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38394407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Biliary atresia is a progressive, idiopathic, obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction in the neonatal period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276222"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Biliary atresia (BA) is a progressive fibro-obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction in the neonatal period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Biliary atresia (BA) is a progressive inflammatory fibrosclerosing disease of the biliary system and a major cause of neonatal cholestasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38992031"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "Biliary atresia (BA) is a condition unique to infancy. It results from inflammatory destruction of the intrahepatic and extrahepatic bile ducts. It is the most frequent surgically correctable liver disorder in infancy and the most frequent indication for liver transplantation in paediatric age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Biliary atresia is the most frequent cause of chronic cholestasis in infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8005579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Biliary atresia (BA) is a progressive fibrosing cholangiopathy of infancy, the most common cause of cholestatic jaundice in infants and the top indication for liver transplantation in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37207069"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 195,
          "text": " Biliary atresia (BA) is the most common cause of cholestatic jaundice in infancy. Early diagnosis and surgical management, ideally before 60 days of age, result in improved outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185392"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Biliary atresia (BA) is the most common indication for liver transplantation (LT) in pediatric population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28889651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Biliary atresia is the most common indication for liver transplantation in the pediatric age group.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12793295"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 88,
          "text": " Biliary atresia is a progressive biliary injury which occurs only in infants",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22098694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Biliary atresia (BA) is a congenital malformation or an evolutive inflammatory process which, without treatment, leads to cirrhosis, hepatic failure and death within two years of birth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11678017"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 308,
          "text": "Although relatively rare, BA must be excluded in any infant with conjugated hyperbilirubinaemia since the prognosis is improved by early diagnosis and prompt surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15001126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "BACKGROUND: Biliary atresia (BA) is associated with extrahepatic congenital malformations in a minority of affected infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21819536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Biliary atresia with associated structural malformations in Canadian infants.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21819536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Biliary atresia (BA) is a childhood rare disease of the liver and bile ducts that requires prompt surgical intervention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36997770"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Biliary atresia (BA) is a condition unique to infancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Biliary atresia, a progressive obliterative process involving the bile ducts, has its onset in the newborn period",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9229167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Biliary atresia is a serious disease of unknown cause, affecting newborns",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25362914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Biliary Atresia is the most common cause of persistently direct (conjugated) hyperbilirubinemia in the first three months of life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8703270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Biliary atresia, a progressive sclerosis of the extrahepatic biliary tree that occurs only within the first 3 months of life, is one of the most common causes of neonatal cholestasis and accounts for over half of children who undergo liver transplantation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11745039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Biliary atresia (BA) is an obliterative condition of the biliary tract that presents with persistent jaundice and pale stools typically in the first few weeks of life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34884377"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Biliary atresia is a progressive, idiopathic, obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction in the neonatal period",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276222"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "BACKGROUND: The Kasai procedure (KPE) is an important treatment for biliary atresia (BA), the most common cause of neonatal obstructi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734449"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Background \u0026 Aims: Biliary atresia is a fibrosing cholangiopathy affecting neonates that is thought to result from a prenatal environmental insul",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687604"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Biliary atresia (BA) is an inflammatory obliterative cholangiopathy which is very common during neonatal and infancy period",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36974991"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Biliary atresia is the major kind of liver disease that mainly affects the new born infants",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25192893"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Biliary atresia is a devastating neonatal cholangiopathy that affects both extra- and intrahepatic bile ducts progressing to fibrosis and end-stage liver disease by 2 years of age",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31016660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Biliary atresia (BA) is a rare disease characterised by a biliary obstruction of unknown origin that presents in the neonatal period",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16872500"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Biliary atresia is a rare but significant cause of neonatal cholestasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Biliary atresia remains a serious and devastating surgical condition of early childhood. Despite portoenterostomy almost half of these children remain jaundiced and suffer repeated attacks of bacterial cholangitis or variceal haemorrhage. Recently li",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2653529"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Biliary atresia (BA) is a condition unique to infancy. It results from inflammatory destruction of the intrahepatic and extrahepatic bile ducts. It is the most frequent surgically correctable liver disorder in infancy and the most frequent indication",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Biliary atresia is a rare disease of infancy, which has changed within 30 years from being fatal to being a disorder for which effective palliative surgery or curative liver transplantation, or both, are available. Good outcomes for infants depend on",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19914515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Biliary atresia presents as an obliterative cholangiopathy with neonatal jaundice and pale stools. The disease exhibits aetiological heterogeneity with a multiplicity of potential causative factors, both developmental and environmental. A number of c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "PURPOSE: To investigate the course of life of young adults diagnosed with biliary atresia (BA) in infancy by comparing patients who did and did not underwent transplantation with an age-matched Dutch reference group.METHODS: All patients from the Dut",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22626493"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 352,
          "text": " live births. Biliary atresia is the most common extra hepatic cause of cholestasis in late neonatal and i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39047399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Biliary atresia (BA) is a challenging liver disease in infancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34027275"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 368,
          "text": "The neonatal liver is at increased susceptibility to cholestasis, with an incidence ranging from 1 in 2,500 to 1 in 5,000 live births. Etiologies vary, but the most common is biliary atresia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27975109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "BACKGROUND: Biliary atresia (BA) is one of the most common and perplexing causes of neonatal ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23895960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "OBJECTIVES: Biliary atresia (BA) is a rare neonatal liver disease that causes cholestasis and is the leading indication for pediatric liver tran",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30222646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "PURPOSE: Biliary atresia (BA) is the leading cause of obstructive jaundice in the newborn and the major indication for liver transplantation ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18082714"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Although biliary atresia (BA) is a rare neonatal disorder, it remains the leading cause of pediatric end-stage liver disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39371585"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 140,
          "text": "Biliary atresia (BA) is a rare and most severe cholestatic disease in neonates, but the pathogenic mechanisms are unknown",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23872602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Biliary atresia (BA) is a rare newborn liver disease with significant morbidity and mortality, especially if not recognized and treated early in life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35207269"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 139,
          "text": "Biliary atresia (BA) is regarded as a serious neonatal hepatobiliary disease, and its aetiology and pathogenesis remain unclear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34903536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "PURPOSE: Hepatobiliary scintigraphy (HBS) is used to aid in the diagnosis of Biliary Atresia in full-term infants with conjugated hyperbilir",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28818034"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Biliary atresia is a devastating neonatal cholangiopathy that affects both extra- and intrahepatic bile ducts progressing to fibrosis and end-stage liver disease by 2 years of age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31016660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "We addressed growth of biliary atresia (BA) patients living with native livers between ages 0-6 and effects of post-surgical corticosteroid treatment on growth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30519970"
        },
        {
          "offsetInBeginSection": 576,
          "offsetInEndSection": 766,
          "text": "Earlier diagnosis is associated with a better prognosis and biliary atresia should be considered in the differential diagnosis of prolonged jaundice in any infants older than 2 weeks of age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11413879"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 636,
          "text": "Biliary atresia patients had a median age of 3 mo and were from a confined geographic area.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9029644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Biliary atresia (BA) is the most common cause of end-stage liver disease in children and the primary indication for pediatric liver transplantation, yet underlying etiologies remain unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30664273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Biliary atresia is the most common cause of pediatric end-stage liver disease and the leading indication for pediatric liver transplantation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620065"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "In 37 children with extrahepatic biliary atresia between 12 days in 9 years of age we performed 72 duplexsonographic examinations of the portal system and the hepatic artery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2179620"
        },
        {
          "offsetInBeginSection": 516,
          "offsetInEndSection": 625,
          "text": "Biliary atresia cases need to be diagnosed and operated by eight weeks of age so as to have the best results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11132478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "OBJECTIVE: Biliary atresia is the leading cause of extrahepatic obstructive jaundice in the newborn and is the single most frequent indication for liver transplantation in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9041292"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 372,
          "text": "Biliary atresia has an incidence of approximately one in 10,000 live births worldwide. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Despite advances in our understanding of the pathogenesis of biliary atresia (BA), BA remains the most common cause of end-stage liver disease in children and the leading indication for pediatric liver transplantation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28983658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Biliary atresia is the leading cause of cholestasis in infants younger than 3 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11801889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 425,
          "text": "BACKGROUND: Biliary atresia is a progressive biliary injury which occurs only in infants.AIMS: To review the experience of patients surviving into adulthood without the need for liver transplantation in childhood.METHODS: A multicentre review of patients with biliary atresia treated surgically who survived into adulthood without the need for transplantation.RESULTS: Twenty-two patients were identified across four centres.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22098694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Biliary atresia (BA) is the most common cause of end-stage liver disease in children and the primary indication for pediatric liver transplantation, yet underlying etiologies remain unknown. Approximately 10% of infants affected by BA exhibit various laterality defects (heterotaxy) including splenic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30664273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Introduction and importance: Biliary atresia is a rare, progressive cholangiopathy that affects newborns, causing jaundice and other manifes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39525756"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Biliary atresia is a severe neonatal malformation in which the entire extrahepatic biliary tract or part of it is absent and replaced by fibrosclerotic tissue",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11573070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Extrahepatic biliary atresia (EHBA), the etiology of which still remains unclear, occurs exclusively in newborns and has recently been simulated in an ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11676556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Biliary atresia is a disorder of infants in which there is obliteration or discontinuity of the extrahepatic biliary system, resulting in obstruction of bile flow",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9773428"
        },
        {
          "offsetInBeginSection": 129,
          "offsetInEndSection": 291,
          "text": "ran.BACKGROUND: Cholestatic jaundice most probably occurs due to a pathological condition and the most frequent causes in early infancy are neonatal hepatitis and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25584175"
        }
      ],
      "type": "factoid",
      "id": "67cdc78381b102733300001a",
      "ideal_answer": [
        "The expression of nonsynonymous mutations results in the production of mutant proteins from tumor cells, namely tumor-specific antigens called neoantigens. Biliary atresia (BA) is the most common cause of the obstructive type of neonatal cholestasis that requires prompt surgical intervention.",
        "Biliary atresia commonly affects infants, particularly newborns.",
        "Biliary atresia is a rare disease of infancy.",
        "Biliary atresia is a pediatric liver disease that primarily affects newborns, typically presenting within the first few weeks of life. This condition is characterized by progressive fibrosis and obliteration of the bile ducts, leading to cholestasis and eventual liver failure if not treated promptly. The disease is most commonly diagnosed in the neonatal period or early infancy, making infants the most commonly affected age group. Early diagnosis and intervention, such as the Kasai procedure, are critical to improve outcomes and prevent long-term complications such as cirrhosis and the need for liver transplantation. The urgency and severity of biliary atresia make it a significant concern in pediatric hepatology, emphasizing the importance of awareness and early diagnostic approaches among healthcare providers dealing with this age group (PMID 23961607; PMID 38992031). (PMID 23961607) (PMID 38992031)",
        "Biliary atresia (BA) is a rare and most severe cholestatic disease in neonates.",
        "Biliary atresia commonly affects infants, particularly within the first four weeks after birth, with symptoms often manifesting during the neonatal period to early infancy (approximately 0-3 months of age).",
        "Biliary atresia is a rare and most severe cholestatic disease in neonates.",
        "Biliary atresia commonly affects infants in the neonatal period.",
        "Biliary atresia presents in the neonatal period and infancy.",
        "Biliary atresia commonly affects infants and children, particularly during the neonatal period.",
        "Biliary atresia commonly affects infants and is a disease of infancy.",
        "Biliary atresia commonly affects infants and children.",
        "Biliary atresia affects infants, presenting in the neonatal period and early infancy—most often between the second and sixth weeks of life and always within the first three months.",
        "Biliary atresia most commonly affects infants",
        "Biliary atresia commonly affects the neonatal and infancy period, typically within the first few months of life. It is a disease that mainly affects newborn infants, with affected infants exhibiting evidence of biliary obstruction within the first few weeks after birth.",
        "Biliary atresia primarily affects infants, typically presenting within the first few months of life. The exact age range can vary, but it is most commonly seen in infants under one year old.",
        "Biliary atresia commonly affects neonates and infants.",
        "Biliary atresia commonly affects neonates.",
        "Biliary atresia commonly affects infants, presenting in the neonatal period.",
        "Biliary atresia most commonly affects infants and children.",
        "Biliary atresia (BA) is a rare disease characterised by a biliary obstruction of unknown origin that presents in the neonatal period.",
        "Infants are the age group commonly affected by biliary atresia.",
        "Biliary atresia (BA) is a rare disease characterised by a biliary obstruction of unknown origin that presents in the neonatal period. It is the most frequent surgical cause of cholestatic jaundice in this age group.",
        "Biliary atresia commonly affects infants in the neonatal period, typically presenting within the first few weeks of life.",
        "Biliary atresia is a disease of the neonatal period and early infancy, typically presenting within the first few weeks of life—most cases are detected by six to eight weeks of age.",
        "Biliary atresia (BA) is a congenital cholestatic disease that can seriously damage children\u0027s liver function.",
        "Biliary atresia primarily affects neonates, as it is a congenital cholestatic disease that can damage the liver function of infants. This is thought to result from a prenatal environmental insult to the bile duct.",
        "Biliary atresia is most commonly seen in newborns and young infants.",
        "Biliary atresia is principally a congenital disorder affecting neonates, particularly in the first few months of life.",
        "Infants, particularly neonates, are commonly affected by biliary atresia.",
        "Biliary atresia commonly affects infants and neonates.",
        "Biliary atresia is primarily a neonatal disease, typically presenting in the first few weeks of life and almost always within the first three months.",
        "Biliary atresia primarily affects neonates, as it is a congenital cholestatic disease that impacts the bile ducts from birth.",
        "Biliary atresia is commonly seen in newborns and infants less than one year old\ninfants",
        "Biliary atresia commonly affects neonates and infants, typically presenting within the first few months of life. It is a significant cause of cholestasis in the neonatal period and can lead to end-stage liver disease if left untreated.",
        "Biliary atresia is a fibrosing cholangiopathy that commonly affects neonates, typically presenting in the first few weeks of life.",
        "Biliary atresia is a congenital disease that affects neonates, which are infants in the first 28 days of life.",
        "Biliary atresia commonly affects infants.",
        "Biliary atresia is a neonatal disease",
        "Biliary atresia commonly affects neonates, from birth, highlighting its congenital nature and immediate impact on liver function in the first 28 days of life.",
        "Biliary atresia is a fibrosing cholangiopathy affecting neonates that is thought to result from a prenatal environmental insult to the bile duct.",
        "Biliary atresia commonly affects infants, typically manifesting in the neonatal period or early infancy. It is a congenital condition that becomes apparent shortly after birth, primarily impacting newborns and young infants up to one year of age.",
        "Biliary atresia is a fibrosing cholangiopathy affecting neonates and infants with biliary atresia experience gastrointestinal malabsorption.",
        "Biliary atresia commonly affects neonates (newborns) and infants.",
        "Biliary atresia commonly affects infants in the neonatal period, typically within the first few weeks to three months of life, with the condition\u0027s onset often requiring prompt diagnosis and treatment during early infancy.",
        "Biliary atresia is a congenital disorder of the newborn, almost exclusively affecting neonates and very young infants, with the vast majority presenting within the first two months of life.",
        "Neonates to early infancy (approximately 0-4 weeks to early infancy, with treatment and studies focusing on the infant stage).",
        "Biliary atresia commonly affects neonates, as it is a congenital disease that presents in infancy and can seriously damage liver function in children.",
        "Biliary atresia commonly affects neonates, as it is a congenital condition that impacts liver function and bile ducts shortly after birth.",
        "Biliary atresia is a congenital cholestatic disease that primarily affects neonates, often resulting from a prenatal environmental insult to the bile duct.",
        "Biliary atresia (BA) is commonly seen in infants and young children, typically under the age of 2."
      ],
      "exact_answer": [
        [
          "infants",
          "neonates",
          "newborns",
          "babies"
        ]
      ]
    },
    {
      "body": "Manifestations of gluten allergy/intolerance.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38951440",
        "http://www.ncbi.nlm.nih.gov/pubmed/37242236",
        "http://www.ncbi.nlm.nih.gov/pubmed/16436335",
        "http://www.ncbi.nlm.nih.gov/pubmed/37882829",
        "http://www.ncbi.nlm.nih.gov/pubmed/38680259",
        "https://www.ncbi.nlm.nih.gov/pubmed/24395055",
        "https://www.ncbi.nlm.nih.gov/pubmed/29858750",
        "http://www.ncbi.nlm.nih.gov/pubmed/22669527",
        "http://www.ncbi.nlm.nih.gov/pubmed/34659665",
        "http://www.ncbi.nlm.nih.gov/pubmed/30013742",
        "http://www.ncbi.nlm.nih.gov/pubmed/15981987",
        "http://www.ncbi.nlm.nih.gov/pubmed/12485471",
        "http://www.ncbi.nlm.nih.gov/pubmed/9814827",
        "http://www.ncbi.nlm.nih.gov/pubmed/23496382",
        "http://www.ncbi.nlm.nih.gov/pubmed/24728027",
        "http://www.ncbi.nlm.nih.gov/pubmed/31986568",
        "http://www.ncbi.nlm.nih.gov/pubmed/30363819"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 730,
          "offsetInEndSection": 769,
          "text": "diarrhea, abdominal bloating, dyspepsia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38951440"
        },
        {
          "offsetInBeginSection": 875,
          "offsetInEndSection": 979,
          "text": "iron deficiency anemia, infertility/miscarriages, dermatitis, osteoporosis, elevated transaminase levels",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38951440"
        },
        {
          "offsetInBeginSection": 469,
          "offsetInEndSection": 493,
          "text": "irritable bowel syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37242236"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 608,
          "text": "neurological, dermatological, joint, and respiratory disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37242236"
        },
        {
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1155,
          "text": "meteorism, dyspepsia, and nausea ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37242236"
        },
        {
          "offsetInBeginSection": 357,
          "offsetInEndSection": 583,
          "text": "A body of evidence shows that dermatitis herpetiformis is actually a cutaneous manifestation of CD. Autoimmune diseases, allergic diseases, psoriasis and miscellaneous diseases have also been described with gluten intolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16436335"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1233,
          "text": "Triggered by the ingestion of gluten in genetically predisposed individuals, celiac disease is the most common genetically based food intolerance in the world, with a prevalence among approximately 1% of the general population. This enteropathy may appear at any age and is characterized by a wide variety of clinical signs and symptoms that go well beyond the gastrointestinal tract. In young children, gastrointestinal presentations are common and include chronic diarrhea, failure to thrive, and abdominal distention; however, extraintestinal manifestations are becoming increasingly more common. They include numerous conditions such as dermatitis herpetiformis, anemia, dental enamel hypoplasia, recurrent oral aphthae, short stature, osteoporosis, arthritis, neurologic problems, unexplained elevation of transaminase levels, and female infertility. Therefore, diagnosing celiac disease requires a high degree of suspicion, followed by correct screening and a confirmatory test with an intestinal biopsy. After diagnosis, a strict gluten-free diet must be followed, which in most cases will bring a marked improvement of symptoms. However, there are important compliance and quality-of-life problems, especially in adolescents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/24395055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 2437,
          "text": "Celiac disease is a complex immune-mediated gluten-sensitive enteropathy with protean clinical manifestations. It is manifest in genetically predisposed individuals who ingest gluten in varying amounts. In broad terms, it is thought to affect 1% of the population in the USA. More specifically, the prevalence increases drastically from 1:133 in patients not-at-risk, to 1:56 in symptomatic patients, to 1:39 in patients with a second-degree relative with the diagnosis, and to 1:22 in patients with a first-degree relative with the diagnosis. It may be associated with several immune-mediated phenomena, autoimmune diseases, and complicated by vitamin and other trace element deficiencies, bone disease, and malignancy. Our understanding of celiac disease has evolved rapidly over the past two decades. This has led to several lines of enquiry on the condition and potential treatment options. More recently, several entities including gluten intolerance, non-celiac gluten sensitivity, and seronegative celiac disease have been described. These conditions are distinct from allergies or intolerance to wheat or wheat products. There are challenges in defining some of these entities since a large number of patients self-report these conditions. The absence of confirmatory diagnostic tests poses an added dilemma in distinguishing these entities. The differences in spectrum of symptoms and highlights of the variability between the pediatric and adult populations have been studied in some detail. The role of screening for celiac disease is examined in both the general population and \"at risk\" populations. Diagnostic strategies including the best available serologic testing, utility of HLA haplotypes DQ2 and DQ8 which are seen in over 90% of patients with celiac disease as compared with approximately 40% of the general population, and endoscopic evaluation are also reviewed. Comprehensive nutritional management after diagnosis is key to sustained health in patients with celiac disease. Simple algorithms for care based on a comprehensive multidisciplinary approach are proposed. Refractory and non-responsive celiac diseases in the setting of a gluten-free diet are examined as are novel non-dietary therapies. Finally, the association of other disease states including psychiatric illness, infertility, lymphoproliferative malignancy, and mortality is explored with special attention paid to autoimmune and atopic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/29858750"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 661,
          "text": "This case describes a 22-year-old female subject, who had chronic headache, joint pain, urticaria and long period of amenorrhea. Skin prick tests revealed a sensitisation to α-gliadin, while neurological, gynaecological, endocrine and clinical-laboratory examinations did not justify the above-mentioned symptoms. Gluten-free diet resolved chronic symptoms and re-established the menstrual cycle, whereas a temporary gliadin daily diet re-exacerbated all clinical symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22669527"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1192,
          "text": "Dermatitis herpetiformis (DH) is a lifelong, gluten-sensitive, blistering skin disease with pathognomonic immunoglobulin (Ig)A deposits in the papillary dermis. Less than 10% of patients with DH have gastrointestinal symptoms suggestive of coeliac disease, yet they all have gluten-sensitive enteropathy. The rash, too, responds to gluten withdrawal. Therefore, DH provides a unique example of the frequent existence of gastroenterologically \u0027silent\u0027 but dermatologically active coeliac disease. DH and coeliac disease are strictly associated with class II HLA alleles A1*0501 and B1*02 encoding the HLA-DQ2 heterodimer. Coeliac disease segregates in the families of patients with DH, also supporting a shared genetic background. Monozygotic twins, one with DH and the other with coeliac disease, show that environmental, not genetic, factors seem to be responsible for the development of the rash in DH. A clinically silent but immunologically active coeliac disease in the gut could well produce IgA autoantibodies which react also with the connective tissue in the skin. The antigen for deposited IgA and its role, if any, in the blister formation in DH remains, however, to be elucidated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9814827"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Gluten ataxia and other central nervous system disorders could be linked to gluten enteropathy and related autoantibodies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38680259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 913,
          "text": "Celiac disease, with a prevalence around 1% of the general population, is the most common genetically-induced food intolerance in the world. Triggered by the ingestion of gluten in genetically predisposed individuals, this enteropathy may appear at any age, and is characterized by a wide variety of clinical signs and symptoms. Among them, gastrointestinal presentations include chronic diarrhea, abdominal pain, weight loss or failure to thrive in children; but extra-intestinal manifestations are also common, and actually appear to be on the rise. They include a large variety of ailments, such as dermatitis Herpetiformis, anemia, short stature, osteoporosis, arthritis, neurologic problems, unexplained elevation of transaminases, and even female infertility. For the clinician interested in oral diseases, celiac disease can lead to delayed tooth eruption, dental enamel hypoplasia, recurrent oral aphthae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23496382"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 460,
          "text": "Gluten sensitivity that does not fulfill the diagnostic criteria for celiac disease (CD) is increasingly recognized as a frequent and treatable condition with a wide spectrum of manifestations that overlap with the manifestations of FM, including chronic musculoskeletal pain, asthenia, and irritable bowel syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24728027"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 514,
          "text": "Gluten-related disorder groups are manifested by symptoms of gastrointestinal tract disorders, as well as hematological dermatological endocrinological, gynecological, rheumatological and nervous system symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31986568"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 365,
          "text": "GS).BACKGROUND: Non-celiac gluten sensitivity (NCGS) is a condition characterized by gastrointestinal and extra-intestinal symptoms triggered by ingestion of gluten-containing compounds, e.g., wheat, rye, and barley, in subjects without celiac disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34659665"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Non-celiac gluten sensitivity (NCGS) is a condition characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing foods in the absence of celiac disease and wheat allergy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30363819"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Non-celiac gluten sensitivity (NCGS), also referred to as non-celiac wheat sensitivity (NCWS), is a clinical syndrome characterized by both intestinal and extra-intestinal symptoms responsive to the withdrawal of gluten-containing food from the diet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30013742"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Gluten sensitive enteropathy has various manifestations, of which the two major forms are classical coeliac disease (cCD) and dermatitis herpetiformis (DH).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12485471"
        },
        {
          "offsetInBeginSection": 802,
          "offsetInEndSection": 928,
          "text": "Coeliac disease and dermatitis herpetiformis are considered to be two identical forms of the gluten enteropathy manifestations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15981987"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 651,
          "text": "ions. In addition to celiac disease and dermatitis herpetiformis, the cutaneous manifestation of celiac disease, wheat sensitivity also includes nonceliac gluten sensitivity (NCGS), allergic nickel contact mucositis, wheat allergy, amylase-trypsin inhibitor intolerance, and fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) intole",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37882829"
        }
      ],
      "id": "67d7ff2c18b1e36f2e000049",
      "ideal_answer": [
        "Manifestations of gluten allergy/intolerance are diverse, encompassing both gastrointestinal symptoms (diarrhea, abdominal pain, bloating, malabsorption, and weight loss) and extra-intestinal symptoms (skin lesions, dermatitis herpetiformis, urticaria, joint pain, headache, and amenorrhea). Additionally, various dermatological (psoriasis, atopic dermatitis), respiratory, and neurological conditions, including hereditary angioedema, may be associated. The specific presentation varies significantly depending on the underlying condition, whether it be Coeliac Disease, Wheat Allergy, or Non-Celiac Gluten Sensitivity, highlighting the need for precise diagnosis for effective management.",
        "The manifestations of gluten allergy/intolerance include: 1. Celiac disease (CeD) - characterized by gastrointestinal symptoms, malabsorption, and autoimmune responses. 2. Non-celiac gluten sensitivity (NCGS) - presents with intestinal symptoms (e.g., bloating, abdominal pain, diarrhea) and extraintestinal symptoms (e.g., headache, fatigue, joint pain). 3. Wheat allergy - involves allergic reactions to wheat proteins, which can include skin reactions, respiratory issues, and gastrointestinal symptoms. 4. Symptoms associated with NCGS may overlap with irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. 5. Autoimmune disorders linked to NCGS include Hashimoto thyroiditis, dermatitis herpetiformis, and rheumatologic diseases. 6. Neurological symptoms such as gluten ataxia, gluten neuropathy, and psychiatric conditions like depression and anxiety may also occur in NCGS.",
        "Gluten allergy or intolerance, encompassing conditions like celiac disease, non-celiac gluten sensitivity (NCGS), and wheat allergy, presents a diverse array of symptoms across various body systems. These manifestations can be categorized as follows:\n\n1. **Gastrointestinal Symptoms**: Commonly include diarrhea, abdominal bloating, dyspepsia, meteorism, nausea, and irritable bowel syndrome-like symptoms.\n\n2. **Hematological Issues**: May involve iron deficiency anemia due to malabsorption, particularly in celiac disease.\n\n3. **Reproductive Problems**: Can manifest as infertility or miscarriages, often linked to untreated celiac disease affecting hormonal balance or nutrient absorption.\n\n4. **Dermatological Manifestations**: Include skin conditions such as dermatitis herpetiformis, a rash associated with celiac disease.\n\n5. **Skeletal Disorders**: Osteoporosis may occur due to deficiencies in calcium and vitamin D from malabsorption.\n\n6. **Liver Abnormalities**: Elevated transaminase levels indicate liver inflammation, possibly related to autoimmune responses.\n\n7. **Neurological Symptoms**: Encompass headaches, migraines, and more severe conditions like gluten ataxia in celiac disease.\n\n8. **Joint Pain**: Arthritis or joint discomfort can arise from autoimmune reactions.\n\n9. **Respiratory Issues**: Less commonly, asthma or allergic reactions may occur.\n\nThe severity and type of symptoms vary significantly among individuals, with some experiencing primarily gastrointestinal issues while others face neurological or dermatological problems. Recognizing these diverse manifestations is crucial for accurate diagnosis and appropriate treatment."
      ],
      "exact_answer": [
        [
          "diarrhea"
        ],
        [
          "iron deficiency anemia"
        ],
        [
          "irritable bowel syndrome",
          "IBS"
        ],
        [
          "neurological disorders"
        ],
        [
          "dermatological disorders"
        ],
        [
          "joint disorders"
        ],
        [
          "respiratory disorders"
        ],
        [
          "meteorism"
        ],
        [
          "nausea"
        ],
        [
          "abdominal bloating"
        ],
        [
          "dyspepsia"
        ],
        [
          "infertility"
        ],
        [
          "elevated transaminase levels"
        ],
        [
          "osteoporosis"
        ],
        [
          "miscarriages"
        ],
        [
          "dermatitis"
        ],
        [
          "dyspepsia"
        ]
      ]
    },
    {
      "body": "Do T cells enter the CNS in healthy individuals?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26775912",
        "https://www.ncbi.nlm.nih.gov/pubmed/36209092",
        "http://www.ncbi.nlm.nih.gov/pubmed/32948672",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453390",
        "http://www.ncbi.nlm.nih.gov/pubmed/12829791",
        "http://www.ncbi.nlm.nih.gov/pubmed/36209092",
        "http://www.ncbi.nlm.nih.gov/pubmed/10401633",
        "http://www.ncbi.nlm.nih.gov/pubmed/10993917",
        "http://www.ncbi.nlm.nih.gov/pubmed/8843602",
        "http://www.ncbi.nlm.nih.gov/pubmed/32702313",
        "http://www.ncbi.nlm.nih.gov/pubmed/26942913",
        "http://www.ncbi.nlm.nih.gov/pubmed/26133121",
        "http://www.ncbi.nlm.nih.gov/pubmed/11596121",
        "http://www.ncbi.nlm.nih.gov/pubmed/16550326",
        "http://www.ncbi.nlm.nih.gov/pubmed/12161020",
        "http://www.ncbi.nlm.nih.gov/pubmed/8407255",
        "http://www.ncbi.nlm.nih.gov/pubmed/35732977",
        "http://www.ncbi.nlm.nih.gov/pubmed/22837040",
        "http://www.ncbi.nlm.nih.gov/pubmed/28138136",
        "http://www.ncbi.nlm.nih.gov/pubmed/12576700",
        "http://www.ncbi.nlm.nih.gov/pubmed/6191006",
        "http://www.ncbi.nlm.nih.gov/pubmed/23401348"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "T cells within the central nervous system (CNS) have been generally considered pathogenic, especially in the context of neuroinflammatory disease. However, recent findings have revealed varied functions for T cells in the healthy CNS, as well as more complex roles for these cells in infection and injury than previously appreciated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775912"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 484,
          "text": "Further characterization of the state of T cells in the CSF in healthy individuals is important for understanding how T cells provide protective immune surveillance without damaging the delicate environment of the CNS and providing tissue-specific context for understanding immune dysfunction in neuroinflammatory disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "T cells provide critical immune surveillance to the central nervous system (CNS), and the cerebrospinal fluid (CSF) is thought to be a main route for their entry",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 950,
          "text": "Second, while pathogenic T cells contribute to CNS disorders, recent studies, mostly in animal models, show that specific subpopulations of normal beneficial T cells have protective and regenerative effects in several neuroinflammatory and neurodegenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453390"
        },
        {
          "offsetInBeginSection": 698,
          "offsetInEndSection": 988,
          "text": "By comparing profiles of clonally expanded T cells obtained from the CSF of patients with multiple sclerosis (MS) and healthy donors, we report that clonally expanded T cells from the CSF of patients with MS have heightened expression of genes related to T cell activation and cytotoxicity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 64,
          "offsetInEndSection": 247,
          "text": "In healthy individuals, the T cells of the immune system, when activated by an infectious agent, regularly traffic across an intact blood-brain barrier, survey the CNS and then leave.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8843602"
        },
        {
          "offsetInBeginSection": 50,
          "offsetInEndSection": 222,
          "text": "Although CD4 T cells have been reported in the central nervous system, their presence in the healthy brain remains controversial, and their function remains largely unknown",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32702313"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 485,
          "text": "Further characterization of the state of T cells in the CSF in healthy individuals is important for understanding how T cells provide protective immune surveillance without damaging the delicate environment of the CNS and providing tissue-specific context for understanding immune dysfunction in neuroinflammatory disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "T cells provide critical immune surveillance to the central nervous system (CNS), and the cerebrospinal fluid (CSF) is thought to be a main route for their entry.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 1580,
          "offsetInEndSection": 1844,
          "text": "These results support the overall hypothesis that activated memory T cells enter CSF directly from the systemic circulation and monitor the subarachnoid space, retaining the capacity to either initiate local immune reactions or return to secondary lymphoid organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12829791"
        },
        {
          "offsetInBeginSection": 486,
          "offsetInEndSection": 697,
          "text": "Here, we have profiled T cells in the CSF of healthy human donors and have identified signatures related to cytotoxic capacity and tissue adaptation that are further exemplified in clonally expanded CSF T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 486,
          "offsetInEndSection": 635,
          "text": "Here, we have profiled T cells in the CSF of healthy human donors and have identified signatures related to cytotoxic capacity and tissue adaptation ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32948672"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 585,
          "text": "We report here that naive T cells can traffic to the CNS without prior activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10993917"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Despite the mechanical blood-brain barrier, activated T-cells can cross brain vessels. Thus, the CNS is routinely surveyed by immune competent cells; yet the healthy brain is not a target of antigen-specific immune reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10401633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "In the healthy individuum lymphocyte traffic into the central nervous system (CNS) is very low and tightly controlled by the highly specialized blood-brain barrier (BBB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "Although the blood-brain barrier and blood cerebrospinal fluid barrier maintain the central nervous system (CNS) as an immunologically privileged site, T lymphocytes can migrate through unstimulated brain endothelium and epithelium to perform immune surveillance or initiate inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12161020"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "An emerging concept of normal brain immune surveillance proposes that recently and moderately activated central memory T lymphocytes enter the central nervous system (CNS) directly into the cerebrospinal fluid (CSF) via the choroid plexus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26942913"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 217,
          "text": "Little is known about trafficking patterns of leukocytes between the systemic circulation and the noninflamed CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12829791"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 318,
          "text": "An emerging concept of normal brain immune surveillance proposes that recently and moderately activated central memory T lymphocytes enter the central nervous system (CNS) directly into the cerebrospinal fluid (CSF) via the choroid plexus. Within the CSF space, T cells inspect the CNS environment for cognate antigens",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26942913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "In the healthy individuum lymphocyte traffic into the central nervous system (CNS) is very low and tightly controlled by the highly specialized blood-brain barrier (BBB",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16550326"
        },
        {
          "offsetInBeginSection": 705,
          "offsetInEndSection": 846,
          "text": "It is now clear that peripheral naïve T cells not only carry out continuous surveillance within the brain but also maintain neural plasticity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26133121"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 828,
          "text": "This redefining of immune privilege in the brain is a result of the recent re-discovery of the extensive CNS meningeal lymphatic system and the identification of resident T cells in the brain, meningeal layers, and its surrounding cerebrospinal fluid (CSF) in both humans and rodents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35732977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "The CNS, which consists of the brain and spinal cord, is continuously monitored by resident microglia and blood-borne immune cells such as macrophages, dendritic cells and T cells to detect for damaging agents that would disrupt homeostasis and optimal functioning of these vital organs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22837040"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 241,
          "text": "Even in normal condition, a small number of T cells are detected in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12576700"
        },
        {
          "offsetInBeginSection": 781,
          "offsetInEndSection": 1005,
          "text": "There are also few lymphocytes under normal circumstances. These cells circulate from the blood, through the vessel walls and into the perivascular spaces, along the perivascular channels and to the CSF and back to the blood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6191006"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 371,
          "text": "To date, it is well recognized that the central nervous system is subjected to active immunosurveillance, as evidenced by the presence of central memory T cells in cerebrospinal fluid (CSF) of healthy individuals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401348"
        }
      ],
      "id": "680a084018b1e36f2e00014e",
      "ideal_answer": [
        "T cells within the central nervous system (CNS) have been generally considered pathogenic, especially in the context of neuroinflammatory disease. However, recent findings have revealed varied functions for T cells in the healthy CNS, as well as more complex roles for these cells in infection and injury than previously appreciated.",
        "Yes, T cells can enter the CNS in healthy individuals. The central nervous system (CNS) is typically considered an immune-privileged site, but recent findings suggest that immune cells, including T cells, can infiltrate the CNS even in the absence of overt disease. This infiltration is part of the body\u0027s defense mechanism against potential microbial threats and plays a role in the maintenance of CNS integrity (PMID 36209092). The presence of T cells in the CNS of healthy individuals indicates a controlled immune surveillance mechanism that likely contributes to the CNS\u0027s ability to respond to pathogens while maintaining neurological health. This process is nuanced and involves a balance that prevents the development of autoimmunity while allowing for necessary immune responses (PMID 16247180). Thus, under normal conditions, the entry of T cells into the CNS does not necessarily imply pathology but rather a state of preparedness and physiological regulation.",
        "Yes, T cells enter the CNS in healthy individuals, primarily for immune surveillance. They traverse the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier, with central memory T cells being a specific subset involved in this process. This entry mechanism allows for the monitoring of the CNS without initiating an immune response, highlighting the body\u0027s delicate balance in maintaining neurological health.",
        "Yes, T cells can enter the central nervous system (CNS) in healthy individuals. While the CNS is often viewed as an immune-privileged site, there is evidence that immune surveillance takes place there under normal conditions. T cells are capable of migrating into the CNS through the blood-brain barrier and the cerebrospinal fluid. This process is part of the body\u0027s mechanism for immune surveillance and helps maintain homeostasis. However, the presence of T cells in the CNS is carefully regulated to avoid unnecessary inflammation or damage to neural tissues.",
        "Yes, T cells do enter the healthy central nervous system. Under normal, non-inflammatory conditions, T cells cross the blood-brain barrier, contributing to continuous immune surveillance of the CNS. A diverse range of T cells—including activated and resting CD4 memory cells, CD8 T cells, naive T cells, and tissue-resident memory T cells—has been found in cerebrospinal fluid and brain tissues. These T cells typically remain quiescent until activated by a threat, allowing them to maintain readiness for immediate responses while supporting overall brain homeostasis. Studies in both humans and animal models indicate that this routine patrolling by T cells is important not only for early detection and response to potential insults but also for the maintenance of normal cognitive and social brain functions.",
        "Studies have shown that several infiltrating immune cell types, including T cells, are present in non-diseased CNS tissue. Specifically, CD4 memory resting T cells, CD8 T cells, and CD4 memory activated T cells are found in most brain regions with insignificant variation. Additionally, studies demonstrate that T cells can enter CNS through either blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCSFB), with different T cell subsets preferring different routes under various conditions. For instance, Th17 cells preferentially cross BCSFB under both non-inflamed and inflamed conditions. These findings suggest that T cells do enter CNS in healthy individuals as part of normal immune surveillance, although their presence and activity are tightly regulated by brain barriers to maintain CNS homeostasis.",
        "Yes, T cells do enter the central nervous system (CNS) in healthy individuals. This occurs as part of normal immune surveillance, where activated T cells cross the intact blood-brain barrier to survey the CNS and then leave without causing any issues. While significant infiltration is more commonly associated with disease states, such as Parkinson\u0027s disease, the regular trafficking of T cells into the CNS is a natural process in healthy individuals.",
        "Yes, T cells do enter the central nervous system (CNS) in healthy individuals. Recent research indicates that these immune cells have diverse functions within the healthy CNS, beyond their previously recognized role as pathogenic agents in neuroinflammatory diseases. Their presence suggests they play a part in maintaining immune surveillance and regulating processes within the nervous system, even in the absence of infection or injury. This understanding highlights the complexity of T cell roles, encompassing both health and disease states.",
        "T cells can enter the central nervous system (CNS) even in healthy individuals, challenging the prior perception of their exclusively pathogenic role in neuroinflammatory diseases. Recent research highlights their diverse functions in maintaining CNS homeostasis, such as immune surveillance and tissue repair, alongside their involvement in responses to infection and injury. While historically associated with disease progression, these cells now appear to contribute to both protective and regulatory processes in the healthy CNS, underscoring a more nuanced understanding of their physiological roles. This shift emphasizes the complexity of T cell dynamics in the CNS, where their presence and activity are context-dependent, balancing immune defense with tissue integrity.",
        "Yes, T cells do enter the central nervous system (CNS) in healthy individuals. While traditionally viewed as pathogenic, especially in neuroinflammatory contexts, recent research indicates that T cells have diverse roles in the healthy CNS. These roles extend beyond pathology to include surveillance and maintenance functions, contributing to the CNS environment without causing inflammation or damage. Thus, T cells are present and active in the CNS of healthy individuals, performing important regulatory tasks as part of the immune system\u0027s broader patrol mechanisms.",
        "Recent studies highlight that T cells do enter the central nervous system (CNS) in healthy individuals, playing essential roles beyond their traditionally recognized pathogenic functions in neuroinflammatory diseases. These findings demonstrate that diverse T cell subsets contribute to maintaining CNS homeostasis by modulating inflammation and tissue repair during injury, infection, or neurodegeneration. Mechanistic insights reveal how T cells limit excessive immune responses and damage while supporting neural integrity, challenging earlier assumptions of their exclusive involvement in disease pathology. Understanding these processes not only clarifies the adverse effects observed with T cell-depleting therapies but also opens avenues for targeted interventions in CNS disorders."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is urolithiasis the same thing as kidney stones?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39290225",
        "http://www.ncbi.nlm.nih.gov/pubmed/38398427",
        "http://www.ncbi.nlm.nih.gov/pubmed/39042342",
        "http://www.ncbi.nlm.nih.gov/pubmed/30575366",
        "http://www.ncbi.nlm.nih.gov/pubmed/37608670",
        "http://www.ncbi.nlm.nih.gov/pubmed/23363254",
        "http://www.ncbi.nlm.nih.gov/pubmed/39527261",
        "http://www.ncbi.nlm.nih.gov/pubmed/19444769",
        "http://www.ncbi.nlm.nih.gov/pubmed/24384768",
        "http://www.ncbi.nlm.nih.gov/pubmed/37913796",
        "http://www.ncbi.nlm.nih.gov/pubmed/37565942",
        "http://www.ncbi.nlm.nih.gov/pubmed/23483000",
        "http://www.ncbi.nlm.nih.gov/pubmed/33148855",
        "http://www.ncbi.nlm.nih.gov/pubmed/16438249",
        "http://www.ncbi.nlm.nih.gov/pubmed/31209553",
        "http://www.ncbi.nlm.nih.gov/pubmed/39680210",
        "http://www.ncbi.nlm.nih.gov/pubmed/30056408",
        "http://www.ncbi.nlm.nih.gov/pubmed/37542869",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569213",
        "http://www.ncbi.nlm.nih.gov/pubmed/38155376",
        "http://www.ncbi.nlm.nih.gov/pubmed/29859007",
        "http://www.ncbi.nlm.nih.gov/pubmed/31596944",
        "http://www.ncbi.nlm.nih.gov/pubmed/36932340",
        "http://www.ncbi.nlm.nih.gov/pubmed/39550346",
        "http://www.ncbi.nlm.nih.gov/pubmed/39506574",
        "http://www.ncbi.nlm.nih.gov/pubmed/38682062",
        "http://www.ncbi.nlm.nih.gov/pubmed/29515627",
        "http://www.ncbi.nlm.nih.gov/pubmed/27231922",
        "http://www.ncbi.nlm.nih.gov/pubmed/31393255",
        "http://www.ncbi.nlm.nih.gov/pubmed/39344467",
        "http://www.ncbi.nlm.nih.gov/pubmed/38158485",
        "http://www.ncbi.nlm.nih.gov/pubmed/3486510",
        "http://www.ncbi.nlm.nih.gov/pubmed/19038658",
        "http://www.ncbi.nlm.nih.gov/pubmed/38623715"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 170,
          "text": "Urolithiasis is a common and recurrent condition with a rising global incidence. Stones typically develop in the upper urinary tract, primarily the kidneys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39290225"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 87,
          "text": " Urolithiasis, the formation of kidney stones, is a common and severe condition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39042342"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 204,
          "text": "Evidence-based guidelines are published by urological organisations for various conditions, including urolithiasis. In this paper, we provide guidance on the management of kidney stone disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38398427"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 388,
          "text": "Urate urolithiasis refers to a type of urolithiasis, characterized by the formation of kidney stones consisting of uric acid or its salts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30575366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Urolithiasis is a general term referring to the causes and effects of stones anywhere in the urinary tract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19038658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Urolithiasis is a general term that encompasses formulation of urinary tract stones as a sequela of one or more underlying abnormalities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3486510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Urolithiasis (urinary tract calculi or stones) and nephrolithiasis (kidney calculi or stones) are well-documented common occurrences in the general population of the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16438249"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 524,
          "text": "Urinary calculi or stones are the most common cause of acute ureteral obstruction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16438249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "BACKGROUND: Urolithiasis refers to renal or ureteral calculi referred to in lay terminology as a kidney stone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23483000"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Oxalate urolithiasis (nephrolithiasis) is the most frequent type of kidney stone disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24384768"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Kidney stone disease, also known as nephrolithiasis or urolithiasis, is a disorder in which urinary solutes precipitate to form aggregates of crystalline material in the urinary space.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37565942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Urolithiasis is a disease characterized by the presence of stones in the urinary tract, whether in the kidneys, ureters, or bladder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37913796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Urolithiasis is defined as a disease diagnosed by the presence of one or more stones in the urinary tract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38155376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "PURPOSE: Urolithiasis, the formation of kidney stones, is a common and severe c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39042342"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "BACKGROUND: Urolithiasis is a condition where crystalline mineral deposits (stones) form within the ur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29859007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "BACKGROUND: Urolithiasis is a condition where crystalline mineral deposits (stones) form within the ur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31596944"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "BACKGROUNDS: Kidney stone also known as urolithiasis or nephrolithiasis, is one of the oldest diseases known to medicine, however, the gene expression changes and related kidney injury rem",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36932340"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "BACKGROUND: For treatment of urolithiasis, the stone composition is of particular interest, as uric acid (UA) stones can be treated by chem",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39550346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Urolithiasis, commonly known as kidney stones, is characterized by the formation of hard deposits in the urinary tract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37608670"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "OBJECTIVE: Kidney stone disease (nephrolithiasis; urolithiasis) is a clinical entity with long-term course and recurrence, primarily affecting mature and ageing men, involving the formation and presence of urinary stones in the kidneys and urinary tract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33148855"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Urolithiasis, a condition in which calculi are found in the urinary tract, has been known for centuries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30056408"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Kidney stone disease, also known as nephrolithiasis or urolithiasis, is a disorder in which urinary solutes precipitate to form aggregates of crystalline material in the urinary space",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37565942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "PURPOSE: Urolithiasis, the formation of kidney stones, is a common and severe ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39042342"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "OBJECTIVE: Kidney stone disease (nephrolithiasis; urolithiasis) is a clinical entity with long-term course and recurrence, primarily affecting mature and ageing men, involving the formation and presence of urinary stones in the kidneys and ur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33148855"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Kidney stone formation or urolithiasis is a complex process that results from a succession of several physicochemical events including supersaturation, nucleation, growth, aggregation, and retention within the kidneys",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19444769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Background and Objectives: The majority of all kidney stone cases are oxalate urolithiasis wit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38682062"
        },
        {
          "offsetInBeginSection": 1098,
          "offsetInEndSection": 1232,
          "text": "Thus, further understanding of the pathophysiology of kidney stone formation is a research area to manage urolithiasis using new drugs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29515627"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Urolithiasis is a prevalent condition in urology, with extracorporeal shock wave lithotripsy (ESWL) serving as a common treatment for kidney stones under 2 cm.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39680210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Urolithiasis (urinary tract calculi or stones) and nephrolithiasis (kidney calculi or stones) are well-documented common occurrences in the general population of the United States",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16438249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "BACKGROUNDS: Kidney stone also known as urolithiasis or nephrolithiasis, is one of the oldest diseases known to medicine, however, the gene expression changes and related kidney injury re",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36932340"
        },
        {
          "offsetInBeginSection": 95,
          "offsetInEndSection": 284,
          "text": " function. Renal stone disease (urolithiasis) is an increasing form of a common renal disease that is a multifactorial disorder influenced by both intrinsic and extrinsic, mainly environmen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23363254"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Urolithiasis (urinary tract calculi or stones) and nephrolithiasis (kidney calculi or stones) are well-documented common occurrences in the general population of the United States. The etiology of this disorder is multifactorial and is strongly relat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16438249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "BACKGROUND: Calcium oxalate urolithiasis, commonly referred to as kidney stones, is a prevalent condition marked by the development of solid crystals within the uri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39506574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "BACKGROUND: Urolithiasis is the process of forming stones in the kidney, bladder, and/or ur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393255"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Urolithiasis is a painful disorder in which stones are formed in the kidney, bladder or urethra.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28528955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Kidney stone formation or urolithiasis is a complex process that results from a succession of several physicochemical events including supersaturation, nucleation, growth, aggregation, and retention within the kidneys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19444769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "OBJECTIVE: Kidney stone disease (nephrolithiasis; urolithiasis) is a clinical entity with long-term course and recurrence, primarily affecting mature and ageing men, involving the formation and presence of urinary stones in the kidneys and uri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33148855"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Urolithiasis, referred to as the formation of stones in the urinary tract, is a common disease with growing prevalence and high recurrence rate worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35776498"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 102,
          "text": " Urolithiasis is the process of forming stones in the kidney, bladder, and/or urinary tract",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393255"
        },
        {
          "offsetInBeginSection": 26,
          "offsetInEndSection": 129,
          "text": " Urolithiasis, commonly known as kidney stones, is a condition significantly impacted by dietary habits",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39344467"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Urolithiasis or nephrolithiasis is a condition of kidney stone formation and is considered a painful disease of the urinary tract system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38158485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "We reviewed patient records with a first-listed diagnosis of urolithiasis-also known as urinary tract or kidney stone disease, nephrolithiasis-upon discharge from Guam\u0027s sole civilian hospital during 2006 to 2010 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27231922"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Kidney stones and urolithiasis are kidney diseases that have a significant impact on health and well-being, and their incidence is increasing annually owing to factors such as age, sex, ethnicity, and geographical location.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39527261"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "The formation of urinary stone, urolithiasis, is one the oldest known disease affecting human throughout different civilizations and times.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "Kidney stone disease (KSD, also named renal calculi, nephrolithiasis, or urolithiasis) is a common urological disease entailing the formation of minerals and salts that form inside the urinary tract, frequently caused by diabetes, high blood pressure, hypertension, and monogenetic components in most patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38623715"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Urolithiasis is one of most common renal disorders, characterized by the formation of kidney stones (renal calculi) through the crystallization process within the urinary system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37542869"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Urolithiasis is a common urologic problem among adults worldwide. It is interesting that urinary stones tend to recur on the same side an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31209553"
        }
      ],
      "type": "yesno",
      "id": "67cde41a81b102733300001d",
      "ideal_answer": [
        "Urolithiasis, the formation of kidney stones, is a common and severe condition.",
        "Yes, urolithiasis is the same thing as kidney stones.",
        "Yes, urolithiasis refers to any morphological alteration of the urinary system that results in an obstruction of the ureter, nephron or collect system due to formation of calculi.",
        "Yes, urolithiasis is also known as kidney stones. Yes, urolithiasis is the medical term for kidney stones.",
        "Yes, urolithiasis is the medical term for the formation of stones, also known as calculi, in the urinary tract, which includes the kidneys. Therefore, urolithiasis is commonly referred to as kidney stones when the stones are located in the kidneys.",
        "Yes, urolithiasis is the term used for the formation of stones in the urinary tract, and kidney stones are a specific type of urolithiasis. While kidney stones form in the kidneys, urolithiasis can also refer to stones that are located in other parts of the urinary tract, such as the ureters or bladder.",
        "Yes, urolithiasis is the same thing as kidney stones. Urolithiasis, also known as nephrolithiasis or kidney stone disease, is a condition where crystalline mineral deposits, also known as stones, form within the urinary tract.",
        "Yes, urolithiasis refers to kidney stones and other urinary tract calculi.",
        "Yes. Urolithiasis is a term that refers to the formation of stones in the urinary tract, which includes kidney stones.",
        "Yes, urolithiasis refers to kidney stones.",
        "Urolithiasis and kidney stones refer to the same medical condition, which is the formation of small, hard mineral deposits in the kidneys or urinary tract.",
        "Yes. Urolithiasis is another term for kidney stones, also known as nephrolithiasis, which refers to the formation of stones in the urinary tract.",
        "Yes, urolithiasis is commonly known as kidney stones and is characterized by the formation of hard deposits in the urinary tract.",
        "Urolithiasis and kidney stones are the same thing. Urolithiasis refers to the presence of stones in the urinary system, and kidney stones specifically are stones that form in the kidneys. Therefore, kidney stones are a type of urolithiasis.",
        "Yes. Urolithiasis is another term for kidney stones, also known as nephrolithiasis.",
        "Yes, urolithiasis is the medical term for kidney stones.",
        "Yes. Urolithiasis is another term for kidney stone disease, where urinary solutes precipitate to form aggregates of crystalline material in the urinary space.",
        "Yes, urolithiasis is also known as kidney stones. yes",
        "Yes, urolithiasis refers to the formation of stones in the urinary system, which includes the kidneys. Therefore, urolithiasis is commonly known as kidney stones when the stones are located in the kidneys.",
        "Urolithiasis and kidney stones are terms used interchangeably to describe the formation of hard deposits in the urinary tract. These deposits, also known as stones, can cause severe pain and discomfort.",
        "Yes, urolithiasis and kidney stones are the same thing, referring to the formation of hard deposits in the urinary tract.",
        "Yes, urolithiasis is the same thing as kidney stones. Urolithiasis, also known as nephrolithiasis or renal calculi, refers to the formation of stones within the urinary system, specifically in the kidneys. These stones are formed through the crystallization of minerals and salts.",
        "Urolithiasis refers to the formation of kidney stones, a common and recurrent condition. It primarily involves the development of stones in the upper urinary tract, specifically the kidneys.",
        "Yes, urolithiasis is the medical term for kidney stones. Yes, urolithiasis is also known as kidney stones. Yes, urolithiasis is another name for kidney stones.",
        "Yes, urolithiasis is the same thing as kidney stones. They are also known as urinary stones or nephrolithiasis. Urolithiasis is a condition where crystalline mineral deposits (stones) form within the urinary tract, typically in the kidneys.",
        "Yes, urolithiasis is indeed the same as kidney stones, as the references clearly indicate that it refers to the formation of kidney stones.",
        "Yes. Urolithiasis is the medical term for the formation of kidney stones, indicating they are the same condition.",
        "Yes, urolithiasis refers to the formation of stones (calculi) in the urinary tract, which includes kidney stones (nephrolithiasis). The term is often used interchangeably with \"kidney stones\" in clinical contexts, as stones most commonly develop in the kidneys.",
        "Urolithiasis is the medical term for stones in the urinary tract and is synonymous with kidney stones, both describing the formation of crystalline deposits in the urinary system.",
        "Yes, urolithiasis is the formation of kidney stones, as noted in the reference snippets. It refers to the condition where stone formation occurs in the urinary tract, primarily in the kidneys.",
        "[\u0027Yes, urolithiasis and kidney stones are the same condition. Urolithiasis refers to the formation of stones in the urinary tract, and kidney stones are a type of urolithiasis that specifically develop in the kidneys.\u0027]",
        "Yes, urolithiasis is the same thing as kidney stones. Urolithiasis, also known as nephrolithiasis, refers to the formation of stones in the urinary tract, primarily in the kidneys. It is a common and recurrent condition with a rising global incidence.",
        "Yes, urolithiasis is indeed the same thing as kidney stones. Urolithiasis refers to the formation of kidney stones, which is a common and severe condition.",
        "Yes, urolithiasis refers to the formation of kidney stones, which are typically found in the upper urinary tract, primarily the kidneys. The terms are often used interchangeably in medical literature and guidelines for management.",
        "Yes. Urolithiasis refers to the formation of kidney stones, making them the same condition.",
        "Yes, urolithiasis is the same thing as kidney stones. It is a condition where stones form in the kidneys, which can be a common and recurrent problem.",
        "Yes. Urolithiasis is the medical term for the formation of kidney stones, indicating that they are the same condition.",
        "urolithiasis and kidney stones are the same thing.",
        "Yes, urolithiasis refers to the formation of kidney stones.",
        "Yes, available evidence suggests that is urolithiasis the same thing as kidney stones.",
        "Yes. Urolithiasis refers to the formation of kidney stones, making them essentially the same condition.",
        "Urolithiasis refers to the formation of stones anywhere in the urinary tract, including the kidneys. While kidney stones are a common occurrence within this condition, urolithiasis is broader and encompasses all types of urinary stones, not just those in the kidneys.",
        "Urolithiasis is the same condition as kidney stones, primarily characterized by the formation of stones in the kidneys, which are part of the urinary tract. This common condition is noted to have a rising global incidence.",
        "Yes. Urolithiasis is the same thing as kidney stones.",
        "Yes. Urolithiasis, the formation of kidney stones, is a common and severe condition",
        "Yes, urolithiasis is the formation of kidney stones.",
        "Urolithiasis is a common and recurrent condition with a rising global incidence . Stones typically develop in the upper urinary tract, primarily the kidneys .",
        "Urolithiasis and kidney stones are often used interchangeably in practice, referring to stone formation in the urinary tract, primarily in the kidneys, though technically, urolithiasis is a broader condition encompassing kidney stones (nephrolithiasis) among other urinary tract stone formations.",
        "Yes, based on the provided snippets, urolithiasis can be considered the same thing as kidney stones, specifically referring to the condition of having kidney stones, primarily in the upper urinary tract.",
        "Yes, urolithiasis is the same thing as kidney stones. Urolithiasis refers to the formation of stones in the urinary system, which includes the kidneys."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "How do you acquire Legionella pneumophila?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39714278",
        "http://www.ncbi.nlm.nih.gov/pubmed/38363136",
        "http://www.ncbi.nlm.nih.gov/pubmed/38099453",
        "http://www.ncbi.nlm.nih.gov/pubmed/38792686",
        "http://www.ncbi.nlm.nih.gov/pubmed/38757288",
        "https://www.ncbi.nlm.nih.gov/pubmed/16459041",
        "https://www.ncbi.nlm.nih.gov/pubmed/29535972",
        "https://www.ncbi.nlm.nih.gov/pubmed/35208710",
        "https://www.ncbi.nlm.nih.gov/pubmed/37137207",
        "http://www.ncbi.nlm.nih.gov/pubmed/27046155",
        "http://www.ncbi.nlm.nih.gov/pubmed/15448271",
        "http://www.ncbi.nlm.nih.gov/pubmed/3328895",
        "http://www.ncbi.nlm.nih.gov/pubmed/15727299",
        "http://www.ncbi.nlm.nih.gov/pubmed/15329532",
        "http://www.ncbi.nlm.nih.gov/pubmed/17258676",
        "http://www.ncbi.nlm.nih.gov/pubmed/26706971"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 603,
          "text": "2 water jet cutters and 1 floor scrubber",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714278"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Public bath facilities are a major source of Legionella infections in Japan",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38363136"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 123,
          "text": "bronchoscopy-related outbreaks",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38099453"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 157,
          "text": "nosocomial cellulitis ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38792686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Wastewater treatment plants (WWTPs) are increasingly identified as Legionnaires\u0027 disease (LD) sources",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38757288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 2367,
          "text": "Legionellosis is a respiratory disease of public health concern. The bacterium Legionella pneumophila is the etiologic agent responsible for \u003e90% of legionellosis cases in the United States. Legionellosis transmission primarily occurs through the inhalation or aspiration of contaminated water aerosols or droplets. Therefore, a thorough understanding of L. pneumophila detection methods and their performance in various water quality conditions is needed to develop preventive measures. Two hundred and nine potable water samples were collected from taps in buildings across the United States. L. pneumophila was determined using three culture methods: Buffered Charcoal Yeast Extract (BCYE) culture with Matrix-assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) identification, Legiolert® 10- and 100-mL tests, and one molecular method: quantitative Polymerase Chain Reaction (qPCR) assay. Culture and molecular positive results were confirmed by secondary testing including MALDI-MS. Eight water quality variables were studied, including source water type, secondary disinfectant, total chlorine residual, heterotrophic bacteria, total organic carbon (TOC), pH, water hardness, cold- and hot-water lines. The eight water quality variables were segmented into 28 categories, based on scale and ranges, and method performance was evaluated in each of these categories. Additionally, a Legionella genus qPCR assay was used to determine the water quality variables that promote or hinder Legionella spp. occurrence. L. pneumophila detection frequency ranged from 2 to 22% across the methods tested. Method performance parameters of sensitivity, specificity, positive and negative predictive values, and accuracy were \u003e94% for the qPCR method but ranged from 9 to 100% for the culture methods. Water quality influenced L. pneumophila determination by culture and qPCR methods. L. pneumophila qPCR detection frequencies positively correlated with TOC and heterotrophic bacterial counts. The source water-disinfectant combination influenced the proportion of Legionella spp. that is L. pneumophila. Water quality influences L. pneumophila determination. To accurately detect L. pneumophila, method selection should consider the water quality in addition to the purpose of testing (general environmental monitoring versus disease-associated investigations).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37137207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1988,
          "text": "Legionella pneumophila (L. pneumophila) is an opportunistic waterborne pathogen and the causative agent for Legionnaires\u0027 disease, which is transmitted to humans via inhalation of contaminated water droplets. The bacterium is able to colonize a variety of man-made water systems such as cooling towers, spas, and dental lines and is widely distributed in multiple niches, including several species of protozoa In addition to survival in planktonic phase, L. pneumophila is able to survive and persist within multi-species biofilms that cover surfaces within water systems. Biofilm formation by L. pneumophila is advantageous for the pathogen as it leads to persistence, spread, resistance to treatments and an increase in virulence of this bacterium. Furthermore, Legionellosis outbreaks have been associated with the presence of L. pneumophila in biofilms, even after the extensive chemical and physical treatments. In the microbial consortium-containing L. pneumophila among other organisms, several factors either positively or negatively regulate the presence and persistence of L. pneumophila in this bacterial community. Biofilm-forming L. pneumophila is of a major importance to public health and have impact on the medical and industrial sectors. Indeed, prevention and removal protocols of L. pneumophila as well as diagnosis and hospitalization of patients infected with this bacteria cost governments billions of dollars. Therefore, understanding the biological and environmental factors that contribute to persistence and physiological adaptation in biofilms can be detrimental to eradicate and prevent the transmission of L. pneumophila. In this review, we focus on various factors that contribute to persistence of L. pneumophila within the biofilm consortium, the advantages that the bacteria gain from surviving in biofilms, genes and gene regulation during biofilm formation and finally challenges related to biofilm resistance to biocides and anti-Legionella treatments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/29535972"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1104,
          "text": "Legionella pneumophila is defined as a bacterium that can cause severe pneumonia. It is found in the natural environment and in water, and is often found in water tanks. It can be an integral part of biofilms in nature, and the protozoa in which it can live provide it with food and protect it from harmful influences; therefore, it has the ability to move into a sustainable but uncultured state (VBNC). L. pneumophila has been shown to cause infections in dental practices. The most common transmission route is aerosol generated in dental office water systems, which can negatively affect patients and healthcare professionals. The most common way of becoming infected with L. pneumophila in a dental office is through water from dental instruments, and the dental unit. In addition to these bacteria, patients and the dental team may be exposed to other harmful bacteria and viruses. Therefore, it is vital that the dental team regularly maintains and decontaminates the dental unit, and sterilizes all accessories that come with it. In addition, regular water control in dental offices is necessary.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/35208710"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 938,
          "text": "Legionnaires\u0027 disease is one of the major infectious risks related to hospital water systems. It is commonly accepted, that the disease is transmitted to man mostly by inhalation of water aerosols contaminated by Legionella pneumophila. The ability of L. pneumophila to multiply intracellularly within some amoebae better explains the ecology, the pathogenicity, and the virulence of this bacterium against human alveolar macrophages. The presence of these amoebae in water systems located where cases of Legionnaire\u0027s disease broke out, partly explains the difficulty in eradicating Legionella. Some studies also show that amoebae can play a major role in the transmission of the disease to man. Some other studies point out that inhaled amoebae could be involved in the pathogenesis of Legionnaire\u0027s disease. Future strategies to prevent the transmission of Legionella will probably have to include efficient treatments against amoebae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/16459041"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "We present the genomic sequence of Legionella pneumophila, the bacterial agent of Legionnaires\u0027 disease, a potentially fatal pneumonia acquired from aerosolized contaminated fresh water. The genome includes a 45-kilobase pair element that can exist i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15448271"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 475,
          "text": "Pneumonia is acquired by inhalation of environmental aerosols from water sources contaminated by Legionella sp.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3328895"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 261,
          "text": "The infection is acquired by inhalation of aerosols from contaminated water systems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27046155"
        },
        {
          "offsetInBeginSection": 685,
          "offsetInEndSection": 942,
          "text": "Because L. pneumophila 1, responsible of child infection, was only isolated from the hospital pool water for waterbirthing, we conclude that the infant acquired the nosocomial legionellosis by prolonged delivery in contaminated water, perhaps by aspiration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15329532"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 257,
          "text": "Legionellosis is acquired by inhalation of legionellae from contaminated environmental sources.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17258676"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "We present the genomic sequence of Legionella pneumophila, the bacterial agent of Legionnaires\u0027 disease, a potentially fatal pneumonia acquired from aerosolized contaminated fresh water.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15448271"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 203,
          "text": "Disease is acquired by inhaling aerosol contaminated by legionellae",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15727299"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 256,
          "text": "Legionellosis is acquired by inhalation of legionellae from contaminated environmental sources",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17258676"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 474,
          "text": "Pneumonia is acquired by inhalation of environmental aerosols from water sources contaminated by Legionella sp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3328895"
        },
        {
          "offsetInBeginSection": 236,
          "offsetInEndSection": 475,
          "text": "Legionella pneumophila is the species causing most human illness, but other species may predominate in individual institutions. Pneumonia is acquired by inhalation of environmental aerosols from water sources contaminated by Legionella sp.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3328895"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 289,
          "text": " Legionnaires\u0027 disease is normally acquired by inhalation of legionellae from a contaminated environmental source. Water systems of large buildings, such as hospitals, are often contaminated with legionellae and therefore represent a potential risk for the hospital population",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26706971"
        }
      ],
      "id": "67e2b80618b1e36f2e00008f",
      "ideal_answer": [
        "Legionella pneumophila is acquired through inhalation of aerosolized water containing this bacterium, which can come from various sources such as air conditioning systems, hot tubs, and large plumbing systems. Studies have shown that L. pneumophila is a common intracellular parasitic bacterium that infects humans via the respiratory tract, causing Legionnaires\u0027 disease, with fever and pneumonia as the main symptoms. This bacterium is often found in freshwater environments and can grow within protists, such as amoebae, which provides a refuge from desiccation, disinfection, and other remediation strategies. Once inhaled, L. pneumophila can infect human alveolar macrophages and reside in a phagosome that does not fuse with lysosomes, allowing the bacterium to replicate and cause disease. Studies have also identified that seasonal and climatic changes can influence the incidence of L. pneumophila infections, with higher temperatures correlating with increased incidence of Legionnaires\u0027 disease."
      ]
    },
    {
      "body": "What is the role of the choroid plexus in immune surveillance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22902764",
        "http://www.ncbi.nlm.nih.gov/pubmed/34312005",
        "http://www.ncbi.nlm.nih.gov/pubmed/24088808",
        "http://www.ncbi.nlm.nih.gov/pubmed/21440040",
        "http://www.ncbi.nlm.nih.gov/pubmed/11135454",
        "http://www.ncbi.nlm.nih.gov/pubmed/36088417",
        "http://www.ncbi.nlm.nih.gov/pubmed/36388000",
        "http://www.ncbi.nlm.nih.gov/pubmed/1430149",
        "http://www.ncbi.nlm.nih.gov/pubmed/38340002",
        "http://www.ncbi.nlm.nih.gov/pubmed/33821737",
        "http://www.ncbi.nlm.nih.gov/pubmed/25979470",
        "http://www.ncbi.nlm.nih.gov/pubmed/29195132",
        "https://www.ncbi.nlm.nih.gov/pubmed/24088808",
        "https://www.ncbi.nlm.nih.gov/pubmed/27998697",
        "https://www.ncbi.nlm.nih.gov/pubmed/33821737",
        "https://www.ncbi.nlm.nih.gov/pubmed/35203434",
        "http://www.ncbi.nlm.nih.gov/pubmed/29368213",
        "http://www.ncbi.nlm.nih.gov/pubmed/26516722",
        "http://www.ncbi.nlm.nih.gov/pubmed/23774427",
        "http://www.ncbi.nlm.nih.gov/pubmed/22725964",
        "http://www.ncbi.nlm.nih.gov/pubmed/35203434",
        "http://www.ncbi.nlm.nih.gov/pubmed/35882269",
        "http://www.ncbi.nlm.nih.gov/pubmed/19305396",
        "http://www.ncbi.nlm.nih.gov/pubmed/35715859",
        "http://www.ncbi.nlm.nih.gov/pubmed/2784211",
        "http://www.ncbi.nlm.nih.gov/pubmed/33249184",
        "http://www.ncbi.nlm.nih.gov/pubmed/25289890",
        "http://www.ncbi.nlm.nih.gov/pubmed/23095871",
        "http://www.ncbi.nlm.nih.gov/pubmed/39658900",
        "http://www.ncbi.nlm.nih.gov/pubmed/32645014",
        "http://www.ncbi.nlm.nih.gov/pubmed/27898074",
        "http://www.ncbi.nlm.nih.gov/pubmed/20028334",
        "http://www.ncbi.nlm.nih.gov/pubmed/25904790",
        "http://www.ncbi.nlm.nih.gov/pubmed/32431599",
        "http://www.ncbi.nlm.nih.gov/pubmed/26833402",
        "http://www.ncbi.nlm.nih.gov/pubmed/25374259",
        "http://www.ncbi.nlm.nih.gov/pubmed/38838150",
        "http://www.ncbi.nlm.nih.gov/pubmed/32014066",
        "http://www.ncbi.nlm.nih.gov/pubmed/15381333",
        "http://www.ncbi.nlm.nih.gov/pubmed/26942913",
        "http://www.ncbi.nlm.nih.gov/pubmed/26994633",
        "http://www.ncbi.nlm.nih.gov/pubmed/24418937",
        "http://www.ncbi.nlm.nih.gov/pubmed/23741282",
        "http://www.ncbi.nlm.nih.gov/pubmed/37078651",
        "http://www.ncbi.nlm.nih.gov/pubmed/25491682"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365,
          "text": "The choroid plexus (ChP), an epithelial bilayer containing a network of mesenchymal, immune, and neuronal cells, forms the blood-cerebrospinal fluid (CSF) barrier (BCSFB). While best recognized for secreting CSF, the ChP is also a hotbed of immune cell activity and can provide circulating peripheral immune cells with passage into the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34312005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "text": "The choroid plexus is a multifunctional organ that sits at the interface between the blood and cerebrospinal fluid (CSF). It serves as a gateway for immune cell trafficking into the CSF and is in an excellent position to provide continuous immune surveillance by CD4 (+)  T cells, macrophages and dendritic cells and to regulate immune cell trafficking in response to disease and trauma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 1084,
          "text": "Three cell types within the choroid plexus, in particular, may play prominent roles in controlling the development of immune responses within the nervous system: the epithelial cells, which form the blood-CSF barrier, and resident macrophages and dendritic cells in the stromal matrix. Adhesion molecule and chemokine expression by the epithelial cells allows substantial control over the selection of cells that transmigrate. Macrophages and dendritic cells can present antigen within the choroid plexus and/or transmigrate into the cerebral ventricles to serve a variety of possible immune functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 365,
          "text": "Although infiltration of leucocytes to the injured central nervous system has recently been shown to be orchestrated by the brain\u0027s choroid plexus, the immunological mechanism that maintains this barrier and regulates its activity as a selective gate is poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 593,
          "text": "Here, we hypothesized that CD4(+) effector memory T cells, recently shown to reside at the choroid plexus stroma, regulate leucocyte trafficking through this portal through their interactions with the choroid plexus epithelium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 733,
          "offsetInEndSection": 893,
          "text": "In vitro findings revealed that the expression of immune cell trafficking determinants by the choroid plexus epithelium is specifically induced by interferon-γ.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1120,
          "text": "Tumour necrosis factor-α and interferon-γ reciprocally controlled the expression of their receptors by the choroid plexus epithelium, and had a synergistic effect in inducing the epithelial expression of trafficking molecules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 387,
          "text": "It serves as a gateway for immune cell trafficking into the CSF and is in an excellent position to provide continuous immune surveillance by CD4 (+)  T cells, macrophages and dendritic cells and to regulate immune cell trafficking in response to disease and trauma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 768,
          "text": "Three cell types within the choroid plexus, in particular, may play prominent roles in controlling the development of immune responses within the nervous system: the epithelial cells, which form the blood-CSF barrier, and resident macrophages and dendritic cells in the stromal matrix.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 910,
          "offsetInEndSection": 1085,
          "text": "Macrophages and dendritic cells can present antigen within the choroid plexus and/or transmigrate into the cerebral ventricles to serve a variety of possible immune functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 766,
          "text": " Three cell types within the choroid plexus, in particular, may play prominent roles in controlling the development of immune responses within the nervous system: the epithelial cells, which form the blood-CSF barrier, and resident macrophages and dendritic cells in the stromal matri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 909,
          "offsetInEndSection": 1083,
          "text": " Macrophages and dendritic cells can present antigen within the choroid plexus and/or transmigrate into the cerebral ventricles to serve a variety of possible immune function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 530,
          "text": "Normally, immune cells migrate into the central nervous system microenvironment through choroid plexus and interact with the central nervous system resident cells through either through neuromediators or immunomediators",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23774427"
        },
        {
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1259,
          "text": "Finally, their role in the control of immune cell traffic between the blood and the CSF confers on the choroid plexuses a function in neuroimmune regulation and implicates them in neuroinflammation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "The choroid plexus (ChP) of the cerebral ventricles is a source of cerebrospinal fluid (CSF) production and also plays a key role in immune surveillance at the level of blood-to-CSF-barrier (BCSFB)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35882269"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 555,
          "text": "Specifically, the choroid plexus (CP), an epithelial layer that forms the blood-cerebrospinal fluid barrier, is able to modulate the cognitive function, through changes in the neuroinflammatory response and in brain immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33249184"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 1032,
          "text": "The choroid plexus acts as an immunological niche where several types of peripheral immune cells can be found within the stroma including dendritic cells, macrophages, and T cells. Including the epithelia cells, these cells perform immunosurveillance, detecting pathogens and changes in the cytokine milieu. As such, their activation leads to the release of homing molecules to induce chemotaxis of circulating immune cells, driving an immune response at the choroid plexus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36088417"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 865,
          "text": "The choroid plexus acts as an immunological niche where several types of peripheral immune cells can be found within the stroma including dendritic cells, macrophages, and T cells. Including the epithelia cells, these cells perform immunosurveillance, detecting pathogens and changes in the cytokine milieu.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36088417"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Stromal macrophages of the choroid plexus situated at an interface between the brain and peripheral immune system constitutively express major histocompatibility class II antigens.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1430149"
        },
        {
          "offsetInBeginSection": 1828,
          "offsetInEndSection": 2170,
          "text": "Collectively, our findings attribute a novel immunological plasticity to the choroid plexus epithelium, allowing it to serve, through interferon-γ signalling, as a tightly regulated entry gate into the central nervous system for circulating leucocytes immune surveillance under physiological conditions, and for repair following acute injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 1783,
          "offsetInEndSection": 1917,
          "text": "Taken together, our observations imply a previously unappreciated function of the choroid plexus in the immunosurveillance of the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11135454"
        },
        {
          "offsetInBeginSection": 404,
          "offsetInEndSection": 597,
          "text": "The primary purpose of the CP is to secrete CSF, but it also plays a role in the immune surveillance of the central nervous system (CNS) and in the removal of neurotoxic compounds from the CSF.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35203434"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 562,
          "text": "Originally consider as being only responsible for the production of cerebrospinal fluid, it is now widely recognized that the CP is also involved in immunosurveillance and immune cell trafficking. Histopathology studies have found several immunological changes in donor tissue, including the accumulation of inflammatory cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39658900"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 339,
          "text": "The choroid plexus (CP) is a highly vascularized organ located in the brain ventricles and contains a single epithelial cell layer forming the blood-cerebrospinal fluid barrier (BCSFB). This barrier is crucial for immune surveillance in health and is an underestimated gate for entry of immune cells during numerous inflammatory disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25979470"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "The choroid plexus (ChP) of the cerebral ventricles is a source of cerebrospinal fluid (CSF) production and also plays a key role in immune surveillance at the level of blood-to-CSF-barrier (BCSFB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35882269"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "The main functions of the choroid plexus (CP) are the production of cerebral spinal fluid (CSF), the formation of the blood-CSF barrier, and regulation of immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32645014"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "The choroid plexus (CP) has a key role in maintaining brain homeostasis by producing cerebrospinal fluid (CSF), by mediating transport of nutrients and removing metabolic products from the central nervous system and by responding to peripheral inflammatory signals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898074"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 556,
          "text": "Specifically, the choroid plexus (CP), an epithelial layer that forms the blood-cerebrospinal fluid barrier, is able to modulate the cognitive function, through changes in the neuroinflammatory response and in brain immune surveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33249184"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "The choroid plexus is able to modulate the cognitive function, through changes in the neuroinflammatory response and in brain immune surveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29195132"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 365,
          "text": "While best recognized for secreting CSF, the ChP is also a hotbed of immune cell activity and can provide circulating peripheral immune cells with passage into the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34312005"
        },
        {
          "offsetInBeginSection": 818,
          "offsetInEndSection": 1036,
          "text": "Our results identify distinct molecular requirements and ports of lymphocyte entry into uninflamed versus inflamed CNS and suggest that the CCR6-CCL20 axis in the choroid plexus controls immune surveillance of the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19305396"
        },
        {
          "offsetInBeginSection": 733,
          "offsetInEndSection": 922,
          "text": "In particular, we elaborate on the role of CCR6/CCL20 axis in migration through the choroid plexus and the involvement of this pathway in immune surveillance of and autoimmunity in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22725964"
        },
        {
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1260,
          "text": "Finally, their role in the control of immune cell traffic between the blood and the CSF confers on the choroid plexuses a function in neuroimmune regulation and implicates them in neuroinflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368213"
        },
        {
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1212,
          "text": "These effects correlate with increased immune surveillance at the borders of the brain; specifically, at the choroid plexus (CP), an epithelial layer that resides at the junction between the blood circulation, and the brain and plays a key role in maintaining and restoring brain homeostasis, regulating cerebrospinal-fluid (CSF) production and neurotropic factors composition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095871"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 531,
          "text": "Normally, immune cells migrate into the central nervous system microenvironment through choroid plexus and interact with the central nervous system resident cells through either through neuromediators or immunomediators.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23774427"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 385,
          "text": "It serves as a gateway for immune cell trafficking into the CSF and is in an excellent position to provide continuous immune surveillance by CD4 (+)  T cells, macrophages and dendritic cells and to regulate immune cell trafficking in response to disease and traum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22902764"
        },
        {
          "offsetInBeginSection": 404,
          "offsetInEndSection": 596,
          "text": "The primary purpose of the CP is to secrete CSF, but it also plays a role in the immune surveillance of the central nervous system (CNS) and in the removal of neurotoxic compounds from the CSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35203434"
        },
        {
          "offsetInBeginSection": 1828,
          "offsetInEndSection": 2169,
          "text": "Collectively, our findings attribute a novel immunological plasticity to the choroid plexus epithelium, allowing it to serve, through interferon-γ signalling, as a tightly regulated entry gate into the central nervous system for circulating leucocytes immune surveillance under physiological conditions, and for repair following acute injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "The choroid plexus (CP) plays a major role in controlling the entry of substances and immune cells into the brain as it forms the blood-cerebrospinal fluid barrier (BCSFB) in the brain ventricles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32431599"
        },
        {
          "offsetInBeginSection": 319,
          "offsetInEndSection": 505,
          "text": "The choroid plexus epithelium secretes cerebrospinal fluid, growth factors, neuropeptides, and lipids into the ventricles and also serves as a gateway for immune cells to enter the brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38340002"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 346,
          "text": "The CP is also implicated in the passage of peripheral immune signals and circulation of immune cells into the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25374259"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 370,
          "text": "Choroid plexus (ChP) plays critical roles in barrier function and immune response modulation and expresses the ACE2 receptor and the chromosome 21-encoded TMPRSS2 protease, suggesting its substantial role in establishing SARS-CoV-2 infection in the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38838150"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 597,
          "text": "In several models of CNS pathologies, circulating immune cells were shown to display an indispensable role in the resolution of the neuroinflammatory response. The recruitment of such cells to the CNS involves activation of the choroid plexus (CP) of the brain for leukocyte trafficking, through a mechanism that requires IFN-γ signaling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790"
        },
        {
          "offsetInBeginSection": 419,
          "offsetInEndSection": 597,
          "text": "The recruitment of such cells to the CNS involves activation of the choroid plexus (CP) of the brain for leukocyte trafficking, through a mechanism that requires IFN-γ signaling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25904790"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The choroid plexus (CP) plays a major role in controlling the entry of substances and immune cells into the brain as it forms the blood-cerebrospinal fluid barrier (BCSFB) in the brain ventricles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32431599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1260,
          "text": "The barrier between the blood and the ventricular cerebrospinal fluid (CSF) is located at the choroid plexuses. At the interface between two circulating fluids, these richly vascularized veil-like structures display a peculiar morphology explained by their developmental origin, and fulfill several functions essential for CNS homeostasis. They form a neuroprotective barrier preventing the accumulation of noxious compounds into the CSF and brain, and secrete CSF, which participates in the maintenance of a stable CNS internal environment. The CSF circulation plays an important role in volume transmission within the developing and adult brain, and CSF compartments are key to the immune surveillance of the CNS. In these contexts, the choroid plexuses are an important source of biologically active molecules involved in brain development, stem cell proliferation and differentiation, and brain repair. By sensing both physiological changes in brain homeostasis and peripheral or central insults such as inflammation, they also act as sentinels for the CNS. Finally, their role in the control of immune cell traffic between the blood and the CSF confers on the choroid plexuses a function in neuroimmune regulation and implicates them in neuroinflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 311,
          "text": "In addition to being the main source of cerebrospinal fluid (CSF) secretion, the choroid plexuses are involved in the supply and distribution of peptides to brain, the removal of toxic metabolites, the excretion of xenobiotics, and the delivery of drugs as an alternative route to the blood-brain barrier (BBB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15381333"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "The choroid plexus (CP) is considered to be a point of leukocyte entry into the CNS during normal immune surveillance and in neuroinflammatory diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25289890"
        },
        {
          "offsetInBeginSection": 835,
          "offsetInEndSection": 1211,
          "text": "These effects correlate with increased immune surveillance at the borders of the brain; specifically, at the choroid plexus (CP), an epithelial layer that resides at the junction between the blood circulation, and the brain and plays a key role in maintaining and restoring brain homeostasis, regulating cerebrospinal-fluid (CSF) production and neurotropic factors composition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "An emerging concept of normal brain immune surveillance proposes that recently and moderately activated central memory T lymphocytes enter the central nervous system (CNS) directly into the cerebrospinal fluid (CSF) via the choroid plexus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26942913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "The choroid plexus is able to modulate the cognitive function, through changes in the neuroinflammatory response and in brain immune surveillance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29195132"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 364,
          "text": "Although infiltration of leucocytes to the injured central nervous system has recently been shown to be orchestrated by the brain\u0027s choroid plexus, the immunological mechanism that maintains this barrier and regulates its activity as a selective gate is poorly understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24088808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Prior work demonstrated that immune surveillance of the brain occurs primarily through the blood-cerebrospinal (CSF) fluid barrier rather than the blood-brain barrier endothelium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21440040"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 603,
          "text": "In contrast with previous findings, increasing interleukin (IL)-4 and IL-10 in brain by a recently-developed adenoviral delivery method, had detrimental effects in an animal model of AD, and the ability to isolate the choroid plexus has opened the debate on the role of this specialized tissue in immune surveillance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26516722"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Epiplexus cells are a population of innate immune cells in the choroid plexus of the brain ventricles. They are thought to contribute to the immune component of the blood-cerebrospinal-fluid-barrier (BCSFB). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "The choroid plexus is the site of the blood-cerebrospinal fluid (CSF) barrier (BCSFB) and has also been considered as a possible route for peripheral immune signals and cells to transfer to the central nervous system. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23741282"
        },
        {
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1260,
          "text": "By sensing both physiological changes in brain homeostasis and peripheral or central insults such as inflammation, they also act as sentinels for the CNS. Finally, their role in the control of immune cell traffic between the blood and the CSF confers on the choroid plexuses a function in neuroimmune regulation and implicates them in neuroinflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "The choroid plexus (CP) is considered to be a point of leukocyte entry into the CNS during normal immune surveillance and in neuroinflammatory diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25289890"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Prior work demonstrated that immune surveillance of the brain occurs primarily through the blood-cerebrospinal (CSF) fluid barrier rather than the blood-brain barrier endothelium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21440040"
        },
        {
          "offsetInBeginSection": 1236,
          "offsetInEndSection": 1404,
          "text": "Together, our data highlights the role of the CP in immune homeostasis and indicates the occurrence of mild inflammatory processes in the CP of progressive MS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32014066"
        }
      ],
      "id": "680a21ff18b1e36f2e000151",
      "ideal_answer": [
        "The choroid plexus (ChP) is a multifunctional organ that sits at the interface between the blood and cerebrospinal fluid (CSF).\nWhile best recognized for secreting CSF, the ChP is also a hotbed of immune cell activity and can provide circulating peripheral immune cells with passage into the central nervous system (CNS). Three cell types within the choroid plexus, in particular, may play prominent roles in controlling the development of immune responses within the nervous system: the epithelial cells, which form the blood-CSF barrier, and resident macrophages and dendritic cells in the stromal matrix. Adhesion molecule and chemokine expression by the epithelial cells allows substantial control over the selection of cells that transmigrate. Macrophages and dendritic cells can present antigen within the choroid plexus and/or transmigrate into the cerebral ventricles to serve a variety of possible immune functions.",
        "Choroid plexus plays a crucial role in immune surveillance, serving as a gateway for immune cell trafficking into cerebrospinal fluid (CSF) and providing continuous immune surveillance by CD4+ T cells, macrophages, and dendritic cells. Studies demonstrate that choroid plexus epithelial cells regulate immune cell trafficking through expression of adhesion molecules and chemokines, allowing substantial control over selection of cells that transmigrate. Epithelial cells, resident macrophages, and dendritic cells in stromal matrix may play prominent roles in controlling development of immune responses within nervous system. Interferon-γ signalling enables choroid plexus epithelium to serve as a tightly regulated entry gate into central nervous system for circulating leucocytes under physiological conditions and for repair following acute injury. Overall, choroid plexus is a multifunctional organ that maintains and restores brain homeostasis, regulates CSF production and neurotropic factors composition, and plays key role in immune surveillance at blood-to-CSF-barrier.",
        "The choroid plexus (ChP) plays a crucial role in immune surveillance within the central nervous system (CNS). It serves as a gateway for immune cell trafficking into the cerebrospinal fluid (CSF) and is strategically positioned to facilitate continuous immune monitoring by various immune cells, including CD4 (+) T cells, macrophages, and dendritic cells. The epithelial cells of the ChP express adhesion molecules and chemokines that regulate the selection and transmigration of immune cells. Additionally, resident macrophages and dendritic cells within the ChP can present antigens and migrate into the cerebral ventricles, contributing to immune responses. The ChP is particularly significant in the context of diseases like multiple sclerosis, where it is involved in compartmentalized inflammation and immune responses. Overall, the ChP not only secretes CSF but also plays a vital role in maintaining immune homeostasis and responding to CNS injuries and diseases.",
        "The choroid plexus establishes the blood–CSF barrier via a polarized epithelial bilayer whose apical surfaces express VCAM-1, ICAM-1, MAdCAM-1 and chemokines to recruit and selectively transmigrate circulating T cells, macrophages and dendritic cells into the CSF and brain. Resident stromal macrophages and dendritic cells sample antigens and can themselves enter the ventricles to amplify CNS responses. Through interferon-γ signaling the epithelium adapts its barrier properties in health, acute injury or inflammation, tightly regulating leukocyte entry. By secreting CSF along with growth factors, neuropeptides and lipids and by clearing neurotoxic compounds, the choroid plexus maintains CNS homeostasis and orchestrates continuous immune surveillance.",
        "The choroid plexus (ChP) plays a critical role in immune surveillance by acting as a dynamic interface between the blood and cerebrospinal fluid (CSF). It facilitates immune cell trafficking into the central nervous system (CNS) through its epithelial cells, which form the blood-CSF barrier and regulate transmigration via adhesion molecules and chemokines. Resident macrophages and dendritic cells within the ChP stroma contribute to immune surveillance by presenting antigens and modulating immune responses. These cells, along with CD4+ T cells, enable continuous monitoring of systemic immune activity, allowing selective passage of peripheral immune cells into the CSF. The ChP’s dual function as a secretory organ (producing CSF) and an immune hub underscores its importance in maintaining CNS homeostasis and responding to disease or trauma by orchestrating immune interactions within the nervous system."
      ]
    },
    {
      "body": "Has Antibiotic use induced hiccups?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37369596",
        "http://www.ncbi.nlm.nih.gov/pubmed/38450348",
        "https://www.ncbi.nlm.nih.gov/pubmed/15985056",
        "https://www.ncbi.nlm.nih.gov/pubmed/37369596",
        "https://www.ncbi.nlm.nih.gov/pubmed/8619448",
        "http://www.ncbi.nlm.nih.gov/pubmed/34526851",
        "http://www.ncbi.nlm.nih.gov/pubmed/15985056",
        "http://www.ncbi.nlm.nih.gov/pubmed/8619448"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Rare case report of moxifloxacin-induced persistent hiccups.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 188,
          "text": "ere we report an unusual case of a patient with persistent hiccups caused by moxifloxacin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Antibiotic-Induced Hiccups: A Case Report and Brief Literature Review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38450348"
        },
        {
          "offsetInBeginSection": 532,
          "offsetInEndSection": 659,
          "text": "Herein, we report the first case of cefotaxime-induced hiccups and briefly review the literature on antibiotic-induced hiccups.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38450348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 41,
          "text": "Possible azithromycin-associated hiccups.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Rare case report of moxifloxacin-induced persistent hiccups.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/8619448"
        },
        {
          "offsetInBeginSection": 815,
          "offsetInEndSection": 908,
          "text": "To our knowledge, this is the first case report about moxifloxacin-induced persistent hiccups",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Short report: severe hiccups secondary to doxycycline-induced esophagitis during treatment of malaria.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8619448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis. Hiccups were persistent and exhausti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 235,
          "text": "antibiotics may cause drug-induced hiccups.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34526851"
        },
        {
          "offsetInBeginSection": 517,
          "offsetInEndSection": 659,
          "text": "still unknown. Herein, we report the first case of cefotaxime-induced hiccups and briefly review the literature on antibiotic-induced hiccups.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38450348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 338,
          "text": " 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis. Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "A 51-year-old man who was treated with quinine and doxycycline for Plasmodium falciparum malaria acquired in West Africa developed hiccups soon after his first dose of antimalarial therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8619448"
        },
        {
          "offsetInBeginSection": 75,
          "offsetInEndSection": 188,
          "text": "n therapy.CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 187,
          "text": "Here we report an unusual case of a patient with persistent hiccups caused by moxifloxacin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 742,
          "text": "On assessing causality of the adverse drug reaction, the Naranjo scale for moxifloxacin was six, indicating a probable relationship of hiccups with moxifloxacin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 463,
          "text": "Hiccups occurred 2 hours after intravenous injection of moxifloxacin and lasted into evening. On the second day after injection, hiccups occurred again and made it difficult for him to fall asleep",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        },
        {
          "offsetInBeginSection": 75,
          "offsetInEndSection": 189,
          "text": "n therapy.CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 1291,
          "offsetInEndSection": 1444,
          "text": "ten achieved only by a process of elimination. However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism cou",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 451,
          "offsetInEndSection": 658,
          "text": "The exact mechanism responsible for this adverse drug reaction is still unknown. Herein, we report the first case of cefotaxime-induced hiccups and briefly review the literature on antibiotic-induced hiccups",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38450348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis. Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy wi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15985056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "A 51-year-old man who was treated with quinine and doxycycline for Plasmodium falciparum malaria acquired in West Africa developed hiccups soon after his first dose of antimalarial therapy. Endoscopic examination performed when his hiccups became intractable showed an esophageal erosion and ulcer mo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8619448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "A 51-year-old man who was treated with quinine and doxycycline for Plasmodium falciparum malaria acquired in West Africa developed hiccups soon after his first dose of antimalarial therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8619448"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 359,
          "text": "Hiccups occurred 2 hours after intravenous injection of moxifloxacin and lasted into evening",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37369596"
        }
      ],
      "type": "yesno",
      "id": "67fc546c18b1e36f2e000130",
      "ideal_answer": [
        "Yes there are repored cases of antibiotic-induced hiccups",
        "Yes, antibiotic use has been reported to cause drug-induced hiccups.",
        "Yes, antibiotic use has been associated with hiccups.",
        "Yes, it has been reported that antibiotic induced hiccus.",
        "Antibiotic use is not typically associated with hiccups. Hiccups are usually induced by a variety of etiologies such as central nervous disorders, gastrointestinal disorders, cardiovascular disorders, psychogenic factors, and metabolic disorders. Medication-induced hiccups are rare. Therefore, it is unlikely that antibiotic use would cause hiccups.",
        "Yes, hiccups can be caused by antibiotic therapy.",
        "Yes, antibiotic use has been reported to induce hiccups in some cases.",
        "Yes, antibiotic use can induce hiccups in some cases. Although it is a rare side effect, certain antibiotics, like azithromycin, have been associated with causing hiccups. This occurrence is not common and can vary based on individual susceptibility and other factors.",
        "Yes, antibiotics may cause drug-induced hiccups. Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials. There is a reported case of a patient with persistent hiccups caused by moxifloxacin.",
        "Antibiotic use is not a common cause for hiccups. While hiccups can be induced by a variety of etiologies, including gastrointestinal, cardiovascular, and psychogenic factors, they are rarely induced by medications. The provided snippet mentions that hiccups induced by medications are rare. Therefore, it can be concluded that antibiotic use is not likely to induce hiccups.",
        "Yes. Antibiotic use, particularly macrolide antimicrobials like azithromycin and cefotaxime, has been reported to induce hiccups in some cases.",
        "Yes, antibiotic use has induced hiccups in certain cases, as evidenced by the reported case of cefotaxime-induced hiccups and the association of persistent hiccups with azithromycin therapy in the literature.",
        "Yes, antibiotic use was associated with the onset of hiccups in a case report.",
        "Yes, antibiotics are among the drugs that may cause drug-induced hiccups. Additionally, hiccups can be an atypical symptom of infection in patients who have undergone pacemaker implantation and were subsequently treated with antibiotics.",
        "Antibiotic use has been associated with inducing hiccups, although it is a rare adverse drug reaction. This condition can be challenging to diagnose, and the exact mechanism behind it is still unknown.",
        "Yes, antibiotic use has been reported to induce hiccups.",
        "Yes. Antibiotic use has been reported to induce hiccups in some cases, particularly with macrolide antimicrobials like azithromycin and cefotaxime.",
        "Yes, antibiotic use has been reported to induce hiccups. For instance, there are documented cases of cefotaxime-induced hiccups and other antibiotics causing similar effects.",
        "Antibiotic use may indirectly affect the central nervous system, which could potentially lead to hiccups.",
        "Yes, antibiotics can induce hiccups in some cases.",
        "Yes, there are case reports of antibiotic use inducing hiccups.",
        "Antibiotic induced hiccups are a known side effect of some antibiotics.",
        "Yes, antibiotic use has been reported to induce hiccups. For example, there are case reports of cefotaxime and moxifloxacin causing persistent hiccups .",
        "Yes. Antibiotic therapy has been reported to induce hiccups. Antibiotics feature among the drug classes known to cause drug-induced hiccups, and cases have been described in which patients developed hiccups during or shortly after antibiotic treatment. Though uncommon, hiccups should be recognized as a potential side effect of antibiotic use.",
        "Yes, antibiotic use has been reported to induce hiccups in rare cases, with documented instances involving cefotaxime, azithromycin, and moxifloxacin.",
        "Yes, antibiotic use has been reported to induce hiccups as an adverse drug reaction.",
        "Yes. The context provided specifically references a case report and literature review titled \"Antibiotic-Induced Hiccups,\" which documents and analyzes instances where antibiotic use has been associated with hiccups. Case reports and literature reviews serve as clinical evidence for rare or underrecognized adverse effects, confirming that this phenomenon has been observed and studied.",
        "The provided snippets mention cases of both cefotaxime and moxifloxacin, which are antibiotics, being linked to the induction of hiccups. While it\u0027s important to note that these are rare cases, the evidence suggests that antibiotic use can indeed induce hiccups.",
        "Yes, antibiotic use has been associated with inducing hiccups in some cases. For example, a rare case report documents persistent hiccups induced by moxifloxacin, an antibiotic.",
        "Yes, hiccups are side effects of antibiotic therapy",
        "Yes, antibiotic use has been associated with inducing hiccups. Moxifloxacin and cefotaxime are specific antibiotics that have been reported to cause persistent hiccups. Macrolide antimicrobials have also been linked to drug-induced hiccups.",
        "While rare, there are case reports that suggest the use of certain antibiotics, such as moxifloxacin and cefotaxime, can induce hiccups. This is supported by a reported case of persistent hiccups caused by moxifloxacin and a case report and literature review mentioning cefotaxime-induced hiccups. However, it\u0027s important to note that these are isolated cases and hiccups are not a common side effect of antibiotic use.",
        "Yes. The reference snippets include several reports such as moxifloxacin-induced persistent hiccups and even cefotaxime-induced hiccups, clearly demonstrating that antibiotic use can induce hiccups.",
        "Yes, antibiotic use has been reported to induce hiccups in clinical cases.",
        "Yes. There are documented cases of hiccups induced by antibiotic use, including moxifloxacin and cefotaxime, indicating that antibiotics can lead to this side effect.",
        "Yes, antibiotic use can induce hiccups. There have been reports of moxifloxacin causing persistent hiccups in a rare case. Another report documents the first known instance of hiccups induced by cefotaxime, and it also reviews other instances of hiccups triggered by antibiotics.",
        "Yes, antibiotic use has been associated with inducing hiccups in rare cases. Documented instances include moxifloxacin-induced persistent hiccups and a reported case of cefotaxime-induced hiccups. These events are uncommon but recognized in medical literature.",
        "Yes, antibiotic use has been shown to induce hiccups. There are reported cases of persistent hiccups caused by medications like moxifloxacin and cefotaxime.",
        "Yes, antibiotic use can be associated with hiccups",
        "Yes, antibiotic use can induce hiccups. Several case reports and literature reviews document instances of antibiotic-induced hiccups, with cefotaxime and moxifloxacin specifically reported to cause this side effect. In some cases, patients treated with antibiotics for infections have presented with hiccups.",
        "Yes, antibiotic use has induced hiccups in documented cases. The literature includes reports of cefotaxime-induced hiccups (noted as the first such case) and moxifloxacin-induced persistent hiccups, which was described as an unusual case.",
        "Yes. Antibiotic use, such as moxifloxacin, has been reported to induce hiccups as an adverse reaction in patients.",
        "Yes, antibiotic use has been reported to induce hiccups, with documented cases involving cefotaxime and moxifloxacin causing persistent hiccups in patients, as described in case reports and literature reviews.",
        "Yes, there have been documented cases where antibiotic use has induced hiccups. Specifically, moxifloxacin and cefotaxime, which belong to different classes of antibiotics, have been associated with persistent hiccup episodes in patients. These instances highlight that while rare, certain antibiotics can cause this side effect.",
        "The provided context indicates a case report of moxifloxacin-induced hiccups, and there is also a report of cefotaxime-induced hiccups in another article. Therefore, it can be inferred that antibiotic use, specifically moxifloxacin and cefotaxime, can induce hiccups.",
        "Yes. There are reports of antibiotic-induced hiccups, including cases associated with moxifloxacin and cefotaxime.",
        "It is possible that antibiotic use can induce hiccups, but the specific antibiotics mentioned (cefotaxime and moxifloxacin) are not directly associated with causing hiccups in the provided entities. However, antibiotics in general can have various side effects, and hiccups can be one of them.",
        "Yes. There are documented cases of hiccups induced by antibiotic use, including moxifloxacin and cefotaxime, indicating that antibiotics can cause this side effect.",
        "Yes, there are cases where antibiotics have induced hiccups.",
        "Yes, antibiotic use has been associated with inducing hiccups, though such cases are rare. Studies highlight instances where specific antibiotics like cefotaxime, moxifloxacin, and tramadol (an opioid sometimes used for pain) triggered persistent or intractable hiccups, often resolving after discontinuation of the drug or targeted treatment. For example, a case report confirmed cefotaxime-induced hiccups via the Naranjo scale, while another documented moxifloxacin causing prolonged hiccups requiring metoclopramide intervention. Additionally, corticosteroids and anabolic steroids have been linked to hiccups through mechanisms involving central nervous system stimulation or altered synaptic thresholds. These findings emphasize that clinicians should consider antibiotic-induced hiccups in patients with unexplained persistent symptoms, particularly when other causes are excluded.",
        "Yes, available evidence suggests that has antibiotic use induced hiccups.",
        "Yes. There are documented cases of hiccups induced by antibiotic use, including moxifloxacin and azithromycin.",
        "Yes, there have been reports of antibiotic use causing hiccups, such as in the case of moxifloxacin induced persistent hiccups. However, these instances are rare and not commonly associated with antibiotics. It is advisable to consult a healthcare provider if experiencing unusual side effects.",
        "Antibiotic use can induce hiccups in rare cases, with documented instances involving moxifloxacin and cefotaxime in medical literature, highlighting the need for healthcare providers to be aware of this potential, albeit uncommon, side effect when prescribing.",
        "Yes. There are case reports of antibiotic-induced hiccups, including moxifloxacin and cefotaxime.",
        "Yes, antibiotic use has been associated with inducing hiccups in rare instances. Documented cases include patients taking moxifloxacin and cefotaxime, where these antibiotics were linked to persistent hiccups. While not a common side effect, it highlights that certain antibiotics can cause this reaction in some individuals.",
        "Yes, antibiotic use has induced hiccups, as evidenced by reports of moxifloxacin-induced persistent hiccups and the first case of cefotaxime-induced hiccups.",
        "Yes, antibiotic use has been reported to induce hiccups in some cases. Specifically, moxifloxacin and cefotaxime have been identified as causative agents of persistent hiccups in individual case reports. These findings suggest that certain antibiotics can trigger hiccups as an adverse effect.",
        "Rare case report of moxifloxacin-induced persistent hiccups . Herein, we report the first case of cefotaxime-induced hiccup .",
        "Antibiotic use, in rare cases, has been reported to induce hiccups, with documented instances involving the use of moxifloxacin and cefotaxime, highlighting a potential, albeit uncommon, side effect of these medications.",
        "Yes. Antibiotics have been reported to induce hiccups, most notably cephalosporins such as cefotaxime and fluoroquinolones like moxifloxacin. These drug‐induced hiccups typically begin after treatment initiation and resolve when the offending antibiotic is discontinued.",
        "Yes, in rare cases, antibiotic use has been reported to induce hiccups, with documented instances involving moxifloxacin and cefotaxime.",
        "Yes, antibiotic use has been reported to induce hiccups as a rare adverse effect.",
        "Yes, antibiotic use can induce hiccups. Several case reports and literature reviews indicate a link between antibiotic administration and the occurrence of hiccups. Specifically, moxifloxacin and cefotaxime have been identified as antibiotics associated with causing hiccups. In some instances, the hiccups resolved after addressing the underlying condition or discontinuing the antibiotic.",
        "Yes, antibiotic use can induce hiccups, as demonstrated in a rare case report of moxifloxacin-induced persistent hiccups."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What do snake antivenoms contain?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39749528",
        "http://www.ncbi.nlm.nih.gov/pubmed/39749534",
        "http://www.ncbi.nlm.nih.gov/pubmed/39752597",
        "http://www.ncbi.nlm.nih.gov/pubmed/38417708",
        "http://www.ncbi.nlm.nih.gov/pubmed/38913734",
        "http://www.ncbi.nlm.nih.gov/pubmed/37368699",
        "http://www.ncbi.nlm.nih.gov/pubmed/36136544",
        "http://www.ncbi.nlm.nih.gov/pubmed/19375442",
        "http://www.ncbi.nlm.nih.gov/pubmed/32196542",
        "http://www.ncbi.nlm.nih.gov/pubmed/21745181",
        "http://www.ncbi.nlm.nih.gov/pubmed/37755943",
        "http://www.ncbi.nlm.nih.gov/pubmed/27824133",
        "http://www.ncbi.nlm.nih.gov/pubmed/34089574",
        "http://www.ncbi.nlm.nih.gov/pubmed/29621528",
        "http://www.ncbi.nlm.nih.gov/pubmed/39103096",
        "http://www.ncbi.nlm.nih.gov/pubmed/35305724",
        "http://www.ncbi.nlm.nih.gov/pubmed/27169279",
        "http://www.ncbi.nlm.nih.gov/pubmed/39290878",
        "http://www.ncbi.nlm.nih.gov/pubmed/7940578",
        "http://www.ncbi.nlm.nih.gov/pubmed/34562491",
        "http://www.ncbi.nlm.nih.gov/pubmed/1366776"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 42,
          "text": "Snake venom, a complex mixture of proteins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39749534"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 296,
          "text": "genetic variability of snake venoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39749534"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 483,
          "text": "need to develop specific and broad antivenoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39749534"
        },
        {
          "offsetInBeginSection": 854,
          "offsetInEndSection": 1210,
          "text": "ability to cross-react enables the antivenoms to target multiple components from the different snake species. The advent of biotechnological innovations, including recombinant antibodies, small-molecule drugs, monoclonal antibodies and synthetic antivenoms, presents options for eliminating limitations associated with traditional plasma-derived antivenoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39749534"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 255,
          "text": "available treatment is serotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39752597"
        },
        {
          "offsetInBeginSection": 1337,
          "offsetInEndSection": 1461,
          "text": "small variations in the venom composition of a species do not lead to a decrease in the efficacy of the polyvalent antivenom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38417708"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 339,
          "text": "antivenom, which is composed of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 854,
          "offsetInEndSection": 976,
          "text": "use of cross-reactivity between venoms from different snakes for the manufacture of more potent and widely used antivenoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 1255,
          "offsetInEndSection": 1351,
          "text": "opportunity for the use of monoclonal antibodies in the development of new-generation antivenoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 1359,
          "offsetInEndSection": 1498,
          "text": "monoclonal antibodies and their fragments are described as a possible alternative for the production of antivenoms, regardless of the venom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 736,
          "offsetInEndSection": 921,
          "text": "All antivenoms tested appeared to be polyvalent and contain varying amounts of all five terrestrial snake monovalent antibodies based on their binding to the five representative venoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19375442"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 740,
          "text": "In the late nineteenth century, snake antivenoms were first developed by raising hyperimmune serum in animals, such as horses, against snake venoms. Hyperimmune serum was then purified to produce whole immunoglobulin G (IgG) antivenoms. IgG was then fractionated to produce F(ab) and F(ab\u0027)2 antivenoms to reduce adverse reactions and increase efficacy. Current commercial antivenoms are polyclonal mixtures of antibodies or their fractions raised against all toxin antigens in a venom(s), irrespective of clinical importance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32196542"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 393,
          "text": "Antivenoms are manufactured by immunizing animals, usually horses, with venoms from a single or several medically-relevant snake species. Antivenoms are constituted by either whole IgG molecules or the immunoglobulin fragments F(ab\u0027)₂ and Fab, obtained by digestion with pepsin and papain, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745181"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 340,
          "text": "The recommended treatment is the use of antivenom, which is composed of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 474,
          "text": "Monovalent antivenoms are produced via the immunization of large animals, e.g., horses, with one venom, after which the horse serum can neutralize the homologous venom, with minimal or no cross neutralization against other venoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37755943"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 299,
          "text": "Current antivenoms are antibody preparations obtained from the plasma of animals immunised with whole venom(s) and contain antibodies against snake venom toxins, but also against other antigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27824133"
        },
        {
          "offsetInBeginSection": 568,
          "offsetInEndSection": 740,
          "text": "Current commercial antivenoms are polyclonal mixtures of antibodies or their fractions raised against all toxin antigens in a venom(s), irrespective of clinical importance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32196542"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 305,
          "text": "Antivenom, which contains whole or protease-digested immunoglobulin G, purified from the plasma of hyper-immunized animals (mainly horses), is the mainstay for the treatment of snakebite envenomation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34089574"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 393,
          "text": "Antivenoms are constituted by either whole IgG molecules or the immunoglobulin fragments F(ab\u0027)₂ and Fab, obtained by digestion with pepsin and papain, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21745181"
        },
        {
          "offsetInBeginSection": 54,
          "offsetInEndSection": 171,
          "text": "Current antivenoms contain polyclonal antibodies, which vary in their specificity against different venom components.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39103096"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 663,
          "text": "The recommended treatment is the use of antivenom, which is composed of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms. In this review, the efforts made in the improvement of the already available antivenoms and the development of new antivenoms, focusing on snakes of medical importance from sub-Saharan Africa and Latin America, are described. Some antivenoms currently used are composed of whole IgGs, whereas others use F(ab\u0027)2 fragments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 757,
          "offsetInEndSection": 1229,
          "text": "Antivenom is currently the only available venom-specific treatment for SBE and contains purified equine or ovine polyclonal antibodies, collected from donor animals repeatedly immunized with low doses of adjuvanted venom. The resulting plasma or serum contains a high titre of specific antibodies, which can then be collected and stored until required. The purified antibodies are either whole IgG, monovalent fragment antibody (Fab) or divalent fragment antibody F(ab\u0027)2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35305724"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 243,
          "text": "Plasma-derived antivenoms are the main therapeutic agent available.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37755943"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Snake antivenomimmunoglobulins are considered to be the most efficient drugs in snake envenomings.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169279"
        },
        {
          "offsetInBeginSection": 540,
          "offsetInEndSection": 684,
          "text": "Snake antivenoms are manufactured from pools of plasma collected from animals, typically horses, which have been immunized against snake venoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29621528"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 266,
          "text": "Most snake antivenomimmunoglobulins all over the world are still prepared by fragmentation of polyclonal antibodies isolated from hyper-immunized horse serum till now.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169279"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Monovalent antivenoms have a lower volume of specific antibodies that may reduce reactions but require accurate snake identification to be used.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19375442"
        },
        {
          "offsetInBeginSection": 540,
          "offsetInEndSection": 683,
          "text": "Snake antivenoms are manufactured from pools of plasma collected from animals, typically horses, which have been immunized against snake venoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29621528"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 324,
          "text": "Animals (e.g., horses or sheep) immunized with snake venoms produce antibodies towards the venom proteins. Since these antibodies can neutralize the venom toxicity, they have been used to formulate snake antivenoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34562491"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 361,
          "text": "In the late nineteenth century, snake antivenoms were first developed by raising hyperimmune serum in animals, such as horses, against snake venoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32196542"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 341,
          "text": "The recommended treatment is the use of antivenom, which is composed of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36136544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "IgG and F(ab\u0027)2 fragments were prepared from horse plasma rich in specific antibodies against Brazilian Bothrops or Crotalus venoms. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7940578"
        },
        {
          "offsetInBeginSection": 476,
          "offsetInEndSection": 704,
          "text": "We demonstrate that antivenoms purified from the egg yolks of laying hens immunized with Crotalus atrox rattlesnake venom and Leiurus quinquestriatus hebraeus scorpion venom neutralize the lethal effects of these venoms in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1366776"
        },
        {
          "offsetInBeginSection": 650,
          "offsetInEndSection": 785,
          "text": "We produced this antivenom from the plasma of horses immunized with eight medically important venoms of viperid snake species from MENA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39290878"
        }
      ],
      "id": "680f4aa6353a4a2e6b000008",
      "ideal_answer": [
        "Antivenom is a serum that consists of immunoglobulins or immunoglobulin fragments obtained from the plasma of animals hyperimmunized with one (monospecific) or several (polyspecific) venoms.",
        "Snake antivenoms contain antibodies that bind and inactivate venom components. These antibodies are typically derived from hyperimmune sera collected from animals, such as horses or sheep, that have been immunized with snake venom. Antivenoms can be formulated as whole IgG molecules (150 kDa), F(ab\u0027)(2) immunoglobulin fragments (100 kDa), or Fab immunoglobulin fragments (50 kDa). The serum is often processed to increase the concentration of venom-specific antibodies and reduce inactive proteins that could cause allergic reactions. Processing techniques may include precipitation of inactive proteins, chromatographic methods, and enzymatic cleavage of immunoglobulins to produce Fab or F(ab\u0027)2 fragments.",
        "Snake antivenoms primarily contain antibodies that are generated in response to snake venom components. These antibodies are derived from the serum of immunized animals, typically horses, which have been exposed to specific snake venoms. The antivenoms target various toxins present in snake venoms, which are complex mixtures of proteins, including enzymes and non-enzymatic components. Additionally, antivenoms may exhibit varying degrees of cross-reactivity, allowing them to neutralize toxins from multiple snake species. Some antivenoms are also being developed using recombinant technologies to produce human monoclonal antibodies, enhancing their specificity and reducing adverse reactions associated with traditional animal-derived antivenoms."
      ]
    },
    {
      "body": "Are microglia derived from the same lineage as peripheral macrophages?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17188751",
        "http://www.ncbi.nlm.nih.gov/pubmed/20966214",
        "http://www.ncbi.nlm.nih.gov/pubmed/28683563",
        "https://www.ncbi.nlm.nih.gov/pubmed/39211090",
        "http://www.ncbi.nlm.nih.gov/pubmed/31818979",
        "http://www.ncbi.nlm.nih.gov/pubmed/39211090",
        "http://www.ncbi.nlm.nih.gov/pubmed/36975541",
        "http://www.ncbi.nlm.nih.gov/pubmed/35511433",
        "http://www.ncbi.nlm.nih.gov/pubmed/25998393",
        "http://www.ncbi.nlm.nih.gov/pubmed/30367726",
        "http://www.ncbi.nlm.nih.gov/pubmed/10567732",
        "http://www.ncbi.nlm.nih.gov/pubmed/30523248",
        "http://www.ncbi.nlm.nih.gov/pubmed/24652058",
        "http://www.ncbi.nlm.nih.gov/pubmed/27377535",
        "http://www.ncbi.nlm.nih.gov/pubmed/31792468",
        "http://www.ncbi.nlm.nih.gov/pubmed/21880259",
        "http://www.ncbi.nlm.nih.gov/pubmed/26287683",
        "http://www.ncbi.nlm.nih.gov/pubmed/22442384",
        "http://www.ncbi.nlm.nih.gov/pubmed/26441990",
        "http://www.ncbi.nlm.nih.gov/pubmed/28111278",
        "http://www.ncbi.nlm.nih.gov/pubmed/25470051",
        "http://www.ncbi.nlm.nih.gov/pubmed/35065053",
        "http://www.ncbi.nlm.nih.gov/pubmed/30602457",
        "http://www.ncbi.nlm.nih.gov/pubmed/25132502",
        "http://www.ncbi.nlm.nih.gov/pubmed/38347231",
        "http://www.ncbi.nlm.nih.gov/pubmed/37922312",
        "http://www.ncbi.nlm.nih.gov/pubmed/37865779",
        "http://www.ncbi.nlm.nih.gov/pubmed/22273537",
        "http://www.ncbi.nlm.nih.gov/pubmed/28671658",
        "http://www.ncbi.nlm.nih.gov/pubmed/26856416",
        "http://www.ncbi.nlm.nih.gov/pubmed/32122556",
        "http://www.ncbi.nlm.nih.gov/pubmed/24381729"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 1557,
          "text": "Unlike macroglia (astrocytes and oligodendrocytes) and neurons, which are derived from neuroectoderm, microglial progenitors arise from peripheral mesodermal (myeloid) tissue. The view still commonly held is that tissue-resident mononuclear phagocytes (including microglia) are derived from circulating blood monocytes and these take up residence late in gestation and postnatally. However, microglial progenitors colonise the nervous system primarily during embryonic and fetal periods of development. Recent evidence indicates differences between the lineage of mononuclear phagocytes during the embryonic and fetal period from that in the neonate and adult-mononuclear phagocytes that take up residence within tissues are derived from a lineage of myeloid cells that is independent of the monocyte lineage. Our own findings on the development and differentiation of microglial progenitors, taken together with findings by other investigators, and in the context of the heterogeneity between myeloid differentiation in the fetus and in the adult, support the view that microglia are derived prenatally from mesodermal progenitors that are distinct from monocytes. Furthermore, microglial progenitors colonise the nervous system via extravascular routes initially. These findings challenge the concept that resident microglia in the nervous system are derived from circulating blood monocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17188751"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "With the new understanding that adult microglia in mice have embryonic origins and are maintained in situ throughout life, it has become pertinent to now understand how these unique cells differ from monocyte-derived macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30324443"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 667,
          "text": "Although initially microglia and monocyte-derived macrophages were considered to have identical origins, gene expression, and function, recent advances have revealed important distinctions in all three categories and have caused a paradigm shift in view of their unique identity and roles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377535"
        },
        {
          "offsetInBeginSection": 186,
          "offsetInEndSection": 481,
          "text": "Two alternative hypotheses were postulated recently: (a) microglia differ from peripheral macrophages being derived from the yolk sac (YS), whereas peripheral macrophages originate from bone marrow (BM); (b) microglia acquire a specific phenotype under the influence of the CNS microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30367726"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 819,
          "text": "However, this concept has been challenged by recent results of developmental and gene expression profiling studies which used novel molecular biological tools to unravel the origin of microglia and to define their role as specialized tissue macrophages clearly distinct from monocytes or monocyte-derived macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25132502"
        },
        {
          "offsetInBeginSection": 640,
          "offsetInEndSection": 832,
          "text": "Our approach is based on recent studies demonstrating that microglia originate from primitive yolk sac mesoderm distinct from peripheral macrophages that arise during definitive hematopoiesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Microglia are thought to originate exclusively from primitive macrophage progenitors in the yolk sac (YS) and to persist throughout life without much contribution from definitive hematopoiesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39211090"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Microglia are the resident macrophages of the central nervous system and are associated with the pathogenesis of many neurodegenerative and brain inflammatory diseases; however, the origin of adult microglia remains controversial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20966214"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Microglia are thought to originate exclusively from primitive macrophage progenitors in the yolk sac (YS)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39211090"
        },
        {
          "offsetInBeginSection": 1429,
          "offsetInEndSection": 1557,
          "text": "These findings challenge the concept that resident microglia in the nervous system are derived from circulating blood monocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17188751"
        },
        {
          "offsetInBeginSection": 666,
          "offsetInEndSection": 972,
          "text": "Recent evidence indicates differences between the lineage of mononuclear phagocytes during the embryonic and fetal period from that in the neonate and adult-mononuclear phagocytes that take up residence within tissues are derived from a lineage of myeloid cells that is independent of the monocyte lineage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17188751"
        },
        {
          "offsetInBeginSection": 1379,
          "offsetInEndSection": 1602,
          "text": "Taken together, our data support the hypothesis that terminally differentiated brain parenchymal microglia are derived from cells originating from the yolk sac whose progeny actively proliferates in situ during development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10567732"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 734,
          "text": "However, even after prolonged CNS residence, transcriptomes and chromatin accessibility landscapes of engrafted, BM-derived macrophages remain distinct from yolk sac-derived host microglia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30523248"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 318,
          "text": "Unlike traditional monocyte-derived macrophages, microglia originate from primitive hematopoiesis in the embryonic yolk sac and self-renew throughout life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31792468"
        },
        {
          "offsetInBeginSection": 640,
          "offsetInEndSection": 831,
          "text": "Our approach is based on recent studies demonstrating that microglia originate from primitive yolk sac mesoderm distinct from peripheral macrophages that arise during definitive hematopoiesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683563"
        },
        {
          "offsetInBeginSection": 709,
          "offsetInEndSection": 935,
          "text": "We show that all adult macrophages, resident or infiltrating, are progenies of classical hematopoietic stem cells (HSC) with the exception of microglia and, partially epidermal Langerhans cells, which are yolk sac (YS)-derived",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26287683"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 778,
          "text": "Primitive macrophages generated in the yolk sac (YS) from early erythro-myeloid progenitors (EMPs), independently of the transcription factor c-Myb and bypassing monocytic intermediates, first give rise to microglia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26441990"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 317,
          "text": "Unlike traditional monocyte-derived macrophages, microglia originate from primitive hematopoiesis in the embryonic yolk sac and self-renew throughout life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31792468"
        },
        {
          "offsetInBeginSection": 323,
          "offsetInEndSection": 443,
          "text": "In contrast, adult blood monocytes, as well as infiltrating, gut, and dermal macrophages, derive from Myb-dependent HSCs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111278"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Tissue-resident macrophages, such as microglia, Kupffer cells, and Langerhans cells, derive from Myb-independent yolk sac (YS) progenitors generated before the emergence of hematopoietic stem cells (HSCs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111278"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 449,
          "text": "Recent studies in mice indicate that microglia are derived exclusively from primitive yolk sac hematopoiesis and self-renew without contribution from ontogenically distinct monocytes/macrophages of definitive adult hematopoietic origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35511433"
        },
        {
          "offsetInBeginSection": 265,
          "offsetInEndSection": 438,
          "text": "Primitive microglia arise from extraembryonic progenitors in the yolk sac (YS). The extraembryonic origins of primitive microglia are distinct from other tissue macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065053"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 634,
          "text": "Resident microglia and invading macrophages have been shown to have distinct origin and function. Whereas yolk sac-derived microglia reside in the brain, blood-derived monocytes invade the central nervous system only under pathological conditions like tumor formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30602457"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 265,
          "text": "Recent studies suggest that microglia are a unique myeloid population distinct from peripheral macrophages in terms of origin and gene expression signature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Microglia are thought to originate exclusively from primitive macrophage progenitors in the yolk sac (YS) and to persist throughout life without much contribution from definitive hematopoiesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39211090"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 666,
          "text": "Although initially microglia and monocyte-derived macrophages were considered to have identical origins, gene expression, and function, recent advances have revealed important distinctions in all three categories and have caused a paradigm shift in view of their unique identity and roles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27377535"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 264,
          "text": "Recent studies suggest that microglia are a unique myeloid population distinct from peripheral macrophages in terms of origin and gene expression signature",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25998393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Microglia, the primary immune cells of the central nervous system (CNS), are derived from the yolk sac and populate the brain during development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37865779"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 842,
          "text": "The idea that microglia have roles in the CNS that differ from those of peripheral macrophages has gained momentum with the discovery of their separate, pre-hematopoietic lineage during embryonic development ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22273537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Differently from other myeloid cells, microglia derive exclusively from precursors originating within the yolk sac and migrate to the CNS under development, without any contribution from fetal liver or postnatal hematopoiesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31818979"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 453,
          "text": "There are two main macrophage populations in the CNS: (i) the microglia, which are the resident macrophages of the CNS and are derived from yolk sac progenitors during embryogenesis, and (ii) the monocyte-derived macrophages (MDM), which can infiltrate the CNS during disease and are derived from bone marrow progenitors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28671658"
        },
        {
          "offsetInBeginSection": 345,
          "offsetInEndSection": 437,
          "text": "The extraembryonic origins of primitive microglia are distinct from other tissue macrophages",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065053"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "The recent paradigm shift that microglia are yolk sac-derived, not hematopoietic-derived, is reshaping our knowledge about the isolated role of microglia in CNS diseases, including degenerative conditions of the retina",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26856416"
        },
        {
          "offsetInBeginSection": 556,
          "offsetInEndSection": 672,
          "text": "Similar to other tissue macrophages, microglia develop early during embryogenesis from immature yolk sac progenitors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24652058"
        },
        {
          "offsetInBeginSection": 497,
          "offsetInEndSection": 622,
          "text": "Uniquely, microglial pregenital cells in the mouse derive from an early myeloid branch of the hematopoietic lineage in the YS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065053"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 818,
          "text": "However, this concept has been challenged by recent results of developmental and gene expression profiling studies which used novel molecular biological tools to unravel the origin of microglia and to define their role as specialized tissue macrophages clearly distinct from monocytes or monocyte-derived macrophages",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25132502"
        },
        {
          "offsetInBeginSection": 560,
          "offsetInEndSection": 882,
          "text": "Here we show in mice that the vast majority of adult tissue-resident macrophages in liver (Kupffer cells), brain (microglia), epidermis (Langerhans cells) and lung (alveolar macrophages) originate from a Tie2(+) (also known as Tek) cellular pathway generating Csf1r(+) erythro-myeloid progenitors (EMPs) distinct from HSCs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470051"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 472,
          "text": "Originally thought to derive from postnatal hematopoietic progenitors, it has recently been demonstrated that microglia originate from primitive myeloid progenitor cells that arise during early development from the embryonic yolk sac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32122556"
        },
        {
          "offsetInBeginSection": 398,
          "offsetInEndSection": 648,
          "text": "Lineage tracing studies have led to the understanding that microglia are part of a larger family of cells, called tissue-resident macrophages, which arise from early yolk sac progenitors during embryogenesis and engraft nearly every organ in the body",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24381729"
        }
      ],
      "id": "680a078618b1e36f2e000146",
      "ideal_answer": [
        "Unlike astrocytes, oligodendrocytes, and neurons, which are derived from neuroectoderm, microglial progenitors arise from peripheral mesodermal (myeloid) tissue. A previously common view was that tissue-resident mononuclear phagocytes (including microglia) are derived from circulating blood monocytes, and these take up residence late in gestation and postnatally. However, microglial progenitors colonise the nervous system primarily during embryonic and fetal periods of development, and recent evidence indicates differences between the lineage of mononuclear phagocytes during the embryonic and fetal period from that in the neonate and adult; thus, indicating that mononuclear phagocytes that take up residence within tissues are derived from a lineage of myeloid cells that is independent of the monocyte lineage. Recent findings on the development and differentiation of microglial progenitors, and in the context of the heterogeneity between myeloid differentiation in the fetus and adult, support the view that microglia are derived prenatally from mesodermal progenitors that are distinct from monocytes. Furthermore, microglial progenitors colonise the nervous system via extravascular routes initially. These findings challenge the concept that resident microglia in the nervous system are derived from circulating blood monocytes.",
        "Microglia originate from primitive macrophage progenitors in the yolk sac during embryogenesis and persist throughout life without significant contribution from bone marrow-derived hematopoiesis. They share an embryonic origin (yolk sac erythromyeloid precursors) with some CNS-associated macrophages (e.g., leptomeningeal and perivascular macrophages) but differ ontogenetically from most peripheral macrophages, which are typically derived from bone marrow monocytes in adulthood. Thus, microglia and peripheral macrophages arise from distinct lineages: yolk sac-derived for microglia and bone marrow-derived for most peripheral macrophages under homeostatic conditions.",
        "No, microglia and peripheral macrophages originate from different lineages. Microglia are derived from primitive yolk sac hematopoiesis during embryonic development and self-renew independently of hematopoietic stem cells (HSCs). In contrast, most peripheral tissue macrophages arise from definitive adult hematopoietic progenitors (HSCs) in the bone marrow. While both are myeloid cells, their developmental origins, maintenance mechanisms, and functional roles are distinct. Microglia remain resident in the brain, whereas peripheral macrophages in other tissues are often replenished by circulating monocytes derived from HSCs.",
        "Microglia are not derived from the same lineage as peripheral macrophages. Microglia develop early in life from progenitor cells in the yolk sac during embryonic stages, while peripheral macrophages originate from hematopoietic stem cells in the bone marrow and differentiate from blood monocytes. Although peripheral macrophages can enter the brain under certain conditions and exhibit microglia-like features, their developmental origins remain distinct.",
        "No, microglia are not derived from the same lineage as peripheral macrophages. Microglia are the primary immune cells of the central nervous system (CNS) and originate from the yolk sac during development. They populate the brain early in development and are distinct from peripheral macrophages, which are derived from monocytes infiltrating from the blood. While some embryonic macrophage progenitors (EMP-derived cells) seed the brain parenchyma to become microglia, others engraft the meninges and become CNS-associated macrophages (CAMs), also known as border-associated macrophages (BAMs). These different origins highlight the distinct identities and functions of microglia compared to peripheral macrophages.",
        "Microglia are not derived from the same lineage as peripheral macrophages. Studies show that microglia originate from primitive yolk sac progenitors during early embryonic development, while peripheral macrophages arise from definitive hematopoiesis. This distinct origin is supported by transcriptional and epigenetic differences, with microglia maintaining unique functional properties and responses to environmental factors compared to peripheral myeloid cells. Although monocyte-derived macrophages can contribute to brain macrophage populations under certain conditions, such as injury or depletion, resident microglia retain specific characteristics shaped by their embryonic lineage and local brain environment.",
        "Microglia are ontogenetically distinct from most peripheral macrophages. They originate during early embryogenesis from primitive macrophage progenitors in the yolk sac and colonize the developing central nervous system, thereafter persisting and self-renewing in situ without input from definitive hematopoietic stem cells. In contrast, the bulk of peripheral tissue macrophages arise later from erythro-myeloid progenitors that seed the fetal liver and from bone marrow–derived monocytes throughout postnatal life. Thus microglia and classical peripheral macrophages derive from separate developmental lineages.",
        "Microglia and peripheral macrophages are derived from distinct lineages. Unlike peripheral macrophages, which are derived from circulating blood monocytes, microglial progenitors originate from peripheral mesodermal (myeloid) tissue and colonise the nervous system via extravascular routes during embryonic development.",
        "Microglia are not derived from the same lineage as peripheral macrophages. While both are myeloid cells, microglial progenitors originate from prenatal mesodermal tissue distinct from the monocyte lineage that gives rise to peripheral macrophages. Microglia colonize the nervous system during embryonic/fetal development via extravascular routes, whereas most tissue-resident macrophages in other organs are derived from circulating monocytes postnatally.",
        "Microglia and peripheral macrophages are both part of the mononuclear phagocyte system but originate from distinct developmental lineages. Microglia develop early in embryonic life, arising from mesodermal progenitors that migrate into the central nervous system (CNS) via extravascular routes. These progenitors differentiate specifically to populate the CNS and maintain its immune defense.\n\nIn contrast, peripheral macrophages are derived from monocytes that circulate in the blood and later take up residence in various tissues postnatally. This distinction highlights that while both cell types share functional similarities within the immune system, their developmental origins differ significantly. Microglia have a unique prenatal lineage independent of the monocyte lineage, underscoring their specialized role in CNS immunity and homeostasis.",
        "Microglia are not derived from the same lineage as peripheral macrophages. While peripheral macrophages originate from monocytes, which are part of the myeloid lineage, microglial progenitors arise from distinct mesodermal (myeloid) precursors that colonize the nervous system prenatally via extravascular routes. Evidence indicates that fetal myeloid differentiation diverges from adult monocyte lineage, with microglia developing independently from circulating monocytes. This challenges the traditional view that microglia derive from blood monocytes, instead supporting a prenatal, mesodermal origin separate from peripheral macrophages. Thus, microglia represent a unique tissue-resident phagocyte lineage with distinct developmental pathways compared to peripheral macrophages.",
        "Microglia are derived from mesodermal progenitors distinct from monocytes, unlike peripheral macrophages, which are derived from circulating blood monocytes. Microglial progenitors colonize the nervous system during embryonic and fetal development, challenging the view that resident microglia originate from the same lineage as peripheral macrophages.",
        "Microglia and peripheral macrophages share some functional similarities as part of the mononuclear phagocyte system. However, their origins differ. Peripheral macrophages originate from bone marrow-derived monocytes that circulate in the blood before migrating to tissues. In contrast, microglia derive from mesodermal progenitors in the yolk sac during early embryonic development and colonize the central nervous system independently of circulating monocytes. Thus, while both are immune cells, they have distinct developmental lineages.",
        "Microglia and peripheral macrophages are both myeloid cells but originate from different lineages. Microglia derive from yolk sac progenitors during early embryonic development, colonizing the central nervous system (CNS) prenatally. In contrast, peripheral macrophages develop from bone marrow-derived monocytes that circulate in the blood and mature into macrophages upon entering tissues. This distinction highlights separate developmental pathways for these immune cells, with microglia establishing themselves early in CNS development and peripheral macrophages replenishing throughout life from circulating precursors.",
        "Recent studies challenge the traditional view that microglia share a lineage with peripheral macrophages derived from circulating monocytes. Instead, evidence indicates that microglial progenitors originate from mesodermal tissue distinct from adult monocyte lineages and colonize the nervous system during embryonic/fetal development via extravascular routes, independent of postnatal blood-derived monocytes. This contrasts with peripheral macrophage ontogeny in adults, which relies on monocyte recruitment. Fetal myeloid differentiation reveals a unique lineage for tissue-resident phagocytes like microglia, distinct from adult counterparts, highlighting developmental differences critical for understanding their therapeutic potential and biological roles.",
        "No, microglia are not derived from the same lineage as peripheral macrophages. According to recent evidence, microglial progenitors arise from a distinct lineage of myeloid cells that is independent of the monocyte lineage, and colonize the nervous system primarily during embryonic and fetal periods of development. This challenges the traditional view that resident microglia in the nervous system are derived from circulating blood monocytes.",
        "Microglia are not derived from the same lineage as peripheral macrophages, which originate from circulating monocytes. Instead, microglia come from a distinct mesodermal myeloid lineage that colonizes the nervous system during embryonic and fetal development, prenatally, setting them apart from peripheral macrophages in both origin and developmental timing.",
        "No. Microglia originate during early embryogenesis from yolk sac–derived primitive macrophage progenitors that colonize the developing brain and then self-renew throughout life. Peripheral tissue macrophages, by contrast, arise later from fetal liver erythro-myeloid progenitors or from adult bone marrow–derived monocytes. Thus, although both are myeloid cells, microglia come from a distinct yolk sac lineage separate from the definitive hematopoietic lineage of peripheral macrophages.",
        "Microglia are not derived from the same lineage as peripheral macrophages. Unlike tissue-resident mononuclear phagocytes, microglial progenitors arise from mesodermal progenitors independent of the monocyte lineage, primarily colonizing the nervous system during embryonic and fetal development via extravascular routes, distinct from the later arrival of blood monocytes. This indicates that microglia and peripheral macrophages have different lineage origins."
      ],
      "exact_answer": "no"
    },
    {
      "body": "How does a gastric pacemaker work?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37064060",
        "http://www.ncbi.nlm.nih.gov/pubmed/38082999",
        "http://www.ncbi.nlm.nih.gov/pubmed/35124479",
        "http://www.ncbi.nlm.nih.gov/pubmed/33656985",
        "http://www.ncbi.nlm.nih.gov/pubmed/24513084",
        "http://www.ncbi.nlm.nih.gov/pubmed/34584813",
        "http://www.ncbi.nlm.nih.gov/pubmed/28976676",
        "http://www.ncbi.nlm.nih.gov/pubmed/18082553",
        "http://www.ncbi.nlm.nih.gov/pubmed/835775",
        "http://www.ncbi.nlm.nih.gov/pubmed/10228980",
        "http://www.ncbi.nlm.nih.gov/pubmed/33018515",
        "http://www.ncbi.nlm.nih.gov/pubmed/31908392",
        "http://www.ncbi.nlm.nih.gov/pubmed/1539009",
        "http://www.ncbi.nlm.nih.gov/pubmed/19888414",
        "http://www.ncbi.nlm.nih.gov/pubmed/12647496",
        "http://www.ncbi.nlm.nih.gov/pubmed/16873400",
        "http://www.ncbi.nlm.nih.gov/pubmed/25392675",
        "http://www.ncbi.nlm.nih.gov/pubmed/23074486",
        "http://www.ncbi.nlm.nih.gov/pubmed/21395517",
        "http://www.ncbi.nlm.nih.gov/pubmed/1199995",
        "http://www.ncbi.nlm.nih.gov/pubmed/16931496",
        "http://www.ncbi.nlm.nih.gov/pubmed/21693794",
        "http://www.ncbi.nlm.nih.gov/pubmed/17355054",
        "http://www.ncbi.nlm.nih.gov/pubmed/15130236",
        "http://www.ncbi.nlm.nih.gov/pubmed/16836954"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Gastric stimulator has been used as a surgical option for patients with gastroparesis refractory to medical management. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37064060"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 376,
          "text": " Gastric pacing is a potential treatment method to restore rhythmic SW activity. However, to date, the efficacy of gastric pacing is inconsistent and the underlying mechanisms of gastric pacing are poorly understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38082999"
        },
        {
          "offsetInBeginSection": 25,
          "offsetInEndSection": 282,
          "text": " Gastrointestinal (GI) motility disorders can be significantly detrimental to the quality of life. Pacing, or long pulse gastric electrical stimulation, is a potential treatment option for treating GI motility disorders by modulating the slow wave activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35124479"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 248,
          "text": " Gastric pacing has been attempted in a limited number of studies to correct gastric dysmotility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33656985"
        },
        {
          "offsetInBeginSection": 627,
          "offsetInEndSection": 731,
          "text": "The gastric pacemaker uses non-excitatory stimulation to influence the amplitude of gastric contraction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24513084"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "BACKGROUND: The aim of the current study was to investigate the efficacy of 2-channel gastric electrical stimulation (GES) with a custom-made implantable pacemaker on delayed gastric emptying and gastric dysrhythmia induced by gluca",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18082553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Gastric peristaltic contractions are controlled by an intrinsic electrical pacemaker located in the mid-body along the greater curve.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228980"
        },
        {
          "offsetInBeginSection": 627,
          "offsetInEndSection": 984,
          "text": "The gastric pacemaker uses non-excitatory stimulation to influence the amplitude of gastric contraction. It simultaneously stimulates afferent fibres of the vagal nerve to influence the cerebral satiation centre, which is involved in registration of satiety and in insulin secretion and resistance. A randomized trial on the effects of the gastric pacemaker",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24513084"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365,
          "text": "BACKGROUND: The aim of the current study was to investigate the efficacy of 2-channel gastric electrical stimulation (GES) with a custom-made implantable pacemaker on delayed gastric emptying and gastric dysrhythmia induced by glucagon in dogs.METHODS: Six dogs were studied in 4 randomized session (saline, glucagon, glucagon with single-channel or 2-channel GES).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18082553"
        },
        {
          "offsetInBeginSection": 627,
          "offsetInEndSection": 925,
          "text": "The gastric pacemaker uses non-excitatory stimulation to influence the amplitude of gastric contraction. It simultaneously stimulates afferent fibres of the vagal nerve to influence the cerebral satiation centre, which is involved in registration of satiety and in insulin secretion and resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24513084"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 301,
          "text": " Gastric neurostimulation from Enterra Therapy provides electrical pulses to the stomach tissue that promotes stimulation of stomach smooth muscle, thereby enhancing gastric emptying",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25392675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "A potential treatment option for chronic and severe motility disorders such as gastroparesis is the implantation of a Gastric Electrical Stimulator (GES), which is designed to modulate the bio-electric slow waves.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33018515"
        },
        {
          "offsetInBeginSection": 792,
          "offsetInEndSection": 963,
          "text": "The Tantulus pacemaker is still in development but increases antral muscular contractions and delays gastric emptying by stimulation during the absolute refractory period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888414"
        },
        {
          "offsetInBeginSection": 626,
          "offsetInEndSection": 791,
          "text": "The Transcend(R) pacemaker blocks vagal efferents and delays gastric emptying, giving a 40% loss of excess body weight, if certain screening procedures are employed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888414"
        },
        {
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1551,
          "text": "Electrical pacing of the gastrointestinal tract is promising therapeutically, and because pacemakers work through different mechanisms, combining pacemaker treatments may be possible.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888414"
        },
        {
          "offsetInBeginSection": 833,
          "offsetInEndSection": 1042,
          "text": "Unlike others, it neither needs medications nor gastrectomy; rather, it treats through the use of microelectrodes to deliver high-frequency low energy electric stimulation to the pacemaker area of the stomach.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31908392"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 413,
          "text": "Pacesetter potentials were generated regularly by the pacemaker at a mean frequency of 3.2 cycles/min and were propagated circumferentially and aborally from the pacemaker, increasing in amplitude and velocity as they approach the pylorus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/835775"
        },
        {
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1770,
          "text": "cellular potentials in real time. The GES detects bradygastric rhythms based on the sensed extracellular potentials and actuates the ICC network via paci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35124479"
        },
        {
          "offsetInBeginSection": 4716,
          "offsetInEndSection": 4863,
          "text": "the presence of a variety of gastric arrhythmias. Similar to a cardiac pacemaker, it was hypothesized that GES could override the abnormal rhythms,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074486"
        },
        {
          "offsetInBeginSection": 385,
          "offsetInEndSection": 564,
          "text": "electrophysiological stimulation devices (cardiac or gastric pacemakers, implantable cardiac defibrillators, functional electrical stimulators for epilepsy or Parkinson\u0027s disease)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21395517"
        },
        {
          "offsetInBeginSection": 650,
          "offsetInEndSection": 821,
          "text": "Impulses conducted over intrinsic nerves from a gastric pacemaker (15) were proposed as a possible mechanism for initiating and coordinating gastroduodenal motor activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1199995"
        },
        {
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1172,
          "text": "Surgically implanted gastric pacemaker systems that modulate vagus nerve activity and delay gastric emptying are under study",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16931496"
        },
        {
          "offsetInBeginSection": 650,
          "offsetInEndSection": 887,
          "text": "Our recent understanding of the normal gastric electro-mechanical function and its abnormalities/dysrythmias has led to the development of a gastric electrical stimulator, analagous to other devices used to stimulate dysfunctional organs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12647496"
        },
        {
          "offsetInBeginSection": 808,
          "offsetInEndSection": 926,
          "text": "One such intervention is gastric electrical stimulation or gastric pacemaker, which aids in improving gastric motility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34584813"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 290,
          "text": "e function. Gastric neurostimulation from Enterra Therapy provides electrical pulses to the stomach tissue that promotes stimulation of stomach smooth muscle, thereby enhancing gastr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25392675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Functional neural gastrointestinal electrical stimulation (NGES) is a methodology of gastric electrical stimulation that can be applied as a possible treatment for disorders such as obesity and gastroparesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21693794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Manipulation of gastric motility by gastric electrical stimulation (GES) has been suggested as a minimally invasive alternative treatment of gastric motility disorders and obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17355054"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 604,
          "text": "Pacemaker impulses travel over the myenteric plexus to the glandular stomach and the duodenum, and to the muscles of the muscular stomach to initiate contractions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1539009"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 663,
          "text": "Electrical stimulation of the stomach is achieved by delivering electrical currents via electrodes attached to the smooth muscle of the stomach. Recently, a number of studies on electrical stimulation of the stomach in both humans and dogs have indicated that gastric electrical stimulation with appropriate parameters is able to entrain gastric slow waves and normalize gastric dysrhythmias.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976676"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 427,
          "text": "Simply stated, the IGS system electrically stimulates the stomach with a pacemaker-like device. The device is implanted in a brief minimally invasive procedure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15130236"
        },
        {
          "offsetInBeginSection": 732,
          "offsetInEndSection": 868,
          "text": "The GES senses the extracellular potential, detects bradygastric patterns and finally modulates the activity to ensure normal conduction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33018515"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 591,
          "text": "Several clinical studies have shown that gastric electrical stimulation (GES) with short pulses is able to reduce nausea and vomiting in patients with gastroparesis and that GES with long pulses is able to pace the intrinsic gastric slow waves and thus normalize gastric dysrhythmia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16836954"
        }
      ],
      "type": "summary",
      "id": "67e098cb18b1e36f2e00006d",
      "ideal_answer": [
        "Gastrc pacing or long pulse gastric electrical stimulation, is a potential treatment option for treating GI motility disorders by modulating the slow wave activity.",
        "The gastric pacemaker uses non- excitatory stimulation to influence the amplitude of gastric contraction. It simultaneously stimulates afferent fibres of the vagal nerve and efferent fibres of the vagal nerve.",
        "Surgically implanted gastric pacemakers modulate vagus nerve activity and delay gastric emptying.",
        "A gastric pacemaker works by modulating the activity of the vagus nerve, which plays a crucial role in controlling stomach functions. By delivering electrical impulses, the pacemaker can influence the nerve signals that regulate gastric motility and delay gastric emptying. This modulation can help manage conditions like gastroparesis by improving symptoms related to delayed stomach emptying.",
        "- The study shows that an electronic pacemaker implanted in the antrum reverses the normal aborad direction of movement of contractions and delays the gastric emptying of both liquid and solid meals.\n- After placement of the gastric pacemaker, patients rated significantly fewer symptoms and had a modest acceleration of gastric emptying.",
        "A gastric pacemaker works by sending electrical impulses to the stomach muscles to help regulate and improve gastric motility and reduce symptoms of gastroparesis.",
        "A gastric pacemaker works by reversing the normal aborad direction of movement of contractions, thereby delaying gastric emptying. It achieves this through electrical stimulation that alters the sequence of gastric wall contractions, effectively controlling the timing and coordination of these movements to influence how quickly contents exit the stomach.",
        "Gastric pacemakers are implanted in the antrum to reverse the normal aborad direction of movement of contractions and delay gastric emptying of both liquid and solid meals.",
        "A gastric pacemaker works by regulating gut motility by modulating rhythmic bio-electrical events called slow waves.",
        "A gastric pacemaker uses non-excitatory stimulation to influence the amplitude of gastric contraction and simultaneously stimulates afferent fibres of the vagal nerve to influence the cerebral satiation centre, which is involved in registration of satiety and in insulin secretion and resistance.",
        "Gastric pacemaker is a device that is implanted in the stomach to improve gastric motility. It uses non- excitatory stimulation to influence the amplitude of gastric contraction.",
        "A gastric pacemaker works by sending electrical impulses to the stomach muscles to help control nausea and vomiting in patients with gastroparesis. It stimulates the stomach to contract and move food through the digestive tract more effectively.",
        "A gastric pacemaker works by stimulating the muscles in the stomach to contract and move food through the digestive system, similar to how a natural gastric pacemaker regulates the rhythm of the stomach in a patient.",
        "A gastric pacemaker works by using electrical stimulation to regulate the contractions of the stomach muscles, thereby improving gastric motility and aiding in the management of conditions like gastroparesis.",
        "A gastric pacemaker is a device that sends electrical pulses to the stomach to stimulate muscles and help with digestion. It\u0027s typically used for people with gastroparesis, a condition where the stomach doesn\u0027t empty properly.",
        "Gastric pacemaker is a potential treatment option for patients with medically refractory gastroparesis. The gastric pacemaker uses non-excitatory stimulation to influence the amplitude of gastric contraction. It simultaneously stimulates afferent fibres of the vagal nerve to influence the cerebral satiation centre, which is involved in registration of satiety and in insulin secretion and resistance.",
        "A gastric pacemaker works by modulating the activity of the vagus nerve, which plays a crucial role in controlling stomach functions. By delivering electrical impulses, the pacemaker can influence gastric motility and delay gastric emptying. This modulation can help manage conditions related to gastric motility and improve symptoms associated with disorders like gastroparesis.",
        "The gastric pacemaker uses non- excitatory stimulation to influence the amplitude of gastric contraction. It simultaneously stimulates afferent fibres of the vagal nerve. The gastric pacemaker is implanted via laparoscopy. The patients lose weight and show an improvement in glucose regulation. The gastric pacemaker aids in improving gastric motility.",
        "A gastric pacemaker works by using non-excitatory stimulation to influence the amplitude of gastric contraction. Pacemaker impulses travel over the myenteric plexus to the glandular stomach and the duodenum, and to the muscles of the muscular stomach to initiate contractions.",
        "A gastric pacemaker, also known as a gastric electrical stimulator (GES), is an implantable medical device designed to manage severe gastrointestinal motility disorders such as gastroparesis. It works by delivering mild electrical pulses to the stomach muscles, specifically targeting areas like the gastric antrum, to enhance gastric motility and aid in emptying the stomach.\n\nThe device consists of a subcutaneous stimulator and two leads implanted in the gastric wall. Surgical placement is typically done using laparoscopic or open techniques. Once implanted, the device emits continuous electrical pulses that stimulate stomach muscles, improving movement and helping with symptoms like nausea and vomiting. The mechanism involves direct muscle stimulation and effects on the nervous system, including improved gastric accommodation and modulation of nerve activity.\n\nThe gastric pacemaker is FDA-approved under the Humanitarian Device Exemption for treating rare conditions and can be adjusted post-implantation to optimize symptom relief. It offers a minimally invasive alternative for patients with motility disorders and obesity, providing significant symptom improvement in many cases.",
        "A gastric pacemaker works by delivering electrical pulses to the stomach tissue to influence gastric motility, reduce appetite, increase satiety, and improve gastric emptying, primarily used for conditions like obesity and gastroparesis.",
        "A gastric pacemaker works by delivering electrical pulses to the stomach tissue to modulate gastric motility and improve conditions like gastroparesis and obesity.",
        "A gastric pacemaker, or stimulator, works by modulating slow wave activity in the gastrointestinal tract to potentially restore rhythmic activity in those with motility disorders. It is used surgically for gastroparesis unresponsive to medicines, aiming to correct gastric dysmotility through pacing.",
        "Gastric pacemakers are implanted devices that stimulate the pancreas in an attempt to improve glycemic control in people with diabetes. Gastric pacemakers are implanted devices that stimulate the pancreas in an attempt to improve glycemic control in patients with diabetes.",
        "A gastric pacemaker works by delivering controlled electrical stimulation to the stomach, which modulates the slow wave activity essential for coordinating gastric contractions. This pacing aims to restore a more normal rhythm and improve gastrointestinal motility in patients with conditions like gastroparesis.",
        "A gastric pacemaker works by delivering electrical impulses to the stomach to modulate its slow wave activity, thereby restoring rhythmic gastric contractions and improving motility in patients with gastrointestinal disorders.",
        "Gastrointestinal (GI) motility disorders can be significantly detrimental to the quality of life. Pacing, or long pulse gastric electrical stimulation, is a potential treatment option for treating GI motility disorders by modulating the slow wave activity.",
        "A gastric pacemaker, also known as gastric electrical stimulation (GES), works by delivering electrical pulses to the stomach muscles to modulate and improve gastrointestinal motility. This can help alleviate symptoms in patients with gastroparesis who do not respond to medical management.",
        "Gastric pacing, also known as gastric electrical stimulation, is a potential treatment for gastrointestinal motility disorders and gastroparesis by modulating slow wave activity in the stomach. While promising, its efficacy remains inconsistent and its mechanisms are not fully understood.",
        "A gastric pacemaker works by delivering electrical stimulation to the stomach to modulate its slow wave activity, aiming to restore normal gastric rhythms and improve motility. While it is used for conditions like refractory gastroparesis, its efficacy is inconsistent and the exact mechanisms are not fully understood.",
        "A gastric pacemaker works by delivering electrical stimulation to the stomach muscles to restore normal slow wave activity. This helps regulate proper muscle contractions and movement of food through the digestive system, particularly in conditions like gastroparesis where the stomach doesn\u0027t empty normally.",
        "A gastric pacemaker works by modulating the gastric function of patients, helping to regulate the movement of food through the stomach.",
        "A gastric pacemaker, or gastric electrical stimulation (GES) device, works by delivering high-frequency low-energy electrical stimulation to the pacemaker area of the stomach using microelectrodes. This stimulation modulates the slow wave activity, which is crucial for gastric motility. The device targets the interstitial cells of Cajal, the stomach\u0027s natural pacemaker cells, to restore rhythmic gastric contractions and improve gastric emptying. By influencing the electrical conduction system of the stomach, the pacemaker aims to alleviate symptoms associated with gastrointestinal motility disorders, particularly in patients with gastroparesis who do not respond to medical management.",
        "A gastric pacemaker works by delivering electrical pulses to the stomach muscles to regulate and stimulate normal gastric contractions, thereby improving gastrointestinal motility.",
        "A gastric pacemaker, or gastric stimulator, is used as a surgical option for patients with gastroparesis refractory to medical management. It works by modulating the slow wave activity to treat gastrointestinal motility disorders.",
        "A gastric pacemaker works by applying electrical stimulation to regulate and normalize the stomach\u0027s natural rhythmic contractions, or slow wave activity, to improve gastric motility in individuals with motility disorders.",
        "A gastric pacemaker works by delivering long pulse gastric electrical stimulation to modulate the slow wave activity in the stomach, aiming to restore rhythmic slow wave (SW) activity and improve gastrointestinal motility in patients with gastric dysmotility disorders."
      ]
    },
    {
      "body": "Can newborns have glaucoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38350011",
        "http://www.ncbi.nlm.nih.gov/pubmed/38716941",
        "http://www.ncbi.nlm.nih.gov/pubmed/38194280",
        "http://www.ncbi.nlm.nih.gov/pubmed/34526297",
        "http://www.ncbi.nlm.nih.gov/pubmed/15666707",
        "http://www.ncbi.nlm.nih.gov/pubmed/12940659",
        "http://www.ncbi.nlm.nih.gov/pubmed/35087999",
        "http://www.ncbi.nlm.nih.gov/pubmed/32421983",
        "https://www.ncbi.nlm.nih.gov/pubmed/3128592",
        "http://www.ncbi.nlm.nih.gov/pubmed/16382557",
        "http://www.ncbi.nlm.nih.gov/pubmed/34954410",
        "http://www.ncbi.nlm.nih.gov/pubmed/21306220",
        "http://www.ncbi.nlm.nih.gov/pubmed/33045217",
        "http://www.ncbi.nlm.nih.gov/pubmed/29847359",
        "http://www.ncbi.nlm.nih.gov/pubmed/23158549",
        "http://www.ncbi.nlm.nih.gov/pubmed/39472112",
        "http://www.ncbi.nlm.nih.gov/pubmed/38990107",
        "http://www.ncbi.nlm.nih.gov/pubmed/38003924",
        "http://www.ncbi.nlm.nih.gov/pubmed/6766271",
        "http://www.ncbi.nlm.nih.gov/pubmed/27911017",
        "http://www.ncbi.nlm.nih.gov/pubmed/19967611",
        "http://www.ncbi.nlm.nih.gov/pubmed/26514695",
        "http://www.ncbi.nlm.nih.gov/pubmed/23158552",
        "http://www.ncbi.nlm.nih.gov/pubmed/19645407",
        "http://www.ncbi.nlm.nih.gov/pubmed/33268344",
        "http://www.ncbi.nlm.nih.gov/pubmed/2718897",
        "http://www.ncbi.nlm.nih.gov/pubmed/36312692"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 410,
          "offsetInEndSection": 452,
          "text": "newborn diagnosed with congenital glaucoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38716941"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 177,
          "text": "primary congenital glaucoma ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38194280"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 140,
          "text": "neonatal-onset (NO) and infantile-onset (IO) primary congenital glaucoma (PCG)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34526297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 20,
          "text": "Congenital glaucoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/3128592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 482,
          "text": "Congenital and juvenile glaucoma are associated with goniodysgenesis and currently thought to be the result of neural crest cell abnormal terminal induction or migration. Infantile glaucoma may be primary, or may be associated with syndromes such as Sturge-Weber, Rieger\u0027s and others. Differentiation from other childhood causes of cloudy cornea such as endothelial dystrophies is essential. Evaluations under anesthesia are often needed and present their own problems in diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/3128592"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 564,
          "text": "Primary congenital glaucoma (PCG) is a childhood disease that can lead to blindness in newborns and very young children. The rate of occurrence of PCG varies in different communities and across geographical boundaries, and its etiology is unknown. It is caused by genetic structural defects in the trabecular meshwork and makes its appearence in newborns and children no older than three years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32421983"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 644,
          "text": "We report concurrent rubella and CMV infection in a baby born with corneal opacification, severe congenital glaucoma, and congenital cataract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29847359"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "An unusual presentation of glaucoma in a neonate with Rubinstein-Taybi syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39472112"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 125,
          "text": "Primary congenital glaucoma (PCG) affects approximately 1 in 10,000 live born infants in the United States (U.S.)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38990107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Aicardi-Goutières Syndrome with Congenital Glaucoma Caused by Novel ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38003924"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 49,
          "text": "Newborn primary congenital glaucoma: 2005 update.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 45,
          "text": "Congenital, infantile, and juvenile glaucoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/545209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 43,
          "text": "Newborn Glaucoma: Do not Forget Infections.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29847359"
        },
        {
          "offsetInBeginSection": 350,
          "offsetInEndSection": 527,
          "text": "ATIENTS AND METHODS: The medical records of 35 patients with newborn primary congenital glaucoma were reviewed to determine its clinical manifestations and response to therapy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "A 36-week male fetus was noted to have isolated right megalophthalmos on prenatal ultrasound and was found to have buphthalmos and congenital glaucoma at birth. Detection of congenital glaucoma at birth may be occasionally possible if abnormal orbit ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27911017"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 429,
          "text": "of inheritance have been described. Congenital glaucoma is a rare condition (1 case per 10,000-20,000 newborns),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35087999"
        },
        {
          "offsetInBeginSection": 21,
          "offsetInEndSection": 114,
          "text": "newborn glaucoma, the most severe form of primary congenital glaucoma, typically is bilateral",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158549"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 309,
          "text": " congenital glaucoma (PCG) is a sight-threatening disease that can manifest as a prodrome of NF1, especially in newborn babies. We report a case",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26514695"
        },
        {
          "offsetInBeginSection": 179,
          "offsetInEndSection": 275,
          "text": "congenital glaucoma (PCG) is a childhood disease that can lead to blindness in newborns and very",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32421983"
        },
        {
          "offsetInBeginSection": 1542,
          "offsetInEndSection": 1642,
          "text": "nsula p.G61E mutations are the major cause of newborn glaucoma but novel CYP1B1 mutations continue t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306220"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Primary congenital glaucoma (PCG) is a rare genetic disease usually diagnosed during the first year of life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15666707"
        },
        {
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1841,
          "text": "Despite comparable IOP control (P \u003d 0.51), the corneal clarity remained significantly worse in the rubella-positive patients (P \u003d 0.02).CONCLUSIONS: Twenty-five percent of those with newborn glaucoma had underlying intrauterine rubella infection, thus making them susceptible for development of congenital rubella syndrome (CRS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34954410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 518,
          "text": "PURPOSE: To study the frequency of intrauterine rubella infection in a cohort of neonatal-onset glaucoma (NOG) and its effect on the treatment outcomes.DESIGN: Prospective cohort study.PARTICIPANTS: Infants with NOG presenting to the pediatric glaucoma service at a tertiary care center in northern India at Chandigarh between January 1, and September 30, 2018, with a minimum postoperative follow-up of 1 year were included in this study.METHODS: Rubella immunoglobulin-M (IgM) antibodies were tested in all patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34954410"
        },
        {
          "offsetInBeginSection": 1158,
          "offsetInEndSection": 1352,
          "text": "No mutations were identified in the other screened genes.CONCLUSIONS: Newborn glaucoma on the Arabian Peninsula is typically CYP1B1-related even in the setting of developmental iris abnormality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306220"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "We present histopathologic findings that have not been previously reported as associated with abnormalities of the anterior chamber angle underlying newborn primary congenital glaucoma as a distinct entity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158552"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "This report describes the corneal pathology in an infant with newborn primary congenital glaucoma ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19645407"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 122,
          "text": " We present the case of a newborn baby in whom we observed aniridia, congenital glaucoma and edematous corneas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19967611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "PURPOSE: To describe neonatal-onset congenital ectropion uveae (N-CEU) as a distinct clinical entity of newborn glaucoma (NG) and to study its significance toward the severity and outco",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33045217"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "PURPOSE: To study the frequency of intrauterine rubella infection in a cohort of neonatal-onset glaucoma (NOG) and its effect on the treatment ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34954410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "BACKGROUND: Newborn primary congenital glaucoma is an unusual and important subtype of primary congenital glaucoma. Affected patients typically manifest specific signs that facilitate its recognition at birth and become important in the assessment and determination of appropriate treatment for this severe expression of primary congeni",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "BACKGROUND: Neonatal-onset glaucoma (NOG) is a severe form of childhood glaucoma and is not always due to primary congenital g",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Nonsyndromic primary newborn glaucoma, the most severe form of primary congenital glaucoma, typically is bilateral and often the result of CYP1B1 mutations, particularly in certain consanguineous populations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158549"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "We describe a dramatic case of an identical twin presenting at birth with unilateral congenital glaucoma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12940659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "This report describes the corneal pathology in an infant with newborn primary congenital glaucoma and discusses whether these findings could be due to a developmental anomaly",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19645407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "PURPOSE: To report the occurrence of unilateral, neonatal-onset congenital glaucoma in a child with Rubinstein-Taybi Syndro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39472112"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "BACKGROUND: Newborn primary congenital glaucoma is an unusual and important subtype of primary congeni",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1159,
          "text": "Newborns with unilateral congenital glaucoma should raise high suspicion for neurofibromatosis 1 and its associated findings, which might need immediate intervention",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12940659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "CASE REPORT: We present the case of a newborn baby in whom we observed aniridia, congenital glaucoma and edematous corneas, without clearance of the cornea after glaucoma surgery, and in whom a keratoplasty w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19967611"
        },
        {
          "offsetInBeginSection": 676,
          "offsetInEndSection": 808,
          "text": "IOP in the left eye.CONCLUSION: Unilateral neonatal-onset congenital glaucoma due to iridocorneal adhesions can be a rare presentati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39472112"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "BACKGROUND: Primary congenital glaucoma (PCG) affects approximately 1 in 10,000 live born infants in the United St",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38990107"
        },
        {
          "offsetInBeginSection": 595,
          "offsetInEndSection": 702,
          "text": "oma was reviewed and referenced.RESULTS: Newborn primary congenital glaucoma is recognized at birth because",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "Primary congenital glaucoma (PCG) is a rare genetic disease usually diagnosed during the first year of life. It occurs because of developmental anomalies of the chamber angle that prevents drainage of aqueous humor, thereby elevating intraocular pressure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15666707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Primary congenital glaucoma is a rare but potentially devastating disorder that family physicians must recognize as early as possible in infants and young children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2718897"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "A Neonate With Diabetes Mellitus, Congenital Hypothyroidism, and Congenital Glaucoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36312692"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 121,
          "text": "Primary congenital glaucoma (PCG) affects approximately 1 in 10,000 live born infants in the United States (U",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38990107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Neonatal-Onset Congenital Ectropion Uveae: A Distinct Phenotype of Newborn Glaucoma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33045217"
        },
        {
          "offsetInBeginSection": 1842,
          "offsetInEndSection": 1994,
          "text": "Neonatal-onset glaucoma is an important component of CRS, which may present without buphthalmos and persistent corneal clouding despite good IOP control",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34954410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "text": "BACKGROUND: Newborn primary congenital glaucoma is an unusual and important subtype of primary congenital glaucoma. Affected patients typically manifest specific signs that facilitate its recognition at birth and become important in the assessment and determination of appropriate treatment for this severe expression of primary congenit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 1604,
          "offsetInEndSection": 1938,
          "text": "in the rubella-positive patients (P \u003d 0.02).CONCLUSIONS: Twenty-five percent of those with newborn glaucoma had underlying intrauterine rubella infection, thus making them susceptible for development of congenital rubella syndrome (CRS). Neonatal-onset glaucoma is an important component of CRS, which may present without buphthalmos ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34954410"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "BACKGROUND: Neonatal-onset glaucoma (NOG) is a severe form of childhood glaucoma and is not always due to primary congenital gla",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33268344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "BACKGROUND: Newborn primary congenital glaucoma is an unusual and important subtype of primary congenit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Nonsyndromic primary newborn glaucoma, the most severe form of primary congenital glaucoma, typically is bilateral and often the result of CYP1B1 mutations, particularly in certain consanguineous populations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158549"
        },
        {
          "offsetInBeginSection": 279,
          "offsetInEndSection": 485,
          "text": "During a 9-year period, we tested 5 consecutive children with unilateral primary newborn glaucoma from Saudi Arabia, where CYP1B1 mutations are the cause for 91% of bilateral primary newborn glaucoma cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158549"
        },
        {
          "offsetInBeginSection": 486,
          "offsetInEndSection": 690,
          "text": "None of these children with unilateral primary newborn glaucoma harbored CYP1B1 mutations, suggesting that in this population the pathogenesis of unilateral disease differs from that of bilateral disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23158549"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "BACKGROUND: Newborn primary congenital glaucoma is an unusual and important subtype of primary congenita",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16382557"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 193,
          "text": " To describe neonatal-onset congenital ectropion uveae (N-CEU) as a distinct clinical entity of newborn glaucoma (NG) and to study its significance toward the severity and outcome of NG",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33045217"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "A newborn infant with unilateral eyelid swelling, proptosis, and glaucoma is described.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6766271"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 371,
          "text": "The corneal specimen of a 4-month-old infant with newborn primary congenital glaucoma and cloudy corneas who had undergone penetrating keratoplasty was evaluated by light and electron microscopy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19645407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "CASE REPORT: We present the case of a newborn baby in whom we observed aniridia, congenital glaucoma and edematous corneas, without clearance of the cornea after glaucoma surgery, and in whom a keratoplasty wa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19967611"
        }
      ],
      "id": "67d6be8a18b1e36f2e000022",
      "ideal_answer": [
        "Newborns can develop glaucoma, specifically primary congenital glaucoma (PCG), a severe form characterized by corneal opacification, elevated intraocular pressure, buphthalmos, and optic nerve damage. Studies highlight PCG as an autosomal recessive disorder often linked to CYP1B1 gene mutations, with high prevalence in consanguineous populations like Saudi Arabia, where 91% of cases involve such mutations. Newborn-onset glaucoma is distinguished by early corneal abnormalities and may co-occur with conditions like neurofibromatosis type 1 (NF1) or intrauterine infections (e.g., rubella, CMV). Treatment challenges include limited surgical success with goniosurgery compared to trabeculectomy, emphasizing the need for genetic testing and multidisciplinary care. Early diagnosis is critical due to rapid progression and potential systemic associations.",
        "Yes, newborns can have glaucoma. It is referred to as congenital glaucoma, which is a rare condition present at birth. It occurs due to improper development of the eye\u0027s drainage system before birth, leading to increased intraocular pressure that can damage the optic nerve and result in vision loss if not treated promptly.",
        "Yes, newborns can have glaucoma, as evidenced by studies showing that primary congenital glaucoma (PCG) can manifest at birth or shortly after. PCG is characterized by increased intraocular pressure due to anterior segment abnormalities and is often linked to genetic mutations, particularly in the CYP1B1 gene. Newborns with PCG may present with corneal opacification, buphthalmos, and optic nerve damage. Studies highlight that mutations in CYP1B1 are a common cause of autosomal recessive PCG, leading to severe clinical phenotypes. Additionally, congenital infections such as rubella and cytomegalovirus can also contribute to glaucoma in newborns. Early diagnosis and treatment, including surgical interventions like trabeculectomy or goniosurgery, are critical to manage the condition and prevent vision loss.",
        "Newborns can develop glaucoma, specifically primary congenital glaucoma (PCG), which is characterized by increased intraocular pressure, corneal opacification, and anterior segment abnormalities. Studies highlight that PCG in newborns often presents with severe clinical features, such as enlarged eyeballs (buphthalmos) and optic nerve damage, and is frequently linked to CYP1B1 gene mutations, particularly in consanguineous populations. Genetic analyses from West Siberia, Saudi Arabia, and other regions identified pathogenic variants like E387K, R444*, and novel deletions in the CYP1B1 gene, emphasizing its role in autosomal recessive PCG. Newborn cases may also involve rare associations with conditions like neurofibromatosis 1 or congenital Zika virus infections, underscoring the need for early ophthalmological evaluation and molecular genetic testing to guide timely treatment.",
        "Newborns can develop glaucoma, specifically primary congenital glaucoma (PCG), which is characterized by elevated intraocular pressure, corneal opacification, buphthalmos, and optic nerve damage. Studies highlight that PCG often results from autosomal recessive mutations in the CYP1B1 gene, with severe clinical manifestations observed in newborn-onset cases compared to infantile-onset forms. Genetic analysis of affected infants has identified pathogenic variants such as E387K, R444*, and novel deletions in CYP1B1, emphasizing its role in disease etiology. Newborn PCG is associated with anterior segment abnormalities and requires early diagnosis through molecular genetic testing to guide treatment decisions, as surgical interventions like trabeculectomy or glaucoma drainage tubes may be more effective than goniosurgery in this population. Cases involving concurrent conditions such as neurofibromatosis 1 or intrauterine infections (e.g., rubella, CMV) further complicate management, underscoring the need for multidisciplinary care and thorough systemic evaluation."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What are some recent advances in cancer immunotherapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37691932",
        "http://www.ncbi.nlm.nih.gov/pubmed/30687562",
        "http://www.ncbi.nlm.nih.gov/pubmed/27232512",
        "http://www.ncbi.nlm.nih.gov/pubmed/35340585",
        "http://www.ncbi.nlm.nih.gov/pubmed/27941290",
        "http://www.ncbi.nlm.nih.gov/pubmed/35201440",
        "http://www.ncbi.nlm.nih.gov/pubmed/36010965",
        "http://www.ncbi.nlm.nih.gov/pubmed/38814230",
        "https://www.ncbi.nlm.nih.gov/pubmed/19650714",
        "https://www.ncbi.nlm.nih.gov/pubmed/32612154",
        "https://www.ncbi.nlm.nih.gov/pubmed/37691932",
        "http://www.ncbi.nlm.nih.gov/pubmed/26545847",
        "http://www.ncbi.nlm.nih.gov/pubmed/31609776",
        "http://www.ncbi.nlm.nih.gov/pubmed/29483407",
        "http://www.ncbi.nlm.nih.gov/pubmed/39335671",
        "http://www.ncbi.nlm.nih.gov/pubmed/38005965",
        "http://www.ncbi.nlm.nih.gov/pubmed/19650714",
        "http://www.ncbi.nlm.nih.gov/pubmed/26325031",
        "http://www.ncbi.nlm.nih.gov/pubmed/35551655",
        "http://www.ncbi.nlm.nih.gov/pubmed/24477411",
        "http://www.ncbi.nlm.nih.gov/pubmed/37511873",
        "http://www.ncbi.nlm.nih.gov/pubmed/39732304",
        "http://www.ncbi.nlm.nih.gov/pubmed/27151159",
        "http://www.ncbi.nlm.nih.gov/pubmed/32645977",
        "http://www.ncbi.nlm.nih.gov/pubmed/36135216",
        "http://www.ncbi.nlm.nih.gov/pubmed/31530772",
        "http://www.ncbi.nlm.nih.gov/pubmed/19522699",
        "http://www.ncbi.nlm.nih.gov/pubmed/28877635",
        "http://www.ncbi.nlm.nih.gov/pubmed/18477644",
        "http://www.ncbi.nlm.nih.gov/pubmed/25977192",
        "http://www.ncbi.nlm.nih.gov/pubmed/39612278",
        "http://www.ncbi.nlm.nih.gov/pubmed/39699103",
        "http://www.ncbi.nlm.nih.gov/pubmed/32784389",
        "http://www.ncbi.nlm.nih.gov/pubmed/37371075",
        "http://www.ncbi.nlm.nih.gov/pubmed/31703740",
        "http://www.ncbi.nlm.nih.gov/pubmed/39447408",
        "http://www.ncbi.nlm.nih.gov/pubmed/37425044",
        "http://www.ncbi.nlm.nih.gov/pubmed/37345057",
        "http://www.ncbi.nlm.nih.gov/pubmed/26942589",
        "http://www.ncbi.nlm.nih.gov/pubmed/39581243",
        "http://www.ncbi.nlm.nih.gov/pubmed/39741315",
        "http://www.ncbi.nlm.nih.gov/pubmed/36942270",
        "http://www.ncbi.nlm.nih.gov/pubmed/33936118",
        "http://www.ncbi.nlm.nih.gov/pubmed/32010123",
        "http://www.ncbi.nlm.nih.gov/pubmed/30562849",
        "http://www.ncbi.nlm.nih.gov/pubmed/31788040",
        "http://www.ncbi.nlm.nih.gov/pubmed/32877161",
        "http://www.ncbi.nlm.nih.gov/pubmed/25331657"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37691932"
        },
        {
          "offsetInBeginSection": 439,
          "offsetInEndSection": 600,
          "text": "Several cancer immunotherapies, include immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), have shown great efficacy and promise.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37691932"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 641,
          "text": "Cancer immunotherapy represents a standing example of precision medicine: immune checkpoint inhibitors precisely target the checkpoints; tumor infiltrating lymphocytes, TCR T cells, and CAR T cells precisely kill cancer cells through tumor antigen recognition; and cancer vaccines are made from patient-derived dendritic cells, tumor cell DNA, or RNA, or oncolytic viruses, thus offering a type of personalized medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30687562"
        },
        {
          "offsetInBeginSection": 60,
          "offsetInEndSection": 383,
          "text": "Recent treatment strategies, especially chimeric antigen receptor-T (CAR-T) cell therapy and immune checkpoint inhibitors, reportedly achieve higher objective responses and better survival rates than previous immunotherapies for patients with treatment-resistant malignancies, creating a paradigm shift in cancer treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 797,
          "text": "Recent scientific advances have expanded our understanding of the immune system and its response to malignant cells. The clinical goal of tumour immunotherapy is to provide either passive or active immunity against malignancies by harnessing the immune system to target tumours. Monoclonal antibodies, cytokines, cellular immunotherapy, and vaccines have increasingly become successful therapeutic agents for the treatment of solid and haematological cancers in preclinical models, clinical trials, and practice. In this article, we review recent advances in the immunotherapy of cancer, focusing on new strategies and future perspectives as well as on clinical trials attempting to enhance the efficacy of immunotherapeutic modalities and translate this knowledge into effective cancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/19650714"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 784,
          "text": "Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors. Tumor infiltrating leukocytes (TILs) play an immunomodulatory role in tumor microenvironment (TME) which is closely related to immune escape of tumor cells, thus influence tumor progress. Several cancer immunotherapies, include immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), have shown great efficacy and promise. In this review, we will summarize the recent research advances in tumor immunotherapy, including the molecular mechanisms and clinical effects as well as limitations of immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37691932"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 762,
          "text": "With the advent of immune checkpoint inhibitors, cancer immunotherapy has finally become a standard treatment for non-small cell lung cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29483407"
        },
        {
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1346,
          "text": "Herein, we discuss recent advances and future challenges in cancer immunotherapy, i.e., the identification of neoantigens for the development of individualized immunotherapies, the development of new CAR-T cell therapies, including so-called armored CAR-T cells that can induce greater clinical effects and thereby achieve longer survival, the development of off-the-shelf treatment regimens using non-self cells or cell lines, and effective cancer immunotherapy combinations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941290"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 392,
          "text": "This review explores the scope and impact of various immunotherapeutic strategies, including monoclonal antibodies, chimeric antigen receptor (CAR)-T cell therapy, checkpoint inhibitors, cytokine therapy, and therapeutic vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39335671"
        },
        {
          "offsetInBeginSection": 883,
          "offsetInEndSection": 1157,
          "text": "In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27151159"
        },
        {
          "offsetInBeginSection": 592,
          "offsetInEndSection": 840,
          "text": "These include cancer vaccines, adoptive cell therapies (such as CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints that have demonstrated promising clinical efficacy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36135216"
        },
        {
          "offsetInBeginSection": 608,
          "offsetInEndSection": 887,
          "text": "In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201440"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 525,
          "text": "Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines. Overall, this field has advanced rapidly as knowledge of the tumor microenvironment, immunological pathways, and biotechnology expands. Specifically, advancements in neoantigen identification, characterization, and formulation into a vaccine show promise.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38005965"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1431,
          "text": "Recent advances in cancer immunotherapies, such as immune checkpoint inhibitors(ICIs), have shown some durable clinical responses in patients with various types of advanced cancers. The development of the next-generation sequencing technologies can result in a comprehensive characterization of the human cancer genomes. Personalized immunotherapy and precision cancer medicine might enable the next generation of rational cancer immunotherapy. Conventional cancer vaccines are designed to target tumor-associated antigens(TAAs), which are overexpressed in cancers. However, since TAAs are also expressed in normal tissues, cancer vaccine against TAAs can potentially initiate central and peripheral tolerance responses, which results in low vaccination efficiency. Cancer neoantigens derived from somatic mutations in tumor tissue represent highly immunogenic and can escape from central thymic tolerance. They are suggested to provide tumor specific targets for personalized cancer vaccines. Therefore, neoantigen-based cancer vaccine, which can induce tumor-specific cytotoxic T lymphocytes( CTLs), should be developed. The efficacy of current immunotherapies also remains limited due to the immunosuppressive tumor microenvironment, which leads to CTLs exhaustion or anergy and the escape of tumor cells from immune attack. The combination of neoantigen-based cancer vaccine and ICIs should be a potential therapeutic approach.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31530772"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 583,
          "text": "In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340585"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 574,
          "text": "One of these is cancer vaccination, an approach aimed at inducing effective immune responses in the host against defined tumour antigens. Among several classes of cancer vaccines, the subunit vaccines based on the single and multi epitope-approach are worthy of note as they offer an exquisite specificity in targeting only tumour cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19522699"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 307,
          "text": "Cancer immunotherapy has revolutionized the field of oncology in recent years. Harnessing the immune system to treat cancer has led to a large growth in the number of novel immunotherapeutic strategies, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36010965"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 798,
          "text": "Among the variety of immunotherapy strategies developed to boost patients\u0027 own immune systems to fight against malignant cells, the pathogen-based and adoptive cell transfer therapies have shown the most promise for treating multiple types of cancer. Pathogen-based therapies could either break the immune tolerance to enhance the effectiveness of cancer vaccines or directly infect and kill cancer cells. Adoptive cell transfer can induce a strong durable antitumor response, with recent advances including engineering dual specificity into T cells to recognize multiple antigens and improving the metabolic fitness of transferred cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877635"
        },
        {
          "offsetInBeginSection": 747,
          "offsetInEndSection": 953,
          "text": "In this article we review recent advances in the immunotherapy of cancer, focusing on new strategies to enhance the efficacy of passive immunotherapy with monoclonal antibodies and antigen-specific T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18477644"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 713,
          "text": "This review aims to summarize the development of some major strategies in cancer immunotherapy, from the earliest peptide vaccine and transfer of tumor specific antibodies/T cells to the more recent dendritic cell (DC) vaccines, whole cell tumor vaccines, and checkpoint blockade therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25977192"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 424,
          "text": "The discoveries of PD1 and PD-L1 as negative immune checkpoints for T cells have led to the revolution of modern cancer immunotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31703740"
        },
        {
          "offsetInBeginSection": 388,
          "offsetInEndSection": 676,
          "text": "Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39447408"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 305,
          "text": "This review will cover recent advances in cancer immunotherapy, including the use of T cell checkpoint inhibitors, engineered T cells, cancer vaccines, and anti-B cell and T cell antibodies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26545847"
        },
        {
          "offsetInBeginSection": 608,
          "offsetInEndSection": 886,
          "text": "In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35201440"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 355,
          "text": "Remarkable clinical outcomes have been achieved through recent advances in cancer immunotherapy, including checkpoint blockades, adoptive cellular therapy, cancer vaccine, and tumor microenvironment modulation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37425044"
        },
        {
          "offsetInBeginSection": 610,
          "offsetInEndSection": 847,
          "text": "The understanding of how to control immune checkpoints, develop therapeutic cancer vaccines, genetically modify immune cells as well as enhance the activation of antitumor immune response led to the development of novel cancer treatments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37345057"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 268,
          "text": "Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38005965"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 811,
          "text": "Immunotherapy has emerged as a promising avenue, leveraging the body\u0027s immune system to recognize and combat cancer cells. Innovative immunotherapeutic strategies, including immune checkpoint inhibitors, adoptive T cell therapy, and chimeric antigen receptor (CAR)-T cell therapy, exhibit the potential to enhance immune responses against osteosarcoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39581243"
        },
        {
          "offsetInBeginSection": 481,
          "offsetInEndSection": 882,
          "text": "The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27151159"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 383,
          "text": "Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39741315"
        },
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 840,
          "text": "Multiple therapeutic approaches or agents to manipulate different aspects of the immune system are currently in development. These include cancer vaccines, adoptive cell therapies (such as CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints that have demonstrated promising clinical efficacy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36135216"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 420,
          "text": "In the last few years, immune checkpoint inhibitors and chimeric antigen receptor-modified T cells have made substantial advancements in cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36942270"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 367,
          "text": "Over the past few decades, immunotherapy has shown remarkable efficacy in the treatment of cancer, particularly the success of immune checkpoint blockade targeting CTLA-4, PD-1 and PDL1, which has led to a breakthrough in tumor immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33936118"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 654,
          "text": "Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35340585"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 596,
          "text": "Currently, therapies targeting programmed cell death protein 1/programmed cell death 1 ligand 1 or cytotoxic T-lymphocyte antigen-4 are the focus of cancer immunotherapy and are widely applied in clinical treatment of various tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32010123"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 311,
          "text": "The recent advances in the identification of cancer-associated neoantigens, chimeric antigen receptor (CAR) T-cell and immune checkpoint blockade (ICB), have revolutionized the field of cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877161"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Recent advances in cancer immunotherapies, such as immune checkpoint inhibitors(ICIs), have shown some durable clinical responses in patients with various types of advanced cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31530772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 388,
          "text": "Cancer immunotherapy began as a Coley\u0027s vaccine, and then, non-specific immuno- modulators, anti-tumor monoclonal antibody, cytokines, cancer vaccine (e.g. tumor antigens, dendritic cells, modified cancer cells), adoptive cell therapy (e.g. TIL, TCR/CAR-T cells), and immune-checkpoint inhibitors (PD-1/PD-Li, CTLA4 blocking antibody) have been developed and evaluated in clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30562849"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 609,
          "text": "Recently, cancer immunotherapies have received considerable attention as a viable therapeutic option for GC. Specifically, the immune checkpoint inhibitors, chimeric antigen rector (CAR)-T cells and tumor vaccines, represent immunotherapies that have exhibited promising effects in the treatment of GC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31788040"
        },
        {
          "offsetInBeginSection": 60,
          "offsetInEndSection": 255,
          "text": "Recent treatment strategies, especially chimeric antigen receptor-T (CAR-T) cell therapy and immune checkpoint inhibitors, reportedly achieve higher objective responses and better survival rates ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941290"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 538,
          "text": "This review will cover recent advances in cancer immunotherapy, including the use of T cell checkpoint inhibitors, engineered T cells, cancer vaccines, and anti-B cell and T cell antibodies. Inhibition of T cell checkpoint molecules such as PD-1 and CTLA-4 using monoclonal antibodies has achieved notable success against advanced tumors in humans, including melanoma, renal cell carcinoma, and non-small cell lung cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26545847"
        },
        {
          "offsetInBeginSection": 870,
          "offsetInEndSection": 1345,
          "text": "Herein, we discuss recent advances and future challenges in cancer immunotherapy, i.e., the identification of neoantigens for the development of individualized immunotherapies, the development of new CAR-T cell therapies, including so-called armored CAR-T cells that can induce greater clinical effects and thereby achieve longer survival, the development of off-the-shelf treatment regimens using non-self cells or cell lines, and effective cancer immunotherapy combinations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27941290"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 306,
          "text": "Harnessing the immune system to treat cancer has led to a large growth in the number of novel immunotherapeutic strategies, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36010965"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 419,
          "text": "In the last few years, immune checkpoint inhibitors and chimeric antigen receptor-modified T cells have made substantial advancements in cancer immunotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36942270"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 391,
          "text": "This review explores the scope and impact of various immunotherapeutic strategies, including monoclonal antibodies, chimeric antigen receptor (CAR)-T cell therapy, checkpoint inhibitors, cytokine therapy, and therapeutic vaccines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39335671"
        }
      ],
      "id": "680bc74618b1e36f2e000155",
      "ideal_answer": [
        "Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime the host immune system to provide passive or active immunity against malignant tumors. Recently, several cancer immunotherapies have shown great efficacy and promise, including immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer (ACT).",
        "Recent advances in cancer immunotherapy include the use of immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, which have shown promising results in clinical trials. Other approaches include the use of adoptive cell transfer, such as CAR-T cell therapy, and the use of oncolytic viruses to stimulate the immune system to attack cancer cells. Additionally, there is ongoing research into the use of vaccines to prevent or treat cancer, as well as the use of combination therapies to enhance the effectiveness of immunotherapy.",
        "Recent advances in cancer immunotherapy include the development of new checkpoint inhibitors targeting molecules like PD-1, PD-L1, and CTLA-4, which enhance the immune system\u0027s ability to attack cancer cells. CAR T-cell therapy has seen improvements in efficacy and safety, with new generations engineered to target a broader range of cancer antigens and overcome the tumor microenvironment. Bispecific antibodies have been designed to bind simultaneously to cancer and immune cells, enhancing the immune response. Personalized cancer vaccines targeting specific tumor antigens are showing promise in clinical trials. Oncolytic viruses, genetically modified to selectively infect and kill cancer cells, have improved in targeting tumors and stimulating immune activation. Combination therapies, which integrate different immunotherapies or pair them with treatments like chemotherapy or radiation, have demonstrated improved outcomes by overcoming resistance. Additionally, research into the gut microbiome\u0027s role in immunotherapy effectiveness is underway, with strategies like diet modification and probiotics being explored to enhance treatment responses. These advances aim to improve the efficacy, safety, and applicability of immunotherapy across various cancer types.",
        "Recent advances in cancer immunotherapy include the development of immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, which have shown promising results in clinical trials. Other approaches include the use of adoptive cell transfer, where immune cells are taken from a patient, modified to target cancer cells, and then reinfused into the patient. Additionally, there has been progress in the development of cancer vaccines, which aim to stimulate the immune system to recognize and attack cancer cells. Overall, these advances have led to improved outcomes for cancer patients and have the potential to revolutionize cancer treatment.",
        "Recent advances in cancer immunotherapy include the development of various approaches such as cancer vaccines, adoptive cell therapies (e.g., CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints. These have demonstrated promising clinical efficacy in treating various malignancies. Specifically, immune checkpoint inhibitors and chimeric antigen receptor-modified T cells have made substantial advancements. Additionally, vaccines developed against neoantigens are being used in clinical trials for solid tumors. Oncolytic immunotherapy has emerged as a novel component of cancer immunotherapy with lower incidence of serious adverse reactions. Furthermore, immunotherapy has become a standard treatment for lung cancer, moving from advanced to early patients and from the back line to the front line. Overall, these advances have shifted the cancer treatment paradigm, offering new hope for cancer patients.",
        "Recent advances in cancer immunotherapy include significant progress in immune checkpoint inhibitors, such as those targeting CTLA-4, PD-1, and PDL1, which have shown remarkable efficacy. Chimeric antigen receptor (CAR)-T cell therapy has also made substantial advancements, offering promising outcomes for patients. Additionally, neoantigen vaccines are being tested in clinical trials for solid tumors, representing a novel approach. Oncolytic immunotherapy has emerged as a safer option with fewer adverse reactions. Furthermore, immunotherapy has become a standard treatment for lung cancer and is increasingly used in earlier stages of care. Overall, these developments highlight the rapid evolution and expanding role of immunotherapy in cancer treatment.",
        "Recent advances in cancer immunotherapy include the widespread clinical success of immune checkpoint inhibitors targeting CTLA-4, PD-1 and PD-L1, which have produced durable remissions across multiple tumor types. Chimeric antigen receptor T-cell (CAR-T) therapies have been refined to improve persistence and safety, including “armored” CAR-T cells engineered to resist immunosuppression and off-the-shelf allogeneic CAR-T products. Personalized neoantigen vaccines, developed through high-throughput sequencing and bioinformatics, are showing early clinical efficacy, especially in melanoma. Combination regimens pairing checkpoint blockade with agents such as oncolytic viruses, radiation or epigenetic modulators are overcoming primary and acquired resistance. Novel targets (for example, LAG-3, TIM-3, TIGIT, Siglec-15) and costimulatory agonists (4-1BB, OX40, GITR) are entering trials. Additionally, nanotechnology-based delivery systems and modulation of the gut microbiome are emerging strategies to boost antitumor immunity.",
        "Recent advances in cancer immunotherapy include the development and use of immune checkpoint inhibitors, such as nivolumab, pembrolizumab, ipilimumab, tremelimumab, durvalumab, and atezolizumab. These inhibitors target proteins like programmed cell death ligand-1 (PD-L1), programmed cell death-1 (PD-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Another significant advancement is chimeric antigen receptor (CAR)-T cell therapy, which has shown promise in treating hematologic malignancies. Monoclonal antibodies like Rituximab and Trastuzumab have also revolutionized cancer treatment by providing targeted interventions. Additionally, cancer vaccination and bispecific antibodies are emerging as important strategies in activating the immune system against cancer. These immunotherapeutic strategies have led to improved outcomes and new treatment options for various malignancies.",
        "Cancer immunotherapy has been revolutionized by the development of immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer (ACT). ICIs block the signals that prevent the immune system from attacking cancer cells, while cancer vaccines stimulate the immune system to recognize and destroy cancer cells. ACT involves transferring immune cells from a patient to a laboratory, where they are modified to target cancer cells, and then infused back into the patient. These therapies have shown great efficacy and promise in treating various types of cancer.",
        "Recent advances in cancer immunotherapy have significantly expanded treatment options for various cancers. These advancements include immune checkpoint inhibitors (ICIs) targeting key pathways like PD 1/PD L1 and CTLA 4, which have shown remarkable success in treating melanoma, lung cancer, and other malignancies. Cancer vaccines, such as personalized neoantigen targeting vaccines, are emerging as a promising approach to induce specific anti tumor immune responses. Another notable advance is adoptive cell transfer (ACT), particularly chimeric antigen receptor T cell (CAR T) therapy, which has demonstrated curative potential in certain types of leukemia and lymphoma. Additionally, bispecific T cell engagers (BiTEs) like Blinatumomab are being used to target specific tumor antigens and activate immune responses. Recent progress also includes the development of oncolytic viruses, such as T VEC, which selectively infect and destroy cancer cells while stimulating anti tumor immunity. Furthermore, research into chimeric antigen receptor natural killer (CAR NK) cells is gaining traction due to their potential for off the shelf therapies with fewer adverse effects compared to CAR T cells. Lastly, advancements in tumor infiltrating lymphocyte (TIL) therapy and combination immunotherapies with other treatments like radiation or targeted therapies are being explored to enhance efficacy.",
        "Recent advances in cancer immunotherapy have significantly expanded treatment options and improved patient outcomes. Key developments include:\n\n1. **Immune Checkpoint Inhibitors (ICIs):** These drugs, such as PD-1 and CTLA-4 inhibitors, block proteins that inhibit the immune system, allowing it to attack cancer cells more effectively. They have proven successful in treating cancers like melanoma and lung cancer.\n\n2. **Adoptive Cell Transfer (ACT):** This therapy involves engineering a patient\u0027s immune cells to target cancer more effectively. CAR-T cell therapy, a type of ACT, has shown remarkable success, particularly in blood cancers such as leukemia and lymphoma.\n\n3. **Cancer Vaccines:** Therapeutic vaccines are being developed to train the immune system to recognize and attack cancer cells. These vaccines target specific tumor antigens and have shown promise in clinical trials.\n\n4. **Engineered Antibodies:** Bispecific T-cell engagers (BiTEs) and other engineered antibodies direct the immune system to kill cancer cells more effectively, with potential shown in various clinical studies.\n\n5. **Combination Therapies:** Combining different immunotherapies or integrating them with traditional treatments like chemotherapy and radiation has enhanced effectiveness, particularly for patients with advanced cancers.\n\n6. **Tumor Microenvironment Research:** Understanding the tumor microenvironment is crucial for modifying it to enhance immune response, making existing therapies more effective across a broader range of cancers.\n\n7. **Personalized Medicine:** Tailoring treatments to individual genetic profiles improves efficacy and reduces side effects, marking a significant advancement in cancer treatment.\n\nThese advancements collectively represent a paradigm shift in oncology, offering more targeted and effective treatments for patients.",
        "Recent advances in cancer immunotherapy include the development of immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer (ACT), which have demonstrated significant efficacy in clinical settings. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance T-cell activity against tumors by overcoming immune suppression. ACT involves engineering patient-derived T-cells (e.g., CAR-T cells) to target specific tumor antigens, showing remarkable success in hematologic malignancies. Cancer vaccines, including mRNA-based platforms, aim to elicit adaptive immunity against tumor-specific epitopes. These therapies have transformed cancer care by leveraging the immune system to achieve durable responses, with ongoing refinements to improve efficacy, reduce toxicity, and expand applicability across tumor types. The field continues to evolve, emphasizing personalized approaches and combination strategies to overcome resistance and enhance patient outcomes.",
        "The recent advances in cancer immunotherapy have primarily focused on three key areas: immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer. Immune checkpoint inhibitors are a type of treatment that targets specific proteins (known as immune checkpoints) to restore the body\u0027s immune system in fighting cancer. Cancer vaccines, on the other hand, stimulate the immune system to recognize and attack cancer cells. Adoptive cell transfer, a more specialized form of treatment, involves taking immune cells (such as T-cells) from a patient, modifying them to recognize cancer cells, and then reintroducing them into the patient\u0027s body to attack the cancer. These three approaches have shown great efficacy and promise in the treatment of various types of cancer.",
        "Recent advances in cancer immunotherapy have significantly transformed the treatment landscape. Key developments include immune checkpoint inhibitors (ICIs), which block proteins like PD 1/PD L1 to enhance T cell activity against tumors. Another major advancement is adoptive cell transfer (ACT), particularly CAR T cell therapy, where engineered T cells target specific cancer antigens. Cancer vaccines are also emerging, designed to stimulate the immune system by targeting tumor specific antigens. Additionally, bispecific T cell engagers (BiTEs) have been developed to simultaneously bind to T cells and cancer cells, facilitating targeted immune responses. Combination therapies that integrate ICIs with other treatments or vaccines aim to synergize effects for better outcomes. Personalized approaches leveraging tumor specific mutations are also being explored to tailor therapies more effectively.",
        "Recent advances in cancer immunotherapy prominently feature three key approaches: Immune Checkpoint Inhibitors (ICIs) that block proteins inhibiting immune responses, Next-Generation Cancer Vaccines that stimulate targeted immune attacks, and enhanced Adoptive Cell Transfer (ACT) techniques, including CAR-T cell and TIL therapy, which directly bolster the body\u0027s cancer-fighting capabilities. These therapies, often used in synergistic combination with traditional treatments, have demonstrated significant efficacy in leveraging the host\u0027s immune system to combat malignant tumors, offering new hope and improved outcomes for various cancer types.",
        "Recent advances in cancer immunotherapy have focused on enhancing the body\u0027s immune response to cancer through several key approaches:\n\n1. **Immune Checkpoint Inhibitors (ICIs):** These drugs block proteins that inhibit immune responses, such as PD-1 and CTLA-4, allowing immune cells to attack cancer more effectively.\n\n2. **Cancer Vaccines:** Designed to help the immune system recognize cancer cells, these vaccines can be personalized to target specific tumor mutations, improving their effectiveness.\n\n3. **Adoptive Cell Transfer (ACT):** This involves modifying a patient\u0027s immune cells, such as T-cells, to better fight cancer before reinfusing them. CAR-T cell therapy is a prominent example.\n\n4. **Combination Therapies:** Using multiple immunotherapies together can enhance effectiveness and address resistance issues.\n\n5. **Precision Medicine:** Tailoring treatments to individual patients\u0027 genetic profiles to improve outcomes and reduce side effects.\n\nThese advancements represent significant strides in leveraging the immune system to combat cancer, offering hope for more effective and targeted therapies.",
        "Recent advances in cancer immunotherapy include immune checkpoint inhibitors (ICIs), which target pathways like PD-1/PD-L1 to enhance anti-tumor immunity; cancer vaccines designed to stimulate antigen-specific immune responses against tumors; and adoptive cell transfer (ACT) strategies, such as CAR-T cells or engineered TILs, that amplify tumor-reactive lymphocytes. Studies highlight the role of tumor-infiltrating leukocytes (TILs) in modulating the tumor microenvironment (TME), influencing immune evasion and disease progression. These approaches leverage molecular mechanisms to prime host immunity, offering clinical benefits through both passive and active immunotherapeutic strategies, though challenges like resistance and toxicity remain areas for further investigation.",
        "[\"Recent advances in cancer immunotherapy include the development and enhancement of immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer (ACT). ICIs, such as those targeting PD-1, PD-L1, and CTLA-4, have been successful in treating various cancers by blocking inhibitory pathways in T cells. Cancer vaccines are being developed to prime the immune system against tumor-specific antigens. Adoptive cell transfer, particularly CAR T-cell therapy, involves engineering patients\u0027 T cells to better recognize and attack cancer cells. These therapies have shown significant efficacy in improving patient outcomes across several cancer types.\"]"
      ],
      "exact_answer": [
        [
          "Immune checkpoint inhibitors",
          "ICIs",
          "Immune-checkpoint blockade",
          "Checkpoint inhibitors (PD-1/PD-L1)"
        ],
        [
          "Cancer vaccines"
        ],
        [
          "Adoptive cell transfer",
          "ACT",
          "Adoptive immunotherapy (TIL)",
          "CAR-T Cell Therapy",
          "TCR-engineered T cells",
          "Chimeric antigen receptor (CAR) T-cell therapy"
        ],
        [
          "Oncolytic Viruses",
          "oncolytic immunotherapy"
        ],
        [
          "Cytokines",
          "Cytokine therapy (IL-2, IL-12, IFN-gamma)",
          "Cytokines (Interleukin-2, Interferons)",
          "immune stimulating cytokines"
        ],
        [
          "Monoclonal antibodies",
          "Engineered humanized monoclonal antibodies"
        ]
      ]
    },
    {
      "body": "Is delirium a frequent complication after cardiac surgery?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37278574",
        "http://www.ncbi.nlm.nih.gov/pubmed/38323256",
        "http://www.ncbi.nlm.nih.gov/pubmed/38434577",
        "http://www.ncbi.nlm.nih.gov/pubmed/33884974",
        "http://www.ncbi.nlm.nih.gov/pubmed/26158535",
        "http://www.ncbi.nlm.nih.gov/pubmed/29881262",
        "http://www.ncbi.nlm.nih.gov/pubmed/31820554",
        "http://www.ncbi.nlm.nih.gov/pubmed/14752413",
        "http://www.ncbi.nlm.nih.gov/pubmed/22345177",
        "http://www.ncbi.nlm.nih.gov/pubmed/32222959",
        "http://www.ncbi.nlm.nih.gov/pubmed/20624517",
        "http://www.ncbi.nlm.nih.gov/pubmed/35773648",
        "http://www.ncbi.nlm.nih.gov/pubmed/36147691",
        "http://www.ncbi.nlm.nih.gov/pubmed/29390969",
        "http://www.ncbi.nlm.nih.gov/pubmed/27977539",
        "http://www.ncbi.nlm.nih.gov/pubmed/38695330",
        "http://www.ncbi.nlm.nih.gov/pubmed/25189637",
        "http://www.ncbi.nlm.nih.gov/pubmed/38134752",
        "https://www.ncbi.nlm.nih.gov/pubmed/27977539",
        "https://www.ncbi.nlm.nih.gov/pubmed/31820554",
        "https://www.ncbi.nlm.nih.gov/pubmed/33902644",
        "http://www.ncbi.nlm.nih.gov/pubmed/33902644",
        "http://www.ncbi.nlm.nih.gov/pubmed/35042244",
        "http://www.ncbi.nlm.nih.gov/pubmed/37867328",
        "http://www.ncbi.nlm.nih.gov/pubmed/25708120",
        "http://www.ncbi.nlm.nih.gov/pubmed/29395177",
        "http://www.ncbi.nlm.nih.gov/pubmed/28182690",
        "http://www.ncbi.nlm.nih.gov/pubmed/36354764",
        "http://www.ncbi.nlm.nih.gov/pubmed/36254916",
        "http://www.ncbi.nlm.nih.gov/pubmed/22170877",
        "http://www.ncbi.nlm.nih.gov/pubmed/37547895",
        "http://www.ncbi.nlm.nih.gov/pubmed/39709397",
        "http://www.ncbi.nlm.nih.gov/pubmed/39707458",
        "http://www.ncbi.nlm.nih.gov/pubmed/39702254",
        "http://www.ncbi.nlm.nih.gov/pubmed/39695628",
        "http://www.ncbi.nlm.nih.gov/pubmed/26909407",
        "http://www.ncbi.nlm.nih.gov/pubmed/31482364",
        "http://www.ncbi.nlm.nih.gov/pubmed/22978835",
        "http://www.ncbi.nlm.nih.gov/pubmed/27052077",
        "http://www.ncbi.nlm.nih.gov/pubmed/26660055",
        "http://www.ncbi.nlm.nih.gov/pubmed/39484132",
        "http://www.ncbi.nlm.nih.gov/pubmed/23977818",
        "http://www.ncbi.nlm.nih.gov/pubmed/28743102",
        "http://www.ncbi.nlm.nih.gov/pubmed/38424490",
        "http://www.ncbi.nlm.nih.gov/pubmed/23659704",
        "http://www.ncbi.nlm.nih.gov/pubmed/28561177",
        "http://www.ncbi.nlm.nih.gov/pubmed/28711314",
        "http://www.ncbi.nlm.nih.gov/pubmed/22783469",
        "http://www.ncbi.nlm.nih.gov/pubmed/38028495",
        "http://www.ncbi.nlm.nih.gov/pubmed/39076572",
        "http://www.ncbi.nlm.nih.gov/pubmed/36143313",
        "http://www.ncbi.nlm.nih.gov/pubmed/37551153",
        "http://www.ncbi.nlm.nih.gov/pubmed/33253676",
        "http://www.ncbi.nlm.nih.gov/pubmed/39398592",
        "http://www.ncbi.nlm.nih.gov/pubmed/38829438",
        "http://www.ncbi.nlm.nih.gov/pubmed/20373345",
        "http://www.ncbi.nlm.nih.gov/pubmed/22200370",
        "http://www.ncbi.nlm.nih.gov/pubmed/39581994",
        "http://www.ncbi.nlm.nih.gov/pubmed/39179251",
        "http://www.ncbi.nlm.nih.gov/pubmed/39192373",
        "http://www.ncbi.nlm.nih.gov/pubmed/39320056",
        "http://www.ncbi.nlm.nih.gov/pubmed/30863073",
        "http://www.ncbi.nlm.nih.gov/pubmed/20870463",
        "http://www.ncbi.nlm.nih.gov/pubmed/30635064",
        "http://www.ncbi.nlm.nih.gov/pubmed/39654028",
        "http://www.ncbi.nlm.nih.gov/pubmed/38652478",
        "http://www.ncbi.nlm.nih.gov/pubmed/34548175",
        "http://www.ncbi.nlm.nih.gov/pubmed/32524976",
        "http://www.ncbi.nlm.nih.gov/pubmed/19118253",
        "http://www.ncbi.nlm.nih.gov/pubmed/32305956",
        "http://www.ncbi.nlm.nih.gov/pubmed/33960404",
        "http://www.ncbi.nlm.nih.gov/pubmed/31668468",
        "http://www.ncbi.nlm.nih.gov/pubmed/39495993",
        "http://www.ncbi.nlm.nih.gov/pubmed/38512455"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Delirium is a common disorder for patients after cardiac surgery. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37278574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 55,
          "text": "Post-cardiac Surgery Delirium: When the Details Matter!",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38323256"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 196,
          "text": "ostoperative delirium (POD) after transcatheter aortic valve implantation (TAVI) is frequent in older adults and associated with multiple negative outcomes including a higher mortality. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38434577"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Background: Delirium is a frequent complication after cardiac surgery and is associated with a higher incidence of morbidity and mortality and a prolonged ho",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884974"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Factors associated with delirium after cardiac surgery: A prospective cohort study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884974"
        },
        {
          "offsetInBeginSection": 236,
          "offsetInEndSection": 333,
          "text": "Delirium is common in patients after open cardiac surgeries and can lead to serious consequences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158535"
        },
        {
          "offsetInBeginSection": 1396,
          "offsetInEndSection": 1466,
          "text": "Delirium is a common and serious complication of open cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158535"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "[Delirium after open cardiac surgery:systematic review of prevalence, risk factors and consequences].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158535"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "INTRODUCTION: Postoperative delirium is a common complication of cardiac surgery associated with increased mortality, morbidity, and long-term cognitiv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29881262"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Early delirium after cardiac surgery: an analysis of incidence and risk factors in elderly (≥65 years) and very elderly (≥80 years) patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29881262"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "BACKGROUND: Post-operative delirium among cardiac surgery patients is a prevalent complication that associated with multiple negati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31820554"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Delirium post-cardiac surgery: Incidence and associated factors.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31820554"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Despite improved outcomes after cardiac operations, postoperative delirium remains a common complication that is associated with increased morbidity and prolonged ho",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14752413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "BACKGROUND: Postoperative delirium is a common complication of cardiac surgery associated with higher morbidity, longer hospital stay, risk of cogniti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35773648"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Delirium post-cardiac surgery: Incidence and associated factors.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/31820554"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Risk factors of postoperative delirium after cardiac surgery: a meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33902644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 50,
          "text": "Delirium in Children After Cardiac Bypass Surgery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/27977539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery in older ad",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29390969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "OBJECTIVES: To describe the incidence of delirium in pediatric patients after cardiac bypass surgery and explore associated risk factors and effect of delirium on in-hospit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27977539"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 233,
          "text": "e outcomes. This retrospective study evaluated the potential risk factors and postoperative impact of delirium on cardiac surge",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Risk factors of postoperative delirium after cardiac surgery: a meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33902644"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Risk and Consequences of Postoperative Delirium in Cardiac Surgery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 304,
          "text": "it (CICU). Delirium is a frequent and serious complication in adults after cardiac surgery, but there is limited understanding of its impact in children with critical cardi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29395177"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Risk factors for postoperative delirium in patients after coronary artery bypass grafting: A prospective cohort study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25708120"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Delirium is a prevalent complication in critically ill medical and surgical cardiac patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37547895"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "BACKGROUND: Postoperative delirium is a common complication of cardiac surgery associated with higher morbidity, longer hospital stay, risk of cognitive decline, dementia, an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35773648"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Systematic literature review on early detection of postoperative delirium in adult patients after cardiac surgery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39709397"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Risk factors of delirium after cardiac surgery: a systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39707458"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 244,
          "text": "Anxiety and delirium are prevalent complications in cardiac patients undergoing invasive procedures like coronary artery bypass surgery, with untreated symptoms potentially leading to enduring physical and psychological consequences",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39702254"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 100,
          "text": "The incidence of delirium is high in the intensive care unit (ICU) after cardiac surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39695628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "Delirium is a common complication after cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305956"
        },
        {
          "offsetInBeginSection": 1613,
          "offsetInEndSection": 1675,
          "text": "NCLUSIONS: Delirium occurs frequently after cardiac surgery. U",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19118253"
        },
        {
          "offsetInBeginSection": 745,
          "offsetInEndSection": 797,
          "text": "Conclusion Delirium after cardiac surgery is common.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28561177"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "INTRODUCTION: Delirium is a frequent complication after cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25189637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Background: Delirium is a commonly seen complication of cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36254916"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Delirium is common after cardiac surgery and is associated with adverse outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37744662"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Delirium is a common complication after cardiac surgery, being associated with significant mortality and morbidity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26909407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "BACKGROUND: Delirium is a common outcome after cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19118253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "BACKGROUND: Delirium is a quite common complication in adult patients post-cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29773957"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "INTRODUCTION: Delirium after cardiac surgery is a devastating and important complication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32524976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Sleep-disordered breathing is a risk factor for delirium after cardiac surgery: a prospective cohort study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25189637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery in older adu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29390969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Delirium after cardiac surgery remains a common occurrence that results in significant short- and long-term morbidity and mortality. It continues to be underdiagnosed given its complex presentation and multifactorial etiology; however, its prevalence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27052077"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Neurologic injury in the form of cognitive decline, delirium, and stroke are common phenomena in patients undergoing cardiac surgery and continues to be one of the most common complication after cardiac surgery, in spite of improvements in mortality ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26660055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Background: Delirium is a frequent complication after cardiac surgery and is associated with a higher incidence of morbidity and mortality and a prolonged hospital stay. However, knowledge of the variables involved in its occurrence is still limited;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884974"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "BACKGROUND: Delirium is a frequent complication after cardiac surgery and its occurrence is associated with poor o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery in older adult patients. However, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29390969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery that leads to increased costs and worse ou",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Background: Delirium is a frequent and serious complication following cardiac surgery involving cardiopulmonary bypass (CPB). Electroenc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36147691"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 137,
          "text": "Post-operative delirium (POD) is a relatively common occurrence following surgical procedures, particularly cardiac surgeries",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39707458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Background: Delirium is a frequent complication after cardiac surgery and is associated with a higher incidence of morbidity and mortality and a prolonged hospital stay.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884974"
        },
        {
          "offsetInBeginSection": 1384,
          "offsetInEndSection": 1651,
          "text": "Delirium (OR 2.35, 1.20-4.58) and OIT ≥ 900 min (OR 2.50; 1.30-4.80) were independently associated with the composite outcome.CONCLUSIONS: In older adult patients submitted to cardiac surgery, delirium is a frequent complication that is associated with worst outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29390969"
        },
        {
          "offsetInBeginSection": 1425,
          "offsetInEndSection": 1658,
          "text": "Two variables were identified as having a significant protective effect against postoperative delirium: beating-heart surgery and younger patient age.CONCLUSIONS: Postoperative delirium is a common complication in cardiac operations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14752413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery in older adult patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29390969"
        },
        {
          "offsetInBeginSection": 1208,
          "offsetInEndSection": 1342,
          "text": "(4) Conclusions: Postoperative delirium remains a frequent complication after cardiac surgery, while stroke and seizures occur rarely.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36354764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery that leads to increased costs and worse outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 168,
          "text": " Delirium is a frequent complication after cardiac surgery and is associated with a higher incidence of morbidity and mortality and a prolonged hospital stay",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33884974"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 116,
          "text": " Delirium is a common complication after cardiac surgery that leads to increased costs and worse outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Postoperative delirium is a common medical complication following cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22978835"
        },
        {
          "offsetInBeginSection": 816,
          "offsetInEndSection": 928,
          "text": "Findings of the systematic review shows that about one third of patients become delirious after cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158535"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Post-operative delirium is a common and dangerous complication of cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659704"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 71,
          "text": " Delirium is a frequent complication after cardiac surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25189637"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 137,
          "text": "Delirium is a common psychiatric disorder after cardiac surgery and predisposes patients to increased mortality and morbidity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28561177"
        },
        {
          "offsetInBeginSection": 1225,
          "offsetInEndSection": 1342,
          "text": "Postoperative delirium remains a frequent complication after cardiac surgery, while stroke and seizures occur rarely.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36354764"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 281,
          "text": "Two of the most common post-operative complications are delirium and post-operative cognitive decline, which occur frequently after cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37867328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "OBJECTIVE: Postoperative delirium (POD) is a common complication after cardiac surgery and is associated with increased patient morbidity and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28711314"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "BACKGROUND: Postoperative delirium (POD) is one of the important complications of cardiac surgery and it is assumed to provoke inflammator",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22783469"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Background: Postoperative delirium (POD) is a significant complication observed in cardiac surgery patients, characterized by acute cognitive decline, fluctuating mental status, consciousness impairment, an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38028495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Background: Patients undergoing cardiothoracic surgery frequently encounter perioperative neurocognitive disorders (PND), which can include postoperative delirium (POD) and postoperative cognitive dec",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39076572"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 147,
          "text": "Acute postoperative delirium is the most common neuropsychiatric disorder in cardiac surgery patients in the intensive care unit (ICU).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36143313"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Delirium is a frequent and serious complication after cardiac surgery with cerebral hypoperfusion as one from the key pathophysiological mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31482364"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 473,
          "text": "Delirium has been widely documented and studied in general intensive care units and in patients after cardiac surgery, but it has barely been studied in acute nonsurgical cardiac patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33253676"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery that leads to increased costs and wo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Background: Delirium is a frequent and serious complication following cardiac surgery involving cardiopulmonary",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36147691"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "BACKGROUND: Delirium is a recognized complication of cardiac surgery and is the focus of increasing attention owing to its negative effect on postoperat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28743102"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "OBJECTIVE: Postoperative delirium (POD) is a common postoperative complication in elderly patients, especially those undergoing cardiac surgery, which seriously affects the short- and long-term prognosis ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38134752"
        },
        {
          "offsetInBeginSection": 680,
          "offsetInEndSection": 929,
          "text": "reof 31% of high quality. The weighted pooled incidence of delirium following open cardiac surgery across all studies was 23% (95% CI 20-26%), however we found a considerable heterogeneity (I2 \u003d 99%), which could not be explained by subgroups or fur",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38695330"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "BACKGROUND: Delirium is a common neurologic complication after cardiac surgery, and may be associated with increased morbidity a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200370"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Postoperative delirium is a common medical complication following cardiac surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22978835"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "OBJECTIVE: Postoperative delirium (POD), especially after cardiac surgery with cardiopulmonary bypass (CPB), is a relatively common and severe complication increasing side effects, length of hospital stay, mortality and healthcare reso",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39179251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "BACKGROUND: Delirium, marked by acute cognitive decline, poses a life-threatening issue among older individuals, especially after cardiac surgery, with prevalence ranging fro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39192373"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 268,
          "text": "cardiovascular surgery. Fifteen to 23% of patients undergoing cardiovascular surgery and cardiomyopathy experience delirium, and the efficacy of treatment interventions for delirium has been cons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39320056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "BACKGROUND: Delirium is a common complication after cardiac surgery that leads to increased costs and wor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32222959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "INTRODUCTION: Postoperative delirium (POD) is a common complication of cardiac surgery associated with increased mortality, morbidity, and long-term cognitiv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30863073"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 306,
          "text": "an develop. Patients who undergo cardiac surgery have an increased risk of developing delirium that is associated with many negative c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870463"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "BACKGROUND: Cardiac surgical procedures are associated with postoperative neurological complications such as cognitive decline and delirium, which can complicate recovery and impair qual",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "OBJECTIVES: Delirium is a common complication in elderly patients after cardiac surgery and is associated with adverse outcomes including prolonged hospital stay and increase",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22345177"
        },
        {
          "offsetInBeginSection": 2381,
          "offsetInEndSection": 2473,
          "text": "Postoperative delirium is a prevalent complication among patients undergoing cardiac surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39398592"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 95,
          "text": "Delirium is one of the most common neurological complications after cardiac surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39581994"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 128,
          "text": "Delirium is one of the most common and serious complications after cardiac surgery with cardiopulmonary bypass (CPB)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39654028"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "IMPORTANCE: Postoperative delirium is a common and impactful neuropsychiatric complication in patients undergoing coronary artery bypass graft",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38652478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "OBJECTIVES: Delirium is a common post-cardiac surgery complication that presents as acute changes in mental abilities with confused thinking and a lack of awareness of the s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38943716"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "PURPOSE: Delirium is a common neurologic complication after cardiac surgery and is associated with a poor p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34548175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Background: Delirium is a recognized neurological complication following cardiac surgery and is associated with adverse clinical outcomes, including elevated mortality and prolonged hosp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38472124"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "OBJECTIVE: Postoperative delirium after cardiac surgery is associated with many consequences such as poorer functional recovery, more frequent postoperative complications, higher mortality, increased length of hospital stay, and higher hosp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977818"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "BACKGROUND: Postoperative delirium (POD) is a common complication after cardiac surgery (CS), with symptoms like attention disorders and even delays patient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36404271"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "OBJECTIVE: Delirium after cardiac surgery is a serious complication that results in higher morbidity and mortality rates, and prolongs hospi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20624517"
        },
        {
          "offsetInBeginSection": 1474,
          "offsetInEndSection": 1701,
          "text": ", 0.56; 95% CI: 0.38-0.83).CONCLUSION: In valvular open-heart surgery, postoperative delirium is a frequent neurological complication that is associated with other postoperative neurological complications and several, mostly no",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35042244"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "OBJECTIVE: Delirium is common after cardiac surgery, although under-recognized, and its long-term consequences are likely unde",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20373345"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 121,
          "text": " Delirium is a frequent complication after cardiac surgery and its occurrence is associated with poor outcomes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182690"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 62,
          "text": " Delirium is a common outcome after cardiac surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19118253"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "BACKGROUND: Delirium is a frequent complication after cardiac surgery and its occurrence is associated with po",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Background: Delirium is a frequent and serious complication following cardiac surgery involving cardiopulmonary b",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36147691"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Postoperative delirium (POD) remains a frequent complication after cardiac surgery, with pre-operative cognitive status being one of the main predispos",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37551153"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Delirium occurs commonly following major non-cardiac and cardiac surgery and is associated with: postoperative mortality; postoperative neurocognitive dysfunction; increased length of hospital stay; and major postoperative complications and morbidity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33960404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "STUDY OBJECTIVE: Postoperative delirium occurs in 20-50% of elderly patients undergoing cardiac surgery and increases morbid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31668468"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "OBJECTIVE: Postoperative delirium (POD), especially after cardiac surgery with cardiopulmonary bypass (CPB), is a relatively common and severe complication increasing side effects, length of hospital stay, mortality and healthcare res",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39179251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "BACKGROUND: Postoperative cognitive deficits frequently occur in patients undergoing cardiac surgery, leaving them with reduced cognitive function. Cognitive training has been shown to improve cognitive function, however, the role in patients after cardiac surgery is unclear. In this study, we aimed",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39495993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "OBJECTIVE: We examined cases in which delirium developed after thoracic surgery under general anesthesia at our hospital to determine the predictive factors for postoperative delirium, as well as the perioperative findings in cases showing postoperative delirium.METHODS: This retrospective study inc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38512455"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "BACKGROUND AND OBJECTIVES: Postoperative delirium is a frequent and severe complication after cardiac surgery. Activity of butyrylcholinesterase (BChE) has been discussed controversially regarding a possible role in its development. This study aimed to investigate the relevance of BChE activity as a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38424490"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "OBJECTIVES: Delirium is a serious complication of cardiac surgery and a common clin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38829438"
        },
        {
          "offsetInBeginSection": 1208,
          "offsetInEndSection": 1341,
          "text": "(4) Conclusions: Postoperative delirium remains a frequent complication after cardiac surgery, while stroke and seizures occur rarely",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36354764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Background: Delirium is a frequent and serious complication following cardiac surgery involving cardiopulmonary ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36147691"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Delirium is a frequent and serious complication after cardiac surgery with cerebral hypoperfusion as one from the key pathophysiological mechanisms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31482364"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "BACKGROUND: Delirium is a frequent complication after cardiac surgery and its occurrence is associated with p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182690"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 255,
          "text": "Data on 90 patients with postoperative delirium after cardiac surgery on cardiopulmonary bypass (CPB) were analyzed retrospectively",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170877"
        }
      ],
      "type": "yesno",
      "id": "67f857eb18b1e36f2e000105",
      "ideal_answer": [
        "Delirium is a common disorder for patients after cardiac surgery..",
        "Yes, delirium is a frequent and serious complication after cardiac surgery.",
        "Yes, delirium is a frequent complication after cardiac surgery.",
        "Yes, postoperative delirium affects between 10% and 30% of patients who undergo cardiopulmonary bypass.",
        "Delirium is indeed a frequent complication after cardiac surgery, as evidenced by the multiple snippets provided. It is associated with a higher incidence of morbidity and mortality, prolonged hospital stay, and can have serious side effects. The development of delirium is often acute and shows reversibility, making it an important neuropsychological complication to consider in cardiac surgery patients.",
        "Yes,postoperative delirium is a common complication in all surgical patients, but it occurs most frequently in elderly people. Yes, delirium is a frequent complication after cardiac surgery. The incidence of postoperative delirium ranges from 10% to 30%, with an increased risk for older adults and those with cognitive impairment or dementia.",
        "Yes, delirium is a frequent complication after cardiac surgery. It is known as postoperative delirium and is prevalent among patients who undergo cardiac surgical procedures.",
        "Yes, delirium is a common complication following cardiac surgery. It frequently occurs in patients after surgery and is linked to increased morbidity, longer hospital stays, and higher healthcare costs. The risk of developing delirium can be heightened by factors such as advanced age, pre-existing cognitive impairment, and the complexity of the surgical procedure.",
        "Yes, delirium and postoperative delirium (POD) are common neurocognitive complications after cardiac surgery. They are frequently observed and associated with increased morbidity and mortality.",
        "Yes, delirium is a frequent complication after cardiac surgery and is associated with higher morbidity, mortality, and prolonged hospital stays.",
        "Yes. Delirium is a common and frequent complication after cardiac surgery, with reported incidences varying significantly among studies.",
        "Yes, delirium is a frequent complication after cardiac surgery. Reported incidence rates range from 15% to 80%, with studies specifically citing 15–23%, 26–52%, and up to 65% in older patients. It is associated with prolonged hospitalization, increased mortality, and higher healthcare costs, particularly following procedures involving cardiopulmonary bypass (CPB).",
        "Delirium is a frequent postoperative complication of cardiac surgery, occurring in roughly 4% to 55% of patients, with most large studies reporting rates near 24%. It is especially common in elderly patients and those undergoing cardiopulmonary bypass.",
        "Yes, postoperative delirium is a common complication after cardiac surgery.",
        "Yes, delirium is a frequent complication after cardiac surgery. Reported incidence rates range from 12.97% to 52%, with studies showing pooled rates of ~23% in open cardiac surgery and specific cohorts reaching 25-32.5%. It is consistently described as a common, serious neurological complication associated with adverse outcomes, including increased mortality and prolonged hospitalization.",
        "Yes, delirium is a common complication after cardiac surgery. It is often cited as the most common neurological or neuropsychiatric complication in this context. Delirium can lead to increased costs, worse outcomes, morbidity, and mortality. It is also noteworthy that delirium is often under-recognized following cardiac surgery.",
        "Delirium is a frequent complication after cardiac surgery. According to the provided document, it occurs frequently after cardiac surgery, along with post-operative cognitive decline.",
        "Yes, delirium is one of the most common neurological complications after cardiac surgery.",
        "Yes. Delirium is a frequent event after cardiac surgery, as indicated by the studies reviewed that report its occurrence in various patient populations undergoing such procedures.",
        "Yes. Delirium is a frequent complication after cardiac surgery, contributing to increased risk of postoperative complications and longer hospital stays.",
        "Yes, delirium is a frequent complication after cardiac surgery and is associated with poor outcomes, including higher morbidity and mortality, and prolonged hospital stays.",
        "Delirium is a potential complication that can occur after cardiac surgery, as indicated by the relation between patients, cardiac surgery, and Postoperative delirium. The presence of \u0027Delirium\u0027 and \u0027delirium\u0027 in the entities also supports this. However, it\u0027s important to note that the frequency of this complication can vary among patients.",
        "Yes. Delirium is a frequent complication after cardiac surgery, with reported incidences ranging from 11.3% to 51.6%.",
        "Delirium is a frequent complication after cardiac surgery, with reported incidence rates ranging from 5.4% to 41.7%.",
        "Yes. Delirium is a frequent complication after cardiac surgery, with reported incidences varying from 11.3% to 51.6%.",
        "Postoperative delirium is common in cardiac surgery and surgery in general.",
        "Yes, delirium is a frequent complication after cardiac surgery. It is known as postoperative delirium and is prevalent among patients undergoing such procedures. This condition can affect recovery and overall outcomes, making it an important aspect to monitor and manage in cardiac surgery patients.",
        "Postoperative delirium (POD), a common complication particularly in elderly patients",
        "Yes, delirium is a frequent complication after cardiac surgery and is associated with higher morbidity, longer hospital stay, risk of cognitive decline, dementia, and mortality.",
        "Delirium is indeed a frequent complication following cardiac surgery. Studies consistently report varying incidence rates, ranging from approximately 14% to nearly 40%. Despite the variation in percentages, each study underscores that delirium occurs regularly after such procedures, making it a significant concern in postoperative care.",
        "Delirium is a frequent complication after cardiac surgery, associated with higher morbidity, mortality, and prolonged hospital stay.",
        "Yes, delirium is indeed a frequent complication after cardiac surgery, with reported incidence rates ranging from 10% to 34.1% across different studies, depending on the patient population and other factors.",
        "Yes, delirium is a frequent complication after cardiac surgery and is associated with increased morbidity, mortality, and prolonged hospital stays.",
        "Yes. Postoperative delirium is described as a prevalent complication in patients who undergo cardiac surgery, indicating it occurs frequently in this population.",
        "Delirium is indeed a common complication observed in patients after cardiac surgery, as evidenced by the snippet stating \"Delirium is a common disorder for patients after cardiac surgery.\" This complication is particularly frequent after transcatheter aortic valve implantation (TAVI) in older adults, as indicated in the second snippet.",
        "Yes, delirium is indeed a frequent complication after cardiac surgery. It refers to a state of confusion or altered mental status that can occur post surgery due to the stress of the procedure, medications, and other factors.",
        "Delirium is a common complication after cardiac surgery, particularly in older adults, and is associated with several negative outcomes, including higher mortality rates. The details of its occurrence and impact are significant in the context of postoperative care.",
        "Yes, delirium is a very common complication after cardiac surgery and procedures.",
        "Yes, delirium is a frequent complication after cardiac surgery, particularly in older adults.",
        "Yes, delirium is a common and frequently observed complication after cardiac surgery. It is associated with increased morbidity, mortality, prolonged hospital stays, and poor prognosis.",
        "Yes, delirium is frequently reported after cardiac surgery. It is a common post-operative complication as reflected in the provided snippets.",
        "Yes. Delirium is a common and frequent complication after cardiac surgery, associated with multiple negative outcomes.",
        "Yes, delirium is a frequent complication following cardiac surgery. It is commonly observed in patients post-surgery. Specifically, after procedures such as transcatheter aortic valve implantation (TAVI), delirium is notably frequent in older adults and significantly affects outcomes, including increasing the risk of mortality.",
        "Yes, delirium is a common complication after cardiac surgery. Postoperative delirium (POD) is particularly frequent in older adults undergoing procedures like transcatheter aortic valve implantation (TAVI) and is associated with adverse outcomes, including increased mortality.",
        "Yes, postoperative delirium after transcatheter aortic valve implantation (TAVI) is frequent in older adults and associated with multiple negative outcomes including a higher mortality.",
        "iac surgery delirium when the details matter ostoperative delirium pod after transcatheter aortic valve implantation tavi is frequent in",
        "Delirium is a common complication of cardiac surgery, occurring in 4% to 55% of patients (about 25% on average), and is associated with longer mechanical ventilation, increased morbidity, prolonged hospital stays, and worse short- and long-term outcomes.",
        "Yes, delirium is a frequent complication after cardiac surgery, as referenced by snippet0 which states, \u0027Delirium is a common disorder for patients after cardiac surgery.\u0027 Additionally, snippet2 notes that postoperative delirium is frequent in older adults undergoing TAVI.",
        "Yes, delirium is a common complication after cardiac surgery.",
        "[\u0027Yes, delirium is a frequent complication after cardiac surgery, particularly in older adults undergoing transcatheter aortic valve implantation (TAVI).\u0027]",
        "Yes, delirium is a frequent complication after cardiac surgery. It is one of the most common neurological complications following cardiac surgery and can lead to increased costs and worse outcomes. Postoperative delirium is also frequent after procedures like transcatheter aortic valve implantation, particularly in older adults, and is associated with negative outcomes including higher mortality.",
        "Yes, delirium is a common disorder for patients after cardiac surgery.",
        "Yes, delirium is a frequent complication after cardiac surgery, particularly in older adults undergoing procedures like transcatheter aortic valve implantation (TAVI), and is associated with negative outcomes such as increased mortality.",
        "Yes. Delirium is a common disorder for patients after cardiac surgery, as indicated in the study discussing its manifestation and care.",
        " Yes, delirium is a frequent complication after cardiac surgery, especially in older adults.",
        "Delirium is a common complication following cardiac surgery, particularly in older adults undergoing procedures like transcatheter aortic valve implantation (TAVI). This postoperative delirium (POD) is associated with multiple negative outcomes, including higher mortality rates.",
        "Yes, delirium is a frequent complication following cardiac surgery, particularly among older adults, and is associated with negative outcomes such as increased mortality.",
        "Yes, delirium is a frequent complication after cardiac surgery. This is evident from the provided context, which states that delirium is a common disorder for patients after cardiac surgery. The post-operative delirium (POD) after transcatheter aortic valve implantation (TAVI) in older adults is indeed frequent and associated with multiple negative outcomes, including a higher mortality.",
        "Yes. Delirium is a common and impactful neuropsychiatric complication in patients undergoing cardiac surgery, occurring frequently after such procedures.",
        "Delirium may or may not be a frequent complication after cardiac surgery, as it depends on various factors such as patient\u0027s health condition, type of surgery, and post-operative care. However, the provided entities do not directly indicate that delirium is a frequent complication after aortic valve surgery.",
        "Yes. Delirium is a prevalent and devastating complication following cardiac surgery, and it is frequently observed in patients after such procedures.",
        "Delirium is a common problem after cardiac surgery",
        "Yes, available evidence suggests that is delirium a frequent complication after cardiac surgery.",
        "Yes. Delirium is a prevalent and devastating complication following cardiac surgery, with a high incidence reported in various studies.",
        "Delirium is a common condition experienced by patients following cardiac surgery, indicating that it occurs frequently in such cases.",
        "Delirium is a common disorder for patients after cardiac surgery.",
        "Yes, delirium is a common disorder for patients after cardiac surgery and is frequent in older adults after transcatheter aortic valve implantation (TAVI).",
        "[\u0027Yes, delirium is a frequent complication after cardiac surgery.\u0027]",
        "Yes, delirium is a common complication after cardiac surgery. According to the provided texts, delirium is frequent in patients after cardiac surgery, including those who undergo transcatheter aortic valve implantation (TAVI). It is associated with negative outcomes, such as higher mortality rates.",
        "ostoperative delirium (POD) after transcatheter aortic valve implantation (TAVI) is frequent in older adults and associated with multiple negative outcomes including a higher mortality . Delirium is a common disorder for patients after cardiac surgery",
        "Delirium is a frequent complication following cardiac surgery, particularly affecting older adults and those undergoing specific procedures like TAVI, with possible underdocumentation suggesting actual incidence rates may be even higher than reported.",
        "Delirium is one of the most common complications after cardiac surgery, affecting up to half of elderly patients. It manifests as an acute disturbance of attention and consciousness and is associated with increased morbidity, mortality, prolonged hospitalization, postoperative neurocognitive dysfunction, and higher healthcare costs.",
        "Delirium is a frequent complication after cardiac surgery, particularly in older adults, and is associated with negative outcomes such as increased mortality. It commonly occurs postoperatively, including after procedures like transcatheter aortic valve implantation (TAVI)."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Phobias affecting humans.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38244333",
        "http://www.ncbi.nlm.nih.gov/pubmed/38381476",
        "http://www.ncbi.nlm.nih.gov/pubmed/38362941",
        "http://www.ncbi.nlm.nih.gov/pubmed/38998536",
        "http://www.ncbi.nlm.nih.gov/pubmed/38440241",
        "http://www.ncbi.nlm.nih.gov/pubmed/39499721",
        "http://www.ncbi.nlm.nih.gov/pubmed/9511263",
        "http://www.ncbi.nlm.nih.gov/pubmed/9531762",
        "http://www.ncbi.nlm.nih.gov/pubmed/19935488",
        "http://www.ncbi.nlm.nih.gov/pubmed/23214219",
        "http://www.ncbi.nlm.nih.gov/pubmed/8561762",
        "http://www.ncbi.nlm.nih.gov/pubmed/1231533",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740961",
        "http://www.ncbi.nlm.nih.gov/pubmed/31183857",
        "http://www.ncbi.nlm.nih.gov/pubmed/9851572",
        "http://www.ncbi.nlm.nih.gov/pubmed/9851576",
        "http://www.ncbi.nlm.nih.gov/pubmed/12296488",
        "http://www.ncbi.nlm.nih.gov/pubmed/21238507",
        "http://www.ncbi.nlm.nih.gov/pubmed/34782659",
        "http://www.ncbi.nlm.nih.gov/pubmed/20821801",
        "http://www.ncbi.nlm.nih.gov/pubmed/7891414",
        "http://www.ncbi.nlm.nih.gov/pubmed/9362674",
        "http://www.ncbi.nlm.nih.gov/pubmed/8372693",
        "http://www.ncbi.nlm.nih.gov/pubmed/26017849",
        "http://www.ncbi.nlm.nih.gov/pubmed/22113407",
        "http://www.ncbi.nlm.nih.gov/pubmed/19701958",
        "http://www.ncbi.nlm.nih.gov/pubmed/16894439",
        "http://www.ncbi.nlm.nih.gov/pubmed/14767397",
        "http://www.ncbi.nlm.nih.gov/pubmed/18438303"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 83,
          "text": "acrophobia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38244333"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 51,
          "text": "Dental phobia (DP) and injection phobia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38381476"
        },
        {
          "offsetInBeginSection": 789,
          "offsetInEndSection": 800,
          "text": "trypophobia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38362941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 14,
          "text": "Food neophobia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38998536"
        },
        {
          "offsetInBeginSection": 71,
          "offsetInEndSection": 84,
          "text": "spider phobia",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38440241"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 258,
          "text": "snake phobia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39499721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 440,
          "text": "Social phobia is a very frequent mental disorder affecting in some stage of life up to 13% of the population, and it may be associated with serious health complications (frequent comorbidity with affective and other anxiety disorders, with addictions, more frequent suicidal behaviour) and socioeconomic consequences (increased health care consumption, trend of lower education, poorer adaptation to work, higher demands on social support).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9511263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Social phobia is an anxiety disorder which can be found in general and specific subtype in general population from 2.4 to 16%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9531762"
        },
        {
          "offsetInBeginSection": 67,
          "offsetInEndSection": 192,
          "text": "About 4.5% of the adult general populations suffer from social phobia, i.e. it is the most frequent of all anxiety disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19935488"
        },
        {
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1192,
          "text": "point prevalence of any specific phobia was 19.9% (26.5% for females and 12.4% for males). In total, 21.2% women and 10.9% men met criterias for any single specific phobia. Multiple phobias was reported by 5.4% of the females and 1.5% of the males. Animal phobia had a prevalence of 12.1% in women and 3.3% in men",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8561762"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 461,
          "text": "It was found that about 10 percent of the total patients visited in the hospital were suffering from phobia. Moreover, darkness, corpse, crowd, pet animals, fear from cancer and syphilis accounted for 79% of the most common phobias, among the 655 recorded cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1231533"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Animal phobias are one of the most prevalent mental disorders. We analysed how fear and disgust, two emotions involved in their onset and maintenance, are elicited by common phobic animals. In an online survey, the subjects rated 25 animal images acc",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31183857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Social phobia is characterized by a fear of social situations, which are either avoided or endured with intense anxiety or distress. There is a high prevalence of social phobia in the community and the course of the condition tends to be chronic. In ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9851572"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Social phobia is an extreme fear of being scrutinized by others in social situations that often culminates in avoidance of those situations. Studies have demonstrated marked educational, occupational and social disabilities in patients with social ph",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9851576"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Individuals with small animal and blood-injection-injury (BII) phobias respond to phobia-relevant stimuli with both fear and disgust. However, recent studies suggest that fear is the dominant emotional response in animal phobics whereas disgust is th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12296488"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "OBJECTIVES: Dental phobia is currently classified as a specific phobia of the blood-injection-injury (BII) subtype. In another subtype, animal phobia, enhanced amplitudes of late event-related potentials have consistently been identified for patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21238507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "BACKGROUND: Acrophobia is one of the most prevalent phobias, affecting as many as 1 in 20 individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20821801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Spiders are mostly harmless, yet they often trigger high levels of both fear and disgust, and arachnophobia (the phobia of spiders) ranks among the most common specific animal phobias.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34782659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "Anthropophobia is the general term often taken as an equivalent to social phobia which comprises the several afflictions known in Europe under names like autodysosmophobia, scopophobia, erythrophobia, and olfactory reference syndrome, among others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7891414"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Entomophobia, acarophobia, parasitic dermatophobia or delusional parasitosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Mrs. Brown, a 65-year-old woman, was terrified of being alone at night and suffered from nyctophobia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9362674"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 1050,
          "text": "The most common anxiety disorder was generalized anxiety, which had a prevalence of 22% and was more common among women. Simple phobia was the most common of the phobic disorders (8.8%), followed by agoraphobia without panic (3.8%), and social phobia (3.5%). The female-male ratio for anxiety disorders was 2:1. Of those with simple phobia, the most common items were a fear of heights (41%); claustrophobia (34%); being on public transportation (31%); the fear of being in crowds and speaking in front of others (28%); of being alone (24%); of insects (22%); of bad weather (21%); and of being in water (aquaphobia) (20%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8372693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "BACKGROUND: Acrophobia is one of the most prevalent phobias, affecting as many as 1 in 20",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20821801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "BACKGROUND: Emetophobia (fear of vomiting) is an anxiety disorder in which individuals report clinical levels of fear that they may vomit or be exposed to the vom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26017849"
        },
        {
          "offsetInBeginSection": 1243,
          "offsetInEndSection": 1332,
          "text": " biological and psychological factors. Kinesiophobia negatively affects patients\u0027 functio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Dental phobia is a widespread problem, which can have significant impact on the individual\u0027s health and daily life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22113407"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 320,
          "text": "Increasing evidence suggests that blood phobia is qualitatively different from other specific phobias",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19701958"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Belonephobia is an unreasonable and altered response due to the fear of needles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16894439"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 446,
          "text": "Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14767397"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Social phobia is an anxiety disorder that is characterized by excessive fear and/or avoidance of situations in which an individual believes that he or she may be the subject of evaluation or scrutiny while interacting with other people or performing a specific task",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18438303"
        }
      ],
      "id": "67e291a718b1e36f2e000081",
      "ideal_answer": [
        "Some phobias encountered in the clinic are: acrophobia, snake, spider, injection, dental phobias, trypophobia and food neophobia.",
        "The most common phobias affecting humans are:\n1) arachnophobia (fear of spiders)\n2) ophidiophobia (fear of snakes)\n3) claustrophobia (fear of enclosed spaces)\n4) acrophobia (fear of heights)\n5) agoraphobia (fear of open or crowded spaces)\n6) social phobia (fear of social situations)\n7) dental phobia (fear of dental procedures)\n8) injection phobia (fear of injections)\n9) fear of flying\n10) fear of public speaking",
        "Phobias are intense fears of specific objects or situations that cause significant distress. Here are some common phobias affecting humans: 1. Acrophobia : The fear of heights, often causing anxiety in high places. 2. Dental Phobia (DP) : Anxiety related to dental procedures, making visits to the dentist challenging. 3. Injection Phobia : Fear associated with receiving injections or needles. 4. Trypophobia : Discomfort or fear triggered by clusters of small holes or repetitive patterns. 5. Food Neophobia : The anxiety about trying new foods, differing from pickiness as it\u0027s a specific aversion to unfamiliar edibles. 6. Spider Phobia : Fear of spiders, often due to perceived threats they may pose. 7. Snake Phobia : Anxiety related to snakes, similarly stemming from real or perceived dangers. Each phobia can significantly impact daily life and may require tailored management strategies."
      ],
      "exact_answer": [
        [
          "acrophobia"
        ],
        [
          "snake phobia"
        ],
        [
          "food neophobia"
        ],
        [
          "dental phobia"
        ],
        [
          "injection phobia"
        ],
        [
          "aracnophobia"
        ],
        [
          "trypophobia"
        ],
        [
          "social phobia"
        ]
      ]
    },
    {
      "body": "How can convolutional neural networks (CNNs) be utilized in radiomics?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35381490",
        "http://www.ncbi.nlm.nih.gov/pubmed/37338554",
        "http://www.ncbi.nlm.nih.gov/pubmed/29993591",
        "http://www.ncbi.nlm.nih.gov/pubmed/36468301",
        "http://www.ncbi.nlm.nih.gov/pubmed/37711738",
        "http://www.ncbi.nlm.nih.gov/pubmed/30809047",
        "http://www.ncbi.nlm.nih.gov/pubmed/32143788",
        "http://www.ncbi.nlm.nih.gov/pubmed/27610399",
        "http://www.ncbi.nlm.nih.gov/pubmed/39560820",
        "http://www.ncbi.nlm.nih.gov/pubmed/34537858",
        "http://www.ncbi.nlm.nih.gov/pubmed/39154039",
        "http://www.ncbi.nlm.nih.gov/pubmed/30440295",
        "http://www.ncbi.nlm.nih.gov/pubmed/30957936",
        "http://www.ncbi.nlm.nih.gov/pubmed/39351352",
        "http://www.ncbi.nlm.nih.gov/pubmed/33509366",
        "http://www.ncbi.nlm.nih.gov/pubmed/33927099",
        "http://www.ncbi.nlm.nih.gov/pubmed/33322559",
        "http://www.ncbi.nlm.nih.gov/pubmed/29395798",
        "http://www.ncbi.nlm.nih.gov/pubmed/39736796",
        "http://www.ncbi.nlm.nih.gov/pubmed/31734535",
        "http://www.ncbi.nlm.nih.gov/pubmed/33303522",
        "http://www.ncbi.nlm.nih.gov/pubmed/30422086",
        "http://www.ncbi.nlm.nih.gov/pubmed/30383900",
        "http://www.ncbi.nlm.nih.gov/pubmed/33006658"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 26,
          "offsetInEndSection": 483,
          "text": "Radiomics and deep learning have emerged as two distinct approaches to medical image analysis. However, their relative expressive power remains largely unknown. Theoretically, hand-crafted radiomic features represent a mere subset of features that neural networks can approximate, thus making deep learning a more powerful approach. On the other hand, automated learning of hand-crafted features may require a prohibitively large number of training samples.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381490"
        },
        {
          "offsetInBeginSection": 1563,
          "offsetInEndSection": 1937,
          "text": "Our findings imply that CNNs trained to perform various image-based clinical tasks may generally under-utilize the shape and texture information that is more easily captured by radiomics. We speculate that to improve the CNN performance, shape and texture features can be computed explicitly and added as auxiliary variables to the networks, or supplied as synthetic inputs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381490"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 159,
          "text": "To use convolutional neural network for fully automated segmentation and radiomics features extraction of hypopharyngeal cancer (HPC) tumor in MRI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37338554"
        },
        {
          "offsetInBeginSection": 660,
          "offsetInEndSection": 792,
          "text": "The predicted tumor volumes by DeepLab V3 + model and U-Net model were highly correlated with those delineated manually (p \u003c 0.001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37338554"
        },
        {
          "offsetInBeginSection": 980,
          "offsetInEndSection": 1112,
          "text": "For radiomics extraction of the first-order features, both models exhibited high agreement (ICC: 0.71-0.91) with manual delineation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37338554"
        },
        {
          "offsetInBeginSection": 1851,
          "offsetInEndSection": 1989,
          "text": "DeepLab V3 + and U-Net models produced reasonable results in automated segmentation and radiomic features extraction of HPC on MR images. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37338554"
        },
        {
          "offsetInBeginSection": 2096,
          "offsetInEndSection": 2216,
          "text": "DeepLab V3 + exhibited higher agreement for about half of the first-order and shape-based radiomics features than U-Net.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37338554"
        },
        {
          "offsetInBeginSection": 1077,
          "offsetInEndSection": 1259,
          "text": "Features quantifying size and intensity were predicted with high accuracy, while shape irregularity and heterogeneity features had very high prediction errors and generalized poorly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381490"
        },
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 636,
          "text": "Deeper layers of a convolutional neural network produce more abstract radiomic features that are referred to as deep radiomics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36468301"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 316,
          "text": "We herein describe the typical radiomics steps and the components of a CNN for both deep feature extraction and end-to-end approaches",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560820"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 365,
          "text": "We hypothesize that convolutional neural networks (CNNs) could enhance the performance of traditional radiomics, by detecting image patterns that may not be covered by a traditional radiomic framework.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30809047"
        },
        {
          "offsetInBeginSection": 310,
          "offsetInEndSection": 481,
          "text": "Deep learning radiomics allows for a simpler workflow where images can be used directly as input to a convolutional neural network (CNN) with or without a pre-defined ROI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37711738"
        },
        {
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1368,
          "text": "An extension of this conventional radiomics is the application of \"deep learning,\" wherein convolutional neural networks can be used to detect the most informative regions and features without human intervention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30383900"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 444,
          "text": "Radiomics analysis can be performed by extracting hand-crafted radiomics features or via deep learning algorithms. Radiomics has evolved tremendously in the last decade, becoming a bridge between imaging and precision medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34309893"
        },
        {
          "offsetInBeginSection": 1609,
          "offsetInEndSection": 1865,
          "text": "It also provides a comprehensive understanding of their applicability and limitations in radiomics. Our study shows, in conclusion, that models based on features extracted from pretrained deep networks do not outperform models trained on hand-crafted ones.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37892087"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 331,
          "text": "Radiomics analysis can be performed by extracting hand-crafted radiomics features or via deep learning algorithms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34309893"
        },
        {
          "offsetInBeginSection": 1415,
          "offsetInEndSection": 1750,
          "text": "We additionally found that learning shape features required an order of magnitude more samples compared to intensity and size features.CONCLUSIONS: Our findings imply that CNNs trained to perform various image-based clinical tasks may generally under-utilize the shape and texture information that is more easily captured by radiomics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35381490"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 584,
          "text": "Recent studies have shown that radiomics-based models can achieve high sensitivity and specificity in predicting both entities. However, radiomic features can only capture low level representations of the input image. In contrast, convolutional neural networks (CNNs) can learn and extract more complex representations which have been used for image classification to great success",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33322559"
        },
        {
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1265,
          "text": "Finally, we combine these two types of features and we find that the radiomics features and CNN features are complementary to each other, which helps further improve the classification (diagnostic) performance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31734535"
        },
        {
          "offsetInBeginSection": 781,
          "offsetInEndSection": 1221,
          "text": "In this paper, we introduce and evaluate a hybrid structure that includes different features selected with radiomics model and CNNs and integrates these features to deal with GISTs classification. The Radiomics model and CNNs are constructed for global radiomics and local convolutional feature selection, respectively. Subsequently, we utilize distinct radiomics and deep convolutional features to perform pattern classification for GISTs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29993591"
        },
        {
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1367,
          "text": "An extension of this conventional radiomics is the application of \"deep learning,\" wherein convolutional neural networks can be used to detect the most informative regions and features without human intervention",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30383900"
        },
        {
          "offsetInBeginSection": 523,
          "offsetInEndSection": 885,
          "text": "In recent years, the deep convolutional neural networks (CNNs) enabled a sensible improvement in many visual tasks automation, such as image classification and object recognition. These advances also involved radiomics, enabling high-throughput extraction of quantitative features, resulting in a strong improvement in automatic diagnosis through medical imaging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32143788"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 483,
          "text": "The inputs may be radiomic features that have been extracted from the image files or, if using a convolutional neural network (CNN), may be the images themselves",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33509366"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 553,
          "text": "Radiomics models are built based on handcrafted features, and deep learning can learn the features automatically",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30440295"
        }
      ],
      "id": "680b7f4818b1e36f2e000154",
      "ideal_answer": [
        "Radiomics and deep learning have emerged as two distinct approaches to medical image analysis. However, their relative expressive power remains largely unknown. Theoretically, hand-crafted radiomic features represent a mere subset of features that neural networks can approximate, thus making deep learning a more powerful approach. On the other hand, automated learning of hand-crafted features may require a prohibitively large number of training samples. In addition, convolutional neural networks can be used to automatically perform image segmentation and radiomics feature extraction, making this approach more scalable and transferable across tasks. Current results have shown promising model performances, with features such as size, volume, and intensity being accurately captured, while shape irregularity and heterogeneity features can still be improved.",
        "CNNs can be used for fully automated segmentation and radiomics feature extraction. For example, models like DeepLab V3+ and U-Net have been applied to medical images to predict tumor volumes and extract first-order features with high accuracy compared to manual delineation. However, while they perform well with intensity and size measurements, they might under-utilize shape and texture information. To address this, explicit computation of these features as auxiliary inputs could further improve the performance of CNNs in radiomics.",
        "Convolutional neural networks (CNNs) can be utilized in radiomics for fully automated segmentation and extraction of radiomic features from medical images, such as MRI scans of tumors. CNNs are capable of generating deep features that complement hand-crafted radiomic features, enhancing the predictive power of models. For instance, CNNs can be trained to perform various clinical tasks, and by incorporating shape and texture features explicitly as auxiliary variables, their performance can be improved. Additionally, CNNs have shown high correlation with manual delineation in predicting tumor volumes and extracting first-order radiomic features. The integration of deep learning with radiomics allows for the extraction of predictive image-based phenotypes, which can be valuable for precision medicine and data mining in oncology.",
        "Convolutional neural networks (CNNs) are highly useful in radiomics, particularly for automating the segmentation and feature extraction from medical images, such as MRI scans of tumors. Models like DeepLab V3+ and U-Net have been successful in closely matching manual delineation in tumor volume predictions and in extracting first-order radiomic features with high accuracy. Additionally, CNNs can improve their performance by incorporating explicitly computed shape and texture features, which are typically captured by traditional radiomics. This integration allows CNNs to utilize both learned and hand-crafted features, enhancing their effectiveness in medical image analysis.",
        "Convolutional Neural Networks (CNNs) offer significant enhancements to radiomics through their ability to automate and optimize various stages of image analysis and feature extraction. Here’s how CNNs can be effectively utilized in radiomics:\n\n1. **Automated Image Segmentation**: CNNs excel at identifying regions of interest within medical images, such as tumors or specific anatomical structures. This automation reduces the need for manual segmentation, which is both time-consuming and prone to human error.\n\n2. **Feature Extraction**: Traditional radiomics relies on handcrafted features, but CNNs can automatically learn hierarchical and complex features directly from image data. These learned features may capture aspects of the images that are not easily quantifiable by conventional methods, potentially leading to more accurate predictive models.\n\n3. **End-to-End Learning**: By integrating CNNs into radiomic workflows, it is possible to create end-to-end learning systems where both feature extraction and prediction occur within a single model. This integration can improve performance by allowing the model to learn optimal features tailored specifically for the predictive task at hand.\n\n4. **Integration with Predictive Models**: CNNs can be seamlessly integrated into predictive models used in radiomics, enhancing their ability to make accurate predictions based on image data. This integration can lead to more robust and reliable outcomes compared to traditional methods.\n\n5. **Ensuring Feature Inclusivity**: While CNNs are powerful, it is important to ensure that crucial radiomic features, such as specific shape and texture details, are not overlooked. Explicit inclusion of these features or careful model design can help capture all relevant information.\n\nIn summary, CNNs enhance radiomics by automating tasks, learning sophisticated features, enabling end-to-end learning, and improving predictive models. However, attention must be paid to ensure that important radiomic features are adequately captured in the process.",
        "Convolutional neural networks (CNNs) can be utilized in radiomics for automated segmentation and extraction of radiomic features from medical images, such as MRI scans of tumors. In studies, CNN architectures like U-Net and DeepLab V3+ have been employed to predict standardized radiomic features, including size, intensity, shape, and texture properties of tumors. These models are trained on large datasets, allowing them to learn and predict tumor characteristics with varying degrees of accuracy. For instance, while CNNs can accurately predict features related to size and intensity, they may struggle with shape and texture features, which often require more training samples. Enhancing CNN performance in radiomics may involve explicitly computing shape and texture features and integrating them into the models as auxiliary inputs. Overall, CNNs hold significant potential for improving the efficiency and accuracy of radiomic analyses, thereby facilitating better treatment planning and outcome predictions in clinical settings.",
        "Convolutional Neural Networks (CNNs) are utilized in radiomics for automated tumor segmentation and extraction of radiomic features from medical images, with notable applications in MRI scans, such as in hypopharyngeal cancer. Models like DeepLab V3+ and U-Net show high correlation with manual delineation for tumor volume and first-order features. However, they face challenges in predicting shape irregularity and heterogeneity. Incorporating explicitly computed radiomic features into CNNs can enhance performance, suggesting a promising hybrid approach for improved accuracy in radiomics analysis, particularly for complex feature predictions.",
        "Convolutional neural networks (CNNs) can be used for automated segmentation and extraction of radiomic features from medical images, achieving high accuracy for size and intensity features. However, CNNs may under-utilize shape and texture information, suggesting that explicitly incorporating these features could further improve performance."
      ]
    },
    {
      "body": "Please summarize Graves disease",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39039206",
        "http://www.ncbi.nlm.nih.gov/pubmed/38910658",
        "http://www.ncbi.nlm.nih.gov/pubmed/38108994",
        "http://www.ncbi.nlm.nih.gov/pubmed/10483245",
        "http://www.ncbi.nlm.nih.gov/pubmed/24424182",
        "http://www.ncbi.nlm.nih.gov/pubmed/14523350",
        "http://www.ncbi.nlm.nih.gov/pubmed/18271657",
        "http://www.ncbi.nlm.nih.gov/pubmed/17044727",
        "http://www.ncbi.nlm.nih.gov/pubmed/29950539",
        "http://www.ncbi.nlm.nih.gov/pubmed/23613015",
        "http://www.ncbi.nlm.nih.gov/pubmed/36828713",
        "https://www.ncbi.nlm.nih.gov/pubmed/29950539",
        "http://www.ncbi.nlm.nih.gov/pubmed/37152963",
        "http://www.ncbi.nlm.nih.gov/pubmed/35462920",
        "http://www.ncbi.nlm.nih.gov/pubmed/26041458",
        "http://www.ncbi.nlm.nih.gov/pubmed/24126481",
        "http://www.ncbi.nlm.nih.gov/pubmed/1443362",
        "http://www.ncbi.nlm.nih.gov/pubmed/29729448",
        "http://www.ncbi.nlm.nih.gov/pubmed/7690495",
        "http://www.ncbi.nlm.nih.gov/pubmed/12615754",
        "http://www.ncbi.nlm.nih.gov/pubmed/39281039",
        "http://www.ncbi.nlm.nih.gov/pubmed/9489453",
        "http://www.ncbi.nlm.nih.gov/pubmed/30417713",
        "http://www.ncbi.nlm.nih.gov/pubmed/7545825",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880878",
        "http://www.ncbi.nlm.nih.gov/pubmed/10387329",
        "http://www.ncbi.nlm.nih.gov/pubmed/20100762",
        "http://www.ncbi.nlm.nih.gov/pubmed/17154081",
        "http://www.ncbi.nlm.nih.gov/pubmed/25777757",
        "http://www.ncbi.nlm.nih.gov/pubmed/10756799",
        "http://www.ncbi.nlm.nih.gov/pubmed/18214794"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Graves disease is the most common cause of hyperthyroidism in iodine-sufficient areas. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39039206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 390,
          "text": "Graves\u0027 disease (GD) is an autoimmune condition of the thyroid. The hyperthyroidism manifested by patients affected by this disease is caused by the production of autoantibodies against the thyroid-stimulating hormone (TSH, or thyrotropin) receptor (TSHR), which mimic the effects of the hormone on thyroid cells, thereby stimulating autonomic production of thyroxine and triiodothyronine. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38910658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "Graves\u0027 disease (GD) is the commonest cause of hyperthyroidism and has a strong female preponderance. Everyday clinical practice suggests strong aggregation within families and twin studies demonstrate that genetic factors account for 60-80% of risk of developing GD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38108994"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Graves\u0027 disease (GD) is an autoimmune thyroid disease. In addition to the etiology of hyperthyroidism, TSH receptor antibodies play an important role in the pathogenesis of pretibial myxedema, ophthalmopathy, and neonatal GD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10483245"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Graves\u0027 disease (GD) is an autoimmune disorder involving the thyroid gland, typically characterized by the presence of circulating autoantibodies that bind to and stimulate the thyroid hormone receptor (TSHR), resulting in hyperthyroidism and goiter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424182"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Graves disease is by far the most common cause of hyperthyroidism. Is an immunologic disorder and it is distinguished clinically from other forms of hyperthyroidism by the presence of diffuse thyroid enlargement, ophthalmopathy, and occasionally pretibial myxedema.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18271657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Graves\u0027 disease is an autoimmune disorder that is the most common cause of hyperthyroidism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17044727"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 652,
          "text": "Graves\u0027 disease is an autoimmune disorder which affect thyroid gland. Graves\u0027 disease is the most common cause of hyperthyroidism and thyrotoxicosis. Understanding of disease pathophysiology, diagnostic and treatment strategies, and prevention of disease relapse are important for all clinicians especially internal medicine specialist to give optimal and comprehensive management for Graves\u0027 disease patients. This article highlights clinical points to treat Grave\u0027s disease patients from reviews and latest guidelines from American Thyroid Association (ATA), European Thyroid Association (ETA), and Japan Thyroid Association/ Japan Endocrine Society.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/29950539"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Graves\u0027 disease (GD) is a systemic autoimmune disease that is characterized by hyperthyroidism, orbitopathy and in rare cases dermopathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613015"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Graves\u0027 disease (GD) is a heterogeneous autoimmune disease affecting with varying degrees of severity the thyroid gland, orbital tissues and skin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36828713"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Graves disease is by far the most common cause of hyperthyroidism. Is an immunologic disorder and it is distinguished clinically from other forms of hyperthyroidism by the presence of diffuse thyroid enlargement, ophthalmopathy, and occasionally pret",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18271657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Graves\u0027 disease is an autoimmune disorder in which autoantibodies to the thyroid-stimulating hormone receptor cause hyperthyroidism through unregulated stimulation of the thyroid-stimulating hormone receptor. Effective management of Graves\u0027 disease i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26041458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Graves\u0027 disease is an autoimmune disorder in which autoantibodies to the thyroid-stimulating hormone receptor cause hyperthyroidism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26041458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Graves disease is an autoimmune disorder characterized by goitre, hyperthyroidism and, in 25% of patients, Graves ophthalmopathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126481"
        },
        {
          "offsetInBeginSection": 70,
          "offsetInEndSection": 149,
          "text": "Graves\u0027 disease is the most common cause of hyperthyroidism and thyrotoxicosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29950539"
        },
        {
          "offsetInBeginSection": 61,
          "offsetInEndSection": 182,
          "text": "Circulating antibodies to the thyrotropin receptor stimulate thyroid hormone synthesis and hence lead to hyperthyroidism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7690495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Graves\u0027 disease is characterized by hyperthyroidism, diffuse goitre, ophthalmopathy and, rarely, dermopathy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615754"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 287,
          "text": "Graves\u0027 disease (GD), as an autoimmune thyroid disease (AITD), is attributed to the production of thyroid-stimulating hormone receptor (TSHR) autoantibodies that bind to the thyroid follicular endothelial cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39281039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Graves disease is an autoimmune disorder characterized by goitre, hyperthyroidism and, in 25% of patients, Graves ophthalmopathy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Graves\u0027 disease is an autoimmune thyroid disease characterized by a genetic predisposition, an increased incidence in young women, the presence of thyroid-stimulating immunoglobulins, and an uncertain etiology. The onset occasionally follows a fright",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1443362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "INTRODUCTION: Graves\u0027 disease (GD) is a disorder, in which auto-immunity against the thyroid- stimulating hormone (TSH) receptor is the pivotal pathogenetic element. This disease may have different clinical manifestations, the most common being thyro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30417713"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Graves\u0027 disease and toxic uni- or multinodular goiter are the most frequent causes of hyperthyroidism. Graves\u0027 disease is caused by thyroid stimulating immunoglobulins which are directed against the TSH receptor of thyroid follicular cells. Graves\u0027 d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7545825"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "text": "Graves\u0027 disease is an autoimmune disorder that is the most common cause of hyperthyroidism. Other symptoms associated with the disease are goitre, ophthalmopathy, and psychiatric manifestations such as mood and anxiety disorders and, sometimes, cognitive dysfunction. Graves\u0027 hyperthyroidism may result in these latter manifestations via the induction of hyperactivity of the adrenergic nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17044727"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Graves\u0027 disease is the most common cause of hyperthyroidism and is classically characterized by the clinical triad of diffuse toxic goiter, infiltrative ophthalmopathy with exophthalmos and an infiltrative dermopathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "text": "The pathogenesis Graves\u0027 disease, an autoimmune disorder, is not fully understood. Immune disturbances, genetic predisposition and environmental factors, affecting thyroid gland, appear to play the main role in contribution and development of the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9489453"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "The classic clinical triad of Graves\u0027 disease is hyperthyroidism, diffuse goiter, and exophthalmos.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10387329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Graves disease is an autoimmune disorder characterized by thyroid enlargement and hyperthyroidism. Thyrotropin receptor (TSHR) autoantibodies bind the TSHR on the membrane of thyroid follicular cells and stimulate cell proliferation and thyroid-hormone synthesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Graves\u0027 disease (GD) is an autoimmune chronic thyroiditis frequently associated with development of Graves\u0027 orbitopathy (GO) characterized by proptosis, strabismus, impairment of visual function, ocular surface inflammation and dry eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29729448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Graves\u0027 disease is an autoimmune disease characterized by goiter and hyperthyroidism, and 25% patients develop GO.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35462920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Graves\u0027 disease is an autoimmune disorder in which autoantibodies to the thyroid-stimulating hormone receptor cause hyperthyroidism through unregulated stimulation of the thyroid-stimulating hormone receptor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26041458"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Graves\u0027 disease is a well-known organ-specific autoimmune disease, in which stimulatory anti-thyrotropin (TSH) receptor antibodies cause hyperthyroidism and diffuse goiter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17154081"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "text": "Graves\u0027 disease (GD), the most common cause of hyperthyroidism, is an autoimmune disease directly caused by circulating autoantibodies that bind and activate the TSH receptor, inducing metabolic activation of the thyroid gland; this may be associated with important cardiac (atrial fibrillation) and ocular (ophthalmopathy) complications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33565844"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 528,
          "text": "Graves\u0027 disease is characterized by goiter, hyperthyroidism, and the orbital complication known as Graves\u0027 orbitopathy (GO), or thyroid eye disease. The hyperthyroidism in Graves\u0027 disease is caused by stimulation of function of thyrotropin hormone receptor (TSHR), resulting from the production of agonist antibodies to the receptor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25777757"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 389,
          "text": "Graves\u0027 disease (GD) is a systemic autoimmune disease that is characterized by hyperthyroidism, orbitopathy and in rare cases dermopathy. Graves\u0027 orbitopathy (GO) is an inflammatory disease of eye and orbit which occurs in about 30-60% of patients. Hyperthyroidism occurs due to the presence of stimulating TSHR-autoantibodies (TRAbs) leading to increased serum levels of thyroid hormones.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613015"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 342,
          "text": "Graves\u0027 disease is characterized by goiter, hyperthyroidism, and the orbital complication known as Graves\u0027 orbitopathy (GO), or thyroid eye disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25777757"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 585,
          "text": "Graves\u0027-Basedow disease is the most common form of autoimmune thyroiditis, responsible for the majority of the cases of hyperthyroidism, affecting young women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10756799"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Graves\u0027 disease is a complex autoimmune disorder characterized by multiple systemic manifestations of overproduction of thyroid hormone, and in some cases, orbitopathy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18214794"
        }
      ],
      "type": "summary",
      "id": "67cde43c81b102733300001e",
      "ideal_answer": [
        "Graves disease is the most common cause of hyperthyroidism in iodine-sufficient areas. The main responsible mechanism is related to autoantibodies that bind and activate the thyrotropin receptor (TSHR). Although Graves hyperthyroidism is relatively common, no causal treatment options are available. The hyperthyroidism manifested by patients affected by this disease is caused by the production of autoantibodies against the thyroid-stimulating hormone (TSH, or thyrotropin) receptor (TSHR), which mimic the effects of the hormone on thyroid cells, thereby stimulating autonomic production of thyroxine and triiodothyronine.",
        "Graves\u0027 disease is an autoimmune condition that causes hyperthyroidism, where the thyroid gland produces excessive hormones. Symptoms can include an enlarged thyroid, eye issues, and other systemic problems. Risk factors for Graves\u0027 disease include environmental, genetic, and immunological factors. Recent studies indicate that SARS-CoV-2 infection can induce Graves\u0027 disease in post-COVID-19 patients.",
        "Graves\u0027 disease (GD) is an autoimmune disorder involving the thyroid gland, typically characterized by the presence of circulating autoantibodies that bind to and stimulate the thyroid hormone receptor (TSHR), resulting in hyperthyroidism and goiter.",
        "Graves\u0027 disease (GD) is a common autoimmune disorder characterized by the presence of anti-TSH receptor autoantibodies that result in excessive T4 hormone production and hyperthyroidism.",
        "Graves\u0027 disease (GD) is a systemic autoimmune disease that is characterized by hyperthyroidism, orbitopathy and in rare cases dermopathy.",
        "Graves\u0027 disease is an autoimmune disorder that causes hyperthyroidism, where the immune system attacks the thyroid gland, leading to an overproduction of thyroid hormones.",
        "Graves\u0027 disease (GD) is a systemic autoimmune disorder characterized by hyperthyroidism, orbitopathy, and in rare cases, dermopathy. It is caused by autoantibodies to the thyroid-stimulating hormone receptor, leading to unregulated stimulation and overproduction of thyroid hormones  .",
        "Graves disease is a condition characterized by an overactive thyroid gland, resulting from an autoimmune response that stimulates the thyroid to produce excessive thyroid hormones.",
        "Graves\u0027 disease (GD) is an autoimmune disease characterized by goiter and hyperthyroidism, and 25% patients develop GO.",
        "Graves\u0027 disease (GD) is an autoimmune disorder in which autoantibodies to the thyroid-stimulating hormone receptor cause hyperthyroidism through unregulated stimulation of the thyroid-stimulating hormone receptor. It is characterized by hyperthyroidism, goiter, and in some cases, orbitopathy and dermopathy .",
        "Graves\u0027 disease is an autoimmune disorder affecting the thyroid, causing hyperthyroidism, characterized by symptoms like goiter and eye issues, diagnosed through hormone and antibody tests, and treated with medication, radioiodine, or surgery.",
        "Graves\u0027 disease is an autoimmune disorder causing hyperthyroidism due to antibodies stimulating the thyroid-stimulating hormone receptor, with symptoms like goiter and eye issues, and is treated with medication, radioactive iodine, or surgery.",
        "Graves\u0027 disease is the commonest cause of hyperthyroidism and is an autoimmune condition of the thyroid characterized by the production of autoantibodies against the thyroid-stimulating hormone receptor, leading to the stimulation of thyroid hormone production.",
        "Graves\u0027 disease is an autoimmune condition causing hyperthyroidism by producing autoantibodies that stimulate the TSH receptor. It is the most common cause of hyperthyroidism in iodine-sufficient areas and shows a strong familial and female preponderance.",
        "Graves\u0027 disease is the most common cause of hyperthyroidism in iodine-sufficient areas and is an autoimmune disorder where antibodies stimulate the TSH receptor, leading to excess thyroid hormone production. It predominantly affects women and has a strong genetic component, accounting for 60-80% of the risk.",
        "Graves\u0027 disease is an autoimmune thyroid condition, characterized by TSH receptor autoantibodies leading to hyperthyroidism, predominantly affecting females, and having a strong genetic component, making it the most common cause of hyperthyroidism in iodine-sufficient areas.",
        "Graves\u0027 disease is the most common cause of hyperthyroidism, particularly affecting females and having strong genetic factors (60-80% risk). It\u0027s an autoimmune condition where autoantibodies stimulate thyroid cells to overproduce thyroid hormones.",
        "Graves\u0027 disease (GD) is an autoimmune condition of the thyroid and the most common cause of hyperthyroidism in iodine-sufficient areas. It is caused by the production of autoantibodies against the thyroid-stimulating hormone receptor (TSHR), which mimic the effects of the hormone on thyroid cells, thereby stimulating the production of thyroxine and triiodothyronine."
      ]
    },
    {
      "body": "Are there any studies on the genetics of suicide?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39774242",
        "http://www.ncbi.nlm.nih.gov/pubmed/37559484",
        "http://www.ncbi.nlm.nih.gov/pubmed/11727895",
        "http://www.ncbi.nlm.nih.gov/pubmed/14965851",
        "http://www.ncbi.nlm.nih.gov/pubmed/19306130",
        "http://www.ncbi.nlm.nih.gov/pubmed/9616797",
        "https://www.ncbi.nlm.nih.gov/pubmed/20977922",
        "https://www.ncbi.nlm.nih.gov/pubmed/34030748",
        "http://www.ncbi.nlm.nih.gov/pubmed/34030748",
        "http://www.ncbi.nlm.nih.gov/pubmed/31698394",
        "http://www.ncbi.nlm.nih.gov/pubmed/39305971",
        "http://www.ncbi.nlm.nih.gov/pubmed/39645539"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1303,
          "text": "There is good evidence from recent studies that depression is familial, and that a substantial proportion of the variation in liability is explained by genes. Suicidal behavior, including completed suicide, also seems to cluster in families. First-degree relatives of individuals who have committed suicide (included dizygotic twins) have more than twice the risk of the general population. For identical co-twins of suicides, the relative risk increases to about 11. Applying a simple structural equation model to the published data suggests a heritability for completed suicide of about 43% (95% confidence intervals 25-60). It is not known at present whether the genes predisposing to suicide are identical with those predisposing to affective disorder, but since only about half of those committing suicide have a diagnosis of depression, it seems probable that the overlap is incomplete. The mode of inheritance of suicidal behavior is almost certain to be complex, involving many genes. There have already been some initial studies of allelic association with polymorphisms in candidate genes such as those involved in serotonergic transmission. Further progress is likely to come from candidate gene and linkage disequilibrium studies that are capable of detecting multiple genes of small effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727895"
        },
        {
          "offsetInBeginSection": 869,
          "offsetInEndSection": 1046,
          "text": "Molecular genetics studies have searched inconclusively for associations of suicidal behavior with genes mainly for proteins required for central serotonergic neurotransmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14965851"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 222,
          "text": "Family, twin, and adoption studies have demonstrated that there is a genetic dimension to suicide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19306130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1647,
          "text": "Suicidal ideation, suicide attempt (SA) and suicide are significantly heritable phenotypes. However, the extent to which these phenotypes share genetic architecture is unclear. This question is of great relevance to determining key risk factors for suicide, and to alleviate the societal burden of suicidal thoughts and behaviors (STBs). To help address the question of heterogeneity, consortia efforts have recently shifted from a focus on suicide within the context of major psychopathology (e.g. major depressive disorder, schizophrenia) to suicide as an independent entity. Recent molecular studies of suicide risk by members of the Psychiatric Genomics Consortium and the International Suicide Genetics Consortium have identified genome-wide significant loci associated with SA and with suicide death, and have examined these phenotypes within and outside of the context of major psychopathology. This review summarizes important insights from epidemiological and biometrical research on suicide, and discusses key empirical findings from molecular genetic examinations of STBs. Polygenic risk scores for these phenotypes have been observed to be associated with case-control status and other risk phenotypes. In addition, estimated shared genetic covariance with other phenotypes suggests specific medical and psychiatric risks beyond major depressive disorder. Broadly, molecular studies suggest a complexity of suicide etiology that cannot simply be accounted for by depression. Discussion of the state of suicide genetics, a growing field, also includes important ethical and clinical implications of studying the genetic risk of suicide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34030748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 2242,
          "text": "Suicide behavior (SB) spans a spectrum ranging from suicidal ideation to suicide attempts and completed suicide. Strong evidence suggests a genetic susceptibility to SB, including familial heritability and common occurrence in twins. This review addresses recent molecular genetic studies in SB that include case-control association, genome gene-expression microarray, and genome-wide association (GWA). This work also reviews epigenetics in SB and pharmacogenetic studies of antidepressant-induced suicide. SB fulfills criteria for a complex genetic phenotype in which environmental factors interact with multiple genes to influence susceptibility. So far, case-control association approaches are still the mainstream in SB genetic studies, although whole genome gene-expression microarray and GWA studies have begun to emerge in recent years. Genetic association studies have suggested several genes (e.g., serotonin transporter, tryptophan hydroxylase 2, and brain-derived neurotrophic factor) related to SB, but not all reports support these findings. The case-control approach while useful is limited by present knowledge of disease pathophysiology. Genome-wide studies of gene expression and genetic variation are not constrained by our limited knowledge. However, the explanatory power and path to clinical translation of risk estimates for common variants reported in genome-wide association studies remain unclear because of the presence of rare and structural genetic variation. As whole genome sequencing becomes increasingly widespread, available genomic information will no longer be the limiting factor in applying genetics to clinical medicine. These approaches provide exciting new avenues to identify new candidate genes for SB genetic studies. The other limitation of genetic association is the lack of a consistent definition of the SB phenotype among studies, an inconsistency that hampers the comparability of the studies and data pooling. In summary, SB involves multiple genes interacting with non-genetic factors. A better understanding of the SB genes by combining whole genome approaches with case-control association studies, may potentially lead to developing effective screening, prevention, and management of SB.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/20977922"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 337,
          "text": "Suicidal ideation, suicide attempt (SA) and suicide are significantly heritable phenotypes. However, the extent to which these phenotypes share genetic architecture is unclear. This question is of great relevance to determining key risk factors for suicide, and to alleviate the societal burden of suicidal thoughts and behaviors (STBs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34030748"
        },
        {
          "offsetInBeginSection": 525,
          "offsetInEndSection": 926,
          "text": "Analysis of epigenetic mechanisms (methylation of the DNA, modifications of histone proteins and (networks of) miRNA), which link the interaction between genes and the environment, could importantly contribute to better understanding of suicidal behaviour. Recent studies on suicidal behaviour and DNA methylation show differences in DNA methylation pattern, with numerous sites among suicide victims.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31698394"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Suicidal ideation, suicide attempt (SA) and suicide are significantly heritable phenotypes. However, the extent to which these phenotypes share genetic architecture is unclear. This question is of great relevance to determining key risk factors for s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34030748"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 220,
          "text": "Clinical studies show that a family history of suicide is associated with a raised risk of both attempts at suicide and completed suicide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9616797"
        },
        {
          "offsetInBeginSection": 1499,
          "offsetInEndSection": 1707,
          "text": "Altogether, our data show a distinct pattern of DNA methylation, the genomic distribution of differentially methylated sites, gene enrichment, and pathways in MDD suicide compared to non-suicide MDD subjects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39645539"
        },
        {
          "offsetInBeginSection": 796,
          "offsetInEndSection": 916,
          "text": "Recent genome-wide association studies have uncovered specific genomic loci associated with specific suicidal behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39305971"
        }
      ],
      "id": "67e2958018b1e36f2e000084",
      "ideal_answer": [
        "Studies have investigated the genetics of suicide, exploring its heritability and genetic correlations with psychiatric disorders. Genome-wide association studies (GWAS) using data from the UK Biobank identified genetic loci associated with self-harm ideation and behavior, highlighting shared genetic aetiology between suicidal and non-suicidal self-harm. Polygenic risk scores for these traits predicted suicide-related outcomes in independent samples. Research on cardiovascular disease patients found increased psychiatric risks post-diagnosis, with minimal impact from genetic predisposition. GWAS on mood disorders linked polygenic scores for depression to suicidal ideation and attempts, suggesting partial genetic overlap. Ethical concerns regarding direct-to-consumer testing of suicide risk were raised, emphasizing caution due to potential misinterpretation and stigma. Studies in veterans identified associations between genetic factors and suicidal behaviors but noted underdocumentation in clinical settings. Preadolescent suicidality was linked to PTSD-related polygenic scores, with environmental stressors playing a significant role. Family studies of bipolar disorder showed high affective disorder rates among relatives without increased suicide attempts, indicating complex heritability. VMAT1 gene variants were not associated with suicidal behavior, while SLE patients exhibited higher suicide risk tied to depression and neuropsychiatric manifestations, with shared genetic haplotypes. Lastly, polygenic scores for depression correlated with suicidal behaviors, underscoring the role of genetics in suicide risk alongside environmental factors. These studies collectively indicate that genetics contribute to suicide risk, often intertwined with psychiatric conditions and environmental stressors, though further research is needed for clarity.",
        "Studies on genetics of suicide have identified several key findings. Genome-wide association studies (GWAS) using data from UK Biobank and other cohorts have found genetic correlations between self-harm ideation, behavior, and suicide-related traits, with polygenic risk scores predicting suicide attempts and thoughts in independent samples. Research also links cardiovascular disease to increased risks of psychiatric disorders and suicide attempts, though genetic susceptibility does not significantly modify these associations. GWAS on mood disorders like depression and bipolar disorder have found pleiotropy between psychiatric conditions and suicidal ideation, while polygenic scores for major depressive disorder predict suicidal behaviors. Studies in high-risk populations, such as veterans with schizophrenia or bipolar disorder, highlight associations between genetic factors, substance use, and suicide behaviors, emphasizing the need for improved screening. Additionally, research on preadolescents suggests that stress-susceptibility genes may contribute to early-life suicidality. Ethical concerns regarding direct-to-consumer genetic testing for suicide risk are also noted, stressing caution and proper counseling. Overall, these studies provide evidence of a genetic component in suicide risk, though further research is needed to fully understand the underlying mechanisms."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What are some common post-translational modifications of proteins?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37143582",
        "http://www.ncbi.nlm.nih.gov/pubmed/37675097",
        "http://www.ncbi.nlm.nih.gov/pubmed/17033665",
        "http://www.ncbi.nlm.nih.gov/pubmed/15174136",
        "http://www.ncbi.nlm.nih.gov/pubmed/35400524",
        "http://www.ncbi.nlm.nih.gov/pubmed/1582530",
        "http://www.ncbi.nlm.nih.gov/pubmed/22947645",
        "http://www.ncbi.nlm.nih.gov/pubmed/31631532",
        "http://www.ncbi.nlm.nih.gov/pubmed/37795435",
        "http://www.ncbi.nlm.nih.gov/pubmed/38764597",
        "http://www.ncbi.nlm.nih.gov/pubmed/38995731",
        "http://www.ncbi.nlm.nih.gov/pubmed/38559018",
        "http://www.ncbi.nlm.nih.gov/pubmed/38151445",
        "http://www.ncbi.nlm.nih.gov/pubmed/38869790",
        "http://www.ncbi.nlm.nih.gov/pubmed/38934375",
        "http://www.ncbi.nlm.nih.gov/pubmed/11677779",
        "http://www.ncbi.nlm.nih.gov/pubmed/38213532",
        "http://www.ncbi.nlm.nih.gov/pubmed/20332821",
        "http://www.ncbi.nlm.nih.gov/pubmed/39739642",
        "http://www.ncbi.nlm.nih.gov/pubmed/32759169",
        "http://www.ncbi.nlm.nih.gov/pubmed/23001859",
        "http://www.ncbi.nlm.nih.gov/pubmed/30279071",
        "http://www.ncbi.nlm.nih.gov/pubmed/32178365",
        "http://www.ncbi.nlm.nih.gov/pubmed/29184018",
        "http://www.ncbi.nlm.nih.gov/pubmed/26825284",
        "http://www.ncbi.nlm.nih.gov/pubmed/21819967",
        "http://www.ncbi.nlm.nih.gov/pubmed/39199296",
        "http://www.ncbi.nlm.nih.gov/pubmed/26853265",
        "http://www.ncbi.nlm.nih.gov/pubmed/20680393",
        "http://www.ncbi.nlm.nih.gov/pubmed/34999219",
        "http://www.ncbi.nlm.nih.gov/pubmed/19158082",
        "http://www.ncbi.nlm.nih.gov/pubmed/19003198",
        "http://www.ncbi.nlm.nih.gov/pubmed/16267872",
        "http://www.ncbi.nlm.nih.gov/pubmed/33423730",
        "http://www.ncbi.nlm.nih.gov/pubmed/21500857",
        "http://www.ncbi.nlm.nih.gov/pubmed/19700364",
        "http://www.ncbi.nlm.nih.gov/pubmed/38315372",
        "http://www.ncbi.nlm.nih.gov/pubmed/39710032",
        "http://www.ncbi.nlm.nih.gov/pubmed/36471658",
        "http://www.ncbi.nlm.nih.gov/pubmed/26598646",
        "http://www.ncbi.nlm.nih.gov/pubmed/25860252",
        "http://www.ncbi.nlm.nih.gov/pubmed/31151270",
        "http://www.ncbi.nlm.nih.gov/pubmed/37236503",
        "http://www.ncbi.nlm.nih.gov/pubmed/39728102",
        "http://www.ncbi.nlm.nih.gov/pubmed/39716009",
        "http://www.ncbi.nlm.nih.gov/pubmed/37415097",
        "http://www.ncbi.nlm.nih.gov/pubmed/33013775",
        "http://www.ncbi.nlm.nih.gov/pubmed/24129315",
        "http://www.ncbi.nlm.nih.gov/pubmed/31422938",
        "http://www.ncbi.nlm.nih.gov/pubmed/31864228",
        "http://www.ncbi.nlm.nih.gov/pubmed/24793144",
        "http://www.ncbi.nlm.nih.gov/pubmed/38141531",
        "http://www.ncbi.nlm.nih.gov/pubmed/22340633",
        "http://www.ncbi.nlm.nih.gov/pubmed/25271713",
        "http://www.ncbi.nlm.nih.gov/pubmed/39098853",
        "http://www.ncbi.nlm.nih.gov/pubmed/38964538",
        "http://www.ncbi.nlm.nih.gov/pubmed/39368550",
        "http://www.ncbi.nlm.nih.gov/pubmed/38966971"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 781,
          "text": "Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent bonds on the backbones or amino acid side chains of proteins and expand the diversity of proteins, which provides the basis for the emergence of organismal complexity. To date, more than 650 types of protein modifications, such as the most well-known phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short-chain and long-chain acylation modifications, redox modifications, and irreversible modifications, have been described, and the inventory is still increasing. By changing the protein conformation, localization, activity, stability, charges, and interactions with other biomolecules, PTMs ultimately alter the phenotypes and biological processes of cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37143582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 451,
          "text": "Protein post-translational modification (PTM) is a regulatory mechanism for protein activity modulation, localization, expression, and interactions with other cellular molecules. It involves the addition or removal of specific chemical groups on the amino acid residues of proteins. Its common forms include phosphorylation, ubiquitylation, methylation, and acetylation. Emerging research has highlighted lactylation, succinylation, and glycosylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37675097"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 408,
          "text": "Whereas glycosylation represents the most common modification, additional PTMs, including carboxylation, hydroxylation, sulfation and amidation, are characteristic of some products.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17033665"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 441,
          "text": "Post-translational modifications (PTMs) are known to regulate biological processes by controlling protein function. The effect of a PTM on protein function depends critically on the position and the number of modifications. While there are convenient methods available to qualitatively examine modifications like phosphorylation, glycosylation, acetylation and methylation, methods available for their quantitative assessment are cumbersome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15174136"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 894,
          "text": "With a limited scope, this review attempts to discuss some PTMs of high frequency with recognized importance in cancer biology, including phosphorylation, acetylation, glycosylation, palmitoylation and ubiquitination, as well as their implications in clinical applications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35400524"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 349,
          "text": "Post-translational modifications such as acetylation, phosphorylation, sulfation, methylation, hydroxylation, ADP-ribosylation, maturation, amidation, carboxylation, adenylylation, glycosylation, ubiquitination, and prenylation are extensively reviewed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1582530"
        },
        {
          "offsetInBeginSection": 673,
          "offsetInEndSection": 889,
          "text": "most common post-translational modifications, such as glycosylation and glycation, phosphorylation, sulfation, redox modifications (i.e. sulfydration and nitrosylation), methylation, acetylation, and ubiquitinylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31631532"
        },
        {
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1179,
          "text": "Some of these modifications include phosphorylation, glycosylation, methylation, acetylation, and ubiquitination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37795435"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 699,
          "text": "In this review, we discuss recent studies on crosstalk between three of the most common protein PTMs in plant cells, being phosphorylation, ubiquitination, and sumoylation, and we highlight the diverse underlying mechanisms as well as signaling outputs of such crosstalk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30279071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Phosphorylation and proteolysis are among the most common post-translational modifications (PTMs), and play critical roles in various biological processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Lysine acetylation/deacetylation is increasingly being recognized as common post-translational modification that appears to be broadly operational throughout the cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20680393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Asymmetric dimethylation of arginine residues is a common posttranslational modification of proteins carried out by type I protein arginine methyltransferases, including PRMT1 and -3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158082"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 427,
          "text": "Common protein modifications include variable glycosylation, misfolding and aggregation, oxidation of methionine, deamidation of asparagine and glutamine, and proteolysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19003198"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 905,
          "text": "In this review the state of art of the platforms applied for the enrichment of specific and most common post-translational modifications, such as glycosylation and glycation, phosphorylation, sulfation, redox modifications (i.e. sulfydration and nitrosylation), methylation, acetylation, and ubiquitinylation, are described.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31631532"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 762,
          "text": "The major types of protein covalent modifications, such as phosphorylation, acetylation, glycosylation, methylation, and ubiquitylation, can be classified according to the type of amino acid side chain modified, the category of the modifying enzyme, and the extent of reversibility. Chemical events such as protein splicing, green fluorescent protein maturation, and proteasome autoactivations also represent posttranslational modifications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16267872"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 370,
          "text": "Its common forms include phosphorylation, ubiquitylation, methylation, and acetylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37675097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Proteins exert their roles in life activities via post-translational modifications(PTMs),which include phosphorylation,acetylation,ubiquitination,glycosylation,and methylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33423730"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 276,
          "text": "As one of the most common post-translational modifications (PTMs), glycosylation can greatly affect proteins\u0027 features and functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38315372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Lysine acetylation is a common reversible post-translational modification of proteins that plays a key role in regulating gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36471658"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 948,
          "text": "The most commonly observed PTMs are the phosphorylation of serine, threonine, and tyrosine residues, followed by acetylation, glycosylation, and amidation. In addition to PTMs that involve the modification of a certain amino acid (phosphorylation, hydrophobic groups for membrane localisation, or chemical groups like acylation), or the conjugation of peptides (SUMOylation, NEDDylation), structural changes such as the formation of disulphide bridge, protein cleavage or splicing can also be classified as PTMs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38213532"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "In eukaryotic cells, many proteins undergo extensive post-translational modifications (PTMs) such as methylation, acetylation, phosphorylation, glycosylation, and ubiquitination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25860252"
        },
        {
          "offsetInBeginSection": 409,
          "offsetInEndSection": 594,
          "text": "Protein post-translational modifications, such as ubiquitination, phosphorylation, methylation, and acetylation, play important roles in the regulation of protein stability and activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Among post-translational modifications of proteins, acetylation, phosphorylation, and ubiquitination are most extensively studied over the last several decades",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37236503"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Protein glycosylation, a vital post-translational modification, is pivotal in various biological processes and disease pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Glycosylation is a ubiquitous and the most structurally diverse post-translational modification of proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728102"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Protein phosphorylation is an important post-translational modification that regulates almost all cellular processes, such as cellular metabolism, growth, differentiation, signal transduction, and gene regulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716009"
        },
        {
          "offsetInBeginSection": 601,
          "offsetInEndSection": 742,
          "text": "Methylation modifications on non-histone lysine and arginine residues have been identified as common PTMs critical to various life processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39710032"
        },
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 605,
          "text": "Common PTMs include phosphorylation, acetylation, ubiquitination, methylation, and glycosylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37415097"
        },
        {
          "offsetInBeginSection": 479,
          "offsetInEndSection": 610,
          "text": "The most common PTMs include phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, NEDDylation, and glycosylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33013775"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 341,
          "text": "Common PTMs include phosphorylation, acetylation, ubiquitination, glycosylation, SUMOylation, methylation, sulfation, and nitrosylation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39199296"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Protein methylation is a common posttranslational modification that mostly occurs on arginine and lysine residues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129315"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Glycosylation is a ubiquitous and the most structurally diverse post-translational modification of proteins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728102"
        },
        {
          "offsetInBeginSection": 509,
          "offsetInEndSection": 606,
          "text": "Common PTMs include phosphorylation, acetylation, ubiquitination, methylation, and glycosylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37415097"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 279,
          "text": "Among them, the best known are phosphorylation, methylation, acetylation, and also cleavage or binding of small peptides (ubiquitination, SUMOylation and NEDDylation).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31864228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "N-terminal methionine excision (NME) and N-terminal acetylation (NTA) are two of the most common protein post-translational modifications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001859"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Post-translational modification of proteins by covalent attachment of sugars to the protein backbone (protein glycosylation) is the most common post-translational modification in the eucaryotic cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14683428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Amino acid hydroxylation is a common post-translational modification, which generally regulates protein interactions or adds a functional group that can be further modified.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Protein phosphorylation and glycosylation are the most common post-translational modifications observed in biology, frequently on the same protein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21500857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Glycosylation is one of the most common post-translational modifications of proteins, which plays essential roles in regulating the biological functions of proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Post-translational protein modifications by ubiquitin, SUMO and other ubiquitin-like modifiers is common and essential for all eukaryotic organisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31422938"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Glycosylation is one of the most common post-translational modifications of proteins, which plays essential roles in regulating the biological functions of proteins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Lysine acetylation is a common post-translational modification of proteins in plants",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38964538"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Protein acetylation is a common and reversible posttranslational modification tightly governed by protein acetyltransferases and deacetylases crucial for various biological processes in both eukaryotes and prokaryotes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39356671"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 275,
          "text": "As one of the most common post-translational modifications (PTMs), glycosylation can greatly affect proteins\u0027 features and functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38315372"
        }
      ],
      "id": "680c174d353a4a2e6b000001",
      "ideal_answer": [
        "Protein post-translational modifications (PTMs) refer to the breaking or generation of covalent bonds on the backbones or amino acid side chains of proteins and expand the diversity of proteins, which provides the basis for the emergence of organismal complexity. To date, more than 650 types of protein modifications, such as the most well-known phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short-chain and long-chain acylation modifications, redox modifications, and irreversible modifications, have been described, and the inventory is still increasing. By changing the protein conformation, localization, activity, stability, charges, and interactions with other biomolecules, PTMs ultimately alter the phenotypes and biological processes of cells.",
        "Post-translational modifications (PTMs) are covalent chemical modifications of proteins that typically occur after translation. They involve the addition or removal of specific chemical groups on the amino acid residues of proteins, significantly increasing protein complexity and diversity. Some common PTMs include the addition of small groups, such as phosphorylation, long-chain modifications like glycosylation, and small proteins like ubiquitination. PTMs also include the interconversion of chemical groups, such as the formation of pyroglutamic acid. These modifications can alter a protein\u0027s physical or chemical properties, activity, localization, or stability, affecting many aspects of protein functions and playing crucial roles in regulating a variety of cellular physiological and pathological processes.",
        "Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent bonds on the backbones or amino acid side chains of proteins and expand the diversity of proteins, which provides the basis for the emergence of organismal complexity. To date, more than 650 types of protein modifications, such as the most well-known phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short- and long-chain acylation modifications, redox modifications, and irreversible modifications, have been described, and the inventory is still increasing. By changing the protein conformation, localization, activity, stability, charges, and interactions with other biomolecules, PTMs ultimately alter the phenotypes and biological processes of cells.",
        "Common post-translational modifications (PTMs) include phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, acylation (short- and long-chain), redox modifications, and irreversible modifications. These processes involve covalent changes to protein backbones or side chains, altering their conformation, stability, activity, localization, and interactions. Over 650 PTM types have been identified, with these examples playing critical roles in regulating cellular functions and phenotypes. For instance, phosphorylation modulates enzyme activity, ubiquitination targets proteins for degradation, and glycosylation affects protein folding and signaling. PTMs expand proteomic diversity, enabling complex biological processes and cellular responses. The inventory of known PTMs continues to grow as research advances. (199 words)",
        "Protein post-translational modifications (PTMs) are a diverse group of covalent modifications that occur on the backbones or side chains of proteins, expanding their functionality and contributing to the complexity of organisms. Some common PTMs include phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, and acylation. Phosphorylation involves the addition of a phosphate group to a protein, altering its conformation, localization, activity, stability, charges, and interactions with other biomolecules. Ubiquitination is the process of adding one or more ubiquitin groups to a protein, often leading to protein degradation. Glycosylation is the covalent attachment and further modification of carbohydrate residues to a protein, which can affect protein folding, stability, and localization. Methylation involves the addition of a methyl group to a protein, often influencing protein-protein interactions and stability. SUMOylation is the process of conjugating a SUMO protein to a target protein via an isopeptide bond, which can regulate protein activity and localization. Acylation refers to the addition of short-chain or long-chain acyl groups to proteins, which can affect protein stability and localization. These modifications play crucial roles in various biological processes, ultimately altering the phenotypes and functions of cells.",
        "Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent bonds on the backbones or amino acid side chains of proteins and expand the diversity of proteins, which provides the basis for the emergence of organismal complexity. To date, more than 650 types of protein modifications, such as the most well-known phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short-chain and long-chain acylation modifications, redox modifications, and irreversible modifications, have been described, and the inventory is still increasing. By changing the protein conformation, localization, activity, stability, charges, and interactions with other biomolecules, PTMs ultimately alter the phenotypes and biological processes of cells.",
        "Common post-translational modifications (PTMs) of proteins include phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short-chain and long-chain acylation, redox modifications, and irreversible modifications. These covalent alterations to protein backbones or amino acid side chains regulate diverse cellular processes by modulating protein conformation, localization, activity, stability, charge, and interactions with other biomolecules. Over 650 PTM types have been identified, highlighting their role in expanding proteomic diversity and enabling organismal complexity. Dysregulation of these modifications disrupts protein function and is implicated in various diseases, underscoring their importance as potential therapeutic targets for diagnostic and prognostic applications.",
        "Post-translational modifications (PTMs) are covalent modifications of proteins that occur during or after protein synthesis. They involve the addition or removal of specific chemical groups on amino acid residues, significantly increasing protein complexity and diversity. Some common PTMs include phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short-chain and long-chain acylation modifications, and redox modifications. These modifications can alter a protein\u0027s physical or chemical properties, activity, localization, stability, charges, and interactions with other biomolecules, ultimately influencing cellular phenotypes and biological processes. PTMs play crucial roles in regulating protein functions and numerous cellular processes."
      ],
      "exact_answer": [
        [
          "Phosphorylation"
        ],
        [
          "Ubiquitination"
        ],
        [
          "Glycosylation",
          "glycation"
        ],
        [
          "Methylation"
        ],
        [
          "SUMOylation"
        ],
        [
          "Acylation",
          "Short-chain and long-chain acylation",
          "acetylation"
        ],
        [
          "Redox modifications",
          "sulfydration",
          "nitrosylation"
        ],
        [
          "NEDDylation"
        ],
        [
          "Amidation"
        ],
        [
          "Sulfation"
        ],
        [
          "Hydroxylation"
        ]
      ]
    },
    {
      "body": "Do MiOXSYS and OxiSperm measure ROS(Reactive Oxygen Species) in sperm?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36455546",
        "http://www.ncbi.nlm.nih.gov/pubmed/29124237",
        "http://www.ncbi.nlm.nih.gov/pubmed/34679669",
        "http://www.ncbi.nlm.nih.gov/pubmed/33377541",
        "http://www.ncbi.nlm.nih.gov/pubmed/33381879",
        "http://www.ncbi.nlm.nih.gov/pubmed/27695529",
        "http://www.ncbi.nlm.nih.gov/pubmed/27260688",
        "http://www.ncbi.nlm.nih.gov/pubmed/28294377",
        "http://www.ncbi.nlm.nih.gov/pubmed/32882928",
        "http://www.ncbi.nlm.nih.gov/pubmed/35514536",
        "http://www.ncbi.nlm.nih.gov/pubmed/33660452",
        "http://www.ncbi.nlm.nih.gov/pubmed/36726595"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 487,
          "text": "The evaluation of ROS in semen seems promising as a potential diagnostic tool for male infertility and male preconception care with a number of clinically available tests on the market (MiOXSYS, luminol chemiluminescence and OxiSperm)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35204147"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "MiOXSYS® and OxiSperm® II assays appear to provide no clinical utility for determining oxidative stress in human sperm-results from repeated semen collections.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 347,
          "offsetInEndSection": 522,
          "text": " To determine the natural fluctuations in semen redox indicators (MiOXSYS® and OxiSperm® II) within and between men and their association with markers of sperm oxidative stres",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 1978,
          "offsetInEndSection": 2124,
          "text": "These findings suggest that MiOXSYS® and OxiSperm® II systems for the measurement of sperm oxidative stress may have limited diagnostic potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 488,
          "text": "The evaluation of ROS in semen seems promising as a potential diagnostic tool for male infertility and male preconception care with a number of clinically available tests on the market (MiOXSYS, luminol chemiluminescence and OxiSperm).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35204147"
        },
        {
          "offsetInBeginSection": 1090,
          "offsetInEndSection": 1419,
          "text": "MiOXsys is a more stable assay for assessing OS than chemiluminescence methods and permits greater flexibility for sample handling. MiOXsys could be implemented to complement semen analysis as part of routine diagnostic testing for male infertility and may be useful in identifying contributing factors to idiopathic infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33377541"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 236,
          "text": "Recently, a new measurement method has been developed to measure the overall oxidation-reduction potential (ORP) in a semen sample known as the MiOXSYS system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33381879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "MiOXSYS: a novel method of measuring oxidation reduction potential in semen and seminal plasma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27260688"
        },
        {
          "offsetInBeginSection": 1497,
          "offsetInEndSection": 1610,
          "text": "USSION: Neither MiOXSYS® nor OxiSperm® II assays were predictive of sperm function or sperm oxidative stress. Thi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 1497,
          "offsetInEndSection": 1720,
          "text": "USSION: Neither MiOXSYS® nor OxiSperm® II assays were predictive of sperm function or sperm oxidative stress. This was likely due at least in part to limited understanding of their biochemistry and clinical application. As ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 1497,
          "offsetInEndSection": 1970,
          "text": "USSION: Neither MiOXSYS® nor OxiSperm® II assays were predictive of sperm function or sperm oxidative stress. This was likely due at least in part to limited understanding of their biochemistry and clinical application. As a result, these assays seem to provide no additional clinical utility beyond that of a standard semen analysis, highlighting the imperative for the development of new robust point-of-care devices for accurately determining sperm oxidative stress.CONC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 1816,
          "offsetInEndSection": 2151,
          "text": "In this paper, we discuss the measurement of ORP by the MiOXSYS System as a real-time assessment of seminal oxidative stress, and argue that it is a potential valuable clinical test that should be incorporated into the male infertility workup and become an important guide to the treatment of oxidative stress-induced male infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695529"
        },
        {
          "offsetInBeginSection": 293,
          "offsetInEndSection": 807,
          "text": "The cyclic cascade of redox reactions weakens sperm function which leads to poor semen parameters and eventual sterility. There is a need for advanced diagnostic tests that can quickly and accurately detect OS. Most commonly used assays can only measure single constituents of OS. However, the MiOXSYS System introduces a new strategy to detect OS by measuring the oxidation-reduction potential (ORP)--a direct evaluation of the redox balance between ROS and antioxidants. The MiOXSYS System has shown promise as a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124237"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 154,
          "text": "lity Oxidative System (MiOXSYS) has been proposed as a rapid and promising technology for the evaluation of sperm oxidative stress. In this ca",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35514536"
        },
        {
          "offsetInBeginSection": 1393,
          "offsetInEndSection": 1606,
          "text": "Fluctuations in semen redox levels varied greater between men than within men over the study period.DISCUSSION: Neither MiOXSYS® nor OxiSperm® II assays were predictive of sperm function or sperm oxidative stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 400,
          "text": "This study measures ORP and evaluates the effect of exogenous induction of oxidative stress by cumene hydroperoxide (CH) on ORP in fresh and frozen semen using the MiOXSYS Analyzer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28294377"
        },
        {
          "offsetInBeginSection": 583,
          "offsetInEndSection": 765,
          "text": "the MiOXSYS System introduces a new strategy to detect OS by measuring the oxidation-reduction potential (ORP)--a direct evaluation of the redox balance between ROS and antioxidants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124237"
        },
        {
          "offsetInBeginSection": 1512,
          "offsetInEndSection": 1613,
          "text": " MiOXSYS® nor OxiSperm® II assays were predictive of sperm function or sperm oxidative stress. This w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36455546"
        },
        {
          "offsetInBeginSection": 504,
          "offsetInEndSection": 765,
          "text": "Most commonly used assays can only measure single constituents of OS. However, the MiOXSYS System introduces a new strategy to detect OS by measuring the oxidation-reduction potential (ORP)--a direct evaluation of the redox balance between ROS and antioxidants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Purpose: The MiOXSYS system is a new technique to analyze the semen oxidative reduction potential (ORP) that may use to classify the level of sperm DNA ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36726595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "MiOXSYS: a novel method of measuring oxidation reduction potential in semen and seminal plasma",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27260688"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Purpose: The MiOXSYS system is a new technique to analyze the semen oxidative reduction potential (ORP) that may use to classify the level of sperm DNA i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36726595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Male Infertility Oxidative System (MiOXSYS) has been proposed as a rapid and promising technology for the evaluation of sperm oxidative stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35514536"
        },
        {
          "offsetInBeginSection": 795,
          "offsetInEndSection": 1048,
          "text": "The introduction of an alternative electrochemical system (MiOXSYS®) was designed to address this problem. This assay records the static oxido-reductive potential of semen and then creates an index by dividing this measurement by the sperm concentration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39731844"
        },
        {
          "offsetInBeginSection": 319,
          "offsetInEndSection": 476,
          "text": "MiOXSYS has been developed to evaluate the seminal static oxidation-reduction potential (sORP) and it has been proposed as an effective diagnostic biomarker.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32882928"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "Oxidation-reduction potential (ORP) is a newer integrated measure of the balance between total oxidants (reactive oxygen species-ROS) and reductants (antioxidants) that reflects oxidative stress in a biological system. This study measures ORP and evaluates the effect of exogenous induction of oxidative stress by cumene hydroperoxide (CH) on ORP in fresh and frozen semen using the MiOXSYS Analyzer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28294377"
        },
        {
          "offsetInBeginSection": 574,
          "offsetInEndSection": 764,
          "text": "However, the MiOXSYS System introduces a new strategy to detect OS by measuring the oxidation-reduction potential (ORP)--a direct evaluation of the redox balance between ROS and antioxidants",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124237"
        },
        {
          "offsetInBeginSection": 1812,
          "offsetInEndSection": 2031,
          "text": "A novel biomarker, the Male infertility Oxidative System (MiOXSYS®), is a paradigm shift towards that goal, offering a quantification of OS via a quick, reliable, and reproducible measurement of the ORP. Moderation or \"",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34679669"
        },
        {
          "offsetInBeginSection": 813,
          "offsetInEndSection": 864,
          "text": "he sORP was measured by using the MiOXSYS™ system. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33660452"
        },
        {
          "offsetInBeginSection": 1117,
          "offsetInEndSection": 1345,
          "text": "The MiOXSYS™ System is a novel technology based on a galvanostatic measure of electrons; it presents static ORP (sORP) measures with static referring to the passive or current state of activity between oxidants and antioxidants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695529"
        }
      ],
      "type": "yesno",
      "id": "67e0053118b1e36f2e000067",
      "ideal_answer": [
        "The evaluation of ROS in semen seems promising as a potential diagnostic tool for male infertility and male preconception care with a number of clinically available tests on the market (MiOXSYS, luminol chemiluminescence and OxiSperm)",
        "MiOXSYS and OxiSperm do not measure ROS directly. MiOXSYS measures oxidation reduction potential (sORP) while OxiSperm is not mentioned in the document. ROS levels are measured using a chemiluminescence assay.",
        "Both MiOXSYS and OxiSperm measure Reactive Oxygen Species (ROS) in sperm. This is evident from the documents which state that ROS levels are calculated using MiOXSYS, and OxiSperm is also a method used to measure ROS in sperm samples. Additionally, it is mentioned that ROS are continuously produced in semen, which is a key component of both MiOXSYS and OxiSperm assays. Furthermore, the documents indicate that ROS levels are negatively correlated with sperm motility and vitality, which suggests that these methods are used to measure ROS in sperm samples.",
        "MiOXSYS and OxiSperm are two clinically available tests that measure ROS (Reactive Oxygen Species) in semen, specifically in sperm. They are potential diagnostic tools for male infertility and male preconception care.",
        "No. MiOXSYS and OxiSperm do not measure reactive oxygen species (ROS) directly; they assess oxidative stress through redox potential and other indicators, but not ROS concentrations themselves.",
        "No. Neither MiOXSYS nor OxiSperm assays were predictive of sperm function or sperm oxidative stress, and semen analysis cannot identify reactive oxygen species (ROS).",
        "No, MiOXSYS and OxiSperm do not measure ROS (Reactive Oxygen Species) in sperm directly. MiOXSYS measures the oxidation-reduction potential (ORP), which is a direct evaluation of the redox balance between ROS and antioxidants.",
        "MiOXSYS and OxiSperm are both associated with measuring ROS (Reactive Oxygen Species) in sperm.",
        "No. MiOXSYS and OxiSperm do not measure reactive oxygen species (ROS) directly; they measure oxidative stress indicators and redox potential, which are related but not direct measurements of ROS.",
        "MiOXSYS and OxiSperm measure oxidative stress, not directly ROS.",
        "No. MiOXSYS and OxiSperm do not measure reactive oxygen species (ROS) directly; they assess oxidative stress through other parameters such as oxidation-reduction potential (ORP).",
        "Yes, it is possible to use MiOXSYS and OxiSpermII (Oxisperm test) for measuring the reactive oxygen species (ROS) in semen samples.",
        "No, MiOXSYS and OxiSperm do not measure ROS(Reactive Oxygen Species) in sperm. They measure oxidation-reduction potential.",
        "The MiOXSYS system measures the oxidation-reduction potential (ORP), which provides an indirect evaluation of the redox balance between reactive oxygen species (ROS) and antioxidants in sperm. It does not directly measure ROS levels. On the other hand, the OxiSperm kit is specifically used to determine the amount of reactive oxygen species in sperm, providing a direct measurement of ROS levels.",
        "No, MiOXSYS measures the oxidation-reduction potential (ORP) which is a direct evaluation of the redox balance between ROS and antioxidants, while OxiSperm does not provide clinical utility for determining oxidative stress in human sperm.",
        "MiOXSYS measures static oxidation–reduction potential (sORP) in semen, providing a global readout of the balance between oxidants and antioxidants rather than quantifying specific ROS species. OxiSperm directly measures sperm ROS levels using a chemiluminescent or colorimetric assay to detect reactive oxygen species.",
        "Yes, both MiOXSYS and OxiSperm are designed to measure aspects related to Reactive Oxygen Species (ROS) in sperm, with MiOXSYS specifically measuring static oxidation-reduction potential (sORP) as an indicator of oxidative stress, while OxiSperm\u0027s NBT-reactivity is intended to assess ROS levels, although its clinical utility is questioned in the provided abstracts.",
        "The MiOXSYS and OxiSpermII assays measure oxidative stress indirectly by evaluating oxidation-reduction potential (ORP) or antioxidant capacity in semen, rather than directly quantifying ROS levels. These systems assess the overall redox balance (pro-oxidants vs. antioxidants) associated with oxidative stress but do not specifically measure ROS concentrations in sperm.",
        "The snippets provided suggest that while MiOXSYS and OxiSperm are tests used to evaluate reactive oxygen species (ROS) in semen, the results from these tests do not seem to provide clinical utility for determining oxidative stress in human sperm. This implies that they do not measure ROS in sperm.",
        "Yes, both MiOXSYS® and OxiSperm® II assays are used to measure redox indicators in sperm related to ROS, even though their clinical utility appears to be limited.",
        "[\u0027Yes, MiOXSYS and OxiSperm are designed to measure Reactive Oxygen Species (ROS) in sperm. However, the clinical utility of these tests for determining oxidative stress in human sperm has been questioned due to inconsistent results from repeated semen collections.\u0027]",
        "No, MiOXSYS and OxiSperm do not measure ROS in sperm. They appear to provide no clinical utility for determining oxidative stress in human sperm, based on results from repeated semen collections.",
        "MiOXSYS® and OxiSperm® II are systems designed to measure sperm oxidative stress and semen redox indicators. While they are marketed as clinical tests for evaluating reactive oxygen species (ROS) in semen for male infertility assessment, studies suggest they may have limited diagnostic potential and clinical utility.",
        "Yes, MiOXSYS and OxiSperm measure ROS in sperm. However, their clinical utility for determining oxidative stress in human sperm is limited, as results from repeated semen collections suggest that the natural fluctuations in semen redox indicators within and between men may be significant.",
        "Both MiOXSYS® and OxiSperm® II systems measure reactive oxygen species (ROS) and sperm oxidative stress. However, their diagnostic potential and clinical utility for determining oxidative stress in human sperm are considered limited, as indicated by findings from repeated semen collections, suggesting natural fluctuations in semen redox indicators.",
        "Yes, MiOXSYS and OxiSperm are designed to measure reactive oxygen species (ROS) in sperm. These tests are intended as diagnostic tools for evaluating oxidative stress, which is linked to male infertility. However, studies have indicated that while they measure ROS, their clinical utility and reliability may be limited.",
        "The provided context indicates that MiOXSYS and OxiSperm do not appear to provide clinical utility for determining oxidative stress in human sperm, as results from repeated semen collections suggest natural fluctuations in semen redox indicators within and between men and their association with markers of sperm oxidative stress may be limited, potentially suggesting limited diagnostic potential for these systems.",
        "No. MiOXSYS and OxiSperm assays do not effectively measure ROS in sperm and provide limited diagnostic potential for oxidative stress.",
        "MiOXSYS® and OxiSperm® II are designed to assess oxidative stress in semen by measuring redox indicators—specifically, oxidation-reduction potential (ORP) for MiOXSYS® and NBT-reactivity for OxiSperm® II. However, studies indicate these assays have limited clinical utility for reliably detecting sperm reactive oxygen species (ROS). For example, while high ORP values in MiOXSYS® correlated with reduced sperm motility and morphology, these associations were largely driven by normalization to sperm concentration rather than direct ROS measurement. Similarly, OxiSperm® II showed no significant links to sperm function or oxidative stress markers like DNA fragmentation or lipid peroxidation. Fluctuations in redox levels varied more between individuals than within them, suggesting inconsistent reproducibility. Overall, these findings highlight that neither assay effectively predicts sperm oxidative stress beyond standard semen analysis, underscoring the need for improved tools with clearer biochemical validation and clinical relevance.",
        "No. MiOXSYS and OxiSperm assays do not measure reactive oxygen species (ROS) directly; they are not predictive of sperm function or oxidative stress.",
        "MiOXSYS and OxiSperm are designed to measure Reactive Oxygen Species (ROS) in sperm, affirming their technical capability. However, their clinical utility for assessing oxidative stress in human sperm is limited and questionable, suggesting a disconnect between their intended function and practical application in diagnosing male infertility.",
        "MiOXSYS and OxiSperm measure oxidative stress in sperm, which is related to ROS (Reactive Oxygen Species) levels.",
        "MiOXSYS and OxiSperm are assays designed to measure oxidative stress in sperm, which includes Reactive Oxygen Species (ROS). However, according to recent studies, these systems may have limited diagnostic potential and may not accurately reflect ROS levels in sperm. While they are marketed as tests for measuring oxidative stress, their clinical utility is questionable.",
        "The evaluation of ROS in semen seems promising as a potential diagnostic tool for male infertility and male preconception care . MiOXSYS and OxiSperm® II assays appear to provide no clinical utility for determining oxidative stress in human sperm- results from repeated semen collections .",
        "MiOXSYS and OxiSperm are designed to measure Reactive Oxygen Species (ROS) in sperm, targeting aspects of oxidative stress. However, recent research uniformly suggests that despite their intended use, they have limited clinical utility and accuracy in effectively assessing ROS in sperm, questioning their reliability in this context.",
        "OxiSperm assays directly detect and quantify reactive oxygen species in semen, typically by a colorimetric reaction that reflects superoxide and other ROS levels. MiOXSYS does not measure ROS per se but instead measures static oxidation–reduction potential (sORP), providing an overall index of the balance between oxidants and antioxidants in the sample.",
        "No, MiOXSYS and OxiSperm do not measure ROS (Reactive Oxygen Species) in sperm. They are used to evaluate oxidative stress in semen, but they do not specifically measure ROS.",
        "Yes, both MiOXSYS and OxiSperm measure ROS (Reactive Oxygen Species) in sperm."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Which parasitic infections can cause anemia?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38865402",
        "http://www.ncbi.nlm.nih.gov/pubmed/37863671",
        "http://www.ncbi.nlm.nih.gov/pubmed/39368731",
        "http://www.ncbi.nlm.nih.gov/pubmed/38182648",
        "http://www.ncbi.nlm.nih.gov/pubmed/38809265",
        "http://www.ncbi.nlm.nih.gov/pubmed/38857772",
        "http://www.ncbi.nlm.nih.gov/pubmed/16941042",
        "http://www.ncbi.nlm.nih.gov/pubmed/19868324",
        "http://www.ncbi.nlm.nih.gov/pubmed/10438896",
        "http://www.ncbi.nlm.nih.gov/pubmed/38151048",
        "https://www.ncbi.nlm.nih.gov/pubmed/10409794",
        "https://www.ncbi.nlm.nih.gov/pubmed/22160444",
        "https://www.ncbi.nlm.nih.gov/pubmed/3295690",
        "https://www.ncbi.nlm.nih.gov/pubmed/34581794",
        "http://www.ncbi.nlm.nih.gov/pubmed/23420905",
        "http://www.ncbi.nlm.nih.gov/pubmed/20008186",
        "http://www.ncbi.nlm.nih.gov/pubmed/9253675",
        "http://www.ncbi.nlm.nih.gov/pubmed/39289696",
        "http://www.ncbi.nlm.nih.gov/pubmed/39194139",
        "http://www.ncbi.nlm.nih.gov/pubmed/39000364",
        "http://www.ncbi.nlm.nih.gov/pubmed/38981502",
        "http://www.ncbi.nlm.nih.gov/pubmed/25733630",
        "http://www.ncbi.nlm.nih.gov/pubmed/17874326",
        "http://www.ncbi.nlm.nih.gov/pubmed/18725923",
        "http://www.ncbi.nlm.nih.gov/pubmed/3295690",
        "http://www.ncbi.nlm.nih.gov/pubmed/10722628",
        "http://www.ncbi.nlm.nih.gov/pubmed/39735841",
        "http://www.ncbi.nlm.nih.gov/pubmed/39718172",
        "http://www.ncbi.nlm.nih.gov/pubmed/39716228",
        "http://www.ncbi.nlm.nih.gov/pubmed/39705264",
        "http://www.ncbi.nlm.nih.gov/pubmed/14518163",
        "http://www.ncbi.nlm.nih.gov/pubmed/11060728",
        "http://www.ncbi.nlm.nih.gov/pubmed/31738750",
        "http://www.ncbi.nlm.nih.gov/pubmed/2332643",
        "http://www.ncbi.nlm.nih.gov/pubmed/28057071",
        "http://www.ncbi.nlm.nih.gov/pubmed/12197322",
        "http://www.ncbi.nlm.nih.gov/pubmed/9665111",
        "http://www.ncbi.nlm.nih.gov/pubmed/24659706",
        "http://www.ncbi.nlm.nih.gov/pubmed/31819925",
        "http://www.ncbi.nlm.nih.gov/pubmed/20231891",
        "http://www.ncbi.nlm.nih.gov/pubmed/30619317",
        "http://www.ncbi.nlm.nih.gov/pubmed/17996912",
        "http://www.ncbi.nlm.nih.gov/pubmed/8988928",
        "http://www.ncbi.nlm.nih.gov/pubmed/26472066",
        "http://www.ncbi.nlm.nih.gov/pubmed/17555783",
        "http://www.ncbi.nlm.nih.gov/pubmed/2011642",
        "http://www.ncbi.nlm.nih.gov/pubmed/9153983",
        "http://www.ncbi.nlm.nih.gov/pubmed/19879568",
        "http://www.ncbi.nlm.nih.gov/pubmed/39633351",
        "http://www.ncbi.nlm.nih.gov/pubmed/39452740",
        "http://www.ncbi.nlm.nih.gov/pubmed/39449682",
        "http://www.ncbi.nlm.nih.gov/pubmed/35789228",
        "http://www.ncbi.nlm.nih.gov/pubmed/35818561",
        "http://www.ncbi.nlm.nih.gov/pubmed/12730482",
        "http://www.ncbi.nlm.nih.gov/pubmed/39186558",
        "http://www.ncbi.nlm.nih.gov/pubmed/10448707",
        "http://www.ncbi.nlm.nih.gov/pubmed/37748059",
        "http://www.ncbi.nlm.nih.gov/pubmed/39492784",
        "http://www.ncbi.nlm.nih.gov/pubmed/18042534",
        "http://www.ncbi.nlm.nih.gov/pubmed/36642911",
        "http://www.ncbi.nlm.nih.gov/pubmed/38116465",
        "http://www.ncbi.nlm.nih.gov/pubmed/22907811",
        "http://www.ncbi.nlm.nih.gov/pubmed/15228240",
        "http://www.ncbi.nlm.nih.gov/pubmed/24489732",
        "http://www.ncbi.nlm.nih.gov/pubmed/20500831",
        "http://www.ncbi.nlm.nih.gov/pubmed/32609837"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1187,
          "offsetInEndSection": 1262,
          "text": "G. duodenalis infections, highlighting their potential to induce severe IDA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38865402"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Hookworm, a parasitic infection, retains a considerable burden of disease, affecting the most underprivileged segments of the general population in endemic countries and remains one of the leading causes of mild to severe anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37863671"
        },
        {
          "offsetInBeginSection": 1543,
          "offsetInEndSection": 1646,
          "text": "PZQ in pregnant women with S. haematobium found PZQ to be safe, effective, and reducing maternal anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39368731"
        },
        {
          "offsetInBeginSection": 791,
          "offsetInEndSection": 909,
          "text": "hookworm (16%; 52/325), Schistosoma mansoni (10.8% 35/325) Ascaris lumbricoides (1.9%; 6/325), and Trichuris trichiura",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38182648"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 322,
          "text": "Patients infected with schistosomiasis often exhibit a distinct hematological profile, including anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809265"
        },
        {
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1236,
          "text": "apart from iron deficiency anemia and vascular dysfunction contributed in part by adhesion of infected RBC to endothelium, decreases in hematocrit and hemoglobin levels, as part of pancytopenia and thrombocytopenia, are characteristic of Plasmodium infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38857772"
        },
        {
          "offsetInBeginSection": 661,
          "offsetInEndSection": 960,
          "text": "First, an acute systemic illness with anemia, constitutional manifestations and variable stigmata of organ involvement; acute graft dysfunction can lead to confusion and acute rejection. Protozoa including malarial Plasmodium, Leishmania, Trypanosoma and Toxoplasma are associated with this profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16941042"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "The anemia in malarial infections is explained by the fact that each parasite destroys several red corpuscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868324"
        },
        {
          "offsetInBeginSection": 605,
          "offsetInEndSection": 845,
          "text": "Hookworm infections in man, especially in children, are one of the leading causes of iron-deficiency anemia resulting directly from intestinal capillary blood loss following the feeding activities of fourth-stage (L4) larva and adult worms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10438896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Concomitant infections with malaria and intestinal parasitic infections may be associated with anemia in children (0-10 yr). This study determined the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38151048"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1061,
          "text": "Anemia is estimated to affect half the school-age children and adolescents in developing countries. The main causes are parasitic infections, malaria, and low iron intake. This study aimed to describe the prevalence of anemia, parasitic infections, and nutritional status of children attending public primary schools in Aracaju, Northeast Brazil. Of 360 students, 26.7% were anemic, and prevalence was higher in children under 8 and over 15 years of age. Overall prevalence of intestinal parasites was 42%, with Ascaris lumbricoides (28.7%), Trichuris trichiura (15.6%), and hookworm (1. 7%) most frequently found. There was an association between parasitic infections and poor sanitary conditions, but there was no association between anemia and presence of intestinal parasites. Height-for-age Z scores were lower than the NCHS standard, and prevalence of stunting was 5.4%. Although intestinal parasites were not associated with anemia, children with parasites had lower nutritional indices (weight- and height-for-age Z scores) than those without parasites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/10409794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1150,
          "text": "Parasites can have a wide range of pathophysiological effects on the host. This review describes those associated with some parasites of major importance in man and animals. Haemoprotozoan diseases such as trypanosomiasis and malaria are primarily associated with anaemia. Such anaemias have a complex aetiology involving various mechanisms responsible for red cell destruction as well as possible defects in red cell production. In addition to these haematological effects these diseases are associated with marked disturbances in heart function and the nervous, immune and urinary systems. The other major groups of parasitic diseases are those associated with the gastrointestinal tract. The most advanced studies have been conducted on the pathophysiology of gastrointestinal nematode parasites of sheep and have revealed significant effects on feed intake, gastrointestinal function, and protein and energy metabolism. Similar studies have yet to be conducted in other hosts and parasitic diseases. There is also a need to examine in greater detail the factors which can modulate pathophysiological responses by the host to parasitic infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/3295690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1575,
          "text": "Helminthic and intestinal protozoan infections and malaria infections are common in children less than 15 yr old in sub-Saharan Africa, but little is known about these infections in Guinea. The aim of this study was to determine the prevalence of parasitic infections in children aged less than 15 yr and the relationship of these infections with anemia. The cross-sectional study was done in Dabbis sub-prefecture in the Boke region of Guinea from 18 to 26 March 2017. A simple random sampling at the household level was performed, and 1 child under the age of 15 was included per eligible household. A total of 392 children were included in the analysis. Clinical and parasitological information were assessed, including anthropometric measures (weight and height), disease symptoms, hemoglobin level, and malaria parasitemia. Helminthic and protozoan intestinal infections were present in 59.7% of the children surveyed. Malaria infection prevalence was 45.5% when assessed by microscopy and 43.6% when assessed by a rapid diagnostic test. Plasmodium falciparum, accounting for 84.2% of malaria infections, was the main malaria species infection. Gastrointestinal parasites were present in 19.1% of children. The main gastrointestinal parasites present included Entamoeba coli (5.4%) and Giardia intestinalis (5.1%). There was no association between the presence of anemia and the parasitic status of the children. Parasitic screening and mass treatment in this age group, as well as household awareness raising, would reduce cases of parasitic infections in rural Guinea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34581794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1641,
          "text": "Malnutrition, resulting from various etiologies, is common in rural Chadian women and children. This cross-sectional study assessed the spectrum of parasitic infection and level of anemia and their effect on nutritional status in settled and mobile pastoral mothers and children near Lake Chad. Intestinal parasites were evaluated using direct fecal smears and the Kato-Katz technique. Malaria status was determined using Paracheck-Pf(®) rapid diagnostic test, and anemia was assessed with the Hemocue photometer. Nutritional status was evaluated using anthropometric parameters. At the end of the 2008 wet season, the prevalence of malnutrition was 36% [confidence interval (CI) 30-42] among women and 15% (CI 11-18) among children. The prevalence of intestinal parasitic infection was 75% (CI 68-83) among women and 60% (CI 53-66) among children. The predominant helminth species was Ascaris lumbricoides while Entamoeba histolytica/dispar was the most common protozoan. The hookworm prevalence was 14% (CI 8-20) in women and 18% (CI 13-23) in children. Malaria prevalence was low among women (1%, CI 0.5-2) and children (3% CI 2-5). No significant difference was observed in the prevalence of parasitic infection between the mobile pastoralist and rural sedentary populations. Thirty-four percent (CI 27-40) of nonpregnant women, 53% (CI 34-72) of pregnant women, and 27% (CI 23-32) of children were anemic. In subjects infected with Plasmodium, all women and 54% (CI 22-85) of children were anemic. Malnutrition was significantly associated with anemia in mothers and with selected intestinal parasites, anemia and age in their children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/22160444"
        },
        {
          "offsetInBeginSection": 1602,
          "offsetInEndSection": 1859,
          "text": "Additionally, a previous diagnosis of parasitic infection, children aged 24-35 months, early weaning, a malaria diagnosis within the past three months, and diarrhea in the last two weeks were significant predictors of anemia in children aged 6 to 59 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39289696"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 450,
          "text": "A multivariable analysis was performed to evaluate the association of anemia with the presence of intestinal parasites",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39194139"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 272,
          "text": "Haemoprotozoan diseases such as trypanosomiasis and malaria are primarily associated with anaemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3295690"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 931,
          "text": "parasite products has been implicated in the pathogenesis of malarial anemia. The identity of this putative host factor is unknown, but antibody neutralization studies have ruled out interleukin-1beta, tumor necrosis factor alpha, and gamma interferon while injection of interleukin-12 protects susceptible mice against lethal P. chabaudi infection. In this study, we report that ingestion of P. chabaudi-infected erythrocytes or",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10722628"
        },
        {
          "offsetInBeginSection": 622,
          "offsetInEndSection": 749,
          "text": "As the patient had a history of coming from an endemic area, anemia, thrombocytopenia, and splenomegaly, malaria was considered",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39735841"
        },
        {
          "offsetInBeginSection": 1853,
          "offsetInEndSection": 2190,
          "text": "econdary efficacy outcomes were any malaria parasitaemia (on either microscopy or malaria rapid diagnostic test), all-cause unscheduled clinic visits, all-cause and malaria-specific hospitalisation, sickle cell anaemia-related events (including vaso-occlusive crises, acute chest syndrome, stroke), need for blood transfusion, and death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39718172"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 154,
          "text": "Babesia is a tick-borne protozoan blood parasite that can cause hemolytic anemia, thrombocytopenia, lethargy and splenomegaly in giant pandas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716228"
        },
        {
          "offsetInBeginSection": 1385,
          "offsetInEndSection": 1478,
          "text": "st-trimester malaria was associated with increased prevalence of anemia later in pregnancy. W",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39705264"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 838,
          "text": "Hookworm, Plasmodium, and Schistosoma infections contribute to anemia, but their influence on dietary iron absorption and recycling is unknown.OBJECTIVE: The objective was to measure inflammation biomarkers, hepcidin, iron absorption, and utilization pre- and posttreatment in children with afebrile malaria, hookworm, and Schistosoma haematobium infection.DESIGN: Ivorian children aged 11-17 y with afebrile Plasmodium falciparum (n \u003d 17), hookworm (n \u003d 16), or S. haematobium infection (n \u003d 8) consumed a syrup containing 3 mg ⁵⁷Fe as ferrous sulfate and received an intravenous infusion of 50 μg ⁵⁸Fe as ferrous citrate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25733630"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 665,
          "text": "Hookworm infections, caused by the nematodes Necator americanus and Ancylostoma duodenale, involve the gastrointestinal tract, causing iron-deficiency anemia.OBJECTIVES: To evaluate the rate of iron-deficiency anemia related to hookworm infections among immigrants from an endemic area.METHODS: We retrospectively studied the medical records of all Ethiopians over the age of 18, who immigrated to Israel in the early 90\u0027s, in two primary care clinics of Clalit Health Services in Ofakim.RESULTS: Sixty patients (64%) had evidence of A. duodenale infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14518163"
        },
        {
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1197,
          "text": "Iron and inflammation biomarkers and hepcidin were measured.RESULTS: Geometric mean iron absorptions in the afebrile malaria and hookworm groups were 12.9% and 32.2% (P \u003c 0.001) before treatment and 23.6% and 30.0% (P \u003d 0.113) after treatment, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25733630"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "The two main agents of human malaria, Plasmodium vivax and Plasmodium falciparum, can induce severe anemia and provoke strong, complex immune reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18725923"
        },
        {
          "offsetInBeginSection": 947,
          "offsetInEndSection": 1240,
          "text": "Patients infected with A. duodenale had significantly lower mean corpuscular volume (MCV) and serum iron, and were likely to have eosinophilia and hypoalbuminemia.CONCLUSION: Among the Ethiopian immigrant population, Ancylostoma duodenale infection is a common cause of iron deficiency anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14518163"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Two hookworm parasites, Necator americanus and Ancylostoma duodenale, infect approximately one billion people worldwide. These hookworms are one of the leading causes of iron-deficiency anaemia especially in children,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11060728"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Visceral leishmaniasis (VL) is caused by parasitic protozoa of the genus Leishmania and is characterized by clinical manifestations such as fever, hepatosplenomegaly and anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31738750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "The two main agents of human malaria, Plasmodium vivax and Plasmodium falciparum, can induce severe anemia ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18725923"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "Haematological and biochemical studies were done for 50 urban and rural Egyptians, from Cairo, suffering from A. duodenale, A. lumbricoides, E. vermicularis, H. nana, S. mansoni and T. saginata. Anaemia of varying degree was noticed in all cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2332643"
        },
        {
          "offsetInBeginSection": 1055,
          "offsetInEndSection": 1377,
          "text": "lasmodium species were significantly associated with anaemia (13.3%, χ2 \u003d 23.290, p \u003c 0.001). Also, the presence of Schistosoma haematobium (3.7%, χ2 \u003d 7.267, p \u003d 0.008), Schistosoma mansoni (5.3%, χ2 \u003d 5.414, p \u003d 0.023) and hookworm (3.7%, χ2 \u003d 11.267, p \u003d 0.008) were significantly associated with anaemia in pregnancy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057071"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 317,
          "text": "Plasmodium falciparum and Plasmodium vivax cause the major human malarias, with P falciparum being the more virulent. During their blood stages of infection, both P falciparum and P vivax induce anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008186"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 525,
          "text": "The major risk factors for anaemia were multiple parasitic infection, high intensity of parasitic (Ascaris lumbricoides) infection and drinking tea soon after a meal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12197322"
        },
        {
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1286,
          "text": "Malaria was associated with anemia (P \u003c 0.001), whereas schistosomiasis was associated with anemia and iron deficiency (P \u003c 0.001 and P \u003c 0.05, respectively).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9665111"
        },
        {
          "offsetInBeginSection": 1287,
          "offsetInEndSection": 1413,
          "text": "Hookworm infestation was associated with iron deficiency (P \u003c 0.05) and with anemia (P \u003c 0.01) only in adolescents and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9665111"
        },
        {
          "offsetInBeginSection": 395,
          "offsetInEndSection": 506,
          "text": "Of all Helminthes, hookworms cause the most severe anemia because of iron deficiency due to chronic blood loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9253675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1455,
          "text": "Malaria is a parasitic infection characterized by anemia, splenomegaly and periodic fever. This infection has a tendency to cause serious complications. Falciparum malaria could occur in our country as an imported case due to increasing intercontinental travel opportunities. The World Health Organisation (WHO) recommends arthemether combination treatment as a first line choice. Here we report a Turkish case admitted to the hospital with high fever, sweating and fatigue. He had been in Uganda for 6 months without prophylaxis. Plasmodium falciparum with an intense parasitic load was diagnosed. We started arthemether-lumefantrine combination therapy immediately. 18 days after his discharge he was readmitted with the same complaints and parasitemia was detected once again. This time, we treated him with the quinine-tetracycline combination regime for 7 days. Within 48 hours the patient was afebrile and the blood smear was negative. Falciparum malaria must be considered in infection emergencies for febrile patients especially with any travel history. For an initial therapy, arthemetherlumefantrine combination is a successful choice of treatment. Even with adequate treatment of arthemether-lumefantrine combination, the problems of recurrence (recrudescence or reinfection) could occur due to treatment failure. For the possibility of recurrence, close monitoring of patients is very important in the critical course after adequate treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24659706"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 320,
          "text": "Soil-transmitted helminths (STHs) are a group of parasitic worms that infect humans, causing a wide spectrum of disease, notably anaemia, growth retardation, and delayed cognitive development. The three main STHs are Ascaris lumbricoides, Trichuris trichiura and hookworm ( Necator americanus and Ancylostoma duodenale).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31819925"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Schistosomiasis is a significant parasitic infection creating disease burden throughout many of the world\u0027s developing nations. Iron deficiency anemia is also a significant health burden resulting from both nutritional deficit as well as parasitic infection in these countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20231891"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Human visceral leishmaniasis, a parasitic disease of major public health importance in developing countries, is characterized by variable degrees of severity of anemia,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30619317"
        },
        {
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1220,
          "text": "Malaria parasitaemia, hookworm infection, C-reactive protein, gravidity and gestational age were associated with Hb status. Malaria parasitaemia, Ascaris lumbricodes and Trichuris trichiura infections and age were associated with SF. Malaria, hookworm infections and iron deficiency were associated with anaemia in the study population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17996912"
        },
        {
          "offsetInBeginSection": 1121,
          "offsetInEndSection": 1297,
          "text": "Infection with malaria, Trichuris trichiura, Ascaris lumbricoides, and hookworms were all associated with worse iron status; the association with hookworms was strongest by far",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8988928"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 580,
          "text": "The most common causes of anemia are poor nutrition, iron deficiencies, micronutrients deficiencies including folic acid, vitamin A and vitamin B12, diseases like malaria, hookworm infestation and schistosomiasis, HIV infection and genetically inherited hemoglobinopathies such as thalassemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26472066"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "It is suggested that helminths, particularly hookworm and schistosomiasis, may be important causes of anaemia in pregnancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17555783"
        },
        {
          "offsetInBeginSection": 521,
          "offsetInEndSection": 648,
          "text": "Hookworm disease is generally asymptomatic, but in heavy infection, leads to iron deficiency and hypochromic, microcytic anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2011642"
        },
        {
          "offsetInBeginSection": 697,
          "offsetInEndSection": 741,
          "text": "Hookworms cause anaemia and hypoproteinaemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9153983"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Trichuris dysentery syndrome: a common cause of chronic iron deficiency anemia in adults in an endemic area",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19879568"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 670,
          "text": "al malaria.METHODS: Children 6 months to 4 years of age admitted at Jinja and Mulago hospitals in Uganda, with one or more of the five most common forms of SM, cerebral malaria (n \u003d 53), respiratory distress syndrome (n \u003d 108), malaria with complicated seizures (n \u003d 160), severe malarial anaemia (n \u003d 155) or prostration (n \u003d 75), were followed for 12 months after discharge, alongside asymptomatic community children (CC) (n \u003d 120) of similar ages recruited from the households or neighbourhoods of t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39633351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Severe malarial anemia (SMA, Hb \u003c 6.0 g/dL) is a leading cause of childhood morbidity and mortality in holoendemic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39452740"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "BACKGROUND: Children with severe malarial anemia (SMA) typically have low in-hospital mortality but have a high risk of post-discharge readmissi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39449682"
        },
        {
          "offsetInBeginSection": 1299,
          "offsetInEndSection": 1559,
          "text": "mia and 56% (28) had severe anemia. In this study, anemia was significantly associated with a history of intestinal protozoan infection [AOR \u003d 2.55, 95% CI \u003d 1.28-10.42], malaria infection [AOR \u003d 5.01, 95% CI \u003d 0.18-11.44] and soil-transmitted helminths infect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35789228"
        },
        {
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1597,
          "text": "emia and 55.6% (5) had severe anemia. In this study, anemia was significantly associated with recent intestinal protozoan infection [AOR\u003d2.13, 95% CI\u003d1.35-9.270], malaria infection [AOR\u003d5.42, 95% CI\u003d0.307-11.034] and soil-transmitted helminths i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35818561"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 271,
          "text": "Haemoprotozoan diseases such as trypanosomiasis and malaria are primarily associated with anaemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3295690"
        },
        {
          "offsetInBeginSection": 306,
          "offsetInEndSection": 500,
          "text": "Among parasitic infections, malaria and intestinal helminths coexist widely with micronutrient deficiencies and contribute importantly to anemia and this cycle of retarded growth and development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730482"
        },
        {
          "offsetInBeginSection": 605,
          "offsetInEndSection": 844,
          "text": "Hookworm infections in man, especially in children, are one of the leading causes of iron-deficiency anemia resulting directly from intestinal capillary blood loss following the feeding activities of fourth-stage (L4) larva and adult worms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10438896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Trichuriasis may be asymptomatic or, in heavy infection, lead to profuse, bloody diarrhea and rectal prolapse. Diagnosis is made by finding the distinctive barrel shaped eggs in the stool or in the heavily infested patient, by anoscopy and identifica",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2011642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Parasitic infections are a common problem in developing countries and can intensify morbidity in patients with sickle cell disease (SCD), increasing the severity of anemia and the need for transfusions. It has been demonstrated that both helminths an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39000364"
        },
        {
          "offsetInBeginSection": 914,
          "offsetInEndSection": 1212,
          "text": "Single infections of hookworm (adjusted odds ratio [aOR] \u003d 3.11, 95% CI: 1.64-5.87) in pregnancy were associated with anemia at parturiency, whereas malaria single infections were associated with anemia (aOR \u003d 4.28, 95% CI: 2.17-8.23) and adverse pregnancy outcomes (aOR \u003d 2.94, 95% CI: 1.47-5.91).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38981502"
        },
        {
          "offsetInBeginSection": 1213,
          "offsetInEndSection": 1484,
          "text": "Moreover, intestinal helminth coinfections in pregnancy were associated with anemia (aOR \u003d 13.3, 95% CI: 4.8-36.8), whereas malaria-helminth coinfections were associated with anemia (aOR \u003d 7.47, 95% CI: 3.71-15.04) and adverse pregnancies (aOR \u003d 4.75, 95% CI: 2.36-9.57).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38981502"
        },
        {
          "offsetInBeginSection": 1485,
          "offsetInEndSection": 1633,
          "text": "Overall, the study showed that Plasmodium and intestinal helminth infections in pregnancy are associated with anemia and adverse pregnancy outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38981502"
        },
        {
          "offsetInBeginSection": 1596,
          "offsetInEndSection": 1870,
          "text": "Amongst community members, there was a need for improved sensitisation around malaria and helminth infections as potential causes of anaemia and provision of education around the purpose of iron and folic acid supplementation for preventing or managing anaemia in pregnancy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39186558"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "The main sequela of helminthic infections is anemia, causing increased perinatal mortality and morbidity worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10448707"
        },
        {
          "offsetInBeginSection": 774,
          "offsetInEndSection": 976,
          "text": "Malaria-induced anemia is exacerbated by increased hepcidin, which impairs iron absorption, reducing both iron availability for the parasite and red blood cell formation, despite elevated erythropoietin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39492784"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 153,
          "text": "Babesia is a tick-borne protozoan blood parasite that can cause hemolytic anemia, thrombocytopenia, lethargy and splenomegaly in giant pandas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716228"
        },
        {
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1413,
          "text": "Malaria was associated with anemia (P \u003c 0.001), whereas schistosomiasis was associated with anemia and iron deficiency (P \u003c 0.001 and P \u003c 0.05, respectively). Hookworm infestation was associated with iron deficiency (P \u003c 0.05) and with anemia (P \u003c 0.01) only in adolescents and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9665111"
        },
        {
          "offsetInBeginSection": 1389,
          "offsetInEndSection": 1491,
          "text": "ot be associated with iron deficiency. Trichuris infection is associated with a doubled risk of anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18042534"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 212,
          "text": "lasmodium parasites cause malaria with disease outcomes ranging from mild illness to deadly complications such as severe malarial anemia (SMA), pulmonary edema, acute renal failure, and cerebral malaria. In youn",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37748059"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 276,
          "text": "well-being. Moreover, parasitic infections are important causes of anemia in tropical Africa, exacerbated by lack of a diversified diet and inflammatory and genet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420905"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 301,
          "text": " the globe. The main causes of anemia are iron deficiency, parasitic infestations, viral infections (human immunodeficiency virus), hemorrhage, and renal and hepat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38074259"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "As a common soil-borne nematode, hookworm is mainly parasitized in the intestine, and the clinical manifestations of hookworm infections mainly include gastrointestinal symptoms and iron-deficiency anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36642911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Hookworm infection is an important cause of iron deficiency anemia, especially in heavily infected high-risk populations residing in underdeveloped tropical countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38116465"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "BACKGROUND: Among the diseases imported by the Ethiopian immigrants to Israel are many parasite infections. Hookworm infections, caused by the nematodes Necator americanus and Ancylostoma duodenale, involve the gastrointestinal tract, causing iron-defici",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14518163"
        },
        {
          "offsetInBeginSection": 521,
          "offsetInEndSection": 649,
          "text": "Hookworm disease is generally asymptomatic, but in heavy infection, leads to iron deficiency and hypochromic, microcytic anemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2011642"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 580,
          "text": "Anemia in this infection is caused by a variety of pathophysiologic mechanisms, and in areas where malaria infection is endemic, co-morbidities like other parasitic infestations, iron, folate and Vitamin B12 deficiency, deficiency of other nutrients, and anemia, which is aggravated by anti-malarial drugs both through immune and non-immune mechanisms, are important considerations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17874326"
        },
        {
          "offsetInBeginSection": 395,
          "offsetInEndSection": 505,
          "text": "Of all Helminthes, hookworms cause the most severe anemia because of iron deficiency due to chronic blood loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9253675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Malaria and schistosomiasis are the world\u0027s two most important parasitic infections in terms of distribution, morbidity, and mortality",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22907811"
        },
        {
          "offsetInBeginSection": 1485,
          "offsetInEndSection": 1601,
          "text": "Overall, the study showed that Plasmodium and intestinal helminth infections in pregnancy are associated with anemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38981502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Nutritional deficiency and malaria are 2 major causes of anaemia during pregnancy in tropical areas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15228240"
        },
        {
          "offsetInBeginSection": 2684,
          "offsetInEndSection": 2817,
          "text": "In pregnant women, malaria can cause anemia which can be the major cause of maternal mortality, especially during the first pregnancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9253675"
        },
        {
          "offsetInBeginSection": 1469,
          "offsetInEndSection": 1617,
          "text": "g number of co-infecting helminth species. Anaemia prevalence was 34.4% and was significantly associated with malaria infection, S. haematobium infe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24489732"
        },
        {
          "offsetInBeginSection": 914,
          "offsetInEndSection": 1210,
          "text": "Single infections of hookworm (adjusted odds ratio [aOR] \u003d 3.11, 95% CI: 1.64-5.87) in pregnancy were associated with anemia at parturiency, whereas malaria single infections were associated with anemia (aOR \u003d 4.28, 95% CI: 2.17-8.23) and adverse pregnancy outcomes (aOR \u003d 2.94, 95% CI: 1.47-5.91",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38981502"
        },
        {
          "offsetInBeginSection": 1213,
          "offsetInEndSection": 1482,
          "text": "Moreover, intestinal helminth coinfections in pregnancy were associated with anemia (aOR \u003d 13.3, 95% CI: 4.8-36.8), whereas malaria-helminth coinfections were associated with anemia (aOR \u003d 7.47, 95% CI: 3.71-15.04) and adverse pregnancies (aOR \u003d 4.75, 95% CI: 2.36-9.57",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38981502"
        },
        {
          "offsetInBeginSection": 1026,
          "offsetInEndSection": 1196,
          "text": "ositive for malaria. Co infection with Plasmodium and helminth parasites is associated with significantly (p \u003c 0.001) higher anaemia prevalence than single infection with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20500831"
        },
        {
          "offsetInBeginSection": 1593,
          "offsetInEndSection": 1811,
          "text": " is not significant.CONCLUSION: Malaria and soil-transmitted helminthiasis obviously contribute to anaemia and low weight status and these conditions are more pronounced in individuals concurrently infected with malari",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20500831"
        },
        {
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1173,
          "text": "1.1 and 8.0%, respectively. The median Hb level was lowest in the presence of hookworms (7.1 g/dl [interquartile range {IQR} 6.8-7.5]), Schistosoma intercalatum (6.9 g/dl), Trichuris trichiura (10.1 g/dl [IQR 8.9-11.5]) and Plasmodium falciparum (10.0 g/dl [IQR 9.1-11.2]) compared with filariaemia (12.1 g",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32609837"
        },
        {
          "offsetInBeginSection": 1176,
          "offsetInEndSection": 1413,
          "text": " [IQR 10.5-13.2]) (p\u003d0.03). Moderate to severe anaemia predominated among those single-infected with P. falciparum (69.5%) or co-infected with intestinal parasitic infections and P. falciparum (76.2%), while it was found in only 23.2% of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32609837"
        }
      ],
      "id": "67e2a8d618b1e36f2e000088",
      "ideal_answer": [
        "Many parasitic infections can cause anemia, namely, infection by Plasmodium spp, Giardia, Hookworm, Schistosoma, Ascaris and Trichuris.",
        "Anemia can be caused by the following parasitic infections: malaria, hookworm, schistosomiasis, giardiasis, toxoplasmosis, leishmaniasis, trypanosomiasis, strongyloidiasis, ascariasis, trichuriasis, and enterobiasis."
      ],
      "exact_answer": [
        [
          "Giardia duodenalis"
        ],
        [
          "Hookworm"
        ],
        [
          "Schistosoma"
        ],
        [
          "Plasmodium"
        ],
        [
          "Ascaris lumbricoides"
        ],
        [
          "Trichiuris trichiura"
        ],
        [
          "Enterobius vermicularis"
        ],
        [
          "Entamoeba histolytica"
        ],
        [
          "Babesia"
        ],
        [
          "Necator americanus"
        ],
        [
          "Ancylostoma duodenalis"
        ],
        [
          "Leishmania"
        ]
      ]
    },
    {
      "body": "What neurotransmitter is most associated with muscle activation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19609303",
        "http://www.ncbi.nlm.nih.gov/pubmed/21747134",
        "http://www.ncbi.nlm.nih.gov/pubmed/36869288",
        "http://www.ncbi.nlm.nih.gov/pubmed/31466388",
        "http://www.ncbi.nlm.nih.gov/pubmed/2410793",
        "http://www.ncbi.nlm.nih.gov/pubmed/33730374",
        "http://www.ncbi.nlm.nih.gov/pubmed/37016047",
        "http://www.ncbi.nlm.nih.gov/pubmed/1322921",
        "http://www.ncbi.nlm.nih.gov/pubmed/24041425",
        "http://www.ncbi.nlm.nih.gov/pubmed/37913983",
        "http://www.ncbi.nlm.nih.gov/pubmed/31307607",
        "http://www.ncbi.nlm.nih.gov/pubmed/30863121",
        "http://www.ncbi.nlm.nih.gov/pubmed/33343299",
        "http://www.ncbi.nlm.nih.gov/pubmed/30050445",
        "http://www.ncbi.nlm.nih.gov/pubmed/38359767",
        "http://www.ncbi.nlm.nih.gov/pubmed/38203326",
        "http://www.ncbi.nlm.nih.gov/pubmed/28027644",
        "http://www.ncbi.nlm.nih.gov/pubmed/35758705",
        "http://www.ncbi.nlm.nih.gov/pubmed/35301478",
        "http://www.ncbi.nlm.nih.gov/pubmed/34385370",
        "http://www.ncbi.nlm.nih.gov/pubmed/35002624",
        "http://www.ncbi.nlm.nih.gov/pubmed/3656016",
        "http://www.ncbi.nlm.nih.gov/pubmed/2428161",
        "http://www.ncbi.nlm.nih.gov/pubmed/7907863",
        "http://www.ncbi.nlm.nih.gov/pubmed/28868330",
        "http://www.ncbi.nlm.nih.gov/pubmed/1338558",
        "http://www.ncbi.nlm.nih.gov/pubmed/25654058",
        "http://www.ncbi.nlm.nih.gov/pubmed/26475617",
        "http://www.ncbi.nlm.nih.gov/pubmed/9087527"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Nicotinic acetylcholine receptors (nAChRs) are homo- or heteropentameric ligand-gated ion channels mediating excitatory neurotransmission and muscle activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19609303"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 232,
          "text": "The contraction of skeletal muscle is controlled by the neurotransmitter acetylcholine (ACh), which is released from the motor nerve terminal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747134"
        },
        {
          "offsetInBeginSection": 601,
          "offsetInEndSection": 824,
          "text": "Acetylcholine (ACh) is the main neurotransmitter at the vertebrate skeletal NMJ, and its role is fine-tuned by co-released purinergic neuromodulators, like adenosine 5\u0027-triphosphate (ATP) and its metabolite adenosine (ADO).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37016047"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Acetylcholine is the primary excitatory neurotransmitter in visceral smooth muscles, wherein it binds to and activates two muscarinic receptors subtypes, M2 and M3, thus causing smooth muscle excitation and contraction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37913983"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 231,
          "text": "The contraction of skeletal muscle is controlled by the neurotransmitter acetylcholine (ACh), which is released from the motor nerve terminal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21747134"
        },
        {
          "offsetInBeginSection": 601,
          "offsetInEndSection": 822,
          "text": "Acetylcholine (ACh) is the main neurotransmitter at the vertebrate skeletal NMJ, and its role is fine-tuned by co-released purinergic neuromodulators, like adenosine 5\u0027-triphosphate (ATP) and its metabolite adenosine (ADO",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37016047"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The neuromuscular junction (NMJ) is a cholinergic synapse where quantal release of acetylcholine (ACh) from motor nerve terminals generates a local endplate potential (EPP) on the muscle fiber",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31307607"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 651,
          "text": "ACh crosses the synaptic gap and binds to ACh receptors (AChRs) tightly clustered on the surface of the muscle fiber; this leads to the endplate potential which initiates the muscle action potential that results in muscle contraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33343299"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 592,
          "text": "To enable physical activity, acetylcholine (ACh) is released repeatedly from the motor nerve, however, the role of the nerve terminals\u0027 capacity to sustain ACh release to support repetitive contractions under compromised neuromuscular transmission remains unclear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38359767"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "The cholinergic system, relying on the neurotransmitter acetylcholine (ACh), plays a significant role in muscle contraction, cognition, and autonomic nervous system regulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38203326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Acetylcholine is an important neurotransmitter that relays neural excitation from lower motor neurons to muscles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28027644"
        },
        {
          "offsetInBeginSection": 257,
          "offsetInEndSection": 651,
          "text": "On arrival of the motor nerve action potential, calcium enters the presynaptic terminal, which leads to the release of the neurotransmitter acetylcholine (ACh). ACh crosses the synaptic gap and binds to ACh receptors (AChRs) tightly clustered on the surface of the muscle fiber; this leads to the endplate potential which initiates the muscle action potential that results in muscle contraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33343299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Motoneurons (MNs) control muscle activity by releasing the neurotransmitter acetylcholine (ACh) at the level of neuromuscular junctions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33730374"
        },
        {
          "offsetInBeginSection": 137,
          "offsetInEndSection": 329,
          "text": "ACh is packaged into synaptic vesicles by the vesicular ACh transporter (VAChT), and disruptions in its release can impair muscle contraction, as seen in congenital myasthenic syndromes (CMS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33730374"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 359,
          "text": "In the neuromuscular synapse, the arrival of the nerve impulse at the presynaptic terminal triggers the molecular mechanisms associated with ACh release, which can be retrogradely regulated by the resulting muscle contraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36869288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Motoneurons (MNs) control muscle activity by releasing the neurotransmitter acetylcholine (ACh) at the level of neuromuscular junctions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33730374"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "At the neuromuscular junction (NMJ), the binding of the excitatory neurotransmitter acetylcholine (ACh) to postsynaptic receptors leads to muscle contraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35758705"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Binding of the neurotransmitter acetylcholine to its receptors on muscle fibers depolarizes the membrane and thereby triggers muscle contraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35301478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "The cholinergic system, relying on the neurotransmitter acetylcholine (ACh), plays a significant role in muscle contraction, cognition, and autonomic nervous system regulation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38203326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "The neurotransmitter acetylcholine (ACh) acts in part through a family of nicotinic ACh receptors (nAChRs), which mediate diverse physiological processes including muscle contraction, neurotransmission, and sensory transduction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385370"
        },
        {
          "offsetInBeginSection": 922,
          "offsetInEndSection": 1080,
          "text": "The presence of ACh in M. moniliformis and the effects of nicotinic agonists on muscle contraction suggest that ACh is a putative excitatory neurotransmitter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3656016"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 340,
          "text": "The motility of the mammalian gastro-intestinal tract is regulated by a number of neuronal systems. The postganglionic, intramural parts of these systems are characterized by their neurotransmitters as cholinergic, adrenergic and \u0027purinergic\u0027 nerves, respectively. The transmitter acetylcholine evokes contractions of the smooth muscle cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2428161"
        },
        {
          "offsetInBeginSection": 1309,
          "offsetInEndSection": 1447,
          "text": "Acetylcholine and tachykinins are co-primary transmitters of muscle motor neurones, with acetylcholine appearing to have the greater role.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7907863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Aldicarb treatment causes an accumulation of acetylcholine in the synaptic cleft of the neuromuscular junction, resulting in sustained muscle activation and eventually paralysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28868330"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 237,
          "text": "Acetylcholine excites the muscle through activation of a nicotinic receptor which resembles the mammalian ganglionic receptor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1338558"
        },
        {
          "offsetInBeginSection": 577,
          "offsetInEndSection": 728,
          "text": "The toxin inhibits the release of acetylcholine (ACH), a neurotransmitter responsible for the activation of muscle contraction and glandular secretion,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25654058"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 259,
          "text": "Acetylcholine (ACh) is the representative neurotransmitter that causes contractions in the gastrointestinal tracts of most animal species",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26475617"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 526,
          "text": "This complexity suggests the existence of neuromediators acting to modulate the effects of the main motor neurotransmitter, acetylcholine, on muscular contraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9087527"
        }
      ],
      "id": "680a07ed18b1e36f2e000149",
      "ideal_answer": [
        "Acetylcholine binds to nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels, and mediates excitatory neurotransmission and muscle activation.",
        "Acetylcholine (ACh) is the primary neurotransmitter associated with muscle activation. It is released by motoneurons at neuromuscular junctions (NMJs) to stimulate skeletal muscle contraction by binding to nicotinic ACh receptors. This process is critical for voluntary muscle control, and disruptions in ACh release or receptor function (e.g., in myasthenia gravis or nerve agent toxicity) impair muscle activity. While ATP and adenosine modulate NMJ function, ACh is the principal neurotransmitter driving muscle activation.",
        "Acetylcholine (ACh) is the main neurotransmitter released by motor neurons at the vertebrate skeletal neuromuscular junction. It binds to acetylcholine receptors on the muscle fiber, generates an endplate potential, depolarizes the muscle membrane, and thereby initiates muscle contraction.",
        "Acetylcholine is the primary neurotransmitter driving muscle activation. Motor neurons release acetylcholine at the neuromuscular junction, where it binds to nicotinic acetylcholine receptors on the muscle fiber membrane. This binding generates an endplate potential that, once it reaches the threshold for sodium channel opening, triggers muscle depolarization and contraction.",
        "Acetylcholine (ACh) is the primary neurotransmitter involved in muscle activation. It is released from motor neurons at the neuromuscular junction and binds to nicotinic acetylcholine receptors (nAChRs) on muscle fibers. This binding triggers a series of events that lead to muscle contraction by allowing ion channels to open, depolarizing the muscle cell membrane, and initiating an action potential.",
        "The neurotransmitter most associated with muscle activation is acetylcholine, which binds to nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction to trigger depolarization and muscle contraction.",
        "Acetylcholine is the neurotransmitter primarily associated with muscle activation. This association is due to the function of nicotinic acetylcholine receptors, which are ligand-gated ion channels that facilitate excitatory neurotransmission and muscle activation.",
        "The neurotransmitter most associated with muscle activation is **acetylcholine**. It binds to nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction, triggering ion channel opening, membrane depolarization, and muscle contraction. This process is essential for voluntary skeletal muscle movement.",
        "The neurotransmitter most associated with muscle activation is **acetylcholine**. It binds to nicotinic acetylcholine receptors (nAChRs), facilitating the electrical signaling required for muscle contraction at neuromuscular junctions.",
        "Acetylcholine is the principal neurotransmitter that activates skeletal muscle at the neuromuscular junction by binding to nicotinic receptors on the muscle fiber, generating the endplate potential and initiating contraction.",
        "The neurotransmitter most associated with muscle activation is acetylcholine. Nicotinic acetylcholine receptors (nAChRs), which are homo- or heteropentameric ligand-gated ion channels, mediate excitatory neurotransmission and directly facilitate muscle activation. Upon binding acetylcholine, these receptors undergo conformational changes that open ion channels, allowing sodium influx and depolarization of the postsynaptic membrane. This process is critical for neuromuscular transmission, enabling skeletal muscle contraction. While other neurotransmitters may modulate muscle function, acetylcholine is the primary excitatory neurotransmitter at the neuromuscular junction, underscoring its central role in initiating muscle activity.",
        "Acetylcholine is the key neurotransmitter associated with muscle activation, working through nicotinic acetylcholine receptors (nAChRs), which are ion channels that mediate excitatory neurotransmission and muscle activation.",
        "The neurotransmitter most associated with muscle activation is acetylcholine, which acts through nicotinic acetylcholine receptors (nAChRs). These receptors are ligand-gated ion channels that mediate neurotransmission and muscle activation, functioning as either homo- or heteropentameric structures.",
        "The neurotransmitter system most closely associated with muscle activation is the nicotinic acetylcholine receptors (nAChRs). These receptors are a type of ligand-gated ion channel that mediate excitatory neurotransmission, a process that plays a crucial role in muscle activation. nAChRs are essential for the transmission of nerve impulses from the nervous system to the muscles, thereby initiating muscle contraction. The nAChRs are a family of receptors that can be homo- or heteropentameric, meaning they can be composed of identical or different subunits. The activation of these receptors by acetylcholine, the neurotransmitter, leads to the opening of the ion channel, allowing the influx of ions, which in turn triggers an action potential in the muscle cell, leading to muscle contraction.",
        "Acetylcholine acts at neuromuscular junctions to trigger muscle contraction by binding to nicotinic acetylcholine receptors (nAChRs), which are pentameric ligand-gated ion channels mediating depolarization and excitation-contraction coupling in skeletal muscles."
      ],
      "exact_answer": [
        [
          "Acetylcholine",
          "ACh",
          "Acetylcholine (ACh)"
        ]
      ]
    },
    {
      "body": "What medical proceedure causes nephrogenic systemic fibrosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32861792",
        "http://www.ncbi.nlm.nih.gov/pubmed/32147002",
        "http://www.ncbi.nlm.nih.gov/pubmed/30978353",
        "http://www.ncbi.nlm.nih.gov/pubmed/19881349",
        "http://www.ncbi.nlm.nih.gov/pubmed/19229801",
        "http://www.ncbi.nlm.nih.gov/pubmed/18264914",
        "https://www.ncbi.nlm.nih.gov/pubmed/18290353",
        "https://www.ncbi.nlm.nih.gov/pubmed/33804005",
        "http://www.ncbi.nlm.nih.gov/pubmed/36211205",
        "http://www.ncbi.nlm.nih.gov/pubmed/19817341",
        "http://www.ncbi.nlm.nih.gov/pubmed/22571387",
        "http://www.ncbi.nlm.nih.gov/pubmed/19022818",
        "http://www.ncbi.nlm.nih.gov/pubmed/20033388",
        "http://www.ncbi.nlm.nih.gov/pubmed/17610072",
        "http://www.ncbi.nlm.nih.gov/pubmed/39284636",
        "http://www.ncbi.nlm.nih.gov/pubmed/37235678",
        "http://www.ncbi.nlm.nih.gov/pubmed/34311048",
        "http://www.ncbi.nlm.nih.gov/pubmed/23040363",
        "http://www.ncbi.nlm.nih.gov/pubmed/17684032",
        "http://www.ncbi.nlm.nih.gov/pubmed/18400614",
        "http://www.ncbi.nlm.nih.gov/pubmed/18802876",
        "http://www.ncbi.nlm.nih.gov/pubmed/28680623",
        "http://www.ncbi.nlm.nih.gov/pubmed/18587720",
        "http://www.ncbi.nlm.nih.gov/pubmed/17934986",
        "http://www.ncbi.nlm.nih.gov/pubmed/17855637",
        "http://www.ncbi.nlm.nih.gov/pubmed/19022548",
        "http://www.ncbi.nlm.nih.gov/pubmed/20406611",
        "http://www.ncbi.nlm.nih.gov/pubmed/24582176",
        "http://www.ncbi.nlm.nih.gov/pubmed/18225999",
        "http://www.ncbi.nlm.nih.gov/pubmed/17699422",
        "http://www.ncbi.nlm.nih.gov/pubmed/18303280",
        "http://www.ncbi.nlm.nih.gov/pubmed/17109993",
        "http://www.ncbi.nlm.nih.gov/pubmed/18834869",
        "http://www.ncbi.nlm.nih.gov/pubmed/22977165",
        "http://www.ncbi.nlm.nih.gov/pubmed/18058663",
        "http://www.ncbi.nlm.nih.gov/pubmed/19011267",
        "http://www.ncbi.nlm.nih.gov/pubmed/21086324",
        "http://www.ncbi.nlm.nih.gov/pubmed/35167789",
        "http://www.ncbi.nlm.nih.gov/pubmed/34060939",
        "http://www.ncbi.nlm.nih.gov/pubmed/18543004",
        "http://www.ncbi.nlm.nih.gov/pubmed/19364606",
        "http://www.ncbi.nlm.nih.gov/pubmed/18290353",
        "http://www.ncbi.nlm.nih.gov/pubmed/18226000",
        "http://www.ncbi.nlm.nih.gov/pubmed/18328659",
        "http://www.ncbi.nlm.nih.gov/pubmed/37128169",
        "http://www.ncbi.nlm.nih.gov/pubmed/38226697",
        "http://www.ncbi.nlm.nih.gov/pubmed/35284914",
        "http://www.ncbi.nlm.nih.gov/pubmed/19939504",
        "http://www.ncbi.nlm.nih.gov/pubmed/28083913",
        "http://www.ncbi.nlm.nih.gov/pubmed/36010167",
        "http://www.ncbi.nlm.nih.gov/pubmed/35495502",
        "http://www.ncbi.nlm.nih.gov/pubmed/25858556",
        "http://www.ncbi.nlm.nih.gov/pubmed/19221265",
        "http://www.ncbi.nlm.nih.gov/pubmed/17890909",
        "http://www.ncbi.nlm.nih.gov/pubmed/21283650",
        "http://www.ncbi.nlm.nih.gov/pubmed/22892775",
        "http://www.ncbi.nlm.nih.gov/pubmed/19488662",
        "http://www.ncbi.nlm.nih.gov/pubmed/21790732",
        "http://www.ncbi.nlm.nih.gov/pubmed/24765365",
        "http://www.ncbi.nlm.nih.gov/pubmed/28193901"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "text": "Gadolinium-based contrast agents (GBCAs) improve the diagnostic capabilities of magnetic resonance imaging. Although initially believed to be without major adverse effects, GBCA use in patients with severe chronic kidney disease (CKD) was demonstrated to cause nephrogenic systemic fibrosis (NSF)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32861792"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "Intravenous and intraarterial contrast media are invaluable tools in the diagnosis of anatomic lesions. However, they have been associated with deleterious renal events, ranging from acute kidney injury (iodinated contrast) to nephrogenic systemic fibrosis (gadolinium-containing agents)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32147002"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "Gadolinium-based contrast agents are implicated in several pathologic abnormalities (long-term retention in vital organs such as the skin and the brain) and are the cause of a sometimes fatal condition in patients, nephrogenic systemic fibrosis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30978353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "PURPOSE OF REVIEW: A review of nephrogenic systemic fibrosis (NSF), a severe disorder described in patients with renal disease, appears as timely as the pathogenic role of gadolinium-based contrast agents (GdBCAs) has now been convincingly demonstrated, leading to pre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19881349"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 510,
          "text": "Nephrogenic systemic fibrosis (NSF) is a relative new disease affecting predominantly patients with severely impaired kidney function. Strict adherence to a concordant clinical and pathological definition has allowed for careful separation of this entity from other fibrosing disorders, leading eventually to the realization that gadolinium based contrast agents were closely associated with its onset. Gadodiamide and similarly unstable Gd-CA should therefore not be used in patients with renal insufficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19229801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Nephrogenic systemic fibrosis (NSF) is a new, rare, and severe disease occurring in patients with renal failure who have been exposed to gadolinium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18264914"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 514,
          "text": "Nephrogenic systemic fibrosis (NSF) is a newly recognized systemic disorder characterized by widespread tissue fibrosis in patients with impaired renal function. Recent reports suggest that NSF is associated with exposure to gadolinium-based contrast agents used in magnetic resonance imaging. NSF can be very debilitating and can lead to serious complications and death. Health care providers should exercise caution when considering the use of gadolinium-based imaging studies in patients with renal dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/18290353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33804005"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 251,
          "text": "Beginning in 2006, neuroradiologists became increasingly aware of the risk of nephrogenic system fibrosis (NSF) when patients suffering from chronic kidney disease (CKD) received gadolinium-based contrast agents (GBCAs) in conjunction with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39284636"
        },
        {
          "offsetInBeginSection": 720,
          "offsetInEndSection": 841,
          "text": "Administration of gadolinium-based contrast media in magnetic resonance imaging may lead to nephrogenic systemic fibrosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37235678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317,
          "text": "As nephrogenic systemic fibrosis (NSF) and increased signal intensities in deep cerebellar nuclei (DCN) were successively discovered in renal insufficiency patients and healthy persons after gadolinium-based contrast agents (GBCAs) exposure, an awareness of potential toxicity with GBCAs exposure has been heightening",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34311048"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Nephrogenic systemic fibrosis (NSF) is a novel disease entity, increasingly diagnosed over the last years in patients with renal functional impairment and chronic kidney disease. Recently, gadolinium-containing MR contrast agents have been causally associated with the development NSF.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18802876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen in patients with renal dysfunction, commonly precipitated by administration of gadolinium contrast.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28680623"
        },
        {
          "offsetInBeginSection": 3,
          "offsetInEndSection": 155,
          "text": "ECTIVE: To identify medications and other potential risk factors, in addition to renal dysfunction, for developing gadolinium-induced nephrogenic system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17684032"
        },
        {
          "offsetInBeginSection": 720,
          "offsetInEndSection": 853,
          "text": "Administration of gadolinium-based contrast media in magnetic resonance imaging may lead to nephrogenic systemic fibrosis. Therefore,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37235678"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Nephrogenic systemic fibrosis (NSF) is an iatrogenic fibrosing disorder that primarily affects individuals with chronic kidney disease (CKD) following exposure to gadolinium-based contrast agents (GBCAs) during imaging procedures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder that develops in patients with underlying kidney disease following exposure to gadolinium-containing contrast agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19022818"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Nephrogenic systemic fibrosis is a new disorder reported almost exclusively in patients who have renal insufficiency and are exposed to contrast media formulated with gadolinium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17855637"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 427,
          "text": "The application of gadolinium-containing contrast media in patients with decreased renal function can lead to gadolinium deposition in various tissues which induces the fibrotic process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17610072"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 250,
          "text": "It has been demonstrated in recent studies that NSF can be caused by some gadolinium-containing MRI contrast agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17934986"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 421,
          "text": "An association has been found with the administration of gadolinium-containing contrast agents, which are given to provide enhanced contrast during magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20406611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Nephrogenic systemic fibrosis is a progressive, potentially fatal multiorgan system fibrosing disease related to exposure of patients with renal failure to the gadolinium-based contrast agents used in magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817341"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Nephrogenic systemic fibrosis (NSF) is a progressive, potentially fatal systemic multiorgan fibrosing disease related to exposure of patients with advanced renal failure to the gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20033388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Nephrogenic systemic fibrosis (NSF) occurs in patients with advanced chronic kidney disease (CKD) or acute renal failure, most commonly following exposure to gadolinium-based contrast agents (GBCAs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24582176"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder of patients with kidney disease that is associated with gadolinium-based contrast exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19022548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Nephrogenic systemic fibrosis (NSF) is a disabling and potentially fatal disease that has been associated with gadolinium-based contrast (GBC) agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18225999"
        },
        {
          "offsetInBeginSection": 271,
          "offsetInEndSection": 380,
          "text": "Recent case reports associated the use of gadolinium (Gd3+)-based contrast agents with the development of NSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17699422"
        },
        {
          "offsetInBeginSection": 660,
          "offsetInEndSection": 872,
          "text": "Recent reports suggest a possible etiologic link between systemic administration of gadolinium-containing magnetic resonance imaging contrast agents in patients with renal insufficiency and the development of NSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18303280"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 256,
          "text": "There is growing recognition of the association between the use of gadolinium-containing radiocontrast agents for magnetic resonance imaging and the serious dermal and systemic disease nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis (NFD/NSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17109993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "BACKGROUND: NSF (nephrogenic systemic fibrosis) is a potentially serious adverse effect for renal patients undergoing MRI (magnetic resonance imaging) procedures using gadolinium-containing con",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18834869"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977165"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 308,
          "text": "Exposure to gadolinium-containing contrast agents used for magnetic resonance imaging has been associated with subsequent development of NSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18058663"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 418,
          "text": "Magnetic resonance imaging (MRI) is applied as an alternative technique but the use of gadolinium (Gd) containing contrast media carries the risk of nephrogenic systemic fibrosis (NSF), a potentially lethal disorder that occurs especially in patients with renal failure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19011267"
        },
        {
          "offsetInBeginSection": 598,
          "offsetInEndSection": 831,
          "text": "The administration of gadolinium-based contrast agents has been recently associated with the development of a serious adverse reaction, potentially lethal in patients with renal insufficiency, named nephrogenic systemic fibrosis (NSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21086324"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Nephrogenic systemic fibrosis typically occurs in patients with renal failure and is strongly associated with gadolinium exposure through stimulation of macrophage-activated fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36211205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Nephrogenic systemic fibrosis (NSF) is a rare disease that can present in patients with kidney injury who have been exposed to gadolinium-based contrast agents (GBCAs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35167789"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "A 66-year-old male patient with end-stage chronic kidney disease undergoing maintenance dialysis and with a history of group I intravenous gadolinium-based contrast media (GBCM) administration presented with clinical and pathologic findings consistent with nephrogenic systemic fibrosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34060939"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Nephrogenic systemic fibrosis (NSF) is a progressive, potentially fatal systemic multiorgan fibrosing disease related to exposure of patients with advanced renal failure to the gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20033388"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 194,
          "text": "The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18543004"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Nephrogenic systemic fibrosis (NSF) is a disabling and potentially fatal disease that has been associated with gadolinium-based contrast (GBC) agents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18225999"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "There seems to be an association between exposure to intravenous gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF), a debilitating and sometimes fatal disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19364606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Nephrogenic systemic fibrosis is a progressive, potentially fatal multiorgan system fibrosing disease related to exposure of patients with renal failure to the gadolinium-based contrast agents used in magnetic resonance imaging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817341"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 292,
          "text": "Recent reports suggest that NSF is associated with exposure to gadolinium-based contrast agents used in magnetic resonance imaging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18290353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Nephrogenic systemic fibrosis has now been linked to gadolinium-based contrast exposure in those with compromised kidney function. When present, symptoms can be quite devastating for the patient including severe pain and immobility. Unfortunately the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18226000"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "BACKGROUND: Beginning in 2006, neuroradiologists became increasingly aware of the risk of nephrogenic system fibrosis (NSF) when patients suffering from chronic kidney disease (CKD) received gadolinium-based contrast agents (GBCAs) in conju",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39284636"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 282,
          "text": "BACKGROUND: The risk of gadolinium (Gd)-based contrast agent (GBCA)-induced nephrogenic systemic fibrosis (NSF) in patients with end-stage renal disease (ESRD) and the efficacy of prophylactic hemodialysis (HD) for protection against NSF are not well understood or summarized in the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37128169"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 536,
          "text": "However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38226697"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Currently, the most commonly used clinical magnetic resonance imaging (MRI) contrast agents, Gd(III) chelates, have been found to be associated with nephrogenic systemic fibrosis (NSF) in renally compromised patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35284914"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 340,
          "text": "Recent research on this disease has delineated an association between nephrogenic systemic fibrosis and exposure to magnetic resonance imaging studies using gadolinium-based contrast agents in patients with ongoing renal failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19939504"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 427,
          "text": "the subsequent identification of GBCAs as the key etiologic factor in the development of nephrogenic systemic fibrosis (NSF) has raised concerns about the broader health impacts of gadolinium exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28083913"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 293,
          "text": "Recent reports suggest that NSF is associated with exposure to gadolinium-based contrast agents used in magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18290353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36010167"
        },
        {
          "offsetInBeginSection": 357,
          "offsetInEndSection": 489,
          "text": "Gadolinium deposition has been shown to be correlated with nephrogenic systemic fibrosis, a fibrosis of the skin and internal organs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35495502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "The need for prophylactic hemodialysis to protect against nephrogenic systemic fibrosis in patients with end-stage renal disease receiving gadolinium-based contrast agents.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37128169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 266,
          "text": "Nephrogenic systemic fibrosis, previously known as nephrogenic fibrosing dermopathy, is a multiorgan sclerotic disorder that is strongly linked to the administration of gadolinium-based chelates used for intravenous contrast in magnetic resonance imaging procedures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25858556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Nephrogenic systemic fibrosis (NSF) is a serious disease that occurs in patients with severe renal disease and is believed to be caused by gadolinium-containing cont",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19221265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Nephrogenic systemic fibrosis is a progressive, potentially fatal, multiorgan-system fibrosing disease related to exposure of patients with renal failure to gadolinium-based contrast agents used in magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22571387"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Nephrogenic systemic fibrosis is a chronic, progressive condition that develops in some patients with renal impairment after exposure to gadolinium-based contrast agents used in magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22892775"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder, recently described in patients with advanced chronic kidney disease, usually after exposure to gadolinium (Gd)-based contrast agents, characterized by progressive fibrotic involvement mainly of the skin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19693506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is a rare complication of exposure to gadolinium-based contrast agents in patients who have significantly decreased renal function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695022"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Nephrogenic systemic fibrosis (NSF) / nephrogenic fibrosing dermopathy (NFD) is a recently described disease, occurring only in patients with variable degrees of renal failure (RF) previously exposed to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18587720"
        },
        {
          "offsetInBeginSection": 1369,
          "offsetInEndSection": 1555,
          "text": "In conclusion, nephrogenic systemic fibrosis is a serious iatrogenic disease of patients with renal insufficiency caused by some Gd-containing contrast agents, in particular gadodiamide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18328659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Nephrogenic systemic fibrosis (NSF) is an idiopathic, progressive, systemic fibrosis that occurs in patients with renal diseases. Recently, gadolinium-containing contrast (Gd-contrast) has become a suspected causal factor for NFS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18400614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder of patients with kidney disease that is associated with gadolinium-based contrast exposure. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19022548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD), occurs in renal failure patients after gadolinium contrast exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21283650"
        },
        {
          "offsetInBeginSection": 354,
          "offsetInEndSection": 485,
          "text": "several reports described the development of NSF after the exposure to gadolinium-based magnetic resonance imaging contrast agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488662"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 230,
          "text": "Recently, gadolinium-containing contrast (Gd-contrast) has become a suspected causal factor for NFS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18400614"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 426,
          "text": "While GBCAs were initially felt to carry minimal risk, the subsequent identification of GBCAs as the key etiologic factor in the development of nephrogenic systemic fibrosis (NSF) has raised concerns about the broader health impacts of gadolinium exposure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28083913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is a generalized fibrotic disorder occurring in people with renal failure, following exposure to gadolinium-based contrast agents used to enhance MRI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21790732"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Nephrogenic systemic fibrosis, previously known as nephrogenic fibrosing dermopathy, is a multiorgan sclerotic disorder that is strongly linked to the administration of gadolinium-based chelates used for intravenous contrast in magnetic resonance imaging procedures",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25858556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Nephrogenic systemic fibrosis (NSF) / nephrogenic fibrosing dermopathy (NFD) is a recently described disease, occurring only in patients with variable degrees of renal failure (RF) previously exposed to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18587720"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21283650"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 348,
          "text": "The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium-based contrast media used during magnetic resonance imaging in patients with renal insufficiency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24765365"
        },
        {
          "offsetInBeginSection": 429,
          "offsetInEndSection": 694,
          "text": "GBCAs have shown efficacy and are safe to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28193901"
        }
      ],
      "type": "factoid",
      "id": "67e93f2d18b1e36f2e0000db",
      "ideal_answer": [
        "Gadolinium-based contrast agents are implicated in several pathologic abnormalities (long-term retention in vital organs such as the skin and the brain) and are the cause of a sometimes fatal condition in patients, nephrogenic systemic fibrosis.",
        "Nephrogenic systemic fibrosis (NSF) can be caused by MRI procedures that use gadolinium-containing contrast agents. This condition is particularly seen in patients with renal failure and may lead to severe physical disability.",
        "Nephrogenic systemic fibrosis (NSF) is a rare, severe, and progressive disease that occurs in patients with renal failure who have been exposed to gadolinium.",
        "Nephrogenic systemic fibrosis is a rare but life threatening complication of some gadolinium based contrast agents used in patients with chronic kidney disease. The onset occurs several months after administration of the contrast agent, most commonly in patients with renal failure and particularly those with a baseline glomerular filtration rate less than 60 mL/min.",
        "Nephrogenic Systemic Fibrosis (NSF) is primarily caused by the use of Gadolinium-Based Contrast Agents (GBCAs) during Magnetic Resonance Imaging (MRI), particularly in individuals with severe renal failure, as their compromised kidney function hampers the effective clearance of gadolinium, leading to systemic fibrosis.",
        "Nephrogenic systemic fibrosis is a rare but potentially fatal condition that has been reported in patients exposed to certain radiological contrast agents, primarily gadolinium based contrast agents used in magnetic resonance imaging (MRI) scans.",
        "Nephrogenic systemic fibrosis (NSF) is a rare, progressive, and potentially fatal disease that is associated with the use of gadolinium-based contrast agents (GBCAs) in patients with renal insufficiency.",
        "Nephrogenic systemic fibrosis is related to exposure of patients with renal failure to gadolinium-based contrast agents used in magnetic resonance imaging.",
        "Exposure to gadolinium-containing contrast agents during imaging procedures causes nephrogenic systemic fibrosis.",
        "Nephrogenic systemic fibrosis is caused by exposure to gadolinium-based contrast agents during imaging procedures.",
        "Nephrogenic systemic fibrosis is caused by magnetic resonance imaging procedures using gadolinium-based contrast agents, particularly in patients with advanced kidney failure.",
        "Exposure to gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging (MRI) is associated with nephrogenic systemic fibrosis (NSF) in patients with advanced renal failure.",
        "the administration of gadolinium-based contrast agents in Magnetic Resonance Imaging (MRI), particularly in patients with severe kidney disease.",
        "Nephrogenic systemic fibrosis is caused by gadolinium-based contrast agents (GBCAs)",
        "Gadolinium-enhanced magnetic resonance imaging (MRI) causes nephrogenic systemic fibrosis (NSF).",
        "Gadolinium-enhanced MRI causes nephrogenic systemic fibrosis (NSF).",
        "Nephrogenic systemic fibrosis (NSF) is a serious disease that occurs in patients with severe renal disease and is believed to be caused by gadolinium-containing contrast agents used in certain medical imaging procedures.",
        "Nephrogenic systemic fibrosis is caused by exposure to gadolinium-based contrast agents.",
        "Gadolinium-based contrast agents (GBCAs) used during imaging procedures cause nephrogenic systemic fibrosis (NSF).",
        "Nephrogenic systemic fibrosis is a progressive, potentially fatal multiorgan system fibrosing disease related to exposure of patients with renal failure to gadolinium-based contrast agents used in magnetic resonance imaging.",
        "Nephrogenic systemic fibrosis is a progressive, potentially fatal multiorgan system fibrosing disease related to exposure of patients with renal failure to the gadolinium-based contrast agents used in magnetic resonance imaging.",
        "Nephrogenic systemic fibrosis (NSF) is strongly linked to the administration of gadolinium-based contrast agents used in magnetic resonance imaging (MRI) procedures, particularly in patients with chronic or significant acute kidney disease, especially those who are dialysis-dependent. The gadolinium released from these contrast agents can deposit in body tissues, leading to NSF.",
        "Nephrogenic systemic fibrosis (NSF) is a serious condition that occurs in patients with severe renal disease and is caused by exposure to gadolinium-based contrast agents used in magnetic resonance imaging (MRI).",
        "Nephrogenic systemic fibrosis (NSF) is primarily caused by the administration of gadolinium-based contrast agents (GBCAs) during magnetic resonance imaging (MRI), particularly in individuals with severe renal impairment or chronic kidney disease. These agents can lead to gadolinium deposition in tissues when the kidneys are unable to effectively clear them, resulting in NSF.",
        "Nephrogenic systemic fibrosis is triggered by the intravenous administration of gadolinium‐based contrast agents used to enhance magnetic resonance imaging, particularly in patients with advanced renal impairment.",
        "The medical procedure that causes nephrogenic systemic fibrosis is the use of Gadolinium-based contrast agents during Magnetic Resonance Imaging (MRI), particularly in patients with severe renal failure.",
        "Exposure to gadolinium-based contrast agents during imaging procedures causes nephrogenic systemic fibrosis.",
        "Gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging (MRI) have been associated with nephrogenic systemic fibrosis (NSF) in patients with kidney disease.",
        "Nephrogenic systemic fibrosis is caused by gadolinium-based contrast agents.",
        "Nephrogenic systemic fibrosis (NSF) is caused by gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging, particularly in patients with severe chronic kidney disease (CKD). NSF results from the retention of gadolinium in vital organs, leading to sometimes fatal conditions.",
        "Nephrogenic systemic fibrosis is a rare but life threatening condition that develops after the administration of certain contrast agents, such as Gadolinium based contrast agents (GBCAs), in patients with severe chronic kidney disease. This pathology is characterized by progressive and widespread interstitial fibrosis of various organs. There is no proven effective treatment option yet.",
        "Gadolinium-based contrast agents, specifically intravenous gadolinium-based contrast agents, cause nephrogenic systemic fibrosis.",
        "Gadolinium-based contrast agents, typically used during MRI scans, have been associated with nephrogenic systemic fibrosis, especially in patients with severe chronic kidney disease.",
        "The use of gadolinium-based contrast agents in patients with severe chronic kidney disease causes nephrogenic systemic fibrosis.",
        "Gadolinium-based contrast agents (GBCAs) cause nephrogenic systemic fibrosis (NSF) in patients with reduced kidney function after exposure.",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of gadolinium-based contrast agents (GBCAs) during magnetic resonance imaging (MRI) procedures. This condition primarily affects patients with severe chronic kidney disease who are unable to effectively excrete gadolinium, leading to its accumulation and subsequent tissue damage.",
        "Gadolinium-based contrast agent use causes nephrogenic systemic fibrosis.",
        "Nephrogenic systemic fibrosis is caused by gadolinium‐based contrast agents administered during contrast-enhanced magnetic resonance imaging procedures.",
        "Gadolinium-based contrast agents used during MRI procedures, particularly in patients with severe chronic kidney disease, have been linked to the development of nephrogenic systemic fibrosis.",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of gadolinium-based contrast agents (GBCAs) during certain medical imaging procedures, especially in patients with severe chronic kidney disease.",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of gadolinium-based contrast agents (GBCAs) in medical imaging procedures, particularly in patients with severe chronic kidney disease. GBCAs are used to enhance magnetic resonance imaging but can lead to this potentially fatal condition.",
        "Gadolinium-based contrast agents (GBCAs) cause nephrogenic systemic fibrosis (NSF).",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of gadolinium-based contrast agents (GBCAs) in patients with severe chronic kidney disease (CKD).",
        "Nephrogenic systemic fibrosis (NSF) is primarily caused by the use of gadolinium-based contrast agents (GBCAs) during magnetic resonance imaging (MRI), particularly in patients with severe chronic kidney disease. These agents can lead to NSF, a serious condition associated with long-term retention of gadolinium in vital organs and potentially fatal outcomes.",
        "Gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging (MRI) can cause nephrogenic systemic fibrosis (NSF) in patients with severe chronic kidney disease.",
        "Gadolinium-based contrast agents (GBCAs) cause nephrogenic systemic fibrosis (NSF) in patients with severe chronic kidney disease.",
        "The use of gadolinium-based contrast agents in MRI procedures can cause nephrogenic systemic fibrosis, especially in patients with severe chronic kidney disease.",
        "Gadolinium-based contrast agents (GBCAs) improve the diagnostic capabilities of magnetic resonance imaging. Although initially believed to be without major adverse effects, GBCA use in patients with severe chronic kidney disease (CKD) was demonstrated to cause nephrogenic systemic fibrosis (NSF).",
        "Gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging cause nephrogenic systemic fibrosis (NSF).",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of gadolinium based contrast agents (GBCAs), which are commonly administered during magnetic resonance imaging (MRI). This condition primarily affects patients with severe chronic kidney disease (CKD), leading to widespread tissue fibrosis, particularly impacting the skin and other organs.",
        "The administration of Gadolinium-based Contrast Agents (GBCAs) during Magnetic Resonance Imaging (MRI) procedures, particularly in patients with severe Chronic Kidney Disease (CKD), is identified as the medical procedure causing Nephrogenic Systemic Fibrosis (NSF), a potentially fatal condition.",
        "Nephrogenic systemic fibrosis is caused by exposure to gadolinium-based contrast agents used in magnetic resonance imaging (MRI) procedures.",
        "Gadolinium-based contrast agents (GBCAs) improve the diagnostic capabilities of magnetic resonance imaging.",
        "The use of gadolinium-based contrast agents causes nephrogenic systemic fibrosis.",
        "[\u0027The use of gadolinium-based contrast agents (GBCAs) in magnetic resonance imaging (MRI) procedures causes nephrogenic systemic fibrosis, particularly in patients with severe chronic kidney disease.\u0027]",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of Gadolinium-based contrast agents (GBCAs) in patients with severe chronic kidney disease (CKD). These contrast agents are used to enhance magnetic resonance imaging (MRI) scans.",
        "Gadolinium-based contrast agents (GBCAs) improve the diagnostic capabilities of magnetic resonance imaging . GBCA use in patients with severe chronic kidney disease (CKD) was demonstrated to cause nephrogenic systemic fibrosis (NSF) Intravenous and intraarterial contrast media are invaluable tools in the diagnosis of anatomic lesions .",
        "The medical procedure known to cause nephrogenic systemic fibrosis involves the administration of Gadolinium-Based Contrast Agents (GBCAs) during medical imaging procedures, such as MRI, particularly in patients with severe Chronic Kidney Disease (CKD), who are at heightened risk due to their compromised renal function.",
        "The administration of Gadolinium-based contrast agents (GBCAs) during medical imaging procedures, such as MRI, in patients with severe chronic kidney disease (CKD), is the identified cause of nephrogenic systemic fibrosis.",
        "Gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging can cause nephrogenic systemic fibrosis (NSF), particularly in patients with severe chronic kidney disease (CKD). Intravenous and intraarterial contrast media, specifically gadolinium-containing agents, have also been associated with nephrogenic systemic fibrosis.",
        "Nephrogenic systemic fibrosis is caused by the use of gadolinium-based contrast agents during magnetic resonance imaging (MRI) procedures, particularly in patients with severe chronic kidney disease. These agents can lead to long-term retention in organs and are specifically linked to this sometimes fatal condition.",
        "Gadolinium-based contrast agents (GBCAs) cause nephrogenic systemic fibrosis (NSF) when used in patients with severe chronic kidney disease (CKD). GBCAs enhance the diagnostic capabilities of magnetic resonance imaging, but have been linked to NSF in this patient population.",
        "Nephrogenic systemic fibrosis (NSF) is caused by the use of gadolinium-based contrast agents (GBCAs) in patients with severe chronic kidney disease (CKD) during magnetic resonance imaging (MRI) procedures."
      ],
      "exact_answer": [
        [
          "use of Gadolinium-based contrast agents"
        ]
      ]
    },
    {
      "body": "Is obesity a risk factor for sleep apnea?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39761731",
        "http://www.ncbi.nlm.nih.gov/pubmed/39242062",
        "http://www.ncbi.nlm.nih.gov/pubmed/39533739",
        "http://www.ncbi.nlm.nih.gov/pubmed/21794205",
        "http://www.ncbi.nlm.nih.gov/pubmed/21717814",
        "http://www.ncbi.nlm.nih.gov/pubmed/17879582",
        "http://www.ncbi.nlm.nih.gov/pubmed/19700044",
        "http://www.ncbi.nlm.nih.gov/pubmed/16770557",
        "http://www.ncbi.nlm.nih.gov/pubmed/16160021",
        "http://www.ncbi.nlm.nih.gov/pubmed/3906303",
        "http://www.ncbi.nlm.nih.gov/pubmed/19202911",
        "http://www.ncbi.nlm.nih.gov/pubmed/36622567",
        "http://www.ncbi.nlm.nih.gov/pubmed/39464513",
        "https://www.ncbi.nlm.nih.gov/pubmed/32436658",
        "https://www.ncbi.nlm.nih.gov/pubmed/33511092",
        "https://www.ncbi.nlm.nih.gov/pubmed/35574039",
        "https://www.ncbi.nlm.nih.gov/pubmed/37512076",
        "http://www.ncbi.nlm.nih.gov/pubmed/39687652",
        "http://www.ncbi.nlm.nih.gov/pubmed/23722707",
        "http://www.ncbi.nlm.nih.gov/pubmed/18250211",
        "http://www.ncbi.nlm.nih.gov/pubmed/18198258",
        "http://www.ncbi.nlm.nih.gov/pubmed/20944981",
        "http://www.ncbi.nlm.nih.gov/pubmed/31815206",
        "http://www.ncbi.nlm.nih.gov/pubmed/35370882",
        "http://www.ncbi.nlm.nih.gov/pubmed/37512076",
        "http://www.ncbi.nlm.nih.gov/pubmed/39726679",
        "http://www.ncbi.nlm.nih.gov/pubmed/12082447",
        "http://www.ncbi.nlm.nih.gov/pubmed/27769628",
        "http://www.ncbi.nlm.nih.gov/pubmed/18573643",
        "http://www.ncbi.nlm.nih.gov/pubmed/16880061",
        "http://www.ncbi.nlm.nih.gov/pubmed/22818968",
        "http://www.ncbi.nlm.nih.gov/pubmed/37758218",
        "http://www.ncbi.nlm.nih.gov/pubmed/24731017",
        "http://www.ncbi.nlm.nih.gov/pubmed/35216654",
        "http://www.ncbi.nlm.nih.gov/pubmed/26316318",
        "http://www.ncbi.nlm.nih.gov/pubmed/12733328",
        "http://www.ncbi.nlm.nih.gov/pubmed/28697288",
        "http://www.ncbi.nlm.nih.gov/pubmed/17525876",
        "http://www.ncbi.nlm.nih.gov/pubmed/11004862",
        "http://www.ncbi.nlm.nih.gov/pubmed/17210276",
        "http://www.ncbi.nlm.nih.gov/pubmed/38634170",
        "http://www.ncbi.nlm.nih.gov/pubmed/39583933",
        "http://www.ncbi.nlm.nih.gov/pubmed/39609575",
        "http://www.ncbi.nlm.nih.gov/pubmed/39584369",
        "http://www.ncbi.nlm.nih.gov/pubmed/19532087",
        "http://www.ncbi.nlm.nih.gov/pubmed/3542725",
        "http://www.ncbi.nlm.nih.gov/pubmed/20451027",
        "http://www.ncbi.nlm.nih.gov/pubmed/39535853",
        "http://www.ncbi.nlm.nih.gov/pubmed/28774733",
        "http://www.ncbi.nlm.nih.gov/pubmed/29339193",
        "http://www.ncbi.nlm.nih.gov/pubmed/30040909",
        "http://www.ncbi.nlm.nih.gov/pubmed/15334042",
        "http://www.ncbi.nlm.nih.gov/pubmed/36752245",
        "http://www.ncbi.nlm.nih.gov/pubmed/17626108",
        "http://www.ncbi.nlm.nih.gov/pubmed/29955085",
        "http://www.ncbi.nlm.nih.gov/pubmed/12742277"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 271,
          "text": "prevalence of sleep apnea is significantly increasing due to the epidemic of obesity, physical inactivity, and diabetes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39242062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Obstructive sleep apnea (OSA) and type 2 diabetes are both closely related to obesity and their prevalence is increasing due to the rising average body weight in Western countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21794205"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 380,
          "text": "Of major medical concern is the fact that the prevalence of sleep apnea is significantly increasing due to the epidemic of obesity, physical inactivity, and diabetes mellitus which are important risk factors for the development and persistence of sleep apnea in individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39242062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "The dramatic increase in the worldwide prevalence of obesity has paralleled the increase in the prevalence of obstructive sleep apnea (OSA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21717814"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Obstructive sleep apnea is a common disorder, and obesity is a known risk factor for its development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1122,
          "text": "The purpose of this review was to analyze the available literature on the subject of obesity and obstructive sleep apnea. We searched for available articles for the time period from 2013 to 2023. Obesity is listed as one of the most important health issues. Complications of obesity, with obstructive sleep apnea (OSA) listed among them, are common problems in clinical practice. Obesity is a well-recognized risk factor for OSA, but OSA itself may contribute to worsening obesity. Bariatric surgery is a treatment of choice for severely obese patients, especially with present complications, and remains the only causative treatment for patients with OSA. Though improvement in OSA control in patients after bariatric surgery is well-established knowledge, the complete resolution of OSA is achieved in less than half of them. The determination of subpopulations of patients in whom bariatric surgery would be especially advantageous is an important issue of OSA management. Increasing the potential of non-invasive strategies in obesity treatment requires studies that assess the efficacy and safety of combined methods.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/37512076"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Role of Adenotonsillectomy and Tonsillectomy in Children with Down Syndrome Who Develop Obstructive Sleep Apnea by Obesity as a Risk Factor.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/35574039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1982,
          "text": "Obesity is a complex condition that interweaves biological, developmental, environmental, behavioral, and genetic factors; it is a significant public health problem. The most common cause of obesity throughout childhood and adolescence is an inequity in energy balance; that is, excess caloric intake without appropriate caloric expenditure. Adiposity rebound (AR) in early childhood is a risk factor for obesity in adolescence and adulthood. The increasing prevalence of childhood and adolescent obesity is associated with a rise in comorbidities previously identified in the adult population, such as Type 2 Diabetes Mellitus, Hypertension, Non-alcoholic Fatty Liver disease (NAFLD), Obstructive Sleep Apnea (OSA), and Dyslipidemia. Due to the lack of a single treatment option to address obesity, clinicians have generally relied on counseling dietary changes and exercise. Due to psychosocial issues that may accompany adolescence regarding body habitus, this approach can have negative results. Teens can develop unhealthy eating habits that result in Bulimia Nervosa (BN), Binge- Eating Disorder (BED), or Night eating syndrome (NES). Others can develop Anorexia Nervosa (AN) as they attempt to restrict their diet and overshoot their goal of \"being healthy.\" To date, lifestyle interventions have shown only modest effects on weight loss. Emerging findings from basic science as well as interventional drug trials utilizing GLP-1 agonists have demonstrated success in effective weight loss in obese adults, adolescents, and pediatric patients. However, there is limited data on the efficacy and safety of other weight-loss medications in children and adolescents. Nearly 6% of adolescents in the United States are severely obese and bariatric surgery as a treatment consideration will be discussed. In summary, this paper will overview the pathophysiology, clinical, and psychological implications, and treatment options available for obese pediatric and adolescent patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33511092"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1684,
          "text": "One-seventh of the world\u0027s adult population, or approximately one billion people, are estimated to have OSA. Over the past four decades, obesity, the main risk factor for OSA, has risen in striking proportion worldwide. In the past 5 years, the WHO estimates global obesity to affect almost two billion adults. A second major risk factor for OSA is advanced age. As the prevalence of the ageing population and obesity increases, the vulnerability towards having OSA increases. In addition to these traditional OSA risk factors, studies of the global population reveal select contributing features and phenotypes, including extreme phenotypes and symptom clusters that deserve further examination. Untreated OSA is associated with significant comorbidities and mortality. These represent a tremendous threat to the individual and global health. Beyond the personal toll, the economic costs of OSA are far-reaching, affecting the individual, family and society directly and indirectly, in terms of productivity and public safety. A better understanding of the pathophysiology, individual and ethnic similarities and differences is needed to better facilitate management of this chronic disease. In some countries, measures of the OSA disease burden are sparse. As the global burden of OSA and its associated comorbidities are projected to further increase, the infrastructure to diagnose and manage OSA will need to adapt. The use of novel approaches (electronic health records and artificial intelligence) to stratify risk, diagnose and affect treatment are necessary. Together, a unified multi-disciplinary, multi-organizational, global approach will be needed to manage this disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/32436658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Obstructive sleep apnea (OSA) is often a lifestyle disease associated with obesity, which is rapidly evolving as a major health concern with diverse multisystemic implications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687652"
        },
        {
          "offsetInBeginSection": 453,
          "offsetInEndSection": 654,
          "text": "Central obesity is associated with OSAS and metabolic syndrome, and there is evidence that obstructive sleep apnea is an independent risk factor for obesity, glucose intolerance and insulin resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20944981"
        },
        {
          "offsetInBeginSection": 306,
          "offsetInEndSection": 520,
          "text": " AHI \u003e or \u003d 30) is a risk factor for cardiovascular diseases and death. In addition, OSA is widely prevalent in patients with obesity, diabetes, and hypertension which are the major risk factors for cardiovascular ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19202911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "CONTEXT: The prevalence of obstructive sleep apnea (OSA) increases with obesity, and OSA has been linked to increased cardiovascular risk via hypoxemia and sleep di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31815206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 301,
          "text": "Obstructive sleep apnea is a growing health concern, affecting nearly one billion people worldwide; increasingly recognized as an independent cardiovascular risk factor associated with incident obesity, insulin resistance, hypertension, arrhythmias, stroke, coronary artery disease, and heart failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35370882"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 481,
          "text": "Obesity is a well-recognized risk factor for OSA, but OSA itself may contribute to worsening obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37512076"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Obesity is a major risk factor for obstructive sleep apnea patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339193"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "BACKGROUND: Obesity is the most important risk factor for obstructive sleep apnea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17879582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Obesity is a strong risk factor for the development and progression of sleep apnea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19023624"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 477,
          "text": "Obesity is a strong risk factor for sleep apnea, and there are some data to suggest sleep apnea may influence obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16160021"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 561,
          "text": "Obesity and particularly central adiposity are potent risk factors for sleep apnea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250211"
        },
        {
          "offsetInBeginSection": 506,
          "offsetInEndSection": 600,
          "text": "Obesity is the primary risk factor for obstructive sleep apnea, which commonly disrupts sleep.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19904074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "RATIONALE: Obesity is a major risk factor for obstructive sleep apnea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30040909"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 194,
          "text": "Obesity has long been recognised as an important risk factor associated with obstructive sleep apnea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38634170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "STUDY OBJECTIVES: While obesity is the most common risk factor for the development of obstructive sleep apnea, the correlation between measures of obesity and apnea severity is only moderate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12683472"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Obesity is a main risk factor for sleep apnea syndrome (SAS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082447"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Obesity is a main risk factor for sleep apnea syndrome (SAS). The prevalence of SAS is especially high in massive obesity and in visceral obesity. The mechanisms of obstructive apneas in obesity are poorly known, but an increase in upper airway colla",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082447"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Obesity is a significant risk factor in the pathogenesis of obstructive sleep apnoea (OSA) altering airway anatomy and collapsibility, and respiratory control. The association between obesity and OSA has led to an increasing focus on the role of weig",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818968"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Obstructive sleep apnea (OSA) and obesity are highly prevalent and bidirectionally associated. OSA is underrecognized, however, particularly in women. By mechanisms that overlap with those of obesity, OSA increases the risk of developing, or having p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37758218"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 179,
          "text": "sleep. Obesity is the most important risk factor for OSA. From the recent reports,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19202911"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 129,
          "text": "sleep apnea is associated with obesity and metabolic syndrome, leading to greater cardiovascular risk. Severely obese",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731017"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 234,
          "text": ". Childhood obesity appears to be associated with an increased prevalence of sleep apnea syndrome. Sleep apnea is an inestimable risk factor for",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39464513"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 112,
          "text": "TIVES: Asthma and obesity are risk factors for obstructive sleep apnea (OSA) in children but their li",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35216654"
        },
        {
          "offsetInBeginSection": 28,
          "offsetInEndSection": 178,
          "text": "association between obesity and obstructive sleep apnea (OSA) in preschool and school-age children. Parents of obese and randomly chosen normal weight",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316318"
        },
        {
          "offsetInBeginSection": 965,
          "offsetInEndSection": 1344,
          "text": "High risk of sleep apnea was positively associated with abdominal obesity (PR \u003d 1.31, 95% CI: 1.17-1.47) and general obesity (PR \u003d 2.19, 95% CI: 0.90-5.32), marginally significant at p \u003c 0.1).CONCLUSIONS: Chinese and Korean immigrants living in the USA who are at high risk of sleep apnea have higher abdominal obesity, even after accounting for sociodemographic characteristics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36622567"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Both obesity and obstructive sleep apnea (OSA) are complex disorders with multiple risk factors, which interact in a complicated fashion to determine the overall phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16160021"
        },
        {
          "offsetInBeginSection": 1227,
          "offsetInEndSection": 1462,
          "text": "Conversely, environmental stressors such as intermittent hypoxia and sleep fragmentation produced by OSA may interact with obesity susceptibility genes to modulate the importance that these loci have on defining obesity-related traits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16160021"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 154,
          "text": "Obesity is the most important risk factor for OSA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19202911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Obesity is known to predispose to obstructive sleep apnea (OSA), a condition characterized by repeated episodes of apnea or hypopnea during sleep, due to the interruption of airflow through the nose and mouth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12733328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Obesity, along with hypertrophy of the adenoids and the tonsils, represents one of the major risk factors for obstructive sleep apnea (OSA) in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27769628"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 158,
          "text": " obesity is the major risk factor for OSA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28697288"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 294,
          "text": "In the future, obstructive sleep apnoea (OSA) may become even more important because obesity as a main risk factor is increasingly prevalent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17525876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "STUDY AIM: Obstructive sleep apnoea (OSA) is strongly associated with obesity, especially abdomin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11004862"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 256,
          "text": "Besides, it is known that obesity constitutes a risk factor for obstructive sleep apnoea (OSA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210276"
        },
        {
          "offsetInBeginSection": 296,
          "offsetInEndSection": 506,
          "text": "This article reviews the established evidence supporting obesity as a risk factor for obstructive sleep apnea and discusses the evidence suggesting that obesity is also a consequence of obstructive sleep apnea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 295,
          "text": "The prevalence of obesity is increasing worldwide, and a corresponding increase in the prevalence of obstructive sleep apnea and its cardiovascular and noncardiovascular consequences is likely.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 507,
          "offsetInEndSection": 655,
          "text": "There is evidence that treating obesity reduces the severity of obstructive sleep apnea and that treating obstructive sleep apnea decreases obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 1764,
          "offsetInEndSection": 1969,
          "text": "End-tidal CO(2), Paco(2), and bicarbonate levels were within the normal range.CONCLUSIONS: Obesity is a risk factor for OSAHS, and the degree of obesity is positively correlated with the severity of OSAHS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18198258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "BACKGROUND: Obesity is a risk factor for obstructive sleep apnea-hypopnea syndrome (OSAHS) in adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18198258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Obstructive sleep apnea (OSA) is often a lifestyle disease associated with obesity,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39687652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "The occurrence of obstructive sleep apnea (OSA) syndrome is related to not only the overall obesity, but also the local distribution of fat.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39609575"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 531,
          "text": "ancy-onset OSA.METHODS: Pregnant women with overweight / obesity and snoring were recruited at \u003c13 weeks gestation and underwent level III home sleep apnea testing and 24-hour ABPM at enrollment and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39584369"
        },
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 580,
          "text": "Obesity is the most established and primary risk factor given that body mass index, visceral fat, and neck circumference are major predictors in the clinical expression of OSA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18573643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Obstructive sleep apnea is a common disorder, and obesity is a known risk factor for its development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 476,
          "text": "Obesity is a strong risk factor for sleep apnea, and there are some data to suggest sleep apnea may influence obesity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16160021"
        },
        {
          "offsetInBeginSection": 296,
          "offsetInEndSection": 505,
          "text": "This article reviews the established evidence supporting obesity as a risk factor for obstructive sleep apnea and discusses the evidence suggesting that obesity is also a consequence of obstructive sleep apnea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "PURPOSE OF REVIEW: The purpose of this review is to summarize the evidence for the association between obesity and obstructive sleep apnea (OSA), as well as predisposing risk factors and treatment strategies for OSA amo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19532087"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 307,
          "text": "Obesity is associated with an increase in the prevalence and the severity of OSA and is a major factor in the persistence and aggravation of OSA over time",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27769628"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 480,
          "text": "Obesity is a well-recognized risk factor for OSA, but OSA itself may contribute to worsening obesity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37512076"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 386,
          "text": "Obesity and snoring, both of which increase with age, have been identified as risk factors for sleep-related breathing disorders, as have hypertension and heart disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3542725"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Obstructive sleep apnea is a common disorder, and obesity is a known risk factor for its development. The prevalence of obesity is increasing worldwide, and a corresponding increase in the prevalence of obstructive sleep apnea and its cardiovascular ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Obstructive sleep apnea (OSA) is characterized by repeated episodes of apnea and hypopnea during sleep. Obesity is the most important risk factor for OSA. From the recent reports, the prevalence of OSA is high. Data have shown that severe OSA (the me",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19202911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "PURPOSE OF REVIEW: The purpose of this review is to summarize the evidence for the association between obesity and obstructive sleep apnea (OSA), as well as predisposing risk factors and treatment strategies for OSA amongst obese patients.RECENT FIND",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19532087"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Current evidence suggests a role for obstructive sleep apnea (OSA) in the development of cardiovascular disorders. However, obesity is an active confounder in this relationship. OSA and obesity share similar pathophysiologic mechanisms potentially le",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20451027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Obstructive sleep apnea is a common disorder and affects approximately 4% of middle-aged men and 2% of middle-aged women. Obstructive sleep apnea is clearly associated with obesity, with more than 50% of patients having a body mass index\u003e30 kg/m2. Su",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16770557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Background: Previous studies have established a connection between obesity and obstructive sleep apnea (OSA), novel surrogate markers of adipose accumulation may serve as more critical and reliable factors for co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726679"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 213,
          "text": "ses in adulthood. While obstructive sleep apnea (OSA) is bidirectionally linked to obesity, its developmental origins are",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39535853"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 301,
          "text": "obesity. However, the directionality of associations of OSA with cardiometabolic risk markers is unclear, as obesity increases risk for OSA, and OSA results in excess weight gain and its metabolic cons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28774733"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 82,
          "text": "Obesity is a significant risk factor for obstructive sleep apnea (OSA)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39583933"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 223,
          "text": "Previous studies have established a connection between obesity and obstructive sleep apnea (OSA), novel surrogate markers of adipose accumulation may serve as more critical and reliable factors for consideration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726679"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 230,
          "text": "While obstructive sleep apnea (OSA) is bidirectionally linked to obesity, its developmental origins are sparsely studied",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39535853"
        },
        {
          "offsetInBeginSection": 296,
          "offsetInEndSection": 405,
          "text": "This article reviews the established evidence supporting obesity as a risk factor for obstructive sleep apnea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700044"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Obstructive sleep apnea is associated with obesity and metabolic syndrome, leading to greater cardiovascular risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731017"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Obstructive sleep apnea (OSA) is the most common form of sleep-disordered breathing and frequently coexists with obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15334042"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Obesity is a primary risk factor for the development of obstructive sleep apnea in humans, but the impact of obesity on central sleep apnea is less clear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "PURPOSE OF REVIEW: The purpose of this review is to summarize the evidence for the association between obesity and obstructive sleep apnea (OSA), as well as predisposing risk factors and treatment strategies for OSA amon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19532087"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 269,
          "text": "e of death. Obstructive sleep apnea syndrome (OSAS) is certainly one of the important risk factors that links obesity and cardiova",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36752245"
        },
        {
          "offsetInBeginSection": 274,
          "offsetInEndSection": 442,
          "text": "While obesity is not essential for the development of the obstructive sleep apnea syndrome, a significant percentage of patients with obstructive sleep apnea are obese.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3906303"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 376,
          "text": "abolism. Obesity, a major risk factor for obstructive sleep apnea (OSA), has been also associated with metabolic dysre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24288006"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731017"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Obesity, along with hypertrophy of the adenoids and the tonsils, represents one of the major risk factors for obstructive sleep apnea (OSA) in children. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27769628"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 247,
          "text": "Obstructive sleep apnea is clearly associated with obesity, with more than 50% of patients having a body mass index\u003e30 kg/m2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16770557"
        },
        {
          "offsetInBeginSection": 314,
          "offsetInEndSection": 508,
          "text": "Obesity is a major risk factor for develop-ing obstructive sleep apnea and the metabolic syndrome, which are associated with increased cardiovascular and cerebrovascular morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16880061"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Obesity is a significant risk factor in the pathogenesis of obstructive sleep apnoea (OSA) altering airway anatomy and collapsibility, and respiratory control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818968"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 607,
          "text": "Obesity is an important risk factor in obstructive sleep apnea syndrome, and anthropometric measurements showing body fat distribution are of great importance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36164953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "BACKGROUND: Obstructive sleep apnoea (OSA) and obesity are two common conditions affecting the Australian population; obesity is the major risk fa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28697288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Obesity is an important risk factor for obstructive sleep apnoea syndrome (OSAS), insulin resistance and cardiovascular disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17626108"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 244,
          "text": "sfunction. Obesity is considered a major risk factor for the development and progression of OSA and the resulting cognitive ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29955085"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 403,
          "text": "Obesity, gender, genetic, and hormonal factors mediate risk for OSA and interact in a multifaceted manner in the pathogenesis of this disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18573643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Obstructive sleep apnea is associated with obesity and metabolic syndrome, leading to greater cardiovascular risk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24731017"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 293,
          "text": "In the future, obstructive sleep apnoea (OSA) may become even more important because obesity as a main risk factor is increasingly prevalent",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17525876"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 540,
          "text": "Obesity is strongly linked to an increased risk of OSA, and weight loss can reduce the severity of OSA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12742277"
        }
      ],
      "id": "67e2bde318b1e36f2e000093",
      "ideal_answer": [
        "Yes. Obesity is the most important and well-established risk factor for obstructive sleep apnea. Excess body fat, especially around the neck and upper airway, increases airway collapsibility during sleep. Higher body mass index, visceral adiposity and larger neck circumference all correlate strongly with both the likelihood of developing sleep apnea and its severity. Overweight and obese individuals are significantly more prone to obstructive sleep apnea than those with normal weight."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What cancer hallmarks are characteristically promoted by tumor microenvironment components, such as pericytes?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26000022",
        "http://www.ncbi.nlm.nih.gov/pubmed/36579669",
        "http://www.ncbi.nlm.nih.gov/pubmed/21376230",
        "http://www.ncbi.nlm.nih.gov/pubmed/31303863",
        "http://www.ncbi.nlm.nih.gov/pubmed/34179005",
        "http://www.ncbi.nlm.nih.gov/pubmed/36682706",
        "http://www.ncbi.nlm.nih.gov/pubmed/23785117",
        "http://www.ncbi.nlm.nih.gov/pubmed/28553358",
        "http://www.ncbi.nlm.nih.gov/pubmed/31147872",
        "http://www.ncbi.nlm.nih.gov/pubmed/32767843",
        "https://www.ncbi.nlm.nih.gov/pubmed/26000022",
        "https://www.ncbi.nlm.nih.gov/pubmed/31303863",
        "http://www.ncbi.nlm.nih.gov/pubmed/32534480",
        "http://www.ncbi.nlm.nih.gov/pubmed/33010018",
        "http://www.ncbi.nlm.nih.gov/pubmed/31147875",
        "http://www.ncbi.nlm.nih.gov/pubmed/27608497",
        "http://www.ncbi.nlm.nih.gov/pubmed/38652261",
        "http://www.ncbi.nlm.nih.gov/pubmed/27635044",
        "http://www.ncbi.nlm.nih.gov/pubmed/28920957"
      ],
      "duplicate_tmp": {
        "from": "version 11",
        "type": 1,
        "id": [
          "644f0ca257b1c7a315000089"
        ]
      },
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 423,
          "text": "The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21376230"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 1019,
          "text": "Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the \"tumor microenvironment.\"",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21376230"
        },
        {
          "offsetInBeginSection": 470,
          "offsetInEndSection": 677,
          "text": "Biochemical and physical cues from the TME serve an essential role in regulating tumor onset and progression. They are also associated with resistance to treatment and poor prognosis in patients with cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36579669"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 768,
          "text": "Pericytes are also capable of tumor homing and are important cellular components of the tumor microenvironment (TME). In this review, we highlight the contribution of pericytes to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction, and discuss how collectively these hallmarks could be tackled by therapies targeting pericytes, providing a rationale for cancer drugs aiming at the TME.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000022"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Pericytes are multipotent perivascular cells whose involvement in vasculature development is well established.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000022"
        },
        {
          "offsetInBeginSection": 434,
          "offsetInEndSection": 768,
          "text": "In this review, we highlight the contribution of pericytes to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction, and discuss how collectively these hallmarks could be tackled by therapies targeting pericytes, providing a rationale for cancer drugs aiming at the TME.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000022"
        },
        {
          "offsetInBeginSection": 752,
          "offsetInEndSection": 1026,
          "text": "In this review, we highlight the contribution of pericytes and cancer stem cells to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction, and discuss therapies targeting pericytes and cancer stem cells in CRC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303863"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 566,
          "text": "Pericytes have various interactions with different components of the TME, such as constituting the pre-metastatic niche, promoting the growth of cancer cells and drug resistance through paracrine activity, and inducing M2 macrophage polarization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36682706"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 750,
          "text": "Pericytes are also capable of tumor homing and are important cellular components of the tumor microenvironment (TME), contributing to the formation of vessels and promoting metastasis; however, they have not been considered very important as a therapeutic target in cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Pericytes are important cellular components of the tumor microenviroment with established roles in angiogenesis and metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28553358"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 751,
          "text": "Pericytes are also capable of tumor homing and are important cellular components of the tumor microenvironment (TME), contributing to the formation of vessels and promoting metastasis; however, they have not been considered very important as a therapeutic target in cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303863"
        },
        {
          "offsetInBeginSection": 1232,
          "offsetInEndSection": 1460,
          "text": "These findings reveal a novel involvement of the LOX family of enzymes in migration and angiogenic properties of pericytes, with implications in tumor development and in therapeutic targeting tumor microenvironment constituents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28553358"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 614,
          "text": "Pericytes are also capable of tumor homing and are important cellular components of the tumor microenvironment (TME). In this review, we highlight the contribution of pericytes to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000022"
        },
        {
          "offsetInBeginSection": 752,
          "offsetInEndSection": 954,
          "text": "In this review, we highlight the contribution of pericytes and cancer stem cells to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Pericytes are important cellular components of the tumor microenviroment with established roles in angiogenesis and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28553358"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 509,
          "text": "Perivascular cells, including vascular smooth muscle cells (vSMCs) and pericytes, are involved in new vessel formation and in promoting stem cell maintenance and proliferation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28920957"
        },
        {
          "offsetInBeginSection": 434,
          "offsetInEndSection": 767,
          "text": "In this review, we highlight the contribution of pericytes to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction, and discuss how collectively these hallmarks could be tackled by therapies targeting pericytes, providing a rationale for cancer drugs aiming at the TME",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000022"
        },
        {
          "offsetInBeginSection": 752,
          "offsetInEndSection": 1025,
          "text": "In this review, we highlight the contribution of pericytes and cancer stem cells to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction, and discuss therapies targeting pericytes and cancer stem cells in CRC",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303863"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 661,
          "text": "Pericytes are also capable of tumor homing and are important cellular components of the tumor microenvironment (TME), contributing to the formation of vessels and promoting metastasis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303863"
        },
        {
          "offsetInBeginSection": 1525,
          "offsetInEndSection": 1857,
          "text": "Due to their role in regulating the blood-brain barrier permeability, promoting angiogenesis, tumor growth, clearing extracellular matrix for infiltrating GBM cells and in helping GBM cells evade immune surveillance, pericytes could be ideal therapeutic targets for stymieing or exploiting their role within the GBM microenvironment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872"
        },
        {
          "offsetInBeginSection": 1364,
          "offsetInEndSection": 1523,
          "text": "Pericytes are multipotent perivascular cells that play a vital role within the GBM microenvironment by assisting in tumor initiation, survival, and progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872"
        },
        {
          "offsetInBeginSection": 1364,
          "offsetInEndSection": 1858,
          "text": "Pericytes are multipotent perivascular cells that play a vital role within the GBM microenvironment by assisting in tumor initiation, survival, and progression. Due to their role in regulating the blood-brain barrier permeability, promoting angiogenesis, tumor growth, clearing extracellular matrix for infiltrating GBM cells and in helping GBM cells evade immune surveillance, pericytes could be ideal therapeutic targets for stymieing or exploiting their role within the GBM microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31147872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Vascular pericytes, an important cellular component in the tumor microenvironment, are often associated with tumor vasculatures, and their functions in cancer invasion and metastasis are poorly understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27608497"
        }
      ],
      "id": "680c137818b1e36f2e000158",
      "ideal_answer": [
        "The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list: reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the tumor microenvironment (TME). Indeed, biochemical and physical cues from the TME serve an essential role in regulating tumor onset and progression. They are also associated with resistance to treatment and poor prognosis in patients with cancer. For example, pericytes, multipotent perivascular cells that are an important component of the TME, have been shown to contribute to some classical hallmarks of cancer, namely, tumor angiogenesis, growth, metastasis, and evasion of immune destruction.",
        "Studies highlight that tumor microenvironment components such as pericytes promote key cancer hallmarks including angiogenesis, metastasis, immune evasion, and drug resistance. Pericytes contribute to angiogenesis by regulating vascular stability and permeability, supporting tumor growth through paracrine signaling, and facilitating extracellular matrix remodeling for invasion. They also aid in metastasis by forming pre-metastatic niches and enabling tumor cell dissemination via basement membrane degradation. Immune evasion is enhanced as pericytes modulate immune cell activity and create an immunosuppressive environment, while their interactions with cancer stem cells further drive therapy resistance. Additionally, pericytes influence tumor progression through LOX family enzyme-mediated migration and tube formation, underscoring their role in sustaining malignant phenotypes across multiple cancers like colorectal, glioblastoma, and pancreatic ductal adenocarcinoma.",
        "The tumor microenvironment, including pericytes, significantly influences several cancer hallmarks. Pericytes play a crucial role in sustained angiogenesis by contributing to the formation and stabilization of new blood vessels, which are essential for tumor growth and survival. They also facilitate invasion and metastasis by influencing the remodeling of the extracellular matrix, allowing cancer cells to invade surrounding tissues. Additionally, pericytes help cancer cells resist apoptosis by enhancing survival signals, contributing to resistance to cell death. Furthermore, pericytes and other components of the tumor microenvironment aid in immune evasion by suppressing immune responses, enabling cancer cells to avoid detection and destruction by the immune system. These interactions underscore the complex role of the tumor microenvironment in supporting cancer progression and the development of various hallmarks.",
        "Tumor microenvironment components such as pericytes contribute to multiple cancer hallmarks including tumor angiogenesis, growth, metastasis, and evasion of immune destruction. Pericytes support angiogenesis by regulating vascular development and basement membrane remodeling, facilitate tumor progression through paracrine signaling that promotes cancer cell proliferation and drug resistance, and aid in immune evasion by modulating the tumor microenvironment to suppress antitumor immunity. Additionally, pericytes contribute to metastasis by forming pre-metastatic niches and enhancing extracellular matrix remodeling, while their interactions with stromal cells and immune components further sustain tumor survival and therapeutic resistance. Studies highlight their role in promoting angiogenic vascular networks, supporting tumor cell infiltration, and maintaining a pro-tumorigenic microenvironment through complex interplay with cancer-associated fibroblasts, macrophages, and endothelial cells.",
        "Pericytes in the tumor microenvironment promote several cancer hallmarks, including:  \n1. **Angiogenesis**: Pericytes stabilize tumor vasculature, enabling nutrient delivery and supporting endothelial cell survival.  \n2. **Invasion/Metastasis**: They facilitate vascular permeability, aiding cancer cell intravasation/extravasation, and secrete matrix metalloproteinases (MMPs) to degrade the extracellular matrix.  \n3. **Immune Evasion**: Pericytes suppress T-cell activity and recruit immunosuppressive cells (e.g., regulatory T cells, macrophages) via cytokine secretion (e.g., TGF-β, IL-10).  \n4. **Sustained Proliferation**: They release growth factors (e.g., VEGF, PDGF) that directly stimulate tumor cell growth.  \n5. **Resistance to Cell Death**: Pericyte-derived signals (e.g., survivin) enhance tumor cell survival under stress (e.g., hypoxia, chemotherapy).  \n\nTheir dual role in vessel stabilization/destruction and stromal crosstalk makes them critical enablers of tumor progression and therapy resistance.",
        "Pericytes in the tumor microenvironment contribute to several key cancer hallmarks. They promote abnormal blood vessel formation by disrupting normal endothelial interactions and signaling, which supports tumor growth. They also enhance cellular proliferation and create a nurturing environment for tumor initiation and expansion. In addition, pericytes play a role in enabling tumor cell invasion and migration, facilitating metastasis. They help tumors evade the immune system by fostering an immunosuppressive environment that protects tumor cells from immune attack. Furthermore, pericytes are involved in the development of chemoresistance, allowing tumors to survive various therapies, and they may increase cancer stem cell characteristics, which boosts the tumor’s ability to initiate and progress.",
        "The tumor microenvironment (TME) components, including pericytes, play a significant role in promoting several classical hallmarks of cancer. These include tumor angiogenesis, which is the formation of new blood vessels to supply the tumor with nutrients and oxygen; tumor growth, which is the increase in size and mass of the tumor; metastasis, which is the spread of cancer cells from the primary site to other parts of the body; and evasion of immune destruction, which is the ability of cancer cells to avoid being targeted and destroyed by the immune system. Pericytes, as part of the TME, contribute to these processes by interacting with cancer stem cells and other stromal components, thereby facilitating a pro-tumorigenic environment.",
        "Pericytes in the tumor microenvironment characteristically promote four key cancer hallmarks: Tumor Angiogenesis (facilitating vessel formation), Tumor Growth (supporting proliferation), Metastasis (enhancing cancer cell migration), and Evasion of Immune Destruction (modulating the immune microenvironment). These processes are influenced by pericyte-mediated paracrine signaling, including pathways involving LOX/LOXL enzymes (notably LOXL3) and TGF-β-induced IGFBP-3. Targeting LOX enzymes may offer a therapeutic strategy to impair pericyte migration and angiogenic capabilities, highlighting a potential avenue for cancer treatment.",
        "Pericytes in the tumor microenvironment (TME) contribute to several cancer hallmarks. They promote angiogenesis by stabilizing blood vessels and facilitating new vessel formation, which supports tumor growth. Pericytes also aid metastasis by enabling tumor cell invasion and spread through interactions with other TME components. Additionally, they support tumor growth and proliferation by providing structural support and secreting growth factors. Furthermore, pericytes contribute to immune evasion by modulating immune responses, potentially recruiting immunosuppressive cells or producing cytokines that shield cancer cells from immune attack. Their role in drug resistance is also notable, as they may create barriers or signaling pathways that reduce treatment efficacy. Overall, pericytes play a significant role in fostering key aspects of tumor progression and survival within the TME.",
        "Perivascular stromal cells such as pericytes foster multiple cancer hallmarks by secreting growth factors, cytokines, chemokines and proteases that sustain tumor cell proliferation and survival, promote neoangiogenesis, enhance cancer cell motility and invasion, and facilitate metastatic dissemination. They create a niche that supports cancer stemness and dormancy, suppresses anti‐tumor immunity, remodels the extracellular matrix, increases vascular permeability, and contributes to resistance against chemotherapy, radiotherapy and anti‐angiogenic treatments.",
        "Pericytes, as components of the tumor microenvironment, significantly contribute to promoting several cancer hallmarks. They enhance angiogenesis by supporting blood vessel formation and function, thereby facilitating tumor growth and proliferation. Pericytes also play a role in metastasis through mechanisms involving signaling pathways such as FGF-2 and TGF-β receptor activation. Additionally, they contribute to immune evasion by creating an immunosuppressive environment, which aids tumors in avoiding immune destruction. Furthermore, pericytes interact with other tumor microenvironment components, such as cancer-associated fibroblasts and tumor-associated macrophages, through paracrine factors, influencing tumor growth and microenvironment modulation. Overall, pericytes are integral to the tumor microenvironment, promoting key cancer hallmarks through complex interactions and signaling pathways.",
        "The tumor microenvironment (TME), including components such as pericytes, plays a significant role in promoting several cancer hallmarks. These include inducing angiogenesis by supporting the formation of functional vasculature necessary for tumor growth. Pericytes also contribute to activating invasion and metastasis by aiding in extracellular matrix degradation, facilitating cancer cell spread. Additionally, they assist cancer cells in resisting cell death through pro survival signals or protective niches. Pericytes may influence evading immune destruction by modulating immune responses within the TME and support reprogramming energy metabolism by affecting nutrient supply and metabolic pathways.",
        "Pericytes in the tumor microenvironment (TME) are known to promote several key cancer hallmarks. They significantly contribute to angiogenesis by supporting the formation of new blood vessels, which is essential for tumor growth and progression. Additionally, pericytes facilitate metastasis by aiding tumor cells in invading surrounding tissues and migrating through the bloodstream. They also play a role in creating an immunosuppressive environment, helping tumors evade immune detection and destruction. Furthermore, pericytes may contribute to therapy resistance by modulating the TME, thereby supporting tumor survival and proliferation. These activities align with hallmarks such as sustaining proliferative signaling, evading growth suppressors, resisting cell death, inducing angiogenesis, and activating invasion and metastasis.",
        "Tumor microenvironment components such as pericytes are implicated in promoting several cancer hallmarks, including tumor angiogenesis through regulation of vascular stability and endothelial cell interactions, facilitation of tumor growth by supporting nutrient supply and extracellular matrix remodeling, enhancement of metastasis via paracrine signaling and pre-metastatic niche formation, and evasion of immune destruction by modulating immune cell polarization and creating an immunosuppressive environment. Pericytes also interact with cancer-associated fibroblasts and macrophages to sustain pro-tumorigenic signaling, while their involvement in hypoxia-driven angiogenesis and resistance to therapy underscores their role in shaping the tumor\u0027s adaptive and aggressive behavior. Studies highlight that targeting these interactions could disrupt critical pathways driving progression and treatment resistance.",
        "Studies demonstrate that tumor microenvironment (TME) components such as pericytes promote several cancer hallmarks, including angiogenesis, tumor growth, metastasis, and evasion of immune destruction. Pericytes contribute to angiogenesis by regulating vascular stability and promoting endothelial cell proliferation, while their paracrine activity supports tumor growth through factors that enhance cancer cell survival and drug resistance. They facilitate metastasis by remodeling the extracellular matrix, enabling tumor cell invasion and dissemination, as seen in glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDAC). Additionally, pericytes aid immune evasion by modulating macrophage polarization (e.g., M2 phenotype induction) and creating immunosuppressive niches. These roles are underscored across multiple cancers, highlighting their significance in sustaining tumor progression and resistance to therapy.",
        "Studies highlight that components of the tumor microenvironment (TME), including pericytes, promote several core and emerging cancer hallmarks. Pericytes contribute to **tumor angiogenesis** by supporting vascular stability, facilitate **tumor growth** through paracrine signaling, enhance **metastasis** via extracellular matrix remodeling, and aid in **evasion of immune destruction** by modulating immune cell activity. These roles align with classical hallmarks such as sustaining proliferative signaling and resisting cell death, while also intersecting with emerging hallmarks like metabolic reprogramming and immune evasion. TME components dynamically interact with tumor cells to drive progression and treatment resistance, underscoring their significance in therapeutic strategies targeting the stromal niche.",
        "Studies have shown that tumor microenvironment components, such as pericytes, characteristically promote several cancer hallmarks, including tumor angiogenesis, growth, metastasis, and evasion of immune destruction. Pericytes are multipotent perivascular cells that play a vital role in regulating blood-brain barrier permeability, promoting angiogenesis, tumor growth, and helping cancer cells evade immune surveillance. These cells contribute to formation of vessels and promote metastasis, and their interaction with other components of tumor microenvironment, such as endothelial cells, fibroblasts, and immune cells, creates a dynamic environment that sustains cancer cell proliferation. Additionally, pericytes display immune properties and may serve as an in vivo reservoir of stem cells, contributing to regeneration of diverse tissues and tumor development. Targeting pericytes and other tumor microenvironment components is considered a promising approach for developing effective anticancer therapeutics, as they are involved in resistance to treatment and poor prognosis in patients with cancer.",
        "Tumor microenvironment elements such as pericytes drive several core cancer hallmarks. They foster angiogenesis by stabilizing and remodeling blood vessels, supply mitogenic and survival signals that sustain proliferative signaling and resist cell death, remodel the extracellular matrix to enable invasion and metastasis, and suppress anti-tumor immune responses to facilitate immune evasion. By orchestrating these processes, pericytes support tumor growth, dissemination and therapy resistance."
      ],
      "exact_answer": [
        [
          "Angiogenesis",
          "Inducing angiogenesis",
          "tumor angiogenesis"
        ],
        [
          "Growth",
          "Sustaining proliferative signaling"
        ],
        [
          "Metastasis",
          "Activating invasion and metastasis"
        ],
        [
          "Evasion of immune destruction",
          "Evading immune destruction",
          "immune evasion"
        ]
      ]
    },
    {
      "body": "XIST proteins mediate what cellular process?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35585273",
        "http://www.ncbi.nlm.nih.gov/pubmed/32362602",
        "http://www.ncbi.nlm.nih.gov/pubmed/19727951",
        "http://www.ncbi.nlm.nih.gov/pubmed/2034278",
        "http://www.ncbi.nlm.nih.gov/pubmed/26816113",
        "http://www.ncbi.nlm.nih.gov/pubmed/32535328",
        "http://www.ncbi.nlm.nih.gov/pubmed/27115694",
        "http://www.ncbi.nlm.nih.gov/pubmed/9039849",
        "http://www.ncbi.nlm.nih.gov/pubmed/11780141",
        "http://www.ncbi.nlm.nih.gov/pubmed/26282267",
        "http://www.ncbi.nlm.nih.gov/pubmed/32908311",
        "http://www.ncbi.nlm.nih.gov/pubmed/27659978",
        "https://www.ncbi.nlm.nih.gov/pubmed/35597241",
        "http://www.ncbi.nlm.nih.gov/pubmed/27492478",
        "http://www.ncbi.nlm.nih.gov/pubmed/39433641",
        "http://www.ncbi.nlm.nih.gov/pubmed/32025035",
        "http://www.ncbi.nlm.nih.gov/pubmed/19164542",
        "http://www.ncbi.nlm.nih.gov/pubmed/34722536",
        "http://www.ncbi.nlm.nih.gov/pubmed/32379046",
        "http://www.ncbi.nlm.nih.gov/pubmed/17681633",
        "http://www.ncbi.nlm.nih.gov/pubmed/19923898",
        "http://www.ncbi.nlm.nih.gov/pubmed/35717799",
        "http://www.ncbi.nlm.nih.gov/pubmed/29237010",
        "http://www.ncbi.nlm.nih.gov/pubmed/35584662",
        "http://www.ncbi.nlm.nih.gov/pubmed/34131144",
        "http://www.ncbi.nlm.nih.gov/pubmed/38586055",
        "http://www.ncbi.nlm.nih.gov/pubmed/37291424",
        "http://www.ncbi.nlm.nih.gov/pubmed/26190105",
        "http://www.ncbi.nlm.nih.gov/pubmed/33735607",
        "http://www.ncbi.nlm.nih.gov/pubmed/23093590",
        "http://www.ncbi.nlm.nih.gov/pubmed/38889283",
        "http://www.ncbi.nlm.nih.gov/pubmed/27780979",
        "http://www.ncbi.nlm.nih.gov/pubmed/35028010",
        "http://www.ncbi.nlm.nih.gov/pubmed/38747697",
        "http://www.ncbi.nlm.nih.gov/pubmed/9099757",
        "http://www.ncbi.nlm.nih.gov/pubmed/39639337",
        "http://www.ncbi.nlm.nih.gov/pubmed/23415223",
        "http://www.ncbi.nlm.nih.gov/pubmed/35915095",
        "http://www.ncbi.nlm.nih.gov/pubmed/21541345",
        "http://www.ncbi.nlm.nih.gov/pubmed/21298085",
        "http://www.ncbi.nlm.nih.gov/pubmed/37315471",
        "http://www.ncbi.nlm.nih.gov/pubmed/34112668",
        "http://www.ncbi.nlm.nih.gov/pubmed/30496473",
        "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
        "http://www.ncbi.nlm.nih.gov/pubmed/21660507",
        "http://www.ncbi.nlm.nih.gov/pubmed/32047616",
        "http://www.ncbi.nlm.nih.gov/pubmed/28947659",
        "http://www.ncbi.nlm.nih.gov/pubmed/38813842",
        "http://www.ncbi.nlm.nih.gov/pubmed/39261346",
        "http://www.ncbi.nlm.nih.gov/pubmed/38783307",
        "http://www.ncbi.nlm.nih.gov/pubmed/12429693",
        "http://www.ncbi.nlm.nih.gov/pubmed/21765457",
        "http://www.ncbi.nlm.nih.gov/pubmed/16789828",
        "http://www.ncbi.nlm.nih.gov/pubmed/38663040",
        "http://www.ncbi.nlm.nih.gov/pubmed/28143937",
        "http://www.ncbi.nlm.nih.gov/pubmed/35483442",
        "http://www.ncbi.nlm.nih.gov/pubmed/20950563",
        "http://www.ncbi.nlm.nih.gov/pubmed/18057104",
        "http://www.ncbi.nlm.nih.gov/pubmed/30535390",
        "http://www.ncbi.nlm.nih.gov/pubmed/17353271",
        "http://www.ncbi.nlm.nih.gov/pubmed/17445943",
        "http://www.ncbi.nlm.nih.gov/pubmed/37932452",
        "http://www.ncbi.nlm.nih.gov/pubmed/39365876"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "X inactivation is the means of equalizing the dosage of X chromosomal genes in male and female eutherian mammals, so that only one X is active in each cell. The XIST locus (in cis) on each additional X chromosome initiates the transcriptional silence of that chromosome, making it an inactive X",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35585273"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 93,
          "text": "Xist is a long noncoding RNA involved in the X chromosome inactivation in females",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32362602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 335,
          "text": "Long noncoding RNAs (lncRNAs) such as Xist, Air, and Kcnq1ot1 are required for epigenetic silencing of multiple genes in cis within large chromosomal domains, including distant genes located hundreds of kilobase pairs away. Recent evidence suggests that all three of these lncRNAs are functional and that they silence gene expression, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19727951"
        },
        {
          "offsetInBeginSection": 781,
          "offsetInEndSection": 914,
          "text": "The similar map positions and expression patterns for Xist in mouse and man suggest that this gene may have a role in X inactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2034278"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Xist drives spatial compartmentalization of DNA and protein to orchestrate initiation and maintenance of X inactivation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "To achieve dosage compensation of X-linked gene expression, female mammalian cells inactivate one X chromosome through a process called X-chromosome inactivation (XCI). A central component of this process is the X-encoded long non-coding RNA Xist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27115694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "New Xist-Interacting Proteins in X-Chromosome Inactivation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27115694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1063,
          "text": "X inactivation (XCI) is triggered by upregulation of XIST, which coats the chromosome in cis, promoting formation of a heterochromatic domain (Xi). XIST role beyond initiation of XCI is only beginning to be elucidated. Here, we demonstrate that XIST loss impairs differentiation of human mammary stem cells (MaSCs) and promotes emergence of highly tumorigenic and metastatic carcinomas. On the Xi, XIST deficiency triggers epigenetic changes and reactivation of genes overlapping Polycomb domains, including Mediator subunit MED14. MED14 overdosage results in increased Mediator levels and hyperactivation of the MaSC enhancer landscape and transcriptional program, making differentiation less favorable. We further demonstrate that loss of XIST and Xi transcriptional instability is common among human breast tumors of poor prognosis. We conclude that XIST is a gatekeeper of human mammary epithelium homeostasis, thus unveiling a paradigm in the control of somatic cell identity with potential consequences for our understanding of gender-specific malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/35597241"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 359,
          "text": "X-inactivation is facilitated by the master regulator Xist long non-coding RNA, which coats the inactive-X and facilitates heterochromatinization through recruiting different chromatin modifiers and changing the X-chromosome 3D conformation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39433641"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Non-coding Xist RNA plays an essential role in X chromosome inactivation (XCI) in female mammals. It coats the X chromosome in cis and mediates the recruitment of many proteins involved in gene silencing and heterochromatinization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34722536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "X chromosome inactivation (X-inactivation) is triggered by X-linked noncoding Xist RNA, which is expressed asymmetrically from one of the two X chromosomes in females and coats it in cis to induce chromosome-wide silencing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747039"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "In mammals, dosage compensation is achieved by transcriptional silencing of one of the two female X chromosomes. X inactivation is dynamically regulated in development. The non-coding Xist RNA localizes to the inactive X, initiates gene repression in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17681633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "In mammals, silencing of one of the two X chromosomes is necessary to achieve dosage compensation. The non coding RNA Xist triggers X inactivation. Gene silencing by Xist is only possible in certain developmental contexts that only exist in cells of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923898"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Chromosome silencing by Xist RNA occurs in two steps; localisation in cis within the nuclear matrix to form a domain that corresponds to the territory of the inactive X chromosome elect, and transduction of silencing signals from Xist RNA to the unde",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26816113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Female eutherians transcriptionally silence one X chromosome to balance gene dosage between the sexes. X-chromosome inactivation (XCI) is initiated by the lncRNA Xist, which assembles many proteins within the inactive X chromosome (Xi) to trigger gen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35717799"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 345,
          "text": "The molecular basis of how Xist RNA initiates chromosomal silencing and what proteins participate in this process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34722536"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 525,
          "text": "Xist accumulates in cis on the future inactive X chromosome, triggering a cascade of events that provoke the stable silencing of the entire chromosome, with relatively few genes remaining active. How Xist spreads, what are its binding",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "X chromosome inactivation (XCI) is mediated by the non-coding RNA Xist, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35584662"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 347,
          "text": "upregulation of the long non-coding RNA Xist, which mediates chromosome-wide gene silencing. Cell differentiation, Xist upregulation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34131144"
        },
        {
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1304,
          "text": "Strikingly, XIST, the long-noncoding RNA responsible for X inactivation, hybridization signal was found to be highly dispersed in the female neuronal but not non-neuronal nuclei suggesting weak X inactivation in female hDRG neurons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38586055"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 415,
          "text": "During X chromosome inactivation (XCI), the noncoding Xist RNA coats the X chromosome, triggers gene silencing and forms a dense body of heterochromatin from which the transcription machinery appears to be excluded",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291424"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "The long non-coding RNA X-inactive specific transcript (XIST) mediates the transcriptional silencing of genes on the X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27602518"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 238,
          "text": "Silencing of a single X chromosome in female cells is mediated by the non-coding RNA Xist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26190105"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 402,
          "text": "XCI depends on the long noncoding RNA Xist, which coats the inactive X chromosome in cis and triggers a cascade of events that ultimately lead to chromosome-wide transcriptional silencing that is stable for the lifetime of an organism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The Xist long noncoding RNA orchestrates X chromosome inactivation, a process that entails chromosome-wide silencing and remodeling of the three-dimensional (3D) structure of the X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492478"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 532,
          "text": "The X inactive specific transcript (Xist) is an untranslated RNA that is required for dosage compensation in mammals. It coats and silences 1 of the 2 X chromosomes in female cells and initiates a chromosomewide change in chromatin structure that includes the recruitment of Polycomb proteins,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19164542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "The long non-coding RNA (lncRNA) XIST establishes X chromosome inactivation (XCI) in female cells in early development and thereafter is thought to be largely dispensable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33735607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "In female mammals, one of the two X chromosomes in each cell is transcriptionally silenced in order to achieve dosage compensation between the genders in a process called X chromosome inactivation. The master regulator of this process is the long non-coding RNA Xist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "The transcriptional silencing of one of the female X-chromosomes is a finely regulated process that requires accumulation in cis of the long non-coding RNA X-inactive-specific transcript (Xist) followed by a series of epigenetic modifications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23093590"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 467,
          "text": "A lncRNA X-inactive specific transcript (XIST) is well known as a factor that regulates the physiological process of chromosome dosage compensation for females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38889283"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 417,
          "text": "Recent work studying the molecular mechanisms of several key examples - including Xist, which orchestrates X chromosome inactivation - has provided new insights into how lncRNAs can control cellular functions by acting in the nucleus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27780979"
        },
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 443,
          "text": "This study focused on the lncRNA X-inactive specific transcript (XIST), which participates in the regulation of X chromosome inactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35028010"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 347,
          "text": "Xist encodes a long noncoding RNA which is a central player to induce X-chromosome inactivation in female mammals and has two major splicing variants: long and short isoforms of Xist RNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29237010"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 773,
          "text": "As an example we describe pull-down of proteins interacting with ncRNA XIST, which assists in the recruitment of the polycomb-repressive complex-2 (PRC2) and drives X-chromosomal inactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27659978"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 418,
          "text": "The long non-coding RNA Xist establishes an intra-chromosomal compartment by localizing at a high concentration in a territory spatially close to its transcription locus2 and binding diverse proteins3-5 to achieve X-chromosome inactivation (XCI)6,7.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32908311"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "The long non-coding RNA (lncRNA) Xist is crucially involved in a process called X chromosome inactivation (XCI), the transcriptional silencing of one of the two X chromosomes in female mammals to achieve X dosage compensation between the sexes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38747697"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 350,
          "text": "The long noncoding RNA X-inactive specific transcript (lncRNA XIST) plays a crucial role in the process of X chromosome inactivation (XCI) in cells of the female, a process that ensures the balanced expression of X-linked genes between sexes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39639337"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 226,
          "text": "In mammals, X chromosome inactivation (XCI) is triggered by Xist RNA to equalize gene expression between the sexes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415223"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 260,
          "text": "Initiation of XCI depends on Xist RNA, which triggers silencing of one of the two X chromosomes, except for XCI escape genes that continue to be biallelically expressed",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915095"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 394,
          "text": "Because Xist RNA silences the X chromosome from which it is transcribed, the activation of Xist transcription marks the initiation of the XCI process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38747697"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 336,
          "text": "In placental mammals non-coding XIST RNA triggers silencing of one X (Xi) and recruits a characteristic suite of epigenetic modifications, including the histone mark H3K27me3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21541345"
        },
        {
          "offsetInBeginSection": 340,
          "offsetInEndSection": 407,
          "text": "Spreading of Xist RNA leads to silencing of the X chromosome in cis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21298085"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 280,
          "text": "eponderance. X inactive specific transcript (XIST) is a long non-coding RNA (lncRNA) and a key regulator of X-chromosome inactivation which is related to the sex-bias of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37315471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "X-inactive specific transcript (Xist) RNA directs the process of X chromosome inactivation in mammals by spreading in cis along the chromosome from which it is transcribed and recruiting chromatin modifiers to silence gene transcription",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34112668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "X-inactive-specific transcript (Xist) is a long noncoding RNA (lncRNA) essential for inactivating one of the two X chromosomes in mammalian females",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30496473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "The Xist (X inactive specific transcript) gene plays an essential role in X chromosome inactivation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9099757"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Xist drives spatial compartmentalization of DNA and protein to orchestrate initiation and maintenance of X inactivation",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 387,
          "offsetInEndSection": 611,
          "text": "Several recent studies on XCI focusing on identification and characterization of Xist RNA-protein interactors, revealed new factors involved in gene silencing, genome topology and nuclear membrane attachment, amongst others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28236732"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 669,
          "text": "XCI depends on the long noncoding RNA Xist, which coats the inactive X chromosome in cis and triggers a cascade of events that ultimately lead to chromosome-wide transcriptional silencing that is stable for the lifetime of an organism. In recent years, the discovery of proteins that interact with Xist have led to new insights into how the initiation of XCI occurs. Nevertheless, there are still various unknowns about the mechanisms by which Xist orchestrates and maintains stable X-linked silencing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Female mammals express the long noncoding X inactivation-specific transcript ( Xist) RNA to initiate X chromosome inactivation (XCI) that eventually results in the formation of the Barr body. Xist encompasses half a dozen repeated sequence stretches ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32047616"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "X chromosome inactivation (XCI) is the process whereby one of the X chromosomes in female mammalian cells is silenced to equalize X-linked gene expression with males. XCI depends on the long noncoding RNA Xist, which coats the inactive X chromosome i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "XIST RNA triggers the transformation of an active X chromosome into a condensed, inactive Barr body and therefore provides a unique window into transitions of higher-order chromosome architecture. Despite recent progress, how XIST RNA localizes and i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28947659"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 168,
          "text": "the X-chromosome inactivation regulator Xist",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38813842"
        },
        {
          "offsetInBeginSection": 71,
          "offsetInEndSection": 258,
          "text": "Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) is a central regulator for X chromosome inactivation, and its abnormal expression is a primary feature of breast cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39261346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "The marsupial specific RSX lncRNA is the functional analogue of the eutherian specific XIST, which coordinates X chromosome inactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38783307"
        },
        {
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1143,
          "text": "Xist encodes an RNA molecule that plays critical roles in the choice of which X chromosome remains active, and in the initial spread and establishment of silencing on the inactive X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12429693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Xist represents a paradigm for the function of long non-coding RNA in epigenetic regulation, although how it mediates X-chromosome inactivation (XCI) remains largely unexplained.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32025035"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 225,
          "text": "X-chromosome inactivation is initiated in early embryogenesis by the Xist RNA that localizes to the inactive X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21765457"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 356,
          "text": "The X inactive specific transcript (Xist) is an untranslated RNA that is required for dosage compensation in mammals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19164542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 368,
          "text": "A critical step in X-chromosome inactivation (XCI), which results in the dosage compensation of X-linked gene expression in mammals, is the coating of the presumptive inactive X chromosome by the large noncoding Xist RNA, which then leads to the recruitment of other factors essential for the heterochromatinisation of the inactive X and its transcriptional silencing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16789828"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 724,
          "text": "Xist, an essential lncRNA for X chromosome inactivation (XCI), interacts with 81 proteins from chromatin modification, nuclear matrix, and RNA remodeling pathways. The Xist RNA-protein particle assembles in two steps coupled with the transition from pluripotency to differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Xist RNA has been established as the master regulator of X-chromosome inactivation (XCI) in female eutherian mammals, but its mechanism of action remains unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31456285"
        },
        {
          "offsetInBeginSection": 753,
          "offsetInEndSection": 901,
          "text": "Moreover, the Xist locus, which orchestrates X-chromosome inactivation, has provided key insights into regulation and function of regulatory domains",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38663040"
        },
        {
          "offsetInBeginSection": 808,
          "offsetInEndSection": 903,
          "text": "Recent results have demonstrated that Xist is both necessary and sufficient for X inactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 942,
          "text": " X-inactive specific transcript (XIST), a key player in X-chromosome inactivation that encodes an RNA that coats the silent X chromosom",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28143937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "X-inactive-specific transcript (Xist) is a long noncoding RNA (lncRNA) essential for inactivating one of the two X chromosomes in mammalian females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30496473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "The Xist (X inactive specific transcript) gene plays an essential role in X chromosome inactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9099757"
        },
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 472,
          "text": "X-inactive specific transcript (XIST), one of the first lncRNAs to be discovered, is chiefly responsible for X chromosome inactivation: an evolutionary process of dosage compensation between the sex chromosomes of males and females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35483442"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 231,
          "text": "eponderance. X inactive specific transcript (XIST) is a long non-coding RNA (lncRNA) and a key regulator of X-chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37315471"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Xist RNA has been established as the master regulator of X-chromosome inactivation (XCI) in female eutherian mammals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31456285"
        },
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 795,
          "text": "Up-regulated lncRNA Xist initiates X chromosome inactivation process and attracts specific chromatin modifiers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30017906"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "The gene Xist initiates the chromosomal silencing process of X inactivation in mammals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11780141"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "The Xist long noncoding RNA orchestrates X chromosome inactivation, a process that entails chromosome-wide silencing and remodeling of the three-dimensional (3D) structure of the X chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27492478"
        },
        {
          "offsetInBeginSection": 670,
          "offsetInEndSection": 966,
          "text": "Here, we review recent work elucidating the role of Xist and its protein partners in mediating chromosome-wide transcriptional repression, as well as discuss a model by which Xist may compartmentalize proteins across the inactive X chromosome to enable both the initiation and maintenance of XCI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 217,
          "text": "This process, known as X-chromosome inactivation, relies on monoallelic activation of the Xist gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20950563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Expression of Xist, which triggers X inactivation, is negatively regulated in cis by an antisense gene, Tsix, transcribed along the entire Xist gene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18057104"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 329,
          "text": "X chromosome inactivation and genomic imprinting are two classic epigenetic regulatory processes that cause mono-allelic gene expression. In female mammals, mono-allelic expression of the long non-coding RNA gene X-inactive specific transcript (XIST) is essential for initiation of X chromosome inactivation upon differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30535390"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Xist RNA has been established as the master regulator of X-chromosome inactivation (XCI) in female eutherian mammals, but its mechanism of action remains unclear. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31456285"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Transcription of the Xist gene triggers X chromosome inactivation in cis and is therefore silenced on the X chromosome that remains active. DNA methylation contributes to this silencing, but the mechanism is unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17353271"
        },
        {
          "offsetInBeginSection": 189,
          "offsetInEndSection": 289,
          "text": "The prototype has long been the Xist ncRNA, which induces X-chromosome inactivation in female cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17445943"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 319,
          "text": "The process of X chromosome inactivation results in the transcriptional silencing of one of the two X chromosomes in mammalian females. A large heterogeneous nuclear RNA that is expressed exclusively from the inactive X chromosome (XIST--X Inactive Specific Transcripts) has been implicated in the inactivation process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9039849"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 353,
          "text": "X chromosome inactivation (XCI), the silencing of one of the two X chromosomes in XX female cells, equalises the dosage of X-linked genes relative to XY males. The process is mediated by the non-coding RNA X inactive specific transcript (Xist) that binds in cis and propagates along the inactive X chromosome elect, triggering chromosome-wide silencing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21660507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "The gene Xist initiates the chromosomal silencing process of X inactivation in mammals. Its product, a noncoding RNA, is expressed from and specifically associates with the inactive X chromosome in female cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11780141"
        },
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 485,
          "text": "During X-inactivation, Xist accumulates in cis on the future inactive X chromosome, triggering a cascade of events that provoke the stable silencing of the entire chromosome, with relatively few genes remaining active",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "The Xist lncRNA mediates X chromosome inactivation (XCI). Here w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32379046"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 476,
          "text": "The long noncoding RNA (lncRNA) X-inactive specific transcript (XIST) is involved in X chromosome inactivation (XCI) in female placental mammals, a process that ensures the balanced expression dosage of X-linked genes between sexes. XIST i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36157489"
        },
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 604,
          "text": "Xist, an essential lncRNA for X chromosome inactivation (XCI), interacts with 81 proteins from chromatin modification, nuclear matrix, and RNA remodeling pathways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843628"
        },
        {
          "offsetInBeginSection": 670,
          "offsetInEndSection": 965,
          "text": "Here, we review recent work elucidating the role of Xist and its protein partners in mediating chromosome-wide transcriptional repression, as well as discuss a model by which Xist may compartmentalize proteins across the inactive X chromosome to enable both the initiation and maintenance of XCI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 291,
          "text": "X-chromosome inactivation (XCI) is initiated by the lncRNA Xist, which assembles many proteins within the inactive X chromosome (Xi) to trigger gene silencing and heterochromatin formation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35717799"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "X chromosome inactivation (XCI) is mediated by the non-coding RNA Xist, which directs chromatin modification and gene silencing in cis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35584662"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "X chromosome inactivation (XCI) in mammals is mediated by Xist RNA which functions in cis to silence genes on a single X chromosome in XX female cells, thereby equalising levels of X-linked gene expression relative to XY males",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38654121"
        },
        {
          "offsetInBeginSection": 167,
          "offsetInEndSection": 401,
          "text": "XCI depends on the long noncoding RNA Xist, which coats the inactive X chromosome in cis and triggers a cascade of events that ultimately lead to chromosome-wide transcriptional silencing that is stable for the lifetime of an organism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32535328"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 226,
          "text": "Shortly after fertilization, upregulation of Xist RNA from one X chromosome initiates XCI, leading to chromosome-wide gene silencing",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37932452"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "X chromosome inactivation (XCI) balances X-linked gene dosage between sexes. Unstimulated T cells lack cytological enrichment of X-inactive specific transcript (Xist) RNA and heterochromatic modifications on the inactive X chromosome (Xi), which are involved in maintenance of XCI, and these modifica",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39365876"
        },
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 794,
          "text": "Up-regulated lncRNA Xist initiates X chromosome inactivation process and attracts specific chromatin modifiers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30017906"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 329,
          "text": "This progress has largely revolved around the discovery of the X inactive specific transcript (Xist) gene, which is known now to represent the master switch locus regulating X inactivation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391"
        },
        {
          "offsetInBeginSection": 808,
          "offsetInEndSection": 902,
          "text": "Recent results have demonstrated that Xist is both necessary and sufficient for X inactivation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 246,
          "text": "Random X chromosome inactivation is mediated by Xist RNA expressed from the inactive X chromosome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30496473"
        }
      ],
      "type": "factoid",
      "id": "67ca061181b102733300000a",
      "ideal_answer": [
        "Xist is a long noncoding RNA involved in the X chromosome inactivation in females.",
        "XIST proteins mediate the cellular process of X chromosome inactivation (XCI), which involves the silencing of one of the X chromosomes in female mammalian cells to equalize X-linked gene expression with males.",
        "XIST proteins mediate X-chromosome inactivation.",
        "The role of the noncoding RNA Xist in X chromosome inactivation as a model for gene silencing.",
        "XIST proteins mediate the transcriptional silencing of genes on the X chromosome.",
        "XIST proteins mediate X chromosome inactivation, a process that achieves dosage compensation between the genders in female mammals by silencing one of the two X chromosomes in each cell.",
        "XIST proteins mediate the process of X chromosome inactivation (XCI), which is crucial for balancing the expression dosage of X-linked genes between sexes in female placental mammals.",
        "XIST proteins are involved in the regulation of gene silencing, specifically in X chromosome inactivation. Therefore, the cellular process mediated by XIST proteins is X chromosome inactivation.",
        "XIST proteins mediate chromosome-wide silencing of the inactive X chromosome.",
        "XIST proteins mediate the process of X-chromosome inactivation, which involves transcriptional silencing of genes on the X chromosome.",
        "XIST does not encode proteins; instead, it is a long non-coding RNA (lncRNA). XIST RNA mediates the cellular process of X-chromosome inactivation (XCI) in female mammals. It plays a central role in silencing one of the two X chromosomes to achieve dosage compensation between sexes.",
        "XIST proteins mediate the process of chromosome-wide transcriptional repression, particularly in the context of X chromosome inactivation (XCI). This involves the recruitment of various proteins to silence one of the X chromosomes in female cells.",
        "XIST proteins mediate X chromosome inactivation, a process that silences one of the X chromosomes in female mammalian cells to equalize X-linked gene expression with males.",
        "XIST-associated proteins mediate X chromosome inactivation, driving chromosome-wide transcriptional silencing by recruiting chromatin modifiers, remodeling the nuclear matrix, and promoting heterochromatin formation.",
        "XIST proteins mediate X chromosome inactivation.",
        "The XIST proteins, being a type of long noncoding RNA, are involved in the biogenesis of macromolecules, specifically in the process of X chromosome inactivation, which is a cellular process that equalizes the dosage of X chromosomal genes in eutherian mammals.",
        "Xist, a long noncoding RNA, mediates X chromosome inactivation, a process that ensures equal dosage of X chromosome genes by silencing one of the X chromosomes in each female cell, contributing to epigenetic silencing of large chromosomal domains.",
        "X inactivation is the means of equalizing the dosage of X chromosomal genes in male and female eutherian mammals, so that only one X is active in each cell.",
        "XIST proteins mediate X chromosome inactivation and epigenetic silencing.",
        "XIST plays a crucial role in the process of X chromosome inactivation by initiating the transcriptional silencing of one X chromosome.",
        "XIST proteins mediate the epigenetic silencing of the X chromosome during X chromosome inactivation.",
        "XIST proteins mediate the cellular process of X chromosome inactivation (XCI).",
        "XIST mediates X chromosome inactivation by initiating the transcriptional silencing of one X chromosome, ensuring dosage compensation between males and females.",
        "Xist is a long noncoding RNA involved in X chromosome inactivation in females",
        "[\u0027XIST proteins mediate the transcriptional silencing of the inactive X chromosome in female eutherian mammals during X inactivation.\u0027]",
        "XIST proteins are involved in the process of X chromosome inactivation in females, which is a means of equalizing the dosage of X chromosomal genes between male and female eutherian mammals.",
        "XIST is not a protein but a long noncoding RNA that mediates X chromosome inactivation in female mammals, equalizing X chromosomal gene dosage between males and females by silencing one X chromosome. XIST acts in cis to initiate transcriptional silencing of the chromosome from which it is expressed.",
        "XIST proteins mediate the process of X chromosome inactivation.",
        "XIST proteins mediate the X chromosome inactivation process in female eutherian mammals.",
        "XIST proteins mediate the process of X chromosome inactivation (XCI).",
        "XIST proteins mediate eutherian mammal gene expression, XIST proteins mediate mouse gene expression, XIST proteins mediate noncoding gene expression, XIST proteins mediate X chromosome gene expression, XIST proteins mediate X chromosomal expression",
        "XIST proteins mediate the process of X chromosome inactivation in females by initiating the transcriptional silence of one of the X chromosomes.",
        "XIST proteins mediate the cellular process of X chromosome inactivation.",
        "[\u0027XIST (X-inactive specific transcript) is not a protein but a long noncoding RNA that mediates the cellular process of X chromosome inactivation in female mammals.\u0027]",
        "XIST does not encode a protein, but rather a long noncoding RNA (lncRNA). XIST lncRNA mediates X chromosome inactivation in females, initiating the transcriptional silence of one X chromosome to equalize gene expression between males and females.",
        "XIST-associated proteins drive chromosome-wide transcriptional silencing of the inactive X chromosome, reorganizing its structure and recruiting chromatin modifiers to establish and maintain X-chromosome inactivation for dosage compensation.",
        "XIST proteins mediate X chromosome inactivation through epigenetic silencing.",
        "XIST proteins mediate the inactivation of the X chromosome.",
        "XIST is a long noncoding RNA, not a protein, that mediates X chromosome inactivation in female mammals by initiating transcriptional silencing of one X chromosome, thereby equalizing gene dosage between males and females through epigenetic silencing of genes in cis.",
        "XIST proteins mediate X chromosome inactivation in female eutherian mammals. This process equalizes the dosage of X chromosomal genes by transcriptionally silencing all but one X chromosome in each cell, ensuring only one active X chromosome per cell.",
        "XIST proteins mediate the process of X chromosome inactivation in females, which is essential for equalizing the dosage of X chromosomal genes between male and female eutherian mammals.",
        "XIST proteins mediate the process of X inactivation in female eutherian mammals, which involves the transcriptional silencing of one of the two X chromosomes in each cell.",
        "[\u0027XIST proteins mediate the cellular process of X chromosome inactivation.\u0027]"
      ],
      "exact_answer": [
        [
          "X-Inactivation"
        ]
      ]
    },
    {
      "body": "Typical age range of onset of systemic scleroderma.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37031645",
        "http://www.ncbi.nlm.nih.gov/pubmed/37060032",
        "http://www.ncbi.nlm.nih.gov/pubmed/39350191",
        "http://www.ncbi.nlm.nih.gov/pubmed/24646463",
        "https://www.ncbi.nlm.nih.gov/pubmed/31586983",
        "http://www.ncbi.nlm.nih.gov/pubmed/8565568",
        "http://www.ncbi.nlm.nih.gov/pubmed/37100631"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 729,
          "offsetInEndSection": 775,
          "text": "The mean age at the disease onset was 37±14.7 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37031645"
        },
        {
          "offsetInBeginSection": 531,
          "offsetInEndSection": 578,
          "text": "mean age at SSc onset was 42.3 ± 15.1 years old",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37060032"
        },
        {
          "offsetInBeginSection": 963,
          "offsetInEndSection": 1050,
          "text": "At disease onset females tended to be younger (46.51 ± 13.52) than males (50.5 ± 16.64)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39350191"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Peak age at onset of systemic sclerosis (SSc) is between 20 and 50 years, although SSc is also described in both young and elderly patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646463"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 840,
          "text": "Systemic sclerosis is a multi-organ connective tissue disease characterised by dysfunction and impaired morphology of the blood vessels with non-specific inflammation and progressive fibrosis. In the majority of cases, the onset is observed between 30-50 years of age; in many cases, however, the diagnosis is established in patients \u003c 20 years of age or \u003e 75 years of age. The course of late-onset systemic sclerosis is markedly different from that in early- onset disease. In late-onset patients, limited systemic sclerosis, pulmonary hypertension, primary heart involvement, and anti-centromere antibodies are more commonly observed. Moreover, the diagnosis of systemic sclerosis in patients \u003e 60 years of age is associated with poor prognosis, higher mortality rates, and an increased risk of neoplasms, as compared to younger patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/31586983"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 276,
          "text": "The average age of onset of scleroderma was 43.6 +/- 10 years (range 20-73)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8565568"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 277,
          "text": "The average age of onset of scleroderma was 43.6 +/- 10 years (range 20-73).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8565568"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 125,
          "text": " Systemic sclerosis (SSc) is a rare auto-immune disease, affecting principally women between 40 and 60 years old",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37100631"
        }
      ],
      "id": "67e26d6218b1e36f2e000074",
      "ideal_answer": [
        "At disease onset, females tend to be younger (46.51 ± 13.52) than males (50.5 ± 16.64)",
        "Systemic scleroderma typically begins in adulthood, often around middle age. The median age at diagnosis is approximately 50 years, but the onset can range from as young as 10 years to as old as 84 years. In some studies, the mean age of onset is reported to be around 43.5 years, particularly in patients who also have breast cancer. This variability indicates that while systemic scleroderma most commonly starts around middle age, it can occur earlier or later in life.",
        "Systemic sclerosis typically begins in adulthood, most often between 20 and 50 years of age, with a peak in the fourth and fifth decades. Based on a mean onset of 45 ± 15 years, cases are classified as early-onset (≤ 30 years), standard-onset (31–59 years) or late-onset (≥ 60 years). Fewer than 10% of cases appear before age 20 and about 9% present at age 65 or older.",
        "The typical age of onset for systemic scleroderma (systemic sclerosis) varies by population. In most studies, the peak incidence occurs between **55-69 years**, with mean ages reported in the **mid-50s** (e.g., mean age ~57 years). However, in South Asian and Iranian populations, onset often occurs at younger ages (~35-40 years), particularly among females. Geographic and ethnic differences influence age trends.",
        "The typical age range for the onset of systemic scleroderma is generally considered to be in adulthood, with most cases occurring between the late 30s and mid-50s. Studies indicate that while the average age at onset varies slightly—ranging from approximately 37 to 42 years—the condition can develop as early as the late 20s or as late as the 60s due to individual variations. Additionally, there may be a slight gender difference, with females tending to experience onset around 46.5 years and males slightly later at about 50.5 years. Overall, systemic scleroderma is most commonly diagnosed in adults within this broader age range.",
        "Systemic scleroderma (SSc) typically presents in two distinct age groups: juvenile-onset SSc (jSSc) and adult-onset SSc (aSSc). Studies indicate that jSSc has an average disease onset at 8.8±4.1 years, with diffuse cutaneous subset being predominant, while aSSc commonly manifests around 37±14.7 to 42.3±15.1 years of age, often associated with the limited cutaneous subset. In Latvia, SSc onset averaged 46.5±13.52 years in females and 50.5±16.64 years in males, aligning with adult-onset patterns observed globally. These findings highlight a bimodal age distribution for SSc, with juvenile cases emerging in early childhood and adult-onset typically occurring between late teens to middle adulthood."
      ],
      "exact_answer": [
        [
          "50+-16 years"
        ]
      ]
    },
    {
      "body": "What glial cells are responsible for myelination in the CNS?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34046407",
        "http://www.ncbi.nlm.nih.gov/pubmed/9061442",
        "http://www.ncbi.nlm.nih.gov/pubmed/35465398",
        "http://www.ncbi.nlm.nih.gov/pubmed/3066310",
        "http://www.ncbi.nlm.nih.gov/pubmed/22192173",
        "http://www.ncbi.nlm.nih.gov/pubmed/25288117",
        "http://www.ncbi.nlm.nih.gov/pubmed/27930937",
        "http://www.ncbi.nlm.nih.gov/pubmed/30356886",
        "http://www.ncbi.nlm.nih.gov/pubmed/3531873",
        "http://www.ncbi.nlm.nih.gov/pubmed/31760634",
        "http://www.ncbi.nlm.nih.gov/pubmed/38503504",
        "https://www.ncbi.nlm.nih.gov/pubmed/26101081",
        "https://www.ncbi.nlm.nih.gov/pubmed/31726662",
        "https://www.ncbi.nlm.nih.gov/pubmed/35465398",
        "https://www.ncbi.nlm.nih.gov/pubmed/36324281",
        "https://www.ncbi.nlm.nih.gov/pubmed/37653126",
        "https://www.ncbi.nlm.nih.gov/pubmed/38503504",
        "http://www.ncbi.nlm.nih.gov/pubmed/39061389",
        "http://www.ncbi.nlm.nih.gov/pubmed/29726608",
        "http://www.ncbi.nlm.nih.gov/pubmed/31782103",
        "http://www.ncbi.nlm.nih.gov/pubmed/38132442",
        "http://www.ncbi.nlm.nih.gov/pubmed/39714111",
        "http://www.ncbi.nlm.nih.gov/pubmed/39566199",
        "http://www.ncbi.nlm.nih.gov/pubmed/39554158",
        "http://www.ncbi.nlm.nih.gov/pubmed/39411401",
        "http://www.ncbi.nlm.nih.gov/pubmed/35536759",
        "http://www.ncbi.nlm.nih.gov/pubmed/26857216",
        "http://www.ncbi.nlm.nih.gov/pubmed/38615095",
        "http://www.ncbi.nlm.nih.gov/pubmed/32317939",
        "http://www.ncbi.nlm.nih.gov/pubmed/34356682",
        "http://www.ncbi.nlm.nih.gov/pubmed/23806613",
        "http://www.ncbi.nlm.nih.gov/pubmed/11274346",
        "http://www.ncbi.nlm.nih.gov/pubmed/22422202",
        "http://www.ncbi.nlm.nih.gov/pubmed/37127087",
        "http://www.ncbi.nlm.nih.gov/pubmed/21215300",
        "http://www.ncbi.nlm.nih.gov/pubmed/39571959",
        "http://www.ncbi.nlm.nih.gov/pubmed/16875686",
        "http://www.ncbi.nlm.nih.gov/pubmed/27055915",
        "http://www.ncbi.nlm.nih.gov/pubmed/1713717",
        "http://www.ncbi.nlm.nih.gov/pubmed/18979053",
        "http://www.ncbi.nlm.nih.gov/pubmed/32612996",
        "http://www.ncbi.nlm.nih.gov/pubmed/16563220",
        "http://www.ncbi.nlm.nih.gov/pubmed/30302529",
        "http://www.ncbi.nlm.nih.gov/pubmed/16206168",
        "http://www.ncbi.nlm.nih.gov/pubmed/31048318",
        "http://www.ncbi.nlm.nih.gov/pubmed/22074600",
        "http://www.ncbi.nlm.nih.gov/pubmed/38744490",
        "http://www.ncbi.nlm.nih.gov/pubmed/25682762",
        "http://www.ncbi.nlm.nih.gov/pubmed/30237763",
        "http://www.ncbi.nlm.nih.gov/pubmed/28549068",
        "http://www.ncbi.nlm.nih.gov/pubmed/33108748",
        "http://www.ncbi.nlm.nih.gov/pubmed/29118449",
        "http://www.ncbi.nlm.nih.gov/pubmed/8790426",
        "http://www.ncbi.nlm.nih.gov/pubmed/30957306",
        "http://www.ncbi.nlm.nih.gov/pubmed/32460418",
        "http://www.ncbi.nlm.nih.gov/pubmed/28548216",
        "http://www.ncbi.nlm.nih.gov/pubmed/38488548",
        "http://www.ncbi.nlm.nih.gov/pubmed/31159496",
        "http://www.ncbi.nlm.nih.gov/pubmed/23375677",
        "http://www.ncbi.nlm.nih.gov/pubmed/25807062",
        "http://www.ncbi.nlm.nih.gov/pubmed/24259565",
        "http://www.ncbi.nlm.nih.gov/pubmed/39558879",
        "http://www.ncbi.nlm.nih.gov/pubmed/39548653",
        "http://www.ncbi.nlm.nih.gov/pubmed/39537633",
        "http://www.ncbi.nlm.nih.gov/pubmed/39528474",
        "http://www.ncbi.nlm.nih.gov/pubmed/26567743",
        "http://www.ncbi.nlm.nih.gov/pubmed/38655345",
        "http://www.ncbi.nlm.nih.gov/pubmed/24768715",
        "http://www.ncbi.nlm.nih.gov/pubmed/36701970",
        "http://www.ncbi.nlm.nih.gov/pubmed/25650722",
        "http://www.ncbi.nlm.nih.gov/pubmed/32571126",
        "http://www.ncbi.nlm.nih.gov/pubmed/38978971",
        "http://www.ncbi.nlm.nih.gov/pubmed/21720767",
        "http://www.ncbi.nlm.nih.gov/pubmed/21818782",
        "http://www.ncbi.nlm.nih.gov/pubmed/16768245",
        "http://www.ncbi.nlm.nih.gov/pubmed/39464137",
        "http://www.ncbi.nlm.nih.gov/pubmed/39495111",
        "http://www.ncbi.nlm.nih.gov/pubmed/27829268",
        "http://www.ncbi.nlm.nih.gov/pubmed/11460179",
        "http://www.ncbi.nlm.nih.gov/pubmed/34595379",
        "http://www.ncbi.nlm.nih.gov/pubmed/21589880",
        "http://www.ncbi.nlm.nih.gov/pubmed/36324281",
        "http://www.ncbi.nlm.nih.gov/pubmed/27551677",
        "http://www.ncbi.nlm.nih.gov/pubmed/11276118",
        "http://www.ncbi.nlm.nih.gov/pubmed/12524181",
        "http://www.ncbi.nlm.nih.gov/pubmed/37629092",
        "http://www.ncbi.nlm.nih.gov/pubmed/1377283",
        "http://www.ncbi.nlm.nih.gov/pubmed/16543121",
        "http://www.ncbi.nlm.nih.gov/pubmed/25710531",
        "http://www.ncbi.nlm.nih.gov/pubmed/35370556",
        "http://www.ncbi.nlm.nih.gov/pubmed/36645033",
        "http://www.ncbi.nlm.nih.gov/pubmed/17685481",
        "http://www.ncbi.nlm.nih.gov/pubmed/26015546",
        "http://www.ncbi.nlm.nih.gov/pubmed/27152449",
        "http://www.ncbi.nlm.nih.gov/pubmed/37272718",
        "http://www.ncbi.nlm.nih.gov/pubmed/30374292",
        "http://www.ncbi.nlm.nih.gov/pubmed/37767930",
        "http://www.ncbi.nlm.nih.gov/pubmed/38950628",
        "http://www.ncbi.nlm.nih.gov/pubmed/24586768",
        "http://www.ncbi.nlm.nih.gov/pubmed/26801084",
        "http://www.ncbi.nlm.nih.gov/pubmed/33419250",
        "http://www.ncbi.nlm.nih.gov/pubmed/38766750",
        "http://www.ncbi.nlm.nih.gov/pubmed/35940122",
        "http://www.ncbi.nlm.nih.gov/pubmed/35736620"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 618,
          "text": " In the vertebrate central nervous system (CNS), oligodendrocytes myelinate neuronal axons to increase conduction velocity and provide trophic support. Myelination can be modified by local signaling at the axon-myelin interface, potentially adapting sheaths to support the metabolic needs and physiology of individual neurons. However, neurons and oligodendrocytes are not wholly responsible for crafting the myelination patterns seen in vivo. Other cell types of the CNS, including microglia and astrocytes, modify myelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34046407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Oligodendrocytes, derived from stem cell precursors which arise in subventricular zones of the developing central nervous system, have as their specialist role the synthesis and maintenance of myelin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9061442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Myelination is regulated by various glial cells in the central nervous system (CNS), including oligodendrocytes (OLs), microglia, and astrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465398"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "text": "In the vertebrate central nervous system (CNS), oligodendrocytes myelinate neuronal axons to increase conduction velocity and provide trophic support.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34046407"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 618,
          "text": "However, neurons and oligodendrocytes are not wholly responsible for crafting the myelination patterns seen in vivo. Other cell types of the CNS, including microglia and astrocytes, modify myelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34046407"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "The myelin sheaths that surround axons in the CNS are made and maintained by oligodendrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3066310"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 378,
          "text": "Oligodendrocytes in the central nervous system (CNS) and Schwann cells (SCs) in the peripheral nervous system (PNS) wrap their plasma membranes around axons to organize myelinated nerve fibers that allow rapid saltatory conduction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22192173"
        },
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 596,
          "text": "Myelination by OLs not only supports axonal conduction but also undergoes adaptive modifications in response to neuronal activity, which is vital for cognitive processing and memory functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061389"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 507,
          "text": "Oligodendrocytes are glial cells found within the central nervous system involved in the production of myelin and the myelination of axons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714111"
        },
        {
          "offsetInBeginSection": 986,
          "offsetInEndSection": 1091,
          "text": "Nevertheless, the number and length of myelin sheaths produced by mature oligodendrocytes were unaffected",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39566199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Oligodendrocyte progenitor cells (OPCs) are highly dynamic, widely distributed glial cells of the central nervous system (CNS) that are responsible for generating myelinating oligodendrocytes during development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39554158"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Myelination of the central nervous system is mediated by specialized glial cells called oligodendrocytes (OLs)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39411401"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 396,
          "text": "One of these events is the generation of oligodendrocytes, the glial cells of the CNS responsible for axon myelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30237763"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 426,
          "text": "Within the central nervous system (CNS), myelination is carried out by highly specialized glial cells, oligodendrocytes. The formation of myelin is a prolonged aspect of CNS development that occurs well into adulthood in humans, continuing throughout life in response to injury or as a component of neuroplasticity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38503504"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 255,
          "text": "In the central nervous system (CNS), oligodendrocytes are specialized glial cells responsible for myelin formation and maintenance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26857216"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Oligodendrocytes are the glial cells responsible for myelin formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21589880"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Increasing studies have demonstrated multiple signaling molecules responsible for oligodendrocytes and Schwann cells development such as migration, differentiation, myelination, and axo-glial interaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31760634"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 481,
          "text": "In the rat optic nerve there are two distinct types of astrocyte: type-1 astrocytes develop from one type of precursor cell, and type-2 astrocytes develop from bipotential, oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells, that initially give rise to oligodendrocytes (which make myelin in the CNS), and then to type-2 astrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3531873"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Oligodendrocytes, the myelin-forming cells of the central nervous system (CNS), and astrocytes constitute macroglia. This review deals with the recent progress related to the origin and differentiation of the oligodendrocytes, their relationships to ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Myelination is regulated by various glial cells in the central nervous system (CNS), including oligodendrocytes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465398"
        },
        {
          "offsetInBeginSection": 534,
          "offsetInEndSection": 618,
          "text": "Other cell types of the CNS, including microglia and astrocytes, modify myelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34046407"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 275,
          "text": "OLs are the myelin-forming cells in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465398"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 533,
          "text": "However, neurons and oligodendrocytes are not wholly responsible for crafting the myelination patterns seen in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34046407"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 332,
          "text": "Specialized glial cells, termed Schwann cells in the PNS and oligodendrocytes in the CNS, wrap axons to form myelin, a compacted, multilayered sheath comprising specific proteins and lipids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16875686"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 184,
          "text": "Oligodendrocytes in the CNS and Schwann cells in the PNS are the glial cells responsible for generating the myelin sheath.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27055915"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Oligodendrocytes are the glial cells responsible for the formation of myelin around axons of the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35536759"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Oligodendrocyte progenitor cells (OPCs) are highly dynamic, widely distributed glial cells of the central nervous system (CNS) that are responsible for generating myelinating oligodendrocytes during development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39554158"
        },
        {
          "offsetInBeginSection": 626,
          "offsetInEndSection": 814,
          "text": "One approach to these problems is to study in vitro the developmental and cellular biology of oligodendrocytes--the glial cells responsible for the synthesis and maintenance of CNS myelin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1713717"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "In vertebrates, oligodendrocytes (OLs) are glial cells of the central nervous system (CNS) responsible for the formation of the myelin sheath that surrounds the axons of neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38615095"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 585,
          "text": "This results in aberrant neural cell development, cytotoxicity, and loss of the primary myelin-producing cells of the CNS, the oligodendrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18979053"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 236,
          "text": "Oligodendrocytes are the myelinating cells of the central nervous system (CNS) that insulate and provide trophic support to neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32612996"
        },
        {
          "offsetInBeginSection": 1362,
          "offsetInEndSection": 1530,
          "text": "Significantly, Kir4.1 are also expressed by oligodendrocytes, the myelin-forming cells of the CNS, and the genetic ablation of Kir4.1 results in severe hypomyelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16563220"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 644,
          "text": "Oligodendrocytes are specialized glia that extend multiple actin-based protrusions to form the multilayered myelin membrane that spirally wraps around axons, increasing conduction speed and promoting long-term axonal integrity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30302529"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 807,
          "text": "Finally, oligodendrocytes, the myelinating cells of the CNS, are very sensitive to excessive glutamate signaling, which can lead to the apoptosis or necrosis of these cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16206168"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 394,
          "text": "Among these, the myelin sheath elaborated by oligodendrocytes acts as a dynamic partner to the axons it enwraps and can no longer be considered as an inert membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22422202"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 273,
          "text": "It relies on the interaction of the axons and the oligodendrocytes: the glial cells producing CNS myelin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31048318"
        },
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 597,
          "text": "Myelination by OLs not only supports axonal conduction but also undergoes adaptive modifications in response to neuronal activity, which is vital for cognitive processing and memory functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Oligodendrocytes are responsible for myelinating central nervous system (CNS) axons and rapid electrical transmission through saltatory conduction of action potentials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37127087"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 761,
          "text": "In this study, we found that, in injured optic nerves, oligodendrocyte precursor cells (OPCs) undergo transient proliferation but fail to differentiate into mature myelination-competent oligodendrocytes, reminiscent of what is observed in human progressive multiple sclerosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33108748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "The oligodendrocyte is the myelin-forming cell in the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8790426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "In the central nervous system (CNS), myelin sheaths around axons are formed by glial cells named oligodendrocytes (OLs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30957306"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Oligodendrocytes, the myelinating cells in the vertebrate central nervous system, produce myelin sheaths to enable saltatory propagation of action potentials",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32460418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Oligodendroglia are cells responsible for creating myelin sheaths for axons in the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28548216"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 274,
          "text": "OLs are the myelin-forming cells in the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465398"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 488,
          "text": "Oligodendrocytes are the myelin-forming cells in the central nervous system and play critical roles in the conduction of action potentials, supply of metabolic components for axons, and other functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38488548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "In the central nervous system, oligodendrocytes wrap axons with myelin sheaths, which is essential for rapid transfer of electric signals and their trophic support",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31159496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Oligodendroglia are cells of the central nervous system (CNS) that form myelin sheath, which insulates neuronal axons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23375677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "The development and regeneration of myelin by oligodendrocytes, the myelin-forming cells of the central nervous system (CNS), requires profound changes in cell shape that lead to myelin sheath initiation and formation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25807062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Oligodendrocytes, the myelin-forming cells of the CNS, exquisitely tailor the thickness of individual myelin sheaths to the diameter of their target axons to maximize the speed of action potential propagation, thus ensuring proper neuronal connectivity and function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259565"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 508,
          "text": "Oligodendrocytes are glial cells found within the central nervous system involved in the production of myelin and the myelination of axons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Myelination is the process by which oligodendrocytes ensheathe axons to form myelin sheaths.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39571959"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Oligodendrocytes (OLGs) are the myelin-producing cells in the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39548653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Oligodendrocytes are critical for CNS myelin formation and are involved in preterm-birth brain injury (PBI) and multiple sclerosis (MS), both of which lack effective treatments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39537633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Oligodendrocytes (OL) are myelin-forming glial cells in the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38655345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "Oligodendrocytes are neuroglial cells responsible, within the central nervous system, for myelin sheath formation that provides an electric insulation of axons and accelerate the transmission of electrical signals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24768715"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Mature oligodendrocytes are myelin forming glial cells which are responsible for myelination of neuronal axons in the white matter of the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36701970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Myelination is a complex process that involves both neurons and the myelin forming glial cells, oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25650722"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Myelination has evolved as a mechanism to ensure fast and efficient propagation of nerve impulses along axons. Within the central nervous system (CNS), myelination is carried out by highly specialized glial cells, oligodendrocytes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38503504"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 528,
          "text": "Oligodendrocytes are the myelin-forming cells in the CNS that are needed for the propagation of action potentials along axons and additionally serve to support neurons by neurotrophic factors (NFTs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Oligodendrocytes are the glial cells responsible for the formation of myelin around axons of the central nervous system (CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35536759"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Oligodendrocytes (OLs) are glial cells responsible for the formation of myelin sheaths in the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38978971"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "The myelin sheaths that surround axons in the CNS are made and maintained by oligodendrocytes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3066310"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "During normal brain development, axons are myelinated by mature oligodendrocytes (OLGs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Tissue transglutaminase activity is involved in the differentiation of oligodendrocyte precursor cells into myelin-forming oligodendrocytes during CNS remyelination",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21818782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Myelin is a biologically active mutilamellar that is formed by oligodendrocytes (OLs) in the central nervous system (CNS) and ensheathes axons (Ishii et al., Proc Natl Acad Sci USA 106:14605-14610, 2009).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21720767"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Myelination of the central nervous system is mediated by specialized glial cells called oligodendrocytes (OLs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39411401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "In the mammalian central nervous system, axonal myelination, executed by mature oligodendrocytes (MOLs), enables rapid neural transmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39558879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Oligodendrocytes extend numerous cellular processes that wrap multiple times around axons to generate lipid-rich myelin sheaths.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39528474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Myelin, along with the oligodendrocytes (OLs) that produce it, is essential for proper central nervous system (CNS) function in vertebrates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39464137"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Timely differentiation and myelin formation by oligodendrocytes are essential for the physiological functioning of the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39495111"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Myelination is regulated by various glial cells in the central nervous system (CNS), including oligodendrocytes (OLs), microglia, and astrocytes. Myelination of the CNS requires the generation of functionally mature OLs from OPCs. OLs are the myelin-forming cells in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465398"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "The dysfunction of myelinating glial cells, the oligodendrocytes, within the central nervous system (CNS) can result in the disruption of myelin, the lipid-rich multi-layered membrane structure that surrounds most vertebrate axons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38132442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Oligodendrocytes and Schwann cells are engaged in myelin production, maintenance and repairing respectively in the central nervous system (CNS) and the peripheral nervous system (PNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11460179"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Oligodendrocytes (OLGs) are the myelin-producing cells in the central nervous system (CNS)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39548653"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 451,
          "text": "By also generating new oligodendrocytes in the adult CNS, OPCs allow formation of new myelin sheaths in response to environmental and behavioral changes and play a crucial role in regenerating myelin following demyelination (remyelination)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39554158"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "In the central nervous system (CNS), the myelin sheath is synthesised by oligodendrocytes as a specialised subdomain of an extended plasma membrane, reminiscent of the segregated membrane domains of polarised cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11276118"
        },
        {
          "offsetInBeginSection": 1267,
          "offsetInEndSection": 1422,
          "text": "In the CNS, the hybridization signal of ASPA appeared to be restricted primarily to oligodendrocytes, the primary myelin synthesizing cell type in the CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12524181"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 308,
          "text": "Oligodendrocytes play a vital role in maintaining the integrity of myelin, the protective sheath around nerve fibres essential for efficient signal transmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37629092"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 169,
          "text": "In the central nervous system (CNS), myelin is synthesized by oligodendrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32317939"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "We have taken a transgenic approach in an effort to specifically transform oligodendrocytes, the myelinating glial cells of the central nervous system (CNS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1377283"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 233,
          "text": "Oligodendrocytes form CNS myelin; the prevailing hypothesis being that they do it by extending a process that circumnavigates the axon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762"
        },
        {
          "offsetInBeginSection": 702,
          "offsetInEndSection": 810,
          "text": "Myelin membranes are matured in and transported by myelinophore organelles within an oligodendrocyte process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "CNS myelin sheath is stochastically built by homotypic fusion of myelin membranes within the bounds of an oligodendrocyte process.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Myelinating glial cells (MGCs), oligodendrocytes (OLs) in the central nervous system (CNS) and Schwann cells (SCs) in the peripheral nervous system (PNS), generate myelin sheaths that insulate axons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29726608"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 289,
          "text": "Specialized glial cells-oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS)-form myelin by repeatedly wrapping axon segments.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22074600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Oligodendrocytes (OLs) and Schwann cells (SCs) have traditionally been thought of as the exclusive myelinating glial cells of the central and peripheral nervous systems (CNS and PNS), respectively, for a little over a century.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30356886"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "NG2-expressing neural progenitor cells (i.e., NG2 glial cells) maintain their proliferative and migratory activities even in the adult mammalian central nervous system (CNS) and produce myelinating oligodendrocytes and astrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28195192"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 642,
          "text": "Apart from oligodendrocytes, the two other main glial cell types of the CNS, microglia and astrocytes, play a pivotal role in remyelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38132442"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 182,
          "text": "Oligodendrocytes are the myelinating cells of the central nervous system (CNS)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32612996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Myelination is regulated by various glial cells in the central nervous system (CNS), including oligodendrocytes (OLs), microglia, and astrocytes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35465398"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "The formation of the myelin sheath in the CNS is the endpoint of a defined developmental program along which oligodendrocytes progress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16543121"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 257,
          "text": "CNS myelin, a multilamellar differentiation of the oligodendrocyte plasma membrane, ensheaths axons to facilitate electrical conduction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25710531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Mature oligodendrocytes are myelin forming glial cells which are responsible for myelination of neuronal axons in the white matter of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36701970"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Oligodendrocytes (OLs) are the myelinating cells of the central nervous system (CNS), which are derived from OL precursor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36645033"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Oligodendrocytes form myelin sheaths around axons in the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17685481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Myelination in the central nervous system is the process by which oligodendrocytes form myelin sheaths around the axons of neurons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26015546"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Myelination of axons in the central nervous system results from the remarkable ability of oligodendrocytes to wrap multiple axons with highly specialized membrane",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152449"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Oligodendrocytes produce lipid-rich myelin sheaths that provide metabolic support to the underlying axon and facilitate saltatory conduction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272718"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 312,
          "text": "Oligodendrocytes, the myelinating glia of the CNS, have an intrinsic tendency to wrap myelin around any permissive structure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Myelination by oligodendrocytes is critical for fast axonal conduction and for the support and survival of neurons in the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37767930"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Oligodendrocytes are the myelinating glial cells of the central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586768"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Oligodendrocytes are the myelinating glial cells of the central nervous system (CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26801084"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Oligodendrocytes, the myelinating cells in the central nervous system (CNS), are critical for producing myelin throughout the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33419250"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Oligodendrocytes, the myelin-producing glial cells of the central nervous system (CNS), crucially contribute to myelination and circuit function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38744490"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 276,
          "text": "Oligodendrocytes perform essential roles in the central nervous system, including myelin sheath formation, axonal metabolism, and neuroplasticity regulation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38766750"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 395,
          "text": "One of these events is the generation of oligodendrocytes, the glial cells of the CNS responsible for axon myelination",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30237763"
        },
        {
          "offsetInBeginSection": 396,
          "offsetInEndSection": 581,
          "text": "Differentiated plasma membranes called myelin membranes are generated by oligodendrocytes (also called oligodendroglial cells), which are glial cells that wrap neuronal axons in the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940122"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Oligodendrocytes (oligodendroglial cells) are glial cells that wrap neuronal axons with their differentiated plasma membranes called myelin membranes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35736620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Oligodendrocytes, the myelin-forming cells of the central nervous system (CNS), and astrocytes constitute macroglia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11274346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Oligodendrocyte precursor cells (OPCs) are recognized as the progenitors responsible for the generation of oligodendrocytes, which play a critical role in myelination of central nervous system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39468810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Oligodendrocyte progenitor cells (OPCs) represent a subtype of glia, giving rise to oligodendrocytes, the myelin-forming cells in the central nervous system (CNS)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38920654"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 268,
          "text": "OPCs are responsible for generating oligodendrocytes (OLs), the myelinating cells of the CNS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38950628"
        }
      ],
      "id": "680a21eb18b1e36f2e000150",
      "ideal_answer": [
        "In the vertebrate central nervous system (CNS), oligodendrocytes myelinate neuronal axons to increase conduction velocity and provide trophic support. However, myelination can be modified by local signaling at the axon-myelin interface, potentially adapting sheaths to support the metabolic needs and physiology of individual neurons. Thus, while oligodendrocytes are responsible for the synthesis of myelin in the CNS, other cell types such as microglia and astrocytes, can modify myelination.",
        "In the central nervous system (CNS), the primary cells responsible for the process of myelination are oligodendrocytes. These specialized glial cells play a crucial role in the formation of myelin sheaths around axons, which are essential for the rapid and efficient transmission of electrical impulses across nerve cells. Oligodendrocytes extend multiple layers to densely sheath axons, thereby facilitating faster signal propagation and providing axonal support (PMID 36324281). This myelination process is vital for the proper functioning of the CNS, influencing both neural connectivity and the speed of neural transmission (PMID 26101081).\n\nWhile other glial cells such as microglia and astrocytes are involved in the regulation of myelination, their roles are more supportive, such as in myelin phagocytosis and the maintenance of the myelin environment, rather than the direct formation of myelin (PMID 35465398). Therefore, the primary responsibility for myelination in the CNS distinctly lies with oligodendrocytes.",
        "In the Central Nervous System (CNS), oligodendrocytes are the primary glial cells responsible for generating myelin sheaths. Supportively, microglia play a crucial role in debris removal to facilitate remyelination, while type-2 astrocytes contribute to maintaining the myelinated environment, particularly in the formation and function of nodes of Ranvier, thereby aiding in the efficient transmission of nerve impulses.",
        "In the central nervous system (CNS), oligodendrocytes (OLs) are the primary glial cells responsible for myelinating axons, forming lipid-rich myelin sheaths that enable rapid saltatory conduction of action potentials and provide metabolic support to neurons. Studies highlight their critical role in both developmental myelination and remyelination following injury or disease, with oligodendrocyte precursor cells (OPCs) differentiating into mature OLs to repair damaged myelin. While microglia and astrocytes contribute indirectly by clearing debris and modulating inflammation during demyelination, the direct formation of myelin sheaths is exclusively attributed to oligodendrocytes. Their dysfunction or loss leads to hypomyelination, axonal degeneration, and impaired cognitive and motor functions, as observed in conditions like multiple sclerosis and Down syndrome.",
        "Oligodendrocytes are responsible for myelinating central nervous system (CNS) axons, increasing conduction velocity and providing trophic support. Studies have shown that oligodendrocytes play a crucial role in forming myelin sheaths, which enable rapid saltatory conduction of action potentials. In addition to oligodendrocytes, other glial cells such as microglia and astrocytes also contribute to myelination by modifying myelin sheaths and regulating neuronal activity. Microglia can phagocytose myelin debris, permitting remyelination, while astrocytes can activate and trigger the development of neuroinflammation in demyelinated regions. Overall, oligodendrocytes are key players in myelination, and their interaction with other glial cells is essential for maintaining healthy myelin and facilitating proper neuronal function.",
        "Oligodendrocytes (OLs) are the definitive glial cells responsible for myelination in the Central Nervous System (CNS). While they are the sole myelin-sheath formers, microglia and astrocytes, particularly type-2 astrocytes, provide crucial supportive functions. These include debris removal for remyelination (microglia), and contributions to the node of Ranvier structure and the overall myelinated environment (astrocytes), thereby facilitating the myelination process, its maintenance, and regeneration, but not directly producing myelin sheaths.",
        "Oligodendrocytes (OLs) are the primary glial cells responsible for myelination in the central nervous system (CNS). They generate the myelin sheath that surrounds neuronal axons, enabling rapid saltatory conduction of action potentials and providing structural support. Oligodendrocyte progenitor cells (OPCs) also contribute to remyelination by differentiating into mature OLs following demyelination. Other glial cells, such as microglia and astrocytes, play supportive roles in myelination; microglia assist by clearing myelin debris, while astrocytes interact with oligodendrocyte lineage cells to facilitate myelin formation and regeneration.",
        "Oligodendrocytes are the glial cells primarily responsible for myelination in the central nervous system (CNS). They produce myelin sheaths that insulate axons, enabling rapid transmission of electrical signals. While oligodendrocytes are the main myelinating cells, other glial cells like microglia and astrocytes also play a role in regulating myelination within the CNS.",
        "In the central nervous system (CNS), the primary glial cells responsible for myelinating neuronal axons are oligodendrocytes. These cells form myelin sheaths that enhance nerve conduction velocity and provide trophic support to neurons. While other glial cells, such as astrocytes and microglia, play roles in modifying or influencing the myelination process, it is oligodendrocytes that directly craft the myelin sheaths essential for neuronal function.",
        "Oligodendrocytes (OLs) are the primary glial cells responsible for myelination in the central nervous system (CNS). They form the myelin sheath around neuronal axons, enabling rapid saltatory conduction of action potentials. Oligodendrocyte progenitor cells (OPCs) also contribute to this process by differentiating into mature OLs during remyelination. While astrocytes and microglia play supportive roles in maintaining the environment conducive to myelination, OLs are specifically tasked with generating and repairing the myelin sheaths essential for efficient neural communication.",
        "In the vertebrate central nervous system (CNS), it is the oligodendrocytes that myelinate neuronal axons to increase conduction velocity and provide trophic support. Other cell types of the CNS, including microglia and astrocytes, modify myelination, but in terms of primary responsibility for myelination in the CNS, it is the oligodendrocytes.",
        "In the central nervous system (CNS), the primary glial cells responsible for myelination are oligodendrocytes. These cells form the myelin sheath around neuronal axons, which is crucial for increasing nerve conduction velocity and providing trophic support to neurons.\n\nHowever, the process of myelination is not solely the responsibility of oligodendrocytes. Other glial cells, including microglia and astrocytes, also play significant roles. These cells influence and modify the patterns of myelination through various signaling mechanisms, contributing to the overall regulation and adaptation of myelin sheaths in response to neuronal needs.\n\nIn summary:\n- **Oligodendrocytes**: Primarily responsible for creating the myelin sheath.\n- **Microglia and Astrocytes**: Assist in shaping and regulating myelination patterns through interactions and signaling with neurons and oligodendrocytes.",
        "Oligodendrocytes are responsible for myelinating central nervous system (CNS) axons, forming the myelin sheath that facilitates rapid saltatory conduction and provides structural and metabolic support. Studies highlight their role in both initial myelination and remyelination processes, with oligodendrocyte precursor cells (OPCs) differentiating into mature oligodendrocytes to repair demyelinated regions. While microglia and astrocytes contribute to myelin maintenance, phagocytosis of debris, and modulation of inflammatory responses, they do not directly form myelin sheaths. The coordination between oligodendrocytes and other glial cells is critical for myelination dynamics, but the primary responsibility for myelination lies with oligodendrocytes.",
        "Oligodendrocytes are the glial cells responsible for myelination in the vertebrate central nervous system (CNS). They form myelin sheaths around neuronal axons to enhance conduction velocity and provide metabolic support. While microglia and astrocytes can modify myelination patterns, oligodendrocytes are the primary cells directly executing this function.",
        "Oligodendrocytes are the glial cells responsible for myelination in the central nervous system (CNS). They form myelin sheaths around axons, providing electrical insulation and accelerating the transmission of electrical signals. This myelination process is crucial for the fast and efficient propagation of nerve impulses along axons. In addition to their role in myelination, oligodendrocytes also support neurons by providing neurotrophic factors. While oligodendrocytes are primarily responsible for myelination, other cell types in the CNS, such as microglia and astrocytes, can also modify myelination patterns.",
        "In the vertebrate central nervous system (CNS), **oligodendrocytes** are the primary glial cells responsible for myelinating neuronal axons, enhancing conduction velocity and providing metabolic support. While oligodendrocytes directly form myelin sheaths, other CNS glial cells—such as **microglia** and **astrocytes**—modulate myelination through local signaling at the axon-myelin interface, adapting sheaths to neuronal metabolic demands. However, the core process of myelination is executed by oligodendrocytes, with additional regulatory roles played by non-neuronal cells. This interplay highlights the complexity of myelin dynamics, where oligodendrocytes remain the principal architects of myelin structure, while astrocytes and microglia contribute to its refinement and homeostasis.",
        "Oligodendrocytes are the primary glial cells responsible for myelination in the central nervous system (CNS), as they myelinate neuronal axons to increase conduction velocity and provide support. Additionally, microglia and astrocytes can influence and modify myelination patterns in the CNS.",
        "In the vertebrate central nervous system, oligodendrocytes are the primary glial cells responsible for myelinating neuronal axons, which increases conduction velocity and provides trophic support. Other glial cells, including microglia and astrocytes, also modify myelination patterns in vivo.",
        "In the central nervous system (CNS), oligodendrocytes are the primary glial cells responsible for myelination, a process that increases conduction velocity and provides trophic support to neuronal axons. Myelination can be modified by local signaling at the axon-myelin interface, potentially adapting sheaths to support the metabolic needs and physiology of individual neurons. Other cell types of the CNS, such as microglia and astrocytes, may also modify myelination, but oligodendrocytes play the most significant role in this process.",
        "In the central nervous system (CNS), myelination is primarily carried out by oligodendrocytes (OLs), which form the lipid-rich myelin sheaths around axons to enhance conduction velocity and provide metabolic support. Studies highlight that oligodendrocyte progenitor cells (OPCs) differentiate into mature OLs during remyelination following demyelinating insults, such as in multiple sclerosis or traumatic injury. While microglia and astrocytes contribute indirectly by clearing myelin debris and modulating inflammation to facilitate repair, the direct responsibility for myelin formation lies with oligodendrocytes. Research further emphasizes that disruptions in OL lineage development, including impaired OPC differentiation, underlie hypomyelination observed in conditions like Down syndrome and chronic demyelinating diseases. Thus, oligodendrocytes are central to both initial myelination and remyelination processes in the CNS.",
        "In the CNS, oligodendrocytes are primarily responsible for myelinating neuronal axons. This process involves wrapping around axons to create myelin sheaths, which increase conduction velocity and offer trophic support to neurons. While other glial cells like microglia and astrocytes influence myelination patterns, oligodendrocytes are the key players in forming these protective structures.",
        "Oligodendrocytes are the primary glial cells responsible for myelination in the Central Nervous System (CNS), achieved by forming a myelin sheath around neuronal axons. This process significantly enhances the speed of electrical impulse conduction and provides essential nutrients to neurons. While oligodendrocytes and neurons primarily determine myelination patterns, other CNS glial cells, notably microglia and astrocytes, play a secondary role in modifying these patterns to adapt to the specific metabolic and physiological needs of individual neurons, thus fine-tuning the myelination process.",
        "In the central nervous system (CNS), oligodendrocytes are primarily responsible for myelinating neuronal axons to enhance conduction velocity and provide metabolic support. While studies highlight that microglia and astrocytes also influence myelination by interacting with oligodendrocytes during development, these non-oligodendroglial glial cells modify myelination patterns indirectly through regulatory mechanisms rather than directly forming myelin sheaths. Their roles include pruning excess myelin, maintaining homeostasis, and modulating neuronal activity to shape adaptive myelination strategies in response to neural demands.",
        "Oligodendrocytes are the glial cells primarily responsible for myelination in the central nervous system (CNS). They wrap neuronal axons with myelin membranes, forming myelin sheaths that provide electrical insulation and support rapid signal transmission. While oligodendrocytes are the main myelinating cells, other glial cells like microglia and astrocytes also play a role in modulating myelination."
      ],
      "exact_answer": [
        [
          "Oligodendrocytes",
          "Oligodendrocytes (OLs)",
          "OLs",
          "oligodendrocyte lineage cells",
          "Oligodendroglial cells"
        ]
      ]
    },
    {
      "body": "What is BIONDA",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36700097",
        "https://www.ncbi.nlm.nih.gov/pubmed/36700097"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 502,
          "text": "BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of diseases. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "BIONDA: a free database for a fast information on published biomarkers",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 492,
          "text": "dly way. To address this, BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "BIONDA: a free database for a fast information on published biomarkers.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "BIONDA: a free database for a fast information on published biomarkers.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 501,
          "text": "To address this, BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 688,
          "offsetInEndSection": 960,
          "text": "This allows frequent content updates.Availability and implementation: BIONDA is freely accessible via a user-friendly web application at http://bionda.mpc.ruhr-uni-bochum.de. The current BIONDA code is available at GitHub via https://github.com/mpc-bioinformatics/bionda.S",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 491,
          "text": "dly way. To address this, BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 492,
          "text": "ss this, BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36700097"
        }
      ],
      "type": "factoid",
      "id": "67fa3c5818b1e36f2e000109",
      "ideal_answer": [
        "BIONDA is a free database for a fast information on published biomarkers",
        "BIONDA is a free text mining-based online database designed to provide structured information on molecular biomarkers, including genes, proteins, and miRNAs, for various diseases. It extracts relevant information from Europe PMC publication abstracts and high-quality sources like UniProt and Disease Ontology, allowing for frequent content updates.",
        "BIONDA is a free online database that provides structured information on molecular biomarkers, including genes, proteins, and miRNAs, related to various diseases. The database extracts its content from biomedical texts and high-quality sources, utilizing text mining techniques to offer comprehensive data for research and reference purposes.",
        "BIONDA is a free database for biomarkers.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of diseases.",
        "BIONDA is a free, text mining-based online database that provides rapid access to published molecular biomarkers (genes, proteins, miRNAs) across all disease types. It serves as a centralized resource for biomarker information retrieval.",
        "BIONDA is a free text mining-based online database.",
        "BIONDA is a free, text-mining online database for molecular biomarkers (genes, proteins, miRNAs) related to various diseases. It extracts biomarker information from sources like Europe PMC, UniProt, and Disease Ontology. BIONDA is accessible via a user-friendly web application at http://bionda.mpc.ruhr-uni-bochum.de. Note that \"Bionda Piemontese\" also refers to a breed of chicken.",
        "BIONDA is a free database that provides information on published biomarkers, extracted from biomedical texts and structured for researchers.",
        "BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs, and for all kinds of diseases.",
        "BIONDA, an acronym, stands for Biomarker-integrated Optimal Diagnostic Algorithm. It is a computational tool designed to assist in the diagnosis of various diseases by integrating multiple biomarkers and clinical data to provide a more accurate and personalized diagnosis.",
        "BIONDA is a free text mining-based online database for molecular biomarkers, including genes, proteins, and miRNAs, for all kinds of diseases.",
        "BIONDA is a free online database that uses text mining to provide information on molecular biomarkers related to various diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of diseases. The contained structured information on published biomarkers is extracted automatically from Europe PMC publication abstracts and high-quality sources like UniProt and Disease Ontology. This allows frequent content updates.",
        "BIONDA is a free database for a fast information on published biomarkers.",
        "BIONDA is a free database that provides fast access to information on published biomarkers.",
        "BIONDA is a free text mining-based online database for molecular biomarkers, including genes, proteins, and miRNAs, and for all kinds of diseases. Studies implemented BIONDA as an intelligent system that extracts relevant information from biomedical texts and provides it as structured information to researchers in a user-friendly way. BIONDA contains structured information on published biomarkers extracted automatically from Europe PMC publication abstracts and high-quality sources like UniProt and Disease Ontology, allowing for frequent content updates. It is freely accessible via a user-friendly web application and its code is available at GitHub. Studies utilize BIONDA to evaluate genetic structure and variability of certain breeds, such as Bionda Piemontese, and to detect industrial chicken meat among indigenous products, considering issues that could affect assignment accuracy.",
        "BIONDA is a free online database providing structured information on molecular biomarkers, including genes, proteins, and miRNAs, for various diseases, extracted from biomedical texts and high-quality sources.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs, as well as all kinds of diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs for all kinds of diseases. It contains structured information on published biomarkers that is extracted automatically from Europe PMC publication abstracts and high-quality sources like UniProt and Disease Ontology. BIONDA is freely accessible via a user-friendly web application.",
        "BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs and for all kinds of diseases. The contained structured information on published biomarkers is extracted automatically from PubMed abstracts.",
        "BIONDA is a free online database that provides fast information on published biomarkers, including genes, proteins, and miRNAs, for various diseases.",
        "BIONDA is a free text mining based online database designed to provide comprehensive information on molecular biomarkers such as genes, proteins, and miRNAs across various diseases. It serves as a valuable resource for researchers by compiling data from diverse sources using advanced text mining techniques.",
        "BIONDA is a free text mining-based online database for molecular biomarkers, including genes, proteins, and miRNAs, that covers all kinds of diseases.",
        "BIONDA (Biological information Online for molecular biology DataBase) is a text mining approach for extracting biological data from literature to support the study of molecular biology. The current version of BIONDA includes a wide spectrum of organisms, and for human it covers all the TFs known up to date.",
        "BIONDA is a free online database that provides rapid information on published biomarkers, including genes, proteins, and miRNAs across various diseases. It operates through a text mining-based system.",
        " BIONDA implement free text mining-based online database molecular biomarker include gene protein mirna kind disease . Bionda free database fast information publish biomarker .",
        "BIONDA is a free text mining-based online database that provides fast access to information on published molecular biomarkers, such as genes, proteins, and miRNAs, across various diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs across all kinds of diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs for all kinds of diseases.",
        "BIONDA is a free online database designed for fast access to information on published biomarkers. It includes details on various molecular biomarkers, including genes, proteins, and miRNAs, and spans a broad spectrum of diseases.",
        "BIONDA is a free, text mining-based online database that provides fast access to published molecular biomarkers (genes, proteins, miRNAs) across all diseases.",
        "BIONDA is a free text-mining-based online database delivering fast information on published molecular biomarkers—including genes, proteins and miRNAs—across all kinds of diseases via a user-friendly web application.",
        "[\u0027BIONDA is a free text mining-based online database for molecular biomarkers, including genes, proteins, and miRNAs, for various diseases.\u0027]",
        "BIONDA is a free text mining-based online database designed for molecular biomarkers, including genes, proteins, and miRNAs, and it covers all kinds of diseases.",
        "BIONDA is a free online text mining database that provides information about molecular biomarkers (genes, proteins, and miRNAs) associated with various diseases, making it a valuable resource for biomarker research.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs, designed to extract structured information from biomedical texts.",
        "BIONDA is a free online database that provides fast information on published biomarkers, including genes, proteins, and miRNAs, for all kinds of diseases.",
        "BIONDA is a free text mining-based online database providing fast information on published biomarkers, including genes, proteins, and miRNAs, applicable to various diseases.",
        "BIONDA is a free online database designed to provide fast access to information on published molecular biomarkers, including genes, proteins, and miRNAs, across various diseases. Utilizing text mining technology, it efficiently compiles data from scientific literature, offering a comprehensive resource for researchers and clinicians seeking quick retrieval of biomarker information.",
        "BIONDA is a free, online database that provides rapid access to information on published molecular biomarkers, including genes, proteins, and microRNAs (miRNAs), for various diseases. It serves as a valuable resource for researchers and healthcare professionals seeking to understand the relationships between these biomarkers and diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers related to genes, proteins, miRNAs, and various diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins, and miRNAs and for all kinds of diseases.",
        "BIONDA is an online database designed to provide free access to molecular biomarker data, including genes, proteins, and miRNAs, across various diseases. It leverages text mining technology to extract and organize information from scientific literature, making it a valuable resource for researchers studying biomarkers in different pathological conditions.",
        "BIONDA is a freely accessible online database utilizing text mining technology to provide rapid access to published molecular biomarkers, including genes, proteins, and miRNAs, associated with various diseases, facilitating research and disease understanding.",
        "BIONDA is a freely accessible online database designed for quick retrieval of information on published molecular biomarkers. It utilizes text mining to gather data on genes, proteins, and miRNAs associated with various diseases, serving as a valuable resource for researchers and medical professionals seeking efficient access to biomarker information.",
        "BIONDA is a free text-mining-based online database designed to provide structured information on molecular biomarkers such as genes, proteins, and miRNAs across various diseases. It automatically extracts data from Europe PMC studies and integrates high-quality resources like UniProt and Disease Ontology to ensure accurate and up-to-date content. The platform offers researchers user-friendly access to this curated information through a web application, with frequent updates enabled by automated extraction processes. BIONDA is publicly accessible at http://bionda.mpc.ruhr-uni-bochum.de, and its codebase is available on GitHub for transparency and collaboration.",
        "[\u0027BIONDA is a free, text mining-based online database that provides information on published biomarkers, including genes, proteins, and miRNAs, for various diseases.\u0027]",
        "BIONDA is a free online database for molecular biomarkers, including genes, proteins, and miRNAs, associated with various diseases. It uses text mining-based technology to provide fast access to published biomarker information.",
        "BIONDA was implemented as a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs . The database is a free database for fast information",
        "BIONDA is a freely accessible online database that utilizes automated text mining from reputable biomedical sources to provide frequently updated, structured information on published molecular biomarkers (including genes, proteins, and miRNAs) for various diseases, offering users quick and reliable access to this critical health information.",
        "BIONDA is a free online database that provides fast access to published molecular biomarker information. It uses text mining to extract and organize data on genes, proteins and microRNAs associated with various diseases, and is available through a user-friendly web application.",
        "BIONDA is a free online database for quick access to published molecular biomarker information across various diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers and diseases.",
        "BIONDA is a free text mining-based online database for molecular biomarkers including genes, proteins and miRNAs for all kinds of diseases. It contains structured information on published biomarkers extracted automatically from Europe PMC publication abstracts and high-quality sources like UniProt and Disease Ontology. BIONDA is freely accessible via a user-friendly web application.",
        "BIONDA is a free, text mining-based online database that provides fast access to published information on molecular biomarkers, such as genes, proteins, and miRNAs, across a wide range of diseases.",
        "BIONDA is a free text mining-based online database designed to provide fast access to information on molecular biomarkers, including genes, proteins, and miRNAs, across various diseases.",
        "BIONDA is a free online database that uses text mining to identify molecular biomarkers such as genes, proteins, and miRNAs for various diseases.",
        "[\u0027BIONDA is a free text mining-based online database that serves as a resource for molecular biomarkers, including genes, proteins, and miRNAs, for various diseases. It provides fast information on published biomarkers.\u0027]"
      ],
      "exact_answer": [
        [
          "Biomarker database"
        ]
      ]
    },
    {
      "body": "Indications for Electro-convulsive therapy.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35951050",
        "http://www.ncbi.nlm.nih.gov/pubmed/36344233",
        "http://www.ncbi.nlm.nih.gov/pubmed/36513894",
        "http://www.ncbi.nlm.nih.gov/pubmed/37314167",
        "http://www.ncbi.nlm.nih.gov/pubmed/39510644",
        "http://www.ncbi.nlm.nih.gov/pubmed/39079239",
        "http://www.ncbi.nlm.nih.gov/pubmed/32658056",
        "http://www.ncbi.nlm.nih.gov/pubmed/32642948",
        "http://www.ncbi.nlm.nih.gov/pubmed/37722210",
        "http://www.ncbi.nlm.nih.gov/pubmed/16984007",
        "http://www.ncbi.nlm.nih.gov/pubmed/33321557",
        "https://www.ncbi.nlm.nih.gov/pubmed/18385009",
        "http://www.ncbi.nlm.nih.gov/pubmed/7149085",
        "http://www.ncbi.nlm.nih.gov/pubmed/18385009",
        "http://www.ncbi.nlm.nih.gov/pubmed/32151451",
        "http://www.ncbi.nlm.nih.gov/pubmed/37582353",
        "http://www.ncbi.nlm.nih.gov/pubmed/34277291",
        "http://www.ncbi.nlm.nih.gov/pubmed/38371130",
        "http://www.ncbi.nlm.nih.gov/pubmed/35506976",
        "http://www.ncbi.nlm.nih.gov/pubmed/12581624",
        "http://www.ncbi.nlm.nih.gov/pubmed/31714466",
        "http://www.ncbi.nlm.nih.gov/pubmed/15564821",
        "http://www.ncbi.nlm.nih.gov/pubmed/10811552",
        "http://www.ncbi.nlm.nih.gov/pubmed/7095769",
        "http://www.ncbi.nlm.nih.gov/pubmed/39629831",
        "http://www.ncbi.nlm.nih.gov/pubmed/21158560",
        "http://www.ncbi.nlm.nih.gov/pubmed/19820553"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1129,
          "text": "unipolar depression (57.7%), followed by schizophrenia spectrum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35951050"
        },
        {
          "offsetInBeginSection": 965,
          "offsetInEndSection": 1038,
          "text": "unipolar depression (41%), psychotic disorder (23%), and bipolar disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36344233"
        },
        {
          "offsetInBeginSection": 800,
          "offsetInEndSection": 810,
          "text": "depression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36513894"
        },
        {
          "offsetInBeginSection": 266,
          "offsetInEndSection": 360,
          "text": "treatment-resistant major depression, bipolar disorders, and treatment-resistant schizophrenia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37314167"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 567,
          "text": "treatment-resistant mood disorder/psychosis and catatonia although it has been effectively used for other conditions including neuroleptic malignant syndrome, refractory self-injurious behavior",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39510644"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 200,
          "text": "treatment-resistant depression, bipolar and schizophrenic patient groups, and suicide attempt histories",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39079239"
        },
        {
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1390,
          "text": "major depression (38.4%), psychotic depression (30.9%), and bipolar disorder with depressive episodes ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32658056"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 148,
          "text": "severe affective and psychotic disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32642948"
        },
        {
          "offsetInBeginSection": 273,
          "offsetInEndSection": 324,
          "text": "bipolar, depressive and primary psychotic disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37722210"
        },
        {
          "offsetInBeginSection": 1501,
          "offsetInEndSection": 1562,
          "text": "major depressive disorder, bipolar disorder and schizophrenia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37722210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "ECT (electro-convulsive therapy) has been used for the treatment of depressive patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16984007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "OBJECTIVE: Electro-convulsive therapy (ECT) has been established as a treatment modality for patients with treatment-resistant depression and with some specific subtypes of ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33321557"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1913,
          "text": "Curative electroconvulsive therapy (ECT) remains a very useful treatment, still irreplaceable for some specific rare cases, as long as other brain stimulation methods, such as transcranial magnetic stimulation, remain experimental. ECT must be preceded by a rigorous evaluation of its therapeutic index, based on its advantages and risks compared with other potential treatments, in view of the patient\u0027s medical and psychiatric history. The principal indication is very severe depressive illness. In view of its efficacy and speed of action, ECT may be a first-line treatment for life-threatening depression and a second line treatment for patients with major depressive disorder who do not respond or respond incompletely to antidepressant drugs. ECT can be given to patients with catatonia, including as first-line treatment for some. ECT remains an important treatment option for depression in the elderly, especially those with depression and reversible dementia. Other indications classically considered, although for fewer patients and never as first-line treatment, are difficult-to-treat patients whose acute mania, mixed mania, schizo-affective state or schizophrenia has failed to respond to an adequate dose of psychotropic drugs and can be considered drug-refractory. It has also been used in Parkinson\u0027s psychosis and drug-resistant epilepsy. Preventive or maintenance ECT is appropriate for a few depressed patients who respond to it and it alone. It is the only effective option for these severely and recurrently depressed, medication-resistant patients. Some technical issues remain very empirical: seizure threshold determination, number of sessions, and concomitant pharmacotherapy. The practice of ECT must comply with very strict rules: information to and consent by the patient or family, performance at a hospital center by a team including a psychiatrist, anesthetist, and trained nurses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/18385009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Convulsive therapy is a specific therapy for patients with melancholia and catatonia, with a high success rate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7149085"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 274,
          "text": " Electro-convulsive therapy (ECT) is the most effective treatment for treatment resistant mood disorders and catatonia. ECT also appears to be an effective treatment in combination with clozapine in the context of treatment resistant schizophrenia spectrum disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32151451"
        },
        {
          "offsetInBeginSection": 1933,
          "offsetInEndSection": 2132,
          "text": "ECT can be incorporated as standard protocol in the treatment of catatonia and associated psychiatric symptoms when managing a patient with anti-NMDAR encephalitis associated with catatonic features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34277291"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 453,
          "text": "The treatment of catatonia related to psychiatric illnesses is well documented as it typically responds to benzodiazepines and electroconvulsive therapy (ECT). However, the treatment of catatonia related to neurological disorders has shown to be more difficult, particularly when associated with Lewy Body Dementia (LBD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38371130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 397,
          "text": "Electroconvulsive therapy (ECT) has a reputation for rapid alleviation of symptoms, mainly in depressive disorders. In the current literature little attention has been paid to speed of response of psychotic symptoms in schizophrenia. We present the case of a 67-year old woman, diagnosed with schizophrenia and presenting with clozapine-resistant psychotic symptoms that swiftly remitted with ECT.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35506976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Electroconvulsive therapy (ECT) is used to treat patients with major depressive disorder, manic episodes and other serious mental disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581624"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Electroconvulsive therapy (ECT) is a well-tolerated, well-established, and efficacious treatment in adults, particularly in the setting of severe mood and psychotic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31714466"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "OBJECTIVE: Electro-convulsive therapy (ECT) has been established as a treatment modality for patients with treatment-resistant depression and with some specific subtypes of depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33321557"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 747,
          "text": "The principal indication is very severe depressive illness. In view of its efficacy and speed of action, ECT may be a first-line treatment for life-threatening depression and a second line treatment for patients with major depressive disorder who do not respond or respond incompletely to antidepressant drugs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18385009"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 392,
          "text": "ECT may be considered when there is a lack of response to two or more trials of pharmacotherapy or when the severity of symptoms precludes waiting for a response to pharmacological treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15564821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 381,
          "text": "Electroconvulsive therapy (ECT) is used increasingly in the older adult population for major depression, particularly when depression is not responsive to medications, when antidepressants are not tolerated due to side effects, or when depression is accompanied by life-threatening complications such as severe weight loss or catatonia where a rapid definitive response is required",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10811552"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "ECT is an effective psychiatric treatment for severe depression, mania, catatonic states, and, to a lesser degree, some schizophrenias. Complications are minimal and the risk of death extremely low, lower than that for an inadequately treated depress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7095769"
        },
        {
          "offsetInBeginSection": 573,
          "offsetInEndSection": 663,
          "text": "Current catatonia treatment guidelines include the use of benzodiazepines followed by ECT.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39629831"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 366,
          "text": "Electroconvulsive therapy (ECT) is a recognized and effective treatment in adults for several psychiatric and neurological conditions in which the use of pharmacotherapy is ineffective, untimely or contraindicated. It has been used with success in mood and psychotic disorders, catatonia, neuroleptic malignant syndrome, Parkinson\u0027s disease and intractable seizures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21158560"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Electroconvulsive therapy (ECT) is an established therapeutic method for the treatment of severe mental disorders refractory to pharmaco- and psychotherapy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37582353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "Electroconvulsive therapy (ECT) is an established therapeutic method for the treatment of severe mental disorders refractory to pharmaco- and psychotherapy. ECT is a first-line treatment option in delusional disorders, severe depression with acute suicidal tendency or life-threatening catatonia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37582353"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 459,
          "text": "Although electroconvulsive therapy (ECT) is employed in the treatment of several psychiatric disorders, it is most frequently used today to treat severe depressive episodes and remains the most effective treatment available for those disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19820553"
        }
      ],
      "id": "6810c54b353a4a2e6b000011",
      "ideal_answer": [
        "Electro-convulsive therapy (ECT) is primarily indicated for: treatment-resistant depression, suicidal depression, elderly depression, bipolar depression, psychotic depression, and depression during pregnancy or postpartum. Emerging or less common indications include chronic pain, schizophrenia, mania, and severe drug-treatment-resistant depression. In rare, carefully considered cases, ECT may be used for neuroleptic malignant syndrome. Notably, its application in severe depression among pre-pubertal children is controversial and requires cautious evaluation. ECT for Wilson\u0027s Disease with psychiatric manifestations is also a recognized, albeit rare, application.",
        "Electro-convulsive therapy (ECT) is indicated for various psychiatric conditions, including major depression, schizophrenia, mania, and severe depressive illness. Studies have shown ECT to be effective in treating these conditions, particularly in cases where patients are resistant to pharmacotherapy. For instance, studies have demonstrated that ECT can facilitate recovery in patients with potentially drug treatment-resistant psychotic disorders, such as schizophrenia and severe depression. Additionally, ECT has been used to control homicidal impulses in pregnant patients with acute psychosis and has been found to be safe and effective in this population. Studies have also explored use of ECT in pre-pubertal children, finding it to be a life-saving treatment in cases of severe depression with catatonic features. Overall, indications for ECT include depression refractory to two medication trials, emergency situations due to severe suicidal ideation or physical deterioration, and certain types of schizophrenia and mania that have not responded to adequate pharmacotherapy."
      ],
      "exact_answer": [
        [
          "major depression"
        ],
        [
          "schizophrenia"
        ],
        [
          "psychosis"
        ],
        [
          "bipolar disorder"
        ],
        [
          "mood disorders"
        ],
        [
          "catatonia"
        ],
        [
          "neuroleptic malignant syndrome"
        ],
        [
          "refractory self-injurious behavior"
        ],
        [
          "suicide attempt history"
        ],
        [
          "severe affective disoder"
        ]
      ]
    },
    {
      "body": "What is a common chromosome-level gain in glioblastoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21884817",
        "http://www.ncbi.nlm.nih.gov/pubmed/39534304",
        "http://www.ncbi.nlm.nih.gov/pubmed/35118384",
        "http://www.ncbi.nlm.nih.gov/pubmed/8203461",
        "http://www.ncbi.nlm.nih.gov/pubmed/8536240",
        "http://www.ncbi.nlm.nih.gov/pubmed/3335011",
        "http://www.ncbi.nlm.nih.gov/pubmed/12503074",
        "http://www.ncbi.nlm.nih.gov/pubmed/11063794",
        "http://www.ncbi.nlm.nih.gov/pubmed/25117714",
        "https://www.ncbi.nlm.nih.gov/pubmed/25622821",
        "https://www.ncbi.nlm.nih.gov/pubmed/29632085",
        "https://www.ncbi.nlm.nih.gov/pubmed/30187121",
        "https://www.ncbi.nlm.nih.gov/pubmed/38285005",
        "http://www.ncbi.nlm.nih.gov/pubmed/29632085",
        "http://www.ncbi.nlm.nih.gov/pubmed/25622821",
        "http://www.ncbi.nlm.nih.gov/pubmed/19602687",
        "http://www.ncbi.nlm.nih.gov/pubmed/15837741",
        "http://www.ncbi.nlm.nih.gov/pubmed/38285005",
        "http://www.ncbi.nlm.nih.gov/pubmed/26091668",
        "http://www.ncbi.nlm.nih.gov/pubmed/16110500",
        "http://www.ncbi.nlm.nih.gov/pubmed/7497447",
        "http://www.ncbi.nlm.nih.gov/pubmed/11701945",
        "http://www.ncbi.nlm.nih.gov/pubmed/17907599",
        "http://www.ncbi.nlm.nih.gov/pubmed/15696966",
        "http://www.ncbi.nlm.nih.gov/pubmed/35468210",
        "http://www.ncbi.nlm.nih.gov/pubmed/9260757",
        "http://www.ncbi.nlm.nih.gov/pubmed/17145331",
        "http://www.ncbi.nlm.nih.gov/pubmed/17203188",
        "http://www.ncbi.nlm.nih.gov/pubmed/16167544",
        "http://www.ncbi.nlm.nih.gov/pubmed/11302337",
        "http://www.ncbi.nlm.nih.gov/pubmed/17447852",
        "http://www.ncbi.nlm.nih.gov/pubmed/12845540",
        "http://www.ncbi.nlm.nih.gov/pubmed/39078448",
        "http://www.ncbi.nlm.nih.gov/pubmed/30530503",
        "http://www.ncbi.nlm.nih.gov/pubmed/12810256"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 191,
          "text": "Glioblastoma (GBM) is the most common and aggressive form of glioma. GBM frequently displays chromosome (chr) 7 gain, chr 10 loss and/or EGFR amplification (chr7+/chr10-/EGFRamp).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35118384"
        },
        {
          "offsetInBeginSection": 674,
          "offsetInEndSection": 849,
          "text": "These cytogenomic methods revealed classical findings associated with glioblastoma, such as a lack of IDH and TERT mutations, gain of chromosome 7, and loss of chromosome 10. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39534304"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Glioblastomas are cytogenetically heterogeneous tumors that frequently display alterations of chromosomes 7, 9p, and 10q.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21884817"
        },
        {
          "offsetInBeginSection": 685,
          "offsetInEndSection": 868,
          "text": "Gains of chromosome 7 (97%), with or without epidermal growth factor receptor (EGFR) amplification, and losses of chromosomes 9p (83%) and 10 (91%) were the most frequent alterations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21884817"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Glioblastoma is the commonest primary malignant brain tumor, with a very poor prognosis and short overall survival. It is characterized by its high intra- and intertumoral heterogeneity, in terms of both the level of single-nucleotide variants, copy number alterations, and aneuploidy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39534304"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 509,
          "text": "Nonrandom chromosomal gains and losses were identified with overrepresentation of chromosome 7 and underrepresentation of chromosome 10 as the most frequent events (1 of 2 astrocytomas, 7 of 7 glioblastomas).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8203461"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 629,
          "text": "The most common numerical chromosome aberrations were +7, -9, -10, -14, and loss of a sex chromosome. Structural changes involved predominantly the following chromosome arms: 1q, 2q, 6q, 7q, 9p, 14q, 17p, and 18p. Losses of chromosomes 9, 10, and 14, often occurring simultaneously and in polyploid clones, were observed almost exclusively in high-grade gliomas, and appear to constitute important events during glioma progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8536240"
        },
        {
          "offsetInBeginSection": 470,
          "offsetInEndSection": 659,
          "text": "Statistically significant numerical deviations in the near-diploid group were gains of chromosome 7 (26 of 32; P less than 0.001), and losses of chromosome 10 (19 of 32; P less than 0.001).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3335011"
        },
        {
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1441,
          "text": "Comparative genomic hybridization showed that the most frequent region of gain was chromosome 7p, whereas the most frequent losses occurred on chromosomes 10q and 13q. The only statistically significant association was found for 7p gain and 10q loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Chromosomal abnormalities in human glioblastomas: gain in chromosome 7p correlating with loss in chromosome 10q.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503074"
        },
        {
          "offsetInBeginSection": 372,
          "offsetInEndSection": 648,
          "text": "We identified three major genetic subgroups within these glioblastoma multiforme tumors: tumors with chromosome 7 gain and chromosome 10 loss, tumors with only chromosome 10 loss in the absence of chromosome 7 gain, and tumors without copy number change in chromosomes 7 or 10",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15837741"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 211,
          "text": "Glioblastoma (GBM) is characterized by chromosome 7 copy number gains, notably 7q34, potentially contributing to therapeutic resistance, yet the underlying oncogenes have not been fully characterized",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38285005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 471,
          "text": "Glioblastoma is the most frequently occurring and invariably fatal primary brain tumor in adults. The vast majority of glioblastomas is characterized by chromosomal copy number alterations, including gain of whole chromosome 7 and loss of whole chromosome 10. Gain of whole chromosome 7 is an early event in gliomagenesis that occurs in proneural-like precursor cells, which give rise to all isocitrate dehydrogenase (IDH) wild-type glioblastoma transcriptional subtypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29632085"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 471,
          "text": "The vast majority of glioblastomas is characterized by chromosomal copy number alterations, including gain of whole chromosome 7 and loss of whole chromosome 10. Gain of whole chromosome 7 is an early event in gliomagenesis that occurs in proneural-like precursor cells, which give rise to all isocitrate dehydrogenase (IDH) wild-type glioblastoma transcriptional subtypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29632085"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "Glioblastoma is the most frequently occurring and invariably fatal primary brain tumor in adults. The vast majority of glioblastomas is characterized by chromosomal copy number alterations, including gain of whole chromosome 7 and loss of whole chromosome 10.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29632085"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 259,
          "text": "The vast majority of glioblastomas is characterized by chromosomal copy number alterations, including gain of whole chromosome 7 and loss of whole chromosome 10.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29632085"
        },
        {
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1358,
          "text": "Comparative genomic hybridization showed that the most frequent region of gain was chromosome 7p, whereas the most frequent losses occurred on chromosomes 10q and 13q.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Glioblastoma multiforme (GBM) is characterized by intratumoral heterogeneity as to both histomorphology and genetic changes, displaying a wide variety of numerical chromosome aberrations the most common of which are monosomy 10 and trisomy 7.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11701945"
        },
        {
          "offsetInBeginSection": 222,
          "offsetInEndSection": 350,
          "text": "Cytogenetically, karyotypes of glioblastomas are very complex with trisomy 7 and monosomy 10 as the most frequent abnormalities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17907599"
        },
        {
          "offsetInBeginSection": 685,
          "offsetInEndSection": 772,
          "text": "Chromosomal gains were observed frequently for 7q (33.3%), 7p (20.0%), and 17q (13.3%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15696966"
        },
        {
          "offsetInBeginSection": 411,
          "offsetInEndSection": 554,
          "text": "The alterations in the glioblastomas were complex, and most frequently showed the characteristic gain of chromosome 7 and loss of chromosome 10",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11063794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "BACKGROUND: Glioblastoma (GBM) is an aggressive tumor that frequently exhibits gain of chromosome 7, loss of chromosome 10, and aberrantly activated receptor tyrosine kinase signal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35468210"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 381,
          "text": "The most common order of evolutionary events is 1) chromosome (chr) 7 gain and chr10 loss, followed by 2) CDKN2A loss and/or TP53 mutation, and 3) alterations canonical for specific subtypes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25117714"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 190,
          "text": "Two frequently reported aberrations are trisomy 7 and monosomy 10",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9260757"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Glioblastoma multiforme (GBM) is characterized by intratumoral heterogeneity in both histomorphological and genetic changes, displaying a wide variety of numerical chromosome aberrations, the most common of which are trisomy 7 and monosomy 10",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16167544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "Cytogenetic and molecular genetic studies of glioblastoma multiforme (GBM) have shown that the most frequent alterations are gains of chromosome 7, losses of 9p loci and chromosome 10, and gene amplification, primarily of the epidermal growth factor receptor (EGFR) gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302337"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 507,
          "text": "Nonrandom chromosomal gains and losses were identified with overrepresentation of chromosome 7 and underrepresentation of chromosome 10 as the most frequent events (1 of 2 astrocytomas, 7 of 7 glioblastomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8203461"
        },
        {
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1038,
          "text": "The CGH and karyotypic data were consistent in showing gain of chromosome 7 accompanied by a loss of chromosome 10 as the most frequent abnormality, followed by a loss of 9p in 17 of 22 GBM cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302337"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 477,
          "text": "Trisomy/polysomy of chromosome 7, monosomy of chromosome 10, EGFR gene amplification and p53 deletion have been described as the typical genetic markers for tumor classification and prediction of possible response to therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17447852"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "Cytogenetic and molecular genetic studies of glioblastoma multiforme (GBM) have shown that the most frequent alterations are gains of chromosome 7, losses of 9p loci and chromosome 10, and gene amplification, primarily of the epidermal growth factor receptor (EGFR) gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302337"
        },
        {
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1039,
          "text": "The CGH and karyotypic data were consistent in showing gain of chromosome 7 accompanied by a loss of chromosome 10 as the most frequent abnormality, followed by a loss of 9p in 17 of 22 GBM cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302337"
        },
        {
          "offsetInBeginSection": 699,
          "offsetInEndSection": 859,
          "text": "Regional and numerical increases in chromosome 7 copy number were the most frequently seen abnormality (10/20 tumors), followed by loss of chromosome 10 (8/20).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12845540"
        },
        {
          "offsetInBeginSection": 1176,
          "offsetInEndSection": 1315,
          "text": "The loss of chromosomes 10 and 9p and the gain of chromosomes 7 and 19 were the most frequent chromosomal alterations in both tumour parts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17203188"
        },
        {
          "offsetInBeginSection": 294,
          "offsetInEndSection": 493,
          "text": "To clarify this question, the most common cytogenetic aberration, gain of chromosome 7, was chosen and in situ hybridization was performed on paraffin-embedded tissue sections of three glioblastomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7497447"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Glioblastoma multiforme (GBM) is characterized by intratumoral heterogeneity in both histomorphological and genetic changes, displaying a wide variety of numerical chromosome aberrations, the most common of which are trisomy 7 and monosomy 10. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16167544"
        },
        {
          "offsetInBeginSection": 699,
          "offsetInEndSection": 817,
          "text": "Regional and numerical increases in chromosome 7 copy number were the most frequently seen abnormality (10/20 tumors),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12845540"
        },
        {
          "offsetInBeginSection": 843,
          "offsetInEndSection": 991,
          "text": "The CGH and karyotypic data were consistent in showing gain of chromosome 7 accompanied by a loss of chromosome 10 as the most frequent abnormality,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11302337"
        },
        {
          "offsetInBeginSection": 411,
          "offsetInEndSection": 555,
          "text": "The alterations in the glioblastomas were complex, and most frequently showed the characteristic gain of chromosome 7 and loss of chromosome 10.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11063794"
        },
        {
          "offsetInBeginSection": 237,
          "offsetInEndSection": 501,
          "text": "Despite the substantial variation in numerical chromosome alterations among the cell lines, several distinct and glioma growth-associated losses or gains were frequently observed, that is, losses of chromosomes 10, 13, and 22 and gain of chromosome 7 in particular",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12810256"
        }
      ],
      "id": "67fd5d6518b1e36f2e000138",
      "ideal_answer": [
        "Glioblastoma is the most common primary malignant brain tumor, with a very poor prognosis and short overall survival. It is characterized by high intra- and intertumoral heterogeneity, in terms of both the level of single-nucleotide variants, copy number alterations, and aneuploidy. From these chromosomal aberrations, gains of chromosome 7, with or without epidermal growth factor receptor (EGFR) amplification, and losses of chromosome 10 are the most frequent alterations.",
        "The most common chromosome-level gain in glioblastoma is **chromosome 7** (trisomy 7 or copy number gain), frequently observed alongside loss of chromosome 10 (-10). This alteration, termed **+7/-10**, is a hallmark genetic feature of IDH-wildtype glioblastoma and is associated with key oncogenic drivers such as *EGFR* amplification. Chromosome 7 gains, including polysomy or specific regions like 7q34, are recurrently reported in glioblastoma studies and linked to tumor progression and poor prognosis.",
        "A common chromosome-level gain in glioblastoma is **trisomy of chromosome 7** (gain of an extra copy), frequently observed alongside **monosomy of chromosome 10** (loss of one copy). Chromosome 7 polysomy (multiple extra copies) is also noted, often associated with **EGFR gene amplification**, a hallmark alteration in glioblastoma (IDH-wildtype). These chromosomal changes are recurrently identified in molecular profiling and contribute to tumor aggressiveness and poor prognosis.",
        "A common chromosome-level gain in glioblastoma is the gain of chromosome 7. This is frequently observed in glioblastomas, including IDH-wildtype glioblastomas, where it often occurs alongside chromosome 10 loss. The region 7p12, which includes the epidermal growth factor receptor (EGFR) gene, is also subject to frequent amplifications in glioblastomas. Polysomy of chromosome 7 is found in a large percentage of gliomas and glioblastomas.",
        "The most common chromosome-level gain in glioblastoma is **chromosome 7**, frequently observed as part of the cytogenetic hallmarks of the disease. This gain often occurs alongside losses of chromosome 10 and/or amplification of the *EGFR* gene (located on chromosome 7). Studies report chromosome 7 gain in up to 97% of glioblastoma cases, highlighting its prevalence in tumorigenesis.",
        "The most common chromosome-level gain in glioblastoma is **chromosome 7** (chr7+), frequently observed alongside loss of chromosome 10 (chr10−) and/or EGFR amplification (located on chr7). This cytogenetic alteration is a hallmark of glioblastoma, with studies reporting chr7 gain in up to 97% of cases.",
        "A common chromosome-level gain in glioblastoma (GBM) is **chromosome 7 gain**, observed in approximately 97% of cases, often accompanied by **epidermal growth factor receptor (EGFR) amplification**. This alteration is frequently associated with **chromosome 10 loss** (91% prevalence) and **chromosome 9p loss** (83% prevalence), contributing to the cytogenetic heterogeneity of GBM. These genomic changes, including **chr7+/chr10-** and **EGFR amplification**, are hallmark features linked to tumor aggressiveness and poor prognosis. While other alterations like **IDH1/2** or **TERT promoter mutations** are less common, the combination of **chromosome 7 gain** and **10 loss** remains a defining characteristic of classical GBM. This genomic instability underpins the tumor\u0027s high intra- and intertumoral variability, complicating therapeutic strategies.",
        "Glioblastoma (GBM), the most common and aggressive primary malignant brain tumor, frequently displays chromosome 7 gain (97% of cases), often accompanied by chromosome 10 loss and/or EGFR amplification. These cytogenetic alterations are classical findings associated with this highly heterogeneous tumor.",
        "A common chromosome-level gain in glioblastoma is Chromosome 7, observed in approximately 97% of cases. This alteration is often associated with the loss of chromosomes 9p and 10, and/or amplification of the EGFR gene, contributing to the tumor\u0027s cytogenetic heterogeneity and poor prognosis.",
        "A common chromosome-level gain in glioblastoma (GBM) is **chromosome 7**, observed in approximately 97% of cases across multiple studies using high-density single-nucleotide polymorphism arrays, fluorescence *in situ* hybridization, and whole-genome sequencing. This alteration often co-occurs with epidermal growth factor receptor (*EGFR*) amplification in a subset of tumors (29%) and is part of the classical genetic profile (chromosome 7 gain, chromosome 10 loss, and/or *EGFR* amplification) seen in about two-thirds of GBMs. These findings highlight chromosome 7 gain as one of the most frequent cytogenetic abnormalities in GBM, alongside losses on chromosomes 9p and 10q, underscoring its role in tumor pathogenesis and potential prognostic relevance when combined with other genetic alterations.",
        "Glioblastoma is the commonest primary malignant brain tumor, with a very poor prognosis and short overall survival. It is characterized by its high intra- and intertumoral heterogeneity, in terms of both the level of single- nucleotide variants, copy number alterations, and aneuploidy. Gains of chromosome 7 (97%), with or without epidermal growth factor receptor (EGFR) amplification, and losses of chromosomes 9p (83%) and 10 (91%) were the most frequent alterations.",
        "A common chromosome-level gain in glioblastoma is the gain of chromosome 7 (chr7+). This alteration is frequently observed in glioblastoma, often accompanied by loss of chromosome 10 (chr10-) and/or EGFR amplification. The gain of chromosome 7 is a characteristic cytogenetic feature of glioblastoma, as reported in multiple studies.",
        "Glioblastoma (GBM) is the most common and aggressive form of glioma . GBM frequently displays chromosome (chr) 7 gain, chr 10 loss and/or EGFR amplification . It is characterized by its high intra- and intertumoral heterogeneity, in terms of the level of single-nucleotide variants, copy number alterations, and aneuploidy .",
        "A common chromosome-level gain in glioblastoma is the gain of chromosome 7, which occurs in the majority of cases and is often accompanied by EGFR amplification. This alteration is a classical cytogenetic finding in glioblastoma and is frequently observed alongside loss of chromosome 10."
      ],
      "exact_answer": [
        [
          "Chromosome 7",
          "Gain of chromosome 7",
          "Trisomy 7",
          "Chromosome 7 gain"
        ]
      ]
    },
    {
      "body": "What is the gene target for  Zanidatamab?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38358339",
        "http://www.ncbi.nlm.nih.gov/pubmed/36914633",
        "http://www.ncbi.nlm.nih.gov/pubmed/36400106",
        "http://www.ncbi.nlm.nih.gov/pubmed/37276871",
        "http://www.ncbi.nlm.nih.gov/pubmed/39114870",
        "http://www.ncbi.nlm.nih.gov/pubmed/38262242",
        "http://www.ncbi.nlm.nih.gov/pubmed/36000541",
        "http://www.ncbi.nlm.nih.gov/pubmed/34626563",
        "http://www.ncbi.nlm.nih.gov/pubmed/38266541",
        "http://www.ncbi.nlm.nih.gov/pubmed/33894300"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358339"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 715,
          "text": "Zanidatamab binds adjacent HER2 molecules in trans and initiates distinct HER2 reorganization, as shown by polarized cell surface HER2 caps and large HER2 clusters,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 415,
          "text": " Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 318,
          "text": "Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary tract cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "BACKGROUND: HER2 is overexpressed or amplified in a subset of biliary tract cancer. Zanidatamab, a bispecific antibody targeting two distinct HER2 epi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871"
        },
        {
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1188,
          "text": "Early phase trials of dabrafenib plus trametinib (BRAF and MEK inhibition) and zanidatamab (a bispecific HER2-antibody) have yielded encouraging response rates",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626563"
        },
        {
          "offsetInBeginSection": 885,
          "offsetInEndSection": 1028,
          "text": "Various anti-HER2 therapies, including trastuzumab, pertuzumab, trastuzumab-deruxtecan, zanidatamab and neratinib, have undergone investigation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38266541"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 494,
          "text": "Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and pertuzumab, has demonstrated safety and activity in HER2+ tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38262242"
        },
        {
          "offsetInBeginSection": 1232,
          "offsetInEndSection": 1385,
          "text": "Collectively, we show that zanidatamab has multiple and distinct mechanisms of action derived from the structural effects of biparatopic HER2 engagement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors. We determined the antitumor activity of zanidatamab in ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "BACKGROUND: HER2 is overexpressed or amplified in a subset of biliary tract cancer. Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited. Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358339"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 418,
          "text": "tic impact. Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. The",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 430,
          "text": "s limited. Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38262242"
        },
        {
          "offsetInBeginSection": 287,
          "offsetInEndSection": 455,
          "text": "treatment resistance remains a problem. Here, we engineer an anti-HER2 IgG1 bispecific, biparatopic antibody (Ab), zanidatamab, with unique and enhanced functionalities",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914633"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 679,
          "text": "Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary tract cancer.METHODS: HERIZON-BTC-01 is a global, multicentre, single-arm, phase 2b trial of zanidatamab in patients with HER2-amplified, unresectable, locally advanced, or metastatic biliary tract cancer with disease progression on previous gemcitabine-based therapy, recruited at 32 clinical trial sites in nine countries in North America, South America, Asia, and Europe.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 368,
          "text": "Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 424,
          "text": "Zanidatamab is an antibody designed to destroy cancer cells that have higher-than-normal HER2 protein or gene levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39114870"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 413,
          "text": " Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106"
        },
        {
          "offsetInBeginSection": 296,
          "offsetInEndSection": 494,
          "text": " Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and pertuzumab, has demonstrated safety and activity in HER2+ tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38262242"
        },
        {
          "offsetInBeginSection": 78,
          "offsetInEndSection": 254,
          "text": "Among those therapeutic targets, the human epidermal growth factor receptor-2 (HER-2) signaling pathway is one of the most popular targets for translational research in cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33894300"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 484,
          "text": "s limited. Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and pertuzumab, has demonstrated safety and activity in HE",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38262242"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 760,
          "text": "Zanidatamab binds adjacent HER2 molecules in trans and initiates distinct HER2 reorganization, as shown by polarized cell surface HER2 caps and large HER2 clusters, not observed with trastuzumab or tras + pert",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36400106"
        },
        {
          "offsetInBeginSection": 551,
          "offsetInEndSection": 761,
          "text": "Zanidatamab binds adjacent HER2 molecules in trans and initiates distinct HER2 reorganization, as shown by polarized cell surface HER2 caps and large HER2 clusters, not observed with trastuzumab or tras + pert.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36914633"
        },
        {
          "offsetInBeginSection": 72,
          "offsetInEndSection": 305,
          "text": "act cancer. Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited tolerability and preliminary anti-tumour activity in HER2-expressing or HER2 (also known as ERBB2)-amplified treatment-refractory biliary ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37276871"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 367,
          "text": "Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36000541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38358339"
        }
      ],
      "type": "factoid",
      "id": "67fb046e18b1e36f2e00010c",
      "ideal_answer": [
        "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors",
        "Zanidatamab is a HER2 targeted antibody cFcportin fusion protein for the treatment of metastatic or inoperable breast cancer.",
        "The gene target for Zanidatamab is HER2 (also known as ERBB2), with the antibody specifically binding to two distinct non-overlapping domains of the HER2 protein, facilitating its therapeutic action.",
        "Zanidatamab is a HER2 directed monoclonal antibody drug targeting HER2.",
        "Zanidatamab targets the gene HER2.",
        "Zanidatamab targets the human epidermal growth factor receptor 2 (HER2).",
        "Zanidatamab targets the HER2 gene, also known as ERBB2.",
        "HER2 (also known as ERBB2) is the gene target for Zanidatamab.",
        "Zanidatamab targets the **HER2 protein**, which is encoded by the **ERBB2 gene**. It is a bispecific antibody that binds two distinct extracellular domains (ECD2 and ECD4) of HER2, inhibiting signaling and driving antitumor activity in HER2-overexpressing or amplified cancers.",
        "Zanidatamab targets ERBB2 (the gene encoding human epidermal growth factor receptor 2, HER2).",
        "Zanidatamab is a bispecific HER2-directed antibody targeting the extracellular domains 2 and 4.",
        "Zanidatamab targets the **HER2 (ERBB2)** gene. It is a bispecific antibody that binds two distinct domains of the HER2 protein, making it effective against HER2-amplified or HER2-overexpressing cancers. This is consistently highlighted across multiple studies and clinical contexts.",
        "Zanidatamab targets the human epidermal growth factor receptor 2 (HER2), also known as ERBB2. HER2 is a receptor tyrosine kinase that plays an oncogenic role in various solid tumors. Zanidatamab is engineered as a bispecific, biparatopic antibody that binds adjacent HER2 molecules, initiating distinct HER2 reorganization.",
        "Zanidatamab is a bispecific antibody that targets the human epidermal growth factor receptor 2 (HER2).",
        "The gene target for Zanidatamab is HER2 (also known as ERBB2).",
        "Zanidatamab targets the HER2 gene.",
        "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors.",
        "Zanidatamab is a HER2 targeted antibody. It is being developed for the treatment of breast cancer.",
        "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody.",
        "Zanidatamab is a bispecific antibody that targets the HER2 (ERBB2) gene, which is known to be amplified or overexpressed in various cancers.",
        "The gene target for Zanidatamab is HER2 (also known as ERBB2 or Human Epidermal growth factor Receptor 2), to which the antibody binds at two distinct, non-overlapping domains.",
        "Zanidatamab targets the HER2 gene, a receptor tyrosine kinase involved in the development of breast, gastric, and other solid tumors.",
        "Zanidatamab is a bispecific antibody that targets HER2.",
        "Zanidatamab targets the HER2 gene, which is responsible for the expression of the human epidermal growth factor receptor 2 on the cell surface. This gene is involved in the biosynthetic process of the receptor, which is a part of the metabolic process in cells.",
        "Zanidatamab is a bispecific antibody designed to target the HER2 protein. This receptor plays a crucial role in cell growth and differentiation, and its overexpression contributes to cancer progression. By targeting HER2, Zanidatamab effectively combats solid tumors where HER2 is amplified or expressed, demonstrating significant antitumor activity.",
        "Zanidatamab is a bispecific antibody targeting two distinct HER2 epitopes.",
        "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2) targeted antibody.",
        "Zanidatamab targets the human epidermal growth factor receptor 2 (HER2) gene, also known as ERBB2. It is a bispecific antibody that binds to two distinct epitopes of HER2.",
        "Zanidatamab is designed to target HER2, also known as ERBB2, which is overexpressed or amplified in certain tumors.",
        "Zanidatamab targets ERBB2, also known as HER2.",
        "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody",
        "Zanidatamab targets the human epidermal growth factor receptor 2 (HER2), also known as ERBB2. It is a bispecific antibody that binds to two distinct epitopes of HER2, initiating HER2 reorganization and clustering on the cell surface.",
        "Zanidatamab is a bispecific antibody that targets the human epidermal growth factor receptor 2 (HER2), also known as ERBB2.",
        "The gene target for Zanidatamab is HER2, also known as ERBB2, which it binds to through two distinct epitopes to treat HER2-amplified or HER2-expressing cancers.",
        "Zanidatamab targets the human epidermal growth factor receptor 2 (HER2) gene.",
        "The gene target for Zanidatamab is HER2 (human epidermal growth factor receptor 2). It is a bispecific antibody that binds to two distinct epitopes of HER2, making it effective in treating HER2-expressing or amplified cancers.",
        "Zanidatamab is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Therefore, the gene target for Zanidatamab is HER2.",
        "Zanidatamab, HER2, cell surface, expressing, locally advanced, metastatic biliary tract cancer",
        "Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2) targeted antibody that has demonstrated antitumor activity in a broad range of HER2 amplified/expressing solid tumors.",
        "The gene target for Zanidatamab is ERBB2, which encodes for the HER2 (human epidermal growth factor receptor 2) protein, commonly referred to as HER2.",
        "Zanidatamab specifically targets the HER2 protein, which is encoded by the ERBB2 gene. This makes ERBB2 the gene associated with Zanidatamab\u0027s mechanism of action in treating HER2-expressing or amplified cancers.",
        "The gene target for Zanidatamab is HER2, also known as ERBB2.",
        "[\u0027The gene target for Zanidatamab is HER2 (also known as ERBB2).\u0027]",
        "The gene target for Zanidatamab is HER2 (Human Epidermal Growth Factor Receptor 2), also known as ERBB2. Zanidatamab is a bispecific antibody that targets two non-overlapping domains of HER2, exhibiting antitumor activity in HER2-amplified/expressing solid tumors.",
        "The gene target for Zanidatamab is HER2 (Human Epidermal Growth Factor Receptor 2), also known by its official gene symbol ERBB2.",
        "Zanidatamab is a bispecific monoclonal antibody that targets the HER2 oncoprotein, which is encoded by the ERBB2 gene.",
        "ERBB2 (commonly referred to as HER2)",
        "Zanidatamab targets the human epidermal growth factor receptor 2 (HER2) gene, also known as ERBB2, by binding to two distinct, non-overlapping domains on the HER2 protein, making it effective in treating HER2-expressing or HER2-amplified cancers.",
        "[\u0027The gene targets for Zanidatamab are HER2 and ERBB2.\u0027]"
      ],
      "exact_answer": [
        [
          "HER-2"
        ]
      ]
    },
    {
      "body": "How do you diagnose HIV infection?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39642281",
        "http://www.ncbi.nlm.nih.gov/pubmed/39637742",
        "http://www.ncbi.nlm.nih.gov/pubmed/10697641",
        "http://www.ncbi.nlm.nih.gov/pubmed/8684160",
        "http://www.ncbi.nlm.nih.gov/pubmed/24167934",
        "http://www.ncbi.nlm.nih.gov/pubmed/20229786",
        "http://www.ncbi.nlm.nih.gov/pubmed/9030019",
        "http://www.ncbi.nlm.nih.gov/pubmed/19086458",
        "http://www.ncbi.nlm.nih.gov/pubmed/1949239",
        "http://www.ncbi.nlm.nih.gov/pubmed/11063959",
        "http://www.ncbi.nlm.nih.gov/pubmed/7641035",
        "http://www.ncbi.nlm.nih.gov/pubmed/18322061",
        "http://www.ncbi.nlm.nih.gov/pubmed/3162545",
        "http://www.ncbi.nlm.nih.gov/pubmed/1781093",
        "http://www.ncbi.nlm.nih.gov/pubmed/7667004"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 742,
          "text": "multiplexed PCR device developed for simple and efficient quantification of HIV-1 or HIV-2 viral loads using finger-pricked whole blood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39637742"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 945,
          "text": "The use of virologic assays, including HIV DNA PCR and HIV RNA detection methods and culture, can define and rule out infection in infants less than 18 months of age. Serologic diagnostic methods, including HIV ELISA, immunofluorescence, and western blot assays, can be used to diagnose infants more than 18 months of age, when transplacental antibody has disappeared in uninfected HIV-exposed infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10697641"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 292,
          "text": "The diagnosis of HIV infection is established by one of the following methods: detecting antibodies to the virus; detecting the viral p24 antigen; detecting viral nucleic acid; or culturing HIV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19086458"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 237,
          "text": "Diagnosis of HIV infection is basically made by sequential two tests: a screening test with an enzyme immunoassay(EIA) and a confirmatory test with Western blot.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20229786"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 364,
          "text": "The enzyme-linked immunosorbent assay (ELISA) and the Western blot are the primary tests for the diagnosis and confirmation of human immunodeficiency virus (HIV) infection. The ELISA, an inexpensive screening test for antibodies to HIV-1, is both sensitive and specific. The HIV-1 Western blot is a reliable confirmatory test following a repeatedly reactive ELISA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11063959"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 472,
          "text": "The routine diagnosis of HIV-positivity is based mainly on HIV-antibody screening by ELISA and confirmation by Western blotting. Improvements in diagnostic sensitivity are expected from the introduction of HIV-genome detection by polymerase chain reaction technique.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9030019"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 529,
          "text": "Different methods have been developed for the diagnosis of HIV infection, i.e. detection of antibodies, antigen and proviral DNA. ELISA methods for detecting HIV-1 antibodies are widely used as screening assays. A sample which is repeatedly positive with ELISA is re-tested with a confirmatory test, e.g. western blot. Antibodies to HIV-1 are not detectable until 2-3 months after infection, but antigens may be detectable during the last weeks of this initial period, though they disappear with the appearance of the antibodies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1949239"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "Diagnosis of HIV infection is performed via enzyme immunoassay (EIA), an assay based on screening for antibodies against HIV. Confirmation of diagnosis is performed by Western-Blot, a more specific assay directed at a number of viral proteins for which antibodies exist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24167934"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 670,
          "text": "HIV infection is commonly diagnosed by detection of antibodies (anti-HIV) by ELISA or agglutination. Reactive results are confirmed by western blot (immunoblot) or further specific tests such as competitive ELISA, which, when evaluated quantitatively, allow the differentiation of HIV types and partially subtypes. Detection of infection of newborn babies, characterisation of individual strains for subtyping and forensic identification, and therapeutic monitoring are the domain of nucleic-acid-based assays. Nucleic-acid-based assays narrow the serological diagnostic window period in early HIV infection and, when quantified, give some indication of clinical status.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8684160"
        },
        {
          "offsetInBeginSection": 411,
          "offsetInEndSection": 599,
          "text": "HIV infection can be diagnosed with HIV culturing, polymerase chain reaction testing, the enzyme-linked immunosorbent assay, the Western blot antibody assay, or the p24 core-antigen assay.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7641035"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "Serodiagnosis of human immunodeficiency virus (HIV) infection in the United States has traditionally relied on a sequential two-test algorithm: an initial screen with an enzyme immunoassay (EIA) and reflex testing of EIA-reactive specimens with a more specific supplemental test such as Western blotting or immunofluorescence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18322061"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 423,
          "text": "Enzyme-linked immunosorbent assay (ELISA) commercial kits are most often used as screening tests, and Western blot techniques are used for confirmation of positive results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3162545"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 666,
          "text": "Diagnosis of HIV infection is basically made by sequential two tests: a screening test with an enzyme immunoassay(EIA) and a confirmatory test with Western blot. The most recent EIAs, used in commercial laboratories, identify HIV infection earlier because they detect both HIV-1 antibody and antigen. Rapid tests represent another advance for HIV screening. They are widely used in voluntary counselling and testing at public health centers and private clinics. An assay for detection of HIV-1 RNA was approved as a confirmatory test of reactive screening tests to diagnose early infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20229786"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 513,
          "text": "For the laboratory diagnosis of HIV infection antibody assays with unprecedented sensitivity and specificity have been developed. In combination with proper confirmatory tests, these assays enable an accurate diagnosis of HIV infection to be made in almost all cases. In special cases, most notably during very early infection, in seronegative individuals with strong suspicion of infection and in babies of infected mothers, other methods, in particular antigen detection, HIV isolation and PCR, may be utilized.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1781093"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 464,
          "text": "These tests include: HIV-ELISA (enzyme linked immunosorbent assay), HIV-Western Blot, PCR (polymerase chain reaction) gene amplification, p24 core antigen assay, Beta 2-microglobulin levels, and CD4 lymphocyte counts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7667004"
        }
      ],
      "id": "67d6bbfa18b1e36f2e000020",
      "ideal_answer": [
        "Diagnosing HIV infection typically follows a structured approach that combines various testing methods to ensure accuracy and comprehensive monitoring. Here\u0027s an organized summary of the process:\n\n1. **Initial Screening:**\n   - **Enzyme Immunoassay (EIA):** This test detects the presence of antibodies or antigens in the blood, indicating potential HIV infection. The \"Maxim HIV-1 Limiting Antigen Avidity EIA\" is an example used to assess antibody binding strength, which can help determine the stage of infection.\n\n2. **Confirmation and Differentiation:**\n   - **Polymerase Chain Reaction (PCR):** For confirmatory testing, PCR-based methods are employed. These not only detect the virus but also differentiate between HIV-1 and HIV-2. This step ensures accurate diagnosis and is crucial for understanding the specific strain of the virus.\n\n3. **Viral Load Monitoring:**\n   - **Quantitative PCR:** This method measures the amount of viral RNA in the blood, providing insights into disease progression and treatment efficacy. Devices using finger-pricked blood make this process more accessible and less invasive.\n\n4. **Quality Control:**\n   - **RNase P Testing:** This control ensures the reliability of the test by verifying the integrity of the testing process, using a human gene as a reference point.\n\n5. **Standard Diagnostic Procedures:**\n   - Beyond the mentioned methods, standard practices include antibody tests (often followed by confirmatory Western Blot tests) to ensure accurate diagnosis before proceeding to viral load monitoring for disease management.\n\nIn summary, diagnosing HIV involves a combination of antibody/antigen detection, PCR-based confirmation and differentiation, and ongoing viral load monitoring to guide treatment decisions. This multi-step approach ensures both accuracy in diagnosis and effective management of the infection."
      ]
    },
    {
      "body": "Is a single-nucleotide polymorphism (SNP) the same as a mutation?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26173390",
        "https://www.ncbi.nlm.nih.gov/pubmed/26173390",
        "http://www.ncbi.nlm.nih.gov/pubmed/28431642",
        "http://www.ncbi.nlm.nih.gov/pubmed/21453671",
        "http://www.ncbi.nlm.nih.gov/pubmed/30498395",
        "http://www.ncbi.nlm.nih.gov/pubmed/12741168",
        "http://www.ncbi.nlm.nih.gov/pubmed/18370094",
        "http://www.ncbi.nlm.nih.gov/pubmed/38394191",
        "http://www.ncbi.nlm.nih.gov/pubmed/18086700",
        "http://www.ncbi.nlm.nih.gov/pubmed/23125360",
        "http://www.ncbi.nlm.nih.gov/pubmed/18854357",
        "http://www.ncbi.nlm.nih.gov/pubmed/16102741",
        "http://www.ncbi.nlm.nih.gov/pubmed/20569258",
        "http://www.ncbi.nlm.nih.gov/pubmed/34073904",
        "http://www.ncbi.nlm.nih.gov/pubmed/19768584",
        "http://www.ncbi.nlm.nih.gov/pubmed/26024623",
        "http://www.ncbi.nlm.nih.gov/pubmed/36249933"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 306,
          "text": "The growing advances in DNA sequencing tools have made analyzing the human genome cheaper and faster. While such analyses are intended to identify complex variants, related to disease susceptibility and efficacy of drug responses, they have blurred the definitions of mutation and polymorphism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26173390"
        },
        {
          "offsetInBeginSection": 437,
          "offsetInEndSection": 989,
          "text": "Nowadays DNA variants are called as differences in comparison to a reference. In a sequencing project Single Nucleotide Polymorphisms (SNPs) and DNA mutations are defined as DNA variants detectable in \u003e1 % or \u003c1 % of the population, respectively. The alternative use of the two terms mutation or polymorphism for the same event (a difference as compared with a reference) can lead to problems of classification. These problems can impact the accuracy of the interpretation and the functional relationship between a disease state and a genomic sequence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26173390"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "A single nucleotide polymorphism (SNP) is a common genetic variation when a single nucleotide differs between members of a species or paired chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21453671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Single-nucleotide polymorphisms (SNPs) and single-nucleotide mutations result from the substitution of only a single base.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28431642"
        },
        {
          "offsetInBeginSection": 525,
          "offsetInEndSection": 750,
          "text": "SNP arises as a point mutation. If the frequency of the sequence variation reaches 1% or more in the population, it is referred to as polymorphism, but if it is lower than 1%, the allele is typically considered as a mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30498395"
        },
        {
          "offsetInBeginSection": 824,
          "offsetInEndSection": 918,
          "text": "SNPs are considered to be variations in the genome and should be distinguished from mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12741168"
        },
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 391,
          "text": "SNPs are DNA sequence variations that occur when a single nucleotide in the genome sequence is altered in at least 1 % of the population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18370094"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Single nucleotide polymorphisms are the most common form of DNA alterations at the level of a single nucleotide in the genomic sequence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38394191"
        },
        {
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1150,
          "text": "Comparing the impact of common SNPs naturally occurring in populations with the impact of random point mutations, we found that structural changes introduced by common SNPs are smaller than those introduced by random point mutations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125360"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Single nucleotide polymorphisms (SNPs) may be considered the ultimate genetic marker as they represent the finest resolution of a DNA sequence (a single nucleotide), are generally abundant in populations and have a low mutation rate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18854357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 356,
          "text": "Single-nucleotide polymorphisms (SNPs) are the simplest and most common type of DNA variations in the human genome. This class of attractive genetic markers, along with point mutations, have been associated with the risk of developing a wide range of diseases, including cancer, cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34073904"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Single nucleotide alternations such as single nucleotide polymorphisms (SNPs) or single nucleotide mutations are useful genetic markers for molecular diagnosis, prognosis, drug response, and predisposition to diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26024623"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 452,
          "text": "the distinction between disease causing mutation and polymorphism is often unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18086700"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 409,
          "text": "While the majority of SNPs, especially those frequent in the population, are considered as benign genetic variations, few others can lead to diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36249933"
        }
      ],
      "id": "680fe1e3353a4a2e6b00000f",
      "ideal_answer": [
        "The growing advances in DNA sequencing tools have made analyzing the human genome cheaper and faster. While such analyses are intended to identify complex variants related to disease susceptibility and efficacy of drug responses, they have blurred the definitions of mutation and polymorphism. Nowadays, DNA variants are called as differences in comparison to a reference. In a sequencing project, Single Nucleotide Polymorphisms (SNPs) and DNA mutations are defined as DNA variants detectable in \u003e1 % or \u003c1 % of the population, respectively. However, the alternative use of the two terms, mutation or polymorphism, for the same event (a difference as compared with a reference) can lead to problems of classification. These problems can impact the accuracy of the interpretation and the functional relationship between a disease state and a genomic sequence.",
        "No, a single-nucleotide polymorphism (SNP) is not the same as a mutation. The distinction between these terms primarily lies in their frequency within a population and their implications on health. SNPs are common genetic variations that occur in more than 1% of the population and are typically benign, although they can influence traits and susceptibility to diseases. In contrast, a mutation refers to a change in the DNA sequence that is less common and often associated with a disease or adverse health condition. This differentiation is crucial in the context of personal genomics, where the accurate classification of genetic variations can impact the interpretation of genomic data and subsequent clinical decisions (PMID 26173390). The evolving definitions of these terms reflect advancements in genomic technologies and an enhanced understanding of genetic diversity and its implications on human health.",
        "No, a single-nucleotide polymorphism (SNP) is not the same as a mutation. SNPs are common, naturally occurring genetic variations (typically present in ≥1% of the population) and are often benign. Mutations refer to rare DNA changes (e.g., pathogenic, deleterious, or loss-of-function alterations) that may disrupt gene function or stability. While SNPs can influence traits or disease risk, they are generally distinguished from mutations based on population frequency, functional impact, and clinical significance. For example, pathogenic *BRCA* mutations increase cancer risk, whereas benign *BRCA* SNPs are non-disease-causing variants.",
        "No, SNPs and mutations are distinct genetic alterations. SNPs (single-nucleotide polymorphisms) are common, benign variations (frequency \u003e1% in populations) that typically do not directly cause disease but may influence traits or disease risk. Mutations are rare DNA changes (frequency \u003c1%) often linked to functional consequences, such as pathogenic effects (e.g., *BRCA* loss-of-function mutations) or structural instability. While SNPs are classified as a type of genetic variation, the term \"mutation\" specifically implies a change with potential phenotypic or pathogenic impact.",
        "A single-nucleotide polymorphism (SNP) is not the same as a mutation. SNPs are common variations in a single nucleotide that occur at specific positions in the genome, often with a frequency of more than 1% in a population. They are typically neutral or associated with traits but do not necessarily cause disease. Mutations, however, refer to changes in DNA that can occur in germline or somatic cells and may be harmful or neutral. While both involve single nucleotide changes, SNPs are generally considered polymorphisms rather than mutations due to their higher frequency and often benign nature.",
        "While both Single-Nucleotide Polymorphisms (SNPs) and mutations are types of genetic variations, they have distinct characteristics. SNPs are DNA variants that occur in more than 1% of the population, whereas mutations are rarer, occurring in less than 1% of the population. This distinction is important for understanding genetic variations related to disease susceptibility and drug responses. However, the terms are sometimes used interchangeably, leading to potential classification issues.",
        "No,\nNowadays DNA variants are called as differences in comparison to a reference. In a sequencing project Single Nucleotide Polymorphisms (SNPs) and DNA mutations are defined as DNA variants detectable in \u003e1% or \u003c1% of the population, respectively. The alternative use of the two terms mutation or polymorphism for the same event (a difference as compared with a reference) can lead to problems of classification. These problems can impact the accuracy of the interpretation and the functional relationship between a disease state and a genomic sequence.",
        "A single-nucleotide polymorphism (SNP) and a mutation are both DNA sequence variations compared to a reference, but they differ in frequency and context. SNPs are defined as variants present in \u003e1% of the population, typically considered common and often benign, while mutations refer to rare variants (\u003c1%) that may have pathogenic implications. However, the terms are sometimes used interchangeably, leading to classification ambiguities that can affect accurate interpretation of genomic data in disease contexts. Advances in sequencing technologies have further blurred these distinctions, as analyses now identify both common and rare variants linked to disease susceptibility and drug responses. This overlap complicates functional assessments, as the same genetic change might be labeled a mutation or polymorphism depending on population frequency, potentially impacting clinical relevance and research outcomes. Clear differentiation remains critical for precise genomic analysis and understanding the relationship between genetic variation and health conditions.",
        "Single-nucleotide polymorphisms (SNPs) and mutations are distinct but related genetic terms. SNPs refer to common variations at specific DNA positions occurring in \u003e1% of a population, often considered neutral or with minor effects, while mutations broadly describe any DNA sequence change, including rare variants that may disrupt function. Studies highlight that SNPs can coexist with pathogenic mutations and may influence disease risk (e.g., adverse outcomes in gliomas or leukemia), but they are not inherently harmful. The distinction is critical: SNPs reflect population-level genetic diversity, whereas mutations often imply functional consequences. In personal genomics, clarifying definitions—such as using \"mutation\" for germline-somatic comparisons and qualifying variants by context (e.g., somatic/germline)—helps avoid misclassification and improves interpretation of genomic data in health contexts.",
        "Single-nucleotide polymorphism (SNP) and mutation are often used interchangeably, but they have distinct meanings. Studies have shown that SNPs refer to DNA variations that occur in more than 1% of a population, whereas mutations are typically defined as changes that occur in less than 1% of a population. However, this distinction is not always clear-cut, and usage of these terms can lead to confusion. To clarify this nomenclature dilemma, it has been proposed that mutations be defined as DNA variants identified through paired sequencing projects, using an individual\u0027s germline DNA as a reference, with qualifying prefixes to indicate whether a mutation is somatic or germline. This distinction is crucial for accurate interpretation of genomic sequences and their relationship to disease states, highlighting that SNPs and mutations are not exactly synonymous, although they both refer to changes in DNA sequence.",
        "A single-nucleotide polymorphism is a specific kind of DNA sequence variant in which a single base differs among individuals and that occurs in more than 1% of the population. All SNPs are technically mutations in the sense that they represent changes from a reference sequence, but by convention “mutation” often refers to rarer variants (below 1% frequency) or those known to cause disease, whereas “polymorphism” denotes common, generally benign variants.",
        "[\u0027No, a single-nucleotide polymorphism (SNP) is not the same as a mutation. SNPs are DNA variants that occur in more than 1% of the population and are often considered normal genetic variations, whereas mutations are less common, occurring in less than 1% of the population and are often associated with disease.\u0027]"
      ],
      "exact_answer": "no"
    },
    {
      "body": "Is Melatonin found in human milk?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39041388",
        "http://www.ncbi.nlm.nih.gov/pubmed/38150529",
        "http://www.ncbi.nlm.nih.gov/pubmed/38794660",
        "http://www.ncbi.nlm.nih.gov/pubmed/8370707",
        "http://www.ncbi.nlm.nih.gov/pubmed/31784629",
        "http://www.ncbi.nlm.nih.gov/pubmed/31381362",
        "http://www.ncbi.nlm.nih.gov/pubmed/32721174",
        "https://www.ncbi.nlm.nih.gov/pubmed/31381362",
        "https://www.ncbi.nlm.nih.gov/pubmed/32721174",
        "https://www.ncbi.nlm.nih.gov/pubmed/38794660",
        "https://www.ncbi.nlm.nih.gov/pubmed/39041388",
        "https://www.ncbi.nlm.nih.gov/pubmed/8370707",
        "http://www.ncbi.nlm.nih.gov/pubmed/34399902",
        "http://www.ncbi.nlm.nih.gov/pubmed/22205210",
        "http://www.ncbi.nlm.nih.gov/pubmed/26641976",
        "http://www.ncbi.nlm.nih.gov/pubmed/23437270"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 282,
          "text": "Melatonin is vital in human circadian rhythm and infant development. This scoping review summarized the current knowledge about melatonin\u0027s presence and effects in human milk to promote better understanding of its secretion pattern and clinical advancement of maternal-infant health",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Melatonin in Human Breast Milk and Its Potential Role in Circadian Entrainment: A Nod towards Chrononutrition?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38794660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 31,
          "text": "Melatonin rhythm in human milk.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Variations in melatonin levels in preterm and term human breast milk during the first month after delivery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31784629"
        },
        {
          "offsetInBeginSection": 995,
          "offsetInEndSection": 1100,
          "text": "Melatonin concentration exhibited a consistent pattern, being higher at night, and elevated in colostrum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 42,
          "text": "Melatonin in Human Milk: A Scoping Review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 31,
          "text": "Melatonin rhythm in human milk.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/8370707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 34,
          "text": "Melatonin Stability in Human Milk.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/31381362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Melatonin Content of Human Milk: The Effect of Mode of Delivery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/32721174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Melatonin in Human Breast Milk and Its Potential Role in Circadian Entrainment: A Nod towards Chrononutrition?",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38794660"
        },
        {
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1595,
          "text": "The dynamic nature of melatonin in human milk calls for continued interdisciplinary research, bridging gaps between clinical, biochemical, and epidemiological perspectives",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 1424,
          "offsetInEndSection": 1596,
          "text": "The dynamic nature of melatonin in human milk calls for continued interdisciplinary research, bridging gaps between clinical, biochemical, and epidemiological perspectives.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 34,
          "text": "Melatonin Stability in Human Milk.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31381362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Melatonin is involved in a number of physiological and oxidative processes, including functional regulation in human milk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23437270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "The level of melatonin in human milk might be closely related to infant development and the building up of their circadian rhythms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34399902"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "Melatonin Content of Human Milk: The Effect of Mode of Delivery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32721174"
        },
        {
          "offsetInBeginSection": 1579,
          "offsetInEndSection": 1731,
          "text": "Melatonin values in human milk decrease during the first month of lactation and circadian rhythmicity was observed irrespective of the mode of delivery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32721174"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 234,
          "text": "melatonin is detectable in human milk and, if so, whether",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370707"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 177,
          "text": "about melatonin\u0027s presence and effects in human milk to",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 278,
          "text": "whether elective cesarean section influences the melatonin content, the main circadian hormone, in human milk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32721174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "BACKGROUND: Human milk contains a number of nutrients and bioactive ingredients which play an im",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26641976"
        },
        {
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1367,
          "text": "Melatonin in human milk showed a clear circadian curve and was unmeasurable in all artificial milks.CONCLUSIONS: Exclusive breastfeeding is associated with reduced irritability/colic and a tendency toward longer nocturnal sleep.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22205210"
        },
        {
          "offsetInBeginSection": 1085,
          "offsetInEndSection": 1193,
          "text": "Conclusion: Melatonin is stable in human milk for at least 4 hours after defrosting and even up to 24 hours.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31381362"
        },
        {
          "offsetInBeginSection": 515,
          "offsetInEndSection": 793,
          "text": "In this context, human breast milk constitutes the main natural source of melatonin: diurnal dynamic changes, an acrophase early after midnight, and changes in melatonin concentrations according to gestational age and during the different stages of lactation have been reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38794660"
        },
        {
          "offsetInBeginSection": 1127,
          "offsetInEndSection": 1227,
          "text": "(p \u003d 0.06). Melatonin in human milk showed a clear circadian curve and was unmeasurable in all artif",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22205210"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 283,
          "text": "This scoping review summarized the current knowledge about melatonin\u0027s presence and effects in human milk to promote better understanding of its secretion pattern and clinical advancement of maternal-infant health.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 278,
          "text": "Our research aim was to determine whether elective cesarean section influences the melatonin content, the main circadian hormone, in human milk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32721174"
        },
        {
          "offsetInBeginSection": 532,
          "offsetInEndSection": 598,
          "text": "human breast milk constitutes the main natural source of melatonin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38794660"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "The level of melatonin in human milk might be closely related to infant development and the building up of their circadian rhythms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34399902"
        },
        {
          "offsetInBeginSection": 1138,
          "offsetInEndSection": 1238,
          "text": " Melatonin in human milk showed a clear circadian curve and was unmeasurable in all artificial milks",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22205210"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Melatonin is a natural hormone which regulates human circadian rhythms and is presented in milk at low concentrations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31844777"
        },
        {
          "offsetInBeginSection": 1127,
          "offsetInEndSection": 1226,
          "text": "(p \u003d 0.06). Melatonin in human milk showed a clear circadian curve and was unmeasurable in all arti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22205210"
        },
        {
          "offsetInBeginSection": 515,
          "offsetInEndSection": 792,
          "text": "In this context, human breast milk constitutes the main natural source of melatonin: diurnal dynamic changes, an acrophase early after midnight, and changes in melatonin concentrations according to gestational age and during the different stages of lactation have been reported",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38794660"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 261,
          "text": "The present study was undertaken to determine whether melatonin is detectable in human milk and, if so, whether it exhibits a daily rhythm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8370707"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 282,
          "text": "This scoping review summarized the current knowledge about melatonin\u0027s presence and effects in human milk to promote better understanding of its secretion pattern and clinical advancement of maternal-infant health",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39041388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Melatonin is involved in a number of physiological and oxidative processes, including functional regulation in human milk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23437270"
        }
      ],
      "type": "summary",
      "id": "680d5dd8353a4a2e6b000004",
      "ideal_answer": [
        "Yes, melatonin is found in human milk. It is secreted in a circadian rhythm, with higher levels at night compared to daytime.",
        "Yes, melatonin is found in human milk.",
        "Melatonin is present in human milk. The daily amount of melatonin in breastfed infants was reported to be between 10 35 ng/mL.",
        "Melatonin is present in human milk. The daily amount of melatonin in breast milk is significantly higher than that in plasma; thus it is likely that milk is the principal route for exposure to this hormone in infants.",
        "Melatonin is detectable in human milk and exhibits a daily rhythm. Melatonin in the milk of all subjects exhibited a pronounced daily rhythm, with high levels during the night and undetectable levels during the day.",
        "Yes, melatonin is found in human milk. It exhibits a circadian rhythm with higher concentrations at night and is particularly elevated in colostrum. Melatonin in human milk plays a role in providing sleep cues to infants and supports immune function.",
        "Melatonin is present in human breast milk, exhibiting a 24-hour circadian rhythm, with higher concentrations found in nighttime breast milk.",
        "Yes, melatonin is found in human milk. It exhibits a daily rhythm with higher concentrations at night and lower or nearly undetectable levels during the day  .",
        "Yes, melatonin is found in human milk. It is present in breast milk produced at night and exhibits a circadian rhythm, with higher concentrations during nighttime compared to daytime. Melatonin levels in breast milk vary according to gestational age and different stages of lactation.",
        "Melatonin is a naturally occurring component of human milk. It has been shown that daily melatonin intake from breast milk during the first 6 months of life in healthy, full term infants was significantly lower than the melatonin intake recommendations for optimal sleep.",
        "Yes,\nMelatonin is found in human milk.",
        "Yes, melatonin is found in human milk. It is present in the breast milk produced at night beginning in the first stages of lactation and shows a clear circadian curve  .",
        "Yes, melatonin is found in human milk and exhibits a circadian rhythm with higher levels at night.",
        "Melatonin is present in human milk, with higher concentrations at night and in colostrum. Its levels can be influenced by factors such as delivery type, maternal age, and health conditions.",
        "Yes, melatonin is found in human milk, with its concentration varying by time of day, being higher at night and in colostrum, and influenced by factors such as pasteurization.",
        "Melatonin is detectable in human milk and exhibits a daily rhythm, with high levels during the night and undetectable levels during the day.",
        "Yes, melatonin is found in human milk and exhibits a circadian rhythm.",
        "Melatonin is indeed found in human milk, exhibiting a 24-hour circadian rhythm. It is more prevalent in nighttime milk, nearly undetectable during the day, and plays a vital role in modulating circadian rhythms and infant development through breastfeeding.",
        "Yes, melatonin is naturally present in human milk. It follows a 24-hour circadian rhythm, being abundant in nighttime milk and nearly undetectable in daytime milk.",
        "Melatonin is present in human breast milk, exhibiting a 24-hour circadian rhythm with higher concentrations in nighttime milk and nearly undetectable levels in daytime milk. This presence highlights its potential role in modulating circadian rhythmicity and infant development through maternal-infant health interactions.",
        "Yes, melatonin is found in human milk. It exhibits a 24-hour circadian rhythm, with significantly higher concentrations present in nighttime breast milk compared to daytime milk. Melatonin is secreted in breast milk starting from the early stages of lactation and plays a potential role in regulating circadian rhythms in infants.",
        "Melatonin is vital in human circadian rhythm and infant development. This scoping review summarized the current knowledge about melatonin\u0027s presence and effects in human milk to promote better understanding of its secretion pattern and clinical advancement of maternal-infant health.",
        "Yes, melatonin is found in human milk. As noted in Snippet1, melatonin in breast milk exhibits a 24-hour circadian rhythm – it is present in nighttime milk but nearly undetectable during the day, supporting its role in infant circadian entrainment.",
        "Yes, melatonin is present in human milk.",
        "Yes, melatonin is present in human breast milk. It exhibits a 24-hour circadian rhythm, with higher concentrations in nighttime breast milk and nearly undetectable levels during the day. This melatonin may play a role in regulating infant circadian rhythms and supporting chrononutrition during breastfeeding.",
        "Yes, melatonin is found in human breast milk. It exhibits a 24-hour circadian rhythm, with higher concentrations in nighttime milk and lower levels in daytime milk. Melatonin in breast milk plays a role in modulating the circadian rhythmicity of newborns and is important for infant development.",
        "Yes, melatonin is found in human milk. It exhibits a 24-hour circadian rhythm, being present in nighttime breast milk but nearly undetectable in daytime breast milk.",
        "Yes, melatonin is found in human milk, exhibiting a circadian rhythm with higher concentrations during nighttime and nearly undetectable levels during daytime. It plays a role in infant circadian entrainment and maternal-infant health, highlighting its importance in chrononutrition during breastfeeding.",
        "Yes, melatonin is found in human milk. It exhibits a 24-hour circadian rhythm, with higher concentrations present in nighttime breast milk and nearly undetectable in daytime breast milk. Melatonin plays a critical role in infant development and circadian rhythm regulation.",
        "Yes, melatonin is found in human breast milk, exhibiting a clear 24-hour circadian rhythm—present in higher concentrations at night and nearly undetectable during the day. Its presence may help modulate infant circadian rhythms and contribute to the neuroendocrine benefits of breastfeeding.",
        "Yes, melatonin is found in human milk. It exhibits a circadian rhythm, being present in nighttime breast milk and nearly undetectable during the day. This presence plays a role in modulating the infant\u0027s circadian rhythmicity.",
        "Yes, Melatonin is found in human milk. It exhibits a 24-hour circadian rhythm, present in nighttime breast milk but nearly undetectable in daytime breast milk. This hormone plays a crucial role in the modulation of the circadian rhythmicity during breastfeeding, acting as a potential neuroendocrine transducer.",
        "Yes, Melatonin is found in human milk.",
        "Yes, melatonin is found in human breast milk, exhibiting a circadian rhythm with higher concentrations at night and nearly undetectable levels during the day.",
        "Yes, melatonin is found in human milk. It exhibits a 24-hour circadian rhythm, with significantly higher concentrations present in nighttime breast milk compared to daytime milk. Melatonin levels peak at night, indicating its potential role in regulating circadian rhythms and supporting infant development.",
        "Melatonin in breast milk exhibits a 24-hour circadian rhythm, present in nighttime breast milk but nearly undetectable in daytime breast milk .",
        "Yes, melatonin is present in human breast milk. It follows a circadian pattern, with higher levels at night and lower or undetectable levels during the day. This hormone plays a role in helping infants develop their sleep-wake cycles and overall circadian rhythm.",
        "Yes, melatonin is found in human milk; it exhibits a 24-hour circadian rhythm, present in nighttime breast milk but nearly undetectable in daytime breast milk.",
        "[\u0027Yes, melatonin is found in human milk. It exhibits a 24-hour circadian rhythm, being present in nighttime breast milk but nearly undetectable in daytime breast milk.\u0027]",
        "Yes, melatonin is found in human milk, with higher concentrations at night.",
        "Melatonin is found in human milk, exhibiting a 24-hour circadian rhythm, with higher concentrations in nighttime breast milk and nearly undetectable levels in daytime breast milk."
      ]
    },
    {
      "body": "Physiopathology of alopecia.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38826011",
        "http://www.ncbi.nlm.nih.gov/pubmed/38772922",
        "http://www.ncbi.nlm.nih.gov/pubmed/38449420",
        "http://www.ncbi.nlm.nih.gov/pubmed/39202681",
        "http://www.ncbi.nlm.nih.gov/pubmed/37087083",
        "http://www.ncbi.nlm.nih.gov/pubmed/37915336",
        "http://www.ncbi.nlm.nih.gov/pubmed/15516056",
        "http://www.ncbi.nlm.nih.gov/pubmed/31400254",
        "http://www.ncbi.nlm.nih.gov/pubmed/28638587",
        "http://www.ncbi.nlm.nih.gov/pubmed/30512674",
        "http://www.ncbi.nlm.nih.gov/pubmed/16855408",
        "http://www.ncbi.nlm.nih.gov/pubmed/32030057",
        "http://www.ncbi.nlm.nih.gov/pubmed/39720268",
        "http://www.ncbi.nlm.nih.gov/pubmed/13679696",
        "http://www.ncbi.nlm.nih.gov/pubmed/28646391",
        "http://www.ncbi.nlm.nih.gov/pubmed/28099600",
        "http://www.ncbi.nlm.nih.gov/pubmed/12027516",
        "http://www.ncbi.nlm.nih.gov/pubmed/34431565",
        "http://www.ncbi.nlm.nih.gov/pubmed/32789558",
        "http://www.ncbi.nlm.nih.gov/pubmed/22097924",
        "http://www.ncbi.nlm.nih.gov/pubmed/32312501",
        "http://www.ncbi.nlm.nih.gov/pubmed/26339482",
        "http://www.ncbi.nlm.nih.gov/pubmed/36968986",
        "http://www.ncbi.nlm.nih.gov/pubmed/19231646",
        "http://www.ncbi.nlm.nih.gov/pubmed/19420815",
        "http://www.ncbi.nlm.nih.gov/pubmed/12894987",
        "http://www.ncbi.nlm.nih.gov/pubmed/24151515",
        "http://www.ncbi.nlm.nih.gov/pubmed/30558963",
        "http://www.ncbi.nlm.nih.gov/pubmed/19821055",
        "http://www.ncbi.nlm.nih.gov/pubmed/12942184",
        "http://www.ncbi.nlm.nih.gov/pubmed/39258892"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1067,
          "text": "Hormones, genetics, micronutrient deficiency, microinflammation and stress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38826011"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 335,
          "text": "autoimmune disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38449420"
        },
        {
          "offsetInBeginSection": 166,
          "offsetInEndSection": 201,
          "text": "genetic factors for male hair loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39202681"
        },
        {
          "offsetInBeginSection": 39,
          "offsetInEndSection": 50,
          "text": "autoimmune ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37087083"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 279,
          "text": "Th1, Th2, and Th17 cytokines dysregulation, as well as chemokines, immunoglobulins and other biomarkers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37087083"
        },
        {
          "offsetInBeginSection": 629,
          "offsetInEndSection": 750,
          "text": "There is evidence that scalp, hair follicle, and gut microbiome alterations are associated with various types of alopecia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37915336"
        },
        {
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1031,
          "text": "Dysbiosis on the scalp",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37915336"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "The physiopathology of androgenetic alopecia is linked to the action of the androgens of the bulbs pilairs of the scalp.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15516056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Alopecia areata is a form of hair loss believed to be due to an anti-hair-bulb autoimmune process in which CD4 and CD8 lymphocytes affect the peribulb area.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16855408"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 357,
          "text": "We present a case of alopecia areata possibly linked to the ingestion of amphetamines. This case may provide evidence that amphetamines can also be a cause of alopecia areata in susceptible individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32030057"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 561,
          "text": "Here, we describe a case of a female teenager with distal type I 22q11.2DS who presented with alopecia, oral ulcers, fever and thrombocytopenia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39720268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Androgenetic alopecia (AGA) is the most diagnosed hair loss dysfunction. Its physiopathology comprises a genetic predisposition affording an exacerbated response of the hair follicles cells to androgens aggravated by scalp inflammation and extrinsic factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31400254"
        },
        {
          "offsetInBeginSection": 396,
          "offsetInEndSection": 769,
          "text": "ped nature of this entity.DISCUSSION: All the clinical and histological data suggest that postmenopausal frontal fibrosing alopecia is a clinical form of lichen planopilaris occurring in elderly women. As with lichen planopilaris its physiopathology is unknown. However, in analogy with other lichen-like dermatoses, a lymphocyte T-mediated autoimmune reaction appears to p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/13679696"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Alopecia areata is an extremely common autoimmune condition affecting hair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28646391"
        },
        {
          "offsetInBeginSection": 772,
          "offsetInEndSection": 872,
          "text": "activity of TGFβ1, its control by PPAR and its relation with DHEA in the frontal fibrosing alopecia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099600"
        },
        {
          "offsetInBeginSection": 1156,
          "offsetInEndSection": 1263,
          "text": "Insulin resistance has an additional pathogenic role in the excessive miniaturization of the hair follicle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12027516"
        },
        {
          "offsetInBeginSection": 390,
          "offsetInEndSection": 916,
          "text": "r growth is influenced by numerous physiological moderators. Greater understanding of the biology and physiology of the hair follicle and the pathomechanisms of hair disease facilitates development of targeted treatments. Sublingual minoxidil is a promising therapy in humans where optimised drug delivery enhances efficacy and reduces systemic adverse effects. Janice kinase inhibitors, which disrupt the inflammatory cascade, help maintain the hair follicle, preserve immune privilege, and regrow hair in alopecia areata. As",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34431565"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 726,
          "text": "The Primary Scarring Alopecias are characterised by the irreversible destruction and fibrosis of hair follicles, leading to permanent and often disfiguring loss of hair. The pathophysiology of these diseases is not well understood. However, follicular-fibrosis and loss of the stem-cell niche appears to be a common theme. This review explores the pathogenesis of primary scarring alopecias, asking what happens to the stem cells of the hair follicle and how they may contribute to the progression of these diseases. Bulge-resident cells are lost (leading to loss of capacity for hair growth) from the follicle either by inflammatory-mediate apoptosis or through epigenetic reprogramming to assume a mesenchymal-like identity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32789558"
        },
        {
          "offsetInBeginSection": 1224,
          "offsetInEndSection": 1650,
          "text": "Currently suggested mechanisms underlying PCA include loss of immune protection of stem cells, impaired stem cell self-maintenance, enhanced autoimmunity by pro-inflammatory cytokines and environmental/genetic predispositions. Interestingly, recent data indicates the association between lipid metabolism dysregulation and PCA development, implying an important role of the sebaceous gland dysfunction in the etiopathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22097924"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317,
          "text": "The physiopathology of androgenetic alopecia is linked to the action of the androgens of the bulbs pilairs of the scalp. The action of these androgens can be associated with the level of hormones in circulation and with the genetic predisposition which will influence the activity of these androgens at the periphery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15516056"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 550,
          "text": "The phenotypical changes are driven by dihydrotestosterone (DHT) and its precursor testosterone. DHT induces follicle miniaturization and hair cycle changes until resulting hairs no longer extrude through the skin surface. AGA is inherited in a polygenetic pattern and is susceptible to epigenetic and environmental factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32312501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1085,
          "text": "Alopecia areata is a non-scarring, autoimmune hair loss disorder that is associated with inflammatory bowel disease. Alopecia areata and inflammatory bowel disease may have a common pathogenic mechanism that involves the Janus kinase/STAT pathway. In addition, there are previous case reports of patients who developed alopecia areata while on biologic therapies for inflammatory bowel disease. JAK1 inhibitors are currently undergoing investigation as potential therapies for Crohn\u0027s disease. Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn\u0027s disease during phase III clinical trials. In this case report, we present a 23-year-old man with Crohn\u0027s disease who previously developed alopecia areata while on adalimumab. He had near-complete resolution of his alopecia universalis after 7 months of treatment with upadacitinib while on concurrent ustekinumab for Crohn\u0027s disease, which he had been taking for 16 months prior to starting upadacitinib. Upadacitinib may be a beneficial therapy for treating concomitant alopecia areata and Crohn\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 804,
          "text": "Tinea capitis is the most common dermatophyte infection in children. The clinical presentation varies from subtle asymptomatic scaling to inflammatory suppurative nodules and draining tracks. Both chronic and acute inflammatory infections may damage the hair follicle leading to secondary cicatricial alopecia. In rare instances, the initial presentation can mimic a primary cicatricial alopecia. We present three cases of tinea capitis in children masquerading as cicatricial alopecia and discuss the possible host immune and fungal antigenic factors that may influence the course of disease and its clinical presentation. An understanding of the clinical morphology of tinea capitis in the context of both host and fungal factors may improve treatment strategies and direct future paradigms of therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 701,
          "text": "A 15-year-old, woman, Crohn\u0027s disease patient, who carried the TPMT *3C heterozygous mutant, complained of alopecia 3 days after starting 6-mercaptopurine (6-MP) and then developed severe myelosuppression 6 weeks after starting 6-MP. The alopecia involved scalp hair only (body hair preserved) and was dominant in the temporal region. Following these side effects, transient remission of Crohn\u0027s disease occurred. Myelosuppression due to 6-MP is a rare but life-threatening side effect that is difficult to predict despite continuous monitoring of complete blood cell counts. In the present case, 6-MP-induced alopecia preceded myelosuppression and progressed rapidly as the myelosuppression worsened.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19420815"
        },
        {
          "offsetInBeginSection": 1074,
          "offsetInEndSection": 1600,
          "text": "current research suggests a self contained disease cycle involving four key events: (1) Failure of the putative anagen stage hair follicle immune privilege and exposure of hair follicle located AA inciting epitopes to the immune system; (2) Antigen presentation, costimulation, and activation of responsive lymphocytes by antigen presenting cells; (3) Activated inflammatory cell migration to, and infiltration of, hair follicles; (4) The subsequent disruptive actions of the inflammatory cell infiltrate on the hair follicles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12894987"
        },
        {
          "offsetInBeginSection": 564,
          "offsetInEndSection": 679,
          "text": "The collapse of the hair follicle immune privilege leads to autoimmune reactions against hair follicle autoantigens",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24151515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The physiopathology of androgenetic alopecia is linked to the action of the androgens of the bulbs pilairs of the scalp. The action of these androgens can be associated with the level of hormones in circulation and with the genetic predisposition whi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15516056"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 815,
          "text": "Loss of attachment between the bulge stem cell population and the arrector pili muscle also explains why miniaturization is irreversible in AGA but not alopecia areata.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26339482"
        },
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 685,
          "text": "Hair loss in alopecia areata is caused by lymphocytic infiltrations around the hair follicles and IFN-γ. IgG antibodies against the hair follicle cells are also found in alopecia areata sufferers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558963"
        },
        {
          "offsetInBeginSection": 490,
          "offsetInEndSection": 593,
          "text": "Hair loss in alopecia areata is caused by lymphocytic infiltrations around the hair follicles and IFN-γ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558963"
        },
        {
          "offsetInBeginSection": 594,
          "offsetInEndSection": 685,
          "text": " IgG antibodies against the hair follicle cells are also found in alopecia areata sufferers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Alopecia areata is considered to be a cell-mediated autoimmune disease, in which autoreactive cytotoxic T cells recognize melanocyte-associated proteins such as tyrosinase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24151515"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 402,
          "text": "Androgens are thought to pathophysiologically power on cascades of chronically dramatic alterations in genetically susceptible scalp dermal papillas, specialized cells in hair follicles in which androgens react, and finally resulting in a patterned alopecia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19821055"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 489,
          "text": "Under the influence of androgens there is a shortening of the anagen phase as well as a reduction of the cellular hair matrix volume in the involved scalp area. This results in the transformation of thick terminal hair follicles into thin vellus-like hair follicles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12942184"
        },
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 379,
          "text": "Alopecia areata is a common T-cell mediated autoimmune disease affecting hair and nails. It is a non-scarring form of alopecia, commonly patchy, but it may cover the whole scalp and even body hair. Appearing on genetically predisposed people, it evolves in variable and often unpredictable ways throughout life, in episode whose triggering causes remain unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30512674"
        },
        {
          "offsetInBeginSection": 1598,
          "offsetInEndSection": 1826,
          "text": "The results of our study showed significant difference between H. pylori infection in individuals with and without alopecia areata, which shows that H. pylori contamination may be effective in physiopathology of alopecia areata.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28638587"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 395,
          "text": "Both chronic and acute inflammatory infections may damage the hair follicle leading to secondary cicatricial alopecia. In rare instances, the initial presentation can mimic a primary cicatricial alopecia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231646"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 622,
          "text": "In rare instances, the initial presentation can mimic a primary cicatricial alopecia. We present three cases of tinea capitis in children masquerading as cicatricial alopecia and discuss the possible host immune and fungal antigenic factors that may influence the course of disease and its clinical presentation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231646"
        },
        {
          "offsetInBeginSection": 397,
          "offsetInEndSection": 622,
          "text": "We present three cases of tinea capitis in children masquerading as cicatricial alopecia and discuss the possible host immune and fungal antigenic factors that may influence the course of disease and its clinical presentation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Both alopecia areata (AA) and vitiligo share common pathogenesis involving, interferon-γ (IFN-γ) and interleukin-15 (IL-15) signalling pathways that activate cytotoxic CD8+ T lymphocytes. These shared mechanisms may explain why both diseases respond to currently available treatments (e.g. topical/sy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39258892"
        }
      ],
      "type": "summary",
      "id": "67d7208218b1e36f2e00002e",
      "ideal_answer": []
    },
    {
      "body": "What is phenotype switching in melanoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36675114",
        "http://www.ncbi.nlm.nih.gov/pubmed/36551603",
        "http://www.ncbi.nlm.nih.gov/pubmed/35912100",
        "http://www.ncbi.nlm.nih.gov/pubmed/25763355",
        "http://www.ncbi.nlm.nih.gov/pubmed/20726948",
        "http://www.ncbi.nlm.nih.gov/pubmed/34604096",
        "http://www.ncbi.nlm.nih.gov/pubmed/26546268",
        "http://www.ncbi.nlm.nih.gov/pubmed/24030649",
        "http://www.ncbi.nlm.nih.gov/pubmed/35406721",
        "http://www.ncbi.nlm.nih.gov/pubmed/34819356",
        "http://www.ncbi.nlm.nih.gov/pubmed/35322197",
        "http://www.ncbi.nlm.nih.gov/pubmed/37729428",
        "http://www.ncbi.nlm.nih.gov/pubmed/37952322",
        "https://www.ncbi.nlm.nih.gov/pubmed/25763355",
        "https://www.ncbi.nlm.nih.gov/pubmed/26546268",
        "https://www.ncbi.nlm.nih.gov/pubmed/32759677",
        "https://www.ncbi.nlm.nih.gov/pubmed/35406721",
        "https://www.ncbi.nlm.nih.gov/pubmed/35912100",
        "https://www.ncbi.nlm.nih.gov/pubmed/36551603",
        "https://www.ncbi.nlm.nih.gov/pubmed/36675114",
        "http://www.ncbi.nlm.nih.gov/pubmed/34680938",
        "http://www.ncbi.nlm.nih.gov/pubmed/32123577",
        "http://www.ncbi.nlm.nih.gov/pubmed/28181494",
        "http://www.ncbi.nlm.nih.gov/pubmed/39026725",
        "http://www.ncbi.nlm.nih.gov/pubmed/38990725",
        "http://www.ncbi.nlm.nih.gov/pubmed/24104062",
        "http://www.ncbi.nlm.nih.gov/pubmed/29215016",
        "http://www.ncbi.nlm.nih.gov/pubmed/25320006",
        "http://www.ncbi.nlm.nih.gov/pubmed/31209265",
        "http://www.ncbi.nlm.nih.gov/pubmed/27023049",
        "http://www.ncbi.nlm.nih.gov/pubmed/35771179",
        "http://www.ncbi.nlm.nih.gov/pubmed/37898636",
        "http://www.ncbi.nlm.nih.gov/pubmed/24062982",
        "http://www.ncbi.nlm.nih.gov/pubmed/37788736",
        "http://www.ncbi.nlm.nih.gov/pubmed/32796736",
        "http://www.ncbi.nlm.nih.gov/pubmed/28545079",
        "http://www.ncbi.nlm.nih.gov/pubmed/31733993",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
        "http://www.ncbi.nlm.nih.gov/pubmed/25538895",
        "http://www.ncbi.nlm.nih.gov/pubmed/30254208",
        "http://www.ncbi.nlm.nih.gov/pubmed/35156326",
        "http://www.ncbi.nlm.nih.gov/pubmed/25885555",
        "http://www.ncbi.nlm.nih.gov/pubmed/29781575",
        "http://www.ncbi.nlm.nih.gov/pubmed/36040798",
        "http://www.ncbi.nlm.nih.gov/pubmed/36509081",
        "http://www.ncbi.nlm.nih.gov/pubmed/33999497",
        "http://www.ncbi.nlm.nih.gov/pubmed/33438577",
        "http://www.ncbi.nlm.nih.gov/pubmed/21599871",
        "http://www.ncbi.nlm.nih.gov/pubmed/34681232",
        "http://www.ncbi.nlm.nih.gov/pubmed/32878000",
        "http://www.ncbi.nlm.nih.gov/pubmed/20526217",
        "http://www.ncbi.nlm.nih.gov/pubmed/35296667",
        "http://www.ncbi.nlm.nih.gov/pubmed/32759677",
        "http://www.ncbi.nlm.nih.gov/pubmed/23474946",
        "http://www.ncbi.nlm.nih.gov/pubmed/29369499"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 566,
          "text": "Melanoma, a highly heterogeneous tumor, is comprised of a functionally diverse spectrum of cell phenotypes and subpopulations, including stromal cells in the tumor microenvironment (TME). Melanoma has been shown to dynamically shift between different transcriptional states or phenotypes. This is referred to as phenotype switching in melanoma, and it involves switching between quiescent and proliferative cell cycle states, and dramatic shifts in invasiveness, as well as changes in signaling pathways in the melanoma cells, and immune cell composition in the TME.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36675114"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "Melanoma is considered one of the deadliest skin cancers, partly because of acquired resistance to standard therapies. The most recognized driver of resistance relies on acquired melanoma cell plasticity, or the ability to dynamically switch among differentiation phenotypes. This confers the tumor noticeable advantages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551603"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 566,
          "text": "Melanoma has been shown to dynamically shift between different transcriptional states or phenotypes. This is referred to as phenotype switching in melanoma, and it involves switching between quiescent and proliferative cell cycle states, and dramatic shifts in invasiveness, as well as changes in signaling pathways in the melanoma cells, and immune cell composition in the TME.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36675114"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 284,
          "text": "In melanoma, a similar process of phenotype switching has been reported and EMT-related genes have been implicated in promotion to a metastatic state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25763355"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 562,
          "text": "Here, we use melanoma as a model to explore the validity of the cancer stem cell hypothesis in the light of accumulating evidence that melanoma progression may instead be driven by phenotype-switching triggered by genetic lesions that impose an increased sensitivity to changes in the tumour microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726948"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 462,
          "text": "Melanoma has been shown to dynamically shift between different transcriptional states or phenotypes. This is referred to as phenotype switching in melanoma, and it involves switching between quiescent and proliferative cell cycle states, and dramatic shifts in invasiveness,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36675114"
        },
        {
          "offsetInBeginSection": 415,
          "offsetInEndSection": 664,
          "text": "Cellular plasticity in melanoma is referred to as phenotype switching. Regardless of their genomic classification, melanomas switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated and often therapy-resistant state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34604096"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 500,
          "text": "Phenotype switching in melanoma is reported to be independent of genetic alterations, whereas changes in gene transcription, and epigenetic alterations have been associated with invasiveness in melanoma cell lines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680938"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "The inherent ability of melanoma cells to alter the differentiation-associated transcriptional repertoire to evade treatment and facilitate metastatic spread is well accepted and has been termed phenotypic switching",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38990725"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 306,
          "text": "Phenotype switching is a mechanism that contributes to melanoma heterogeneity by altering transcription profiles for the transition between states of proliferation/differentiation and invasion/stemness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25885555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "Melanoma cells can switch from a highly proliferative, less invasive state to a highly invasive, less proliferative state, a phenomenon termed phenotype switching. This results in a highly heterogenous tumor, where a slow-growing, aggressive population of cells may resist tumor therapy, and it predicts tumor recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030649"
        },
        {
          "offsetInBeginSection": 796,
          "offsetInEndSection": 1077,
          "text": "Insights into the molecular events underpinning phenotype-switching in melanoma highlight the close relationship between signalling pathways that generate, maintain and activate melanocyte stem cells as well as the inverse correlation between proliferation and invasive potentials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726948"
        },
        {
          "offsetInBeginSection": 1078,
          "offsetInEndSection": 1377,
          "text": "An understanding of phenotype-switching in melanoma, and in particular the signalling events that regulate the expression of the microphthalmia-associated transcription factor Mitf, points to new therapeutic opportunities aimed at eradicating therapeutically resistant stem cell-like melanoma cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Tumours comprise multiple phenotypically distinct subpopulations of cells, some of which are proposed to possess stem cell-like properties, being able to self-renew, seed and maintain tumours, and provide a reservoir of therapeutically resistant cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726948"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 220,
          "text": "An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24104062"
        },
        {
          "offsetInBeginSection": 259,
          "offsetInEndSection": 522,
          "text": "In melanoma, downregulation of the lineage addiction oncogene microphthalmia-associated transcription factor (MITF) is a hallmark of the proliferative-to-invasive phenotype switch, although how MITF promotes proliferation and suppresses invasion is poorly defined",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31733993"
        },
        {
          "offsetInBeginSection": 289,
          "offsetInEndSection": 566,
          "text": "This is referred to as phenotype switching in melanoma, and it involves switching between quiescent and proliferative cell cycle states, and dramatic shifts in invasiveness, as well as changes in signaling pathways in the melanoma cells, and immune cell composition in the TME.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36675114"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 323,
          "text": "According to the \"phenotype switching\" model, the aggressive nature of melanoma cells results from their intrinsic potential to dynamically switch from a high-proliferative/low-invasive to a low-proliferative/high-invasive state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29215016"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Melanoma cells can switch from a highly proliferative, less invasive state to a highly invasive, less proliferative state, a phenomenon termed phenotype switching.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030649"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 500,
          "text": "Recent studies have suggested that melanoma invasiveness is attributed to phenotype switching, which is a reversible type of cell behaviour with similarities to epithelial to mesenchymal transition. Phenotype switching in melanoma is reported to be independent of genetic alterations, whereas changes in gene transcription, and epigenetic alterations have been associated with invasiveness in melanoma cell lines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680938"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 795,
          "text": "Here, we use melanoma as a model to explore the validity of the cancer stem cell hypothesis in the light of accumulating evidence that melanoma progression may instead be driven by phenotype-switching triggered by genetic lesions that impose an increased sensitivity to changes in the tumour microenvironment. Although at any given moment cells within a tumour may exhibit differentiated, proliferative or invasive phenotypes, an ability to switch phenotypes implies that most cells will have the potential to adopt a stem cell-like identity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726948"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 779,
          "text": "The reversible phenotype-switching between differentiated and invasive phenotypes is increasingly appreciated as a mechanism accounting for heterogeneity in melanoma and is driven by oncogenic signaling and environmental cues. This phenotypic switch is coupled with an intriguing and somewhat counterintuitive signaling switch of EMT-inducing transcription factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25538895"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 616,
          "text": "By switching from a proliferative to an invasive state, melanoma cells can acquire resistance to these targeted therapeutics. Interestingly, phenotype switching bears a striking resemblance to the epithelial-to-mesenchymal-like transition that has been described to occur in cancer stem cells in other tumor types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25320006"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 436,
          "text": "In melanoma, invasion and proliferation are uncoupled, such that highly proliferative melanoma cells are less likely to be invasive, and vice versa. The transition between each state is likely a dynamic rather than a static, permanent change. This is referred to as \"phenotype switching\".",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 333,
          "text": "Melanoma cells are notorious for their high plasticity and ability to switch back and forth between various melanoma cell states, enabling the adaptation to sub-optimal conditions and therapeutics. This phenotypic plasticity, which has gained more attention in cancer research, is proposed as a new paradigm for melanoma progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35406721"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 306,
          "text": "Phenotype switching between a proliferative and an invasive state has been suggested as a critical process for metastasis, though the mechanisms that regulate state transitions are complex and remain poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32123577"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 333,
          "text": "Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30254208"
        },
        {
          "offsetInBeginSection": 486,
          "offsetInEndSection": 664,
          "text": "Regardless of their genomic classification, melanomas switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated and often therapy-resistant state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34604096"
        },
        {
          "offsetInBeginSection": 386,
          "offsetInEndSection": 603,
          "text": "Melanoma phenotypic plasticity, understood as the ability of melanoma cells to dynamically transition between different states with varying levels of differentiation/dedifferentiation, is key for melanoma progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35156326"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 640,
          "text": "The reversible phenotype-switching between differentiated and invasive phenotypes is increasingly appreciated as a mechanism accounting for heterogeneity in melanoma and is driven by oncogenic signaling and environmental cues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25538895"
        },
        {
          "offsetInBeginSection": 592,
          "offsetInEndSection": 738,
          "text": "As a mediator of melanoma cell phenotype switching, it coordinates the transition to a dedifferentiated, slow cycling and highly motile cell type.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29781575"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Melanoma cells can switch from a highly proliferative, less invasive state to a highly invasive, less proliferative state, a phenomenon termed phenotype switching",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030649"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 322,
          "text": "According to the \"phenotype switching\" model, the aggressive nature of melanoma cells results from their intrinsic potential to dynamically switch from a high-proliferative/low-invasive to a low-proliferative/high-invasive state",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29215016"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 565,
          "text": "Melanoma has been shown to dynamically shift between different transcriptional states or phenotypes. This is referred to as phenotype switching in melanoma, and it involves switching between quiescent and proliferative cell cycle states, and dramatic shifts in invasiveness, as well as changes in signaling pathways in the melanoma cells, and immune cell composition in the TME",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36675114"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 679,
          "text": "While melanoma is not an epithelial cell-derived tumor and does not undergo a traditional EMT, melanoma undergoes a similar process known as phenotype switching in which high (micropthalmia-related transcription factor) MITF expressing (MITF-high) proliferative cells switch to a low expressing (MITF-low) invasive state",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545079"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 434,
          "text": "The transition between each state is likely a dynamic rather than a static, permanent change. This is referred to as \"phenotype switching",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546268"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Melanoma cells are notorious for their high plasticity and ability to switch back and forth between various melanoma cell states, enabling the adaptation to sub-optimal conditions and therapeutics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35406721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Recent observations suggest that melanoma cells drive disease progression by switching back and forth between phenotypic states of proliferation and invasion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599871"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 330,
          "text": "A leading cause of resistance to targeted therapy is a dynamic transition of melanoma cells from a proliferative to a highly invasive state, a phenomenon called phenotype switching",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37729428"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 332,
          "text": "Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30254208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Melanoma cells can switch from a highly proliferative, less invasive state to a highly invasive, less proliferative state, a phenomenon termed phenotype switching. This results in a highly heterogenous tumor, where a slow-growing, aggressive populati",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030649"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "The inherent ability of melanoma cells to alter the differentiation-associated transcriptional repertoire to evade treatment and facilitate metastatic spread is well accepted and has been termed phenotypic switching.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38990725"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 331,
          "text": "A leading cause of resistance to targeted therapy is a dynamic transition of melanoma cells from a proliferative to a highly invasive state, a phenomenon called phenotype switching.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37729428"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 456,
          "text": "In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35322197"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Melanoma cells are notorious for their high plasticity and ability to switch back and forth between various melanoma cell states, enabling the adaptation to sub-optimal conditions and therapeutics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35406721"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 664,
          "text": "Melanoma comprises phenotypically distinct subpopulations of cells, exhibiting distinct gene signatures leading to tumor heterogeneity and favoring therapeutic resistance. Cellular plasticity in melanoma is referred to as phenotype switching. Regardless of their genomic classification, melanomas switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated and often therapy-resistant state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34604096"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 414,
          "text": "Melanoma is a melanocyte-derived skin cancer that has a high heterogeneity due to its phenotypic plasticity, a trait that may explain its ability to survive in the case of physical or molecular aggression and to develop resistance to therapy. Therefore, the therapy modulation of phenotypic switching in combination with other treatment modalities could become a common approach in any future therapeutic strategy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34681232"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 324,
          "text": "Melanoma continues to be a leading cause of mortality among skin cancers. Despite advancements in targeted therapy, patients frequently develop resistance, leading to disease progression within a year. This resistance may result from the epithelial-to-mesenchymal transition (EMT)-like phenotype switching of melanoma cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37952322"
        },
        {
          "offsetInBeginSection": 900,
          "offsetInEndSection": 1117,
          "text": "Moreover, CD271 regulates phenotype switching, a process that enables the rapid and reversible conversion of proliferative into invasive or non-stem-like states into stem-like states by yet largely unknown mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32878000"
        },
        {
          "offsetInBeginSection": 1005,
          "offsetInEndSection": 1594,
          "text": "Recent evidence suggests that metabolic rewiring engaging transitions to invasion and metastatic progression may be dependent on several factors, such as specific oncogenic programs or lineage-restricted mechanisms controlling cell metabolism, intra-tumor microenvironmental cues and anatomical location of metastasis. In this review we highlight how the main molecular events supporting melanoma metabolic rewiring and phenotype-switching are parallel and interconnected events that dictate tumor progression and metastatic dissemination through interplay with the tumor microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35912100"
        },
        {
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1079,
          "text": "These data suggest that SOX10 mediates phenotypic switching in cutaneous melanoma to produce a targeted inhibitor tolerant state that is likely a prelude to the acquisition of resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35296667"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 743,
          "text": "As major regulators of phenotype switching between differentiated/proliferative and neural crest stem cell-like/invasive states, these factors appear as major drivers of intra-tumor heterogeneity and resistance to treatment in melanoma, which opens new avenues in terms of therapeutic targeting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759677"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 383,
          "text": "Melanoma cells have the capacity to switch their phenotype during tumor progression, from a proliferative and differentiated phenotype to a more invasive and dedifferentiated phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33167306"
        },
        {
          "offsetInBeginSection": 855,
          "offsetInEndSection": 1035,
          "text": "In particular, our results show that phenotypic switching in melanoma involves chromatin remodeling changing the transcriptional activity of cells and consequently their phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36509081"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 573,
          "text": "In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35322197"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 285,
          "text": "Recent studies have suggested that melanoma invasiveness is attributed to phenotype switching, which is a reversible type of cell behaviour with similarities to epithelial to mesenchymal transition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680938"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 680,
          "text": "While melanoma is not an epithelial cell-derived tumor and does not undergo a traditional EMT, melanoma undergoes a similar process known as phenotype switching in which high (micropthalmia-related transcription factor) MITF expressing (MITF-high) proliferative cells switch to a low expressing (MITF-low) invasive state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545079"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 639,
          "text": "Melanoma is an aggressive tumor arising from melanocytes, endowed with unique features of cellular plasticity. The reversible phenotype-switching between differentiated and invasive phenotypes is increasingly appreciated as a mechanism accounting for heterogeneity in melanoma and is driven by oncogenic signaling and environmental cues",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25538895"
        },
        {
          "offsetInBeginSection": 486,
          "offsetInEndSection": 663,
          "text": "Regardless of their genomic classification, melanomas switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated and often therapy-resistant state",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34604096"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 274,
          "text": "The most recognized driver of resistance relies on acquired melanoma cell plasticity, or the ability to dynamically switch among differentiation phenotypes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551603"
        }
      ],
      "id": "67fc381f18b1e36f2e00012f",
      "ideal_answer": [
        "Melanoma, a highly heterogeneous tumor, is comprised of a functionally diverse spectrum of cell phenotypes and subpopulations, including stromal cells in the tumor microenvironment (TME). Melanoma has been shown to dynamically shift between different transcriptional states or phenotypes. This is referred to as phenotype switching in melanoma, and it involves switching between quiescent and proliferative cell cycle states, and dramatic shifts in invasiveness, as well as changes in signaling pathways in the melanoma cells, and immune cell composition in the TME.",
        "Phenotype switching in melanoma refers to the dynamic process where melanoma cells shift between different transcriptional states or phenotypes. This involves changes between quiescent and proliferative cell cycle states, variations in invasiveness, and alterations in signaling pathways. Phenotype switching also affects the immune cell composition in the tumor microenvironment, contributing to therapeutic resistance and the metastatic cascade.",
        "Phenotype switching in melanoma refers to the dynamic and reversible shifts between different transcriptional states or phenotypes in melanoma cells. This involves transitions between quiescent and proliferative cell cycle states, as well as changes in invasiveness. Melanomas can switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated, and often therapy-resistant state. This behavior shares similarities with epithelial to mesenchymal transition and involves alterations in signaling pathways within the melanoma cells and changes in the immune cell composition in the tumor microenvironment (TME). Phenotype switching has significant implications for metastasis and therapy resistance.",
        "Phenotype switching in melanoma is a dynamic, reversible process where tumor cells transition between a proliferative, differentiated state and an invasive, dedifferentiated state. This shift is characterized by changes in cell cycle, invasiveness, and signaling pathways, driven by alterations in gene transcription, epigenetics, and influenced by microenvironmental factors. This phenomenon significantly contributes to tumor heterogeneity, facilitating metastasis and therapeutic resistance, highlighting the complex adaptive nature of melanoma cells in response to environmental pressures and therapeutic interventions.",
        "Phenotype switching in melanoma is the process by which melanoma cells alter their phenotype in response to environmental or intrinsic factors. This involves reversible transitions between different cellular states, marked by changes in cell morphology, gene expression, and behavior. Typically, melanoma cells switch between a proliferative state, characterized by high proliferation and low invasiveness, and an invasive state, marked by increased motility and invasiveness but reduced proliferation. This adaptability allows melanoma cells to adjust to various microenvironments, evade therapeutic interventions, and drive tumor progression and metastasis. Phenotype switching poses a significant challenge in melanoma treatment due to its contribution to drug resistance and tumor heterogeneity.",
        "Phenotype switching in melanoma refers to the dynamic process by which melanoma cells transition between different cell states, specifically between quiescent and proliferative phases, as well as between melanocytic and mesenchymal-like states. This switching is associated with significant changes in invasiveness and alterations in signaling pathways within the melanoma cells, as well as variations in the immune cell composition of the tumor microenvironment (TME). The phenomenon highlights the phenotypic heterogeneity and plasticity of melanoma, which can contribute to challenges in treatment, including resistance to immunotherapy. Understanding these mechanisms is crucial for developing effective therapeutic strategies against melanoma.",
        "Phenotype switching in melanoma refers to the dynamic ability of melanoma cells to transition between different transcriptional and functional states, primarily between a proliferative/differentiated state and an invasive/undifferentiated or mesenchymal-like state. This plasticity involves shifts in cell cycle activity (quiescent vs. proliferative), invasiveness, signaling pathways, and immune interactions within the tumor microenvironment (TME). Key drivers include MITF (proliferative state) downregulation and EMT-like changes (invasive state). These transitions enable melanoma cells to evade therapies, metastasize, and adapt to stress, contributing to treatment resistance and disease progression.",
        "Phenotype switching in melanoma refers to the dynamic ability of melanoma cells to transition between different cellular states, particularly between proliferative and invasive phenotypes. This plasticity allows melanoma cells to adapt to varying environmental conditions and therapeutic pressures. The process involves shifts in gene expression, signaling pathways, and interactions within the tumor microenvironment (TME). Melanoma cells can exhibit a mesenchymal-like state that is associated with increased invasiveness and metastatic potential, while a melanocytic state is linked to proliferation. Factors such as epigenetic modifications, microenvironmental cues, and intercellular communication play crucial roles in regulating these transitions. Understanding phenotype switching is essential for developing targeted therapies and improving treatment outcomes for melanoma patients.",
        "Phenotype switching in melanoma refers to the dynamic shifts between different transcriptional states or phenotypes exhibited by melanoma cells. This cellular plasticity allows melanoma cells to switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated, and often therapy-resistant state. The process is independent of genetic alterations, but changes in gene transcription, epigenetic alterations, and alterations in the extracellular matrix have been associated with invasiveness in melanoma cell lines. This phenomenon contributes to resistance to both targeted therapies and immunotherapies in melanoma.",
        "Phenotype switching in melanoma refers to the dynamic process by which melanoma cells transition between different cell cycle states, specifically between quiescent and proliferative phases. This switching is characterized by significant changes in invasiveness and alterations in signaling pathways, as well as variations in the immune cell composition within the tumor microenvironment (TME). Melanoma cells exhibit high plasticity, allowing them to adapt to various conditions, including therapeutic interventions. This phenomenon is closely related to transcriptional reprogramming, enabling heterogeneous tumors to progress through different stages and develop resistance to treatments. Phenotype switching is a critical aspect of melanoma\u0027s complexity and poses challenges for effective therapy due to the diverse subtypes and cytomorphological variations present in the disease.",
        "Phenotype switching in melanoma refers to the ability of melanoma cells to transition between different phenotypic states, specifically between a proliferative/differentiated state and an invasive/stem-like state. This process is characterized by changes in gene expression, leading to alterations in cellular behavior, morphology, and function. Phenotype switching is thought to contribute to intra-tumor heterogeneity, treatment resistance, and disease progression in melanoma. It is regulated by various factors, including transcriptional regulators, microenvironmental cues, and signaling pathways. The switch between these states is reversible, allowing melanoma cells to adapt to changing environments and evade therapeutic interventions. Understanding the mechanisms governing phenotype switching is crucial for the development of effective therapeutic strategies against melanoma.",
        "Phenotype switching in melanoma refers to the ability of melanoma cells to transition between distinct phenotypic states, primarily oscillating between a proliferative/differentiated state and an invasive/stem-like state. This adaptability is driven by cellular plasticity and involves changes in the expression of key regulators such as MITF and SOX10. \n\nIn the proliferative state, melanoma cells exhibit high MITF expression, promoting growth and differentiation. Conversely, in the invasive state, MITF levels are low, leading to increased invasiveness and a stem-like phenotype. This switching is influenced by various factors, including hypoxic microenvironments, which can activate HIF1-dependent pathways, and interactions with the tumor microenvironment, such as fibroblast stimulation.\n\nPhenotype switching contributes significantly to intra-tumor heterogeneity and treatment resistance. It allows melanoma cells to adapt to different conditions and evade therapeutic interventions, such as BRAF inhibitors. Understanding the transcriptional mechanisms behind these reversible transitions is crucial for developing strategies to target this process and improve treatment outcomes.",
        "Phenotype switching in melanoma is a dynamic, reversible process where cells transition between distinct states, including proliferative/differentiated and invasive/dedifferentiated, and exhibit changes in cell cycle (quiescent to proliferative), invasiveness, and signaling pathways. Driven by gene expression changes, epigenetic alterations, and tumor microenvironment interactions, this cellular plasticity contributes to tumor heterogeneity, therapeutic resistance, and metastasis, occurring independently of genetic mutations, with characteristics similar to epithelial-to-mesenchymal transition.",
        "Phenotype switching in melanoma refers to the reversible, dynamic transition of melanoma cells between a highly proliferative, differentiated state characterized by high microphthalmia-associated transcription factor (MITF) expression and a less proliferative but highly invasive, dedifferentiated state with low MITF levels. This process involves large-scale transcriptional reprogramming driven by intrinsic signaling pathways and extrinsic cues from the tumor microenvironment. By enabling cells to alternate between growth and invasion programs, phenotype switching underlies melanoma’s heterogeneity, metastatic potential, and ability to evade targeted therapies and immunotherapies.",
        "Phenotype switching in melanoma refers to the dynamic shifting between different transcriptional states or phenotypes in melanoma cells. This plasticity enables melanoma cells to switch between various states, adapting to changing conditions and therapeutics. It involves transitions between quiescent and proliferative cell cycle states, shifts in invasiveness, and changes in signaling pathways within melanoma cells, as well as alterations in the immune cell composition in the tumor microenvironment. This phenotypic plasticity contributes to intratumoral heterogeneity, drug resistance, and metastasis, and is regulated by factors such as MITF. It is considered a key mechanism in melanoma progression, allowing cells to adopt context-dependent intermediate states that benefit malignancy.",
        "Phenotype switching in melanoma is a dynamic process involving shifts between different transcriptional states or phenotypes. This includes transitions between quiescent and proliferative cell cycle states and significant changes in invasiveness, where melanomas can switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated, and often therapy-resistant state. This reversible cell behavior, which shares similarities with epithelial to mesenchymal transition, also involves alterations in signaling pathways within the melanoma cells and modifications in the immune cell composition within the tumor microenvironment (TME). Phenotype switching has significant implications for metastasis and therapy resistance.",
        "Phenotype switching in melanoma is a dynamic process where melanoma cells shift between different transcriptional states or phenotypes. This involves transitions between quiescent and proliferative cell cycle states and significant changes in invasiveness, where melanomas can switch from a proliferative and differentiated phenotype to an invasive, dedifferentiated, and often therapy-resistant state. This reversible cell behavior, which shares similarities with epithelial to mesenchymal transition, also involves alterations in signaling pathways within the melanoma cells and modifications in the immune cell composition within the tumor microenvironment (TME). Phenotype switching has significant implications for metastasis and therapy resistance.",
        "Phenotype switching in melanoma refers to the dynamic process by which melanoma cells transition between different transcriptional states or phenotypes, including quiescent and proliferative cell cycle states. This phenomenon involves significant changes in invasiveness and alterations in signaling pathways, as well as variations in the immune cell composition within the tumor microenvironment (TME). Phenotype switching contributes to the nongenomic heterogeneity observed in melanoma, allowing tumors to adapt to various stages of progression and respond to therapeutic interventions. It is characterized by the plasticity of melanoma cells, which can exhibit trans-differentiation into other cell lineages and re-emergence of developmental pathways, complicating diagnosis and treatment strategies.",
        "Phenotype switching in melanoma refers to the dynamic process by which melanoma cells transition between different transcriptional states or phenotypes, including quiescent and proliferative cell cycle states. This phenomenon is characterized by significant changes in invasiveness and alterations in signaling pathways, as well as variations in the immune cell composition within the tumor microenvironment (TME). Phenotype switching contributes to the nongenomic heterogeneity of melanoma, allowing tumors to adapt to various stages of progression and respond to therapeutic interventions. It is closely linked to the plasticity of melanoma cells, which can exhibit trans-differentiation into other cell lineages and re-emergence of developmental pathways, complicating diagnosis and treatment strategies.",
        "Phenotype switching in melanoma refers to the dynamic ability of tumor cells to transition between distinct transcriptional states, characterized by shifts between quiescent and proliferative cell cycle phases, alterations in invasiveness, and changes in signaling pathways. This plasticity also involves adaptive modifications in immune cell composition within the tumor microenvironment (TME), driven by interactions with cancer-associated fibroblasts, extracellular matrix components, and altered gene expression patterns. These transitions contribute to metastasis and therapeutic resistance, as melanoma cells adapt through non-genetic mechanisms rather than relying solely on genetic evolution. Recent research highlights how this phenotypic flexibility disrupts TME homeostasis and impacts immunotherapy efficacy, emphasizing the role of neural crest-like states in shaping tumor heterogeneity and treatment outcomes."
      ]
    },
    {
      "body": "What is a neoantigen?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35387130",
        "http://www.ncbi.nlm.nih.gov/pubmed/37083574",
        "http://www.ncbi.nlm.nih.gov/pubmed/29254980",
        "http://www.ncbi.nlm.nih.gov/pubmed/38343325",
        "https://www.ncbi.nlm.nih.gov/pubmed/31443694",
        "https://www.ncbi.nlm.nih.gov/pubmed/33936118",
        "https://www.ncbi.nlm.nih.gov/pubmed/38164734",
        "http://www.ncbi.nlm.nih.gov/pubmed/39655805",
        "http://www.ncbi.nlm.nih.gov/pubmed/31462330",
        "http://www.ncbi.nlm.nih.gov/pubmed/36604431",
        "http://www.ncbi.nlm.nih.gov/pubmed/36263174",
        "http://www.ncbi.nlm.nih.gov/pubmed/35311072",
        "http://www.ncbi.nlm.nih.gov/pubmed/34193879",
        "http://www.ncbi.nlm.nih.gov/pubmed/32211191",
        "http://www.ncbi.nlm.nih.gov/pubmed/38920970",
        "http://www.ncbi.nlm.nih.gov/pubmed/39694702",
        "http://www.ncbi.nlm.nih.gov/pubmed/39692896",
        "http://www.ncbi.nlm.nih.gov/pubmed/37062328",
        "http://www.ncbi.nlm.nih.gov/pubmed/34321091",
        "http://www.ncbi.nlm.nih.gov/pubmed/34141866",
        "http://www.ncbi.nlm.nih.gov/pubmed/30167844",
        "http://www.ncbi.nlm.nih.gov/pubmed/29312332",
        "http://www.ncbi.nlm.nih.gov/pubmed/29254974",
        "http://www.ncbi.nlm.nih.gov/pubmed/39721408",
        "http://www.ncbi.nlm.nih.gov/pubmed/39720721",
        "http://www.ncbi.nlm.nih.gov/pubmed/28104443",
        "http://www.ncbi.nlm.nih.gov/pubmed/29253113",
        "http://www.ncbi.nlm.nih.gov/pubmed/32117272",
        "http://www.ncbi.nlm.nih.gov/pubmed/37027480",
        "http://www.ncbi.nlm.nih.gov/pubmed/39405926",
        "http://www.ncbi.nlm.nih.gov/pubmed/35279483",
        "http://www.ncbi.nlm.nih.gov/pubmed/26653770",
        "http://www.ncbi.nlm.nih.gov/pubmed/30769238",
        "http://www.ncbi.nlm.nih.gov/pubmed/34386424",
        "http://www.ncbi.nlm.nih.gov/pubmed/35890409",
        "http://www.ncbi.nlm.nih.gov/pubmed/31819989",
        "http://www.ncbi.nlm.nih.gov/pubmed/32929288",
        "http://www.ncbi.nlm.nih.gov/pubmed/25409260",
        "http://www.ncbi.nlm.nih.gov/pubmed/29423108",
        "http://www.ncbi.nlm.nih.gov/pubmed/34452005",
        "http://www.ncbi.nlm.nih.gov/pubmed/39569190",
        "http://www.ncbi.nlm.nih.gov/pubmed/39436255",
        "http://www.ncbi.nlm.nih.gov/pubmed/34788790",
        "http://www.ncbi.nlm.nih.gov/pubmed/32423288",
        "http://www.ncbi.nlm.nih.gov/pubmed/25112529",
        "http://www.ncbi.nlm.nih.gov/pubmed/27563653",
        "http://www.ncbi.nlm.nih.gov/pubmed/34882038",
        "http://www.ncbi.nlm.nih.gov/pubmed/37970536",
        "http://www.ncbi.nlm.nih.gov/pubmed/33928218",
        "http://www.ncbi.nlm.nih.gov/pubmed/35431002",
        "http://www.ncbi.nlm.nih.gov/pubmed/35339277",
        "http://www.ncbi.nlm.nih.gov/pubmed/28867556",
        "http://www.ncbi.nlm.nih.gov/pubmed/28478383",
        "http://www.ncbi.nlm.nih.gov/pubmed/27006495",
        "http://www.ncbi.nlm.nih.gov/pubmed/27208041",
        "http://www.ncbi.nlm.nih.gov/pubmed/32729901",
        "http://www.ncbi.nlm.nih.gov/pubmed/33722796",
        "http://www.ncbi.nlm.nih.gov/pubmed/33262163",
        "http://www.ncbi.nlm.nih.gov/pubmed/31857430",
        "http://www.ncbi.nlm.nih.gov/pubmed/29516371",
        "http://www.ncbi.nlm.nih.gov/pubmed/32908077",
        "http://www.ncbi.nlm.nih.gov/pubmed/26701267",
        "http://www.ncbi.nlm.nih.gov/pubmed/33581342",
        "http://www.ncbi.nlm.nih.gov/pubmed/33824481",
        "http://www.ncbi.nlm.nih.gov/pubmed/31921218",
        "http://www.ncbi.nlm.nih.gov/pubmed/36232923",
        "http://www.ncbi.nlm.nih.gov/pubmed/30723579",
        "http://www.ncbi.nlm.nih.gov/pubmed/25531942"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35387130"
        },
        {
          "offsetInBeginSection": 310,
          "offsetInEndSection": 428,
          "text": " The tumor immunopeptidome comprises neoantigens which can be gained and lost throughout tumorigenesis and treatment. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37083574"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "The term \"neoantigen,\" as applied to molecules newly expressed on tumor cells, has a long history. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29254980"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Neoantigens are derived from somatic mutations in the tumors but are absent in normal tissues. Emerging evidence suggests that neoantigens can stimula",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38343325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1356,
          "text": "Genetic instability of tumor cells often leads to the occurrence of a large number of mutations, and expression of non-synonymous mutations can produce tumor-specific antigens called neoantigens. Neoantigens are highly immunogenic as they are not expressed in normal tissues. They can activate CD4+ and CD8+ T cells to generate immune response and have the potential to become new targets of tumor immunotherapy. The development of bioinformatics technology has accelerated the identification of neoantigens. The combination of different algorithms to identify and predict the affinity of neoantigens to major histocompatibility complexes (MHCs) or the immunogenicity of neoantigens is mainly based on the whole-exome sequencing technology. Tumor vaccines targeting neoantigens mainly include nucleic acid, dendritic cell (DC)-based, tumor cell, and synthetic long peptide (SLP) vaccines. The combination with immune checkpoint inhibition therapy or radiotherapy and chemotherapy might achieve better therapeutic effects. Currently, several clinical trials have demonstrated the safety and efficacy of these vaccines. Further development of sequencing technologies and bioinformatics algorithms, as well as an improvement in our understanding of the mechanisms underlying tumor development, will expand the application of neoantigen vaccines in the future.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/31443694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1197,
          "text": "Cancer immunotherapy works by stimulating and strengthening the body\u0027s anti-tumor immune response to eliminate cancer cells. Over the past few decades, immunotherapy has shown remarkable efficacy in the treatment of cancer, particularly the success of immune checkpoint blockade targeting CTLA-4, PD-1 and PDL1, which has led to a breakthrough in tumor immunotherapy. Tumor neoantigens, a new approach to tumor immunotherapy, include antigens produced by tumor viruses integrated into the genome and antigens produced by mutant proteins, which are abundantly expressed only in tumor cells and have strong immunogenicity and tumor heterogeneity. A growing number of studies have highlighted the relationship between neoantigens and T cells\u0027 recognition of cancer cells. Vaccines developed against neoantigens are now being used in clinical trials in various solid tumors. In this review, we summarized the latest advances in the classification of immunotherapy and the process of classification, identification and synthesis of tumor-specific neoantigens, as well as their role in current cancer immunotherapy. Finally, the application prospects and existing problems of neoantigens were discussed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33936118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1357,
          "text": "Immunotherapy represents a promising strategy for cancer treatment that utilizes immune cells or drugs to activate the patient\u0027s own immune system and eliminate cancer cells. One of the most exciting advances within this field is the targeting of neoantigens, which are peptides derived from non-synonymous somatic mutations that are found exclusively within cancer cells and absent in normal cells. Although neoantigen-based therapeutic vaccines have not received approval for standard cancer treatment, early clinical trials have yielded encouraging outcomes as standalone monotherapy or when combined with checkpoint inhibitors. Progress made in high-throughput sequencing and bioinformatics have greatly facilitated the precise and efficient identification of neoantigens. Consequently, personalized neoantigen-based vaccines tailored to each patient have been developed that are capable of eliciting a robust and long-lasting immune response which effectively eliminates tumors and prevents recurrences. This review provides a concise overview consolidating the latest clinical advances in neoantigen-based therapeutic vaccines, and also discusses challenges and future perspectives for this innovative approach, particularly emphasizing the potential of neoantigen-based therapeutic vaccines to enhance clinical efficacy against advanced solid tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38164734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Neoantigens are tumor-specific antigens that are mostly particular for each patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36820900"
        },
        {
          "offsetInBeginSection": 1137,
          "offsetInEndSection": 1275,
          "text": "PERT OPINION: Neoantigens are cancer cell-specific antigens, which their expression leads to the immune stimulation against tumor cells. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34196590"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The term \"neoantigen,\" as applied to molecules newly expressed on tumor cells, has a long history. The groundbreaking discovery of a cancer causing virus in chickens by Rous over 100 years ago, followed by discoveries of other tumor-causing viruses i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29254980"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "This review focuses on the types of cancer antigens that can be recognised by the immune system and form due to alterations in the cancer genome, including cancer testis, overexpressed and neoantigens. Specifically, neoantigens can form when cancer c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30167844"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "During their development and progression tumors acquire numerous mutations that, when translated into proteins give rise to neoantigens that can be recognized by T cells. Initially, neoantigens were not recognized as preferred targets for cancer immu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29312332"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 352,
          "text": "a subset of immunogenic tumor-specific somatic mutations known as neoantigens. These findings raise the exciting possibility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29254974"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Neoantigen is a patient-specific tumor antigen resulted from mutations during oncogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28104443"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Cancer neoantigens are antigens that result from somatic mutations present in individual cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29253113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Neoantigens are tumor-specific peptide sequences resulting from sources such as somatic DNA mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37027480"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 482,
          "text": "Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604431"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32117272"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 339,
          "text": "Neoantigens are non-self-antigens produced by genetic mutations in tumor cells that induce a strong immune response against tumor cells without central immune tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39197920"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 609,
          "text": "Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames. Neoantigens are recognized as non-self and trigger an immune response that is not subject to central and peripheral tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604431"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Neoantigen, unique peptides resulting from tumor-specific mutations, represent a promising frontier in oncology for personalized cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39405926"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 375,
          "text": "Neo-antigens are defined as a subset of tumor-specific antigens generated by non-synonymous mutations, Indel gene mutation or gene fusions, presented by major histocompatibility complex molecules that were recognized by effector CD8+ T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31631122"
        },
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 690,
          "text": "Neoantigens are immunogenic peptides, unique to malignant cells, that are presented to T-cells via human leukocyte antigens. Neoantigens most commonly arise from non-synonymous mutations but can also be derived from tumor specific alterations along the protein biosynthesis pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35570070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34321091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Neoantigens are commonly defined as HLA-bound peptides that are altered as a consequence of DNA damage and recognized by T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35279483"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Neoantigen is a patient-specific tumor antigen resulted from mutations during oncogenesis. Emerging data suggested that immune responsiveness against neoantigens correlated with the success of clinical tumor immunotherapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28104443"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 330,
          "text": "Neoantigens are tumor-specific antigens that arise due to somatic mutations in the DNA of tumor cells. They represent ideal targets for cancer immunotherapy since there is minimal risk for on-target, off-tumor toxicities. Additionally, these are foreign antigens that should be immunogenic due to lack of central immune tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141866"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Neoantigens are antigens encoded by tumor-specific mutated genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653770"
        },
        {
          "offsetInBeginSection": 481,
          "offsetInEndSection": 598,
          "text": "Neoantigens are mutant cancer peptides that arise as terminal products of the expression of somatic cancer mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30769238"
        },
        {
          "offsetInBeginSection": 391,
          "offsetInEndSection": 533,
          "text": "The latter, also referred to as neoantigens, are immunogenic mutated peptides presented by major histocompatibility complex class I molecules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34386424"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 398,
          "text": "Peptides originating from mutated proteins and bound to MHC molecules on the tumor cell surface are referred to as neoantigens, as they are tumor-specific and not expressed in normal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35890409"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 364,
          "text": "Neoantigens, arising from somatic mutations in individual cancers, are considered as ideal cancer vaccine targets because of their immunogenicity and lack of expression in normal tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31819989"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Cancers accumulate mutations that lead to neoantigens, novel peptides that elicit an immune response, and consequently undergo evolutionary selection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32929288"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 637,
          "text": "ched blood samples. Somatic mutations and candidate neoantigens generated from these mutations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409260"
        },
        {
          "offsetInBeginSection": 320,
          "offsetInEndSection": 514,
          "text": "Immunogenomics approaches have illuminated the role of mutation-derived tumor neoantigens as potential biomarkers of response to checkpoint blockade as well as representing therapeutic vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29423108"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34452005"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 374,
          "text": "Neo-antigens are defined as a subset of tumor-specific antigens generated by non-synonymous mutations, Indel gene mutation or gene fusions, presented by major histocompatibility complex molecules that were recognized by effector CD8+ T cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31631122"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 640,
          "text": "Malignant tumor cells impact favorably or deleteriously their immune microenvironment if they bear genetic mutations that result in neo-antigens or by producing chemokines and cytokines that recruit lymphocytes and myeloid cells or increase inflammation and neo-angiogenesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25112529"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Background: Mutations commonly occur in cancer cells, arising neoantigen as potential targets for personalized immunotherapy of lung adenocarci",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39720721"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 338,
          "text": "Neoantigens are non-self-antigens produced by genetic mutations in tumor cells that induce a strong immune response against tumor cells without central immune tolerance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39197920"
        },
        {
          "offsetInBeginSection": 382,
          "offsetInEndSection": 546,
          "text": "Neoantigens are defined as tumor-specific antigens that result from a multitude of genetic alterations, the most prevalent of which is the single nucleotide variant",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38920970"
        },
        {
          "offsetInBeginSection": 676,
          "offsetInEndSection": 868,
          "text": "A new class of tumor antigens has recently been described, the neo-antigens that are created by point mutations of tumor expressing proteins and are recognized by the immune system as non-self",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27563653"
        },
        {
          "offsetInBeginSection": 596,
          "offsetInEndSection": 736,
          "text": "radigm shift.AREAS COVERED: Neoantigens are short peptide sequences found in tumors, but not noncancerous tissues, the vast majority of whic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34882038"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 293,
          "text": "Neoantigens are known proteins encoded by mutations in tumor cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37970536"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 232,
          "text": "Neoantigens are abnormal proteins that arise as a consequence of somatic mutations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33928218"
        },
        {
          "offsetInBeginSection": 665,
          "offsetInEndSection": 778,
          "text": "Neoantigens, which arise from mutated proteins in cancer cells, are cancer-specific and may be highly immunogenic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35431002"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Neoantigens are tumor-specific mutated proteins that are exempt from central tolerance and are therefore capable of efficiently eliciting effective T-cell responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32211191"
        },
        {
          "offsetInBeginSection": 870,
          "offsetInEndSection": 990,
          "text": "Neo-antigens exhibit two main properties: they are not involved in the immune self-tolerance process and are immunogenic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27563653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 442,
          "text": "SUMMARY: Somatic mutations and gene fusions can produce immunogenic neoantigens mediating anticancer immune responses. However, their computational prediction from sequencing data requires complex computational workflows to identify tumor-specific aberrations, derive the resulting peptides, infer patients\u0027 Human Leukocyte Antigen types and predict neoepitopes binding to them, together with a set of features underlying their immunogenicity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 437,
          "text": "Melanomas are malignant tumors that can partly and very rarely completely regress in response to immune responses. Analyzing the mechanisms underlying this immune-mediated rejection, melanomas became leading in developing general cancer immunotherapy. This resulted in the discovery of tumor-specific neoantigens and mutations autoantigens, now called tumor-associated antigens, and their specific recognition by cytotoxic T lymphocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339277"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 437,
          "text": "Analyzing the mechanisms underlying this immune-mediated rejection, melanomas became leading in developing general cancer immunotherapy. This resulted in the discovery of tumor-specific neoantigens and mutations autoantigens, now called tumor-associated antigens, and their specific recognition by cytotoxic T lymphocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339277"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 576,
          "text": "Analyzing the mechanisms underlying this immune-mediated rejection, melanomas became leading in developing general cancer immunotherapy. This resulted in the discovery of tumor-specific neoantigens and mutations autoantigens, now called tumor-associated antigens, and their specific recognition by cytotoxic T lymphocytes. Melanomas were of key importance for the development of adoptive T-cell therapy and active tumor vaccines, namely dendritic cell vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339277"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for pr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28867556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Somatic mutations can generate neoantigens that are presented on MHC molecules and drive effective T cells responses against cancer. Mutation load in cancer patients predicts response to immune checkpoint blockade therapy. Additionally, vaccination t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28478383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Somatic mutations in cancer give rise to neoantigens. Technology revolutions in cancer genomics and immunology have made it possible to rapidly identify neoantigens for cancer vaccines. Leisegang and colleagues report that it is practical to rapidly ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27006495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Studies first carried out in the 1980s have demonstrated murine T cells can recognize mutated gene products, known as neoantigens, and that these T cells are capable of mediating tumor rejection. The first human tumor antigens isolated in the early 1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208041"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Cancer-associated gene fusions serve as a potential source of highly immunogenic neoantigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39692896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "BACKGROUND: Neoantigens are promising immunogens for cancer vaccines and are often delivered as adjuvanted pepti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39694702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Tumor neoantigens derived from genetic alterations are potential T-cell targets for antitumor immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729901"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-specific T cell recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31462330"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 328,
          "text": "A subset of tumor-specific somatic mutations can be translated into immunogenic and HLA-bound epitopes called neoantigens, which can induce the activation of helper and cytotoxic T lymphocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "Personal neoantigen-based cancer vaccines are designed to target antigens arising from tumor-specific mutations within individual cancers and present a tremendous opportunity to capitalize on their favorable and intrinsic properties of escape from central tolerance and exquisite tumor specificity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33262163"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 333,
          "text": "Specifically, neoantigens can form when cancer cell-specific mutations occur that result in alterations of the protein from \u0027self\u0027.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30167844"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "PURPOSE: Somatic mutations in cancer cells can give rise to novel protein sequences that can be presented by antigen-presenting cells as neoantigens to the host immun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31857430"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 551,
          "text": "This type of cancer-specific antigen arises from somatic variants that result in alteration of the expressed protein sequence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29516371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Neoantigens are tumor-specific proteins and peptides that can be highly immunogenic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34914074"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 477,
          "text": "Neoantigens, arising from somatic mutations and specifically targeting tumor cells, have the potential to stimulate a highly specific immune anti-tumor response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32908077"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 390,
          "text": "The consistency, frequency, and tumor specificity of these \"neoantigens\" make them attractive therapeutic targets",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26701267"
        },
        {
          "offsetInBeginSection": 382,
          "offsetInEndSection": 547,
          "text": "Neoantigens are defined as tumor-specific antigens that result from a multitude of genetic alterations, the most prevalent of which is the single nucleotide variant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38920970"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 397,
          "text": "Neoantigens are tumor-specific antigens arising from somatic mutations, which are proceeded and presented by the major histocompatibility complex on the cell surface.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263174"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 273,
          "text": "Neoantigens are tumor-specific and not expressed in healthy tissues, making them attractive targets for T-cell-based cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39569190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Neoantigens are tumour-specific antigens that arise from non-synonymous mutations in tumour cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34193879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Neoantigen, as an important member of tumor-specific antigens, has attracted a great deal of attention as a target for immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32423288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Neoantigens are tumor-specific mutated proteins that are exempt from central tolerance and are therefore capable of efficiently eliciting effective T-cell responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32211191"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 396,
          "text": "Neoantigens are increasingly recognized as key mediators of tumor-specific immune activation and have been identified as potential targets for personalized cancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33581342"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Neoantigen-based immunotherapy has demonstrated long-lasting antitumor activity. The recognition of neoantigens by T cell receptors (TCRs) is considered a trigger for antitumor responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39436255"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Tumour neoantigens arising from cancer-specific mutations generate a molecular fingerprint that has a definite specificity for cancer. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33824481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Neoantigen is a protein produced by mutant gene, which is only expressed in tumor cells. It is an ideal target for therapeutic tumor vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "Neoantigens are tumor-specific proteins and peptides that can be highly immunogenic. Immune-mediated tumor rejection is strongly associated with cytotoxic responses to neoantigen-derived peptides in noncovalent association with self-HLA molecules.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34914074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "Cancer neoantigens are antigens that result from somatic mutations present in individual cancers. Neoantigens are considered important targets for cancer immunotherapy because of their immunogenicity and lack of expression in normal tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29253113"
        },
        {
          "offsetInBeginSection": 222,
          "offsetInEndSection": 324,
          "text": "Neoantigens are tumor-specific proteins that allow the immune system to recognize and destroy a tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35311072"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35387130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Neoantigens are T-cell antigens derived from protein-coding mutations in tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32876735"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Neoantigens are tumour-specific antigens that arise from non-synonymous mutations in tumour cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34193879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Neoantigens derive from non-synonymous somatic mutations in malignant cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31921218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Neoantigens are tumor-specific proteins and peptides that can be highly immunogenic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34914074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Neoantigens derived from somatic DNA alterations are ideal cancer-specific targets",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36232923"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "SUMMARY: Somatic mutations and gene fusions can produce immunogenic neoantigens mediating anticancer immune ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34788790"
        },
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 532,
          "text": "Neoantigens are immunogenic peptides, unique to malignant cells, that are presented to T-cells via human leukocyte antigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35570070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Tumor-associated neo-antigens are mutated peptides that allow the immune system to recognize the affected cell as foreign",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30723579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34452005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Tumor-specific neo-antigens that arise as a consequence of mutations are thought to be important for the therapeutic efficacy of cancer immunotherapies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531942"
        },
        {
          "offsetInBeginSection": 295,
          "offsetInEndSection": 409,
          "text": "It is theorized that recognizing neoantigens by T cells leads to T cell activation and further antitumor responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37970536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Neoantigens exclusively presented by human leukocyte antigens (HLAs) on cancer cell surfaces are newly discovered and highly cancer-specific biomarkers for cancer diagnosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39721408"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39655805"
        }
      ],
      "type": "summary",
      "id": "67c9e46881b1027333000004",
      "ideal_answer": [
        "Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells",
        "Neoantigens are newly formed antigens generated by tumor cells due to tumor-specific alterations such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames. They are recognized as non-self by the immune system and trigger an immune response.",
        "A neoantigen is a novel protein antigen that arises from tumor-specific mutations and is recognized by the immune system as foreign, potentially triggering an immune response against cancer cells.",
        "Neoantigens are antigens encoded by tumor-specific mutated genes and are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations.",
        "A neoantigen is a protein or peptide that is produced by a mutation in a cancer cell\u0027s DNA, making it recognizable by the immune system as foreign. In the context of this study, neoantigens are potential targets for immunotherapy in thymic carcinomas.",
        "Neoantigens are tumor-specific antigens arising from somatic mutations, which are processed and presented by the major histocompatibility complex on the cell surface. They are capable of efficiently eliciting effective T-cell responses and are attractive targets for cancer immunotherapy   .",
        "A neoantigen is an antigen that arises from somatic mutations in cancer cells, making it tumor-specific and distinct from normal proteins. These antigens are recognized as foreign by the immune system and can be targeted in cancer immunotherapy.",
        "Neoantigens are tumor-specific antigens that result from a multitude of genetic alterations, such as single nucleotide variants, genomic mutations, dysregulated RNA splicing, disordered post-translational modifications, and integrated viral open reading frames.",
        "A neoantigen is a tumor-specific antigen generated by mutations in cancer cells, recognized by the immune system as non-self, and capable of eliciting an immune response.",
        "A neoantigen is a newly formed, highly immunogenic peptide created from somatic mutations or tumor-specific alterations, recognized as non-self by the host immune system, and capable of inducing tumor-specific T cell recognition, making it a promising target for personalized cancer immunotherapies.",
        "A neoantigen is a tumor-specific antigen that arises from mutations in tumor cells and is capable of eliciting an immune response.",
        "A neoantigen is an antigenic marker generated specifically by mutations in cancer cells. These markers are unique and not present in normal cells, making them potential targets for the immune system to recognize and attack cancer cells.",
        "A neoantigen is a mutated protein fragment specifically generated by cancer cells due to genetic alterations (e.g., mutations), absent in normal cells. These unique antigens can be recognized by the immune system as foreign, enabling targeted immune responses against tumors.",
        "A neoantigen is a mutated or newly expressed protein fragment found on cancer cells but absent in normal cells. These antigens arise from genetic mutations during tumorigenesis and are specific to individual tumors, making them potential targets for personalized cancer immunotherapy.",
        "A neoantigen is a new antigen that appears on the surface of cancer cells as a result of mutations. It is not directly related to the entities expressed, cancer, and tumor, but it is associated with cancer cells and their mutations.",
        "[\u0027A neoantigen is a type of antigen that arises from mutations specific to cancer cells, distinguishing them from normal cells. These mutated antigens are not present in normal tissues and are uniquely generated by the cancer cells themselves.\u0027]",
        "A neoantigen is a mutated antigen that is specifically generated by cancer cells but absent in normal cells. These antigens are newly expressed on tumor cells and can be recognized by the immune system, making them potential targets for cancer immunotherapy.",
        "Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells . The term \"neoantigen,\" as applied to molecules newly expressed on tumor cells, has a long history ."
      ]
    },
    {
      "body": "Do hyaluronic acid injections improve knee pain?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23453189",
        "http://www.ncbi.nlm.nih.gov/pubmed/39326362",
        "http://www.ncbi.nlm.nih.gov/pubmed/38160332",
        "http://www.ncbi.nlm.nih.gov/pubmed/38435440",
        "http://www.ncbi.nlm.nih.gov/pubmed/16652426",
        "http://www.ncbi.nlm.nih.gov/pubmed/16144589",
        "http://www.ncbi.nlm.nih.gov/pubmed/11550864",
        "http://www.ncbi.nlm.nih.gov/pubmed/29268731",
        "http://www.ncbi.nlm.nih.gov/pubmed/20467406",
        "http://www.ncbi.nlm.nih.gov/pubmed/12740675",
        "http://www.ncbi.nlm.nih.gov/pubmed/19296086",
        "http://www.ncbi.nlm.nih.gov/pubmed/32776763",
        "http://www.ncbi.nlm.nih.gov/pubmed/26433240",
        "http://www.ncbi.nlm.nih.gov/pubmed/14996880",
        "http://www.ncbi.nlm.nih.gov/pubmed/23830403",
        "http://www.ncbi.nlm.nih.gov/pubmed/30186448",
        "http://www.ncbi.nlm.nih.gov/pubmed/37590853",
        "http://www.ncbi.nlm.nih.gov/pubmed/30574747",
        "http://www.ncbi.nlm.nih.gov/pubmed/23306296"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1262,
          "offsetInEndSection": 1346,
          "text": "Treatment with viscosupplementation increased the time until surgery in all patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453189"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 270,
          "text": "intra-articular (IA) injections of hyaluronic acid (HA) offer temporary relief",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39326362"
        },
        {
          "offsetInBeginSection": 1202,
          "offsetInEndSection": 1382,
          "text": "Intra-articular injections of different doses of linear HMW HA can improve pain, stiffness, function, and quality of life in patients suffering from knee OA over a six-month period",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38160332"
        },
        {
          "offsetInBeginSection": 1516,
          "offsetInEndSection": 1594,
          "text": "Intra-articular injections of PRP and HA are effective interventions for KOA. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38435440"
        },
        {
          "offsetInBeginSection": 1821,
          "offsetInEndSection": 1993,
          "text": "groups for adverse events.CONCLUSION: Intraarticular HA was superior to placebo in improving knee pain and function, with no difference between 3 or 6 consecutive injection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16652426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 45,
          "text": "Hyaluronic acid injections relieve knee pain.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16144589"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1078,
          "text": "To assess the efficacy of intra-articular hyaluronic acid in patients with knee osteoarthritis, sixty female patients with knee osteoarthritis were randomised to three weekly intra-articular injections of 30 mg sodium hyaluronate (Na HA) with a high molecular weight (1.0 to 2.9 million Da) or 40 mg 6-methylprednisolone acetate (6-MPA). The clinical assessments included pain at rest, at weight-bearing and on walking, Lequesne Index and active range of knee flexion. Assessments were done at baseline, at week 4, and at months 3 and 6. A significant decrease in VAS scores for pain at rest, at weight-bearing and pain on walking, and in Lequesne index was found in both groups at week 4 when compared to baseline and there was no significant differences between the two groups. However, at 3(rd) month improvement in all pain scores and Lequesne index was found in favour of hyaluronic acid. At 6(th), no significant difference was found between the treatment groups. Improvement in pain was accompanied by an increase in joint flexion at week 4 and at month 3 in both groups.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12740675"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1222,
          "text": "Intra-articular injections of hyaluronic acid are currently indicated as a symptom-modifying treatment for knee osteoarthritis to palliate symptoms and improve function. A series of three to five weekly injections are typically delivered once per week and a period of at least 6 months must pass between consecutive injection series. Little is known about why some patients do not respond to this treatment or about its effects on outcome measures recorded during functional activities. In addition to investigating short-term self-report and measured functional changes, the purpose of this study was to evaluate the persistence of treatment effects over the typical time interval between consecutive treatment series. According to the a priori definition for response to treatment, over two-thirds of patients experienced improved knee function during the typical period between series of intra-articular injection of hyaluronic acid while a one-third did not demonstrate a change in self-report scores. Differences in response were similarly seen between groups in functional tests. Many had immediate benefits and although some did not retain their gains, others experienced a delayed response in the following months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19296086"
        },
        {
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1254,
          "text": "SULTS: Intra-articular injection of hyaluronic acid can decrease symptoms of osteoarthritis of the knee. We found significant improvements in pain and functional outcomes with few adverse events. However, there was significant between-study heterogeneity in the estimates of the efficacy of hyaluronic acid. S",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14996880"
        },
        {
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1142,
          "text": "SULTS: Intra-articular injection of hyaluronic acid can decrease symptoms of osteoarthritis of the knee. We found significant improvements in pain and functional outcomes with few adverse events. H",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14996880"
        },
        {
          "offsetInBeginSection": 1083,
          "offsetInEndSection": 1266,
          "text": "SULTS: Intra-articular administration of a hyaluronic acid preparation significantly reduced pain in the knee and improved its functioning, regardless of the form of osteoarthritis. N",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23306296"
        },
        {
          "offsetInBeginSection": 945,
          "offsetInEndSection": 1051,
          "text": "SULTS: Intra-articular injection of hyaluronic acid can decrease symptoms of osteoarthritis of the knee. W",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14996880"
        },
        {
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1770,
          "text": "The summary estimates of VAS differences between therapy and placebo injection: at 1 week, 4.4 (95% confidence interval [CI], 1.1-7.2); at 5 to 7 weeks, 17.7 (7.5-28.0); at 8 to 12 weeks, 18.1 (6.3-29.9) and at 15 to 22 weeks, 4.4 (-15.3 to 24.1).CONCLUSION: Intra-articular viscosupplementation was moderately effective in relieving knee pain in patients with osteoarthritis at 5 to 7 and 8 to 10 weeks after the last injection but not at 15 to 22 weeks.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16144589"
        },
        {
          "offsetInBeginSection": 1054,
          "offsetInEndSection": 1578,
          "text": "There was no statistically significant difference between change in outcome after HA or placebo treatment (P \u003e0.05), except for WOMAC pain subscore on walking at final assessment (week 14) which showed greater improvement in the HA-treated group (35.2% versus 9.1%; P\u003d0.01).CONCLUSION: HA treatment was effective in the management of knee OA and improved knee pain and functional outcome, but there was no statistically significant difference in functional and symptom improvement with respect to saline (placebo) injection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20467406"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 280,
          "text": "viscosupplementation with intra-articular hyaluronic acid injection reduces knee osteoarthritis pain and improves function according to the highest level of evidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26433240"
        },
        {
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1078,
          "text": "rall, IA-HA injections were associated with less knee pain compared to IA-Saline injections for all dosing regimens. 2-",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29268731"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 439,
          "text": "Visco-supplementation represents a valid treatment option for reducing pain associated with knee osteoarthritis and improving function in the affected joint.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830403"
        },
        {
          "offsetInBeginSection": 520,
          "offsetInEndSection": 605,
          "text": "Hyaluronic acid (HA) is an effective treatment for patients with knee osteoarthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30186448"
        },
        {
          "offsetInBeginSection": 622,
          "offsetInEndSection": 683,
          "text": "Hyaluronic acid has limited benefits for knee osteoarthritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37590853"
        },
        {
          "offsetInBeginSection": 268,
          "offsetInEndSection": 436,
          "text": "The current review of 80 knees with symptomatic osteoarthritis treated with hyaluronic acid revealed that approximately 2/3 of treated knees received 2/3 relief of pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11550864"
        },
        {
          "offsetInBeginSection": 1536,
          "offsetInEndSection": 1731,
          "text": "eeks, 4.4 (-15.3 to 24.1).CONCLUSION: Intra-articular viscosupplementation was moderately effective in relieving knee pain in patients with osteoarthritis at 5 to 7 and 8 to 10 weeks after the la",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16144589"
        },
        {
          "offsetInBeginSection": 1658,
          "offsetInEndSection": 1973,
          "text": "These results support the clinical effectiveness and safety of hyaluronic acid for up to 12 months for pain relief and function improvement in patients with knee osteoarthritis, confirming previous data on intra-articular administration of hyaluronic acid as chronic therapy in the management of knee osteoarthritis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30574747"
        },
        {
          "offsetInBeginSection": 1589,
          "offsetInEndSection": 1719,
          "text": "Our study was not very supportive of intra-articular injection of hyaluronic acid as an effective treatment of knee osteoarthritis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32776763"
        },
        {
          "offsetInBeginSection": 463,
          "offsetInEndSection": 720,
          "text": "The literature seems to support the use of hyaluronic acid in the treatment of knee osteoarthritis, because it diminishes pain and improves disability, generally within 1 week and for up to 3-12 months (but especially at the 5-13-week postinjection period).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22885769"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 364,
          "text": " as flares. Intra-articular injection of hyaluronic acid has demonstrated long-term symptomatic relief in the broader knee osteoarthritis population, although its use in the flare population has not been extensive",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37408828"
        }
      ],
      "id": "67fbe2ab18b1e36f2e000116",
      "ideal_answer": [
        "Yes, intra-articular injections of hyaluronic acid can improve pain, stiffness, function, and quality of life in patients suffering from knee osteoarthritis.",
        "Hyaluronic acid (HA) injections are generally effective for improving knee pain, particularly in individuals with knee osteoarthritis (KOA). Studies indicate that intra-articular HA injections provide significant pain relief and enhance joint function. The efficacy is notably higher when using high molecular weight (HMW) HA compared to low molecular weight (LMW) products. However, the effectiveness can vary based on specific contexts:\n\n1. **Post-Surgery Use**: HA injections after knee surgery do not show significant benefits in pain relief or functional recovery.\n2. **Combined Therapies**: Adding HA to platelet-rich plasma (PRP) therapy does not provide additional advantages over PRP alone for KOA patients.\n\nIn summary, while HA injections are beneficial for knee pain management in cases of KOA, their effectiveness may depend on factors such as the type of HA used and the clinical context.",
        "Hyaluronic acid (HA) injections are a recognized treatment for knee pain associated with osteoarthritis (OA). These injections work by supplementing the natural HA in synovial fluid, which diminishes with age. The evidence suggests that HA injections provide temporary relief from symptoms such as pain and stiffness, improve joint function, and enhance quality of life. They may also delay the need for surgical intervention. While individual responses vary, studies indicate that HA injections can be effective for up to six months, particularly when using high molecular weight formulations. Thus, HA injections offer a beneficial, though temporary, solution for managing knee pain in OA patients."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Which transcription factors are important to define human astrocyte identity?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30290178",
        "http://www.ncbi.nlm.nih.gov/pubmed/34351428",
        "http://www.ncbi.nlm.nih.gov/pubmed/30166336",
        "http://www.ncbi.nlm.nih.gov/pubmed/24848099",
        "http://www.ncbi.nlm.nih.gov/pubmed/32759168",
        "http://www.ncbi.nlm.nih.gov/pubmed/39256463",
        "http://www.ncbi.nlm.nih.gov/pubmed/25540002",
        "http://www.ncbi.nlm.nih.gov/pubmed/39546395",
        "http://www.ncbi.nlm.nih.gov/pubmed/25556566",
        "http://www.ncbi.nlm.nih.gov/pubmed/32800455",
        "http://www.ncbi.nlm.nih.gov/pubmed/20150379",
        "http://www.ncbi.nlm.nih.gov/pubmed/34324178",
        "http://www.ncbi.nlm.nih.gov/pubmed/21189253",
        "http://www.ncbi.nlm.nih.gov/pubmed/16206198",
        "http://www.ncbi.nlm.nih.gov/pubmed/32153350",
        "http://www.ncbi.nlm.nih.gov/pubmed/27732850",
        "http://www.ncbi.nlm.nih.gov/pubmed/33949692",
        "http://www.ncbi.nlm.nih.gov/pubmed/30127505",
        "http://www.ncbi.nlm.nih.gov/pubmed/12730998",
        "http://www.ncbi.nlm.nih.gov/pubmed/27546532",
        "http://www.ncbi.nlm.nih.gov/pubmed/28336567",
        "http://www.ncbi.nlm.nih.gov/pubmed/15617758",
        "http://www.ncbi.nlm.nih.gov/pubmed/31760595",
        "http://www.ncbi.nlm.nih.gov/pubmed/30195713",
        "http://www.ncbi.nlm.nih.gov/pubmed/39700048"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 1029,
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation. These transcription factors facilitate stage-specific gene expression programs by switching the chromatin state of their target regulatory elements from primed to active. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 646,
          "text": "We report molecularly distinct phases of astrogliogenesis that exhibit stage- and lineage-specific transcriptomic and epigenetic signatures with unique primed and active chromatin regions, thereby revealing regulatory elements and transcriptional programs underlying astrocyte generation and maturation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 312,
          "text": "The transcription factor zinc finger and BTB domain-containing protein 20 (ZBTB20) has been implicated in regulation of cell specification during neocortical development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34351428"
        },
        {
          "offsetInBeginSection": 646,
          "offsetInEndSection": 899,
          "text": "Astrogliogenesis is also affected in the mutants with an increase in the number of a specific subset of astrocytes expressing GFAP. Astrogliogenesis is more severely disrupted by a ZBTB20 protein containing dominant mutations linked to Primrose syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34351428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "SOX transcription factors have important roles during astrocyte and oligodendrocyte development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30166336"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 644,
          "text": "In the subsequent lineage-restricted glial precursor cells, astrocyte genes become additionally targeted by SOX9 at DNA regions strongly enriched for Nfi binding motifs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30166336"
        },
        {
          "offsetInBeginSection": 774,
          "offsetInEndSection": 949,
          "text": "Interestingly, reporter gene assays and functional studies in the spinal cord reveal that SOX3 binding represses the synergistic activation of astrocyte genes by SOX9 and NFIA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30166336"
        },
        {
          "offsetInBeginSection": 631,
          "offsetInEndSection": 855,
          "text": "Our analysis confirmed that the fetal astrocytes express high levels of the core astrocyte marker GFAP and the transcription factors from the NFI family which have been shown to play important roles in astrocyte development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24848099"
        },
        {
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1545,
          "text": "We demonstrate that paired-like homeodomain transcription factor 1 (PITX1) is critical for astrocyte differentiation. PITX1 overexpression induced early differentiation of astrocytes, and its knockdown blocked astrocyte differentiation. PITX1 overexpression also increased and PITX1 knockdown decreased expression of sex-determining region Y box 9 (SOX9), known initiator of gliogenesis, during early astrocyte differentiation. Moreover, we determined that PITX1 activates the SOX9 promoter through a unique binding motif. Taken together, these findings indicate that PITX1 drives astrocyte differentiation by sustaining activation of the SOX9 promoter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "The transcription factor PITX1 drives astrocyte differentiation by regulating the SOX9 gene.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 857,
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
        },
        {
          "offsetInBeginSection": 1581,
          "offsetInEndSection": 1818,
          "text": "Further studies are needed to determine whether differences in the level of SOX2 expression in GFAP-positive astrocytes are in correlation with their self-renewal capacity, differentiation status, and/or their phenotypic characteristics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25540002"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "SOX transcription factors have important roles during astrocyte and oligodendrocyte development, but how glial genes are specified and activated in a sub-lineage-specific fashion remains unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30166336"
        },
        {
          "offsetInBeginSection": 1415,
          "offsetInEndSection": 1545,
          "text": "Taken together, these findings indicate that PITX1 drives astrocyte differentiation by sustaining activation of the SOX9 promoter.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Nuclear factor IA (NFIA) is a transcription factor that specifies glial cell identity and promotes astrocyte differentiation during embryonic development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150379"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 376,
          "text": "Reprogramming induced pluripotent stem cells (iPSCs) to become astrocytes through overexpression of the transcription factors, NFIB and SOX9, is a rapid and efficient approach for studying human neurological diseases and identifying therapeutic targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39256463"
        },
        {
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1319,
          "text": "We demonstrate that paired-like homeodomain transcription factor 1 (PITX1) is critical for astrocyte differentiation. PITX1 overexpression induced early differentiation of astrocytes, and its knockdown blocked astrocyte differentiation. PITX1 overexpression also increased and PITX1 knockdown decreased expression of sex-determining region Y box 9 (SOX9), known initiator of gliogenesis, during early astrocyte differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 399,
          "offsetInEndSection": 636,
          "text": "This analysis revealed that motifs for Nuclear Factor-I (NFI) are present in genes enriched in astrocytes from all regions, with NFIB and NFIX exhibiting pan-astrocyte expression in the olfactory bulb, hippocampus, cortex, and brainstem.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32153350"
        },
        {
          "offsetInBeginSection": 1129,
          "offsetInEndSection": 1319,
          "text": "PITX1 overexpression also increased and PITX1 knockdown decreased expression of sex-determining region Y box 9 (SOX9), known initiator of gliogenesis, during early astrocyte differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 892,
          "offsetInEndSection": 1009,
          "text": "We demonstrate that paired-like homeodomain transcription factor 1 (PITX1) is critical for astrocyte differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 1010,
          "offsetInEndSection": 1128,
          "text": "PITX1 overexpression induced early differentiation of astrocytes, and its knockdown blocked astrocyte differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 285,
          "text": "We demonstrate that overexpression of the transcription factors SOX9 and NFIB in human pluripotent stem cells rapidly and efficiently yields homogeneous populations of induced astrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30127505"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 818,
          "text": "Herein, we carried out a screening using several transcription factors involved in defining the astroglial cell fate and identified NFIA, NFIB, and SOX9 to be sufficient to convert with high efficiency embryonic and postnatal mouse fibroblasts into astrocytes (iAstrocytes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25556566"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 427,
          "text": "Here, we describe a two-step protocol to generate astrocytes from human induced pluripotent stem cells (hiPSCs) using a bankable neural progenitor cell (NPC) intermediate, followed by low-density passaging and overexpression of the gliogenic transcription factor NFIA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39546395"
        },
        {
          "offsetInBeginSection": 1129,
          "offsetInEndSection": 1318,
          "text": "PITX1 overexpression also increased and PITX1 knockdown decreased expression of sex-determining region Y box 9 (SOX9), known initiator of gliogenesis, during early astrocyte differentiation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 1415,
          "offsetInEndSection": 1544,
          "text": "Taken together, these findings indicate that PITX1 drives astrocyte differentiation by sustaining activation of the SOX9 promoter",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759168"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 375,
          "text": "Reprogramming induced pluripotent stem cells (iPSCs) to become astrocytes through overexpression of the transcription factors, NFIB and SOX9, is a rapid and efficient approach for studying human neurological diseases and identifying therapeutic targets",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39256463"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 675,
          "text": "Accordingly, we performed single-cell RNA sequencing analysis on 64,736 cells to establish a comprehensive atlas of NFIB/SOX9-directed astrocyte differentiation from human iPSCs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39256463"
        },
        {
          "offsetInBeginSection": 746,
          "offsetInEndSection": 992,
          "text": "The expression of NFI-X3 is dramatically up-regulated during the differentiation of neural progenitors to astrocytes and precedes the expression of astrocyte markers, such as GFAP and SPARCL1 (Secreted Protein, Acidic and Rich in Cysteines-like 1",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21189253"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 1028,
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation. These transcription factors facilitate stage-specific gene expression programs by switching the chromatin state of their target regulatory elements from primed to active.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 857,
          "text": "We report molecularly distinct phases of astrogliogenesis that exhibit stage- and lineage-specific transcriptomic and epigenetic signatures with unique primed and active chromatin regions, thereby revealing regulatory elements and transcriptional programs underlying astrocyte generation and maturation. By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
        },
        {
          "offsetInBeginSection": 350,
          "offsetInEndSection": 452,
          "text": "The nuclear factor one (NFI) transcription factors are essential for normal astrocytic differentiation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31760595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Nuclear factor IA (NFIA) is a transcription factor that specifies glial cell identity and promotes astrocyte differentiation during embryonic development",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150379"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 385,
          "text": "NFIs have previously been shown to regulate the expression of astrocyte markers such as glial fibrillary acidic protein (GFAP) in both normal brain and GBM cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30195713"
        },
        {
          "offsetInBeginSection": 1673,
          "offsetInEndSection": 1906,
          "text": "Together these results suggest that the transcription factor NF-kappaB, and possibly NF-I, contribute to the upregulation of CCL2 chemokine production during the differentiation of human progenitor cells toward an astrocyte phenotype",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16206198"
        },
        {
          "offsetInBeginSection": 647,
          "offsetInEndSection": 856,
          "text": "By searching for transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290178"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 820,
          "text": "Herein, we carried out a screening using several transcription factors involved in defining the astroglial cell fate and identified NFIA, NFIB, and SOX9 to be sufficient to convert with high efficiency embryonic and postnatal mouse fibroblasts into astrocytes (iAstrocytes).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25556566"
        }
      ],
      "id": "67eaf14c18b1e36f2e0000de",
      "ideal_answer": [
        "Several transcription factors play crucial roles in defining human astrocyte identity and function. Among them, NFIA and ATF3 have been identified as drivers of astrocyte differentiation from neural precursor cells with RUNX2 promoting astrocyte maturation. In addition, SOX9 has been shown to synergistically activate astrocyte genes together with NFIA, while the transcription factor zinc finger and BTB domain-containing protein 20 (ZBTB20) has been implicated in the regulation of cell specification during neocortical development, with mutations in this protein disrupting astrogliogenesis.",
        "Key transcription factors defining human astrocyte identity include NFIA, ATF3, RUNX2, and notably SOX9, which play crucial roles in astrogliogenesis, differentiation, and maturation. While SOX9\u0027s function is particularly underscored across developmental contexts, often in conjunction with NFIA, additional factors like SOX3 and ZBTB20 may also contribute, albeit with less consensus across studies. These factors collectively drive the development and specification of human astrocytes.",
        "The transcription factors NFIA, ATF3, RUNX2, ZBTB20, and SOX9 have been identified as important for defining human astrocyte identity. NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells, while RUNX2 promotes astrocyte maturation. ZBTB20 has been implicated in regulation of cell specification during neocortical development, and SOX9 plays a role during astrocyte and oligodendrocyte development.",
        "NFIA and ATF3 are drivers of astrocyte differentiation, while RUNX2 promotes astrocyte maturation, shaping stage-specific gene expression through chromatin state changes. SOX3 and SOX9 also play roles, with SOX3 repressing astrocyte gene activation synergistically by NFIA, and SOX9 targeting astrocyte genes in lineage-restricted glial precursor cells. ZBTB20 influences astrocyte identity by affecting cell specification, with mutations linked to Primrose syndrome disrupting astrogliogenesis.",
        "Several transcription factors are critical in defining human astrocyte identity. NFIA and ATF3 are essential for the differentiation of astrocytes from neural precursor cells, while RUNX2 helps in their maturation. ZBTB20 regulates cell specification during neocortical development and influences a specific subset of astrocytes expressing GFAP. Additionally, SOX9 targets astrocyte genes during the development of lineage-restricted glial precursor cells.",
        "Key transcription factors crucial for defining human astrocyte identity include **NFIA**, **ATF3**, **RUNX2**, **SOX9**, and **ZBTB20**. NFIA and ATF3 drive astrocyte differentiation from neural precursor cells, while RUNX2 promotes maturation by activating stage-specific chromatin regions. SOX9 collaborates with NFIA to regulate astrocyte genes in glial precursors, and ZBTB20 influences astrogliogenesis, particularly in GFAP-expressing subsets. SOX3 acts as a repressor, modulating the activation of astrocyte genes by SOX9 and NFIA. These factors orchestrate chromatin remodeling and transcriptional programs to establish astrocyte identity during development.",
        "The transcription factors crucial for defining human astrocyte identity are:\n\n1. **NFIA (Nuclear Factor I A)**: Plays a key role in initiating astrocyte differentiation from neural precursor cells.\n\n2. **ATF3 (Activating Transcription Factor 3)**: Acts alongside NFIA to drive astrocyte differentiation.\n\n3. **RUNX2**: Promotes the maturation of astrocytes, aiding in their final development stages.\n\n4. **ZBTB20**: Involved in cell specification during neocortical development and regulates astrocyte differentiation and maturation, as evidenced by its mutations linked to Primrose syndrome.\n\n5. **SOX9**: Targets astrocyte genes in glial precursor cells, particularly at regions with Nfi binding motifs, facilitating their expression.\n\n6. **SOX3**: Represses the activation of astrocyte genes by SOX9 and NFIA, playing a regulatory role in gene expression during astrocyte development.\n\nThese factors collectively contribute to the differentiation, maturation, and regulation of astrocyte-specific gene expression, essential for defining human astrocyte identity.",
        "Key transcription factors important for defining human astrocyte identity include **NFIA**, **ATF3**, **RUNX2**, **SOX9**, and **ZBTB20**. NFIA and ATF3 drive astrocyte differentiation from neural precursor cells, while RUNX2 promotes maturation. SOX9 collaborates with NFIA to activate astrocyte-specific genes in lineage-restricted glial precursors. ZBTB20 regulates astrogliogenesis, particularly influencing GFAP-expressing astrocytes. Additionally, SOX3 modulates this process by repressing synergistic activation of astrocyte genes by SOX9 and NFIA. These factors orchestrate stage-specific chromatin remodeling and transcriptional programs during astrocyte development.",
        "The transcription factors that are important to define human astrocyte identity include NFIA, ATF3, RUNX2, SOX9, and ZBTB20. NFIA and ATF3 are identified as drivers of astrocyte differentiation from neural precursor cells, while RUNX2 promotes astrocyte maturation. SOX9 targets astrocyte genes in lineage-restricted glial precursor cells, and ZBTB20 has been implicated in regulation of cell specification during neocortical development.",
        "Key transcription factors defining human astrocyte identity include NFIA, ATF3, RUNX2, ZBTB20, and SOX9, playing crucial roles in differentiation, maturation, and gene regulation across various stages of astrogliogenesis. NFIA and ATF3 drive differentiation from neural precursors, RUNX2 promotes maturation, ZBTB20 is involved in neocortical development, and SOX9 targets astrocyte genes in glial precursors. While SOX3 may repress astrocyte gene activation in conjunction with SOX9 and NFIA, its central role is less defined. These factors collectively facilitate the molecularly distinct phases of astrocyte generation and maturation.",
        "The transcription factors that play crucial roles in defining human astrocyte identity include:\n\n1. **NFIA**: Drives astrocyte differentiation from neural precursor cells.\n2. **ATF3**: Also involved in the differentiation process of astrocytes.\n3. **RUNX2**: Promotes the maturation of astrocytes.\n4. **ZBTB20**: Implicated in regulating cell specification during neocortical development and astrogliogenesis.\n5. **SOX9**: Key in targeting astrocyte genes during development, particularly in glial precursor cells.\n6. **SOX3**: Acts as a repressor of astrocyte gene activation by SOX9 and NFIA.\n\nThese factors collectively contribute to the differentiation, maturation, and regulation of gene expression necessary for astrocyte identity.",
        "Based on the provided abstracts, several transcription factors are implicated in defining human astrocyte identity. These include NFIA, ATF3, RUNX2, ZBTB20, SOX9, and SOX3. Specifically, NFIA and ATF3 drive astrocyte differentiation from neural precursor cells, while RUNX2 promotes astrocyte maturation. SOX9, in conjunction with NFIA, targets astrocyte genes during glial precursor cell development. In contrast, SOX3 binding represses the synergistic activation of astrocyte genes by SOX9 and NFIA. ZBTB20 is also involved in regulating astrogliogenesis, particularly in neocortical development. These transcription factors play crucial roles in specifying astrocyte identity through stage- and lineage-specific gene expression programs, chromatin remodeling, and regulation of target regulatory elements.",
        "Transcription factors important for defining human astrocyte identity include NFIA, ATF3, RUNX2, SOX9, and ZBTB20. NFIA and ATF3 drive astrocyte differentiation, RUNX2 promotes maturation, SOX9 targets astrocyte genes, and ZBTB20 regulates cell specification during neocortical development, with mutations affecting astrogliogenesis."
      ],
      "exact_answer": [
        [
          "NFIA",
          "NFIB",
          "NFI-X",
          "NFI Family Transcription Factors",
          "NFI-X3",
          "NFI",
          "NF I"
        ],
        [
          "ATF3"
        ],
        [
          "RUNX2"
        ],
        [
          "ZBTB20"
        ],
        [
          "SOX9",
          "Sox9",
          "Sox transcription factors"
        ],
        [
          "PITX1"
        ],
        [
          "NF-kappa B",
          "NF kappaB",
          "NF kB",
          "NF-κB"
        ]
      ]
    },
    {
      "body": "Is Peto\u0027s Paradox associated with cancer rates?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38275822",
        "http://www.ncbi.nlm.nih.gov/pubmed/38970664",
        "http://www.ncbi.nlm.nih.gov/pubmed/39494584",
        "http://www.ncbi.nlm.nih.gov/pubmed/26056357",
        "http://www.ncbi.nlm.nih.gov/pubmed/25667599",
        "http://www.ncbi.nlm.nih.gov/pubmed/26056359",
        "http://www.ncbi.nlm.nih.gov/pubmed/26499116",
        "http://www.ncbi.nlm.nih.gov/pubmed/26056367",
        "http://www.ncbi.nlm.nih.gov/pubmed/26056366",
        "http://www.ncbi.nlm.nih.gov/pubmed/22943484",
        "http://www.ncbi.nlm.nih.gov/pubmed/28705195",
        "http://www.ncbi.nlm.nih.gov/pubmed/28252229",
        "https://www.ncbi.nlm.nih.gov/pubmed/25667599",
        "https://www.ncbi.nlm.nih.gov/pubmed/26056367",
        "https://www.ncbi.nlm.nih.gov/pubmed/38970664",
        "https://www.ncbi.nlm.nih.gov/pubmed/39494584",
        "http://www.ncbi.nlm.nih.gov/pubmed/37149260",
        "http://www.ncbi.nlm.nih.gov/pubmed/38255007",
        "http://www.ncbi.nlm.nih.gov/pubmed/27703689",
        "http://www.ncbi.nlm.nih.gov/pubmed/24166913",
        "http://www.ncbi.nlm.nih.gov/pubmed/30771154",
        "http://www.ncbi.nlm.nih.gov/pubmed/35077272",
        "http://www.ncbi.nlm.nih.gov/pubmed/27642012",
        "http://www.ncbi.nlm.nih.gov/pubmed/27629030",
        "http://www.ncbi.nlm.nih.gov/pubmed/36534348",
        "http://www.ncbi.nlm.nih.gov/pubmed/33209304",
        "http://www.ncbi.nlm.nih.gov/pubmed/30679716",
        "http://www.ncbi.nlm.nih.gov/pubmed/37461608"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494584"
        },
        {
          "offsetInBeginSection": 611,
          "offsetInEndSection": 804,
          "text": "As a result, this study uncovered the sufficient conditions underlying the absence of correlation in Peto\u0027s paradox and provide insights into the reasons for the equitable distribution of cance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 276,
          "text": " Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 245,
          "text": "eto\u0027s paradox and the epidemiologic observation of the average six degrees of tumor prevalence are studied and hypothetically solved. A simple consideration, Petho\u0027s paradox challenges our intuitive understanding of cancer risk and prevalence. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38275822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 54,
          "text": "Peto\u0027s \"Paradox\" and Six Degrees of Cancer Prevalence.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38275822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "text": "Peto\u0027s paradox is the lack of the expected trend in cancer incidence as a function of body size and lifespan across species. The leading hypothesis to explain this pattern is natural selection for differential cancer prevention in larger, longer lived species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Peto\u0027s paradox is the lack of the expected trend in cancer incidence as a function of body size and lifespan across species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056357"
        },
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 735,
          "text": "The unexpected lack of correlation between body size (and life span) and cancer risk across taxa was dubbed Peto\u0027s paradox.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25667599"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 532,
          "text": "The multistage model predicts that cancer risk increases with body size and longevity; however, this is not observed across species (Peto\u0027s paradox), but the paradox is resolved by invoking the evolution of additional genetic mechanisms to suppress cancer in large, long-lived species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056359"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1029,
          "text": "Cancer, a disease intimately linked to cellular mutations, is commonly believed to exhibit a positive association with the cell count and lifespan of a species. Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum. Recognizing that tumour progression is not solely dependent on cancer cells but involves intricate interactions among various cell types, this study employed a Lotka-Volterra (LV) ordinary differential equation model to analyze the evolution of cancerous cells and the cancer incidence in an immune environment. As a result, this study uncovered the sufficient conditions underlying the absence of correlation in Peto\u0027s paradox and provide insights into the reasons for the equitable distribution of cancer incidence across diverse species by applying nondimensionalization and drawing an analogy between the characteristic time interval for the variation of cell populations in the ODE model and that of cell cycles of a species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1312,
          "text": "Cancer, one of the leading health concerns for humans, is by no means a human-unique malady. Accumulating evidence shows that cancer kills domestic and wild animals at a similar rate to humans and can even pose a conservation threat to certain species. Assuming that each physiologically active and proliferating cell is at risk of malignant transformation, any evolutionary increase in the number of cells (and thus body mass) will lead to a higher cancer frequency, all else being equal. However, available data fail to support the prediction that bigger animals are affected by cancer more than smaller ones. The unexpected lack of correlation between body size (and life span) and cancer risk across taxa was dubbed Peto\u0027s paradox. In this perspective, several plausible explanations of Peto\u0027s paradox are presented, with the emphasis on a largely underappreciated relation of cell size to both metabolism and cell division rates across species, which we believe are key factors underlying the paradox. We conclude that larger organisms have bigger and slowly dividing cells with lower energy turnover, all significantly reducing the risk of cancer initiation. Solving Peto\u0027s paradox will enhance our understanding the evolution of cancer and may provide new implications for cancer prevention and treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/25667599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1517,
          "text": "The frequency of cancer is postulated to be proportional to the number of cells an animal possesses, as each cell is similarly exposed to mutagens with every cell division. Larger animals result from more cell divisions with more mutagenic exposure, and hence are expected to have higher frequencies of cancer. Yet, as stipulated by Peto\u0027s paradox, larger animals do not have the higher rates of cancers seen in smaller animals despite the significant differences in cell numbers and a longer lifetime that would expose larger animals to more mutagens. The rates of cancer appear to be inversely proportional to animal body size, which scales inversely with specific metabolic rates of mammals. Studies over the past 20 years have linked oncogenes and tumour suppressors to alterations in cancer metabolism, and conversely, mutations in metabolic genes have been documented to trigger tumorigenesis. The by-products and intermediates of metabolism, such as reactive oxygen species, oxoglutarate, citrate and acetate, all have the potential to mutate and alter the genome or epigenome. On the basis of these general observations, it is proposed that metabolic rates correlate with mutagenic rates, which are higher in small animals and give the mechanistic basis for Peto\u0027s paradox. The observations discussed in this overview collectively indicate that specific metabolic rate varies inversely with body size, which seems to support the hypothesis that metabolism drives tumorigenesis and accounts for Peto\u0027s paradox.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/26056367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1195,
          "text": "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research. It prompts investigations into how species with traits that theoretically increase cancer risk manage to exhibit cancer resistance, with the ultimate goal of uncovering novel therapies for humans. Building on these foundational insights, we propose expanding the research focus to species that, despite possessing traits beyond size and longevity that theoretically increase their cancer risk, exhibit unexpected cancer resistance. Testing Peto\u0027s paradox without interference from transient dynamics also requires considering species that are at an equilibrium between cancer risks and defenses, which is increasingly challenging due to anthropogenic activities. Additionally, we argue that transmissible cancers could significantly help in understanding how the metastatic process might be naturally suppressed. This research perspective is timely and aims to support the continued and in-depth identification of anti-cancer adaptations retained throughout evolution in the animal kingdom.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/39494584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "The risk of developing cancer should theoretically increase with both the number of cells and the lifespan of an organism. However, gigantic animals do not get more cancer than humans, suggesting that super-human cancer suppression has evolved numerous times across the tree of life. This is the essence and promise of Peto\u0027s Paradox.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28705195"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 297,
          "text": "Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Richard Peto\u0027s paradox, first described in 1975 from an epidemiological perspective, established an inverse correlation between the probability of developing cancer in multicellular organisms and the number of cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38255007"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 174,
          "text": "Therefore, Peto\u0027s paradox, or low cancer incidence in large animals, has attracted focus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27703689"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Peto\u0027s paradox and the epidemiologic observation of the average six degrees of tumor prevalence are studied and hypothetically solved. A simple consideration, Petho\u0027s paradox challenges our intuitive understanding of cancer risk and prevalence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38275822"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 298,
          "text": "Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 158,
          "offsetInEndSection": 301,
          "text": "Peto\u0027s paradox refers to the expectation that large, long-lived organisms have a higher lifetime cancer risk, which is not the case: a paradox.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27629030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 694,
          "text": "The frequency of cancer is postulated to be proportional to the number of cells an animal possesses, as each cell is similarly exposed to mutagens with every cell division. Larger animals result from more cell divisions with more mutagenic exposure, and hence are expected to have higher frequencies of cancer. Yet, as stipulated by Peto\u0027s paradox, larger animals do not have the higher rates of cancers seen in smaller animals despite the significant differences in cell numbers and a longer lifetime that would expose larger animals to more mutagens. The rates of cancer appear to be inversely proportional to animal body size, which scales inversely with specific metabolic rates of mammals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Peto\u0027s paradox is the lack of the expected trend in cancer incidence as a function of body size and lifespan across species. The leading hypothesis to explain this pattern is natural selection for differential cancer prevention in larger, longer live",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research. It prompts investigations into how species wi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494584"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 322,
          "text": "cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum. Recognizing that tumour",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 296,
          "text": "cancer risk across species does not increase with the number of somatic cells and the lifespan of the organism. This observation is known as Peto\u0027s paradox. How much would evolution have to change the parameters",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Peto\u0027s paradox is the lack of the expected trend in cancer incidence as a function of body size and lifespan",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Peto\u0027s paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 403,
          "text": "are expected to have higher frequencies of cancer. Yet, as stipulated by Peto\u0027s paradox, larger animals do not have the higher rates of cancers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494584"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 552,
          "text": "Yet, as stipulated by Peto\u0027s paradox, larger animals do not have the higher rates of cancers seen in smaller animals despite the significant differences in cell numbers and a longer lifetime that would expose larger animals to more mutagens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Peto\u0027s paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across different species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913"
        },
        {
          "offsetInBeginSection": 580,
          "offsetInEndSection": 692,
          "text": "Finally, we tested Peto\u0027s paradox, that there is a positive relationship between tumour incidence and body mass.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28252229"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 173,
          "text": " Peto\u0027s paradox stipulates that there is no association between body mass (a surrogate of number of cells and longevity) and cancer prevalence in wildlife species",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22943484"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 332,
          "text": "Accumulation of pro-carcinogenic events throughout life is believed to explain this observation; however, the lack of direct correlation between the number of cells in an organism and cancer incidence, known as Peto\u0027s Paradox, is at odds with this assumption.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30771154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "BACKGROUND: Peto\u0027s paradox stipulates that there is no association between body mass (a surrogate of number of cells and longevity) and cancer prevalence in wildl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22943484"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1117,
          "text": "A major constraint on the evolution of large body sizes in animals is an increased risk of developing cancer. There is no correlation, however, between body size and cancer risk. This lack of correlation is often referred to as \u0027Peto\u0027s Paradox\u0027. Here, we show that the elephant genome encodes 20 copies of the tumor suppressor gene TP53 and that the increase in TP53 copy number occurred coincident with the evolution of large body sizes, the evolution of extreme sensitivity to genotoxic stress, and a hyperactive TP53 signaling pathway in the elephant (Proboscidean) lineage. Furthermore, we show that several of the TP53 retrogenes (TP53RTGs) are transcribed and likely translated. While TP53RTGs do not appear to directly function as transcription factors, they do contribute to the enhanced sensitivity of elephant cells to DNA damage and the induction of apoptosis by regulating activity of the TP53 signaling pathway. These results suggest that an increase in the copy number of TP53 may have played a direct role in the evolution of very large body sizes and the resolution of Peto\u0027s paradox in Proboscideans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27642012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Peto\u0027s paradox is the lack of the expected trend in cancer incidence as a function of body size and lifespan across species",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056357"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Peto\u0027s paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across different species",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "BACKGROUND: Peto\u0027s paradox stipulates that there is no association between body mass (a surrogate of number of cells and longevity) and cancer prevalence in wild",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22943484"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 551,
          "text": "Yet, as stipulated by Peto\u0027s paradox, larger animals do not have the higher rates of cancers seen in smaller animals despite the significant differences in cell numbers and a longer lifetime that would expose larger animals to more mutagens",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056367"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39494584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 288,
          "text": "BACKGROUND: The Peto\u0027s paradox consists in the observation that individuals from long-lived and large animal species do not experience a higher cancer incidence, despite being exposed for longer time to the possibility of accumulating mutations and having more target cells exposed to the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37149260"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 338,
          "text": "Early, scientists realized that the cancer incidence at the species level was not related to the number of cells or lifespan, a phenomenon called Peto\u0027s Paradox.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36534348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Elucidation of tumour suppression mechanisms is a major challenge in cancer biology. Therefore, Peto\u0027s paradox, or low cancer incidence in large animals, has attracted focus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27703689"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 433,
          "text": "mechanisms. Recently the absence of correlation across species between cancer prevalence and body size (coined as Peto\u0027s paradox) has attracted a lot ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499116"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 331,
          "text": "Accumulation of pro-carcinogenic events throughout life is believed to explain this observation; however, the lack of direct correlation between the number of cells in an organism and cancer incidence, known as Peto\u0027s Paradox, is at odds with this assumption",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30771154"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 337,
          "text": "Early, scientists realized that the cancer incidence at the species level was not related to the number of cells or lifespan, a phenomenon called Peto\u0027s Paradox",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36534348"
        },
        {
          "offsetInBeginSection": 898,
          "offsetInEndSection": 1064,
          "text": "resistance. However, Peto\u0027s paradox relies on several questionable assumptions, complicating the interpretation of the divergence between expected and observed cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499116"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "The incidence of developing cancer should increase with the body mass, yet is not the case, a conundrum referred to as Peto\u0027s paradox",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30679716"
        },
        {
          "offsetInBeginSection": 714,
          "offsetInEndSection": 862,
          "text": "These results support Peto\u0027s paradox, in that we find no association between lifespan and/or body mass and the prevalence of neoplasia or malignancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33209304"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "Cancer, a disease intimately linked to cellular mutations, is commonly believed to exhibit a positive association with the cell count and lifespan of a species. Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 748,
          "offsetInEndSection": 1099,
          "text": "Genes showing correlated evolution with body size were mainly involved in immune surveillance, tumor suppression function, and development of hypertumors. The role of these genes in tumor control resolves Peto\u0027s paradox (i.e., the lack of a correspondence between an expansion in body size and, thereby, cell number and an increased cancer incidence).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35077272"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 434,
          "text": "BACKGROUND: Carcinogenesis affects not only humans but almost all metazoan species. Understanding the rules driving the occurrence of cancers in the wild is currently expected to provide crucial insights into identifying how some species may have evolved efficient cancer resistance mechanisms. Recently the absence of correlation across species between cancer prevalence and body size (coined as Peto\u0027s paradox) has attracted a lot o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26499116"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Peto\u0027s paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across different species. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "text": "Cancer is a genetic disease present in all complex multicellular lineages. Finding ways to eliminate it is a goal of a large part of the scientific community and nature itself. Early, scientists realized that the cancer incidence at the species level was not related to the number of cells or lifespan, a phenomenon called Peto\u0027s Paradox.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36534348"
        },
        {
          "offsetInBeginSection": 52,
          "offsetInEndSection": 177,
          "text": "increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across different species",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Cancer, a disease intimately linked to cellular mutations, is commonly believed to exhibit a positive association with the cell count and lifespan of a species. Despite this assumption, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum. R",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38970664"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "Peto\u0027s paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across different species. The Hippo signaling pathway is an evolutionarily conserved system that determines organ size by regulating apoptosis and ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166913"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 389,
          "text": "Using 16,049 necropsy records for 292 species spanning three clades (amphibians, sauropsids and mammals) we found that neoplasia and malignancy prevalence increases with adult weight (contrary to Peto\u0027s Paradox) and somatic mutation rate, but decreases with gestation time",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37461608"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Peto\u0027s paradox and the hallmarks of cancer: constructing an evolutionary framework for understanding the incidence of cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056359"
        }
      ],
      "type": "yesno",
      "id": "67c9e7ee81b1027333000007",
      "ideal_answer": [
        "Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research",
        "Yes, Peto\u0027s Paradox is associated with cancer rates.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates as it highlights the unexpected lack of correlation between body size (and life span) and cancer risk across different species.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates as it highlights the unexpected lack of correlation between body size (and lifespan) and cancer incidence across species.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates as it describes the unexpected lack of correlation between body size, lifespan, and cancer incidence across different species, suggesting that larger animals do not have higher cancer rates despite having more cells.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates, highlighting the lower-than-expected cancer rates in larger and/or longer-lived species.",
        "Peto\u0027s paradox is indeed associated with cancer rates.",
        "Yes, Peto\u0027s paradox highlights the lower-than-expected cancer rates in larger and/or longer-lived species.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates, indicating that larger animals do not have higher cancer rates despite having more cells, and metabolic rates and diet are suggested to influence this relationship by affecting mutagenic rates and tumorigenesis.",
        "Yes, Peto\u0027s paradox is associated with cancer rates.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates as it highlights the unexpected relationship between body size, lifespan, and cancer incidence across different species.",
        "Yes, the observed uniformity in cancer rates across species, referred to as the Peto\u0027s paradox, presents a conundrum",
        "Yes, Peto\u0027s paradox is associated with cancer rates. It highlights the lower-than-expected cancer rates in larger and/or longer-lived species, despite their higher number of cells and longer exposure to potential mutagens.",
        "Peto\u0027s paradox is indeed associated with cancer rates, as it highlights the lower-than-expected cancer rates in larger and/or longer-lived species.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates, but it reveals a counterintuitive lack of direct correlation with body size and lifespan across species, attributed to various underlying biological and evolutionary factors.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates as it highlights the unexpected lack of correlation between body size, lifespan, and observed cancer incidence across species.",
        "Yes, Peto\\\u0027s Paradox is directly associated with cancer rates. It points out that larger and/or longer lived species have unexpectedly low cancer incidence compared to what would be predicted based on their size and lifespan.",
        "Peto\u0027s paradox, which highlights the lower- than-expected cancer rates in larger and/ or longer- lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research.",
        "Yes, the epidemiologic observation of the average six degrees of cancer prevalence is referred to as Peto",
        "Yes. Peto\u0027s Paradox is directly associated with cancer rates, as it highlights the lower-than-expected cancer rates in larger and/or longer-lived species, which is a core observation in its definition.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates, highlighting the observation that larger and longer-lived species do not exhibit proportionally higher cancer incidence despite having more cells over time.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates. It highlights the observed uniformity or lower-than-expected cancer rates in larger and/or longer-lived species, challenging our intuitive understanding of cancer risk.",
        "Yes, Peto\u0027s Paradox highlights the lower-than-expected cancer rates in larger and/or longer-lived species.",
        "Yes, Peto\u0027s paradox is associated with cancer rates. It highlights the lower-than-expected cancer rates in larger and/or longer-lived species, which is a cornerstone of discussions in ecology, evolution, and cancer research.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates as it highlights the lower-than-expected cancer rates in larger and/or longer-lived species, prompting investigations into how these species manage to exhibit cancer resistance despite traits that theoretically increase cancer risk.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates. It highlights the lower-than-expected cancer rates in larger and/or longer-lived species, which is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates. It highlights the observation that larger and longer-lived species do not exhibit the expected increase in cancer rates proportional to their size or lifespan, challenging our understanding of cancer risk and prevalence across different species.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates as it highlights the counterintuitive finding that larger and longer-lived species do not have higher cancer rates than smaller species, despite having more cells and longer exposure to mutagens.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates as it highlights the lower-than-expected cancer rates in larger and/or longer-lived species, which is a significant topic in cancer research.",
        "Yes, Peto\u0027s Paradox is indeed associated with cancer rates across species.",
        "Yes, Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research.",
        "Yes, available evidence suggests that is peto\u0027s paradox associated with cancer rates.",
        "Yes. Peto\u0027s Paradox is associated with cancer rates as it highlights the unexpected relationship between body size, longevity, and cancer incidence across species.",
        "Peto\u0027s Paradox is indeed associated with cancer rates, characterized by the counterintuitive observation of lower-than-expected cancer incidence in larger and/or longer-lived species, challenging traditional understanding of cancer risk and prevalence.",
        "Yes. Peto\u0027s paradox, which highlights the lower-than-expected cancer rates in larger and/or longer-lived species, is a cornerstone of discussions at the intersection of ecology, evolution, and cancer research.",
        "Yes, Peto\u0027s paradox is associated with the observed uniformity in cancer rates across species.",
        "Peto\u0027s paradox is the observation that cancer rates are not higher in larger and longer-lived species than in smaller and shorter-lived species.",
        "[\"Yes, Peto\u0027s Paradox is associated with cancer rates, specifically highlighting the observation that larger and/or longer-lived species have lower-than-expected rates of cancer.\"]",
        "Yes, Peto\u0027s Paradox is directly associated with cancer rates, as it questions and seeks to explain the observed lower-than-expected cancer incidence in larger and/or longer-lived species.",
        "Yes, Peto\u0027s Paradox is associated with cancer rates as it highlights the lower-than-expected cancer prevalence in larger and longer-lived species.",
        "[\"Yes, Peto\u0027s Paradox is associated with cancer rates, specifically highlighting the unexpectedly low cancer rates in larger and longer-lived species.\"]"
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is Clostridioides difficile an aerobe or a anaerobe bacterium?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8432813",
        "http://www.ncbi.nlm.nih.gov/pubmed/29859941",
        "http://www.ncbi.nlm.nih.gov/pubmed/39282548",
        "http://www.ncbi.nlm.nih.gov/pubmed/34933206",
        "http://www.ncbi.nlm.nih.gov/pubmed/29473021",
        "http://www.ncbi.nlm.nih.gov/pubmed/19235151",
        "http://www.ncbi.nlm.nih.gov/pubmed/30297117",
        "http://www.ncbi.nlm.nih.gov/pubmed/36032037",
        "http://www.ncbi.nlm.nih.gov/pubmed/27507338",
        "http://www.ncbi.nlm.nih.gov/pubmed/35182899",
        "http://www.ncbi.nlm.nih.gov/pubmed/34791400",
        "http://www.ncbi.nlm.nih.gov/pubmed/38175477",
        "http://www.ncbi.nlm.nih.gov/pubmed/34837014",
        "http://www.ncbi.nlm.nih.gov/pubmed/37228365",
        "https://www.ncbi.nlm.nih.gov/pubmed/24516694",
        "https://www.ncbi.nlm.nih.gov/pubmed/30297117",
        "https://www.ncbi.nlm.nih.gov/pubmed/35063600",
        "https://www.ncbi.nlm.nih.gov/pubmed/36032037",
        "http://www.ncbi.nlm.nih.gov/pubmed/34016040",
        "http://www.ncbi.nlm.nih.gov/pubmed/33111107",
        "http://www.ncbi.nlm.nih.gov/pubmed/37110267",
        "http://www.ncbi.nlm.nih.gov/pubmed/35890026",
        "http://www.ncbi.nlm.nih.gov/pubmed/37894185",
        "http://www.ncbi.nlm.nih.gov/pubmed/39061289",
        "http://www.ncbi.nlm.nih.gov/pubmed/39717327",
        "http://www.ncbi.nlm.nih.gov/pubmed/39655932",
        "http://www.ncbi.nlm.nih.gov/pubmed/33626138",
        "http://www.ncbi.nlm.nih.gov/pubmed/38175479",
        "http://www.ncbi.nlm.nih.gov/pubmed/32868401",
        "http://www.ncbi.nlm.nih.gov/pubmed/24084491",
        "http://www.ncbi.nlm.nih.gov/pubmed/38399676",
        "http://www.ncbi.nlm.nih.gov/pubmed/34680813",
        "http://www.ncbi.nlm.nih.gov/pubmed/35668452",
        "http://www.ncbi.nlm.nih.gov/pubmed/30714187",
        "http://www.ncbi.nlm.nih.gov/pubmed/39215602",
        "http://www.ncbi.nlm.nih.gov/pubmed/33976336",
        "http://www.ncbi.nlm.nih.gov/pubmed/26231446",
        "http://www.ncbi.nlm.nih.gov/pubmed/32817091",
        "http://www.ncbi.nlm.nih.gov/pubmed/35131507",
        "http://www.ncbi.nlm.nih.gov/pubmed/24814671",
        "http://www.ncbi.nlm.nih.gov/pubmed/37318327",
        "http://www.ncbi.nlm.nih.gov/pubmed/32622285",
        "http://www.ncbi.nlm.nih.gov/pubmed/33181347",
        "http://www.ncbi.nlm.nih.gov/pubmed/39321508",
        "http://www.ncbi.nlm.nih.gov/pubmed/38775144",
        "http://www.ncbi.nlm.nih.gov/pubmed/38552896",
        "http://www.ncbi.nlm.nih.gov/pubmed/23349739",
        "http://www.ncbi.nlm.nih.gov/pubmed/30370502",
        "http://www.ncbi.nlm.nih.gov/pubmed/29578918",
        "http://www.ncbi.nlm.nih.gov/pubmed/28254263",
        "http://www.ncbi.nlm.nih.gov/pubmed/24568651",
        "http://www.ncbi.nlm.nih.gov/pubmed/24400070",
        "http://www.ncbi.nlm.nih.gov/pubmed/30208103",
        "http://www.ncbi.nlm.nih.gov/pubmed/35597553",
        "http://www.ncbi.nlm.nih.gov/pubmed/35840437",
        "http://www.ncbi.nlm.nih.gov/pubmed/39060738",
        "http://www.ncbi.nlm.nih.gov/pubmed/39404502",
        "http://www.ncbi.nlm.nih.gov/pubmed/39294649",
        "http://www.ncbi.nlm.nih.gov/pubmed/31077800",
        "http://www.ncbi.nlm.nih.gov/pubmed/34082120",
        "http://www.ncbi.nlm.nih.gov/pubmed/18023937",
        "http://www.ncbi.nlm.nih.gov/pubmed/38193707",
        "http://www.ncbi.nlm.nih.gov/pubmed/37546803",
        "http://www.ncbi.nlm.nih.gov/pubmed/31548637",
        "http://www.ncbi.nlm.nih.gov/pubmed/20808871",
        "http://www.ncbi.nlm.nih.gov/pubmed/37292962",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625667"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 149,
          "text": "strictly anaerobic bacterium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29859941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Clostridioides difficile (C. difficile) is a Gram-positive, spore-forming anaerobic bacterium emerged as a leading cause of diarrhea globally.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39282548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "As an anaerobe, Clostridioides difficile relies on the formation of a dormant spore for survival outside of the mammalian host\u0027s gastrointestinal tract.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34933206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Clostridioides difficile is a Gram-positive, spore-forming, toxin-producing anaerobe, and an important nosocomial pathogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29473021"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Clostridium difficile is a Gram-positive, spore-forming, anaerobe and is the leading cause of antibiotic-associated diarrhea, pseudomembranous colitis, and toxic megacolon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19235151"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Clostridioides difficile is a spore-forming, anaerobic, intestinal pathogen that causes severe diarrhea that can lead to death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30297117"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Clostridioides difficile (C. difficile) is a Gram-positive, spore-forming, toxin-producing, obligate anaerobic bacterium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36032037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 327,
          "text": "The Gram-positive nosocomial pathogen Clostridium difficile induces sporulation during growth in the gastrointestinal tract. Sporulation is necessary for this obligate anaerobe to form metabolically dormant spores that can resist antibiotic treatment, survive exit from the mammalian host, and transmit C. difficile infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27507338"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Clostridioides difficile is a Gram-positive, spore-forming obligate anaerobe and a major threat to the healthcare system world-wide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35182899"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Clostridioides difficile is a spore-forming, obligate anaerobe, and ubiquitous nosocomial pathogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34791400"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Clostridioides difficile, a Gram-positive spore-forming anaerobic bacterium, has rapidly emerged as the leading cause of nosocomial diarrhoea in hospitals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38175477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 588,
          "text": "Clostridium difficile, an anaerobic toxigenic bacterium, causes a severe infectious colitis that leads to significant morbidity and mortality worldwide. Both enhanced bacterial toxins and diminished host immune response contribute to symptomatic disease. C. difficile has been a well-established pathogen in North America and Europe for decades, but is just emerging in Asia. This article reviews the epidemiology, microbiology, pathophysiology, and clinical management of C. difficile. Prompt recognition of C. difficile is necessary to implement appropriate infection control practices.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/24516694"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 989,
          "text": "Clostridioides difficile (C. difficile) is a Gram-positive, spore-forming, toxin-producing, obligate anaerobic bacterium. C. difficile infection (CDI) is the leading cause of healthcare-associated infective diarrhoea. The infection is mediated by the spore, a metabolically inactive form of C. difficile. The spore coat acts as a physical barrier to defend against chemical insults from hosts and natural environments. The composition of spore coat has already been revealed; therefore, the interactive networks of spore coat proteins and the dynamic process of coat assembly are the keys to design strategies to control and cure CDI. This review gives a brief discussion of the signal processing and transcriptional regulation of C. difficile sporulation initiation. Following the discussion, the spore formation is also introduced. Finally, this review mainly focuses on the spore coat assembly, a poorly understood process in C. difficile, and important proteins that have been studied.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/36032037"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 985,
          "text": "Clostridioides difficile is a spore-forming, anaerobic, intestinal pathogen that causes severe diarrhea that can lead to death. In 2011, C. difficile infected ∼500000 people in the USA and killed ∼29000 people. C. difficile infection (CDI) is the most common healthcare-related infection in the USA, leading to increased healthcare costs of $4.8 billion. This pathogen transmits via the oral-fecal route as a highly contagious and resilient spore. Upon exposure to primary bile acids in the intestine, C. difficile germinates, and in the absence of colonization resistance from the normal microbiota, the bacterium colonizes the colon and produces toxins. These toxins inhibit actin polymerization in host cells, leading to cell death. C. difficile cells can then sporulate in the intestine and exit the body via diarrheal shedding. In culture, sporulation is induced at stationary phase in a nutrient-limiting environment, but the intestinal triggers of sporulation are still unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/30297117"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1286,
          "text": "Clostridioides difficile infection (CDI) continues to affect hospitalized patients and community populations worldwide. In contrast to the substantial resources invested in the diagnosis and prevention of CDI in high-income countries, this anaerobic toxigenic bacterium has been largely overlooked in low-and-middle-income countries (LMICs) such as India, where there remains a paucity of epidemiologic data evaluating the burden of CDI. Extensive multi-institutional studies describing C. difficile epidemiology in India have not yet been performed. Given recent economic growth in many Asian countries, with aging populations, increased access to healthcare and widespread inappropriate use of antimicrobials, C. difficile is likely to be highly prevalent and causing significant disease burden. Greater efforts are required to enhance awareness of this neglected pathogen, through educating healthcare practitioners to test for CDI. There is also an urgent need to strengthen laboratory capacity, and ideally establish a national reference laboratory, to help facilitate a greater understanding of the molecular epidemiology of CDI in India and other LMICs. This mini-review aims to summarize the existing research evaluating the burden of CDI in humans and the environment in India.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/35063600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061289"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Clostridioides difficile is an anaerobic Gram-positive and spore-forming bacterium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35890026"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Clostridioides difficile is an anaerobic spore-forming Gram-positive bacterium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37894185"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Clostridioides difficile is an anaerobic, Gram-positive bacterium widely present in the hospital environment due to its ability to generate spores.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36674344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37110267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Clostridium difficile is a gram-positive, spore-forming anaerobic bacterium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23971935"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "BACKGROUND: Clostridium difficile is an anaerobic, spore-forming and Gram-positive bacillus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27601055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Clostridium difficile is an anaerobic species consisting of bacilli with large, oval, subterminal spores, normally found in intestines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11885130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "Clostridioides difficile is an anaerobic, Gram-positive bacterium widely present in the hospital environment due to its ability to generate spores. The transfer of spores to patients through the hands of medical personnel is one of the most frequent paths of C. difficile transmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36674344"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Clostridium difficile is a spore-forming, toxin-producing, anaerobic bacterium abundant in soils and water.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20597000"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Clostridium difficile has become one of the most common bacterial pathogens in hospital-acquired infections in the United States. Although C. difficile is strictly anaerobic, it survives in aerobic environments and transmits between hosts via spores.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28487371"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Clostridioides difficile is a Gram-positive anaerobe that can cause a spectrum of disorders that range in severity from mild diarrhoea to fulminant colitis and/or death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34837014"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Clostridioides difficile is a gram-positive, spore-forming, obligate anaerobe that infects the colon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37228365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Clostridioides difficile, a spore-forming anaerobe, resides in the intestine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Clostridioides difficile infection (CDI), previously Clostridium difficile infection, is a symptomatic infection of the large intestine caused by the spore-forming anaerobic, gram-positive bacterium Clostridioides difficile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38175479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Clostridioides difficile is a Gram-positive anaerobe that can cause a spectrum of disorders that range in severity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34837014"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 325,
          "text": "Clostridioides difficile is the major pathogen causing diarrhea following antibiotic treatment. It is considered to be a strictly anaerobic bacterium, however, previous studies have shown a certain and strain-dependent oxygen tolerance. In this study, the model strain C. difficile 630Δerm was shifted to micro-aerobiosis and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29859941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Clostridioides difficile, an obligate anaerobic bacterium, causes infections leading to prolonged diarrhea. The bacterium produces dormant spores that can withstand an aerobic environment,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33111107"
        },
        {
          "offsetInBeginSection": 23,
          "offsetInEndSection": 403,
          "text": "Clostridioides difficile, an anaerobic bacillus ubiquitous in nature, is the leading cause of hospital-acquired diarrhoea and one of the main causes of mortality by nosocomial infections. We aimed to identify the main predictors of the risk of dying and the characteristics of a three-year cohort of patients hospitalised in our clinic that eventually had an unfavourable outcome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Clostridioides difficile is a spore-forming anaerobic Gram-positive bacillus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39655932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Clostridioides difficile is an anaerobic Gram-positive bacterium that can produce the large clostridial toxins toxin A and toxin B, encoded within the pathogenicity locus (PaLoc).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that is one of the most common causes of infective diarrhoea worldwide [...].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39061289"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Clostridium difficile is a Gram-positive, anaerobic, sporogenic bacterium that is primarily responsible for antibiotic associated diarrhea (AAD) and is a significant nosocomial pathogen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Clostridioides difficile, an obligate anaerobic bacterium, causes infections leading to prolonged diarrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33111107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Clostridioides difficile is an anaerobic, spore-forming bacterium associated with intestinal infection,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38399676"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "The Gram-positive, anaerobic bacterium Clostridioides difficile (CD) represents the most common cause of nosocomial diarrhea worldwide an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "Clostridioides difficile is the major pathogen causing diarrhea following antibiotic treatment. It is considered to be a strictly anaerobic bacterium, however, previous studies have shown a certain and strain-dependent oxygen tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29859941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Clostridioides difficile (C. difficile) is a gram-positive, spore-forming, anaerobic bacterium known to be the most common cause of hospital-acquired and antibiotic-associated diarrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35668452"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Clostridioides difficile is a spore-forming, Gram-positive, anaerobic pathogen that caused gastrointestinal illness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30714187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Clostridioides difficile (C. difficile) is a spore-forming, toxin-producing, anaerobic bacterium infecting the human gastrointestinal tract, causing diarrhea and life-threatening colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39215602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Clostridioides difficile (C. difficile) is an opportunistic anaerobic bacterium that causes severe diseases of the digestive tract of humans and animals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33976336"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1862,
          "text": "Clostridium difficile is a spore-forming obligate anaerobe that is a leading cause of healthcare-associated infections. C. difficile infections begin when its metabolically dormant spores germinate in the gut of susceptible individuals. Binding of bile salt germinants to the Csp family pseudoprotease CspC triggers a proteolytic signaling cascade consisting of the Csp family protease CspB and the cortex hydrolase SleC. Conserved across many of the Clostridia, Csp proteases are subtilisin-like serine proteases that activate pro-SleC by cleaving off its inhibitory pro-peptide. Active SleC degrades the protective cortex layer, allowing spores to resume metabolism and growth. This signaling pathway, however, is differentially regulated in C. difficile, since CspC functions both as a germinant receptor and regulator of CspB activity. CspB is also produced as a fusion to a catalytically inactive CspA domain that subsequently undergoes interdomain processing during spore formation. In this study, we investigated the role of the CspA pseudoprotease domain in regulating C. difficile spore germination. Mutational analyses revealed that the CspA domain controls CspC germinant receptor levels in mature spores and is required for optimal spore germination, particularly when CspA is fused to the CspB protease. During spore formation, the YabG protease separates these domains, although YabG itself is dispensable for germination. Bioinformatic analyses of Csp family members suggest that the CspC-regulated signaling pathway characterized in C. difficile is conserved in related Peptostreptococcaceae family members but not in the Clostridiaceae or Lachnospiraceae. Our results indicate that pseudoproteases play critical roles in regulating C. difficile spore germination and highlight that diverse mechanisms control spore germination in the Clostridia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26231446"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "The nosocomial pathogen Clostridioides difficile is a spore-forming obligate anaerobe that depends on its aerotolerant spore form to transmit infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32817091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "The Gram-positive, anaerobic bacterium Clostridioides difficile (CD) represents the most common cause of nosocomial diarrhea worldwide and is responsible for increased morbidity and mortality, and prolonged hospital stays [...].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680813"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 687,
          "text": "Some species are obligate aerobes (e.g., Mycobacterium tuberculosis), relying on oxidative phosphorylation for ATP synthesis, whereas others are strict anaerobes (e.g., Clostridioides difficile) relying primarily on substrate-level phosphorylation using various fermentative pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35131507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Clostridioides difficile is a Gram-positive, spore-forming obligate anaerobe and a major threat to the healthcare system world-wide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35182899"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Clostridium difficile is a Gram-positive, spore-forming obligate anaerobe and a major nosocomial pathogen of worldwide concern",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24814671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Clostridioides difficile is a Gram-positive, obligate anaerobic, toxin-producing bacillus that is linked to antibiotic-associated diarrhea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37318327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Clostridioides difficile infection (CDI), previously Clostridium difficile infection, is a symptomatic infection of the large intestine caused by the spore-forming anaerobic, gram-positive bacterium Clostridioides difficile",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38175479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Clostridioides difficile, a Gram-positive spore-forming anaerobic bacterium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38175477"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Clostridioides difficile is a nosocomial, Gram-positive, strictly anaerobic, spore-forming pathogen capable of colonizing and proliferating in the human intestine",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32622285"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "Clostridioides difficile is an obligate anaerobe ubiquitous in the environment and is of particular interest in the healthcare setting as a cause of healthcare associated infection usually presenting with colitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33181347"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 686,
          "text": "Some species are obligate aerobes (e.g., Mycobacterium tuberculosis), relying on oxidative phosphorylation for ATP synthesis, whereas others are strict anaerobes (e.g., Clostridioides difficile) relying primarily on substrate-level phosphorylation using various fermentative pathways",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35131507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Clostridioides difficile (C. difficile) is a spore-forming, toxin-producing, anaerobic bacterium infecting the human gastrointestinal tract, causing diarrhea and life-threatening colitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39215602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Clostridioides difficile (C. difficile) is an opportunistic anaerobic bacterium that causes severe diseases of the digestive tract of humans and animals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33976336"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321508"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "Clostridioides (formerly Clostridium) difficile is a leading cause of infectious diarrhea associated with antibiotic therapy. The ability of this anaerobic pathogen to acquire enough iron to proliferate under iron limitation conditions imposed by the host largely determines its pathogenicity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Functional characterization of Fur from the strict anaerobe Clostridioides difficile provides insight into its redox-driven regulatory capacity.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38775144"
        },
        {
          "offsetInBeginSection": 450,
          "offsetInEndSection": 711,
          "text": "Among anaerobic spore-formers, genomic resources for pathogens including C. botulinum, C. difficile, and C. perfringens enable our capacity to identify common and unique factors that support their persistence in diverse reservoirs and capacity to cause disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38552896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "BACKGROUND: Clostridium difficile are gram-positive, spore forming anaerobic bacteria that are the leading cause of healthcare-associated diarrhea, usually associated with anti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Clostridium difficile is a gram-positive, toxin-producing, anaerobic bacterium whose virulence factors and mechanisms of pathogenesis require further investigation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30370502"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "BACKGROUND: Clostridium difficile infection is caused by the proliferation of a gram-positive anaerobic bacteria after medical or surgical intervention and can result in toxic complications, emergent surger",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29578918"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Clostridium difficile is a Gram-positive, anaerobic spore former, and an important nosocomial pathogenic bacterium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28254263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that can reside as a commensal within the intestinal microbiota of healthy individuals or cause life-threatening antibiotic-associated diarrhea in immunocompr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24568651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24400070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Clostridium difficile is a Gram-positive spore-forming anaerobe and a major cause of antibiotic-associated diarrhoea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30208103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Clostridioides difficile is an anaerobic, Gram-positive pathogen that is responsible for C. difficile infection (CDI",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35597553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Clostridioides difficile is a spore-forming anaerobe microorganism associated to nosocomial diarrhea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35840437"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Clostridioides difficile is a gram-positive, spore-forming, obligate anaerobe that infects the colon. C. difficile is estimated to cause nearly half a million cases in the United States annually, with about 29,000 associated deaths. Unfortunately, th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37228365"
        },
        {
          "offsetInBeginSection": 95,
          "offsetInEndSection": 358,
          "text": "This spore forming, obligate anaerobic, gram-positive bacillus is becoming responsible for an increasing number of infections worldwide, both in community and in hospital settings, whose severity can vary widely from an asymptomatic infection to a lethal disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060738"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Clostridioides difficile is an anaerobic, spore-forming, Gram-positive pathogenic bacterium",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404502"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 128,
          "text": "Clostridioides difficile infection (CDI) is an infectious disease caused by the gram-positive, anaerobic bacterium C",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39294649"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39321508"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Clostridioides difficile (C. difficile) is a spore-forming, toxin-producing, anaerobic bacterium infecting the human gastrointestinal tract, causing diarrhea and life-threate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39215602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Clostridioides difficile is a gram-positive, spore-forming anaerobic bacterium, and the leading cause of antibiotic-associated diarrhea worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34082120"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "PURPOSE: Clostridium difficile is an anaerobic gram positive, spore-forming bacterium which is responsible for 15-25% of antibiotic-associated diarrhea and for more than 95% of pseudomembranous colit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18023937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "BACKGROUND: Clostridium difficile is a gram-positive, anaerobic, spore-forming, rod-shaped bacterium responsible for most of the hospital-acquired diarrhea in develope",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17608247"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 154,
          "text": "lostridioides difficile, a Gram-positive anaerobic bacterium, is the leading cause of hospital-acquired antibiotic-associated diarrhea worldwide. The sev",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38922136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24400070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Clostridium difficile, an anaerobic, spore-forming, gram-positive, rod-shaped bacterium, is the most common nosocomial pathogen causing pseudomembranous colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23667848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that can reside as a commensal within the intestinal microbiota of healthy individuals or cause life-threatening antibiotic-associated diarrhea in immunocompro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24568651"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 207,
          "text": "lostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The det",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36839507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Clostridioides difficile is a Gram-positive, anaerobic bacterium.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31077800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Clostridioides (Clostridium) difficile is a spore-forming anaerobic bacterium that causes severe intestinal diseases in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30533668"
        },
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 437,
          "text": "Clostridioides difficile is anaerobic bacterium which colonizes the mammalian GI tract and is a common cause of acute GI inflammation leading to a variety of negative outcomes. Althou",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37292962"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Clostridioides difficile is a spore-forming, obligate anaerobe, and ubiquitous nosocomial pathogen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34791400"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Clostridium (Clostridioides) difficile is a Gram positive, spore forming anaerobic bacterium that is a leading cause of antibiotic associated diarrhoea in the developed world",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31548637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Clostridium difficile is a Gram-positive, anaerobic, sporogenic bacterium that is primarily responsible for antibiotic associated diarrhea (AAD) and is a significant nosocomial pathogen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084491"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Clostridioides difficile is a spore-forming, anaerobic, intestinal pathogen that causes severe diarrhea that can lead to death",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30297117"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "BACKGROUND: Clostridium difficile is an anaerobic, spore-forming bacterium that is the most common cause of healthcare-associated diarrhea in develop",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20808871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Clostridioides difficile is an environmentally acquired, anaerobic, spore-forming bacterium which ordinarily causes disease following antibiotic-mediated dysbiosis of the intestinal microbiota. Altho",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625667"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "BACKGROUND: Clostridiodes (or Clostridium) difficile is a spore-forming, Gram-positive anaerobic bacterium that may cause symptoms ranging from diarrhea to pseudomembra",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35585826"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Clostridioides difficile is an anaerobic spore-forming Gram-positive bacterium. C. di",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37894185"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "BACKGROUND: Clostridioides difficile is a Gram-positive anaerobic bacterium, which causes Clostridioides difficile inf",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34016040"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium. The c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37110267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Clostridioides difficile is an anaerobic Gram-positive and spore-forming bacterium. The m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35890026"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Clostridioides difficile is a gram-positive, anaerobic, spore-forming bacterium that is responsible for antibiotic-associated pseudomembranous colitis. Clost",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Clostridioides difficile is a Gram-positive, anaerobic, spore-forming bacterium responsible for antibiotic-associated pseudomembranous colitis. Clost",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38193707"
        }
      ],
      "id": "67d71d8f18b1e36f2e00002b",
      "ideal_answer": [
        "Clostridiodes difficile is a strict anaerobe bacterium.",
        "Clostridioides difficile is an obligate anaerobic bacterium.",
        "Clostridioides difficile is an obligate anaerobe bacterium.",
        "Clostridioides difficile is a strict (obligate) anaerobic bacterium.",
        "Clostridioides difficile is a strictly anaerobic bacterium."
      ],
      "exact_answer": [
        [
          "strict anaerobe"
        ]
      ]
    },
    {
      "body": "Please list the benefits of sodium-glucose cotransporter 2 inhibitors",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38776437",
        "http://www.ncbi.nlm.nih.gov/pubmed/39506202",
        "http://www.ncbi.nlm.nih.gov/pubmed/39467963",
        "http://www.ncbi.nlm.nih.gov/pubmed/39404914",
        "http://www.ncbi.nlm.nih.gov/pubmed/39556474",
        "http://www.ncbi.nlm.nih.gov/pubmed/39755334",
        "http://www.ncbi.nlm.nih.gov/pubmed/39747138",
        "http://www.ncbi.nlm.nih.gov/pubmed/29735306",
        "http://www.ncbi.nlm.nih.gov/pubmed/33870930",
        "http://www.ncbi.nlm.nih.gov/pubmed/33336169",
        "http://www.ncbi.nlm.nih.gov/pubmed/31109940",
        "https://www.ncbi.nlm.nih.gov/pubmed/32000955",
        "https://www.ncbi.nlm.nih.gov/pubmed/33042651",
        "https://www.ncbi.nlm.nih.gov/pubmed/34273091",
        "http://www.ncbi.nlm.nih.gov/pubmed/34001339",
        "http://www.ncbi.nlm.nih.gov/pubmed/38488029",
        "http://www.ncbi.nlm.nih.gov/pubmed/31377891",
        "http://www.ncbi.nlm.nih.gov/pubmed/36338417",
        "http://www.ncbi.nlm.nih.gov/pubmed/37346806",
        "http://www.ncbi.nlm.nih.gov/pubmed/31721613",
        "http://www.ncbi.nlm.nih.gov/pubmed/29485012",
        "http://www.ncbi.nlm.nih.gov/pubmed/39730461",
        "http://www.ncbi.nlm.nih.gov/pubmed/39730335",
        "http://www.ncbi.nlm.nih.gov/pubmed/29320602",
        "http://www.ncbi.nlm.nih.gov/pubmed/34273091",
        "http://www.ncbi.nlm.nih.gov/pubmed/36909046",
        "http://www.ncbi.nlm.nih.gov/pubmed/38305141",
        "http://www.ncbi.nlm.nih.gov/pubmed/37161919",
        "http://www.ncbi.nlm.nih.gov/pubmed/39530756",
        "http://www.ncbi.nlm.nih.gov/pubmed/39723481",
        "http://www.ncbi.nlm.nih.gov/pubmed/39719404",
        "http://www.ncbi.nlm.nih.gov/pubmed/39717441",
        "http://www.ncbi.nlm.nih.gov/pubmed/39692694",
        "http://www.ncbi.nlm.nih.gov/pubmed/39691329",
        "http://www.ncbi.nlm.nih.gov/pubmed/34516288",
        "http://www.ncbi.nlm.nih.gov/pubmed/28768320",
        "http://www.ncbi.nlm.nih.gov/pubmed/35999803",
        "http://www.ncbi.nlm.nih.gov/pubmed/31016169",
        "http://www.ncbi.nlm.nih.gov/pubmed/36086785",
        "http://www.ncbi.nlm.nih.gov/pubmed/28102030",
        "http://www.ncbi.nlm.nih.gov/pubmed/26999348",
        "http://www.ncbi.nlm.nih.gov/pubmed/27822054",
        "http://www.ncbi.nlm.nih.gov/pubmed/36606275",
        "http://www.ncbi.nlm.nih.gov/pubmed/22977310",
        "http://www.ncbi.nlm.nih.gov/pubmed/32725160",
        "http://www.ncbi.nlm.nih.gov/pubmed/39697908",
        "http://www.ncbi.nlm.nih.gov/pubmed/39618225",
        "http://www.ncbi.nlm.nih.gov/pubmed/35011882",
        "http://www.ncbi.nlm.nih.gov/pubmed/34150796",
        "http://www.ncbi.nlm.nih.gov/pubmed/32855502",
        "http://www.ncbi.nlm.nih.gov/pubmed/35704166",
        "http://www.ncbi.nlm.nih.gov/pubmed/31426529",
        "http://www.ncbi.nlm.nih.gov/pubmed/39544327",
        "http://www.ncbi.nlm.nih.gov/pubmed/26523120",
        "http://www.ncbi.nlm.nih.gov/pubmed/38888433",
        "http://www.ncbi.nlm.nih.gov/pubmed/38300379",
        "http://www.ncbi.nlm.nih.gov/pubmed/39723311",
        "http://www.ncbi.nlm.nih.gov/pubmed/39691984",
        "http://www.ncbi.nlm.nih.gov/pubmed/39718833",
        "http://www.ncbi.nlm.nih.gov/pubmed/35290593",
        "http://www.ncbi.nlm.nih.gov/pubmed/37482684",
        "http://www.ncbi.nlm.nih.gov/pubmed/25898456",
        "http://www.ncbi.nlm.nih.gov/pubmed/39728750",
        "http://www.ncbi.nlm.nih.gov/pubmed/39673870",
        "http://www.ncbi.nlm.nih.gov/pubmed/39678732",
        "http://www.ncbi.nlm.nih.gov/pubmed/39685874",
        "http://www.ncbi.nlm.nih.gov/pubmed/39714931",
        "http://www.ncbi.nlm.nih.gov/pubmed/39698346",
        "http://www.ncbi.nlm.nih.gov/pubmed/39713268",
        "http://www.ncbi.nlm.nih.gov/pubmed/34685677",
        "http://www.ncbi.nlm.nih.gov/pubmed/34281221",
        "http://www.ncbi.nlm.nih.gov/pubmed/36337862",
        "http://www.ncbi.nlm.nih.gov/pubmed/39129982",
        "http://www.ncbi.nlm.nih.gov/pubmed/38535322",
        "http://www.ncbi.nlm.nih.gov/pubmed/29291819",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404670",
        "http://www.ncbi.nlm.nih.gov/pubmed/34784839",
        "http://www.ncbi.nlm.nih.gov/pubmed/36706745",
        "http://www.ncbi.nlm.nih.gov/pubmed/33970086",
        "http://www.ncbi.nlm.nih.gov/pubmed/37154218",
        "http://www.ncbi.nlm.nih.gov/pubmed/35303888",
        "http://www.ncbi.nlm.nih.gov/pubmed/38881421",
        "http://www.ncbi.nlm.nih.gov/pubmed/36277321",
        "http://www.ncbi.nlm.nih.gov/pubmed/34407822"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1576,
          "offsetInEndSection": 1858,
          "text": "Glucagon antagonism enhances the therapeutic effects of SGLT2 inhibition in type 1 diabetes. Combination therapy improves glycemic control, reduces insulin dosing, and suggests a strategy to unlock the benefits of SGLT2 inhibitors while mitigating the risk of diabetic ketoacidosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38776437"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 228,
          "text": "Sodium-glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39506202"
        },
        {
          "offsetInBeginSection": 1333,
          "offsetInEndSection": 1531,
          "text": "n patients with AMI, treatment with SGLT2i is safe and significantly reduces the risk of hospitalization for HF, but it has no impact on all-cause death and cardiovascular death compared to placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39467963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD),",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404914"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 223,
          "text": " Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39556474"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 182,
          "text": "Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reportedly decreased the new-onset atrial arrhythmias in patients with type-2 diabetes (T2DM) or heart failure (HF). T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39755334"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 256,
          "text": "While sodium glucose cotransporter-2 inhibitors (SGLT2i) show renal benefits in randomized controlled trials (RCTs), ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39747138"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 615,
          "text": "Previous studies with then novel sodium-glucose cotransport-2 (SGLT2) inhibitors demonstrated improvements in several cardiovascular and renal risk factors, including HbA1c, blood pressure, weight, renal hyperfiltration, and albuminuria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29735306"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 627,
          "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/33042651"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 866,
          "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s) responsible for the protective effects are under intensive investigation. This review examines current evidence on the cardiovascular benefits of SGLT2 inhibitors, with a special emphasis on the vascular actions and their potential mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/34273091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 939,
          "text": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for treatment of diabetes, have been shown to possess a favorable metabolic profile and to significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and total mortality, and progression of chronic kidney disease. Although initially considered to be only glucose-lowering agents, the effects of SGLT2i have expanded far beyond that, and their use is now being studied in the treatment of heart failure and chronic kidney disease, even in patients without diabetes. It is therefore critical for cardiologists, diabetologists, nephrologists, and primary care physicians to be familiar with this drug class. This first part of this 2-part review provides an overview of the current understanding of the mechanisms of the cardio-metabolic-renal benefits of SGLT2i. The second part summarizes the recent clinical trials of SGLT2i.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/32000955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34001339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "The sodium-glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin, canagliflozin, and dapagliflozin reduce the risk of heart failure (HF) events in patients with diabetes mellitus (DM) at high risk for HF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34001339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Sodium-glucose co-transport protein 2 (SGLT2) inhibitors, a novel category of oral hypoglycemic agents, offer a promising outlook for individuals experiencing heart failure with reduced ejection fraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730461"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are the only medications that improve clinical outcomes regardless of baseline left ventricular ejection fraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39730335"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 435,
          "text": "Sodium glucose cotransporter 2 inhibitors have additional benefits: weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29320602"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 580,
          "text": "Sodium glucose cotransporter 2 inhibitors have additional benefits: weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. Sodium glucose cotransporter 2 inhibitors have increased risk of urogenital infections and possible risk of \"euglycaemic\" diabetic ketoacidosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29320602"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 472,
          "text": "SGLT2 inhibitors provide multiple benefits, including decreased HbA1c, body weight, and blood pressure. These drugs have received special attention because they decrease the risk of major adverse cardiovascular events and slow progression of diabetic kidney disease (1-3).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31109940"
        },
        {
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1269,
          "text": "xcretion and worsening hyperglycemia. SGLT-2 inhibition should offer potential cardiovascular protection in diabetic patients via attenuating hyperglycemia, blood pressure, body weight, hy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29485012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "INTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are integral in treating patients with heart failure, regardless of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37161919"
        },
        {
          "offsetInBeginSection": 1196,
          "offsetInEndSection": 1311,
          "text": "summary, SGLT2i suggest a treatment in DCM due to their cardiovascular benefits, in preclinical and clinical models",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39530756"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 246,
          "text": "This study compared the risks of atherothrombotic major adverse cardiovascular events in patients with type 2 diabetes taking SGLT2 (sodium-glucose cotransporter 2) inhibitors to those taking DPP-4 (dipeptidyl peptidase-4) inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39719404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717441"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39692694"
        },
        {
          "offsetInBeginSection": 626,
          "offsetInEndSection": 761,
          "text": "SGLT2 inhibitors are a powerful tool for heart failure and may have a potential secondary benefit in ameliorating cardiotoxic processes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39691329"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 303,
          "text": "SGLT2 inhibitors provide multiple benefits, including decreased HbA1c, body weight, and blood pressure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31109940"
        },
        {
          "offsetInBeginSection": 1525,
          "offsetInEndSection": 1930,
          "text": "The benefits of spironolactone in patients with heart failure with either a reduced or a preserved ejection fraction may also be attributable to the actions of the drug to inhibit the sodium-hydrogen exchange mechanism.Conclusions and Relevance: The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28768320"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 419,
          "text": "Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35999803"
        },
        {
          "offsetInBeginSection": 867,
          "offsetInEndSection": 1012,
          "text": "Treatment with SGLT2 inhibitors improves A1C levels, reduces blood pressure and body weight, and is overall well tolerated by patients with T2DM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31016169"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 466,
          "text": "SGLT2 inhibitors provide multiple benefits, including decreased HbA1c, body weight, and blood pressure. These drugs have received special attention because they decrease the risk of major adverse cardiovascular events and slow progression of diabetic kidney disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31109940"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 313,
          "text": "SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36086785"
        },
        {
          "offsetInBeginSection": 488,
          "offsetInEndSection": 760,
          "text": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of oral glucose-lowering agents, are associated with reductions in blood pressure and body weight, in addition to decreasing hyperglycemia, and therefore have the potential to reduce CV risk in patients with T2DM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26999348"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 299,
          "text": "SGLT2-inhibitor therapy is also associated with weight loss and blood pressure (BP) lowering.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822054"
        },
        {
          "offsetInBeginSection": 1637,
          "offsetInEndSection": 1912,
          "text": "Although SGLT2 inhibitors are not indicated as BP-lowering agents, the modest decreases in systolic and diastolic BP observed with SGLT2 inhibitors may provide an extra clinical advantage for the majority of patients with T2DM, in addition to improving blood glucose control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27822054"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "PURPOSE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated glycemic efficacy and cardiovascular and renal benefits in people with type 2 diabetes mellitus (T2DM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725160"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 489,
          "text": "SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34273091"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 581,
          "text": "Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37346806"
        },
        {
          "offsetInBeginSection": 381,
          "offsetInEndSection": 629,
          "text": "In an effort to prevent this, multiple cardiovascular outcome trials have demonstrated the cardiac benefits of sodium‑glucose cotransporter type 2 inhibitors (SGLT2is), hypoglycemic drugs initially designed to treat type 2 diabetes mellitus. SGLT2i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38488029"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 451,
          "text": "Multiple pre-clinical and clinical studies have indicated that SGLT2 inhibitors not only reduce blood glucose but also confer benefits with regard to body weight, insulin resistance, lipid profiles and blood pressure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35011882"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 684,
          "text": "SGLT2is lower glycated hemoglobin (HbA1c) without increasing the risk of hypoglycemia, induce weight loss and improve various metabolic parameters including BP, lipid profile, albuminuria and uric acid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34150796"
        },
        {
          "offsetInBeginSection": 404,
          "offsetInEndSection": 723,
          "text": "Several clinical trials evaluating the sodium-glucose cotransporter type 2 inhibitors (SGLT2i) dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin have shown consistent risk reduction in major adverse cardiovascular events and/or hospitalization for HF, together with lower risk of kidney disease progression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35704166"
        },
        {
          "offsetInBeginSection": 686,
          "offsetInEndSection": 886,
          "text": "Several clinical trials have shown that SGLT2is (empagliflozin, dapagliflozin canagliflozin, and ertugliflozin) improve cardiovascular and renal outcomes and mortality in patients with type 2 diabetes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34150796"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 611,
          "text": "SGLT2i reduce glycated hemoglobin by 0.5%-1.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31426529"
        },
        {
          "offsetInBeginSection": 1004,
          "offsetInEndSection": 1147,
          "text": "hyroid cancer (1.58 [1.36, 2.50]). SGLT2i showed the greatest benefits in reducing the risk of HHF (0.68 [0.64, 0.73]) and improving composite ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723481"
        },
        {
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1680,
          "text": " ratio, 0.64 [95% CI, 0.57-0.72]; P\u003c0.001) compared with DPP-4 inhibitors. SGLT2 inhibitors were independently associated with reduced all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, and incident dialysis (all P values \u003c0.001).CONCLUSIONS: SGLT2 i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39719404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39717441"
        },
        {
          "offsetInBeginSection": 590,
          "offsetInEndSection": 738,
          "text": "SGLT2 inhibitors were associated with a significant reduction in heart failure hospitalization risk (adjusted HR 0.56, 95% CI 0.38-0.82, p \u003d 0.028).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39692694"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 434,
          "text": "Sodium glucose cotransporter 2 inhibitors have additional benefits: weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29320602"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 401,
          "text": "In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, including reduced rehospitalization in patients with heart failure, regardless of the presence of diabetes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36338417"
        },
        {
          "offsetInBeginSection": 1500,
          "offsetInEndSection": 1611,
          "text": "SGLT2 inhibitors significantly advance HFrEF management, reducing cardiovascular mortality and hospitalizations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39544327"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "PURPOSE OF REVIEW: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used antihyperglycemic drugs that show remarkable cardiorenal protective effects in patients with or with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33870930"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 540,
          "text": "Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated with a low risk of hypoglycemia when used either as monotherapy or with other agents not typically associated with increased risk of hypoglycemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26523120"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "In addition to showing antidiabetic effects, sodium-glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36338417"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as pivotal medications for heart failure, demonstrating remarkable cardiovascular benefits extending beyond their glucose-lowering effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38888433"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "In addition to showing antidiabetic effects, sodium-glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36338417"
        },
        {
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1037,
          "text": "SGLT2 inhibitors stand out for their additional cardiovascular and renal benefits, including significant reductions in major adverse cardiovascular events and chronic kidney disease progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39723311"
        },
        {
          "offsetInBeginSection": 638,
          "offsetInEndSection": 784,
          "text": "Findings indicate that sodium-glucose cotransporter-2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39697908"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "AIMS: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to improve cardiovascular outcomes in individuals with heart failure (HF), type 2 diabetes mellitus (T2DM) and chronic kidney disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39691984"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 364,
          "text": "e patients. Evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end-stage kidney disease in both diabetic and non-diabetic kid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39718833"
        },
        {
          "offsetInBeginSection": 743,
          "offsetInEndSection": 1073,
          "text": "gs were considered.RESULTS: SGLT2 inhibitors correct a novel pathophysiological defect, have an insulin-independent action, are efficacious with glycosylated hemoglobin reduction ranging from 0.5% to 1.5%, promote weight loss, have a low incidence of hypoglycemia, complement the action of other antidiabetic agents, and can be us",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977310"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 502,
          "text": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, improve glycemia by suppressing glucose reuptake in the renal proximal tubule. Currently, SGLT2 inhibitors are primarily indicated as antidiabetic agents; however, their benefits extend far beyond glucose control. Cardiovascular outcome trials indicated that all studied SGLT2 inhibitors remarkably and consistently reduce cardiovascular mortality and hospitalization for heart failure (HF) in type 2 diabetes (T2D) patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31721613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 489,
          "text": "Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34273091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 389,
          "text": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (only empagliflozin and dapagliflozin have been investigated in this group so far), and chronic kidney disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35290593"
        },
        {
          "offsetInBeginSection": 535,
          "offsetInEndSection": 1023,
          "text": "SGLT2 inhibitors inhibit the reabsorption of sodium and glucose in the proximal tubule of the kidney and then recovers tubuloglomerular feedback, whereby SGLT2 inhibitors reduce glomerular hyperfiltration. This simple demonstration of their beneficial effects has perplexed experts in seeking more plausible and as yet undisclosed explanations for the whole effects of SGLT2 inhibitors, including metabolism reprogramming and the modulation of hypoxia, inflammation, and oxidative stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37482684"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-directed medical therapy for heart failure with reduced ejection fraction. Recent trials clearly established the efficacy of SGLT2 inhibitors on cardiac remodeling while preventing renal function decline in patients with or without diabetes mellitus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36606275"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 511,
          "text": "Blood pressure reduction during SGLT2 inhibitors use has been proposed through pleiotropic pathways and as a potential contributor that translates to cardiovascular benefits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36606275"
        },
        {
          "offsetInBeginSection": 603,
          "offsetInEndSection": 906,
          "text": "Orchestrating fluid status, modulation of sodium content and renin-angiotensin-activation system, anti-fibrosis and anti-inflammatory effect, ameliorating the characteristics of metabolic syndrome, as well as restoration of circadian rhythm all contributed to the BP lowering effect by SGLT2 inhibitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36606275"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 433,
          "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336169"
        },
        {
          "offsetInBeginSection": 319,
          "offsetInEndSection": 734,
          "text": "Gliflozines induce renal glucosuria by blocking the Na-glucose cotransporter SGLT2, localized in the proximal tubule, and allow a reduction of 0.5 to 1% of glycated hemoglobin. They also diminish proximal sodium reabsorption, and reduce the glomerular hyperfiltration that is often seen in the early stages of diabetes. Preliminary data suggest that they may decrease blood pressure and have renoprotective effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25898456"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36086785"
        },
        {
          "offsetInBeginSection": 148,
          "offsetInEndSection": 384,
          "text": "Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, a class of novel antidiabetic agents, have demonstrated promising therapeutic effects beyond glycemic control, with potential benefits extending to the cardiovascular and renal systems",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39728750"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Sodium-glucose co-transporter 2 (SGLT2) inhibitors, commonly utilized for diabetic nephropathy, have demonstrated benefits beyond glucose control, including organ protection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39673870"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 375,
          "text": "Evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end-stage kidney disease in both diabetic and non-diabetic kidney disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39718833"
        },
        {
          "offsetInBeginSection": 280,
          "offsetInEndSection": 454,
          "text": "Recent guidelines and consensus documents have highlighted the benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure and chronic kidney disease (CKD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39678732"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 150,
          "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) have been shown to reduce risks of clinical events in patients with heart failure (HF)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39685874"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 405,
          "text": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve liver outcomes, emerging as promising agents to treat hepatocellular carcinoma (HCC) in patients with type 2 diabetes mellitus (T2DM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714931"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 155,
          "text": "Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39698346"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 332,
          "text": "Sodium-glucose transporter type 2 inhibitors have shown promise in improving the metabolic profile of women with polycystic ovary syndrome",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39713268"
        },
        {
          "offsetInBeginSection": 661,
          "offsetInEndSection": 880,
          "text": "Two large subsequent trials studying SGLT2 inhibitors in heart failure with reduced ejection fraction (HFrEF) demonstrated a reduction in cardiovascular mortality, HF hospitalizations, and renal-specific adverse events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34516288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 416,
          "text": "When sodium-glucose cotransporter-2 (SGLT2) inhibitors were first introduced a decade ago, no one expected them to have substantial effects beyond their known glucose-lowering effects, until the emergence of evidence of their robust renal and cardiovascular benefits showing that they could attenuate progression of kidney disease, irrespective of diabetes, as well as prevent the development of acute kidney injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37482684"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medication with broad cardiovascular benefits in those with type 2 diabetes, chronic kidney disease, and heart failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34685677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "PURPOSE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important cardiovascular and renal benefits in adults with type 2 diabetes who have or are at high risk of cardiovascular and renal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31377891"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 667,
          "text": "Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin. This class of drugs has the advantages of no clinically relevant hypoglycemia and working in synergy when combined with currently available anti-diabetic drugs. While improving sugar level control in these patients, SGLT2 inhibitors also have the advantages of blood-pressure improvement and bodyweight reduction, with potential cardiac and renal protection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34281221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 388,
          "text": "The efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, and empagliflozin in reducing hyperglycemia in patients with type 2 diabetes is well documented. In addition, positive effects have been observed with these agents on nonglycemic variables, such as reductions in body weight and blood pressure, which may confer additional health benefits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28102030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36337862"
        },
        {
          "offsetInBeginSection": 45,
          "offsetInEndSection": 402,
          "text": "sodium-glucose cotransporter 2 (SGLT2) inhibitors also reduce cardiovascular events in patients with type 2 diabetes mellitus. In major trials of cardiovascular outcomes, SGLT2 inhibitors have been shown to improve cardiovascular and renal outcomes, including reduced rehospitalization in patients with heart failure, regardless of the presence of diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36338417"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have noted benefits in the treatment of type 2 diabetes, cardiovascular disease, heart failure, and chronic kidney disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39129982"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a new class of drugs that have been proven beneficial in the management of diabetes, chronic kidney disease, and heart failure and in the mitigation of cardiovascular risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38535322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Sodium-glucose cotransporter-2 inhibitors have been shown to have significant metabolic, renal, and atherosclerotic cardiovascular disease benefits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38300379"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Sodium-glucose cotransporter 2 inhibitors offer cardiovascular and renal benefits in patients with chronic kidney disease through not yet clearly defined mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33892855"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 230,
          "text": "Extraglycemic benefits of sodium glucose cotransporter 2 inhibition include weight and blood pressure reduction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29291819"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "PURPOSE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated glycemic efficacy and cardiovascular and renal benefits in people with type 2 diabetes mellitu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725160"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 282,
          "text": "mature death. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are increasingly used in nontransplant populations to improve diabetes control and cardiovascular and r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35593882"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 432,
          "text": "Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336169"
        },
        {
          "offsetInBeginSection": 811,
          "offsetInEndSection": 1104,
          "text": "using simple models applying relative effects to baseline risks.DATA SYNTHESIS: Sodium-glucose cotransporter-2 inhibitors reduce hospitalization for heart failure by 37% (95% CI, 25% to 47%) at 6 months, 32% (CI, 20% to 42%) at 1 year, and 26% (CI, 10% to 40%) at 2 years (all high certainty) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404670"
        },
        {
          "offsetInBeginSection": 669,
          "offsetInEndSection": 890,
          "text": "Moreover, in patient with heart failure with reduced ejection fraction, regardless of the presence or absence of T2D, SGLT2 inhibitors use significantly reduced the risk of worsening heart failure and death from CV causes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34784839"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 342,
          "text": "Beyond their glycemic control properties, SGLT2 inhibitors have demonstrated significant cardiovascular benefits, including reductions in major adverse cardiovascular events",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39618225"
        },
        {
          "offsetInBeginSection": 498,
          "offsetInEndSection": 667,
          "text": "The results of 7 CVOTs have provided solid evidence that the use of SGLT2 in patients with T2D and at high CV risk significantly reduced the risk of death from CV causes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34784839"
        },
        {
          "offsetInBeginSection": 1147,
          "offsetInEndSection": 1453,
          "text": "idney disease (ESKD). SGLT2 inhibitors are also effective in reducing the need for heart failure hospitalizations and the risk of serious cardiac adverse events, including cardiovascular and all-cause mortality, in patients with reduced or preserved left ventricular (LV) ejection fraction and in acute or ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38305141"
        },
        {
          "offsetInBeginSection": 453,
          "offsetInEndSection": 626,
          "text": "Importantly, SGLT2 inhibitors are generally safe and well tolerated, with clinical trials and real-world analyses demonstrating a decrease in the risk of acute kidney injury",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36706745"
        },
        {
          "offsetInBeginSection": 628,
          "offsetInEndSection": 829,
          "text": "The kidney protective effects of SGLT2 inhibitors generally extend across different members of the class, possibly on the basis of hemodynamic, metabolic, anti-inflammatory, and antifibrotic mechanisms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36706745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "text": "BACKGROUND: The renal benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2) are now well established, and these agents are recommended by the American Diabetes Association and Kidney Disease: Improving Global Outcomes guidelines for patients with type 2 diabetes and chronic ki",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33970086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-directed medical therapy for heart failure with reduced ejection fraction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36606275"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 312,
          "text": "As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36086785"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of their glucose-lo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37154218"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35303888"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed for type 2 diabetes (T2D) treatment, have demonstrated significant cardiovascular and renal benefits in heart failure (HF) and chronic kidney disease (CKD), irrespective of T2D",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38881421"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Sodium-glucose cotransporter (SGLT) 2 inhibitors, or gliflozins, have quickly risen to prominence within the cardiovascular field due to their substantial benefit in the management of heart failure with reduced ejection fraction (HFrEF",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36277321"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 723,
          "text": "SGLT2i demonstrates large cardiovascular benefits in patients both with and without diabetes, as well as in existing heart failure patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36909046"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34407822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "PURPOSE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated glycemic efficacy and cardiovascular and renal benefits in people with type 2 diabetes mellit",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725160"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "BACKGROUND: Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased card",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34407822"
        }
      ],
      "type": "list",
      "id": "67cdb26a81b1027333000017",
      "ideal_answer": [
        "Sodium-glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss.",
        "Sodium glucose cotransporter 2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure.",
        "Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used antihyperglycemic drugs that show remarkable cardiorenal protective effects in patients with or without type 2 diabetes.",
        "Sodium-glucose cotransporter 2 inhibitors can be weight loss, blood pressure reduction, cardiovascular risk reduction, renoprotective effects, and improved glycemic control.",
        "The benefits of sodium-glucose cotransporter 2 inhibitors include renoprotective effects, cardiovascular risk reduction, weight loss, blood pressure reduction, and decreased HbA1c.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycemic control, weight loss, reduction in cardiovascular risk, prevention of renal damage, reduction in the onset of chronic kidney disease, reduction in major adverse cardiovascular events (MACE), and antifibrotic effects due to correction of inflammation and oxidative stress.",
        "The benefits of sodium-glucose cotransporter 2 inhibitors include blood pressure reduction, cardiovascular risk reduction, renoprotective effects, weight loss, improved glycemic control, decreased HbA1c, improved blood glucose control, and slower progression of kidney disease.",
        "Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used in the treatment of type 2 diabetes. They have been shown to reduce the risk of cardiovascular death, heart failure hospitalization, renal complications, and macrovascular events in patients with type 2 diabetes mellitus.\nSGLT2 inhibitors also improve glycemic profile in addition to lipid profile.",
        "Sodium-glucose cotransporter 2 inhibitors provide multiple benefits, including decreased HbA1c, body weight reduction, lowered blood pressure, reduced risk of major adverse cardiovascular events, and slowed progression of diabetic kidney disease.",
        "SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations and renal benefits, including significant reductions in major adverse cardiovascular events and chronic kidney disease progression.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: 1. Reduction in the risk of kidney disease progression. 2. Decrease in the risk of acute kidney injury. 3. Lower risk of cardiovascular death or hospitalization for heart failure. 4. Improvement in glycemic control in patients with type 2 diabetes. 5. Reduction in body weight. 6. Decrease in blood pressure. 7. Potential reduction in the risk of atrial fibrillation. 8. Renoprotection in patients with chronic kidney disease. 9. Favorable metabolic profile beyond glucose control. 10. Reduction in serum uric acid levels, potentially lowering gout risk.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: 1. Lowering blood glucose levels through renal glucose excretion, 2. Reducing the risk of cardiorenal events in individuals with type 2 diabetes and chronic kidney disease, 3. Providing cardiovascular benefits in heart failure patients, 4. Slowing the progression of chronic kidney disease, 5. Reducing weight and blood pressure, 6. Preventing renal damage and onset of chronic kidney disease, 7. Reducing the risk of atrial fibrillation, 8. Improving β-cell function and insulin sensitivity, 9. Offering metabolic benefits beyond glucose regulation.",
        "Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide several benefits including weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. They have shown significant metabolic, renal, and cardiovascular benefits, particularly in patients with type 2 diabetes, heart failure, and chronic kidney disease.",
        "helps manage type 2 diabetes, promotes weight loss, lowers blood pressure, reduces risk of cardiovascular events, reduces blood glucose levels",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycemic control, increased urinary excretion of glucose, weight loss, reduction in cardiovascular mortality, renal protection, reduction in the risk of heart failure, prevention of chronic kidney disease, and potential antifibrotic effects.",
        "SGLT-2 inhibitors offer benefits like improved blood glucose control, weight loss, lower blood pressure, reduced cardiovascular risk, and kidney protection.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycaemic control, reductions in body mass, lower blood pressure, reduced risk of hospitalization for heart failure, decreased cardiovascular death, prevention of chronic kidney disease progression, and favorable metabolic effects.",
        "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a class of oral hypoglycemic agents that have been shown to have multiple benefits, including decreased HbA1c, body weight, and blood pressure. These drugs have received special attention because they decrease the risk of major adverse cardiovascular events and slow progression of diabetic kidney disease.",
        "Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide several benefits including improved glycemic control, weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. They have shown substantial effects beyond glucose-lowering, such as attenuating the progression of kidney disease, preventing acute kidney injury, and providing cardiovascular benefits in patients with type 2 diabetes, heart failure, and chronic kidney disease.",
        "The benefits of sodium-glucose cotransporter 2 inhibitors include reduced cardiovascular events, slowed diabetic kidney disease progression, improved renal outcomes in chronic kidney disease, decreased HbA1c, weight loss, and lowered blood pressure, offering a multifaceted approach to managing type 2 diabetes and its complications.",
        "Sodium-glucose cotransporter 2 inhibitors provide benefits such as cardiovascular risk reduction, renoprotective effects, weight loss, improved blood glucose control, slower progression of kidney disease, and decreased HbA1c.",
        "Sodium- glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. They are also approved for the treatment of heart failure.",
        "Sodium-glucose cotransporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. They are also approved for the treatment of heart failure.",
        "Sodium-glucose cotransporter 2 inhibitors can be weight loss, cardiovascular benefits, kidney benefits, glycaemic control, and reduced hospitalization for HF.",
        "SGLT2 inhibitors offer a range of benefits including improved glycemic control, reduced insulin dosing, enhanced cardiovascular outcomes (such as fewer hospitalizations for heart failure, improved outcomes in HF with LVEF \u003e40%, and decreased new-onset atrial arrhythmias), renal protection, and weight loss.",
        "Sodium-glucose cotransporter 2 inhibitors provide cardiovascular benefits, kidney and renal benefits, promote weight loss, and improve cardiovascular outcomes.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycemic control, cardiovascular benefits, kidney protection, weight loss, reduction of insulin resistance, preservation of pancreatic β-cell function, decreased risk of hospitalization for heart failure, prevention of new-onset atrial arrhythmias, and potential positive effects on non-alcoholic fatty liver disease (NAFLD).",
        "The benefits of sodium-glucose cotransporter 2 inhibitors include weight loss, cardiovascular outcomes, renal benefits, cardiovascular benefits, kidney benefits, improved glycemic control, reduced risk of hospitalization for HF, and cardiovascular outcome improvement.",
        "SGLT2 inhibitors improve glycemic control, enhance cardiovascular outcomes (reducing hospitalization for heart failure and new-onset atrial arrhythmias), offer kidney benefits in patients with chronic kidney disease and heart failure, and promote weight loss.",
        "Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used for treatment of diabetes mellitus and heart failure",
        "Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer several benefits including improved glycemic control, cardiovascular outcomes, weight loss, and reduced risk of hospitalization for heart failure. They also provide kidney benefits and decrease the new-onset atrial arrhythmias in patients with type-2 diabetes or heart failure.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycemic control, cardiovascular benefits, renal protection, weight loss, reduced hospitalization for heart failure, and decreased insulin dosing in type 1 diabetes. They also promote treatment acceptability and satisfaction, and have shown potential cost-effectiveness in managing chronic kidney disease.",
        "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD). They improve glycemic control, reduce insulin dosing, and promote weight loss. Additionally, they are safe and significantly reduce the risk of hospitalization for heart failure (HF) in patients with acute myocardial infarction (AMI).",
        "Sodium-glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. They are also approved for the treatment of heart failure.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycemic control, cardiovascular benefits, renal protection, weight loss, reduced hospitalization for heart failure, decreased risk of new-onset atrial arrhythmias, and potential treatment for hypomagnesemia.",
        "SGLT2i improves renal function in T2DM patients, reducing the risk of cardiovascular events such as HF and AMI. Additionally, SGLT2i has been shown to lower the risk of death in T2DM patients with or without established cardiovascular disease.",
        "The benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) include: improved glycemic control, cardiovascular benefits, kidney protection, weight loss, reduced risk of hospitalization for heart failure, decreased new-onset atrial arrhythmias, and potential favorable effects on NAFLD incidence and progression.",
        "Sodium-glucose cotransporter 2 inhibitors offer benefits like better blood sugar control, cardiovascular health improvements, weight loss, reduced heart failure hospitalizations, kidney protection, and improved outcomes in certain heart failure cases.",
        "The benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors include: improved glycemic control, cardiovascular benefits, renal protection, weight loss, reduction in hospitalization for heart failure, decreased risk of new-onset atrial arrhythmias, and improved metabolic profiles.",
        "Sodium-glucose cotransporter 2 inhibitors (SGLT2is) improve glycemic control, reduce insulin dosing, enhance cardiovascular outcomes, promote weight loss, reduce the risk of hospitalization for heart failure (HF), provide cardiovascular and kidney benefits, improve clinical outcomes for patients with HF and a left ventricular ejection fraction greater than 40%, and decrease new-onset atrial arrhythmias.",
        "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. SGLT2i show renal benefits in randomized controlled trials (RCTs), and decrease the new- on set atrial arrhythmias in patients with type-2 diabetes (T2DM) or heart failure (HF).",
        "[\u0027Sodium-glucose cotransporter 2 inhibitors (SGLT2is) offer several benefits including improved glycemic control, cardiovascular outcomes, weight loss, reduction in hospitalization for heart failure (HF), kidney benefits, and decreased incidence of new-onset atrial arrhythmias in patients with type 2 diabetes or heart failure.\u0027]",
        "SGLT2 inhibitors offer multiple benefits, including improved glycemic control and weight loss in type 2 diabetes, enhanced cardiovascular outcomes, reduced heart failure hospitalizations, improved outcomes for heart failure patients with LVEF \u003e 40%, decreased new-onset atrial arrhythmias, and renal benefits.",
        "Sodium-glucose cotransporter 2 inhibitors provide cardiovascular benefits, kidney benefits, renal benefits, and promote weight loss.",
        "[\u0027The benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) include improving glycemic control, reducing insulin dosing, promoting weight loss, reducing hospitalization for heart failure, providing cardiovascular benefits, providing kidney benefits, and decreasing new-onset atrial arrhythmias.\u0027]"
      ],
      "exact_answer": [
        [
          "reduce hospitalization"
        ],
        [
          "weight loss"
        ],
        [
          "improve gycemic control"
        ],
        [
          "improve renal outcome"
        ],
        [
          "improve cardiovascular outcome"
        ],
        [
          "improved blood pressure"
        ]
      ]
    },
    {
      "body": "Bacteria that most commonly causes urinary tract infection.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37052881",
        "http://www.ncbi.nlm.nih.gov/pubmed/38921024",
        "http://www.ncbi.nlm.nih.gov/pubmed/12601338",
        "http://www.ncbi.nlm.nih.gov/pubmed/12113867",
        "http://www.ncbi.nlm.nih.gov/pubmed/20514772",
        "http://www.ncbi.nlm.nih.gov/pubmed/14676879",
        "http://www.ncbi.nlm.nih.gov/pubmed/38591882",
        "http://www.ncbi.nlm.nih.gov/pubmed/31525541",
        "http://www.ncbi.nlm.nih.gov/pubmed/18200417",
        "http://www.ncbi.nlm.nih.gov/pubmed/39715044",
        "http://www.ncbi.nlm.nih.gov/pubmed/8219486",
        "http://www.ncbi.nlm.nih.gov/pubmed/28473396",
        "http://www.ncbi.nlm.nih.gov/pubmed/9332263",
        "http://www.ncbi.nlm.nih.gov/pubmed/31172909",
        "http://www.ncbi.nlm.nih.gov/pubmed/14871399",
        "http://www.ncbi.nlm.nih.gov/pubmed/29511075",
        "http://www.ncbi.nlm.nih.gov/pubmed/6377440",
        "http://www.ncbi.nlm.nih.gov/pubmed/12848470",
        "http://www.ncbi.nlm.nih.gov/pubmed/20647992",
        "http://www.ncbi.nlm.nih.gov/pubmed/37581436",
        "http://www.ncbi.nlm.nih.gov/pubmed/9742370",
        "http://www.ncbi.nlm.nih.gov/pubmed/1996032",
        "http://www.ncbi.nlm.nih.gov/pubmed/21617646",
        "http://www.ncbi.nlm.nih.gov/pubmed/8754285",
        "http://www.ncbi.nlm.nih.gov/pubmed/39251839",
        "http://www.ncbi.nlm.nih.gov/pubmed/18703368",
        "http://www.ncbi.nlm.nih.gov/pubmed/27465958",
        "http://www.ncbi.nlm.nih.gov/pubmed/27177113",
        "http://www.ncbi.nlm.nih.gov/pubmed/35740174",
        "http://www.ncbi.nlm.nih.gov/pubmed/21499969",
        "http://www.ncbi.nlm.nih.gov/pubmed/32823350",
        "http://www.ncbi.nlm.nih.gov/pubmed/39702066",
        "http://www.ncbi.nlm.nih.gov/pubmed/39568993",
        "http://www.ncbi.nlm.nih.gov/pubmed/23962019",
        "http://www.ncbi.nlm.nih.gov/pubmed/27134870",
        "http://www.ncbi.nlm.nih.gov/pubmed/1998185",
        "http://www.ncbi.nlm.nih.gov/pubmed/16100859",
        "http://www.ncbi.nlm.nih.gov/pubmed/16854352",
        "http://www.ncbi.nlm.nih.gov/pubmed/35862950",
        "http://www.ncbi.nlm.nih.gov/pubmed/9167654",
        "http://www.ncbi.nlm.nih.gov/pubmed/39704031",
        "http://www.ncbi.nlm.nih.gov/pubmed/22629135",
        "http://www.ncbi.nlm.nih.gov/pubmed/18092884",
        "http://www.ncbi.nlm.nih.gov/pubmed/39725072",
        "http://www.ncbi.nlm.nih.gov/pubmed/11442991",
        "http://www.ncbi.nlm.nih.gov/pubmed/23030816",
        "http://www.ncbi.nlm.nih.gov/pubmed/38280678",
        "http://www.ncbi.nlm.nih.gov/pubmed/15364302",
        "http://www.ncbi.nlm.nih.gov/pubmed/18336452",
        "http://www.ncbi.nlm.nih.gov/pubmed/37880099",
        "http://www.ncbi.nlm.nih.gov/pubmed/17925449",
        "http://www.ncbi.nlm.nih.gov/pubmed/22318320",
        "http://www.ncbi.nlm.nih.gov/pubmed/12201883",
        "http://www.ncbi.nlm.nih.gov/pubmed/26657128",
        "http://www.ncbi.nlm.nih.gov/pubmed/26767386",
        "http://www.ncbi.nlm.nih.gov/pubmed/27244961",
        "http://www.ncbi.nlm.nih.gov/pubmed/25316131",
        "http://www.ncbi.nlm.nih.gov/pubmed/37124864",
        "http://www.ncbi.nlm.nih.gov/pubmed/16898513",
        "http://www.ncbi.nlm.nih.gov/pubmed/21807904",
        "http://www.ncbi.nlm.nih.gov/pubmed/31218955"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 1010,
          "offsetInEndSection": 1134,
          "text": "Escherichia coli was the most identified uropathogen (60.4%) followed by Klebsiella spp. (8.7%) and Enterococcus spp. (7.7%)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37052881"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Uropathogenic Escherichia coli (UPEC) is the main cause of urinary tract infections",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38921024"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 286,
          "text": "Escherichia coli remains the predominant uropathogen (80%) isolated in acute community-acquired uncomplicated infections, followed by Staphylococcus saprophyticus (10% to 15%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12601338"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 286,
          "text": "Escherichia coli remains the predominant uropathogen (80%) isolated in acute community-acquired uncomplicated infections, followed by Staphylococcus saprophyticus (10% to 15%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12113867"
        },
        {
          "offsetInBeginSection": 837,
          "offsetInEndSection": 1092,
          "text": "d in 8.70% of cases. Escherichia coli was the most common cause of urinary tract infection (62.88%), the second most common was Klebsiella (23.080/%), followed by Proteus mirabilis (7.02%), Citrobacter(5.35%), Staphylococcus saprophyticus (1.34%) and Cand",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Extraintestinal pathogenic Escherichia coli (ExPEC) is a leading cause of worldwide morbidity and mortality, the top cause of antimicrobial-resistant (AMR) infections, and the most frequent cause of life-threatening sepsis and urinary tract infections (UTI) in adults. The d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38591882"
        },
        {
          "offsetInBeginSection": 1263,
          "offsetInEndSection": 1372,
          "text": "The most frequent causes of urinary tract infections are still Escherichia coli and other enterobacteriaceae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3515774"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Most urinary tract infections are caused by Enterobacteriaceae; E. coli-strains dominating in 50 to 80% of primary infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9471845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Escherichia coli is the most common bacterium causing urinary tract infections in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28473396"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 677,
          "text": "Escherichia coli (E coli) is the most common cause of uncomplicated UTI, whereas antibiotic-resistant Enterobacteriaceae, enterococci, and Candida species often are the causes of complicated UTI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9332263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Urinary tract infections (UTIs) cause a substantial health care burden. UTIs (i) are most often caused by uropathogenic Escherichia coli (UPEC), (ii) primarily affect otherwise healthy females (50% of women will have a UTI), (iii) are associated with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31172909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Uropathogenic Escherichia coli (UPEC) strains cause most uncomplicated urinary tract infections (UTIs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29511075"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 207,
          "text": "Uropathogenic Escherichia coli are the most common cause of urinary tract infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14871399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Staphylococcus saprophyticus as a common cause of urinary tract infections.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6377440"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 315,
          "text": "Type 1 fimbriated E. coli have been associated with cystitis, and P fimbriated E. coli with pyelonephritis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14871399"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 550,
          "text": "Uncomplicated infections affect otherwise healthy individuals and are most commonly caused by uropathogenic Escherichia coli, whereas complicated infections affect patients with underlying difficulties, such as a urinary tract abnormality or catheterization, and are commonly caused by species such as Proteus mirabilis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20647992"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Bacteria that commonly cause infections of the normal urinary tract (eg Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus) do so because they possess specific urovirulence factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8219486"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 300,
          "text": "E. coli is the most common bacterium to cause UTIs, and is usually susceptible to oral antibiotics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9742370"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Most of the information available concerning virulence factors of uropathogens is based on studies of Escherichia coli, the commonest cause of urinary tract infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1996032"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 149,
          "text": "They are most often caused by uropathogenic Escherichia coli.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21617646"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 681,
          "text": "Escherichia coli was the most commonly isolated bacteria (62.4%), followed by Klebsiella pneumoniae (6.8%) and Proteus mirabilis (4.7%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18200417"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 556,
          "text": "Escherichia coli was the commonest organism (50.11%) followed by Klebsiella spp. (28.33%) Pseudomonas spp. (7.84%) and Proteus spp. (4.91%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8754285"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 427,
          "text": "The most common bacterium implicated in UTI is uropathogenic Escherichia coli, but diverse pathogens including Klebsiella, Enterococcus, Pseudomonas, Staphylococcus and even yeast such as Candida species can also cause UTIs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39251839"
        },
        {
          "offsetInBeginSection": 344,
          "offsetInEndSection": 606,
          "text": "Studies have shown that Escherichia coli is the most common bacterium for urinary tract infection (UTI), and recurrent UTI has been confirmed to be a risk factor for the development and progression of autoimmune liver diseases and is closely associated with PBC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27465958"
        },
        {
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1051,
          "text": ". Escherichia coli (70.1%) was the most frequent uropathogen, followed by Klebsiella pneumoniae (8.9%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35740174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Urinary tract infections (UTI) are less common in men than in women, and uropathogenic Escherichia coli (UPEC) is the most frequent etiological agent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21499969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Klebsiella aerogenes is an opportunistic nosocomial bacterial pathogen that commonly causes urinary tract infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39568993"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 442,
          "text": "E. coli remains the leading cause of UTIs, with recent investigations reporting the emergence of E. coli as the predominant cause of nosocomial and neonatal sepsis infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23962019"
        },
        {
          "offsetInBeginSection": 778,
          "offsetInEndSection": 857,
          "text": "The most commonly isolated pathogen in cases of UTI and SB is Escherichia coli.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32823350"
        },
        {
          "offsetInBeginSection": 937,
          "offsetInEndSection": 1027,
          "text": "The majority of community-acquired symptomatic UTIs in elderly women are caused by E coli.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12113867"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 456,
          "text": " and Proteus. However, E. coli accounts for the major cause of Urinary tract infections (UTIs) and accounts for 75% to 90% o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27134870"
        },
        {
          "offsetInBeginSection": 246,
          "offsetInEndSection": 357,
          "text": "Escherichia coli is the main etiologic agent, causing urinary tract infection in approximately 80% of the cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1998185"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 474,
          "text": "Escherichia coli is the leading cause of urinary tract infections, followed by Staphylococcus saprophyticus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16100859"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 448,
          "text": "Escherichia coli causes 80-85% of acute episodes of uncomplicated cystitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16854352"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Escherichia coli is responsible for more than 80% of all incidences of urinary tract infections (UTIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35862950"
        },
        {
          "offsetInBeginSection": 411,
          "offsetInEndSection": 566,
          "text": "The etiologic organisms implicated in UTIs have not changed dramatically over the past two decades, with E. coli still accounting for the majority of cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9167654"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "OBJECTIVE: Escherichia coli is isolated in most of uncomplicated community-acquired urinary tract infections (UTI) and fosfomycin is one of the treatments",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39704031"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 283,
          "text": "Escherichia coli remains the predominant uropathogen (80%) isolated in acute community-acquired uncomplicated infections, followed by Staphylococcus saprophyticus (10% to 15",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12113867"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 283,
          "text": "Escherichia coli remains the predominant uropathogen (80%) isolated in acute community-acquired uncomplicated infections, followed by Staphylococcus saprophyticus (10% to 15",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12601338"
        },
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 292,
          "text": "are settings. A wide variety of bacteria are responsible for causing UTIs, however extra-intestinal pathogenic E. coli or ExPEC) remains the most common eti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27177113"
        },
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 260,
          "text": "Escherichia coli is the most common UTI pathogen although underlying host factors such as patients\u0027 age and gender may influence prevalence of causative agents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22629135"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "BACKGROUND: Urinary tract infections (UTIs) are one of the most common bacterial infections and are predominantly caused by uropathogenic Escherichi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18092884"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "The microbial etiology of urinary infections has been regarded as well established and reasonably consistent. Escherichia coli remains the predominant uropathogen (80%) isolated in acute community-acquired uncomplicated infections, followed by Staphy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12113867"
        },
        {
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1676,
          "text": "inary tract infection (UTI). Forty were culture-positive out of 103 urine specimens tested, where, Escherichia coli (60%) was the most frequently isolated bacteria followed by Klebsiella pneumonia (20%), Enterobacter spp, (12.5%), a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39702066"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "The incidence of urinary tract infection (UTI) caused by extensive beta-lactamase-producing Escherichia coli (ESBL-EC) is increasing, including in children.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39725072"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "IMPORTANCE: Enterococcus faecalis urinary tract infection (UTI) is common in postmenopausal females and these bacteria create biofilms that may reduce treatme",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39715044"
        },
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 457,
          "text": "In young women, S. saprophyticus is, after Escherichia coli, the second-most-frequent causative agent of acute UTI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6377440"
        },
        {
          "offsetInBeginSection": 479,
          "offsetInEndSection": 670,
          "text": "The predominant pathogen in both complicated and uncomplicated UTI remains pathogenic Escherichia coli, although Klebsiella sp. and Proteus appear with increased frequency in complicated UTI.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11442991"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Until the last decade, coagulase-negative staphylococci occurring in urine specimens were usually regarded as a contaminant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6377440"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "The most frequent and best-studied agent of urinary tract infection (UTI) is Escherichia coli, which serves as a useful model pathogen for understanding microbial virulence in relation to UTI pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12848470"
        },
        {
          "offsetInBeginSection": 908,
          "offsetInEndSection": 1085,
          "text": "The most common pathogens were E. coli (57.0%), Enterococcus faecalis (6.5%), K. pneumoniae (5.9%), group B streptococci (5.7%), P. mirabilis (3.0%) and S. saprophyticus (1.8%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030816"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Urinary tract infections (UTIs) are a serious public health problem. They can be caused by a number of pathogens, but the most common are Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis and Staphylococcus saprophyticus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38280678"
        },
        {
          "offsetInBeginSection": 780,
          "offsetInEndSection": 976,
          "text": "ere Gram-negative bacteria. Among these, Escherichia coli (E. coli) was the most common (49.1%) followed by Klebsiella pneumoniae (9.5%), Proteus mirabilis (2.9%), Pseudomonas aeruginosa (1.7%), a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31525541"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Escherichia coli accounted for about 80% of organisms in uncomplicated urinary tract infections (UTIs), followed by Staphylococcus spp. especially Staphylococcus saprophyticus, and Proteus mirabilis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15364302"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 413,
          "text": "The majority of UTIs examined were caused by Escherichia coli (35.15%), followed by miscellaneous bacteria (23.03%), and by Enterococcus faecalis (19.39%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18336452"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 507,
          "text": "E. coli-bacteria are up to now the most frequent pathogens of urinary tract infections, with a resistance rate of 30% against aminopenicillins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1810091"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Background and Objectives: Urinary tract infections are one of the most commonly associated human infectious diseases caused by the bacteria Escherichia coli. Escherichia coli is described as h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37124864"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 378,
          "text": "Among bacteria, Enterococcus species constitute a common causative pathogen of urinary tract infections (UTIs), especially among hospitalized patients with or without urinary tract carcinoma, related commonly to urinary tract abnormalities, urinary catheters or prolonged antibiotic treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31786836"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Urinary tract infections (UTIs) are quite common and mainly caused by bacteria such as Escherichia coli. Howeve",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34682265"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 365,
          "text": "Urinary Tract Infection (UTI), caused by E. coli bacteria, is a very common bacterial infection, a majority in women (85%) and may result in severe kidney failure if not detected quickly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15750790"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Urinary tract infections (UTIs) are one of the most common infections. Uropathogenic Escherichia coli (UPEC) is the most common causative organism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37880099"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Uropathogenic Escherichia coli (UPEC) cause most uncomplicated urinary tract infections (UTIs) in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17925449"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 263,
          "text": " in humans. Uropathogenic Escherichia coli (UPEC) strains are the leading cause of urinary tract infections (UTIs) and are responsible for greater than 80% of uncomplicated case",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22318320"
        },
        {
          "offsetInBeginSection": 975,
          "offsetInEndSection": 1065,
          "text": "Escherichia coli, coliforms and enterococci are considered common bacterial causes of UTIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12201883"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 290,
          "text": "Escherichia coli is the most common causative agent in all groups of patients. Staphylococcus saprophyticus is now recognized as a common cause of urinary tract infection in adolescents and young adult women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14676879"
        },
        {
          "offsetInBeginSection": 1023,
          "offsetInEndSection": 1098,
          "text": "The most prevalent bacteria to cause UTI was Escherichia coli represent 44%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26657128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Urinary tract infections are one of the leading cause of morbidity in admitted patients. Most commonly caused by Escherichia coli, but there are some variants which are commonly reported in urinary tract infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26767386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Urinary tract infection or UTI is most commonly caused by Escherichia coli.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27244961"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "The group of microorganisms causing urinary tract infections includes the Enterobacteriaceae family, particularly E. coli, being the most commonly detected etiologic factor of the above infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1365784"
        },
        {
          "offsetInBeginSection": 887,
          "offsetInEndSection": 1040,
          "text": "Similar to other studies, E. coli was the most common bacteria causing UTI and showed a high rate of resistance against most of the antimicrobial agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25316131"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 330,
          "text": "Escherichia coli remains the predominant uropathogen (80%) isolated in acute community-acquired uncomplicated infections, followed by Staphylococcus saprophyticus (10% to 15%) and Pseudomonas aeruginosa (9",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16898513"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 660,
          "text": "k diffusion method.RESULTS: According to our results, Escherichia coli was the most common etiological agent of UTI (74.6%), followed by Klebsiella spp (11.7%), Staphylococcus saprophyticus (6.4%), and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18703368"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "The most frequent and best-studied agent of urinary tract infection (UTI) is Escherichia coli, which serves as a useful model pathogen for understanding microbial virulence in relation to UTI pathogenesis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12848470"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "Urinary tract infections (UTIs) have complex dynamics, with uropathogenic Escherichia coli (UPEC), the major causative agent, capable of colonization from the urethra to the kidneys in both extracellular and intracellular niches while also producing chronic persistent infections and frequent recurrent disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21807904"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 299,
          "text": "E. coli is the most common bacterium to cause UTIs, and is usually susceptible to oral antibiotics",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9742370"
        },
        {
          "offsetInBeginSection": 553,
          "offsetInEndSection": 640,
          "text": "Uropathogenic E.coli (UPEC) strains are recognized as typical bacterial agents for UTIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31218955"
        },
        {
          "offsetInBeginSection": 407,
          "offsetInEndSection": 551,
          "text": "Among gram-negative bacteria, some members of Enterobacteriaceae such as Escherichia coli (E.coli) strains have significant contribution in UTIs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31218955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Escherichia coli is the most common cause of urinary tract infections (UTIs) in children, and yet the underlying mechanisms of virulence and antibiotic resistance and the overall population structure of the species is poorly understood within this age group. To in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37581436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Proteus mirabilis is a Gram-negative bacterium commonly found in urinary tract infections (UTIs) and catheter-associated urinary tract infections (CAUTIs). The p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39606746"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Objective: Proteus mirabilis is the one of most important pathogens of catheter-associated urinary tract infect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37637463"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Objectives: Uropathogenic Escherichia coli (UPEC) is the most common causative agent of urinary tract infection, accounting for more than 80% of cases worl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37693820"
        }
      ],
      "id": "67e2b0a018b1e36f2e00008b",
      "ideal_answer": [
        "E. coli, Klebsiella spp, Staphylococcus saprophyticus are common bacteria that can cause urinary tract infections. However, E. coli is the bacteria that most commonly causes urinary tract infections.",
        "The most common bacteria that cause urinary tract infections (UTIs) are:\n\n1. Escherichia coli (E. coli) - This is responsible for 75-80% of UTIs.\n2. Klebsiella pneumoniae - Accounts for 5-10% of UTIs.\n3. Proteus mirabilis - Causes about 5-10% of UTIs.\n4. Enterococcus faecalis - Responsible for 5-10% of UTIs.\n5. Staphylococcus saprophyticus - Causes 1-5% of UTIs.\n\nLess common bacteria include:\n\n6. Pseudomonas aeruginosa\n7. Serratia marcescens\n8. Citrobacter species\n\nThese bacteria can cause both uncomplicated and complicated UTIs, depending on factors like age, sex, and underlying medical conditions.",
        "Based on the provided abstracts, Escherichia coli (E. coli) is the most common pathogen causing urinary tract infections (UTIs), accounting for approximately 49.1% to 80% of cases. Other common pathogens include Klebsiella pneumoniae (K. pneumoniae), Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus.\n\nThe prevalence of these pathogens varies across different studies, but E. coli is consistently reported as the leading cause of UTIs. K. pneumoniae is often the second most common pathogen, followed by P. mirabilis, E. faecalis, and S. saprophyticus.\n\nIt\u0027s essential to note that the distribution of pathogens may differ depending on factors such as patient demographics, geographic location, and type of infection (complicated or uncomplicated UTI). However, based on the provided abstracts, E. coli is the most common bacterial cause of UTIs.",
        "The most common bacteria causing urinary tract infections (UTIs) are:\n\n1. **Escherichia coli (E. coli)**: Responsible for approximately 80% of UTI cases, making it the leading cause.\n\n2. **Staphylococcus saprophyticus**: Particularly prevalent in young adult women, accounting for about 10% to 30% of infections in this demographic.\n\n3. **Klebsiella pneumoniae**: More commonly associated with complicated UTIs or specific populations.\n\n4. **Proteus mirabilis and Enterococcus faecalis**: These bacteria are also significant but less common overall, often implicated in particular contexts or populations.\n\nThis hierarchy reflects the typical distribution of pathogens in UTIs, with E. coli being the predominant cause across most cases."
      ],
      "exact_answer": [
        [
          "Escherichia coli"
        ]
      ]
    },
    {
      "body": "Is Bacillus Clausii a probiotic?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38375835",
        "http://www.ncbi.nlm.nih.gov/pubmed/36838205",
        "http://www.ncbi.nlm.nih.gov/pubmed/37446403",
        "http://www.ncbi.nlm.nih.gov/pubmed/15220667",
        "http://www.ncbi.nlm.nih.gov/pubmed/35744764",
        "http://www.ncbi.nlm.nih.gov/pubmed/25973914",
        "http://www.ncbi.nlm.nih.gov/pubmed/35674642",
        "http://www.ncbi.nlm.nih.gov/pubmed/36018495",
        "http://www.ncbi.nlm.nih.gov/pubmed/31888501",
        "http://www.ncbi.nlm.nih.gov/pubmed/36114449",
        "http://www.ncbi.nlm.nih.gov/pubmed/31695928",
        "http://www.ncbi.nlm.nih.gov/pubmed/34151160",
        "http://www.ncbi.nlm.nih.gov/pubmed/36198385",
        "https://www.ncbi.nlm.nih.gov/pubmed/36838205",
        "http://www.ncbi.nlm.nih.gov/pubmed/32724066",
        "http://www.ncbi.nlm.nih.gov/pubmed/39770518",
        "http://www.ncbi.nlm.nih.gov/pubmed/32733389",
        "http://www.ncbi.nlm.nih.gov/pubmed/10919516",
        "http://www.ncbi.nlm.nih.gov/pubmed/39003345",
        "http://www.ncbi.nlm.nih.gov/pubmed/38904672",
        "http://www.ncbi.nlm.nih.gov/pubmed/38879179",
        "http://www.ncbi.nlm.nih.gov/pubmed/38721227",
        "http://www.ncbi.nlm.nih.gov/pubmed/38494525",
        "http://www.ncbi.nlm.nih.gov/pubmed/12654668",
        "http://www.ncbi.nlm.nih.gov/pubmed/17846134",
        "http://www.ncbi.nlm.nih.gov/pubmed/34669274",
        "http://www.ncbi.nlm.nih.gov/pubmed/33604232",
        "http://www.ncbi.nlm.nih.gov/pubmed/23816335",
        "http://www.ncbi.nlm.nih.gov/pubmed/37909941",
        "http://www.ncbi.nlm.nih.gov/pubmed/29428923",
        "http://www.ncbi.nlm.nih.gov/pubmed/25090957",
        "http://www.ncbi.nlm.nih.gov/pubmed/30879230",
        "http://www.ncbi.nlm.nih.gov/pubmed/36771360",
        "http://www.ncbi.nlm.nih.gov/pubmed/37196540",
        "http://www.ncbi.nlm.nih.gov/pubmed/33683700",
        "http://www.ncbi.nlm.nih.gov/pubmed/36380186",
        "http://www.ncbi.nlm.nih.gov/pubmed/31398163"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Bacillus clausii is a commercial spore probiotic known to treat multiple diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38375835"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 322,
          "text": "Spore-forming bacteria of the Bacillus genus have demonstrated potential as probiotics for human use. Bacillus clausii have been recognized as efficacious and safe agents for preventing and treating diarrhea in children and adults, with pronounced immunomodulatory properties during several in vitro and clinical studies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 64,
          "offsetInEndSection": 92,
          "text": " Probiotic Bacillus clausii ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 488,
          "text": "This 12-week open-label, single-center clinical trial evaluated the efficacy of probiotics (Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans (SC208), Bacillus licheniformis (SL307), and Bacillus clausii (SC109))",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37446403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15220667"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 321,
          "text": "Spore-forming bacteria of the Bacillus genus have demonstrated potential as probiotics for human use. Bacillus clausii have been recognized as efficacious and safe agents for preventing and treating diarrhea in children and adults, with pronounced immunomodulatory properties during several in vitro and clinical studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Immunomodulatory and Antioxidant Properties of a Novel Potential Probiotic Bacillus clausii CSI08.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Bacillus clausii is a probiotic that benefits human health.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35744764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973914"
        },
        {
          "offsetInBeginSection": 404,
          "offsetInEndSection": 566,
          "text": "pecific ways. Bacillus clausii (B. clausii) has been in use for many decades as a safe and efficacious probiotic, but its mode of action has not yet been complete",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35674642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Immunomodulatory and Antioxidant Properties of a Novel Potential Probiotic Bacillus clausii CSI08.",
          "beginSection": "title",
          "endSection": "title",
          "document": "https://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Bacillus clausii UBBC07 is a commercial spore probiotic known to reduce diarrhea in children and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32733389"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 357,
          "text": "Both spore and vegetative forms of Bacillus species have been used as probiotics, and they have high stability to the surrounding atmospheric conditions such as heat, gastric conditions, and moisture. The commercial Bacillus probiotic strains in use are B. cereus, B. clausii, B. coagulans, B. licheniformis, B. polyfermenticus, B. pumilus, and B. subtilis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31695928"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "Bacillus clausii is a probiotic that benefits human health. Its key characteristics include the ability to form spores; the resulting tolerance to heat, acid, and salt ensures safe passage through the human gastrointestinal tract with no loss of cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35744764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "INTRODUCTION: Bacillus clausii as a probiotic supplement is increasingly used in both adult and paediatric patient populations. There is limited awareness about potential ad",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151160"
        },
        {
          "offsetInBeginSection": 1040,
          "offsetInEndSection": 1191,
          "text": "We found some probiotic species, viz., Bacillus clausii, Lactobacillus curvatus, Vibrio mediterranei and Vibrio fluvialis, from the Sundarbans mangrove",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39003345"
        },
        {
          "offsetInBeginSection": 524,
          "offsetInEndSection": 945,
          "text": "Probiotic strains isolated from pharmacy products including Lactobacillus sporogenes (strain not labeled), Lactobacillus rhamnosus GG (ATCC53103), Streptococcus faecalis (T-110 JPC), Bacillus mesentericus (TO-AJPC), Bacillus clausii (SIN) and Saccharomyces boulardii (CNCM I-745) were assessed for their probiotic traits including survival, antibiotic susceptibility, and antibacterial activity against pathogenic strains",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38904672"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Bacillus clausii Bacteremia Following Probiotic Use: A Report of Two Cases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38721227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Promising clinical and immunological efficacy of Bacillus clausii spore probiotics for supportive treatment of persistent diarrhea in children.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38494525"
        },
        {
          "offsetInBeginSection": 886,
          "offsetInEndSection": 941,
          "text": "Bacillus Clausii, was used as a probiotic in our study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31741944"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 177,
          "text": "Bacillus clausii (B. clausii) is a spore-forming probiotic that is able to colonize the gut.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724066"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 580,
          "text": "Bacillus clausii (B. clausii) has been in use for many decades as a safe and efficacious probiotic, but its mode of action has not yet been completely elucidated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35674642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Bacillus clausii is a commercial spore probiotic known to treat multiple diseases. An increased interest in exploring the nutraceutical and probiotic properties of various microorganisms has made researchers explore more about these bacteria.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38375835"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 385,
          "text": "Bacillus clausii is a probiotic that benefits human health. Its key characteristics include the ability to form spores; the resulting tolerance to heat, acid, and salt ensures safe passage through the human gastrointestinal tract with no loss of cells. Although B. clausii has been widely used for many decades, the beneficial properties of other probiotics, such as Lactobacillus spp.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35744764"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 387,
          "text": "Bacillus clausii (B. clausii) is a spore-forming probiotic that is able to colonize the gut. A mixture of four B. clausii strains (O/C, T, SIN and N/R) is commonly used for the treatment of AGE, and it has been demonstrated that it can reduce the duration and severity of diarrhea in children with AGE.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724066"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "INTRODUCTION: Bacillus clausii as a probiotic supplement is increasingly used in both adult and paediatric patien",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151160"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Bacillus clausii is a probiotic that benefits human health. Its key characteristics include the ability to form spores; the resulting tolerance to heat, acid, and salt ensures safe passage through the human gastrointestinal tract with no loss of cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35744764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Spore-forming bacteria of the Bacillus genus have demonstrated potential as probiotics for human use. Bacillus clausii have been recognized as efficacious and safe agents for preventing and treating diarrhea in children and adults, with pronounced im",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Bacillus clausii is a gram-positive rod used as a probiotic to treat diarrhea and the side effects of antibiotics such as pseudomembranous colitis. We report a case of B. clausii bacteremia in a non-immunocompromised patient with active peptic ulcer ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Bacillus clausii is a probiotic that benefits human health. Its key characteristics include the ability to form spores;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35744764"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 266,
          "text": "study, the spores and vegetative cells of B. clausii were independently evaluated for probiotic properties such as acid, gastric juice, bile, and intestinal fluid tolerance, adhesion to solvents/mucin and zeta potential. In addition, in silico identification",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33604232"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Bacillus clausii is a commercial spore probiotic known to treat multiple diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38375835"
        },
        {
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1246,
          "text": "Taken together, these beneficial properties provide strong evidence for B. clausii CSI08 as a promising potential probiotic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36838205"
        },
        {
          "offsetInBeginSection": 525,
          "offsetInEndSection": 832,
          "text": "In this narrative literature review, we review the characteristics and mechanisms of action supporting B. clausii as a probiotic and discuss the evidence from clinical studies evaluating B. clausii probiotics for the management of a variety of gastrointestinal disorders and symptoms in children and adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36018495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Spores of various Bacillus species, including B. subtilis, B. cereus and B. clausii, are used as probiotics, although they are generally absent from the normal microflora of man.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10919516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "We carried out content analysis of four batches each of 3 commercially available probiotic formulations of Bacillus clausii.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29428923"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Bacillus clausii is a gram-positive rod used as a probiotic to treat diarrhea and the side effects of antibiotics such as pseudomembranous colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669274"
        },
        {
          "offsetInBeginSection": 295,
          "offsetInEndSection": 566,
          "text": "Here, a murine model of experimental colitis was used to assess the beneficial health effects of Bacillus subtilis SF106 and Bacillus clausii (recently renamed Shouchella clausii) SF174, two spore-forming strains previously characterised in vitro as potential probiotics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38879179"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 721,
          "text": "This study investigates the structure-activity relationship of purified LTA from three probiotic Bacillus strains (Bacillus cereus CH, Bacillus subtilis CU1 and Bacillus clausii O/C).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25090957"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Quantitative and qualitative characterization of commercially available oral suspension of probiotic products containing Bacillus Clausii spores.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36114449"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Alkalihalobacillus clausii (formerly Bacillus clausii) spores lessen antibiotic-induced intestinal injury and reshape gut microbiota composition in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37196540"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 289,
          "text": "Probiotics, such as Enterogermina® (containing four strains of Bacillus clausii) reduce side effects from triple therapy with PPI+antibiotics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36771360"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 58,
          "text": "Bacillus clausii is a probiotic that benefits human health",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35744764"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 176,
          "text": "Bacillus clausii (B. clausii) is a spore-forming probiotic that is able to colonize the gut",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724066"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Bacillus clausii is a gram-positive rod used as a probiotic to treat diarrhea and the side effects of antibiotics such as pseudomembranous colitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Probiotics are live microorganisms that benefit the host in different clinical situations. Bacillus clausii is one of the most frequently used, but it is not without risk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37909941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 299,
          "text": "Probiotics contain beneficial live bacteria that confer several health benefits to the host. For the past 50 years, spore-forming Bacillus species have been used in the form of probiotics. Among these, Bacillus clausii strains are used for the management of acute and antibiotic-associated diarrhoea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36114449"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 304,
          "text": "Enterogermina is a probiotic mix of spores from four strains of Bacillus clausii (O/C, T, N/R and SIN), available in several oral formulations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33683700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Composite genome sequence of Bacillus clausii, a probiotic commercially available as Enterogermina",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31888501"
        },
        {
          "offsetInBeginSection": 525,
          "offsetInEndSection": 831,
          "text": "In this narrative literature review, we review the characteristics and mechanisms of action supporting B. clausii as a probiotic and discuss the evidence from clinical studies evaluating B. clausii probiotics for the management of a variety of gastrointestinal disorders and symptoms in children and adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36018495"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 346,
          "text": "o the host.RESULTS: We report the composite genome of Bacillus clausii ENTPro from a commercially available probiotic Enterogermina® and compare it with the genomes of other",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31888501"
        },
        {
          "offsetInBeginSection": 214,
          "offsetInEndSection": 377,
          "text": "cross-over trial in which two commercial probiotic formulations containing spores of four antibiotic-resistant B. clausii strains (OC, NR, SIN, T) were given as a ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973914"
        },
        {
          "offsetInBeginSection": 1040,
          "offsetInEndSection": 1192,
          "text": "We found some probiotic species, viz., Bacillus clausii, Lactobacillus curvatus, Vibrio mediterranei and Vibrio fluvialis, from the Sundarbans mangrove.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39003345"
        },
        {
          "offsetInBeginSection": 524,
          "offsetInEndSection": 946,
          "text": "Probiotic strains isolated from pharmacy products including Lactobacillus sporogenes (strain not labeled), Lactobacillus rhamnosus GG (ATCC53103), Streptococcus faecalis (T-110 JPC), Bacillus mesentericus (TO-AJPC), Bacillus clausii (SIN) and Saccharomyces boulardii (CNCM I-745) were assessed for their probiotic traits including survival, antibiotic susceptibility, and antibacterial activity against pathogenic strains.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38904672"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 566,
          "text": "Bacillus subtilis SF106 and Bacillus clausii (recently renamed Shouchella clausii) SF174, two spore-forming strains previously characterised in vitro as potential probiotics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38879179"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Bacillus clausii SIN is one of the four strains of B. clausii composing a probiotic administered to humans for the prevention of gastrointestinal side effects due to oral antibiotic therapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12654668"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 470,
          "text": "edical use. Some Bacillus species are currently being used for manufacturing probiotic products consisting of bacterial spores, exhibiting specific features (colonization, immune-stimulation and antimicrobial activity) that can account for their claimed probioti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23816335"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Probiotics are live microorganisms that benefit the host in different clinical situations. Bacillus clausii is one of the most frequently used, but it is not without risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37909941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Bacillus clausii SIN is one of the four strains of B. clausii composing a probiotic administered to humans for the prevention of gastrointestinal side effects due to oral antibiotic therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12654668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "To screen Bacillus clausii UBBC07 as a putative probiotic strain and to examine the protective effect of probiotic-B. clausii UBBC07 spore on uremia on rats induced by acetaminophen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30879230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "OBJECTIVE: To assess the effect of a probiotic strain Bacillus clausii UBBC-07 on gut microbiota and cytokines in IB",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36198385"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "AIMS: This study aimed to investigate the fate of Bacillus clausii spores orally administered as lyophilized or liquid formulation to healthy volun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25973914"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 126,
          "text": "To assess the effect of a probiotic strain Bacillus clausii UBBC-07 on gut microbiota and cytokines in IBD patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36198385"
        },
        {
          "offsetInBeginSection": 255,
          "offsetInEndSection": 459,
          "text": "This study aims to evaluate the effect and the protective mechanisms of a probiotic formulation containing Alkalihalobacillus clausii (formerly Bacillus clausii; BC) spores in an experimental model of AIJ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37196540"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36380186"
        },
        {
          "offsetInBeginSection": 562,
          "offsetInEndSection": 653,
          "text": "we review the characteristics and mechanisms of action supporting B. clausii as a probiotic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36018495"
        },
        {
          "offsetInBeginSection": 85,
          "offsetInEndSection": 180,
          "text": "Bacillus clausii (B. clausii) is a spore-forming probiotic that is able to colonize the gut. A ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724066"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 328,
          "text": "Bacillus clausii is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis and inflammatory bowel diseases. We inv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39770518"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "To screen Bacillus clausii UBBC07 as a putative probiotic strain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30879230"
        },
        {
          "offsetInBeginSection": 39,
          "offsetInEndSection": 88,
          "text": "Bacillus clausii NR, which is used as a probiotic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17846134"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 321,
          "text": "Bacillus clausii is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis and inflammatory bowel diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39770518"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 327,
          "text": "Bacillus clausii is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis and inflammatory bowel diseases. We in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39770518"
        },
        {
          "offsetInBeginSection": 1819,
          "offsetInEndSection": 1957,
          "text": "and sIgA in coprofiltrate.CONCLUSION: Conclusions: So, the probiotic drug containing Bacillus clausii has a positive effect on the humoral",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31398163"
        }
      ],
      "type": "yesno",
      "id": "67e090be18b1e36f2e00006c",
      "ideal_answer": [
        "Bacillus clausii is a commercial spore probiotic known to treat multiple diseases.",
        "Yes, Bacillus clausii is a probiotic known for its beneficial effects on human health.",
        "Yes, Bacillus clausii is a probiotic.",
        "Yes, Bacillus clausii is recognized as a probiotic. Research indicates that spore-forming bacteria of the Bacillus genus, including Bacillus clausii, have shown potential as probiotics suitable for human use (PMID 36838205). This is supported by the identification of Bacillus clausii strains with immunomodulatory and antioxidant properties, which are key characteristics beneficial in probiotics (PMID 36838205). However, it is important to note that while Bacillus clausii is generally considered safe and effective as a probiotic, there have been instances of Bacillus clausii bacteremia reported following probiotic usage in sensitive populations, such as pediatric patients (PMID 37850558). This underscores the need for careful consideration of the context in which this probiotic is used, particularly in individuals with compromised health conditions.",
        "Yes, Bacillus clausii is a widely known and marketed probiotic.",
        "Yes, Bacillus clausii is a probiotic known for its beneficial effects on human health. It is often used to support gut health, improve digestion, and enhance the immune system. Probiotics like Bacillus clausii can help maintain a healthy balance of bacteria in the gut, which is important for overall well-being.",
        "Yes, Bacillus Clausii is a probiotic.",
        "Yes, Bacillus clausii is a probiotic. It is a beneficial bacterium used to support gut health. Often found in probiotic supplements, Bacillus clausii helps maintain or restore the natural balance of intestinal flora.",
        "Yes, Bacillus clausii is a probiotic that benefits human health and is used to treat diarrhea and the side effects of antibiotics.",
        "Yes, Bacillus clausii is a spore-forming probiotic that benefits human health by colonizing the gut and providing physiological, antimicrobial, and immunomodulatory properties.",
        "Yes. Bacillus clausii is recognized as a probiotic bacterium that may confer health benefits, particularly in gastrointestinal health.",
        "Bacillus clausii is a spore-forming, gram-positive probiotic bacterium used to prevent and treat acute and antibiotic-associated diarrhea and other gastrointestinal disorders while surviving gastric acidity, colonizing the gut, and being marketed in oral formulations such as Enterogermina, which contains four antibiotic-resistant strains (O/C, T, N/R, SIN).",
        "Bacillus clausii is indeed a probiotic strain, commonly used to help alleviate antibiotic-associated diarrhea and maintain gut health.",
        "Yes, Bacillus clausii is considered to be a probiotic.",
        "Yes. Bacillus clausii is recognized as a probiotic with beneficial properties for human health, including its use in treating gastrointestinal disorders.",
        "Yes, Bacillus Clausii is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis, and inflammatory bowel diseases.",
        "Bacillus Clausii is a member of the Bacillus genus, which is known for containing probiotics. Bacillus Clausii, specifically, is often used as a probiotic in various medical applications.",
        "Yes. Bacillus clausii is recognized as a probiotic that benefits human health and has been used for many decades as a safe and efficacious probiotic.",
        "Yes, Bacillus Clausii is a probiotic",
        "Yes, Bacillus clausii is a widely known probiotic strain.",
        "Yes, Bacillus clausii is a probiotic known for its benefits to human health. It is used to support gut health and improve the balance of intestinal flora, often being recommended for digestive issues and to enhance the immune system.",
        "Yes, Bacillus Clausii is a spore-forming bacterium used as a probiotic due to its resistance to gastric acidity and intestinal conditions",
        "Yes, Bacillus Clausii is a probiotic that benefits human health and is used to treat various gastrointestinal disorders and symptoms in children and adults.",
        "Yes, Bacillus Clausii is recognized as a probiotic. It is a spore-forming bacterium that provides health benefits by improving gut flora, treating diarrhea, and reducing gastrointestinal side effects from antibiotics. Research highlights its ability to produce compounds that counteract toxins from pathogens, further supporting its role as an effective probiotic.",
        "Bacillus clausii is indeed a probiotic, known for its ability to form spores and provide health benefits to humans.",
        "Yes, Bacillus clausii is indeed a probiotic, as evidenced by its beneficial properties, including spore formation, antimicrobial and immunomodulatory effects, and its established use in commercial probiotic preparations for treating various gastrointestinal disorders.",
        "Yes, Bacillus clausii is a spore-forming probiotic that colonizes the gut and provides health benefits to the host.",
        "Yes. Bacillus clausii is explicitly described in the provided context as a probiotic that provides health benefits to humans.",
        "Yes, Bacillus clausii is a probiotic. It is a spore-forming bacteria with demonstrated efficacy and safety in preventing and treating diarrhea in various studies. This makes it a recognized and effective probiotic agent for human health.",
        "Yes. Bacillus Clausii is considered a probiotic, as it has been recognized for its efficacy and safety in preventing and treating diseases like diarrhea and its immunomodulatory benefits are supported by clinical trials.",
        "Yes, Bacillus clausii is a probiotic known for its efficacy in treating diarrhea and immunomodulatory properties.",
        "Yes. Bacillus clausii is recognized as a safe and efficacious probiotic used for preventing and treating diarrhea and has immunomodulatory properties.",
        "Yes, Bacillus clausii is a probiotic. It is recognized as a commercial spore probiotic with proven efficacy in preventing and treating diarrhea along with pronounced immunomodulatory properties.",
        "Yes, Bacillus clausii is a commercial spore probiotic.",
        "Yes, *Bacillus clausii* is a well-documented probiotic. It is commercially used as a spore-forming probiotic and has demonstrated efficacy in treating gastrointestinal disorders like diarrhea in clinical studies. Its safety, immunomodulatory properties, and therapeutic benefits are supported by in vitro and human trials.",
        "Yes, Bacillus clausii is a commercial spore probiotic known to treat multiple diseases and has been recognized as efficacious and safe for preventing and treating diarrhea in children and adults.",
        "Yes, Bacillus clausii is a spore-forming probiotic bacterium recognized for its safety and efficacy in preventing and treating diarrhea in both children and adults, and it also exhibits immunomodulatory properties according to clinical studies.",
        "Yes. Bacillus clausii is recognized as an efficacious and safe probiotic agent for preventing and treating diarrhea, and it has demonstrated beneficial properties in various studies.",
        "Yes, Bacillus Clausii is a probiotic. It is a commercial spore probiotic known to treat multiple diseases, including diarrhea in children and adults.",
        "Bacillus clausii is a commercial spore probiotic that has been clinically recognized as safe and effective for treating and preventing diarrhea in both children and adults. It demonstrates pronounced immunomodulatory properties and is used in clinical trials alongside other Bacillus species.",
        "Yes, Bacillus clausii is recognized as a probiotic. It is used commercially for its health benefits, including treating diarrhea and demonstrating immunomodulatory properties. Clinical studies and references to it in probiotic evaluations further confirm its status as a probiotic.",
        "Yes, Bacillus Clausii is a probiotic. It has been recognized as an efficacious and safe agent for preventing and treating diarrhea in children and adults, as demonstrated in various studies.",
        "Bacillus Clausii is known to be a probiotic.",
        "Yes, available evidence suggests that is bacillus clausii a probiotic.",
        "Yes, Bacillus clausii is classified as a probiotic because it is a live bacterium known to confer health benefits and is used commercially as a spore probiotic to treat various diseases.",
        "Bacillus Clausii is unequivocally considered a probiotic, supported by its recognized health benefits, immunomodulatory properties, ability to suppress pathogens, and capacity to improve gut microbiota composition, as consistently demonstrated across various studies.",
        "Yes, Bacillus clausii is a commercial spore probiotic known to treat multiple diseases.",
        "Yes, Bacillus clausii is a commercial spore probiotic known to treat multiple diseases and has demonstrated efficacy and safety in preventing and treating diarrhea with pronounced immunomodulatory properties.",
        "Yes, Bacillus clausii is a spore-forming probiotic recognized for its efficacy and safety in preventing and treating diarrhea in children and adults. It is noted for its immunomodulatory properties, as evidenced by various in vitro and clinical studies."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Symptoms of chlamydia genital infection in women.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39759166",
        "http://www.ncbi.nlm.nih.gov/pubmed/39117400",
        "http://www.ncbi.nlm.nih.gov/pubmed/38622501",
        "http://www.ncbi.nlm.nih.gov/pubmed/39651251",
        "http://www.ncbi.nlm.nih.gov/pubmed/37005162",
        "http://www.ncbi.nlm.nih.gov/pubmed/36759099"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Some women infected with Chlamydia trachomatis (CT) are asymptomatic, while others experience lower abdominal discomfort when the inflammatory process extends to the fallopian tubes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39759166"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 213,
          "text": "salpingitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39759166"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 248,
          "text": "pelvic peritonitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39759166"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 299,
          "text": "peritonitis in the upper abdomen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39759166"
        },
        {
          "offsetInBeginSection": 1883,
          "offsetInEndSection": 1923,
          "text": "CT and NG detected only at the anorectum",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39117400"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 170,
          "text": "cervicitis, urethritis, and infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622501"
        },
        {
          "offsetInBeginSection": 63,
          "offsetInEndSection": 180,
          "text": "pelvic inflammatory disease, infertility and other reproductive sequelae when it ascends to the upper genital tract. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39651251"
        },
        {
          "offsetInBeginSection": 296,
          "offsetInEndSection": 406,
          "text": "pelvic inflammatory disease, increasing their risk for ectopic pregnancy, infertility, and chronic pelvic pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37005162"
        },
        {
          "offsetInBeginSection": 535,
          "offsetInEndSection": 703,
          "text": "PID is infection of the female upper genital tract, involving the uterus, fallopian tubes, ovaries, and/or pelvic peritoneum and usually caused by Chlamydia trachomatis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36759099"
        }
      ],
      "id": "67d7fded18b1e36f2e000042",
      "ideal_answer": [
        "Clamydia genital infection can be asymptomatic, and also present as peritonitis, salpingitis, urethritis, chronic pelvic pain, and as infertility in women.",
        "Chlamydia genital infection in women is often asymptomatic but may present with symptoms including vaginal discharge, abnormal uterine bleeding (premenopausal or postmenopausal), pelvic pain, dyspareunia (painful intercourse), lower abdominal pain, and post-coital bleeding. Untreated infections can ascend to the upper genital tract, leading to pelvic inflammatory disease (PID), tubal factor infertility, ectopic pregnancy, or chronic pelvic pain. Notably, asymptomatic cases are common, yet they still pose risks for severe complications like tubal damage. Pelvic examination is critical for symptomatic individuals to rule out PID or tubo-ovarian abscess. Higher bacterial load may correlate with symptomatic presentations.",
        "Symptoms of chlamydia genital infection in women include:\n1. Abnormal vaginal discharge\n2. Cervical columnar epithelial ectopy\n3. Vaginal itching\n4. Lower abdominal pain\n5. Painful cervical bleeding because of endometritis\n6. Dyspareunia\n7. Upper abdominal pain because of perihepatitis\n8. Pelvic Inflammatory Disease (PID)\n9. Ectopic pregnancy\n10. Infertility\n11. Chronic pelvic pain\n12. Cervicitis\n13. Urethritis",
        "Symptoms of chlamydia genital infection in women include:\n1) Vaginal discharge\n2) Painful urination\n3) Lower abdominal pain\n4) Bleeding between periods\n5) Pain during sex\n6) Pelvic inflammatory disease (PID)\n7) Infertility\n8) Ectopic pregnancy\n9) Fitz-Hugh-Curtis syndrome\n10) Peritonitis in the upper abdomen",
        "**Symptoms of Chlamydia Genital Infection in Women:**\n\nChlamydia genital infection in women can vary widely, with some individuals being asymptomatic. However, common symptoms include:\n\n1. **Lower Abdominal Pain:** Discomfort or pain in the lower abdomen is a frequent symptom, especially when the infection spreads to the fallopian tubes.\n\n2. **Abnormal Vaginal Discharge:** This may be noticed as an unusual increase in discharge volume or changes in its appearance and odor.\n\n3. **Dysuria (Painful Urination):** Burning or discomfort during urination can occur, particularly if the infection involves the urethra (urethritis).\n\n4. **Cervicitis Symptoms:** Inflammation of the cervix may lead to pain during intercourse and abnormal discharge.\n\n5. **Pelvic Inflammatory Disease (PID):** If untreated, chlamydia can ascend to the upper genital tract, causing PID. Symptoms include severe lower abdominal pain, fever, abnormal vaginal discharge, and pain during sexual activity.\n\n6. **Complications:** Untreated infections can lead to serious complications such as infertility, ectopic pregnancy, and chronic pelvic pain.\n\nIt is crucial for women with suspected chlamydia infection to seek medical testing and treatment promptly to prevent these complications.",
        "Chlamydia genital infection in women is asymptomatic in most cases but can present with abnormal vaginal discharge that is often mucopurulent, dysuria or urinary discomfort, genital itching or burning, intermenstrual or postcoital bleeding, and pelvic or lower abdominal pain. Sexual intercourse may become painful (dyspareunia). On pelvic examination the cervix can appear swollen, red, friable and may produce mucopurulent endocervical discharge. If the infection ascends, women may develop endometritis, salpingitis or pelvic inflammatory disease characterized by more severe lower abdominal pain, fever and pelvic tenderness, which can lead to complications such as ectopic pregnancy, infertility and chronic pelvic pain.",
        "Symptoms of Chlamydia genital infection in women can range from asymptomatic to severe. Many women with Chlamydia infection are asymptomatic or have minimal symptoms. When symptoms are present, they can include mucopurulent cervicitis with vaginal discharge, painful cervical bleeding due to endometritis, lower abdominal pain with dyspareunia, and upper abdominal pain due to perihepatitis. Other symptoms and signs include urethritis, proctitis, pelvic inflammatory disease (PID), salpingitis, pelvic peritonitis, peritonitis in the upper abdomen, easily induced bleeding from the cervix, and more polymorpho-nuclear cells than epithelial cells in vaginal wet smear. Some women may experience lower abdominal discomfort. Clinical signs can include purulent or yellowish discharge and cervical friability."
      ],
      "exact_answer": [
        [
          "asymptomatic"
        ],
        [
          "lower abdominal discomfort"
        ],
        [
          "salpingitis"
        ],
        [
          "peritonitis"
        ],
        [
          "cervicitis"
        ],
        [
          "urethritis"
        ],
        [
          "infertility"
        ],
        [
          "chronic pelvic pain"
        ]
      ]
    }
  ]
}